assertion_id	disorder_id	disorder_name	source_file	section	section_index	name	description	category	frequency	diagnostic	context	subtype	role	presence	association	accession	age_range	background	base_model	classification	clinical_significance	consequence	data_type	de_novo_rate	definition_type	duration	effect	expressivity	features	genotype	incubation_days	incubation_years	markers	maximum_value	mean_range	minimum_value	model_format	model_id	model_software	model_type	notes	parent_of_origin_effect	penetrance	percentage	phase	platform	population	publication	repository_url	results	review_notes	sample_count	scope	sequence_length	severity	species	specificity	status	subtype_frequency	title	type	unit	scalar_fields_json	complex_fields_json	raw_json
16	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	0	Cardiac surgery	"Surgical repair of conotruncal defects is often required in infancy. Timing and approach depend on the specific cardiac malformation.
"																																																								"{""description"": ""Surgical repair of conotruncal defects is often required in infancy. Timing and approach depend on the specific cardiac malformation.\n"", ""name"": ""Cardiac surgery""}"	{}	"{""description"": ""Surgical repair of conotruncal defects is often required in infancy. Timing and approach depend on the specific cardiac malformation.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Cardiac management is part of standard care."", ""reference"": ""PMID:20301696"", ""snippet"": ""Cardiac anomalies are treated as recommended by cardiologist"", ""supports"": ""SUPPORT""}], ""name"": ""Cardiac surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
17	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	1	Calcium and vitamin D supplementation	"Management of hypocalcemia with calcium and active vitamin D (calcitriol) supplementation.
"																																																								"{""description"": ""Management of hypocalcemia with calcium and active vitamin D (calcitriol) supplementation.\n"", ""name"": ""Calcium and vitamin D supplementation""}"	{}	"{""description"": ""Management of hypocalcemia with calcium and active vitamin D (calcitriol) supplementation.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Calcium supplementation is recommended for hypocalcemia."", ""reference"": ""PMID:20301696"", ""snippet"": ""calcium supplementation and referral to an endocrinologist"", ""supports"": ""SUPPORT""}], ""name"": ""Calcium and vitamin D supplementation"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
18	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	2	Thymus transplantation	"For complete DiGeorge syndrome (thymic aplasia), thymus tissue transplantation can reconstitute T-cell immunity.
"																																																								"{""description"": ""For complete DiGeorge syndrome (thymic aplasia), thymus tissue transplantation can reconstitute T-cell immunity.\n"", ""name"": ""Thymus transplantation""}"	{}	"{""description"": ""For complete DiGeorge syndrome (thymic aplasia), thymus tissue transplantation can reconstitute T-cell immunity.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Thymus transplantation is indicated for complete DiGeorge."", ""reference"": ""PMID:20301696"", ""snippet"": ""rarely, prophylactic antibiotics, IVIG therapy, or thymus tissue implantation are required"", ""supports"": ""SUPPORT""}], ""name"": ""Thymus transplantation"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
19	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	3	Speech therapy	"Management of velopharyngeal insufficiency and hypernasal speech.
"																																																								"{""description"": ""Management of velopharyngeal insufficiency and hypernasal speech.\n"", ""name"": ""Speech therapy""}"	{}	"{""description"": ""Management of velopharyngeal insufficiency and hypernasal speech.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Speech therapy is part of the recommended management."", ""reference"": ""PMID:20301696"", ""snippet"": ""speech therapy"", ""supports"": ""SUPPORT""}], ""name"": ""Speech therapy"", ""treatment_term"": {""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}}"
20	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	4	Immunological monitoring	"Regular monitoring of immune function and vaccination responses. Live vaccines may be contraindicated depending on T-cell function.
"																																																								"{""description"": ""Regular monitoring of immune function and vaccination responses. Live vaccines may be contraindicated depending on T-cell function.\n"", ""name"": ""Immunological monitoring""}"	{}	"{""description"": ""Regular monitoring of immune function and vaccination responses. Live vaccines may be contraindicated depending on T-cell function.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Vaccine precautions based on immune status are recommended."", ""reference"": ""PMID:20301696"", ""snippet"": ""Infants with lymphocyte abnormalities should not be immunized with live vaccines"", ""supports"": ""SUPPORT""}], ""name"": ""Immunological monitoring""}"
35	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	0	Alectinib	Second-generation ALK TKI with excellent CNS penetration. First-line standard of care based on ALEX trial showing superior PFS and OS vs crizotinib. Active against many crizotinib-resistant mutations.																																																								"{""description"": ""Second-generation ALK TKI with excellent CNS penetration. First-line standard of care based on ALEX trial showing superior PFS and OS vs crizotinib. Active against many crizotinib-resistant mutations."", ""name"": ""Alectinib""}"	{}	"{""description"": ""Second-generation ALK TKI with excellent CNS penetration. First-line standard of care based on ALEX trial showing superior PFS and OS vs crizotinib. Active against many crizotinib-resistant mutations."", ""name"": ""Alectinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
36	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	1	Lorlatinib	Third-generation ALK TKI designed to overcome resistance mutations including G1202R. Excellent CNS activity. Can be used first-line (CROWN trial) or after progression on prior ALK TKIs.																																																								"{""description"": ""Third-generation ALK TKI designed to overcome resistance mutations including G1202R. Excellent CNS activity. Can be used first-line (CROWN trial) or after progression on prior ALK TKIs."", ""name"": ""Lorlatinib""}"	{}	"{""description"": ""Third-generation ALK TKI designed to overcome resistance mutations including G1202R. Excellent CNS activity. Can be used first-line (CROWN trial) or after progression on prior ALK TKIs."", ""name"": ""Lorlatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
37	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	2	Brigatinib	Second-generation ALK TKI with broad activity against resistance mutations and good CNS penetration. Alternative to alectinib in first-line or subsequent settings.																																																								"{""description"": ""Second-generation ALK TKI with broad activity against resistance mutations and good CNS penetration. Alternative to alectinib in first-line or subsequent settings."", ""name"": ""Brigatinib""}"	{}	"{""description"": ""Second-generation ALK TKI with broad activity against resistance mutations and good CNS penetration. Alternative to alectinib in first-line or subsequent settings."", ""name"": ""Brigatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
38	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	3	Crizotinib	First-generation ALK TKI that established proof-of-concept for ALK inhibition in lung cancer. Now largely replaced by more potent second/third generation agents due to lower CNS efficacy and resistance.																																																								"{""description"": ""First-generation ALK TKI that established proof-of-concept for ALK inhibition in lung cancer. Now largely replaced by more potent second/third generation agents due to lower CNS efficacy and resistance."", ""name"": ""Crizotinib""}"	{}	"{""description"": ""First-generation ALK TKI that established proof-of-concept for ALK inhibition in lung cancer. Now largely replaced by more potent second/third generation agents due to lower CNS efficacy and resistance."", ""name"": ""Crizotinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
39	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ALK TKIs. ALK-positive tumors often respond to pemetrexed.																																																								"{""description"": ""Platinum-based chemotherapy (pemetrexed-based) used at progression on ALK TKIs. ALK-positive tumors often respond to pemetrexed."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy (pemetrexed-based) used at progression on ALK TKIs. ALK-positive tumors often respond to pemetrexed."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
56	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	0	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.																																																								"{""description"": ""Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment."", ""name"": ""All-Trans Retinoic Acid (ATRA)""}"	{}	"{""description"": ""Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment."", ""name"": ""All-Trans Retinoic Acid (ATRA)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""all-trans-retinoic acid"", ""term"": {""id"": ""CHEBI:15367"", ""label"": ""all-trans-retinoic acid""}}]}}"
57	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	1	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.																																																								"{""description"": ""ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations."", ""name"": ""Arsenic Trioxide (ATO)""}"	{}	"{""description"": ""ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations."", ""name"": ""Arsenic Trioxide (ATO)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""arsenic trioxide"", ""term"": {""id"": ""CHEBI:30621"", ""label"": ""diarsenic trioxide""}}]}}"
58	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	2	ATRA plus Arsenic Trioxide Combination	The combination of ATRA and ATO without chemotherapy achieves greater than 90% cure rates in standard-risk APL. This regimen avoids chemotherapy-related toxicities including secondary malignancies and cardiomyopathy. Represents the standard of care for non-high-risk APL.																																																								"{""description"": ""The combination of ATRA and ATO without chemotherapy achieves greater than 90% cure rates in standard-risk APL. This regimen avoids chemotherapy-related toxicities including secondary malignancies and cardiomyopathy. Represents the standard of care for non-high-risk APL."", ""name"": ""ATRA plus Arsenic Trioxide Combination""}"	{}	"{""description"": ""The combination of ATRA and ATO without chemotherapy achieves greater than 90% cure rates in standard-risk APL. This regimen avoids chemotherapy-related toxicities including secondary malignancies and cardiomyopathy. Represents the standard of care for non-high-risk APL."", ""name"": ""ATRA plus Arsenic Trioxide Combination"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
59	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	3	Chemotherapy-Based Regimens	ATRA combined with anthracycline-based chemotherapy remains an option, particularly for high-risk APL (WBC greater than 10,000/uL) where early death risk is higher. Idarubicin is commonly used. ATO is increasingly incorporated into chemotherapy regimens.																																																								"{""description"": ""ATRA combined with anthracycline-based chemotherapy remains an option, particularly for high-risk APL (WBC greater than 10,000/uL) where early death risk is higher. Idarubicin is commonly used. ATO is increasingly incorporated into chemotherapy regimens."", ""name"": ""Chemotherapy-Based Regimens""}"	{}	"{""description"": ""ATRA combined with anthracycline-based chemotherapy remains an option, particularly for high-risk APL (WBC greater than 10,000/uL) where early death risk is higher. Idarubicin is commonly used. ATO is increasingly incorporated into chemotherapy regimens."", ""name"": ""Chemotherapy-Based Regimens"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
60	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	4	Supportive Care for Coagulopathy	Aggressive blood product support is essential during induction, including platelet transfusions to maintain count above 30-50,000/uL and cryoprecipitate or fibrinogen concentrate to maintain fibrinogen above 150 mg/dL.																																																								"{""description"": ""Aggressive blood product support is essential during induction, including platelet transfusions to maintain count above 30-50,000/uL and cryoprecipitate or fibrinogen concentrate to maintain fibrinogen above 150 mg/dL."", ""name"": ""Supportive Care for Coagulopathy""}"	{}	"{""description"": ""Aggressive blood product support is essential during induction, including platelet transfusions to maintain count above 30-50,000/uL and cryoprecipitate or fibrinogen concentrate to maintain fibrinogen above 150 mg/dL."", ""name"": ""Supportive Care for Coagulopathy"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	Tafamidis	Helps stabilize transthyretin and prevent amyloid fibril formation.						TTR Stabilizer																																																		"{""description"": ""Helps stabilize transthyretin and prevent amyloid fibril formation."", ""name"": ""Tafamidis"", ""role"": ""TTR Stabilizer""}"	{}	"{""description"": ""Helps stabilize transthyretin and prevent amyloid fibril formation."", ""evidence"": [{""explanation"": ""The study shows that tafamidis effectively stabilizes TTR, supporting the statement that it helps stabilize transthyretin."", ""reference"": ""PMID:25872787"", ""snippet"": ""Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated."", ""supports"": ""SUPPORT""}, {""explanation"": ""The evidence indicates that tafamidis stabilizes TTR tetramers, supporting the statement."", ""reference"": ""PMID:31098895"", ""snippet"": ""Tafamidis slowed deterioration of neurological function and maintained health-related quality of life in patients with early-stage ATTR-PN... TTR tetramers were stabilized in nearly all patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports that tafamidis is effective in stabilizing TTR and preventing amyloid fibril formation."", ""reference"": ""PMID:26800456"", ""snippet"": ""Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal became the first line anti-amyloid treatment in stage 1 TTR-FAP. Both drugs slow progression of the disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The review supports that stabilizing TTR is crucial, and tafamidis is one of the compounds that achieve this."", ""reference"": ""PMID:29962408"", ""snippet"": ""The mutations destabilize the tetramer and/or monomer of TTR, and thus the stabilization of TTR is a key strategy for the treatment of TTR-related amyloidosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article states that TTR stabilizers, including tafamidis, have been successfully developed, supporting the statement."", ""reference"": ""PMID:34609369"", ""snippet"": ""Several TTR molecule stabilizers were developed successfully... Silencing the TTR gene using different strategies is flourishing."", ""supports"": ""SUPPORT""}], ""name"": ""Tafamidis"", ""role"": ""TTR Stabilizer"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
94	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	1	Patisiran	Reduces production of transthyretin protein to decrease amyloid formation.						RNA Interference																																																		"{""description"": ""Reduces production of transthyretin protein to decrease amyloid formation."", ""name"": ""Patisiran"", ""role"": ""RNA Interference""}"	{}	"{""description"": ""Reduces production of transthyretin protein to decrease amyloid formation."", ""evidence"": [{""explanation"": ""The abstract clearly states that patisiran reduces the production of transthyretin protein, which aligns with the statement."", ""reference"": ""PMID:30480471"", ""snippet"": ""Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract mentions that patisiran, as an RNAi therapeutic, benefits patients with hereditary transthyretin amyloidosis, indicating its role in reducing transthyretin protein production."", ""reference"": ""PMID:37599395"", ""snippet"": ""Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract explicitly states that patisiran targets and degrades transthyretin mRNA, thus reducing the production of transthyretin protein."", ""reference"": ""PMID:31131842"", ""snippet"": ""Onpattro, also commonly known as patisiran, is a small interfering RNA (siRNA) molecule packaged within a lipid nanoparticle and is transported into the cell to target transthyretin gene (TTR) messenger mRNA (mRNA) by attaching to its complementary sequence. The target mRNA is degraded and both mutant and wild-type amyloid transthyretin (ATTR) protein production becomes suppressed."", ""supports"": ""SUPPORT""}], ""name"": ""Patisiran"", ""role"": ""RNA Interference"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
95	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	2	Inotersen	Reduces TTR protein production to limit amyloid accumulation.						Antisense Oligonucleotide																																																		"{""description"": ""Reduces TTR protein production to limit amyloid accumulation."", ""name"": ""Inotersen"", ""role"": ""Antisense Oligonucleotide""}"	{}	"{""description"": ""Reduces TTR protein production to limit amyloid accumulation."", ""evidence"": [{""explanation"": ""The reference confirms that Inotersen reduces TTR protein production by inhibiting its production in the liver, which aligns with the statement."", ""reference"": ""PMID:30561247"", ""snippet"": ""Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports that Inotersen is used to treat ATTR amyloidosis and implies its role in reducing TTR protein production."", ""reference"": ""PMID:37599395"", ""snippet"": ""'Aims: Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference title directly states that Inotersen is used for the treatment of ATTR amyloidosis, implying its role in reducing TTR protein production."", ""reference"": ""PMID:31343345"", ""snippet"": ""Inotersen treatment for ATTR amyloidosis."", ""supports"": ""SUPPORT""}], ""name"": ""Inotersen"", ""role"": ""Antisense Oligonucleotide"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
96	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	3	Liver Transplant	Considered for hereditary cases to reduce production of mutant TTR.																																																								"{""description"": ""Considered for hereditary cases to reduce production of mutant TTR."", ""name"": ""Liver Transplant""}"	{}	"{""description"": ""Considered for hereditary cases to reduce production of mutant TTR."", ""evidence"": [{""explanation"": ""The literature supports liver transplantation as a therapy to address the production of unstable TTR in hereditary ATTR amyloidosis."", ""reference"": ""PMID:25482846"", ""snippet"": ""Orthotopic liver transplantation (OLT) was implemented as the inaugural disease-modifying therapy because the liver produces the circulating unstable TTR."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of liver transplantation to reduce the production of mutant TTR in hereditary cases of ATTR amyloidosis."", ""reference"": ""PMID:23797140"", ""snippet"": ""Therefore, liver transplantation has become widely accepted as the ultimate curative treatment of this disease in order to prevent the ultimately fatal outcome and ameliorate disabling symptoms."", ""supports"": ""SUPPORT""}], ""name"": ""Liver Transplant"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
97	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	4	Heart Transplant	May be necessary for those with severe cardiomyopathy.																																																								"{""description"": ""May be necessary for those with severe cardiomyopathy."", ""name"": ""Heart Transplant""}"	{}	"{""description"": ""May be necessary for those with severe cardiomyopathy."", ""evidence"": [{""explanation"": ""The statement is supported as heart transplantation is mentioned as a treatment for end-stage heart failure in patients with cardiac amyloidosis."", ""reference"": ""PMID:32304420"", ""snippet"": ""However, the end-stage heart failure is common and HTx could be offered to selected patients, especially if affected by light chain cardiac amyloidosis, to allow to perform the autologous stem cell transplantation after the cardiac transplant."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement is supported as orthotopic heart transplantation is identified as a definitive treatment for end-stage heart failure in amyloid cardiomyopathy patients."", ""reference"": ""PMID:33621542"", ""snippet"": ""Orthotopic heart transplantation (OHT) remains the definitive treatment for patients with end stage heart failure."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement is supported as heart transplantation is described as a rational therapy for advanced transthyretin cardiac amyloidosis."", ""reference"": ""PMID:34922822"", ""snippet"": ""Heart Transplantation (HT) is a rational therapy for advanced transthyretin cardiac amyloidosis (ATTR-CA)..."", ""supports"": ""SUPPORT""}], ""name"": ""Heart Transplant"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
98	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	5	Supportive Care	Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues.																																																								"{""description"": ""Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues."", ""evidence"": [{""explanation"": ""The reference indicates that supportive care is used to manage the symptoms of organ involvement, which can include neuropathy, heart failure, and gastrointestinal issues."", ""reference"": ""PMID:33099432"", ""snippet"": ""Supportive care manages the symptoms of organ involvement and the side effects of treatment."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference highlights the management of cardiovascular symptoms in cardiac amyloidosis, which is part of supportive care."", ""reference"": ""PMID:35235819"", ""snippet"": ""Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrhythmias, conduction disturbances, and profound autonomic dysfunction."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the management of neuromuscular complications, including neuropathy, which is part of supportive care."", ""reference"": ""PMID:35104443"", ""snippet"": ""Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues... The 2 most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses gastrointestinal issues related to amyloidosis, which are managed through supportive care."", ""reference"": ""PMID:7588042"", ""snippet"": ""The gastrointestinal manifestations of amyloidosis."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
114	5	Achondrogenesis Type II	Achondrogenesis_Type_II.yaml	treatments	0	Supportive Care	"No effective treatment exists. Supportive care and palliative measures for affected neonates. Genetic counseling for families.
"																																																								"{""description"": ""No effective treatment exists. Supportive care and palliative measures for affected neonates. Genetic counseling for families.\n"", ""name"": ""Supportive Care""}"	{}	"{""description"": ""No effective treatment exists. Supportive care and palliative measures for affected neonates. Genetic counseling for families.\n"", ""name"": ""Supportive Care""}"
127	6	Achondroplasia	Achondroplasia.yaml	treatments	0	Vosoritide (Voxzogo)	"C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved in 2021 for children aged 5 years and older with open growth plates. Clinical trials demonstrated increased annualized growth velocity.
"																																																								"{""description"": ""C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved in 2021 for children aged 5 years and older with open growth plates. Clinical trials demonstrated increased annualized growth velocity.\n"", ""name"": ""Vosoritide (Voxzogo)""}"	{}	"{""description"": ""C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved in 2021 for children aged 5 years and older with open growth plates. Clinical trials demonstrated increased annualized growth velocity.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This NEJM phase 2 trial demonstrated that vosoritide treatment in children with achondroplasia resulted in sustained increases in growth velocity over 42 months of follow-up."", ""reference"": ""PMID:31269546"", ""snippet"": ""Treatment resulted in a sustained increase in the annualized growth velocity for up to 42 months."", ""supports"": ""SUPPORT""}], ""name"": ""Vosoritide (Voxzogo)"", ""treatment_term"": {""preferred_term"": ""Vosoritide therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
128	6	Achondroplasia	Achondroplasia.yaml	treatments	1	Surgical limb lengthening	"Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.
"																																																								"{""description"": ""Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.\n"", ""name"": ""Surgical limb lengthening""}"	{}	"{""description"": ""Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.\n"", ""name"": ""Surgical limb lengthening"", ""treatment_term"": {""preferred_term"": ""Limb lengthening surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
129	6	Achondroplasia	Achondroplasia.yaml	treatments	2	Foramen magnum decompression	"Surgical decompression may be required for symptomatic foramen magnum stenosis with cervicomedullary compression, which can cause central apnea, hypotonia, or sudden death in infants.
"																																																								"{""description"": ""Surgical decompression may be required for symptomatic foramen magnum stenosis with cervicomedullary compression, which can cause central apnea, hypotonia, or sudden death in infants.\n"", ""name"": ""Foramen magnum decompression""}"	{}	"{""description"": ""Surgical decompression may be required for symptomatic foramen magnum stenosis with cervicomedullary compression, which can cause central apnea, hypotonia, or sudden death in infants.\n"", ""name"": ""Foramen magnum decompression"", ""treatment_term"": {""preferred_term"": ""Foramen magnum decompression"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
130	6	Achondroplasia	Achondroplasia.yaml	treatments	3	Management of spinal stenosis	"Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.
"																																																								"{""description"": ""Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.\n"", ""name"": ""Management of spinal stenosis""}"	{}	"{""description"": ""Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.\n"", ""name"": ""Management of spinal stenosis"", ""treatment_term"": {""preferred_term"": ""Spinal surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
150	7	Achoo Syndrome	Achoo_Syndrome.yaml	treatments	0	Sunglasses	Wearing sunglasses before exposure to bright light may prevent triggering of the reflex.																																		Simple preventive measure; filtering lenses may be less effective if luminance change rather than specific wavelengths is the trigger.																						"{""description"": ""Wearing sunglasses before exposure to bright light may prevent triggering of the reflex."", ""name"": ""Sunglasses"", ""notes"": ""Simple preventive measure; filtering lenses may be less effective if luminance change rather than specific wavelengths is the trigger.""}"	{}	"{""description"": ""Wearing sunglasses before exposure to bright light may prevent triggering of the reflex."", ""name"": ""Sunglasses"", ""notes"": ""Simple preventive measure; filtering lenses may be less effective if luminance change rather than specific wavelengths is the trigger."", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"																																																								"{""description"": ""First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.\n"", ""name"": ""Topical retinoids""}"	{}	"{""description"": ""First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.\n"", ""evidence"": [{""explanation"": ""This systematic review confirms the safety and efficacy of topical retinoids for acne treatment."", ""reference"": ""PMID:30674002"", ""snippet"": ""Topical retinoids are safe and efficacious for the treatment of acne vulgaris."", ""supports"": ""SUPPORT""}], ""name"": ""Topical retinoids"", ""treatment_term"": {""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""retinoid"", ""term"": {""id"": ""NCIT:C68299"", ""label"": ""Retinoid""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}}"
187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"																																																								"{""description"": ""Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.\n"", ""name"": ""Trifarotene""}"	{}	"{""description"": ""Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.\n"", ""evidence"": [{""explanation"": ""This review summarizes randomized trials showing trifarotene efficacy across comedonal and inflammatory acne lesions."", ""reference"": ""PMID:36927117"", ""snippet"": ""Large-scale randomized, controlled clinical trials have demonstrated trifarotene to be safe, well tolerated, and efficacious in reducing both comedones and papules/pustules of acne."", ""supports"": ""SUPPORT""}], ""name"": ""Trifarotene"", ""treatment_term"": {""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""trifarotene"", ""term"": {""id"": ""NCIT:C118577"", ""label"": ""Trifarotene""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}}"
188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"																																																								"{""description"": ""Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.\n"", ""name"": ""Benzoyl peroxide""}"	{}	"{""description"": ""Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.\n"", ""evidence"": [{""explanation"": ""This review establishes benzoyl peroxide as an important first-line treatment for acne that does not promote bacterial resistance."", ""reference"": ""PMID:19761357"", ""snippet"": ""BPO-containing combinations do not induce bacterial resistance and are important first-line treatments for mild to moderate acne vulgaris."", ""supports"": ""SUPPORT""}], ""name"": ""Benzoyl peroxide"", ""treatment_term"": {""preferred_term"": ""antimicrobial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}], ""term"": {""id"": ""MAXO:0001021"", ""label"": ""antimicrobial agent therapy""}}}"
189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"																																																								"{""description"": ""Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.\n"", ""name"": ""Topical antibiotics""}"	{}	"{""description"": ""Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.\n"", ""evidence"": [{""explanation"": ""This systematic review confirms topical antibiotics as a cornerstone treatment for acne."", ""reference"": ""PMID:16086756"", ""snippet"": ""topical antibiotics remain one of the cornerstones of acne management"", ""supports"": ""SUPPORT""}], ""name"": ""Topical antibiotics"", ""treatment_term"": {""preferred_term"": ""antibacterial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""antibiotic"", ""term"": {""id"": ""NCIT:C258"", ""label"": ""Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}}"
190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"																																																								"{""description"": ""Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.\n"", ""name"": ""Clindamycin/adapalene/benzoyl peroxide gel""}"	{}	"{""description"": ""Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.\n"", ""evidence"": [{""explanation"": ""This pooled analysis supports long-term efficacy of the triple-combination gel."", ""reference"": ""PMID:41552868"", ""snippet"": ""At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both)."", ""supports"": ""SUPPORT""}], ""name"": ""Clindamycin/adapalene/benzoyl peroxide gel"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""clindamycin phosphate"", ""term"": {""id"": ""NCIT:C47978"", ""label"": ""Clindamycin Phosphate""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adapalene"", ""term"": {""id"": ""NCIT:C28989"", ""label"": ""Adapalene""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"																																																								"{""description"": ""Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.\n"", ""name"": ""Oral antibiotics""}"	{}	"{""description"": ""Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.\n"", ""evidence"": [{""explanation"": ""This systematic review confirms oral antibiotics as an established comparator treatment for acne in clinical trials."", ""reference"": ""PMID:28542914"", ""snippet"": ""isotretinoin therapy reduced acne lesion counts by a clinically relevant amount, and always by a greater amount than control, which was either placebo (two studies), oral antibiotics (seven studies) or other control"", ""supports"": ""SUPPORT""}, {""explanation"": ""This review documents antibiotic resistance concerns tied to prolonged acne antibiotic use, supporting stewardship in treatment."", ""reference"": ""PMID:36568833"", ""snippet"": ""The overuse of topical and/or systemic antibiotics, the long treatment courses used for acne, and the availability of over-the-counter antibiotic preparations, have led to the worldwide emergence of resistant strains in acne patients."", ""supports"": ""SUPPORT""}], ""name"": ""Oral antibiotics"", ""treatment_term"": {""preferred_term"": ""antibacterial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tetracycline antibiotic"", ""term"": {""id"": ""NCIT:C1595"", ""label"": ""Tetracycline Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}}"
192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"																																																								"{""description"": ""Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.\n"", ""name"": ""Oral isotretinoin""}"	{}	"{""description"": ""Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.\n"", ""evidence"": [{""explanation"": ""This systematic review confirms oral isotretinoin as the most effective treatment for moderate to severe acne."", ""reference"": ""PMID:33085149"", ""snippet"": ""Oral isotretinoin is the most effective treatment for moderate to severe acne and its side effects are mostly dose-dependent."", ""supports"": ""SUPPORT""}], ""name"": ""Oral isotretinoin"", ""treatment_term"": {""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""isotretinoin"", ""term"": {""id"": ""NCIT:C603"", ""label"": ""Isotretinoin""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}}"
193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"																																																								"{""description"": ""Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.\n"", ""name"": ""Hormonal therapy""}"	{}	"{""description"": ""Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.\n"", ""evidence"": [{""explanation"": ""This systematic review confirms the efficacy of hormonal therapies including oral contraceptives and spironolactone for treating acne in women."", ""reference"": ""PMID:28492054"", ""snippet"": ""Hormone-based therapies including combined oral contraceptive medications and spironolactone are considered effective therapies to treat adult acne in women."", ""supports"": ""SUPPORT""}], ""name"": ""Hormonal therapy"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""oral contraceptive"", ""term"": {""id"": ""NCIT:C389"", ""label"": ""Oral Contraceptive""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}], ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"																																																								"{""description"": ""Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.\n"", ""name"": ""Chemical peels""}"	{}	"{""description"": ""Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.\n"", ""evidence"": [{""explanation"": ""This review supports organic acid chemical peels as effective and safe adjuncts for acne-prone skin."", ""reference"": ""PMID:37894698"", ""snippet"": ""The findings of this comprehensive bibliographic review indicate that organic acid-based chemical peels represent effective and safe treatment options for individuals with acne-prone skin."", ""supports"": ""SUPPORT""}], ""name"": ""Chemical peels"", ""treatment_term"": {""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}}"
195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"																																																								"{""description"": ""Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.\n"", ""name"": ""Azelaic acid peel""}"	{}	"{""description"": ""Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.\n"", ""evidence"": [{""explanation"": ""This study reports acne lesion reduction and sebum normalization with 30% azelaic acid peels."", ""reference"": ""PMID:31455112"", ""snippet"": ""Peels with 30% AZA reduced acne lesions and normalized the activity of the sebaceous glands."", ""supports"": ""SUPPORT""}], ""name"": ""Azelaic acid peel"", ""treatment_term"": {""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azelaic acid"", ""term"": {""id"": ""NCIT:C47407"", ""label"": ""Azelaic Acid""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}}"
196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"																																																								"{""description"": ""Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.\n"", ""name"": ""Chemical peels for acne scarring""}"	{}	"{""description"": ""Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.\n"", ""evidence"": [{""explanation"": ""This split-face study supports TCA peels for improving acne scarring."", ""reference"": ""PMID:39483653"", ""snippet"": ""A 30% TCA peel is efficacious and well-tolerated for mild-to-moderate acne scars."", ""supports"": ""SUPPORT""}], ""name"": ""Chemical peels for acne scarring"", ""treatment_term"": {""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""glycolic acid"", ""term"": {""id"": ""NCIT:C83737"", ""label"": ""Glycolic Acid""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical trichloroacetic acid"", ""term"": {""id"": ""NCIT:C125002"", ""label"": ""Topical Trichloroacetic Acid""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}}"
197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"																																																								"{""description"": ""Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.\n"", ""name"": ""Ablative fractional CO2 laser""}"	{}	"{""description"": ""Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.\n"", ""evidence"": [{""explanation"": ""This trial background notes efficacy of CO2 laser for acne scars with notable side effects."", ""reference"": ""PMID:41521693"", ""snippet"": ""Ablative fractional CO2 laser is effective for acne scar treatment but is often associated with side effects such as erythema and dyspigmentation, along with prolonged recovery time."", ""supports"": ""SUPPORT""}], ""name"": ""Ablative fractional CO2 laser"", ""treatment_term"": {""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}}"
198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"																																																								"{""description"": ""Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.\n"", ""name"": ""Post-laser antioxidant serum""}"	{}	"{""description"": ""Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.\n"", ""evidence"": [{""explanation"": ""This split-face trial supports antioxidant serum use after CO2 laser for acne scars."", ""reference"": ""PMID:41521693"", ""snippet"": ""This study found that CE Ferulic led to enhanced wound healing, reduced erythema and melanin levels, and improved skin hydration following laser treatment, suggesting its beneficial application in combination with laser treatment to accelerate skin recovery."", ""supports"": ""SUPPORT""}], ""name"": ""Post-laser antioxidant serum"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vitamin C"", ""term"": {""id"": ""NCIT:C68507"", ""label"": ""Vitamin C""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical vitamin E"", ""term"": {""id"": ""NCIT:C67081"", ""label"": ""Topical Vitamin E""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"																																																								"{""description"": ""Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.\n"", ""name"": ""Blue light therapy""}"	{}	"{""description"": ""Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.\n"", ""evidence"": [{""explanation"": ""This systematic review reports clinical improvement in acne with blue light phototherapy."", ""reference"": ""PMID:34696155"", ""snippet"": ""Studies have shown significant improvements in the overall picture of acne."", ""supports"": ""SUPPORT""}], ""name"": ""Blue light therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"																																																								"{""description"": ""Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.\n"", ""name"": ""Visible light therapy""}"	{}	"{""description"": ""Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.\n"", ""evidence"": [{""explanation"": ""This systematic review summarizes lesion improvement across visible light studies in acne."", ""reference"": ""PMID:39056372"", ""snippet"": ""Overall, 92% of patients achieved partial remission of their acne lesions using visible light therapy."", ""supports"": ""SUPPORT""}], ""name"": ""Visible light therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"																																																								"{""description"": ""Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.\n"", ""name"": ""Photodynamic therapy""}"	{}	"{""description"": ""Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.\n"", ""evidence"": [{""explanation"": ""This review identifies acne as an emerging indication for photodynamic therapy with supportive evidence."", ""reference"": ""PMID:39226531"", ""snippet"": ""Newer indications, for which no approval has yet been granted, but which nevertheless have sufficient evidence of efficacy according to the study situation, are inflammatory (lichen sclerosus, acne) and infectious dermatoses (viral warts, cutaneous leishmaniasis, atypical mycobacteriosis)."", ""supports"": ""SUPPORT""}], ""name"": ""Photodynamic therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""photodynamic therapy"", ""term"": {""id"": ""NCIT:C15300"", ""label"": ""Photodynamic Therapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"																																																								"{""description"": ""Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.\n"", ""name"": ""Nd:YAG laser and intralesional PRP""}"	{}	"{""description"": ""Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.\n"", ""evidence"": [{""explanation"": ""This randomized split-face study supports Nd:YAG laser and PRP injections for inflammatory acne vulgaris."", ""reference"": ""PMID:35084634"", ""snippet"": ""The intralesional PRP injection and 1064 nm long-pulsed Nd:YAG laser are safe and effective methods for controlling inflammatory as well as non-inflammatory acne vulgaris in both adolescents and post-adolescent patients."", ""supports"": ""SUPPORT""}], ""name"": ""Nd:YAG laser and intralesional PRP"", ""treatment_term"": {""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""platelet-rich plasma"", ""term"": {""id"": ""NCIT:C106557"", ""label"": ""Platelet-rich Plasma""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}}"
203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"																																																								"{""description"": ""Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.\n"", ""name"": ""1726 nm laser therapy""}"	{}	"{""description"": ""Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.\n"", ""evidence"": [{""explanation"": ""This review highlights 1726 nm lasers as a sebaceous gland-targeted treatment approach for acne."", ""reference"": ""PMID:38271552"", ""snippet"": ""New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology."", ""supports"": ""SUPPORT""}], ""name"": ""1726 nm laser therapy"", ""treatment_term"": {""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""infrared laser therapy"", ""term"": {""id"": ""NCIT:C66918"", ""label"": ""Infrared Laser Therapy""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}}"
235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	Antiretroviral Therapy	Combination of drugs that suppress HIV replication and preserve immune function.																																																								"{""description"": ""Combination of drugs that suppress HIV replication and preserve immune function."", ""name"": ""Antiretroviral Therapy""}"	{}	"{""description"": ""Combination of drugs that suppress HIV replication and preserve immune function."", ""evidence"": [{""explanation"": ""This indicates that a combination of drugs is used to treat HIV by suppressing its replication and preserving immune function."", ""reference"": ""PMID:11218297"", ""snippet"": ""HIV patients who have detectable viral loads and/or evidence of immunologic dysfunction should be treated with a potent combination antiretroviral regimen."", ""supports"": ""SUPPORT""}, {""explanation"": ""Antiretroviral therapies suppress HIV replication, leading to immune restoration, although incomplete."", ""reference"": ""PMID:11424971"", ""snippet"": ""Suppression of HIV-1 replication results in both laboratory and clinical evidence of immune restoration."", ""supports"": ""SUPPORT""}, {""explanation"": ""While highlighting the side effects, it recognizes antiretroviral medications as a treatment strategy involving a combination of drugs."", ""reference"": ""PMID:21722892"", ""snippet"": ""Antiretroviral medications may have direct toxicity on gametes and embryos."", ""supports"": ""SUPPORT""}, {""explanation"": ""This suggests the need for a combination of drugs to effectively treat HIV."", ""reference"": ""PMID:2550525"", ""snippet"": ""Although many drugs have been developed, none appears singularly effective against all stages of HIV-1 infection."", ""supports"": ""SUPPORT""}, {""explanation"": ""This explicitly states that HAART is a combination of drugs used to treat HIV, aligning with the statement."", ""reference"": ""PMID:31237209"", ""snippet"": ""One of the key therapeutic strategies is Highly Active Antiretroviral Therapy (HAART) or 'AIDS cocktail' in a general sense, which is a customized combination of anti-retroviral drugs designed to combat the HIV infection."", ""supports"": ""SUPPORT""}], ""name"": ""Antiretroviral Therapy"", ""treatment_term"": {""preferred_term"": ""antiretroviral therapy"", ""term"": {""id"": ""MAXO:0000573"", ""label"": ""antiretroviral therapy""}}}"
236	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	1	Prophylaxis for Opportunistic Infections	Preventive treatments to reduce risk of common opportunistic infections.																																																								"{""description"": ""Preventive treatments to reduce risk of common opportunistic infections."", ""name"": ""Prophylaxis for Opportunistic Infections""}"	{}	"{""description"": ""Preventive treatments to reduce risk of common opportunistic infections."", ""evidence"": [{""explanation"": ""The abstract indicates that there are established guidelines for the use of prophylaxis to prevent opportunistic infections in HIV-infected patients, supporting the statement about preventive treatments."", ""reference"": ""PMID:9389311"", ""snippet"": ""The United States Public Health Service and the Infectious Diseases Society of America (USPHS/IDSA) have established disease-specific recommendations for use of prophylaxis for opportunistic infections in HIV-infected patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The document discusses common opportunistic infections in AIDS patients, implying the need for preventive treatments to reduce these risks."", ""reference"": ""PMID:2996829"", ""snippet"": ""The infections most commonly encountered in patients with AIDS are Pneumocystis carinii pneumonia (58%), Candida esophagitis (31%), toxoplasmosis (21%), cytomegalovirus infections (15%), and herpes-simplex virus infections (12%)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that patients were informed about opportunistic infections and treatments were adjusted as new medications became available, supporting the statement about the use of prophylaxis."", ""reference"": ""PMID:2729337"", ""snippet"": ""The subjects in this study are 24 women with AIDS who were treated by members of the Brown University medical faculty from June 1982 through June 1988... When zidovudine became available, it was administered to all remaining patients in the study. All subjects were counseled about HIV infection, its modes of transmission, and the early symptoms of opportunistic infections."", ""supports"": ""SUPPORT""}], ""name"": ""Prophylaxis for Opportunistic Infections"", ""treatment_term"": {""preferred_term"": ""preventative therapy"", ""term"": {""id"": ""MAXO:0000017"", ""label"": ""preventative therapy""}}}"
237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	Treatment of Opportunistic Infections	Specific therapies targeting diagnosed opportunistic infections.																																																								"{""description"": ""Specific therapies targeting diagnosed opportunistic infections."", ""name"": ""Treatment of Opportunistic Infections""}"	{}	"{""description"": ""Specific therapies targeting diagnosed opportunistic infections."", ""evidence"": [{""explanation"": ""The reference indicates that the treatment of opportunistic infections is a crucial aspect of HIV/AIDS management, supporting the statement that specific therapies target diagnosed opportunistic infections."", ""reference"": ""PMID:9336601"", ""snippet"": ""Nevertheless, the prevention, diagnosis, and treatment of opportunistic infections remain important features of management of HIV infection."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference mentions that treating opportunistic infections is a key component in the approaches to AIDS treatment, providing support for the statement."", ""reference"": ""PMID:2435201"", ""snippet"": ""Approaches to the treatment of AIDS have involved attempts to reestablish immune competence as well as treat opportunistic infections."", ""supports"": ""SUPPORT""}, {""explanation"": ""The document explains the importance of treating opportunistic infections, as they are the primary cause of mortality in AIDS patients, hence supporting the statement."", ""reference"": ""PMID:15119284"", ""snippet"": ""While HIV is the culprit, most people who die of AIDS do not die of HIV, per se, but from the numerous infections that the body can no longer control due to the collapse of the immune system."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the importance of recognizing and treating gastrointestinal infections in AIDS patients, supporting the use of specific therapies for opportunistic infections as mentioned in the statement."", ""reference"": ""PMID:9218066"", ""snippet"": ""Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""This documentation emphasizes the management of opportunistic infections in the context of HIV, supporting the statement."", ""reference"": ""PMID:32216642"", ""snippet"": ""The epidemiology and initial approach to diagnosis and treatment of HIV (including the newest antiretroviral guidelines), common syndromes and their management in the ICU, and typical comorbidities and opportunistic infections of patients with HIV infection are discussed."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study explicitly mentions the treatment of opportunistic infections with specific antimicrobial therapies, confirming support for the statement."", ""reference"": ""PMID:2729337"", ""snippet"": ""All opportunistic infections were treated by appropriate, specific antimicrobial therapy."", ""supports"": ""SUPPORT""}], ""name"": ""Treatment of Opportunistic Infections"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	Glucocorticoid Replacement	Hydrocortisone or prednisone to replace cortisol.																																																								"{""description"": ""Hydrocortisone or prednisone to replace cortisol."", ""name"": ""Glucocorticoid Replacement""}"	{}	"{""description"": ""Hydrocortisone or prednisone to replace cortisol."", ""evidence"": [{""explanation"": ""The statement mentions prednisone, but the reference specifically discusses hydrocortisone and cortisone acetate, not prednisone."", ""reference"": ""PMID:18363515"", ""snippet"": ""Starting doses of glucocorticoids should be 15 - 20 mg for hydrocortisone or 20 - 30 mg for cortisone acetate, divided into two or three doses, and preferentially weight-adjusted. There are indications that the synthetic glucocorticoids have undesirable metabolic long-term effects, which make them less suitable as first-line treatment."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference supports the use of hydrocortisone but does not mention prednisone."", ""reference"": ""PMID:22695777"", ""snippet"": ""This necessitated an aggressive volume therapy in addition to an initial therapy with 100 mg hydrocortisone, 8 g glucose and a continuous administration of catecholamines."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference supports the need for glucocorticoid replacement therapy but does not specify prednisone."", ""reference"": ""PMID:23624135"", ""snippet"": ""Patients with Addison's disease require lifelong treatment with glucocorticoids. At present, no glucocorticoid replacement therapy (GRT) can exactly mimic normal physiology."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference supports the need for glucocorticoid replacement but does not specify prednisone."", ""reference"": ""PMID:35100642"", ""snippet"": ""Addison's disease typically results from the autoimmune destruction of the adrenal cortex and requires lifelong replacement with glucocorticoids and mineralocorticoids."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference discusses prednisolone (a form of prednisone) but indicates higher mortality associated with its use in primary adrenal insufficiency."", ""reference"": ""PMID:33993277"", ""snippet"": ""In primary but not in secondary adrenal insufficiency, mortality was higher with prednisolone."", ""supports"": ""PARTIAL""}], ""name"": ""Glucocorticoid Replacement"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
273	10	Addison's Disease	Addisons_Disease.yaml	treatments	1	Mineralocorticoid Replacement	Fludrocortisone to replace aldosterone and manage electrolyte balance.																																																								"{""description"": ""Fludrocortisone to replace aldosterone and manage electrolyte balance."", ""name"": ""Mineralocorticoid Replacement""}"	{}	"{""description"": ""Fludrocortisone to replace aldosterone and manage electrolyte balance."", ""evidence"": [{""explanation"": ""The study indicates that fludrocortisone is used in the management of Addison's disease, although not all patients may require it for maintaining normal sodium balance."", ""reference"": ""PMID:476980"", ""snippet"": ""In four others, PRA remained normal throughout the study, even after fludrocortisone had been discontinued, suggesting that the drug was unnecessary for the maintenance of normal sodium balance in these patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms the use of fludrocortisone as part of the conventional therapy for Addison's disease."", ""reference"": ""PMID:24755997"", ""snippet"": ""Conventional steroid replacement for Addison's disease consists of twice or three-times daily oral hydrocortisone and once-daily fludrocortisone."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of mineralocorticoid replacement therapy, which includes fludrocortisone, for managing adrenal insufficiency."", ""reference"": ""PMID:25247653"", ""snippet"": ""Many of these patients suffer from adrenal insufficiency and have to take either glucocorticoids or a combination of glucocorticoid and mineralocorticoid replacement therapy from birth to avoid life-threatening complications."", ""supports"": ""SUPPORT""}], ""name"": ""Mineralocorticoid Replacement"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
274	10	Addison's Disease	Addisons_Disease.yaml	treatments	2	Salt Supplementation	Increased salt intake to manage hyponatremia.																																																								"{""description"": ""Increased salt intake to manage hyponatremia."", ""name"": ""Salt Supplementation""}"	{}	"{""description"": ""Increased salt intake to manage hyponatremia."", ""evidence"": [{""explanation"": ""The literature mentions the normalization of sodium concentration as part of the treatment for Addison's disease, which supports the statement about increased salt intake."", ""reference"": ""PMID:28132947"", ""snippet"": ""Treatment involves normalisation of sodium concentration and corticosteroids replacement."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates salt craving as a hallmark of Addison's disease, supporting the need for increased salt intake."", ""reference"": ""PMID:20964584"", ""snippet"": ""Primary adrenal insufficiency (i.e. Addison's disease) may well be recognized by clear hall-marks of the disease, such as pigmentation, salt craving, hypotension, and concomitant hyperkalemia."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this reference mentions mineral corticoids, which are related to sodium balance, it does not explicitly support or refute increased salt intake."", ""reference"": ""PMID:18471672"", ""snippet"": ""Mineral corticoids may be useful in complicated cases."", ""supports"": ""PARTIAL""}], ""name"": ""Salt Supplementation"", ""treatment_term"": {""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}}"
275	10	Addison's Disease	Addisons_Disease.yaml	treatments	3	Emergency Medical ID	Patients should carry an ID indicating their condition for emergency situations.																																																								"{""description"": ""Patients should carry an ID indicating their condition for emergency situations."", ""name"": ""Emergency Medical ID""}"	{}	"{""description"": ""Patients should carry an ID indicating their condition for emergency situations."", ""evidence"": [{""explanation"": ""The literature emphasizes the importance of emergency preparedness for Addison's patients, which implicitly supports the need for carrying an ID indicating their condition."", ""reference"": ""PMID:19776201"", ""snippet"": ""The endocrinologist has a responsibility to ensure that Addison's patients have adequate access to life-saving emergency injection materials and repeated, practical training sessions in how to use them, while the general practitioner plays a vital role as in arranging prompt emergency admissions."", ""supports"": ""SUPPORT""}, {""explanation"": ""The mention of continuous education and the ever-present danger of adrenal crisis supports the need for patients to carry an ID for emergency situations."", ""reference"": ""PMID:31321757"", ""snippet"": ""Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD."", ""supports"": ""SUPPORT""}], ""name"": ""Emergency Medical ID"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
276	10	Addison's Disease	Addisons_Disease.yaml	treatments	4	Stress Dose Adjustments	Increased dose of corticosteroids during illness or stress.																																																								"{""description"": ""Increased dose of corticosteroids during illness or stress."", ""name"": ""Stress Dose Adjustments""}"	{}	"{""description"": ""Increased dose of corticosteroids during illness or stress."", ""evidence"": [{""explanation"": ""The literature supports the need for increased doses of corticosteroids during illness or stress for patients with Addison's Disease."", ""reference"": ""PMID:18393745"", ""snippet"": ""Patients with adrenal insufficiency (AI) require additional glucocorticoid doses during surgery or medical illness, but there is no universally accepted regimen for glucocorticoid supplementation therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports the need for increased doses of corticosteroids during stress to prevent adrenal crisis."", ""reference"": ""PMID:29544234"", ""snippet"": ""An adrenal crisis (Addisonian crisis) is an acute life-threatening complication of adrenal insufficiency. It occurs when hydrocortisone demand is not met by supplementation in the context of an infection - often gastrointestinal, fever, trauma, acute psychological or physical stress."", ""supports"": ""SUPPORT""}], ""name"": ""Stress Dose Adjustments"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
302	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	0	Chemotherapy	Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease.																																																								"{""description"": ""Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease."", ""evidence"": [{""explanation"": ""Study shows chemotherapy alone achieves 49% response rate in aggressive ATLL, supporting modest efficacy."", ""reference"": ""PMID:22042945"", ""snippet"": ""The overall response rate ranged from 49% with chemotherapy alone to 81% with combined first-line therapy (chemotherapy with concurrent/sequential ZDV/IFN-)."", ""supports"": ""SUPPORT""}], ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
303	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	1	Mogamulizumab	Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression.																																																								"{""description"": ""Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression."", ""name"": ""Mogamulizumab""}"	{}	"{""description"": ""Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression."", ""evidence"": [{""explanation"": ""International phase II trial showed mogamulizumab demonstrated responses in relapsed/refractory ATLL where chemotherapy showed no activity."", ""reference"": ""PMID:30573506"", ""snippet"": ""mogamulizumab treatment resulted in 11% cORR, with a tolerable safety profile."", ""supports"": ""SUPPORT""}], ""name"": ""Mogamulizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
304	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients.																																																								"{""description"": ""Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients."", ""evidence"": [{""explanation"": ""Study confirms allo-SCT prolongs survival but notes limited candidates due to age and prior treatment response requirements."", ""reference"": ""PMID:30573506"", ""snippet"": ""Allogeneic stem cell transplantation (allo-SCT) can significantly prolong survival, but there are few appropriate candidates"", ""supports"": ""SUPPORT""}], ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
305	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	3	Interferon-alpha and Zidovudine	Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects.																																																								"{""description"": ""Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects."", ""name"": ""Interferon-alpha and Zidovudine""}"	{}	"{""description"": ""Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects."", ""evidence"": [{""explanation"": ""UK study demonstrated ZDV/IFN- significantly prolonged survival in both acute and lymphoma ATLL subtypes."", ""reference"": ""PMID:22042945"", ""snippet"": ""Use of ZDV/IFN- at any time prolonged survival in acute (P < .001) and lymphoma ATLL (P < .001) and was the sole factor associated with reduction in risk of death in aggressive ATLL"", ""supports"": ""SUPPORT""}], ""name"": ""Interferon-alpha and Zidovudine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
327	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	0	Surgical Resection	Hepatic resection is potentially curative for early-stage HCC with preserved liver function. Limited by underlying cirrhosis and multifocal disease in many aflatoxin-exposed populations.																																																								"{""description"": ""Hepatic resection is potentially curative for early-stage HCC with preserved liver function. Limited by underlying cirrhosis and multifocal disease in many aflatoxin-exposed populations."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Hepatic resection is potentially curative for early-stage HCC with preserved liver function. Limited by underlying cirrhosis and multifocal disease in many aflatoxin-exposed populations."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
328	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	1	Liver Transplantation	Curative option for early HCC within Milan criteria (single tumor <=5cm or up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease. Limited by organ availability.																																																								"{""description"": ""Curative option for early HCC within Milan criteria (single tumor <=5cm or up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease. Limited by organ availability."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""Curative option for early HCC within Milan criteria (single tumor <=5cm or up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease. Limited by organ availability."", ""name"": ""Liver Transplantation"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
329	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	2	Locoregional Therapy	Transarterial chemoembolization (TACE), radiofrequency ablation, or microwave ablation for unresectable tumors. Provides local control but not curative for advanced disease.																																																								"{""description"": ""Transarterial chemoembolization (TACE), radiofrequency ablation, or microwave ablation for unresectable tumors. Provides local control but not curative for advanced disease."", ""name"": ""Locoregional Therapy""}"	{}	"{""description"": ""Transarterial chemoembolization (TACE), radiofrequency ablation, or microwave ablation for unresectable tumors. Provides local control but not curative for advanced disease."", ""name"": ""Locoregional Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
330	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	3	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.																																																								"{""description"": ""Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy."", ""name"": ""Systemic Therapy""}"	{}	"{""description"": ""Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy."", ""name"": ""Systemic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sorafenib"", ""term"": {""id"": ""CHEBI:50924"", ""label"": ""sorafenib""}}]}}"
331	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	4	Aflatoxin Exposure Prevention	Public health interventions including proper grain storage, crop rotation, and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically reduces HCC incidence by eliminating the synergistic interaction.																																																								"{""description"": ""Public health interventions including proper grain storage, crop rotation, and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically reduces HCC incidence by eliminating the synergistic interaction."", ""name"": ""Aflatoxin Exposure Prevention""}"	{}	"{""description"": ""Public health interventions including proper grain storage, crop rotation, and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically reduces HCC incidence by eliminating the synergistic interaction."", ""name"": ""Aflatoxin Exposure Prevention"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
355	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	0	Anti-VEGF Injections	First-line for wet AMD (ranibizumab, aflibercept, bevacizumab).																																																								"{""description"": ""First-line for wet AMD (ranibizumab, aflibercept, bevacizumab)."", ""name"": ""Anti-VEGF Injections""}"	{}	"{""description"": ""First-line for wet AMD (ranibizumab, aflibercept, bevacizumab)."", ""evidence"": [{""explanation"": ""Demonstrates the efficacy of anti-VEGF therapy as first-line treatment for neovascular AMD, with significant preservation of visual acuity compared to placebo."", ""reference"": ""PMID:38193957"", ""snippet"": ""In exudative neovascular AMD, 94.6% of patients receiving monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections experience less than a 15-letter visual acuity loss after 12 months compared with 62.2% receiving sham treatment."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-VEGF Injections""}"
356	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	1	AREDS2 Supplements	Vitamins C, E, zinc, lutein, zeaxanthin slow dry AMD progression.																																																								"{""description"": ""Vitamins C, E, zinc, lutein, zeaxanthin slow dry AMD progression."", ""name"": ""AREDS2 Supplements""}"	{}	"{""description"": ""Vitamins C, E, zinc, lutein, zeaxanthin slow dry AMD progression."", ""evidence"": [{""explanation"": ""Quantifies the protective effect of AREDS-type nutritional supplementation in reducing progression to late-stage AMD by approximately 8 percentage points over 5 years."", ""reference"": ""PMID:38193957"", ""snippet"": ""Individuals with AMD who take nutritional supplements consisting of high-dose vitamin C, vitamin E, carotenoids, and zinc have a 20% probability to progress to late-stage AMD at 5 years vs a 28% probability for those taking a placebo."", ""supports"": ""SUPPORT""}], ""name"": ""AREDS2 Supplements""}"
357	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	2	Photodynamic Therapy	Rarely used now, for select wet AMD cases.																																																								"{""description"": ""Rarely used now, for select wet AMD cases."", ""name"": ""Photodynamic Therapy""}"	{}	"{""description"": ""Rarely used now, for select wet AMD cases."", ""name"": ""Photodynamic Therapy""}"
358	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	3	Low Vision Rehabilitation	Magnifiers, adaptive devices for advanced disease.																																																								"{""description"": ""Magnifiers, adaptive devices for advanced disease."", ""name"": ""Low Vision Rehabilitation""}"	{}	"{""description"": ""Magnifiers, adaptive devices for advanced disease."", ""name"": ""Low Vision Rehabilitation""}"
359	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	4	Complement Inhibitors	Pegcetacoplan for geographic atrophy (newer treatment).																																																								"{""description"": ""Pegcetacoplan for geographic atrophy (newer treatment)."", ""name"": ""Complement Inhibitors""}"	{}	"{""description"": ""Pegcetacoplan for geographic atrophy (newer treatment)."", ""name"": ""Complement Inhibitors""}"
360	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	treatments	5	Smoking Cessation	Reduces progression risk.																																																								"{""description"": ""Reduces progression risk."", ""name"": ""Smoking Cessation""}"	{}	"{""description"": ""Reduces progression risk."", ""name"": ""Smoking Cessation""}"
376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.																																																								"{""description"": ""Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure."", ""name"": ""Surgical excision of constriction band with disarticulation""}"	{}	"{""description"": ""Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report documents surgical excision and disarticulation as treatment."", ""reference"": ""PMID:31401977"", ""snippet"": ""She was managed surgically by excision of the band, disarticulated at right fifth metatarsophalangeal joint and skin closure."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical excision of constriction band with disarticulation"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
399	15	Akinetopsia	Akinetopsia.yaml	treatments	0	Treat underlying condition	Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant.																																																								"{""description"": ""Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant."", ""name"": ""Treat underlying condition""}"	{}	"{""description"": ""Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review indicates treatment success when targeting the underlying condition and resistance in organic lesions."", ""reference"": ""PMID:39996018"", ""snippet"": ""Treatments were mostly successful when they were aimed at the underlying condition, while cases due to organic lesions tended to be therapy-resistant."", ""supports"": ""SUPPORT""}], ""name"": ""Treat underlying condition"", ""treatment_term"": {""preferred_term"": ""medical action"", ""term"": {""id"": ""MAXO:0000001"", ""label"": ""medical action""}}}"
400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.																																																								"{""description"": ""Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability."", ""name"": ""Carbamazepine for seizure-related akinetopsia""}"	{}	"{""description"": ""Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This case report shows carbamazepine suppressed seizure-related akinetopsia."", ""reference"": ""PMID:25667833"", ""snippet"": ""We administered carbamazepine 200 mg/day, which suppressed his akinetopsic symptom completely."", ""supports"": ""SUPPORT""}], ""name"": ""Carbamazepine for seizure-related akinetopsia"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""carbamazepine"", ""term"": {""id"": ""CHEBI:3387"", ""label"": ""carbamazepine""}}]}}"
434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	Cholinesterase Inhibitors	Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).																																																								"{""description"": ""Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine)."", ""name"": ""Cholinesterase Inhibitors""}"	{}	"{""description"": ""Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine)."", ""evidence"": [{""explanation"": ""The literature supports that cholinesterase inhibitors, including donepezil and rivastigmine, are used to help with symptoms of Alzheimer's disease by slowing the progression and controlling cognitive symptoms."", ""reference"": ""PMID:24807367"", ""snippet"": ""Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports the use of cholinesterase inhibitors in delaying cognitive decline in Alzheimer's disease."", ""reference"": ""PMID:28671413"", ""snippet"": ""Cholinesterase inhibitors, memantine, and a combination of a cholinesterase inhibitor and memantine have produced statistically significant but clinically small delays in various domains of cognitive and functional decline in select patients with Alzheimer disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature confirms that cholinesterase inhibitors are licensed for use in Alzheimer's disease to alleviate symptoms and delay disease progression."", ""reference"": ""PMID:35608903"", ""snippet"": ""Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer''s disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports that cholinesterase inhibitors are approved symptomatic treatments for Alzheimer's disease."", ""reference"": ""PMID:36412156"", ""snippet"": ""Currently approved medications are symptomatic and include two classes: cholinesterase inhibitors, such as donepezil, and NMDA receptor antagonist memantine."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports that donepezil, a cholinesterase inhibitor, helps improve cognitive function in Alzheimer's disease."", ""reference"": ""PMID:9108896"", ""snippet"": ""Donepezil is a specific and potent acetylcholinesterase inhibitor... Donepezil 5 or 10 mg/day was associated with significant improvements in cognitive function."", ""supports"": ""SUPPORT""}], ""name"": ""Cholinesterase Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
435	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	1	NMDA Receptor Antagonist	Medication that regulates glutamate activity to improve symptoms (e.g., memantine).																																																								"{""description"": ""Medication that regulates glutamate activity to improve symptoms (e.g., memantine)."", ""name"": ""NMDA Receptor Antagonist""}"	{}	"{""description"": ""Medication that regulates glutamate activity to improve symptoms (e.g., memantine)."", ""evidence"": [{""explanation"": ""The abstract confirms that memantine, an NMDA receptor antagonist, is used to treat Alzheimer's Disease by regulating glutamate activity."", ""reference"": ""PMID:12768511"", ""snippet"": ""Memantine, an antagonist of the glutamatergic NMDA receptor, has been recently approved for the treatment of advanced AD. Due to its action mechanism, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies, and a useful symptomatic treatment for AD and vascular dementia."", ""supports"": ""SUPPORT""}, {""explanation"": ""This abstract highlights that memantine, an NMDA receptor antagonist, helps in blocking the negative effects of excessive NMDAR activity in Alzheimer's Disease."", ""reference"": ""PMID:27662322"", ""snippet"": ""Studies indicate that the distinct outcomes of NMDAR-mediated responses are induced by regionalized receptor activities, followed by different downstream signaling pathways. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of extrasynaptic NMDARs promotes cell death and thus contributes to the etiology of AD, which can be blocked by an AD drug, memantine, an NMDAR antagonist that selectively blocks the function of extrasynaptic NMDARs."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although primarily discussing Huntington's Disease, this abstract supports the idea that memantine, an NMDA receptor antagonist, regulates glutamate activity, which is relevant to Alzheimer's Disease treatment."", ""reference"": ""PMID:20943326"", ""snippet"": ""The hypothesis proposed is restoration of medium spiny neurons in Huntington's disease using neural progenitor cell implantation and attenuation of glutamate mediated excitotoxicity using a partial glutamate antagonist - Memantine. Memantine can block the NMDA receptors and will prevent excess calcium influx into the neurons decreases the vulnerability of medium spiny neurons to glutamate mediated excitotoxicity."", ""supports"": ""SUPPORT""}], ""name"": ""NMDA Receptor Antagonist"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	Cognitive Therapy	Non-pharmacological interventions to maintain cognitive function.																																																								"{""description"": ""Non-pharmacological interventions to maintain cognitive function."", ""name"": ""Cognitive Therapy""}"	{}	"{""description"": ""Non-pharmacological interventions to maintain cognitive function."", ""evidence"": [{""explanation"": ""This study specifically highlights the effectiveness of cognitive stimulation in maintaining cognitive functions in patients with moderate Alzheimer's disease."", ""reference"": ""PMID:35621327"", ""snippet"": ""Cognitive stimulation was found to be an effective intervention for people with moderate Alzheimer's disease because it helped to maintain memory function, executive functions, and attention."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by indicating that cognitive stimulation programs help maintain cognitive function in patients with mild to moderate Alzheimer's disease."", ""reference"": ""PMID:28671413"", ""snippet"": ""Cognitive stimulation programs show benefit in maintenance of cognitive function and improved self-reported quality of life in patients with mild to moderate Alzheimer disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference indicates that cognitive stimulation offers temporary benefits and might reduce dementia risk, but it is less clear about long-term maintenance of cognitive function specifically in Alzheimer's disease."", ""reference"": ""PMID:37428401"", ""snippet"": ""CS confers temporary, nonspecific benefits and might slightly reduce dementia risk for neurologically healthy individuals."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the utility of cognitive interventions in maintaining daily functioning, which is related to cognitive function, but does not directly address cognitive maintenance alone."", ""reference"": ""PMID:21643921"", ""snippet"": ""Mental training and cognitive stimulation interventions in AD have been shown to be useful in increasing patients' ability in performing activities of daily living (ADL), allowing them to maintain relative independence."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the statement by indicating that cognitive training, a form of cognitive therapy, has positive effects on cognition in older adults, including those with Alzheimer's disease."", ""reference"": ""PMID:27159433"", ""snippet"": ""Interventions involving physical exercise and cognitive training have consistently shown positive effects on cognition in older adults."", ""supports"": ""SUPPORT""}], ""name"": ""Cognitive Therapy"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
437	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	3	Supportive Care	Includes occupational therapy, speech therapy, and caregiver support.																																																								"{""description"": ""Includes occupational therapy, speech therapy, and caregiver support."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Includes occupational therapy, speech therapy, and caregiver support."", ""evidence"": [{""explanation"": ""The reference highlights the role of occupational therapy in supporting individuals with Alzheimer's disease, which aligns with the statement that includes occupational therapy as part of supportive care."", ""reference"": ""PMID:28809650"", ""snippet"": ""Occupational therapy practitioners play a significant role in supporting adults with Alzheimer's disease and related major neurocognitive disorders, as well as their caregivers, through all phases of the disease process."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the importance of caregiver support through telephone counseling, aligning with the statement that includes caregiver support as part of supportive care."", ""reference"": ""PMID:38883339"", ""snippet"": ""The telephone hotline is a useful component of dementia care in Germany and an important contribution to the National Dementia Strategy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the support needs of individuals with Alzheimer's disease and their caregivers, which aligns with the statement that includes caregiver support as part of supportive care."", ""reference"": ""PMID:29361068"", ""snippet"": ""This article first describes the educational, information, and support needs of individuals living dementia and their family caregivers across all stages of Alzheimer's."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference primarily discusses pharmacological treatments, with some mention of activities of daily living, but does not specifically address occupational therapy or speech therapy."", ""reference"": ""PMID:27651009"", ""snippet"": ""Cholinesterase inhibitors and memantine are used from 15 years, in Alzheimer's disease. Benefits have been demonstrated according to cognition, activities of daily living, affective symptoms and behavior, and global impression of change."", ""supports"": ""PARTIAL""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
438	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	4	Lifestyle Modifications	Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.																																																								"{""description"": ""Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression."", ""name"": ""Lifestyle Modifications""}"	{}	"{""description"": ""Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression."", ""evidence"": [{""explanation"": ""The review highlights the importance of mental and physical exercise in potentially slowing the progression of Alzheimer's disease."", ""reference"": ""PMID:35503939"", ""snippet"": ""The aim of this review is to emphasize the importance of mental activity and aerobic physical exercise as one of the most important health-related activities which may delay the onset or slow down the progression of Alzheimer's dementia."", ""supports"": ""SUPPORT""}, {""explanation"": ""The review suggests that a healthy diet can be a preventative measure for Alzheimer's disease, supporting the role of lifestyle modifications."", ""reference"": ""PMID:32579499"", ""snippet"": ""Combined with the prevention of AD risk factors such as heart disease, diabetes, and with more recent evidence, microbiome dysfunction, there is a substantial foundation for diet as a modifiable risk factor and preventative measure for AD."", ""supports"": ""SUPPORT""}, {""explanation"": ""The systematic review indicates that lifestyle factors such as diet and physical activities may protect against cognitive decline, supporting the statement."", ""reference"": ""PMID:37321363"", ""snippet"": ""Results showed that eating a healthy diet with plenty of fruits and vegetables, and participation in leisure and physical activities may protect against cognitive decline and cognitive impairment among oldest-old regardless of the APOE genotype."", ""supports"": ""SUPPORT""}, {""explanation"": ""The intervention described combines lifestyle modifications and memory support to improve cognitive health, supporting the statement."", ""reference"": ""PMID:38129775"", ""snippet"": ""Rehabilitation approaches to support memory and behavioral/lifestyle interventions are recognized as promising strategies for preserving or improving cognitive health."", ""supports"": ""SUPPORT""}], ""name"": ""Lifestyle Modifications"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
452	18	Alopecia Areata	Alopecia_Areata.yaml	treatments	0	Topical Corticosteroids	First-line for limited disease.																																																								"{""description"": ""First-line for limited disease."", ""name"": ""Topical Corticosteroids""}"	{}	"{""description"": ""First-line for limited disease."", ""name"": ""Topical Corticosteroids""}"
453	18	Alopecia Areata	Alopecia_Areata.yaml	treatments	1	Intralesional Corticosteroids	For localized patches.																																																								"{""description"": ""For localized patches."", ""name"": ""Intralesional Corticosteroids""}"	{}	"{""description"": ""For localized patches."", ""name"": ""Intralesional Corticosteroids""}"
454	18	Alopecia Areata	Alopecia_Areata.yaml	treatments	2	JAK Inhibitors	Baricitinib FDA-approved for severe alopecia areata.																																																								"{""description"": ""Baricitinib FDA-approved for severe alopecia areata."", ""name"": ""JAK Inhibitors""}"	{}	"{""description"": ""Baricitinib FDA-approved for severe alopecia areata."", ""name"": ""JAK Inhibitors""}"
455	18	Alopecia Areata	Alopecia_Areata.yaml	treatments	3	Topical Immunotherapy	DPCP or SADBE for extensive disease.																																																								"{""description"": ""DPCP or SADBE for extensive disease."", ""name"": ""Topical Immunotherapy""}"	{}	"{""description"": ""DPCP or SADBE for extensive disease."", ""name"": ""Topical Immunotherapy""}"
472	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	0	Alpha-1 Antitrypsin Augmentation Therapy	"Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.
"																																																								"{""description"": ""Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.\n"", ""name"": ""Alpha-1 Antitrypsin Augmentation Therapy""}"	{}	"{""description"": ""Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.\n"", ""evidence"": [{""explanation"": ""This review describes augmentation therapy as the specific treatment for alpha-1 antitrypsin deficiency."", ""reference"": ""PMID:22500781"", ""snippet"": ""Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT)."", ""supports"": ""SUPPORT""}], ""name"": ""Alpha-1 Antitrypsin Augmentation Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
473	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	1	Smoking Cessation	"Absolute avoidance of smoking is critical as tobacco smoke accelerates lung destruction by increasing neutrophil burden and oxidizing AAT.
"																																																								"{""description"": ""Absolute avoidance of smoking is critical as tobacco smoke accelerates lung destruction by increasing neutrophil burden and oxidizing AAT.\n"", ""name"": ""Smoking Cessation""}"	{}	"{""description"": ""Absolute avoidance of smoking is critical as tobacco smoke accelerates lung destruction by increasing neutrophil burden and oxidizing AAT.\n"", ""evidence"": [{""explanation"": ""Establishes smoking as a major modifiable risk factor that significantly increases emphysema risk in AAT deficiency"", ""reference"": ""PMID:35715315"", ""snippet"": ""Assessed by CO transfer alteration and CT scan, risk of pulmonary emphysema is increased by tobacco consumption."", ""supports"": ""SUPPORT""}], ""name"": ""Smoking Cessation""}"
474	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	2	Bronchodilators	"Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.
"																																																								"{""description"": ""Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.\n"", ""name"": ""Bronchodilators""}"	{}	"{""description"": ""Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.\n"", ""evidence"": [{""explanation"": ""Confirms inhaled bronchodilators as part of standard treatment guidelines for AAT deficiency-related COPD"", ""reference"": ""PMID:34356027"", ""snippet"": ""Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines."", ""supports"": ""SUPPORT""}], ""name"": ""Bronchodilators"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
475	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	3	Lung Transplantation	"For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.
"																																																								"{""description"": ""For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.\n"", ""name"": ""Lung Transplantation""}"	{}	"{""description"": ""For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.\n"", ""evidence"": [{""explanation"": ""Establishes lung transplantation as appropriate therapeutic option for end-stage AAT deficiency-related emphysema"", ""reference"": ""PMID:20301692"", ""snippet"": ""Lung transplantation may be an appropriate option for individuals with end-stage lung disease."", ""supports"": ""SUPPORT""}], ""name"": ""Lung Transplantation"", ""treatment_term"": {""preferred_term"": ""transplantation procedure"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}}"
476	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	4	Liver Transplantation	"For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.
"																																																								"{""description"": ""For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.\n"", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.\n"", ""evidence"": [{""explanation"": ""Establishes liver transplantation as definitive curative treatment that restores normal AAT production from donor liver"", ""reference"": ""PMID:20301692"", ""snippet"": ""Liver transplantation is the definitive treatment for severe disease (will restore AAT levels)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Documents excellent outcomes in AAT deficiency patients undergoing liver transplantation"", ""reference"": ""PMID:33824927"", ""snippet"": ""Rarely, patients require liver transplant and typically the patient outcomes are excellent."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms liver transplantation as essential therapeutic option for severe ZZ genotype liver disease"", ""reference"": ""PMID:37144533"", ""snippet"": ""PiZZ individuals harbor an up to 20 times higher risk of liver fibrosis and cirrhosis than noncarriers and liver transplantation is currently the only available therapeutic option."", ""supports"": ""SUPPORT""}, {""explanation"": ""Documents that heterozygous donors can be successfully used for AAT deficiency recipients, expanding available donor options"", ""reference"": ""PMID:36808684"", ""snippet"": ""Our case provides initial evidence that A1ATD heterozygote donors may be safely used for pediatric patients with A1ATD, thus expanding the donor pool."", ""supports"": ""SUPPORT""}], ""name"": ""Liver Transplantation"", ""treatment_term"": {""preferred_term"": ""transplantation procedure"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}}"
493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.																																																								"{""description"": ""Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease."", ""name"": ""Multi-Agent Chemotherapy""}"	{}	"{""description"": ""Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease."", ""name"": ""Multi-Agent Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}}"
494	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	1	Surgical Resection	Complete surgical resection with negative margins when feasible without excessive morbidity. Surgery may be delayed until after chemotherapy to facilitate resection.																																																								"{""description"": ""Complete surgical resection with negative margins when feasible without excessive morbidity. Surgery may be delayed until after chemotherapy to facilitate resection."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Complete surgical resection with negative margins when feasible without excessive morbidity. Surgery may be delayed until after chemotherapy to facilitate resection."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
495	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	2	Radiation Therapy	Radiation therapy is used for local control, particularly when complete surgical resection is not possible or margins are positive.																																																								"{""description"": ""Radiation therapy is used for local control, particularly when complete surgical resection is not possible or margins are positive."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Radiation therapy is used for local control, particularly when complete surgical resection is not possible or margins are positive."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
508	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	0	Cholinesterase Inhibitors	Medications such as donepezil, rivastigmine, and galantamine that inhibit acetylcholinesterase to increase acetylcholine availability in the brain, providing modest symptomatic improvement in cognitive function.																																																								"{""description"": ""Medications such as donepezil, rivastigmine, and galantamine that inhibit acetylcholinesterase to increase acetylcholine availability in the brain, providing modest symptomatic improvement in cognitive function."", ""name"": ""Cholinesterase Inhibitors""}"	{}	"{""description"": ""Medications such as donepezil, rivastigmine, and galantamine that inhibit acetylcholinesterase to increase acetylcholine availability in the brain, providing modest symptomatic improvement in cognitive function."", ""name"": ""Cholinesterase Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
509	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	1	NMDA Receptor Antagonist	Memantine blocks NMDA receptors to reduce glutamate excitotoxicity and may provide modest cognitive and functional benefits, particularly in moderate to severe Alzheimer's disease.																																																								"{""description"": ""Memantine blocks NMDA receptors to reduce glutamate excitotoxicity and may provide modest cognitive and functional benefits, particularly in moderate to severe Alzheimer's disease."", ""name"": ""NMDA Receptor Antagonist""}"	{}	"{""description"": ""Memantine blocks NMDA receptors to reduce glutamate excitotoxicity and may provide modest cognitive and functional benefits, particularly in moderate to severe Alzheimer's disease."", ""name"": ""NMDA Receptor Antagonist"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
510	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	2	Cognitive Stimulation and Rehabilitation	Non-pharmacological interventions including cognitive training, reality orientation, and memory rehabilitation to maintain cognitive function and quality of life.																																																								"{""description"": ""Non-pharmacological interventions including cognitive training, reality orientation, and memory rehabilitation to maintain cognitive function and quality of life."", ""name"": ""Cognitive Stimulation and Rehabilitation""}"	{}	"{""description"": ""Non-pharmacological interventions including cognitive training, reality orientation, and memory rehabilitation to maintain cognitive function and quality of life."", ""name"": ""Cognitive Stimulation and Rehabilitation"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
549	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	0	Riluzole	"Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
"																																																								"{""description"": ""Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.\n"", ""name"": ""Riluzole""}"	{}	"{""description"": ""Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.\n"", ""evidence"": [{""explanation"": ""Landmark trial demonstrating riluzole's survival benefit in ALS patients."", ""reference"": ""PMID:8302340"", ""snippet"": ""The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset."", ""supports"": ""SUPPORT""}], ""name"": ""Riluzole"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
550	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	1	Edaravone	"Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.
"																																																								"{""description"": ""Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.\n"", ""name"": ""Edaravone""}"	{}	"{""description"": ""Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.\n"", ""evidence"": [{""explanation"": ""Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients."", ""reference"": ""PMID:28522181"", ""snippet"": ""Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo."", ""supports"": ""SUPPORT""}, {""explanation"": ""Real-world cohort study found long-term intravenous edaravone well tolerated but without additional disease-modifying benefit versus standard therapy."", ""reference"": ""PMID:35006266"", ""snippet"": ""although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit."", ""supports"": ""REFUTE""}], ""name"": ""Edaravone"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
551	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	2	Tofersen	"Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.
"																																																								"{""description"": ""Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.\n"", ""name"": ""Tofersen""}"	{}	"{""description"": ""Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.\n"", ""evidence"": [{""explanation"": ""Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients."", ""reference"": ""PMID:32640130"", ""snippet"": ""In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks."", ""supports"": ""SUPPORT""}], ""name"": ""Tofersen"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
552	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	3	Non-invasive Ventilation	"Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.
"																																																								"{""description"": ""Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.\n"", ""name"": ""Non-invasive Ventilation""}"	{}	"{""description"": ""Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.\n"", ""evidence"": [{""explanation"": ""Randomized controlled trial demonstrated non-invasive ventilation improves quality of life and extends survival in ALS patients with preserved bulbar function."", ""reference"": ""PMID:16426990"", ""snippet"": ""This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period."", ""supports"": ""SUPPORT""}], ""name"": ""Non-invasive Ventilation"", ""treatment_term"": {""preferred_term"": ""noninvasive ventilation"", ""term"": {""id"": ""MAXO:0000506"", ""label"": ""noninvasive ventilation""}}}"
553	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	4	Physical Therapy	"Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.
"																																																								"{""description"": ""Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.\n"", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.\n"", ""evidence"": [{""explanation"": ""Review describes how rehabilitation including physical therapy helps maximize independence and function in ALS patients."", ""reference"": ""PMID:24510737"", ""snippet"": ""Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."", ""supports"": ""SUPPORT""}], ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
554	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	5	Speech Therapy	"Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.
"																																																								"{""description"": ""Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.\n"", ""name"": ""Speech Therapy""}"	{}	"{""description"": ""Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.\n"", ""evidence"": [{""explanation"": ""Review covers multidisciplinary rehabilitation including speech therapy for ALS patients."", ""reference"": ""PMID:24510737"", ""snippet"": ""This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, and to minimize disease-related symptoms."", ""supports"": ""SUPPORT""}], ""name"": ""Speech Therapy"", ""treatment_term"": {""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}}"
555	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	6	Percutaneous Endoscopic Gastrostomy	"Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.
"																																																								"{""description"": ""Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.\n"", ""name"": ""Percutaneous Endoscopic Gastrostomy""}"	{}	"{""description"": ""Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.\n"", ""evidence"": [{""explanation"": ""Dysphagia management review underscores PEG as an essential intervention when nutrition is compromised in ALS."", ""reference"": ""PMID:39207520"", ""snippet"": ""Early discussion of potential treatments such as high-calorie diets or percutaneous endoscopic gastrostomy (PEG) is crucial."", ""supports"": ""SUPPORT""}], ""name"": ""Percutaneous Endoscopic Gastrostomy"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
556	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	7	Multidisciplinary Care	"Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.
"																																																								"{""description"": ""Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.\n"", ""name"": ""Multidisciplinary Care""}"	{}	"{""description"": ""Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.\n"", ""evidence"": [{""explanation"": ""Rehabilitation review emphasizes multidisciplinary care as core to ALS management to optimize function and quality of life."", ""reference"": ""PMID:24510737"", ""snippet"": ""Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."", ""supports"": ""SUPPORT""}], ""name"": ""Multidisciplinary Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
569	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	treatments	0	NSAIDs	First-line therapy for symptom control.																																																								"{""description"": ""First-line therapy for symptom control."", ""name"": ""NSAIDs""}"	{}	"{""description"": ""First-line therapy for symptom control."", ""name"": ""NSAIDs""}"
570	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	treatments	1	TNF Inhibitors	For inadequate response to NSAIDs.																																																								"{""description"": ""For inadequate response to NSAIDs."", ""name"": ""TNF Inhibitors""}"	{}	"{""description"": ""For inadequate response to NSAIDs."", ""name"": ""TNF Inhibitors""}"
571	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	treatments	2	IL-17 Inhibitors	Secukinumab, ixekizumab for active disease.																																																								"{""description"": ""Secukinumab, ixekizumab for active disease."", ""name"": ""IL-17 Inhibitors""}"	{}	"{""description"": ""Secukinumab, ixekizumab for active disease."", ""evidence"": [{""explanation"": ""Clinical trial evidence demonstrating the efficacy of secukinumab, an IL-17A inhibitor, in treating ankylosing spondylitis."", ""reference"": ""PMID:33692806"", ""snippet"": ""The MEASURE trials demonstrated the superiority of Secukinumab against placebo in providing sustained efficacy in relieving signs and symptoms of AS as well as in granting a good retention rate, as demonstrated in the 5-years extension study (135, 136)."", ""supports"": ""SUPPORT""}], ""name"": ""IL-17 Inhibitors""}"
572	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	treatments	3	Physical Therapy	Essential for maintaining mobility and posture.																																																								"{""description"": ""Essential for maintaining mobility and posture."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Essential for maintaining mobility and posture."", ""name"": ""Physical Therapy""}"
616	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	0	Cranial Vault Remodeling	"Surgical release and reshaping of the skull to relieve intracranial pressure and improve cranial shape. Often performed in infancy with additional procedures as needed during growth.
"																																																								"{""description"": ""Surgical release and reshaping of the skull to relieve intracranial pressure and improve cranial shape. Often performed in infancy with additional procedures as needed during growth.\n"", ""name"": ""Cranial Vault Remodeling""}"	{}	"{""description"": ""Surgical release and reshaping of the skull to relieve intracranial pressure and improve cranial shape. Often performed in infancy with additional procedures as needed during growth.\n"", ""name"": ""Cranial Vault Remodeling"", ""treatment_term"": {""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
617	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	1	Midface Advancement	"Le Fort III or monobloc osteotomy to advance the midface, improving appearance, airway, and occlusion. Often performed in childhood or adolescence.
"																																																								"{""description"": ""Le Fort III or monobloc osteotomy to advance the midface, improving appearance, airway, and occlusion. Often performed in childhood or adolescence.\n"", ""name"": ""Midface Advancement""}"	{}	"{""description"": ""Le Fort III or monobloc osteotomy to advance the midface, improving appearance, airway, and occlusion. Often performed in childhood or adolescence.\n"", ""name"": ""Midface Advancement"", ""treatment_term"": {""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
618	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	2	Syndactyly Release	"Staged surgical separation of fused digits to improve hand function. Multiple procedures typically required.
"																																																								"{""description"": ""Staged surgical separation of fused digits to improve hand function. Multiple procedures typically required.\n"", ""name"": ""Syndactyly Release""}"	{}	"{""description"": ""Staged surgical separation of fused digits to improve hand function. Multiple procedures typically required.\n"", ""name"": ""Syndactyly Release"", ""treatment_term"": {""preferred_term"": ""Hand surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
642	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	0	Estrogen Replacement Therapy	Corrects estrogen deficiency and supports normal sexual development and bone health.																																																								"{""description"": ""Corrects estrogen deficiency and supports normal sexual development and bone health."", ""name"": ""Estrogen Replacement Therapy""}"	{}	"{""description"": ""Corrects estrogen deficiency and supports normal sexual development and bone health."", ""evidence"": [{""explanation"": ""The statement claims that estrogen replacement therapy corrects estrogen deficiency and supports bone health. The literature provided supports this by indicating that estradiol replacement leads to skeletal maturation."", ""reference"": ""PMID:18448329"", ""snippet"": ""The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms that estrogen replacement therapy aids in normal sexual development."", ""reference"": ""PMID:26680580"", ""snippet"": ""The overall goal of pubertal sex hormone replacement therapy (HRT) in girls is not only about development of secondary sexual characteristics, but also to establish an adult endocrine and metabolic milieu."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study elaborates on the role of estrogen in bone health, using data from aromatase-deficient subjects to underline its significance."", ""reference"": ""PMID:18567553"", ""snippet"": ""Findings from estrogen-resistant and aromatase-deficient men have provided important insights into the role of estrogen in the male skeleton during growth."", ""supports"": ""SUPPORT""}], ""name"": ""Estrogen Replacement Therapy"", ""treatment_term"": {""description"": ""Therapeutic administration of estrogen to replace deficient endogenous hormone production."", ""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
643	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	1	Antiandrogen Therapy	Adjunctive treatment to mitigate virilization from androgen excess using agents like spironolactone or flutamide.																																		Used in combination with estrogen replacement to counter virilization																						"{""description"": ""Adjunctive treatment to mitigate virilization from androgen excess using agents like spironolactone or flutamide."", ""name"": ""Antiandrogen Therapy"", ""notes"": ""Used in combination with estrogen replacement to counter virilization""}"	{}	"{""description"": ""Adjunctive treatment to mitigate virilization from androgen excess using agents like spironolactone or flutamide."", ""name"": ""Antiandrogen Therapy"", ""notes"": ""Used in combination with estrogen replacement to counter virilization"", ""treatment_term"": {""description"": ""Drug therapy using antiandrogens to block androgen effects and reduce virilization."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
644	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	2	Surgical Management	May be considered for ambiguous genitalia or other anatomical abnormalities.																																																								"{""description"": ""May be considered for ambiguous genitalia or other anatomical abnormalities."", ""name"": ""Surgical Management""}"	{}	"{""description"": ""May be considered for ambiguous genitalia or other anatomical abnormalities."", ""evidence"": [{""explanation"": ""The literature does not mention surgical management as a treatment for aromatase deficiency. Instead, it suggests hormonal replacement therapy as the primary treatment."", ""reference"": ""PMID:19707181"", ""snippet"": ""Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1. Transdermal estradiol treatment at a daily dose of about 25 microg might be adequate for lifelong replacement therapy."", ""supports"": ""REFUTE""}, {""explanation"": ""This literature discusses hormone therapy for transgender individuals but does not specifically address surgical management for ambiguous genitalia or other anatomical abnormalities in the context of aromatase deficiency."", ""reference"": ""PMID:32990485"", ""snippet"": ""Transgender individuals are those whose gender identity differs from that recorded at birth...clinicians can provide hormone therapy (HT) to bring sex hormone levels to the range associated with the patient''s gender identity."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Surgical Management"", ""treatment_term"": {""description"": ""Operative intervention for anatomical abnormalities such as ambiguous genitalia."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
665	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	0	Exposure Cessation	Elimination of arsenic exposure is the primary intervention. Providing clean water through wells drilled to arsenic-free aquifers, water treatment systems, or alternative sources dramatically reduces ongoing exposure and may stabilize premalignant lesions.																																		Public health interventions including arsenic testing of water sources, provision of arsenic-free water, and community education are critical.																						"{""description"": ""Elimination of arsenic exposure is the primary intervention. Providing clean water through wells drilled to arsenic-free aquifers, water treatment systems, or alternative sources dramatically reduces ongoing exposure and may stabilize premalignant lesions."", ""name"": ""Exposure Cessation"", ""notes"": ""Public health interventions including arsenic testing of water sources, provision of arsenic-free water, and community education are critical.""}"	{}	"{""description"": ""Elimination of arsenic exposure is the primary intervention. Providing clean water through wells drilled to arsenic-free aquifers, water treatment systems, or alternative sources dramatically reduces ongoing exposure and may stabilize premalignant lesions."", ""name"": ""Exposure Cessation"", ""notes"": ""Public health interventions including arsenic testing of water sources, provision of arsenic-free water, and community education are critical.""}"
666	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	1	Surgical Excision	Surgical removal of skin cancers and premalignant keratoses. May require multiple procedures given multiplicity of lesions. Mohs surgery for invasive carcinomas in cosmetically sensitive areas.																																																								"{""description"": ""Surgical removal of skin cancers and premalignant keratoses. May require multiple procedures given multiplicity of lesions. Mohs surgery for invasive carcinomas in cosmetically sensitive areas."", ""name"": ""Surgical Excision""}"	{}	"{""description"": ""Surgical removal of skin cancers and premalignant keratoses. May require multiple procedures given multiplicity of lesions. Mohs surgery for invasive carcinomas in cosmetically sensitive areas."", ""name"": ""Surgical Excision"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
667	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	2	Topical Therapy	Topical 5-fluorouracil or imiquimod for superficial lesions and field therapy of areas with multiple keratoses. Photodynamic therapy is also effective for widespread lesions.																																																								"{""description"": ""Topical 5-fluorouracil or imiquimod for superficial lesions and field therapy of areas with multiple keratoses. Photodynamic therapy is also effective for widespread lesions."", ""name"": ""Topical Therapy""}"	{}	"{""description"": ""Topical 5-fluorouracil or imiquimod for superficial lesions and field therapy of areas with multiple keratoses. Photodynamic therapy is also effective for widespread lesions."", ""name"": ""Topical Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
668	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	3	Systemic Cancer Treatment	Standard treatment protocols for lung cancer (surgery, chemotherapy, immunotherapy, radiation) and bladder cancer (TURBT, intravesical therapy, cystectomy, systemic chemotherapy) based on stage and tumor characteristics.																																																								"{""description"": ""Standard treatment protocols for lung cancer (surgery, chemotherapy, immunotherapy, radiation) and bladder cancer (TURBT, intravesical therapy, cystectomy, systemic chemotherapy) based on stage and tumor characteristics."", ""name"": ""Systemic Cancer Treatment""}"	{}	"{""description"": ""Standard treatment protocols for lung cancer (surgery, chemotherapy, immunotherapy, radiation) and bladder cancer (TURBT, intravesical therapy, cystectomy, systemic chemotherapy) based on stage and tumor characteristics."", ""name"": ""Systemic Cancer Treatment"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
669	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	4	Surveillance	Regular dermatologic examination for early detection of skin cancers. Lung cancer surveillance with low-dose CT in high-risk individuals. Urinalysis and cystoscopy for bladder cancer surveillance in heavily exposed populations.																																		Cancer surveillance is critical for early detection given long latency period and high cancer risk in heavily exposed populations.																						"{""description"": ""Regular dermatologic examination for early detection of skin cancers. Lung cancer surveillance with low-dose CT in high-risk individuals. Urinalysis and cystoscopy for bladder cancer surveillance in heavily exposed populations."", ""name"": ""Surveillance"", ""notes"": ""Cancer surveillance is critical for early detection given long latency period and high cancer risk in heavily exposed populations.""}"	{}	"{""description"": ""Regular dermatologic examination for early detection of skin cancers. Lung cancer surveillance with low-dose CT in high-risk individuals. Urinalysis and cystoscopy for bladder cancer surveillance in heavily exposed populations."", ""name"": ""Surveillance"", ""notes"": ""Cancer surveillance is critical for early detection given long latency period and high cancer risk in heavily exposed populations.""}"
711	28	Asthma	Asthma.yaml	treatments	0	Inhaled Corticosteroid	Reduce inflammation and prevent flare-ups.																																																								"{""description"": ""Reduce inflammation and prevent flare-ups."", ""name"": ""Inhaled Corticosteroid""}"	{}	"{""description"": ""Reduce inflammation and prevent flare-ups."", ""evidence"": [{""explanation"": ""This literature supports the statement that inhaled corticosteroids reduce inflammation in asthma."", ""reference"": ""PMID:22559870"", ""snippet"": ""Current guidelines recommend long-term treatment with inhaled corticosteroids (ICS) because of their superior effectiveness in managing the chronic airway inflammation that characterizes persistent asthma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the role of glucocorticoids, which includes inhaled corticosteroids, in reducing airway inflammation in asthma."", ""reference"": ""PMID:9817746"", ""snippet"": ""Glucocorticoids are highly effective in the control of asthma and suppression of airway inflammation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This guideline indicates that inhaled corticosteroids are recommended for improving asthma outcomes, supporting their role in preventing flare-ups."", ""reference"": ""PMID:32868307"", ""snippet"": ""The 2019 Global Initiative for Asthma (GINA) guidelines recommend that all asthma patients be treated with inhaled corticosteroids taken daily or as needed; this improves symptoms and outcomes, even in those with mild disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The findings indicate that early treatment with inhaled corticosteroids reduces lung inflammation and helps prevent further complications, such as reduced breathing pattern complexity, supporting their role in preventive care."", ""reference"": ""PMID:37182593"", ""snippet"": ""Early treatment with inhaled corticosteroids not only diminishes lung inflammation and airway hyper-responsiveness, but also has a protective effect against the reduction of breathing pattern complexity due to asthma."", ""supports"": ""SUPPORT""}], ""name"": ""Inhaled Corticosteroid"", ""treatment_term"": {""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}}"
712	28	Asthma	Asthma.yaml	treatments	1	Long-acting Beta Agonist	Relax the muscles around the airways.																																																								"{""description"": ""Relax the muscles around the airways."", ""name"": ""Long-acting Beta Agonist""}"	{}	"{""description"": ""Relax the muscles around the airways."", ""evidence"": [{""explanation"": ""The literature supports that LABAs help in relaxing the muscles around the airways, thereby improving lung function and providing symptomatic relief in asthma management."", ""reference"": ""PMID:34753370"", ""snippet"": ""Patients experience significant clinical benefits from therapy with long-acting 2-agonists (LABAs) with efficacy to bronchodilate, and prolonged lung function betterment."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although primarily about LAMAs, the literature acknowledges that LABAs are part of the recommended treatment regimen for asthma, which implies their role in relaxing airway muscles."", ""reference"": ""PMID:37489386"", ""snippet"": ""Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting beta2-agonists (ICS + LABA)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates that LABAs, as bronchodilators, help control symptoms related to airway obstruction by relaxing the airway muscles."", ""reference"": ""PMID:32306788"", ""snippet"": ""Contemporary mainstay therapies (inhaled corticosteroids and bronchodilators), prescribed empirically, control symptoms resulting from airways obstruction tolerably well in many patients..."", ""supports"": ""SUPPORT""}], ""name"": ""Long-acting Beta Agonist"", ""treatment_term"": {""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}}"
713	28	Asthma	Asthma.yaml	treatments	2	Leukotriene Modifier	Reduce inflammation, decrease mucus secretion, and prevent airway constriction.																																																								"{""description"": ""Reduce inflammation, decrease mucus secretion, and prevent airway constriction."", ""name"": ""Leukotriene Modifier""}"	{}	"{""description"": ""Reduce inflammation, decrease mucus secretion, and prevent airway constriction."", ""evidence"": [{""reference"": ""PMID:14720013"", ""snippet"": ""Leukotriene modifiers increase the therapeutic options for patients with asthma and, based on recent data, it is expected that future guidelines will describe expanded uses for these agents in clinical circumstances where these drugs are effective."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:11085767"", ""snippet"": ""Their unique mechanism of action results in a combination of both bronchodilator and anti-inflammatory effects."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:19180262"", ""snippet"": ""Cysteinyl leukotrienes, which are derivatives of the 5-lipoxygenase pathway of arachidonic acid metabolism, are important mediators of airway allergic inflammation and have a role in the pathogenetic mechanism of EIB. Montelukast sodium (Singulair, Merck & Co.) is a selective and orally active leukotriene receptor antagonist with demonstrated activity for treating asthma and allergic rhinitis."", ""supports"": ""SUPPORT""}], ""name"": ""Leukotriene Modifier"", ""treatment_term"": {""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}}"
714	28	Asthma	Asthma.yaml	treatments	3	Anti-IgE Therapy	Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response.																																																								"{""description"": ""Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response."", ""name"": ""Anti-IgE Therapy""}"	{}	"{""description"": ""Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response."", ""evidence"": [{""explanation"": ""This reference confirms that anti-IgE therapy is used to treat severe allergic asthma."", ""reference"": ""PMID:29427989"", ""snippet"": ""Severe allergic asthma and severe eosinophilic asthma are two defined phenotypes for which there are efficacious targeted biologic therapies currently available, namely anti-immunoglobulin E (IgE) and anti-interleukin (IL)-5 antibodies, respectively."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports that anti-IgE therapy is used in allergic asthma by targeting and reducing IgE."", ""reference"": ""PMID:20799475"", ""snippet"": ""Among these is anti-IgE, which directly targets IgE serum antibodies, thus inhibiting the central mechanism of immediate type hypersensitivity reactions. Application of anti-IgE antibodies effectively reduces IgE serum levels regardless of allergen specificity."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that anti-IgE therapy, specifically using omalizumab, is effective in treating allergic asthma."", ""reference"": ""PMID:28635659"", ""snippet"": ""Blocking IgE with monoclonal antibodies such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic asthma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference further supports the efficacy of anti-IgE therapy (omalizumab) in treating severe allergic asthma by improving symptoms and reducing exacerbations."", ""reference"": ""PMID:21114196"", ""snippet"": ""Omalizumab improves quality of life of patients with severe persistent allergic asthma that is inadequately controlled by currently available asthma medications. This therapy is well tolerated and significantly improves symptoms, disease control, reducing asthma exacerbations and the need to use high dosage of inhaled corticosteroids."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-IgE Therapy"", ""treatment_term"": {""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}}"
715	28	Asthma	Asthma.yaml	treatments	4	Short-acting Beta Agonist	Provides rapid relief from acute asthma symptoms.																																												Added Short-acting Beta Agonist for completeness in treatment options.												"{""description"": ""Provides rapid relief from acute asthma symptoms."", ""name"": ""Short-acting Beta Agonist"", ""review_notes"": ""Added Short-acting Beta Agonist for completeness in treatment options.""}"	{}	"{""description"": ""Provides rapid relief from acute asthma symptoms."", ""evidence"": [{""explanation"": ""Albuterol, a commonly used short-acting beta agonist, is indicated as a fast-acting medication for the relief of asthma symptoms."", ""reference"": ""PMID:34369231"", ""snippet"": ""Albuterol is the most common fast acting medication for asthma, and it exists in multiple forms, including metered-dose inhaler and nebulized therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""Short-acting beta agonists are recommended as initial therapy for the control of asthma symptoms, indicating their rapid relief properties."", ""reference"": ""PMID:30297688"", ""snippet"": ""Initial therapy in the stepwise approach for asthma management is short-acting -agonist (SABA) therapy as needed for symptom control."", ""supports"": ""SUPPORT""}, {""explanation"": ""The efficacy of SABAs as a first-line therapy in emergency asthma management highlights their role in providing rapid relief from acute asthma symptoms."", ""reference"": ""PMID:27588581"", ""snippet"": ""Results demonstrate the efficacy of short-acting beta-agonist (SABA) delivered by metered-dose inhaler as first-line therapy for younger and older children."", ""supports"": ""SUPPORT""}, {""explanation"": ""The use of quick-relief medication, such as SABAs, by a majority of patients for asthma management is based on their rapid onset of action."", ""reference"": ""PMID:32482150"", ""snippet"": ""A majority of patients uses daily quick-relief medication, with the belief that it is the most important treatment because of its rapid onset of action."", ""supports"": ""SUPPORT""}, {""explanation"": ""Levalbuterol, a single-isomer beta-agonist, is shown to provide effective rapid bronchodilation for asthma management."", ""reference"": ""PMID:11253864"", ""snippet"": ""Clinical studies comparing the effectiveness of (R)-albuterol (levalbuterol) with racemic albuterol established a strong rationale for using single-isomer beta-agonists in place of the racemic mixture: reduced dosages provide equivalent bronchodilatory effects with fewer beta-mediated side effects."", ""supports"": ""SUPPORT""}], ""name"": ""Short-acting Beta Agonist"", ""review_notes"": ""Added Short-acting Beta Agonist for completeness in treatment options."", ""treatment_term"": {""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}}"
741	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	0	Anticoagulation	Warfarin or DOACs to prevent stroke based on CHA2DS2-VASc score.																																																								"{""description"": ""Warfarin or DOACs to prevent stroke based on CHA2DS2-VASc score."", ""name"": ""Anticoagulation""}"	{}	"{""description"": ""Warfarin or DOACs to prevent stroke based on CHA2DS2-VASc score."", ""evidence"": [{""explanation"": ""Meta-analysis of 132,980 patients demonstrates DOACs reduce stroke risk in AF patients."", ""reference"": ""PMID:37573616"", ""snippet"": ""DOAC was associated with a significantly lower risk of stroke or systemic embolism (hazard ratio 0.85, 95% confidence interval 0.75 to 0.96, p = 0.008, I2 = 0%), major bleeding, intracranial hemorrhage, and mortality compared with warfarin."", ""supports"": ""SUPPORT""}], ""name"": ""Anticoagulation"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
742	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	1	Rate Control	Beta blockers, calcium channel blockers, or digoxin.																																																								"{""description"": ""Beta blockers, calcium channel blockers, or digoxin."", ""name"": ""Rate Control""}"	{}	"{""description"": ""Beta blockers, calcium channel blockers, or digoxin."", ""name"": ""Rate Control"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
743	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	2	Rhythm Control	Antiarrhythmic drugs (amiodarone, flecainide, sotalol).																																																								"{""description"": ""Antiarrhythmic drugs (amiodarone, flecainide, sotalol)."", ""name"": ""Rhythm Control""}"	{}	"{""description"": ""Antiarrhythmic drugs (amiodarone, flecainide, sotalol)."", ""name"": ""Rhythm Control"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
744	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	3	Catheter Ablation	Pulmonary vein isolation for rhythm control.																																																								"{""description"": ""Pulmonary vein isolation for rhythm control."", ""name"": ""Catheter Ablation""}"	{}	"{""description"": ""Pulmonary vein isolation for rhythm control."", ""name"": ""Catheter Ablation"", ""treatment_term"": {""preferred_term"": ""radiofrequency ablation therapy"", ""term"": {""id"": ""MAXO:0001395"", ""label"": ""radiofrequency ablation therapy""}}}"
745	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	4	Cardioversion	Electrical or pharmacological restoration of sinus rhythm.																																																								"{""description"": ""Electrical or pharmacological restoration of sinus rhythm."", ""name"": ""Cardioversion""}"	{}	"{""description"": ""Electrical or pharmacological restoration of sinus rhythm."", ""name"": ""Cardioversion""}"
746	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	5	Left Atrial Appendage Closure	Alternative to anticoagulation in selected patients.																																																								"{""description"": ""Alternative to anticoagulation in selected patients."", ""name"": ""Left Atrial Appendage Closure""}"	{}	"{""description"": ""Alternative to anticoagulation in selected patients."", ""name"": ""Left Atrial Appendage Closure""}"
747	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	6	Risk Factor Modification	Weight loss, blood pressure control, sleep apnea treatment.																																																								"{""description"": ""Weight loss, blood pressure control, sleep apnea treatment."", ""name"": ""Risk Factor Modification""}"	{}	"{""description"": ""Weight loss, blood pressure control, sleep apnea treatment."", ""name"": ""Risk Factor Modification""}"
762	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	0	Antifungal Therapy	"Antifungal medications such as fluconazole (100 mg/day for 3 weeks) are first-line therapy for fungal ABS. Nystatin and micafungin are alternatives for refractory cases.
"																																																								"{""description"": ""Antifungal medications such as fluconazole (100 mg/day for 3 weeks) are first-line therapy for fungal ABS. Nystatin and micafungin are alternatives for refractory cases.\n"", ""name"": ""Antifungal Therapy""}"	{}	"{""description"": ""Antifungal medications such as fluconazole (100 mg/day for 3 weeks) are first-line therapy for fungal ABS. Nystatin and micafungin are alternatives for refractory cases.\n"", ""evidence"": [{""explanation"": ""Antifungal medication is a standard treatment for GFS."", ""reference"": ""PMID:33887125"", ""snippet"": ""Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms antifungal drugs are part of standard treatment approach."", ""reference"": ""PMID:34682761"", ""snippet"": ""Treatment typically includes antifungal drugs combined with changes in lifestyle and nutrition."", ""supports"": ""SUPPORT""}], ""name"": ""Antifungal Therapy"", ""treatment_term"": {""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
763	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	1	Low Carbohydrate Diet	"Dietary modification to restrict carbohydrate intake reduces substrate available for microbial fermentation. High-protein diets are recommended with initial complete carbohydrate elimination for approximately 6 weeks.
"																																																								"{""description"": ""Dietary modification to restrict carbohydrate intake reduces substrate available for microbial fermentation. High-protein diets are recommended with initial complete carbohydrate elimination for approximately 6 weeks.\n"", ""name"": ""Low Carbohydrate Diet""}"	{}	"{""description"": ""Dietary modification to restrict carbohydrate intake reduces substrate available for microbial fermentation. High-protein diets are recommended with initial complete carbohydrate elimination for approximately 6 weeks.\n"", ""evidence"": [{""explanation"": ""Low-carbohydrate diet was part of successful treatment regimen."", ""reference"": ""PMID:37060744"", ""snippet"": ""Treatments with antibiotics, a complex probiotic preparation and a low-carbohydrate diet not only alleviated ABS, but also erased ABS relapse during the follow-up observation of one of the patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""Low carbohydrate diet is a recognized treatment approach."", ""reference"": ""PMID:33887125"", ""snippet"": ""Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics."", ""supports"": ""SUPPORT""}], ""name"": ""Low Carbohydrate Diet"", ""treatment_term"": {""preferred_term"": ""Dietary Intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
764	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	2	Probiotic Therapy	"Administration of probiotics containing Lactobacillus species to restore healthy gut microbiome balance and compete with fermenting organisms.
"																																																								"{""description"": ""Administration of probiotics containing Lactobacillus species to restore healthy gut microbiome balance and compete with fermenting organisms.\n"", ""name"": ""Probiotic Therapy""}"	{}	"{""description"": ""Administration of probiotics containing Lactobacillus species to restore healthy gut microbiome balance and compete with fermenting organisms.\n"", ""evidence"": [{""explanation"": ""Complex probiotic preparations were part of successful treatment."", ""reference"": ""PMID:37060744"", ""snippet"": ""Treatments with antibiotics, a complex probiotic preparation and a low-carbohydrate diet not only alleviated ABS"", ""supports"": ""SUPPORT""}, {""explanation"": ""Probiotics are a recognized treatment option."", ""reference"": ""PMID:33887125"", ""snippet"": ""Current treatments for GFS include antibiotics, antifungal medication, low carbohydrate diet, and probiotics."", ""supports"": ""SUPPORT""}], ""name"": ""Probiotic Therapy""}"
765	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	3	Fecal Microbiota Transplantation	"FMT has emerged as a promising option for refractory cases by restoring normal gut microbiome composition and diversity.
"																																																								"{""description"": ""FMT has emerged as a promising option for refractory cases by restoring normal gut microbiome composition and diversity.\n"", ""name"": ""Fecal Microbiota Transplantation""}"	{}	"{""description"": ""FMT has emerged as a promising option for refractory cases by restoring normal gut microbiome composition and diversity.\n"", ""evidence"": [{""explanation"": ""FMT is suggested as a potential treatment for refractory cases."", ""reference"": ""PMID:33887125"", ""snippet"": ""There might be a potential role of fecal microbiota transplant in the treatment of GFS."", ""supports"": ""SUPPORT""}], ""name"": ""Fecal Microbiota Transplantation"", ""treatment_term"": {""preferred_term"": ""Fecal Microbiota Transplantation"", ""term"": {""id"": ""MAXO:0000748"", ""label"": ""fecal microbiota transplantation""}}}"
778	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	treatments	0	Corticosteroids	First-line for warm AIHA.																																																								"{""description"": ""First-line for warm AIHA."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""First-line for warm AIHA."", ""name"": ""Corticosteroids""}"
779	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	treatments	1	Rituximab	Second-line, high response rates.																																																								"{""description"": ""Second-line, high response rates."", ""name"": ""Rituximab""}"	{}	"{""description"": ""Second-line, high response rates."", ""name"": ""Rituximab""}"
780	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	treatments	2	Splenectomy	For refractory warm AIHA.																																																								"{""description"": ""For refractory warm AIHA."", ""name"": ""Splenectomy""}"	{}	"{""description"": ""For refractory warm AIHA."", ""name"": ""Splenectomy""}"
781	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	treatments	3	Complement Inhibitors	Sutimlimab for cold agglutinin disease.																																																								"{""description"": ""Sutimlimab for cold agglutinin disease."", ""name"": ""Complement Inhibitors""}"	{}	"{""description"": ""Sutimlimab for cold agglutinin disease."", ""name"": ""Complement Inhibitors""}"
797	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	treatments	0	Corticosteroids	Prednisone or budesonide for induction.																																																								"{""description"": ""Prednisone or budesonide for induction."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Prednisone or budesonide for induction."", ""name"": ""Corticosteroids""}"
798	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	treatments	1	Azathioprine	Maintenance therapy, allows steroid reduction.																																																								"{""description"": ""Maintenance therapy, allows steroid reduction."", ""name"": ""Azathioprine""}"	{}	"{""description"": ""Maintenance therapy, allows steroid reduction."", ""name"": ""Azathioprine""}"
799	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	treatments	2	Mycophenolate Mofetil	For azathioprine-intolerant patients.																																																								"{""description"": ""For azathioprine-intolerant patients."", ""name"": ""Mycophenolate Mofetil""}"	{}	"{""description"": ""For azathioprine-intolerant patients."", ""name"": ""Mycophenolate Mofetil""}"
800	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	treatments	3	Liver Transplantation	For decompensated cirrhosis or treatment failure.																																																								"{""description"": ""For decompensated cirrhosis or treatment failure."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""For decompensated cirrhosis or treatment failure."", ""name"": ""Liver Transplantation""}"
824	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	0	Glaucoma Pharmacotherapy	Topical medications to reduce intraocular pressure, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. First-line treatment for glaucoma management.																																																								"{""description"": ""Topical medications to reduce intraocular pressure, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. First-line treatment for glaucoma management."", ""name"": ""Glaucoma Pharmacotherapy""}"	{}	"{""description"": ""Topical medications to reduce intraocular pressure, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. First-line treatment for glaucoma management."", ""evidence"": [{""explanation"": ""This reference supports the use of medications as first-line treatment for managing glaucoma in patients."", ""reference"": ""PMID:18929112"", ""snippet"": ""Treatment for glaucoma consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent further optic-nerve damage. Currently available treatments include topical drug (single then multidrug combinations) followed, for those patients on maximal tolerated medical therapy who still need additional IOP reduction, by laser treatments."", ""supports"": ""SUPPORT""}], ""name"": ""Glaucoma Pharmacotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
825	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	1	Glaucoma Surgery	Surgical interventions including trabeculectomy, tube shunt procedures, and angle surgery to control intraocular pressure when medical therapy is insufficient. Surgery is frequently required in ARS-associated glaucoma, particularly in FOXC1-related cases with early onset.																																																								"{""description"": ""Surgical interventions including trabeculectomy, tube shunt procedures, and angle surgery to control intraocular pressure when medical therapy is insufficient. Surgery is frequently required in ARS-associated glaucoma, particularly in FOXC1-related cases with early onset."", ""name"": ""Glaucoma Surgery""}"	{}	"{""description"": ""Surgical interventions including trabeculectomy, tube shunt procedures, and angle surgery to control intraocular pressure when medical therapy is insufficient. Surgery is frequently required in ARS-associated glaucoma, particularly in FOXC1-related cases with early onset."", ""evidence"": [{""explanation"": ""The study discusses various surgical interventions for managing intraocular pressure in patients with Axenfeld-Rieger syndrome."", ""reference"": ""PMID:32357855"", ""snippet"": ""The goal of this study is to compare the effectiveness of various glaucoma surgeries on intraocular pressure (IOP) management in ARS."", ""supports"": ""SUPPORT""}, {""explanation"": ""The case report supports the use of laser and surgical therapy as part of the management for Axenfeld-Rieger syndrome."", ""reference"": ""PMID:33881269"", ""snippet"": ""The article describes a case of 7-year-old child with rare Axenfeld-Rieger syndrome demonstrating the effectiveness and safety of combined laser reconstructive surgeries."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms that surgical management is used for refractory glaucoma cases in ARS."", ""reference"": ""PMID:35733478"", ""snippet"": ""Treatment is predominantly the management of glaucoma and is mostly medical but can be surgical in refractory cases."", ""supports"": ""SUPPORT""}], ""name"": ""Glaucoma Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
826	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	2	Dental Management	Orthodontic and dental treatments to address dental anomalies including hypodontia, microdontia, and enamel hypoplasia. May include prosthetic reconstruction, dental implants, and orthodontic correction.																																																								"{""description"": ""Orthodontic and dental treatments to address dental anomalies including hypodontia, microdontia, and enamel hypoplasia. May include prosthetic reconstruction, dental implants, and orthodontic correction."", ""name"": ""Dental Management""}"	{}	"{""description"": ""Orthodontic and dental treatments to address dental anomalies including hypodontia, microdontia, and enamel hypoplasia. May include prosthetic reconstruction, dental implants, and orthodontic correction."", ""evidence"": [{""explanation"": ""The reference discusses the dental anomalies in Axenfeld-Rieger syndrome and the importance of early diagnosis and interdisciplinary treatment, aligning with the statement about orthodontic and dental treatments to address these anomalies."", ""reference"": ""PMID:22104715"", ""snippet"": ""The patient showed severe hypodontia, microdontia, and short roots. Different treatment options are discussed. Early diagnosis and an interdisciplinary approach are necessary to provide the best short- and long-term treatment plans, as well as treatment and follow-up for individuals with the syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference indicates the management of Axenfeld-Rieger syndrome, which includes addressing dental anomalies, supporting the statement about orthodontic and dental treatments."", ""reference"": ""PMID:33487449"", ""snippet"": ""The management of a Moroccan family with Axenfeld-Rieger syndrome."", ""supports"": ""SUPPORT""}], ""name"": ""Dental Management"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
827	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	3	Regular Ophthalmic Monitoring	Frequent eye exams to monitor intraocular pressure, visual acuity, and anterior segment changes. Essential for early detection and management of glaucoma progression, particularly in pediatric patients.																																																								"{""description"": ""Frequent eye exams to monitor intraocular pressure, visual acuity, and anterior segment changes. Essential for early detection and management of glaucoma progression, particularly in pediatric patients."", ""name"": ""Regular Ophthalmic Monitoring""}"	{}	"{""description"": ""Frequent eye exams to monitor intraocular pressure, visual acuity, and anterior segment changes. Essential for early detection and management of glaucoma progression, particularly in pediatric patients."", ""evidence"": [{""explanation"": ""The literature emphasizes the importance of regular ophthalmic monitoring for managing glaucoma and other ocular issues in Axenfeld-Rieger syndrome."", ""reference"": ""PMID:36926528"", ""snippet"": ""A multi-disciplinary approach including glaucoma specialists and pediatric ophthalmologists produces optimal outcomes as vision is dependent on many factors including glaucoma, refractive error, amblyopia and strabismus."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference emphasizes the critical importance of regular comprehensive ophthalmologic examinations for ARS patients."", ""reference"": ""PMID:33367186"", ""snippet"": ""Glaucoma is the main cause of visual morbidity in patients with ARS, therefore a complete periodic ophthalmological exam is a priority."", ""supports"": ""SUPPORT""}], ""name"": ""Regular Ophthalmic Monitoring""}"
841	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with or without lymph node dissection is the primary treatment for papillary thyroid cancer regardless of BRAF status. Extent of surgery guided by tumor size and nodal involvement.																																																								"{""description"": ""Total thyroidectomy with or without lymph node dissection is the primary treatment for papillary thyroid cancer regardless of BRAF status. Extent of surgery guided by tumor size and nodal involvement."", ""name"": ""Thyroidectomy""}"	{}	"{""description"": ""Total thyroidectomy with or without lymph node dissection is the primary treatment for papillary thyroid cancer regardless of BRAF status. Extent of surgery guided by tumor size and nodal involvement."", ""name"": ""Thyroidectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
842	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	1	Radioiodine Therapy	Adjuvant radioactive iodine (I-131) therapy is used for intermediate and high-risk disease. BRAF-mutant tumors may have reduced radioiodine avidity due to dedifferentiation and NIS suppression.																																																								"{""description"": ""Adjuvant radioactive iodine (I-131) therapy is used for intermediate and high-risk disease. BRAF-mutant tumors may have reduced radioiodine avidity due to dedifferentiation and NIS suppression."", ""name"": ""Radioiodine Therapy""}"	{}	"{""description"": ""Adjuvant radioactive iodine (I-131) therapy is used for intermediate and high-risk disease. BRAF-mutant tumors may have reduced radioiodine avidity due to dedifferentiation and NIS suppression."", ""name"": ""Radioiodine Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.																																																								"{""description"": ""Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer."", ""name"": ""Dabrafenib Plus Trametinib""}"	{}	"{""description"": ""Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer."", ""name"": ""Dabrafenib Plus Trametinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dabrafenib"", ""term"": {""id"": ""CHEBI:75045"", ""label"": ""dabrafenib""}}, {""preferred_term"": ""trametinib"", ""term"": {""id"": ""CHEBI:75998"", ""label"": ""trametinib""}}]}}"
844	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	3	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.																																																								"{""description"": ""Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed."", ""name"": ""Lenvatinib or Sorafenib""}"	{}	"{""description"": ""Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed."", ""name"": ""Lenvatinib or Sorafenib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}}"
862	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	0	Encorafenib plus Cetuximab	FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON CRC trial demonstrated significant improvement in overall survival and response rate compared to standard chemotherapy.																																																								"{""description"": ""FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON CRC trial demonstrated significant improvement in overall survival and response rate compared to standard chemotherapy."", ""name"": ""Encorafenib plus Cetuximab""}"	{}	"{""description"": ""FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON CRC trial demonstrated significant improvement in overall survival and response rate compared to standard chemotherapy."", ""name"": ""Encorafenib plus Cetuximab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
863	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	1	Encorafenib plus Cetuximab plus Binimetinib	Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab. Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity.																																																								"{""description"": ""Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab. Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity."", ""name"": ""Encorafenib plus Cetuximab plus Binimetinib""}"	{}	"{""description"": ""Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab. Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity."", ""name"": ""Encorafenib plus Cetuximab plus Binimetinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
864	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	2	FOLFOXIRI plus Bevacizumab	Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive therapy. TRIBE2 showed benefit in this subgroup.																																																								"{""description"": ""Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive therapy. TRIBE2 showed benefit in this subgroup."", ""name"": ""FOLFOXIRI plus Bevacizumab""}"	{}	"{""description"": ""Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive therapy. TRIBE2 showed benefit in this subgroup."", ""name"": ""FOLFOXIRI plus Bevacizumab"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
865	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	3	Surgical Resection	Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have attenuated benefit.																																																								"{""description"": ""Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have attenuated benefit."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have attenuated benefit."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
879	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	0	Dabrafenib plus Trametinib	Combination of BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E NSCLC. Combination prevents paradoxical MAPK activation and delays resistance compared to BRAF inhibitor alone. Approved based on BRF113928 trial.																																																								"{""description"": ""Combination of BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E NSCLC. Combination prevents paradoxical MAPK activation and delays resistance compared to BRAF inhibitor alone. Approved based on BRF113928 trial."", ""name"": ""Dabrafenib plus Trametinib""}"	{}	"{""description"": ""Combination of BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E NSCLC. Combination prevents paradoxical MAPK activation and delays resistance compared to BRAF inhibitor alone. Approved based on BRF113928 trial."", ""name"": ""Dabrafenib plus Trametinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
880	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	1	Dabrafenib Monotherapy	BRAF inhibitor with activity against V600E mutant. Generally used in combination with trametinib for improved efficacy and reduced paradoxical activation.																																																								"{""description"": ""BRAF inhibitor with activity against V600E mutant. Generally used in combination with trametinib for improved efficacy and reduced paradoxical activation."", ""name"": ""Dabrafenib Monotherapy""}"	{}	"{""description"": ""BRAF inhibitor with activity against V600E mutant. Generally used in combination with trametinib for improved efficacy and reduced paradoxical activation."", ""name"": ""Dabrafenib Monotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
881	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	2	Encorafenib plus Binimetinib	Alternative BRAF/MEK inhibitor combination approved for other V600E tumors (melanoma, colorectal). May be considered for BRAF V600E NSCLC based on mechanism of action.																																																								"{""description"": ""Alternative BRAF/MEK inhibitor combination approved for other V600E tumors (melanoma, colorectal). May be considered for BRAF V600E NSCLC based on mechanism of action."", ""name"": ""Encorafenib plus Binimetinib""}"	{}	"{""description"": ""Alternative BRAF/MEK inhibitor combination approved for other V600E tumors (melanoma, colorectal). May be considered for BRAF V600E NSCLC based on mechanism of action."", ""name"": ""Encorafenib plus Binimetinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
882	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for BRAF V600E NSCLC, though targeted therapy with dabrafenib/trametinib is generally preferred given high response rates.																																																								"{""description"": ""Checkpoint inhibitors may be used for BRAF V600E NSCLC, though targeted therapy with dabrafenib/trametinib is generally preferred given high response rates."", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""Checkpoint inhibitors may be used for BRAF V600E NSCLC, though targeted therapy with dabrafenib/trametinib is generally preferred given high response rates."", ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
883	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy used at progression on targeted therapy or when targeted therapy is contraindicated.																																																								"{""description"": ""Platinum-based chemotherapy used at progression on targeted therapy or when targeted therapy is contraindicated."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy used at progression on targeted therapy or when targeted therapy is contraindicated."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
893	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	0	Dabrafenib plus Trametinib	First-line targeted therapy combining BRAF inhibitor dabrafenib with MEK inhibitor trametinib. Combination therapy achieves higher response rates (approximately 70%) and longer duration of response compared to BRAF inhibitor monotherapy, while reducing paradoxical MAPK activation and cutaneous squamous cell carcinomas.																																																								"{""description"": ""First-line targeted therapy combining BRAF inhibitor dabrafenib with MEK inhibitor trametinib. Combination therapy achieves higher response rates (approximately 70%) and longer duration of response compared to BRAF inhibitor monotherapy, while reducing paradoxical MAPK activation and cutaneous squamous cell carcinomas."", ""name"": ""Dabrafenib plus Trametinib""}"	{}	"{""description"": ""First-line targeted therapy combining BRAF inhibitor dabrafenib with MEK inhibitor trametinib. Combination therapy achieves higher response rates (approximately 70%) and longer duration of response compared to BRAF inhibitor monotherapy, while reducing paradoxical MAPK activation and cutaneous squamous cell carcinomas."", ""name"": ""Dabrafenib plus Trametinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
894	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	1	Vemurafenib plus Cobimetinib	Alternative BRAF plus MEK inhibitor combination. Vemurafenib was the first BRAF inhibitor approved for melanoma. Combined with the MEK inhibitor cobimetinib to improve efficacy and reduce paradoxical activation side effects.																																																								"{""description"": ""Alternative BRAF plus MEK inhibitor combination. Vemurafenib was the first BRAF inhibitor approved for melanoma. Combined with the MEK inhibitor cobimetinib to improve efficacy and reduce paradoxical activation side effects."", ""name"": ""Vemurafenib plus Cobimetinib""}"	{}	"{""description"": ""Alternative BRAF plus MEK inhibitor combination. Vemurafenib was the first BRAF inhibitor approved for melanoma. Combined with the MEK inhibitor cobimetinib to improve efficacy and reduce paradoxical activation side effects."", ""name"": ""Vemurafenib plus Cobimetinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
895	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	2	Encorafenib plus Binimetinib	Third-generation BRAF plus MEK inhibitor combination offering improved tolerability profile. Encorafenib has a longer half-life than other BRAF inhibitors, potentially reducing dosing frequency.																																																								"{""description"": ""Third-generation BRAF plus MEK inhibitor combination offering improved tolerability profile. Encorafenib has a longer half-life than other BRAF inhibitors, potentially reducing dosing frequency."", ""name"": ""Encorafenib plus Binimetinib""}"	{}	"{""description"": ""Third-generation BRAF plus MEK inhibitor combination offering improved tolerability profile. Encorafenib has a longer half-life than other BRAF inhibitors, potentially reducing dosing frequency."", ""name"": ""Encorafenib plus Binimetinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
896	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are also effective in BRAF-mutant melanoma. The optimal sequencing of targeted therapy versus immunotherapy remains an active area of investigation.																																																								"{""description"": ""Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are also effective in BRAF-mutant melanoma. The optimal sequencing of targeted therapy versus immunotherapy remains an active area of investigation."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are also effective in BRAF-mutant melanoma. The optimal sequencing of targeted therapy versus immunotherapy remains an active area of investigation."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
909	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	0	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.																																																								"{""description"": ""PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors."", ""name"": ""Olaparib""}"	{}	"{""description"": ""PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors."", ""name"": ""Olaparib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}]}}"
910	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	1	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.																																																								"{""description"": ""PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy."", ""name"": ""Rucaparib""}"	{}	"{""description"": ""PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy."", ""name"": ""Rucaparib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""rucaparib"", ""term"": {""id"": ""CHEBI:134689"", ""label"": ""rucaparib""}}]}}"
911	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	2	Platinum Chemotherapy	HRR-deficient tumors show increased sensitivity to platinum agents due to inability to repair platinum-induced DNA crosslinks. Carboplatin-based regimens may be considered.																																																								"{""description"": ""HRR-deficient tumors show increased sensitivity to platinum agents due to inability to repair platinum-induced DNA crosslinks. Carboplatin-based regimens may be considered."", ""name"": ""Platinum Chemotherapy""}"	{}	"{""description"": ""HRR-deficient tumors show increased sensitivity to platinum agents due to inability to repair platinum-induced DNA crosslinks. Carboplatin-based regimens may be considered."", ""name"": ""Platinum Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
912	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	3	Androgen Deprivation Therapy	Standard treatment for advanced prostate cancer regardless of HRR status. May be combined with novel hormonal agents like enzalutamide or abiraterone.																																																								"{""description"": ""Standard treatment for advanced prostate cancer regardless of HRR status. May be combined with novel hormonal agents like enzalutamide or abiraterone."", ""name"": ""Androgen Deprivation Therapy""}"	{}	"{""description"": ""Standard treatment for advanced prostate cancer regardless of HRR status. May be combined with novel hormonal agents like enzalutamide or abiraterone."", ""name"": ""Androgen Deprivation Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.																																																								"{""description"": ""Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture."", ""name"": ""Empiric Antibiotic Therapy""}"	{}	"{""description"": ""Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture."", ""evidence"": [{""explanation"": ""This suggests that in cases where lumbar puncture (LP) must be delayed, antibiotics should be administered before LP, but it does not explicitly state that antibiotics should be started immediately after LP."", ""reference"": ""PMID:3287565"", ""snippet"": ""The available evidence suggests that if bacterial meningitis is suspected and LP must be delayed, intravenous antibiotics are warranted before CSF is obtained."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the use of broad-spectrum antibiotics like vancomycin and ceftriaxone for empiric therapy but does not specify the timing related to lumbar puncture."", ""reference"": ""PMID:30496558"", ""snippet"": ""The use of empiric vancomycin plus a third-generation cephalosporin for suspected bacterial meningitis has been recommended since 1997."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference emphasizes the initiation of empiric therapy after obtaining blood cultures, not specifically after lumbar puncture."", ""reference"": ""PMID:20109674"", ""snippet"": ""Empiric antimicrobial and adjunctive therapy should be initiated as soon as a single set of blood cultures has been obtained."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference supports the use of empiric antibiotics but does not specify the timing relative to lumbar puncture."", ""reference"": ""PMID:25822235"", ""snippet"": ""Empiric therapy was ampicillin and gentamicin (n = 116, 44%) or third-generation cephalosporin based (n = 149, 56%)."", ""supports"": ""PARTIAL""}], ""name"": ""Empiric Antibiotic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.																																																								"{""description"": ""Antibiotics tailored to the specific pathogen once identified."", ""name"": ""Targeted Antibiotic Therapy""}"	{}	"{""description"": ""Antibiotics tailored to the specific pathogen once identified."", ""evidence"": [{""explanation"": ""The reference emphasizes the importance of initiating effective antibiotic therapy, which aligns with the concept of tailoring antibiotics to the specific pathogen once identified."", ""reference"": ""PMID:24073921"", ""snippet"": ""Outcome critically depends on the rapid initiation of effective antibiotic therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses the importance of understanding antibiotic resistance profiles to prescribe more effective therapies, supporting the concept of targeted antibiotic therapy."", ""reference"": ""PMID:30468130"", ""snippet"": ""Results of this study provide valuable information about the antibiotic resistance profiles of the etiologic agents of childhood meningitis, which can be used for prescription of more effective empirical therapies."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of specific antibiotics tailored to the pathogen identified, which is a form of targeted antibiotic therapy."", ""reference"": ""PMID:15301673"", ""snippet"": ""Ceftriaxone plus penicillin as empirical treatment was appropriate in 97% of ABM cases in the study population."", ""supports"": ""SUPPORT""}], ""name"": ""Targeted Antibiotic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anti-infective agent"", ""term"": {""id"": ""NCIT:C28254"", ""label"": ""Anti-Infective Agent""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.																																																								"{""description"": ""Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis."", ""name"": ""Dexamethasone""}"	{}	"{""description"": ""Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis."", ""evidence"": [{""explanation"": ""The statement is partially supported because dexamethasone is used to reduce inflammation in bacterial meningitis, but there is limited evidence of its benefit in reducing complications, particularly for pneumococcal meningitis."", ""reference"": ""PMID:10830026"", ""snippet"": ""Dexamethasone has been used in a number of clinical trials to moderate the host response and to improve neurologic outcome of meningitis. Results of six randomized, placebo controlled trials are summarized in this review. Dexamethasone treatment did not lower mortality. Only a moderate, but not a significant reduction in the neurologic and audiologic sequelae was seen in dexamethasone recipients when Haemophilus influenzae type b (Hib) was the causative agent of meningitis. ... Presently, there is little or no evidence showing a benefit of dexamethasone therapy in meningitis caused by S. pneumoniae or N. meningitidis."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the use of corticosteroids, specifically dexamethasone, in reducing inflammation and complications in pneumococcal meningitis."", ""reference"": ""PMID:31668194"", ""snippet"": ""Steroids are mandatory in pneumococcal meningitis but not indicated in pneumococcal pneumonia except in the setting of refractory shock."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of corticosteroids in pneumococcal meningitis to reduce inflammation and complications."", ""reference"": ""PMID:33330135"", ""snippet"": ""Steroid therapy is beneficial and supported in pathogens such as pneumococcal meningitis and tuberculosis."", ""supports"": ""SUPPORT""}], ""name"": ""Dexamethasone"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dexamethasone"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Dexamethasone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.																																																								"{""description"": ""Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure."", ""evidence"": [{""explanation"": ""This reference supports the aspect of fluid and electrolyte management as part of supportive care in bacterial meningitis."", ""reference"": ""PMID:8196986"", ""snippet"": ""Fluid administration in children with meningitis should be conservative in an attempt to minimize cerebral edema and electrolyte disturbances that frequently complicate the course of meningitis."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the importance of fluid and electrolyte management in the supportive care of bacterial meningitis."", ""reference"": ""PMID:16034949"", ""snippet"": ""Careful management of fluid and electrolyte balance is an important supportive therapy. Both over and under hydration are associated with adverse outcomes."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the monitoring of intracranial pressure as part of the supportive care in bacterial meningitis."", ""reference"": ""PMID:29889417"", ""snippet"": ""Control of intracranial pressure (ICP) as well as a good hemodynamic is based on a continuous monitoring of ICP and arterial pressure in order to assure an adapted cerebral perfusion pressure."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference acknowledges the role of intracranial pressure monitoring in the context of bacterial meningitis, thus supporting its inclusion in supportive care."", ""reference"": ""PMID:29088943"", ""snippet"": ""Although intracranial hypertension and subsequent death have long been known to complicate meningitis, no specific guidelines targeting ICP monitoring are available."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the aspect of seizure control as part of supportive care in bacterial meningitis."", ""reference"": ""PMID:29889417"", ""snippet"": ""Seizures should be avoided, the sedation-pain control optimized and ventilation adapted to assure normal oxygenation and normal CO levels."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""fluid therapy"", ""term"": {""id"": ""NCIT:C15693"", ""label"": ""Fluid Replacement Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anticonvulsant agent"", ""term"": {""id"": ""NCIT:C614"", ""label"": ""Anticonvulsant Agent""}}}], ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.																																																								"{""description"": ""Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis."", ""name"": ""Vaccination""}"	{}	"{""description"": ""Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis."", ""evidence"": [{""explanation"": ""This reference confirms that vaccines are available for the prevention of meningococcal, pneumococcal, and Hib meningitis."", ""reference"": ""PMID:15802609"", ""snippet"": ""Effective routine immunization against Hib, pneumococcus and serogroupC meningococcus has had a significant impact on both invasive disease and carriage caused by these encapsulated bacteria."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the availability and effectiveness of the Hib vaccine."", ""reference"": ""PMID:26904695"", ""snippet"": ""The Hib conjugate vaccine is considered protective and safe."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the availability of vaccines for meningococcal, pneumococcal, and Hib meningitis."", ""reference"": ""PMID:10470562"", ""snippet"": ""A comprehensive review of all major agents causing bacterial meningitis--meningococcus of the groups A, B, C, W135, and Y, pneumococcus, and Haemophilus influenzae type B (Hib)--is done in terms of preventing them by chemoprophylaxis or vaccination."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the availability of vaccines for Hib and pneumococcal meningitis."", ""reference"": ""PMID:20407316"", ""snippet"": ""The leading causes of bacterial meningitis and pneumonia in children, Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, are vaccine preventable."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the availability of vaccines for meningococcal meningitis."", ""reference"": ""PMID:22906940"", ""snippet"": ""The meningococcal conjugate vaccines (MCV) are preferred for reasons of immunogenicity and persistence of immunity."", ""supports"": ""SUPPORT""}], ""name"": ""Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""immunologic factor"", ""term"": {""id"": ""NCIT:C307"", ""label"": ""Immunologic Factor""}}, ""value"": {""preferred_term"": ""vaccine"", ""term"": {""id"": ""NCIT:C15260"", ""label"": ""Vaccine""}}}], ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	Supportive Therapy	Addressing specific symptoms like vision support, weight management, and physical therapy.																																																								"{""description"": ""Addressing specific symptoms like vision support, weight management, and physical therapy."", ""name"": ""Supportive Therapy""}"	{}	"{""description"": ""Addressing specific symptoms like vision support, weight management, and physical therapy."", ""evidence"": [{""explanation"": ""The case report discusses the management of symptoms like vision loss and obesity, which aligns with supportive therapy addressing specific symptoms."", ""reference"": ""PMID:15852167"", ""snippet"": ""Based on the history, presentation, ophthalmic clinical examination, obesity, mental retardation and dental alterations, the patient was diagnosed with Bardet-Biedl syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article mentions ongoing research in personalized medicine for BBS, focusing on treatments addressing specific symptoms, which supports the idea of supportive therapy."", ""reference"": ""PMID:29754569"", ""snippet"": ""Advances in the understanding of ciliary biology and diagnostic techniques have opened up the prospect of treating BBS in a patient-specific manner."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses treatments impacting quality of life related to obesity, which is part of supportive therapy."", ""reference"": ""PMID:36647077"", ""snippet"": ""This study highlights the need to address the impaired health-related quality of life in Bardet-Biedl syndrome, and supports utility of setmelanotide for reducing this burden."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article reports on gene therapy to manage vision loss in BBS, which fits under supportive treatment focusing on specific symptoms like vision support."", ""reference"": ""PMID:36700052"", ""snippet"": ""We show that subretinal gene therapy slowed photoreceptor cell death and preserved retinal function in treated eyes. Notably, cone photoreceptors regained their electrical function after gene augmentation."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the notion of addressing specific symptoms such as renal disease, fitting within supportive therapy for BBS."", ""reference"": ""PMID:27245600"", ""snippet"": ""Renal transplantation is indicated in cases of end-stage renal disease (ESRD), but transplant centers may be hesitant to perform the necessary transplant in light of the multitude of metabolic comorbidities these patients often face with the potential to complicate outcomes."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
997	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	1	Genetic Counseling	For affected individuals and families to understand inheritance patterns, risks, and implications.																																																								"{""description"": ""For affected individuals and families to understand inheritance patterns, risks, and implications."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""For affected individuals and families to understand inheritance patterns, risks, and implications."", ""evidence"": [{""explanation"": ""The overview highlights the importance of genetic counseling for identifying the genetic cause of the syndrome, supporting its role as a treatment component."", ""reference"": ""PMID:20301537"", ""snippet"": ""Provide an evaluation strategy to identify the genetic cause of Bardet-Biedl syndrome in a proband (when possible); 4."", ""supports"": ""SUPPORT""}], ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
998	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	2	Surgical Interventions	For polydactyly or other structural anomalies as needed.																																																								"{""description"": ""For polydactyly or other structural anomalies as needed."", ""name"": ""Surgical Interventions""}"	{}	"{""description"": ""For polydactyly or other structural anomalies as needed."", ""evidence"": [], ""name"": ""Surgical Interventions"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
999	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	3	Dietary and Lifestyle Modifications	To manage obesity and associated metabolic conditions.																																																								"{""description"": ""To manage obesity and associated metabolic conditions."", ""name"": ""Dietary and Lifestyle Modifications""}"	{}	"{""description"": ""To manage obesity and associated metabolic conditions."", ""evidence"": [{""explanation"": ""Bardet-Biedl Syndrome (BBS) metabolic management mentions both dietary and lifestyle approaches, which include weight loss strategies."", ""reference"": ""PMID:38302651"", ""snippet"": ""We review current approaches to the metabolic management of patients with BBS, including the use of weight loss medications and bariatric surgery."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although not specific to BBS, this reference supports the use of lifestyle modifications for managing obesity."", ""reference"": ""PMID:27356116"", ""snippet"": ""Comprehensive lifestyle interventions, including nutrition, physical activity, and behavioral therapy, are the foundation for clinical obesity management."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study involving BBS patients includes dietary and lifestyle modifications as part of the treatment to manage obesity."", ""reference"": ""PMID:36647077"", ""snippet"": ""Bardet-Biedl syndrome is a rare genetic disease associated with hyperphagia and early-onset, severe obesity...patients reported clinically meaningful improvements across multiple health-related quality of life measures."", ""supports"": ""SUPPORT""}, {""explanation"": ""Supports lifestyle interventions as foundational treatments for obesity in syndromic conditions like BBS."", ""reference"": ""PMID:37919024"", ""snippet"": ""Similar to the general population, lifestyle interventions focused on nutrition and physical activity form the foundation for treating obesity caused by rare genetic disorders."", ""supports"": ""SUPPORT""}], ""name"": ""Dietary and Lifestyle Modifications"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
1000	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	4	Gene Therapy	Experimental gene augmentation therapy to preserve retinal function in BBS-related retinal degeneration.																																																								"{""description"": ""Experimental gene augmentation therapy to preserve retinal function in BBS-related retinal degeneration."", ""name"": ""Gene Therapy""}"	{}	"{""description"": ""Experimental gene augmentation therapy to preserve retinal function in BBS-related retinal degeneration."", ""evidence"": [{""explanation"": ""The article reports on gene therapy to manage vision loss in BBS, showing promising results in preserving retinal function."", ""reference"": ""PMID:36700052"", ""snippet"": ""We show that subretinal gene therapy slowed photoreceptor cell death and preserved retinal function in treated eyes. Notably, cone photoreceptors regained their electrical function after gene augmentation."", ""supports"": ""SUPPORT""}], ""name"": ""Gene Therapy"", ""treatment_term"": {""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}}"
1001	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	5	Setmelanotide	An MC4R (melanocortin-4 receptor) agonist that activates the melanocortin pathway downstream of impaired leptin receptor signaling. Reduces hyperphagia and promotes weight loss in patients with BBS-associated obesity by bypassing the defective ciliary GPCR trafficking.																																		Approved for chronic weight management in BBS patients with obesity. Targets the MC4R pathway to restore downstream signaling despite upstream BBSome-related defects in hypothalamic ciliary GPCR trafficking.																						"{""description"": ""An MC4R (melanocortin-4 receptor) agonist that activates the melanocortin pathway downstream of impaired leptin receptor signaling. Reduces hyperphagia and promotes weight loss in patients with BBS-associated obesity by bypassing the defective ciliary GPCR trafficking."", ""name"": ""Setmelanotide"", ""notes"": ""Approved for chronic weight management in BBS patients with obesity. Targets the MC4R pathway to restore downstream signaling despite upstream BBSome-related defects in hypothalamic ciliary GPCR trafficking.""}"	{}	"{""description"": ""An MC4R (melanocortin-4 receptor) agonist that activates the melanocortin pathway downstream of impaired leptin receptor signaling. Reduces hyperphagia and promotes weight loss in patients with BBS-associated obesity by bypassing the defective ciliary GPCR trafficking."", ""evidence"": [], ""name"": ""Setmelanotide"", ""notes"": ""Approved for chronic weight management in BBS patients with obesity. Targets the MC4R pathway to restore downstream signaling despite upstream BBSome-related defects in hypothalamic ciliary GPCR trafficking."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1018	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	0	Surgical Excision	Standard treatment for most BCCs with excellent cure rates (95% or higher). Mohs micrographic surgery provides highest cure rates for high-risk tumors through complete margin assessment while preserving tissue.																																																								"{""description"": ""Standard treatment for most BCCs with excellent cure rates (95% or higher). Mohs micrographic surgery provides highest cure rates for high-risk tumors through complete margin assessment while preserving tissue."", ""name"": ""Surgical Excision""}"	{}	"{""description"": ""Standard treatment for most BCCs with excellent cure rates (95% or higher). Mohs micrographic surgery provides highest cure rates for high-risk tumors through complete margin assessment while preserving tissue."", ""name"": ""Surgical Excision"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1019	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.																																																								"{""description"": ""Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia."", ""name"": ""Vismodegib""}"	{}	"{""description"": ""Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia."", ""name"": ""Vismodegib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}]}}"
1020	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	2	Sonidegib	Second SMO inhibitor approved for locally advanced BCC. Similar mechanism of action to vismodegib with comparable efficacy profile. May provide alternative for patients intolerant of vismodegib.																																																								"{""description"": ""Second SMO inhibitor approved for locally advanced BCC. Similar mechanism of action to vismodegib with comparable efficacy profile. May provide alternative for patients intolerant of vismodegib."", ""name"": ""Sonidegib""}"	{}	"{""description"": ""Second SMO inhibitor approved for locally advanced BCC. Similar mechanism of action to vismodegib with comparable efficacy profile. May provide alternative for patients intolerant of vismodegib."", ""name"": ""Sonidegib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1021	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	3	Radiation Therapy	Alternative treatment for patients who are not surgical candidates or refuse surgery. Also used for adjuvant treatment of high-risk tumors with perineural invasion or positive margins.																																																								"{""description"": ""Alternative treatment for patients who are not surgical candidates or refuse surgery. Also used for adjuvant treatment of high-risk tumors with perineural invasion or positive margins."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Alternative treatment for patients who are not surgical candidates or refuse surgery. Also used for adjuvant treatment of high-risk tumors with perineural invasion or positive margins."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
1022	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	4	Topical Therapy	Topical imiquimod (immune response modifier) or 5-fluorouracil may be used for superficial BCC. Not appropriate for nodular or aggressive subtypes.																																																								"{""description"": ""Topical imiquimod (immune response modifier) or 5-fluorouracil may be used for superficial BCC. Not appropriate for nodular or aggressive subtypes."", ""name"": ""Topical Therapy""}"	{}	"{""description"": ""Topical imiquimod (immune response modifier) or 5-fluorouracil may be used for superficial BCC. Not appropriate for nodular or aggressive subtypes."", ""name"": ""Topical Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1023	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	5	Immune Checkpoint Inhibitors	Cemiplimab (anti-PD-1) has shown activity in locally advanced and metastatic BCC refractory to Hedgehog inhibitors, representing a treatment option for this previously difficult population.																																																								"{""description"": ""Cemiplimab (anti-PD-1) has shown activity in locally advanced and metastatic BCC refractory to Hedgehog inhibitors, representing a treatment option for this previously difficult population."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""Cemiplimab (anti-PD-1) has shown activity in locally advanced and metastatic BCC refractory to Hedgehog inhibitors, representing a treatment option for this previously difficult population."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1036	42	Behcet's Disease	Behcets_Disease.yaml	treatments	0	Colchicine	For mucocutaneous manifestations.																																																								"{""description"": ""For mucocutaneous manifestations."", ""name"": ""Colchicine""}"	{}	"{""description"": ""For mucocutaneous manifestations."", ""name"": ""Colchicine""}"
1037	42	Behcet's Disease	Behcets_Disease.yaml	treatments	1	Corticosteroids	For acute flares and severe manifestations.																																																								"{""description"": ""For acute flares and severe manifestations."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""For acute flares and severe manifestations."", ""name"": ""Corticosteroids""}"
1038	42	Behcet's Disease	Behcets_Disease.yaml	treatments	2	Azathioprine	For maintenance and uveitis.																																																								"{""description"": ""For maintenance and uveitis."", ""name"": ""Azathioprine""}"	{}	"{""description"": ""For maintenance and uveitis."", ""name"": ""Azathioprine""}"
1039	42	Behcet's Disease	Behcets_Disease.yaml	treatments	3	TNF Inhibitors	For refractory disease, especially uveitis.																																																								"{""description"": ""For refractory disease, especially uveitis."", ""name"": ""TNF Inhibitors""}"	{}	"{""description"": ""For refractory disease, especially uveitis."", ""name"": ""TNF Inhibitors""}"
1040	42	Behcet's Disease	Behcets_Disease.yaml	treatments	4	Apremilast	For oral ulcers.																																																								"{""description"": ""For oral ulcers."", ""name"": ""Apremilast""}"	{}	"{""description"": ""For oral ulcers."", ""name"": ""Apremilast""}"
1044	43	Bejel	Bejel.yaml	treatments	0	Penicillin therapy	Penicillin therapy is effective for endemic treponematoses.																																																								"{""description"": ""Penicillin therapy is effective for endemic treponematoses."", ""name"": ""Penicillin therapy""}"	{}	"{""description"": ""Penicillin therapy is effective for endemic treponematoses."", ""evidence"": [{""explanation"": ""The abstract notes penicillin therapy is effective for endemic treponematoses."", ""reference"": ""PMID:16615610"", ""snippet"": ""Although penicillin therapy is effective, these infectious diseases have yet to be eliminated."", ""supports"": ""SUPPORT""}], ""name"": ""Penicillin therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1071	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	0	Alpha-Blockers	Relax prostatic smooth muscle (tamsulosin, alfuzosin, silodosin).																																																								"{""description"": ""Relax prostatic smooth muscle (tamsulosin, alfuzosin, silodosin)."", ""name"": ""Alpha-Blockers""}"	{}	"{""description"": ""Relax prostatic smooth muscle (tamsulosin, alfuzosin, silodosin)."", ""name"": ""Alpha-Blockers""}"
1072	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	1	5-Alpha Reductase Inhibitors	Shrink prostate over months (finasteride, dutasteride).																																																								"{""description"": ""Shrink prostate over months (finasteride, dutasteride)."", ""name"": ""5-Alpha Reductase Inhibitors""}"	{}	"{""description"": ""Shrink prostate over months (finasteride, dutasteride)."", ""name"": ""5-Alpha Reductase Inhibitors""}"
1073	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	2	Combination Therapy	Alpha-blocker plus 5-ARI for larger prostates.																																																								"{""description"": ""Alpha-blocker plus 5-ARI for larger prostates."", ""name"": ""Combination Therapy""}"	{}	"{""description"": ""Alpha-blocker plus 5-ARI for larger prostates."", ""name"": ""Combination Therapy""}"
1074	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	3	PDE5 Inhibitors	Tadalafil approved for BPH and erectile dysfunction.																																																								"{""description"": ""Tadalafil approved for BPH and erectile dysfunction."", ""name"": ""PDE5 Inhibitors""}"	{}	"{""description"": ""Tadalafil approved for BPH and erectile dysfunction."", ""name"": ""PDE5 Inhibitors""}"
1075	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	4	TURP	Transurethral resection, gold standard surgical treatment.																																																								"{""description"": ""Transurethral resection, gold standard surgical treatment."", ""name"": ""TURP""}"	{}	"{""description"": ""Transurethral resection, gold standard surgical treatment."", ""name"": ""TURP""}"
1076	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	5	Laser Procedures	HoLEP, PVP for surgical candidates.																																																								"{""description"": ""HoLEP, PVP for surgical candidates."", ""name"": ""Laser Procedures""}"	{}	"{""description"": ""HoLEP, PVP for surgical candidates."", ""name"": ""Laser Procedures""}"
1077	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	6	Minimally Invasive Therapies	UroLift, Rezum for selected patients.																																																								"{""description"": ""UroLift, Rezum for selected patients."", ""name"": ""Minimally Invasive Therapies""}"	{}	"{""description"": ""UroLift, Rezum for selected patients."", ""name"": ""Minimally Invasive Therapies""}"
1078	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	7	ROCK Inhibitors (Experimental)	Y-27632 and GSK269962A target ROCK1/2 to reduce fibrosis, EMT, and proliferation.																																																								"{""description"": ""Y-27632 and GSK269962A target ROCK1/2 to reduce fibrosis, EMT, and proliferation."", ""name"": ""ROCK Inhibitors (Experimental)""}"	{}	"{""description"": ""Y-27632 and GSK269962A target ROCK1/2 to reduce fibrosis, EMT, and proliferation."", ""evidence"": [{""explanation"": ""This evidence demonstrates therapeutic potential of ROCK inhibition in reversing BPH pathology in animal models."", ""reference"": ""PMID:39455522"", ""snippet"": ""At the in vivo level, Y-27632 reversed prostatic hyperplasia and fibrosis in BPH model rats to some extent."", ""supports"": ""SUPPORT""}, {""explanation"": ""This evidence shows ROCK1 inhibition (GSK269962A) prevents stromal hyperplasia by blocking MSC recruitment and differentiation."", ""reference"": ""PMID:38711089"", ""snippet"": ""Inhibition of ROCK1 activation suppressed MSC migration and their potential for stromal differentiation."", ""supports"": ""SUPPORT""}], ""name"": ""ROCK Inhibitors (Experimental)""}"
1079	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	treatments	8	Antioxidant Therapy (Experimental)	Anethole trithione (ATT) inhibits mitochondrial ROS to reduce proliferation and stemness.																																																								"{""description"": ""Anethole trithione (ATT) inhibits mitochondrial ROS to reduce proliferation and stemness."", ""name"": ""Antioxidant Therapy (Experimental)""}"	{}	"{""description"": ""Anethole trithione (ATT) inhibits mitochondrial ROS to reduce proliferation and stemness."", ""evidence"": [{""explanation"": ""This evidence demonstrates antioxidant therapy can reduce key pathogenic features of BPH epithelial cells."", ""reference"": ""PMID:37827216"", ""snippet"": ""In human BPH-1 epithelial cells, ATT decreased mitochondrial metabolism, cell proliferation, and stemness features."", ""supports"": ""SUPPORT""}], ""name"": ""Antioxidant Therapy (Experimental)""}"
1088	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	treatments	0	Supportive care	"Symptom management including speech therapy, physical therapy, educational support, and management of hearing impairment with hearing aids or cochlear implants.
"																																																								"{""description"": ""Symptom management including speech therapy, physical therapy, educational support, and management of hearing impairment with hearing aids or cochlear implants.\n"", ""name"": ""Supportive care""}"	{}	"{""description"": ""Symptom management including speech therapy, physical therapy, educational support, and management of hearing impairment with hearing aids or cochlear implants.\n"", ""name"": ""Supportive care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1114	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	0	Lithium	First-line mood stabilizer, effective for mania and suicide prevention.																																																								"{""description"": ""First-line mood stabilizer, effective for mania and suicide prevention."", ""name"": ""Lithium""}"	{}	"{""description"": ""First-line mood stabilizer, effective for mania and suicide prevention."", ""evidence"": [{""explanation"": ""Lithium is the gold standard mood stabilizer for bipolar disorder with demonstrated efficacy in preventing manic episodes and reducing suicide risk through GSK3 inhibition."", ""reference"": ""PMID:22363263"", ""snippet"": ""Lithium has been reported to reduce suicide rates and prevent manic episodes in individuals with bipolar disorder, major depression, or schizoaffective disorders"", ""supports"": ""SUPPORT""}, {""explanation"": ""Lithium's therapeutic mechanism involves direct inhibition of GSK3 and indirect effects through the Akt/beta-arrestin pathway, providing molecular basis for its mood-stabilizing effects."", ""reference"": ""PMID:22363263"", ""snippet"": ""In 1996, two independent studies (Klein and Melton, 1996; Stambolic et al., 1996) of the effects of lithium on cell signaling and development have identified a direct effect of lithium on the activity of GSK3 both in vitro and in cells."", ""supports"": ""SUPPORT""}], ""name"": ""Lithium""}"
1115	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	1	Valproate	Mood stabilizer, effective for mania.																																																								"{""description"": ""Mood stabilizer, effective for mania."", ""name"": ""Valproate""}"	{}	"{""description"": ""Mood stabilizer, effective for mania."", ""name"": ""Valproate""}"
1116	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	2	Lamotrigine	Mood stabilizer, more effective for depression prevention.																																																								"{""description"": ""Mood stabilizer, more effective for depression prevention."", ""name"": ""Lamotrigine""}"	{}	"{""description"": ""Mood stabilizer, more effective for depression prevention."", ""name"": ""Lamotrigine""}"
1117	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	3	Atypical Antipsychotics	Quetiapine, olanzapine, aripiprazole for mania and maintenance.																																																								"{""description"": ""Quetiapine, olanzapine, aripiprazole for mania and maintenance."", ""name"": ""Atypical Antipsychotics""}"	{}	"{""description"": ""Quetiapine, olanzapine, aripiprazole for mania and maintenance."", ""name"": ""Atypical Antipsychotics""}"
1118	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	4	Antidepressants	Used cautiously with mood stabilizer to prevent switch to mania.																																																								"{""description"": ""Used cautiously with mood stabilizer to prevent switch to mania."", ""name"": ""Antidepressants""}"	{}	"{""description"": ""Used cautiously with mood stabilizer to prevent switch to mania."", ""name"": ""Antidepressants""}"
1119	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	5	Psychotherapy	CBT, interpersonal therapy, psychoeducation.																																																								"{""description"": ""CBT, interpersonal therapy, psychoeducation."", ""name"": ""Psychotherapy""}"	{}	"{""description"": ""CBT, interpersonal therapy, psychoeducation."", ""name"": ""Psychotherapy""}"
1120	46	Bipolar Disorder	Bipolar_Disorder.yaml	treatments	6	ECT	For severe or treatment-resistant episodes.																																																								"{""description"": ""For severe or treatment-resistant episodes."", ""name"": ""ECT""}"	{}	"{""description"": ""For severe or treatment-resistant episodes."", ""name"": ""ECT""}"
1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.																																																								"{""description"": ""Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis."", ""name"": ""Prednisone and Azathioprine""}"	{}	"{""description"": ""Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The trial summary notes existing use of prednisone and azathioprine in chronic hypersensitivity pneumonitis."", ""reference"": ""clinicaltrials:NCT02496182"", ""snippet"": ""Actually HP has been treated with Prednisone and occasionally with Azathioprine, but unfortunately the treatment with these drugs have not an effective result to treat the interstitial fibrosis."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The case report documents corticosteroid treatment for BFL."", ""reference"": ""PMID:39958101"", ""snippet"": ""The patient was diagnosed with BFL and treated with a tapering regimen of oral corticosteroids, starting at 40mg/day."", ""supports"": ""SUPPORT""}], ""name"": ""Prednisone and Azathioprine"", ""treatment_term"": {""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}, {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}]}}"
1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.																																																								"{""description"": ""Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO."", ""name"": ""Mycophenolate Mofetil or Azathioprine""}"	{}	"{""description"": ""Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study explicitly evaluates MMF and azathioprine therapy in chronic hypersensitivity pneumonitis."", ""reference"": ""PMID:27816444"", ""snippet"": ""We aimed to determine the effect of treatment with mycophenolate mofetil (MMF) or azathioprine (AZA) on lung function in patients with cHP."", ""supports"": ""SUPPORT""}], ""name"": ""Mycophenolate Mofetil or Azathioprine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""CHEBI:8764"", ""label"": ""mycophenolate mofetil""}}, {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}]}}"
1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.																																																								"{""description"": ""Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis."", ""name"": ""Pirfenidone""}"	{}	"{""description"": ""Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The randomized trial reports improved progression-free survival with pirfenidone in fibrotic hypersensitivity pneumonitis."", ""reference"": ""PMID:37028940"", ""snippet"": ""Pirfenidone was found to be safe and improved PFS in patients with FHP."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The trial registry specifies pirfenidone as the studied treatment in fibrotic hypersensitivity pneumonitis."", ""reference"": ""clinicaltrials:NCT02958917"", ""snippet"": ""The use of pirfenidone has not been approved for the treatment of FHP. It is considered experimental treatment in this study."", ""supports"": ""SUPPORT""}], ""name"": ""Pirfenidone"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""pirfenidone"", ""term"": {""id"": ""CHEBI:32016"", ""label"": ""pirfenidone""}}]}}"
1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.																																																								"{""description"": ""Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups."", ""name"": ""Nintedanib""}"	{}	"{""description"": ""Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The INBUILD subgroup analysis supports nintedanib for progressive fibrosing ILD, including the hypersensitivity pneumonitis subgroup."", ""reference"": ""PMID:32145830"", ""snippet"": ""The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis"", ""supports"": ""SUPPORT""}], ""name"": ""Nintedanib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""nintedanib"", ""term"": {""id"": ""CHEBI:85164"", ""label"": ""nintedanib""}}]}}"
1174	48	Botulism	Botulism.yaml	treatments	0	Botulinum Antitoxin	Administration of botulinum antitoxin to neutralize circulating toxin.																																																								"{""description"": ""Administration of botulinum antitoxin to neutralize circulating toxin."", ""name"": ""Botulinum Antitoxin""}"	{}	"{""description"": ""Administration of botulinum antitoxin to neutralize circulating toxin."", ""evidence"": [{""explanation"": ""The abstract identifies botulinum antitoxin as the specific treatment."", ""reference"": ""PMID:31157190"", ""snippet"": ""The only specific treatment is botulinum antitoxin."", ""supports"": ""SUPPORT""}], ""name"": ""Botulinum Antitoxin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1178	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	0	Surgical Excision	Surgical removal of symptomatic fibroadenomas.																																																								"{""description"": ""Surgical removal of symptomatic fibroadenomas."", ""name"": ""Surgical Excision""}"	{}	"{""description"": ""Surgical removal of symptomatic fibroadenomas."", ""evidence"": [{""explanation"": ""The abstract states surgical excision as a traditional treatment option."", ""reference"": ""PMID:11270760"", ""snippet"": ""Traditionally, symptomatic fibroadenomas were treated by surgical excision, and this option should always be offered."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Excision"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1179	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	1	Conservative Management	Observation with clinical and imaging follow-up when triple-test evaluation is consistent with fibroadenoma.																																																								"{""description"": ""Observation with clinical and imaging follow-up when triple-test evaluation is consistent with fibroadenoma."", ""name"": ""Conservative Management""}"	{}	"{""description"": ""Observation with clinical and imaging follow-up when triple-test evaluation is consistent with fibroadenoma."", ""evidence"": [{""explanation"": ""The abstract supports conservative management in appropriate cases."", ""reference"": ""PMID:11270760"", ""snippet"": ""There is increasing evidence that a conservative approach is safe and acceptable, provided the result of an adequate triple test is both negative for cancer and consistent with a fibroadenoma."", ""supports"": ""SUPPORT""}], ""name"": ""Conservative Management"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1209	50	Bronchiectasis	Bronchiectasis.yaml	treatments	0	Airway Clearance Techniques	Physical therapies to enhance mucus clearance, such as chest physiotherapy.																																																								"{""description"": ""Physical therapies to enhance mucus clearance, such as chest physiotherapy."", ""name"": ""Airway Clearance Techniques""}"	{}	"{""description"": ""Physical therapies to enhance mucus clearance, such as chest physiotherapy."", ""name"": ""Airway Clearance Techniques"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
1210	50	Bronchiectasis	Bronchiectasis.yaml	treatments	1	Antibiotic Therapy	Used to treat and prevent bacterial infections in the airways.																																																								"{""description"": ""Used to treat and prevent bacterial infections in the airways."", ""name"": ""Antibiotic Therapy""}"	{}	"{""description"": ""Used to treat and prevent bacterial infections in the airways."", ""name"": ""Antibiotic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1211	50	Bronchiectasis	Bronchiectasis.yaml	treatments	2	Bronchodilators	Medications to open airways and improve breathing.																																																								"{""description"": ""Medications to open airways and improve breathing."", ""name"": ""Bronchodilators""}"	{}	"{""description"": ""Medications to open airways and improve breathing."", ""name"": ""Bronchodilators"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1212	50	Bronchiectasis	Bronchiectasis.yaml	treatments	3	Inhaled Corticosteroids	Reduce inflammation in the airways.																																																								"{""description"": ""Reduce inflammation in the airways."", ""name"": ""Inhaled Corticosteroids""}"	{}	"{""description"": ""Reduce inflammation in the airways."", ""name"": ""Inhaled Corticosteroids"", ""treatment_term"": {""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}}"
1213	50	Bronchiectasis	Bronchiectasis.yaml	treatments	4	Surgery	Rarely performed; may include removal of severely affected lung areas if localized and recurrent infections persist.																																																								"{""description"": ""Rarely performed; may include removal of severely affected lung areas if localized and recurrent infections persist."", ""name"": ""Surgery""}"	{}	"{""description"": ""Rarely performed; may include removal of severely affected lung areas if localized and recurrent infections persist."", ""name"": ""Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1214	50	Bronchiectasis	Bronchiectasis.yaml	treatments	5	Vaccinations	Prevent respiratory infections and exacerbations.																																																								"{""description"": ""Prevent respiratory infections and exacerbations."", ""name"": ""Vaccinations""}"	{}	"{""description"": ""Prevent respiratory infections and exacerbations."", ""name"": ""Vaccinations"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
1237	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	0	Intensive Chemotherapy	Intensive, short-duration chemotherapy regimens achieve high cure rates (>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC, hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high risk of CNS involvement.																																																								"{""description"": ""Intensive, short-duration chemotherapy regimens achieve high cure rates (>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC, hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high risk of CNS involvement."", ""name"": ""Intensive Chemotherapy""}"	{}	"{""description"": ""Intensive, short-duration chemotherapy regimens achieve high cure rates (>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC, hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high risk of CNS involvement."", ""name"": ""Intensive Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
1238	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	1	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.																																																								"{""description"": ""Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens."", ""name"": ""Rituximab""}"	{}	"{""description"": ""Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens."", ""name"": ""Rituximab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""rituximab"", ""term"": {""id"": ""CHEBI:64357"", ""label"": ""rituximab""}}]}}"
1239	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	2	Tumor Lysis Syndrome Prophylaxis	Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are essential given the extremely high risk of tumor lysis syndrome from rapid tumor cell death.																																																								"{""description"": ""Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are essential given the extremely high risk of tumor lysis syndrome from rapid tumor cell death."", ""name"": ""Tumor Lysis Syndrome Prophylaxis""}"	{}	"{""description"": ""Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are essential given the extremely high risk of tumor lysis syndrome from rapid tumor cell death."", ""name"": ""Tumor Lysis Syndrome Prophylaxis"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1243	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	0	Antimycobacterial therapy	Antimycobacterial therapy is effective for early lesions.																																																								"{""description"": ""Antimycobacterial therapy is effective for early lesions."", ""name"": ""Antimycobacterial therapy""}"	{}	"{""description"": ""Antimycobacterial therapy is effective for early lesions."", ""evidence"": [{""explanation"": ""The abstract describes antimycobacterial therapy effectiveness in early lesions."", ""reference"": ""PMID:21240839"", ""snippet"": ""While antimycobacterial therapy is often effective for the earliest nodular or ulcerative lesions"", ""supports"": ""SUPPORT""}], ""name"": ""Antimycobacterial therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1244	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	1	Surgical management	Surgery may be required for advanced ulcerated lesions.																																																								"{""description"": ""Surgery may be required for advanced ulcerated lesions."", ""name"": ""Surgical management""}"	{}	"{""description"": ""Surgery may be required for advanced ulcerated lesions."", ""evidence"": [{""explanation"": ""The abstract notes surgery for advanced lesions."", ""reference"": ""PMID:21240839"", ""snippet"": ""for advanced ulcerated lesions, surgery is sometimes necessary."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical management"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1259	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	0	Supportive Care	Multidisciplinary care addressing individual symptoms and complications.																																																								"{""description"": ""Multidisciplinary care addressing individual symptoms and complications."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Multidisciplinary care addressing individual symptoms and complications."", ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1260	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	1	Cardiac Surgery	Surgical correction of congenital heart defects when indicated.																																																								"{""description"": ""Surgical correction of congenital heart defects when indicated."", ""name"": ""Cardiac Surgery""}"	{}	"{""description"": ""Surgical correction of congenital heart defects when indicated."", ""name"": ""Cardiac Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1261	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	2	Seizure Management	Antiepileptic medications for seizure control.																																																								"{""description"": ""Antiepileptic medications for seizure control."", ""name"": ""Seizure Management""}"	{}	"{""description"": ""Antiepileptic medications for seizure control."", ""name"": ""Seizure Management"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1262	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	3	Dermatologic Care	Topical and systemic treatments for ichthyosiform dermatosis management, including topical therapies and IL-17 antagonists for severe cases.																																																								"{""description"": ""Topical and systemic treatments for ichthyosiform dermatosis management, including topical therapies and IL-17 antagonists for severe cases."", ""name"": ""Dermatologic Care""}"	{}	"{""description"": ""Topical and systemic treatments for ichthyosiform dermatosis management, including topical therapies and IL-17 antagonists for severe cases."", ""evidence"": [{""explanation"": ""Flowers et al. 2024 documents the first successful treatment of severe ichthyosiform dermatosis in CHIME syndrome using ixekizumab (IL-17A antagonist), providing a therapeutic option for treatment-resistant cases."", ""reference"": ""PMID:38773877"", ""snippet"": ""Here, we report a case of severe ichthyosiform dermatosis in a child with CHIME syndrome who was recalcitrant to multiple topical medications and dupilumab. This is the first reported case of successful treatment of congenital ichthyosiform dermatosis in a CHIME syndrome patient with ixekizumab, an IL-17A antagonist."", ""supports"": ""SUPPORT""}], ""name"": ""Dermatologic Care"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1263	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	4	Hearing Aids	Assistive devices for conductive hearing loss.																																																								"{""description"": ""Assistive devices for conductive hearing loss."", ""name"": ""Hearing Aids""}"	{}	"{""description"": ""Assistive devices for conductive hearing loss."", ""name"": ""Hearing Aids"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1264	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	5	Educational Support	Special educational services tailored to intellectual disability.																																																								"{""description"": ""Special educational services tailored to intellectual disability."", ""name"": ""Educational Support""}"	{}	"{""description"": ""Special educational services tailored to intellectual disability."", ""name"": ""Educational Support"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
1285	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	0	Supportive Developmental Therapies	"Early intervention services including speech therapy, occupational therapy, and physical therapy to address developmental delays.
"																																																								"{""description"": ""Early intervention services including speech therapy, occupational therapy, and physical therapy to address developmental delays.\n"", ""name"": ""Supportive Developmental Therapies""}"	{}	"{""description"": ""Early intervention services including speech therapy, occupational therapy, and physical therapy to address developmental delays.\n"", ""name"": ""Supportive Developmental Therapies"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1286	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	1	Educational Support	"Individualized educational programs and special education services to support learning. Educational needs vary widely given the range of cognitive impairment from normal IQ to severe intellectual disability.
"																																																								"{""description"": ""Individualized educational programs and special education services to support learning. Educational needs vary widely given the range of cognitive impairment from normal IQ to severe intellectual disability.\n"", ""name"": ""Educational Support""}"	{}	"{""description"": ""Individualized educational programs and special education services to support learning. Educational needs vary widely given the range of cognitive impairment from normal IQ to severe intellectual disability.\n"", ""name"": ""Educational Support""}"
1287	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	2	Feeding Support	"Nutritional support and feeding therapy for infants and children with feeding difficulties, including temporary tube feeding when necessary.
"																																																								"{""description"": ""Nutritional support and feeding therapy for infants and children with feeding difficulties, including temporary tube feeding when necessary.\n"", ""name"": ""Feeding Support""}"	{}	"{""description"": ""Nutritional support and feeding therapy for infants and children with feeding difficulties, including temporary tube feeding when necessary.\n"", ""name"": ""Feeding Support""}"
1288	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	3	Behavioral Management	"Management of behavioral abnormalities including ADHD-like features, autistic behaviors, and aggression through behavioral therapy and potentially pharmacological interventions.
"																																																								"{""description"": ""Management of behavioral abnormalities including ADHD-like features, autistic behaviors, and aggression through behavioral therapy and potentially pharmacological interventions.\n"", ""name"": ""Behavioral Management""}"	{}	"{""description"": ""Management of behavioral abnormalities including ADHD-like features, autistic behaviors, and aggression through behavioral therapy and potentially pharmacological interventions.\n"", ""name"": ""Behavioral Management"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1289	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	4	Genetic Counseling	"Genetic counseling for families regarding recurrence risk, inheritance patterns, and implications of diagnosis. Most cases are de novo with low recurrence risk, but rare familial cases have been reported.
"																																																								"{""description"": ""Genetic counseling for families regarding recurrence risk, inheritance patterns, and implications of diagnosis. Most cases are de novo with low recurrence risk, but rare familial cases have been reported.\n"", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling for families regarding recurrence risk, inheritance patterns, and implications of diagnosis. Most cases are de novo with low recurrence risk, but rare familial cases have been reported.\n"", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
1309	55	Camptodactyly	Camptodactyly.yaml	treatments	0	Physical Therapy	Exercises and splinting to improve range of motion and prevent further contracture. First-line conservative management for mild to moderate cases.																																																								"{""description"": ""Exercises and splinting to improve range of motion and prevent further contracture. First-line conservative management for mild to moderate cases."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Exercises and splinting to improve range of motion and prevent further contracture. First-line conservative management for mild to moderate cases."", ""evidence"": [{""explanation"": ""Systematic review demonstrates that conservative treatment reduces flexion contracture in camptodactyly patients."", ""reference"": ""PMID:30897950"", ""snippet"": ""treatment of camptodactyly with operative or nonoperative measures reduces the degree of flexion contracture in most patients (from pretreatment averages of 20-85 to posttreatment averages of 5-37)"", ""supports"": ""SUPPORT""}], ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
1310	55	Camptodactyly	Camptodactyly.yaml	treatments	1	Serial Splinting	Progressive splinting to gradually extend the affected joints over time.																																																								"{""description"": ""Progressive splinting to gradually extend the affected joints over time."", ""name"": ""Serial Splinting""}"	{}	"{""description"": ""Progressive splinting to gradually extend the affected joints over time."", ""evidence"": [{""explanation"": ""Documents effectiveness of dynamic splinting for camptodactyly treatment."", ""reference"": ""PMID:3693837"", ""snippet"": ""Most of the patients could extend the proximal interphalangeal (PIP) joints within a few months by using the dynamic splint 24 hours a day. After almost full extension of the proximal interphalangeal joint was achieved, splinting for 8 hours a day produced good final results."", ""supports"": ""SUPPORT""}], ""name"": ""Serial Splinting"", ""treatment_term"": {""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}}"
1311	55	Camptodactyly	Camptodactyly.yaml	treatments	2	Surgical Release	Surgical intervention may be necessary for severe cases to release the tendons and improve finger extension. Options include tendon lengthening or volar plate release.																																																								"{""description"": ""Surgical intervention may be necessary for severe cases to release the tendons and improve finger extension. Options include tendon lengthening or volar plate release."", ""name"": ""Surgical Release""}"	{}	"{""description"": ""Surgical intervention may be necessary for severe cases to release the tendons and improve finger extension. Options include tendon lengthening or volar plate release."", ""evidence"": [{""explanation"": ""Systematic review confirms surgery is reserved for severe contractures over 30 degrees or when conservative treatment fails."", ""reference"": ""PMID:30897950"", ""snippet"": ""There was general agreement that surgery should be reserved for contracture >30 or failure to respond to conservative management. Surgery generally led to more complications compared with conservative management."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Release"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1312	55	Camptodactyly	Camptodactyly.yaml	treatments	3	Orthotic Interventions	Use of orthotic devices to support and properly align affected fingers.																																																								"{""description"": ""Use of orthotic devices to support and properly align affected fingers."", ""name"": ""Orthotic Interventions""}"	{}	"{""description"": ""Use of orthotic devices to support and properly align affected fingers."", ""name"": ""Orthotic Interventions"", ""treatment_term"": {""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}}"
1313	55	Camptodactyly	Camptodactyly.yaml	treatments	4	Genetic Counseling	Recommended for syndromic forms to assess inheritance patterns and recurrence risks.																																																								"{""description"": ""Recommended for syndromic forms to assess inheritance patterns and recurrence risks."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Recommended for syndromic forms to assess inheritance patterns and recurrence risks."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
1330	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	0	Cardiac Management	"Management of congenital heart defects, including surgical correction of pulmonary stenosis when indicated.
"																																																								"{""description"": ""Management of congenital heart defects, including surgical correction of pulmonary stenosis when indicated.\n"", ""name"": ""Cardiac Management""}"	{}	"{""description"": ""Management of congenital heart defects, including surgical correction of pulmonary stenosis when indicated.\n"", ""name"": ""Cardiac Management"", ""treatment_term"": {""preferred_term"": ""Cardiac surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1331	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	1	Nutritional Support	"Nutritional interventions for failure to thrive, including tube feeding when necessary.
"																																																								"{""description"": ""Nutritional interventions for failure to thrive, including tube feeding when necessary.\n"", ""name"": ""Nutritional Support""}"	{}	"{""description"": ""Nutritional interventions for failure to thrive, including tube feeding when necessary.\n"", ""name"": ""Nutritional Support"", ""treatment_term"": {""preferred_term"": ""Nutritional support"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
1332	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	"MEK inhibitors are under investigation for treatment of RASopathies, with potential to ameliorate some features. Zebrafish model studies suggest MEK inhibitors could treat progressive phenotypes.
"																																																								"{""description"": ""MEK inhibitors are under investigation for treatment of RASopathies, with potential to ameliorate some features. Zebrafish model studies suggest MEK inhibitors could treat progressive phenotypes.\n"", ""name"": ""MEK Inhibitor Therapy""}"	{}	"{""description"": ""MEK inhibitors are under investigation for treatment of RASopathies, with potential to ameliorate some features. Zebrafish model studies suggest MEK inhibitors could treat progressive phenotypes.\n"", ""evidence"": [{""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""Review summarizing preclinical evidence supporting MEK inhibitor therapy for CFC syndrome based on zebrafish model studies."", ""reference"": ""PMID:38136934"", ""snippet"": ""Encouraging zebrafish model system studies suggested that, in the future, MEK inhibitors could be a suitable treatment of progressive phenotypes of CFC in children."", ""supports"": ""SUPPORT""}], ""name"": ""MEK Inhibitor Therapy"", ""treatment_term"": {""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1357	57	Celiac Disease	Celiac_Disease.yaml	treatments	0	Gluten-Free Diet	Lifelong strict gluten avoidance is the only effective treatment.																																																								"{""description"": ""Lifelong strict gluten avoidance is the only effective treatment."", ""name"": ""Gluten-Free Diet""}"	{}	"{""description"": ""Lifelong strict gluten avoidance is the only effective treatment."", ""name"": ""Gluten-Free Diet""}"
1358	57	Celiac Disease	Celiac_Disease.yaml	treatments	1	Nutritional Supplementation	Iron, calcium, vitamin D, B12 as needed.																																																								"{""description"": ""Iron, calcium, vitamin D, B12 as needed."", ""name"": ""Nutritional Supplementation""}"	{}	"{""description"": ""Iron, calcium, vitamin D, B12 as needed."", ""name"": ""Nutritional Supplementation""}"
1359	57	Celiac Disease	Celiac_Disease.yaml	treatments	2	Monitoring	Regular serology and bone density monitoring.																																																								"{""description"": ""Regular serology and bone density monitoring."", ""name"": ""Monitoring""}"	{}	"{""description"": ""Regular serology and bone density monitoring."", ""name"": ""Monitoring""}"
1360	57	Celiac Disease	Celiac_Disease.yaml	treatments	3	Corticosteroids	For refractory celiac disease.																																																								"{""description"": ""For refractory celiac disease."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""For refractory celiac disease."", ""name"": ""Corticosteroids""}"
1361	57	Celiac Disease	Celiac_Disease.yaml	treatments	4	Dietitian Counseling	Essential for dietary compliance.																																																								"{""description"": ""Essential for dietary compliance."", ""name"": ""Dietitian Counseling""}"	{}	"{""description"": ""Essential for dietary compliance."", ""name"": ""Dietitian Counseling""}"
1379	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	0	HPV Vaccination	Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut.																																																								"{""description"": ""Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut."", ""name"": ""HPV Vaccination""}"	{}	"{""description"": ""Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut."", ""name"": ""HPV Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
1380	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	1	Cone Biopsy/LEEP	Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease.																																																								"{""description"": ""Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease."", ""name"": ""Cone Biopsy/LEEP""}"	{}	"{""description"": ""Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease."", ""name"": ""Cone Biopsy/LEEP"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1381	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	2	Radical Hysterectomy	Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases.																																																								"{""description"": ""Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases."", ""name"": ""Radical Hysterectomy""}"	{}	"{""description"": ""Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases."", ""name"": ""Radical Hysterectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1382	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	3	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.																																																								"{""description"": ""Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone."", ""name"": ""Chemoradiation""}"	{}	"{""description"": ""Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone."", ""name"": ""Chemoradiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}}"
1383	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	4	Pembrolizumab	PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors.																																																								"{""description"": ""PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors."", ""name"": ""Pembrolizumab""}"	{}	"{""description"": ""PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors."", ""name"": ""Pembrolizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1389	59	Chagas disease	Chagas_Disease.yaml	treatments	0	Benznidazole or nifurtimox therapy	Antitrypanosomal therapy for Chagas disease.																																																								"{""description"": ""Antitrypanosomal therapy for Chagas disease."", ""name"": ""Benznidazole or nifurtimox therapy""}"	{}	"{""description"": ""Antitrypanosomal therapy for Chagas disease."", ""evidence"": [{""explanation"": ""The review lists benznidazole and nifurtimox as WHO-recognized therapies."", ""reference"": ""PMID:30111183"", ""snippet"": ""Currently, only benznidazole (BZN) and nifurtimox are recognized by the World Health Organization as effective drugs for treatment of CD."", ""supports"": ""SUPPORT""}], ""name"": ""Benznidazole or nifurtimox therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1395	60	Chikungunya	Chikungunya.yaml	treatments	0	Symptomatic management	Supportive care for acute chikungunya.																																																								"{""description"": ""Supportive care for acute chikungunya."", ""name"": ""Symptomatic management""}"	{}	"{""description"": ""Supportive care for acute chikungunya."", ""evidence"": [{""explanation"": ""The abstract notes that acute chikungunya treatment is symptomatic."", ""reference"": ""PMID:29533749"", ""snippet"": ""Treatment of acute CHIK is symptomatic"", ""supports"": ""SUPPORT""}], ""name"": ""Symptomatic management"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1460	61	Cholera	Cholera.yaml	treatments	0	Oral Rehydration Solution (ORS)	Mixture of clean water, salt, and sugar to replace lost fluids and electrolytes.																																																								"{""description"": ""Mixture of clean water, salt, and sugar to replace lost fluids and electrolytes."", ""name"": ""Oral Rehydration Solution (ORS)""}"	{}	"{""description"": ""Mixture of clean water, salt, and sugar to replace lost fluids and electrolytes."", ""evidence"": [{""explanation"": ""The use of Oral Rehydration Solution (ORS) is supported as a treatment for cholera, as it involves a mixture of water, salts, and glucose to replace lost fluids and electrolytes."", ""reference"": ""PMID:8783513"", ""snippet"": ""For more than two decades, WHO and UNICEF have recommended a single formulation of oral rehydration salts (ORS) solution based on glucose and three salts. This product has proven safe and highly effective in treating and preventing dehydration from diarrhoea of all causes and in all age groups in worldwide use and has substantially contributed to the saving of lives in developing countries."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study emphasizes the effectiveness of glucose-based ORS over sucrose, supporting the use of ORS with clean water, salt, and glucose as a treatment for cholera and related diarrheal diseases."", ""reference"": ""PMID:49561"", ""snippet"": ""The data contrast with the rarity of treatment failures of oral glucose-electrolyte solutions. Glucose, therefore, is preferable to sucrose for oral therapy of diarrhoeal diseases."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference affirms that ORS is a primary treatment method for cholera, consistent with the use of clean water, salt, and sugar to replace lost fluids and electrolytes."", ""reference"": ""PMID:12562304"", ""snippet"": ""The mainstay of therapy of cholera patients is rehydration with oral rehydration salt solution or intravenous Ringer's lactate depending upon the degree of dehydration."", ""supports"": ""SUPPORT""}], ""name"": ""Oral Rehydration Solution (ORS)"", ""treatment_term"": {""preferred_term"": ""hydrotherapy"", ""term"": {""id"": ""MAXO:0000458"", ""label"": ""hydrotherapy""}}}"
1461	61	Cholera	Cholera.yaml	treatments	1	Intravenous Rehydration	Used for severe dehydration when rapid fluid replacement is necessary.																																																								"{""description"": ""Used for severe dehydration when rapid fluid replacement is necessary."", ""name"": ""Intravenous Rehydration""}"	{}	"{""description"": ""Used for severe dehydration when rapid fluid replacement is necessary."", ""evidence"": [{""explanation"": ""The literature clearly states that intravenous rehydration is used for severe dehydration in cholera patients."", ""reference"": ""PMID:8736618"", ""snippet"": ""Patients with severe dehydration should be treated intravenously, as should those patients who do not tolerate oral rehydration solution (ORS)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the use of intravenous rehydration for moderate or severe dehydration, which includes severe dehydration caused by cholera."", ""reference"": ""PMID:3171790"", ""snippet"": ""We compared the efficacy and safety of a single polyelectrolyte solution, Dhaka solution (DS), containing 133 mmol/L sodium, 13 mmol/L potassium, 98 mmol/L chloride, and 48 mmol/L acetate with and without 139 mmol/L (25 gm/L) dextrose in the rapid (4 hours) rehydration of 67 patients with diarrhea and moderate or severe dehydration requiring parenteral fluid therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature discusses the importance of fluid therapy for dehydration but does not explicitly focus on intravenous rehydration for severe dehydration in cholera patients."", ""reference"": ""PMID:35465904"", ""snippet"": ""Fluid therapy is the most important therapeutic measure in patients suffering from dehydration or hypovolemia owing to gastrointestinal diseases. The therapy should be tailored based on the patient's condition, physical examination, and diagnostic findings."", ""supports"": ""PARTIAL""}, {""explanation"": ""The article discusses intravenous fluid therapy in calves, which is not directly relevant to cholera treatment in humans."", ""reference"": ""PMID:19174284"", ""snippet"": ""Severely dehydrated calves that are unable to suckle need intravenous fluids for effective resuscitation."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Intravenous Rehydration"", ""treatment_term"": {""preferred_term"": ""hydrotherapy"", ""term"": {""id"": ""MAXO:0000458"", ""label"": ""hydrotherapy""}}}"
1462	61	Cholera	Cholera.yaml	treatments	2	Antibiotics	Shorten the course of the illness and reduce the severity, examples include doxycycline, azithromycin.																																																								"{""description"": ""Shorten the course of the illness and reduce the severity, examples include doxycycline, azithromycin."", ""name"": ""Antibiotics""}"	{}	"{""description"": ""Shorten the course of the illness and reduce the severity, examples include doxycycline, azithromycin."", ""evidence"": [{""explanation"": ""The reference indicates that antimicrobial treatment, including antibiotics like doxycycline and azithromycin, significantly shortens the duration of diarrhea and reduces stool volume, thereby supporting the statement."", ""reference"": ""PMID:24944120"", ""snippet"": ""Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment (MD -36.77 hours, 95% CI -43.51 to -30.03, 19 trials, 1013 participants, moderate quality evidence). Antimicrobial therapy also reduced the total stool volume by 50% (ROM 0.5, 95% CI 0.45 to 0.56, 18 trials, 1042 participants, moderate quality evidence) and reduced the amount of rehydration fluids required by 40% (ROM 0.60, 95% CI 0.53 to 0.68, 11 trials, 1201 participants, moderate quality evidence)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement as it specifies that antibiotics such as doxycycline shorten the illness duration, aligning with the value description."", ""reference"": ""PMID:11378428"", ""snippet"": ""Antibiotics such as tetracycline and doxycycline shorten the duration of illness but do not significantly affect overall mortality."", ""supports"": ""SUPPORT""}], ""name"": ""Antibiotics"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1463	61	Cholera	Cholera.yaml	treatments	3	Zinc Supplementation	Recommended for children to reduce the duration and severity of diarrhea.																																																								"{""description"": ""Recommended for children to reduce the duration and severity of diarrhea."", ""name"": ""Zinc Supplementation""}"	{}	"{""description"": ""Recommended for children to reduce the duration and severity of diarrhea."", ""evidence"": [{""explanation"": ""This study found that zinc supplementation reduced both the duration and severity of diarrhoea in children with cholera."", ""reference"": ""PMID:18184631"", ""snippet"": ""Zinc supplementation significantly reduced the duration of diarrhoea and stool output in children with cholera. Children with cholera should be supplemented with zinc to reduce its duration and severity."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by recommending zinc supplementation to reduce the duration and severity of diarrhea in children under 5 years of age."", ""reference"": ""PMID:17582575"", ""snippet"": ""Short-course daily zinc supplementation shortens the duration (a 15%-24% reduction) and severity of the episode and is now recommended for the treatment of all episodes of diarrhea occurring among children <5 years of age."", ""supports"": ""SUPPORT""}, {""explanation"": ""This guideline recommends zinc supplementation specifically for children with acute infectious diarrhea."", ""reference"": ""PMID:30269306"", ""snippet"": ""Zinc supplements are recommended in children with acute infectious diarrhea."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature shows that zinc supplementation improves symptom resolution in children with infectious diarrhea, including those caused by rotavirus."", ""reference"": ""PMID:37842003"", ""snippet"": ""Zinc supplementation has previously been shown to improve resolution of symptoms from infectious diarrhea."", ""supports"": ""SUPPORT""}], ""name"": ""Zinc Supplementation"", ""treatment_term"": {""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}}"
1464	61	Cholera	Cholera.yaml	treatments	4	Vaccination	Oral cholera vaccines can provide protection in endemic areas or during outbreaks.																																																								"{""description"": ""Oral cholera vaccines can provide protection in endemic areas or during outbreaks."", ""name"": ""Vaccination""}"	{}	"{""description"": ""Oral cholera vaccines can provide protection in endemic areas or during outbreaks."", ""evidence"": [{""explanation"": ""This supports that oral cholera vaccines can provide protection in endemic areas or during outbreaks."", ""reference"": ""PMID:22634452"", ""snippet"": ""This vaccine should be used in areas where cholera is endemic, particularly in those at risk of outbreaks, in conjunction with other prevention and control strategies."", ""supports"": ""SUPPORT""}, {""explanation"": ""This indicates that oral cholera vaccines can be a valuable tool during outbreaks."", ""reference"": ""PMID:15193408"", ""snippet"": ""Retrospective analysis suggests that mass vaccination with oral cholera vaccines can be a useful adjunct tool for controlling outbreaks, particularly if implemented early in association with other standard control measures."", ""supports"": ""SUPPORT""}, {""explanation"": ""While oral cholera vaccines can provide protection, their efficacy is not optimal in endemic settings, especially for children under five."", ""reference"": ""PMID:36255170"", ""snippet"": ""Efficacies of the currently licensed cholera vaccines are not optimal in endemic settings and low in children below the age of five, a section of the population most susceptible to the disease."", ""supports"": ""PARTIAL""}, {""explanation"": ""The deployment of oral cholera vaccines is suggested for endemic areas and crises, but a clear consensus on their use is lacking."", ""reference"": ""PMID:26494426"", ""snippet"": ""Oral cholera vaccination could be deployed in a diverse range of situations from cholera-endemic areas and locations of humanitarian crises, but no clear consensus exists."", ""supports"": ""PARTIAL""}], ""name"": ""Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
1480	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	treatments	0	IVIG	First-line therapy for most patients.																																																								"{""description"": ""First-line therapy for most patients."", ""name"": ""IVIG""}"	{}	"{""description"": ""First-line therapy for most patients."", ""name"": ""IVIG""}"
1481	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	treatments	1	Corticosteroids	Alternative first-line therapy.																																																								"{""description"": ""Alternative first-line therapy."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Alternative first-line therapy."", ""name"": ""Corticosteroids""}"
1482	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	treatments	2	Plasmapheresis	For refractory cases or acute exacerbations.																																																								"{""description"": ""For refractory cases or acute exacerbations."", ""name"": ""Plasmapheresis""}"	{}	"{""description"": ""For refractory cases or acute exacerbations."", ""name"": ""Plasmapheresis""}"
1483	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	treatments	3	Rituximab	For antibody-positive refractory cases.																																																								"{""description"": ""For antibody-positive refractory cases."", ""name"": ""Rituximab""}"	{}	"{""description"": ""For antibody-positive refractory cases."", ""name"": ""Rituximab""}"
1510	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	0	ACE Inhibitors/ARBs	Reduce proteinuria and slow progression by lowering intraglomerular pressure.																																																								"{""description"": ""Reduce proteinuria and slow progression by lowering intraglomerular pressure."", ""name"": ""ACE Inhibitors/ARBs""}"	{}	"{""description"": ""Reduce proteinuria and slow progression by lowering intraglomerular pressure."", ""evidence"": [{""explanation"": ""RAS inhibitors (ACE inhibitors/ARBs) protect against CKD progression by blocking RAAS-mediated fibrosis and reducing intraglomerular pressure."", ""reference"": ""PMID:38339031"", ""snippet"": ""The clinical evidence suggests that RAS inhibitors may protect against CKD progression, especially post-AKI, though more extensive trials are needed to confirm their full impact."", ""supports"": ""SUPPORT""}], ""name"": ""ACE Inhibitors/ARBs""}"
1511	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	1	SGLT2 Inhibitors	Provide nephroprotection independent of diabetes status.																																																								"{""description"": ""Provide nephroprotection independent of diabetes status."", ""name"": ""SGLT2 Inhibitors""}"	{}	"{""description"": ""Provide nephroprotection independent of diabetes status."", ""evidence"": [{""explanation"": ""SGLT2 inhibitors are recognized as current standard therapy that delays CKD progression through multiple mechanisms beyond glucose control."", ""reference"": ""PMID:38610646"", ""snippet"": ""Current therapies such as renin-angiotensin blockers, mineralocorticoid receptor antagonists, and sodium/glucose cotransporter 2 inhibitors aim to delay progression."", ""supports"": ""SUPPORT""}], ""name"": ""SGLT2 Inhibitors""}"
1512	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	2	Blood Pressure Control	Target less than 130/80 to slow progression.																																																								"{""description"": ""Target less than 130/80 to slow progression."", ""name"": ""Blood Pressure Control""}"	{}	"{""description"": ""Target less than 130/80 to slow progression."", ""name"": ""Blood Pressure Control""}"
1513	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	3	Dietary Protein Restriction	May slow progression in advanced CKD.																																																								"{""description"": ""May slow progression in advanced CKD."", ""name"": ""Dietary Protein Restriction""}"	{}	"{""description"": ""May slow progression in advanced CKD."", ""name"": ""Dietary Protein Restriction""}"
1514	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	4	Erythropoiesis-Stimulating Agents	Treat anemia of CKD.																																																								"{""description"": ""Treat anemia of CKD."", ""name"": ""Erythropoiesis-Stimulating Agents""}"	{}	"{""description"": ""Treat anemia of CKD."", ""name"": ""Erythropoiesis-Stimulating Agents""}"
1515	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	5	Phosphate Binders	Control hyperphosphatemia.																																																								"{""description"": ""Control hyperphosphatemia."", ""name"": ""Phosphate Binders""}"	{}	"{""description"": ""Control hyperphosphatemia."", ""name"": ""Phosphate Binders""}"
1516	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	6	Dialysis	Renal replacement therapy for end-stage disease.																																																								"{""description"": ""Renal replacement therapy for end-stage disease."", ""name"": ""Dialysis""}"	{}	"{""description"": ""Renal replacement therapy for end-stage disease."", ""name"": ""Dialysis""}"
1517	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	treatments	7	Kidney Transplantation	Definitive treatment for end-stage renal disease.																																																								"{""description"": ""Definitive treatment for end-stage renal disease."", ""name"": ""Kidney Transplantation""}"	{}	"{""description"": ""Definitive treatment for end-stage renal disease."", ""name"": ""Kidney Transplantation""}"
1541	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	0	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.																																																								"{""description"": ""First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression."", ""name"": ""Ibrutinib""}"	{}	"{""description"": ""First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression."", ""name"": ""Ibrutinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}]}}"
1542	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.																																																								"{""description"": ""Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab."", ""name"": ""Acalabrutinib""}"	{}	"{""description"": ""Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab."", ""name"": ""Acalabrutinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}]}}"
1543	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	2	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.																																																								"{""description"": ""BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL."", ""name"": ""Venetoclax plus Obinutuzumab""}"	{}	"{""description"": ""BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL."", ""name"": ""Venetoclax plus Obinutuzumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}}"
1544	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	3	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.																																																								"{""description"": ""Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents."", ""name"": ""Chemoimmunotherapy (FCR)""}"	{}	"{""description"": ""Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents."", ""name"": ""Chemoimmunotherapy (FCR)"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}]}}"
1545	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	4	Watch and Wait	Asymptomatic early-stage CLL does not require immediate treatment. Active surveillance with monitoring for disease progression or treatment indications (cytopenias, symptomatic disease, rapid progression) is appropriate for many patients.																																																								"{""description"": ""Asymptomatic early-stage CLL does not require immediate treatment. Active surveillance with monitoring for disease progression or treatment indications (cytopenias, symptomatic disease, rapid progression) is appropriate for many patients."", ""name"": ""Watch and Wait""}"	{}	"{""description"": ""Asymptomatic early-stage CLL does not require immediate treatment. Active surveillance with monitoring for disease progression or treatment indications (cytopenias, symptomatic disease, rapid progression) is appropriate for many patients."", ""name"": ""Watch and Wait"", ""treatment_term"": {""preferred_term"": ""surveillance for malignancies"", ""term"": {""id"": ""MAXO:0001492"", ""label"": ""surveillance for malignancies""}}}"
1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.																																																								"{""description"": ""First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes."", ""name"": ""Imatinib""}"	{}	"{""description"": ""First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes."", ""evidence"": [{""explanation"": ""The Druker phase 1 trial demonstrated that imatinib (STI571) induced complete hematologic responses in the vast majority of chronic phase CML patients."", ""reference"": ""PMID:11287972"", ""snippet"": ""Complete hematologic responses were observed in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""This establishes that imatinib's efficacy proves the oncogene addiction paradigm in CML."", ""reference"": ""PMID:11287972"", ""snippet"": ""Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer."", ""supports"": ""SUPPORT""}], ""name"": ""Imatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}}"
1566	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	1	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.																																																								"{""description"": ""Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy."", ""name"": ""Dasatinib""}"	{}	"{""description"": ""Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy."", ""name"": ""Dasatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}]}}"
1567	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	2	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.																																																								"{""description"": ""Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy."", ""name"": ""Nilotinib""}"	{}	"{""description"": ""Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy."", ""name"": ""Nilotinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""nilotinib"", ""term"": {""id"": ""CHEBI:52172"", ""label"": ""nilotinib""}}]}}"
1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.																																																								"{""description"": ""Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks."", ""name"": ""Ponatinib""}"	{}	"{""description"": ""Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks."", ""evidence"": [{""explanation"": ""This paper identified the T315I gatekeeper mutation that confers resistance to first and second-generation TKIs, establishing the need for third-generation TKIs like ponatinib."", ""reference"": ""PMID:11423618"", ""snippet"": ""In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance."", ""supports"": ""SUPPORT""}], ""name"": ""Ponatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}]}}"
1569	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	4	Allogeneic Stem Cell Transplantation	Potentially curative option historically used as primary therapy before TKI era. Now reserved for patients failing multiple TKIs, those with T315I mutation without ponatinib access, or blast crisis. Significant morbidity and mortality risks.																																																								"{""description"": ""Potentially curative option historically used as primary therapy before TKI era. Now reserved for patients failing multiple TKIs, those with T315I mutation without ponatinib access, or blast crisis. Significant morbidity and mortality risks."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Potentially curative option historically used as primary therapy before TKI era. Now reserved for patients failing multiple TKIs, those with T315I mutation without ponatinib access, or blast crisis. Significant morbidity and mortality risks."", ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
1605	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	0	Smoking Cessation	Stopping smoking to slow disease progression and improve outcomes.																																																								"{""description"": ""Stopping smoking to slow disease progression and improve outcomes."", ""name"": ""Smoking Cessation""}"	{}	"{""description"": ""Stopping smoking to slow disease progression and improve outcomes."", ""evidence"": [{""explanation"": ""The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD."", ""reference"": ""PMID:25496790"", ""snippet"": ""Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes."", ""reference"": ""PMID:19811377"", ""snippet"": ""Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD."", ""reference"": ""PMID:11935838"", ""snippet"": ""The most important intervention is smoking cessation."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference clearly supports the claim that smoking cessation can slow disease progression and improve outcomes for COPD patients."", ""reference"": ""PMID:27576232"", ""snippet"": ""Smoking cessation is the only intervention shown to slow disease progression."", ""supports"": ""SUPPORT""}], ""name"": ""Smoking Cessation"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
1606	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	1	Bronchodilators	Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).																																																								"{""description"": ""Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics)."", ""name"": ""Bronchodilators""}"	{}	"{""description"": ""Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics)."", ""evidence"": [{""explanation"": ""The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD."", ""reference"": ""PMID:29794201"", ""snippet"": ""Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow."", ""reference"": ""PMID:27576232"", ""snippet"": ""Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function."", ""reference"": ""PMID:28757318"", ""snippet"": ""Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease."", ""supports"": ""SUPPORT""}], ""name"": ""Bronchodilators"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1607	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	2	Inhaled Corticosteroids	Reduce airway inflammation and frequency of exacerbations.																																																								"{""description"": ""Reduce airway inflammation and frequency of exacerbations."", ""name"": ""Inhaled Corticosteroids""}"	{}	"{""description"": ""Reduce airway inflammation and frequency of exacerbations."", ""evidence"": [{""explanation"": ""While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced."", ""reference"": ""PMID:20102305"", ""snippet"": ""Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the decline of lung function in COPD."", ""supports"": ""PARTIAL""}, {""explanation"": ""ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation."", ""reference"": ""PMID:37348121"", ""snippet"": ""Current pharmacologic strategies, including first- and second-line therapies such as long-acting 2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD"", ""supports"": ""PARTIAL""}, {""explanation"": ""The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations."", ""reference"": ""PMID:29938633"", ""snippet"": ""The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids."", ""supports"": ""SUPPORT""}, {""explanation"": ""The new evidence indicates that ICS are effective in reducing exacerbations, supporting their role in treatment."", ""reference"": ""PMID:30846476"", ""snippet"": ""Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations."", ""supports"": ""SUPPORT""}], ""name"": ""Inhaled Corticosteroids"", ""treatment_term"": {""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}}"
1608	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	3	Phosphodiesterase-4 Inhibitors	Reduce inflammation and relax airways.																																																								"{""description"": ""Reduce inflammation and relax airways."", ""name"": ""Phosphodiesterase-4 Inhibitors""}"	{}	"{""description"": ""Reduce inflammation and relax airways."", ""evidence"": [{""explanation"": ""The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation."", ""reference"": ""PMID:15699784"", ""snippet"": ""Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils."", ""supports"": ""SUPPORT""}, {""explanation"": ""Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement."", ""reference"": ""PMID:20649375"", ""snippet"": ""Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement."", ""reference"": ""PMID:34731461"", ""snippet"": ""The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the role of PDE inhibitors, specifically kinase inhibitors, in reducing inflammation in COPD."", ""reference"": ""PMID:32361678"", ""snippet"": ""Protein kinases have been implicated in mediating inflammatory signals and airway remodeling associated with reduced lung function in chronic pulmonary disease."", ""supports"": ""SUPPORT""}], ""name"": ""Phosphodiesterase-4 Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1609	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	4	Oxygen Therapy	Long-term oxygen use for patients with severe chronic hypoxemia.																																																								"{""description"": ""Long-term oxygen use for patients with severe chronic hypoxemia."", ""name"": ""Oxygen Therapy""}"	{}	"{""description"": ""Long-term oxygen use for patients with severe chronic hypoxemia."", ""evidence"": [{""explanation"": ""The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia."", ""reference"": ""PMID:24461631"", ""snippet"": ""This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD."", ""reference"": ""PMID:37353334"", ""snippet"": ""Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia."", ""reference"": ""PMID:19462352"", ""snippet"": ""Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD."", ""supports"": ""SUPPORT""}], ""name"": ""Oxygen Therapy"", ""treatment_term"": {""preferred_term"": ""artificial respiration"", ""term"": {""id"": ""MAXO:0000503"", ""label"": ""artificial respiration""}}}"
1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	Pulmonary Rehabilitation	Exercise training, education, and support to improve quality of life and physical conditioning.																																																								"{""description"": ""Exercise training, education, and support to improve quality of life and physical conditioning."", ""name"": ""Pulmonary Rehabilitation""}"	{}	"{""description"": ""Exercise training, education, and support to improve quality of life and physical conditioning."", ""evidence"": [{""explanation"": ""The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support."", ""reference"": ""PMID:29526182"", ""snippet"": ""PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients."", ""reference"": ""PMID:34338012"", ""snippet"": ""Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients."", ""reference"": ""PMID:34955635"", ""snippet"": ""The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by indicating that pulmonary rehabilitation addresses systemic issues in COPD and implies improvement in quality of life and physical conditioning."", ""reference"": ""PMID:24874124"", ""snippet"": ""Pulmonary rehabilitation targets the systemic manifestations of COPD, the causes of which include inactivity, systemic inflammation, hypoxia and corticosteroid treatment."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by detailing the benefits of pulmonary rehabilitation, including exercise training, education, and support, to improve quality of life and physical conditioning."", ""reference"": ""PMID:24507849"", ""snippet"": ""The main objective of pulmonary rehabilitation is to restore muscle function and exercise tolerance, reverse other nonrespiratory consequences of the disease, and help patients to self-manage chronic obstructive pulmonary disease and its exacerbations and symptoms."", ""supports"": ""SUPPORT""}], ""name"": ""Pulmonary Rehabilitation"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
1611	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	6	Lung Volume Reduction Surgery	Surgical removal of damaged lung tissue for severe emphysema.																																																								"{""description"": ""Surgical removal of damaged lung tissue for severe emphysema."", ""name"": ""Lung Volume Reduction Surgery""}"	{}	"{""description"": ""Surgical removal of damaged lung tissue for severe emphysema."", ""evidence"": [{""explanation"": ""The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients."", ""reference"": ""PMID:22189668"", ""snippet"": ""Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD."", ""reference"": ""PMID:33926668"", ""snippet"": ""As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients."", ""reference"": ""PMID:31145187"", ""snippet"": ""Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity."", ""supports"": ""SUPPORT""}], ""name"": ""Lung Volume Reduction Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1612	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	7	Lung Transplantation	Considered in end-stage COPD with severe impairment.																																																								"{""description"": ""Considered in end-stage COPD with severe impairment."", ""name"": ""Lung Transplantation""}"	{}	"{""description"": ""Considered in end-stage COPD with severe impairment."", ""evidence"": [{""explanation"": ""This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD."", ""reference"": ""PMID:17240617"", ""snippet"": ""Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients."", ""reference"": ""PMID:31375190"", ""snippet"": ""End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states."", ""supports"": ""SUPPORT""}, {""explanation"": ""This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD."", ""reference"": ""PMID:36050206"", ""snippet"": ""The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This abstract explicitly mentions the use of lung transplantation for individuals with very severe COPD."", ""reference"": ""PMID:23248802"", ""snippet"": ""Chronic obstructive pulmonary disease...treated by lung transplantation."", ""supports"": ""SUPPORT""}], ""name"": ""Lung Transplantation"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
1613	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	8	Mucolytic Therapy	N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.																																		Variable clinical impact across COPD phenotypes; targets MUC5AC/MUC5B expression and mucus rheology.																						"{""description"": ""N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance."", ""name"": ""Mucolytic Therapy"", ""notes"": ""Variable clinical impact across COPD phenotypes; targets MUC5AC/MUC5B expression and mucus rheology.""}"	{}	"{""description"": ""N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance."", ""name"": ""Mucolytic Therapy"", ""notes"": ""Variable clinical impact across COPD phenotypes; targets MUC5AC/MUC5B expression and mucus rheology."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1614	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	9	Macrolide Antibiotics	Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.																																		Used in chronic bronchitis phenotype; dual anti-inflammatory and antimicrobial effects.																						"{""description"": ""Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns."", ""name"": ""Macrolide Antibiotics"", ""notes"": ""Used in chronic bronchitis phenotype; dual anti-inflammatory and antimicrobial effects.""}"	{}	"{""description"": ""Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns."", ""name"": ""Macrolide Antibiotics"", ""notes"": ""Used in chronic bronchitis phenotype; dual anti-inflammatory and antimicrobial effects."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1615	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	10	Biologic Therapies	Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.																																		Dupilumab (anti-IL-4/IL-13) shows benefit in eosinophilic COPD; anti-IL-33 and anti-TSLP under investigation.																						"{""description"": ""Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets."", ""name"": ""Biologic Therapies"", ""notes"": ""Dupilumab (anti-IL-4/IL-13) shows benefit in eosinophilic COPD; anti-IL-33 and anti-TSLP under investigation.""}"	{}	"{""description"": ""Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets."", ""name"": ""Biologic Therapies"", ""notes"": ""Dupilumab (anti-IL-4/IL-13) shows benefit in eosinophilic COPD; anti-IL-33 and anti-TSLP under investigation."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1637	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	0	Pain Management	Analgesics, nerve blocks, endoscopic therapy.																																																								"{""description"": ""Analgesics, nerve blocks, endoscopic therapy."", ""name"": ""Pain Management""}"	{}	"{""description"": ""Analgesics, nerve blocks, endoscopic therapy."", ""evidence"": [{""explanation"": ""Confirms that pain management in chronic pancreatitis requires a multidisciplinary approach combining lifestyle changes with analgesic medications."", ""reference"": ""PMID:38680261"", ""snippet"": ""Clinicians should follow a holistic approach to the management of CP-associated pain, which must involve lifestyle changes that are coupled with analgesic medications and other pain-relieving interventions."", ""supports"": ""SUPPORT""}], ""name"": ""Pain Management""}"
1638	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	1	Pancreatic Enzyme Replacement	For exocrine insufficiency (lipase with meals).																																																								"{""description"": ""For exocrine insufficiency (lipase with meals)."", ""name"": ""Pancreatic Enzyme Replacement""}"	{}	"{""description"": ""For exocrine insufficiency (lipase with meals)."", ""evidence"": [{""explanation"": ""Meta-analysis of 17 randomized controlled trials demonstrates significant improvement in fat absorption with pancreatic enzyme replacement therapy."", ""reference"": ""PMID:27941156"", ""snippet"": ""PERT improved CFA compared with baseline (83.76.0 vs 63.115.0, p<0.00001)"", ""supports"": ""SUPPORT""}, {""explanation"": ""PERT provides multiple benefits including improved nutrient absorption, reduced steatorrhea, and pain reduction with a favorable safety profile."", ""reference"": ""PMID:27941156"", ""snippet"": ""PERT improved coefficient of nitrogen absorption, reduced faecal fat excretion, faecal nitrogen excretion, faecal weight and abdominal pain, without significant adverse events."", ""supports"": ""SUPPORT""}], ""name"": ""Pancreatic Enzyme Replacement""}"
1639	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	2	Diabetes Management	Insulin often required for type 3c diabetes.																																																								"{""description"": ""Insulin often required for type 3c diabetes."", ""name"": ""Diabetes Management""}"	{}	"{""description"": ""Insulin often required for type 3c diabetes."", ""evidence"": [{""explanation"": ""Chronic pancreatitis is the most common cause of type 3c diabetes, which requires specific management considerations including insulin therapy."", ""reference"": ""PMID:28404095"", ""snippet"": ""The most commonly identified causes of type 3c diabetes are chronic pancreatitis, pancreatic ductal adenocarcinoma, haemochromatosis, cystic fibrosis, and previous pancreatic surgery."", ""supports"": ""SUPPORT""}], ""name"": ""Diabetes Management""}"
1640	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	3	Nutritional Support	Small frequent meals, medium-chain triglycerides.																																																								"{""description"": ""Small frequent meals, medium-chain triglycerides."", ""name"": ""Nutritional Support""}"	{}	"{""description"": ""Small frequent meals, medium-chain triglycerides."", ""evidence"": [{""explanation"": ""High prevalence of malnutrition and vitamin deficiencies in CP patients underscores the importance of nutritional support as a treatment component."", ""reference"": ""PMID:30074926"", ""snippet"": ""There is a high prevalence of fat-soluble vitamin deficiencies, osteopathy, and malnutrition in CP patients, which is underestimated due to a lack of effective diagnosis and suboptimal therapies for EPI."", ""supports"": ""SUPPORT""}], ""name"": ""Nutritional Support""}"
1641	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	4	Alcohol Cessation	Essential to slow progression.																																																								"{""description"": ""Essential to slow progression."", ""name"": ""Alcohol Cessation""}"	{}	"{""description"": ""Essential to slow progression."", ""evidence"": [{""explanation"": ""Large cohort study demonstrates that alcohol cessation reduces key complications of chronic pancreatitis."", ""reference"": ""PMID:38013125"", ""snippet"": ""Alcohol cessation in chronic pancreatitis reduces exocrine insufficiency, abdominal pain, and local complications."", ""supports"": ""SUPPORT""}, {""explanation"": ""Former drinkers show dramatically better outcomes including lower exocrine insufficiency, fewer pseudocysts, and higher relapse-free rates."", ""reference"": ""PMID:38013125"", ""snippet"": ""Compared to patients with LTDH, 'former drinkers' had a lower rate of exocrine insufficiency (29% vs. 59%) and pseudocysts (33% vs. 49%), were more often relapse-free (37% vs. 5%), and had less abdominal pain."", ""supports"": ""SUPPORT""}], ""name"": ""Alcohol Cessation""}"
1642	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	5	Smoking Cessation	Reduces pain and slows progression.																																																								"{""description"": ""Reduces pain and slows progression."", ""name"": ""Smoking Cessation""}"	{}	"{""description"": ""Reduces pain and slows progression."", ""evidence"": [{""explanation"": ""Dose-dependent relationship between smoking and disease severity supports smoking cessation as an important intervention."", ""reference"": ""PMID:38013125"", ""snippet"": ""The cumulative amount of nicotine consumed correlated with overall disease severity and the development of pseudocysts."", ""supports"": ""SUPPORT""}, {""explanation"": ""The strong association between smoking and disease progression (HR 4.9 for calcifications) supports the importance of smoking cessation."", ""reference"": ""PMID:15753536"", ""snippet"": ""Tobacco smoking increased significantly the risk of pancreatic calcifications (hazard ratio (HR) 4.9 (95% confidence interval (CI) 2.3-10.5) for smokers v non-smokers)"", ""supports"": ""SUPPORT""}], ""name"": ""Smoking Cessation""}"
1643	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	6	Endoscopic Therapy	Stricture dilation, stone removal, stenting.																																																								"{""description"": ""Stricture dilation, stone removal, stenting."", ""name"": ""Endoscopic Therapy""}"	{}	"{""description"": ""Stricture dilation, stone removal, stenting."", ""evidence"": [{""explanation"": ""European Society of Gastrointestinal Endoscopy guidelines recommend endoscopic therapy as first-line treatment for painful chronic pancreatitis with obstructed main pancreatic duct."", ""reference"": ""PMID:30654394"", ""snippet"": ""ESGE suggests endoscopic therapy and/or extracorporeal shockwave lithotripsy (ESWL) as the first-line therapy for painful uncomplicated chronic pancreatitis (CP) with an obstructed main pancreatic duct (MPD) in the head/body of the pancreas."", ""supports"": ""SUPPORT""}], ""name"": ""Endoscopic Therapy""}"
1644	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	treatments	7	Surgery	Drainage or resection procedures for refractory pain.																																																								"{""description"": ""Drainage or resection procedures for refractory pain."", ""name"": ""Surgery""}"	{}	"{""description"": ""Drainage or resection procedures for refractory pain."", ""evidence"": [{""explanation"": ""Randomized trial with 7-year follow-up demonstrates that both drainage and resection procedures provide adequate long-term pain relief and quality of life."", ""reference"": ""PMID:18471517"", ""snippet"": ""Both procedures provide adequate pain relief and quality of life after long-term follow-up with no differences regarding exocrine and endocrine function."", ""supports"": ""SUPPORT""}], ""name"": ""Surgery""}"
1662	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	0	Nephrectomy	Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease.																																																								"{""description"": ""Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease."", ""name"": ""Nephrectomy""}"	{}	"{""description"": ""Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease."", ""name"": ""Nephrectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.																																																								"{""description"": ""Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy."", ""name"": ""VEGFR Tyrosine Kinase Inhibitors""}"	{}	"{""description"": ""Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy."", ""name"": ""VEGFR Tyrosine Kinase Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}, {""preferred_term"": ""pazopanib"", ""term"": {""id"": ""CHEBI:71219"", ""label"": ""pazopanib""}}, {""preferred_term"": ""axitinib"", ""term"": {""id"": ""CHEBI:66910"", ""label"": ""axitinib""}}, {""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}]}}"
1664	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	2	Belzutifan	First-in-class HIF-2 inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy.																																																								"{""description"": ""First-in-class HIF-2 inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy."", ""name"": ""Belzutifan""}"	{}	"{""description"": ""First-in-class HIF-2 inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy."", ""name"": ""Belzutifan"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1665	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease.																																																								"{""description"": ""Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""immunotherapy procedure"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}}"
1679	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	0	Wide Surgical Resection	Wide surgical excision with negative margins is the primary treatment. The tendency to arise near tendons and joints may complicate resection. Amputation may be necessary for large or recurrent tumors.																																																								"{""description"": ""Wide surgical excision with negative margins is the primary treatment. The tendency to arise near tendons and joints may complicate resection. Amputation may be necessary for large or recurrent tumors."", ""name"": ""Wide Surgical Resection""}"	{}	"{""description"": ""Wide surgical excision with negative margins is the primary treatment. The tendency to arise near tendons and joints may complicate resection. Amputation may be necessary for large or recurrent tumors."", ""name"": ""Wide Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1680	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	1	Sentinel Lymph Node Biopsy	Given the propensity for lymph node metastasis, sentinel lymph node biopsy is often performed for staging, similar to melanoma management.																																																								"{""description"": ""Given the propensity for lymph node metastasis, sentinel lymph node biopsy is often performed for staging, similar to melanoma management."", ""name"": ""Sentinel Lymph Node Biopsy""}"	{}	"{""description"": ""Given the propensity for lymph node metastasis, sentinel lymph node biopsy is often performed for staging, similar to melanoma management."", ""name"": ""Sentinel Lymph Node Biopsy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1681	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	2	Radiation Therapy	Adjuvant radiation may be used for close or positive margins or for unresectable disease. CCS is relatively radioresistant.																																																								"{""description"": ""Adjuvant radiation may be used for close or positive margins or for unresectable disease. CCS is relatively radioresistant."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Adjuvant radiation may be used for close or positive margins or for unresectable disease. CCS is relatively radioresistant."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
1682	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	3	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.																																																								"{""description"": ""CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy."", ""name"": ""Systemic Therapy""}"	{}	"{""description"": ""CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy."", ""name"": ""Systemic Therapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}}"
1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.																																																								"{""description"": ""Oral vancomycin is first-line treatment for C. difficile infection."", ""name"": ""Vancomycin""}"	{}	"{""description"": ""Oral vancomycin is first-line treatment for C. difficile infection."", ""evidence"": [{""explanation"": ""Clinical review lists oral vancomycin among first-line agents for CDI management."", ""reference"": ""PMID:38508330"", ""snippet"": ""Effective infection management requires appropriate interpretation of diagnostic tests, as well as the use of vancomycin and fidaxomicin as first-line treatment."", ""supports"": ""SUPPORT""}], ""name"": ""Vancomycin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vancomycin"", ""term"": {""id"": ""NCIT:C288"", ""label"": ""vancomycin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.																																																								"{""description"": ""Alternative antibiotic with lower recurrence rates."", ""name"": ""Fidaxomicin""}"	{}	"{""description"": ""Alternative antibiotic with lower recurrence rates."", ""evidence"": [{""explanation"": ""Guideline update highlights fidaxomicin as preferred initial therapy because of reduced recurrence."", ""reference"": ""PMID:38726585"", ""snippet"": ""IDSA/SHEA shifted its preference for initial treatment to fidaxomicin over vancomycin and metronidazole due to its lower recurrence rate."", ""supports"": ""SUPPORT""}, {""explanation"": ""Recent review reinforces fidaxomicin's superiority to vancomycin for initial and recurrent CDI."", ""reference"": ""PMID:39282548"", ""snippet"": ""Management of CDI has evolved, with fidaxomicin emerging as a superior treatment option over vancomycin for initial and recurrent infections due to its reduction of recurrence rate."", ""supports"": ""SUPPORT""}], ""name"": ""Fidaxomicin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""fidaxomicin"", ""term"": {""id"": ""NCIT:C95509"", ""label"": ""fidaxomicin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.																																																								"{""description"": ""Restoration of normal gut microbiota for recurrent infections."", ""name"": ""Fecal microbiota transplantation""}"	{}	"{""description"": ""Restoration of normal gut microbiota for recurrent infections."", ""evidence"": [{""explanation"": ""Review notes FMT as effective for recurrent CDI in restoring microbiota."", ""reference"": ""PMID:38508330"", ""snippet"": ""Novel treatments such as Bezlotoxumab, fecal microbiota transplant, and live biotherapeutic products are proven effective in recurrent C. difficile infection and address dysbiosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""Update article explicitly states FMT effectiveness for recurrent CDI by reestablishing gut balance."", ""reference"": ""PMID:39282548"", ""snippet"": ""Faecal microbiota transplantation (FMT) is effective for recurrent CDI, restoring gut eubiosis."", ""supports"": ""SUPPORT""}], ""name"": ""Fecal microbiota transplantation"", ""treatment_term"": {""preferred_term"": ""fecal microbiota transplantation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""clinical course"", ""term"": {""id"": ""NCIT:C28008"", ""label"": ""Clinical Course""}}, ""value"": {""preferred_term"": ""recurrent disease"", ""term"": {""id"": ""MONDO:0700096"", ""label"": ""recurrent disease""}}}], ""term"": {""id"": ""MAXO:0000748"", ""label"": ""fecal microbiota transplantation""}}}"
1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.																																																								"{""description"": ""Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy."", ""name"": ""Bezlotoxumab""}"	{}	"{""description"": ""Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy."", ""evidence"": [{""explanation"": ""Review notes bezlotoxumab reduces CDI recurrence when used adjunctively with standard antibiotics."", ""reference"": ""PMID:39282548"", ""snippet"": ""Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, has shown promise in reducing recurrence rates."", ""supports"": ""SUPPORT""}], ""name"": ""Bezlotoxumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bezlotoxumab"", ""term"": {""id"": ""NCIT:C121379"", ""label"": ""Bezlotoxumab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1705	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	4	Loop ileostomy with colonic lavage	Organ-preserving surgical approach for fulminant CDI when medical therapy fails.																																																								"{""description"": ""Organ-preserving surgical approach for fulminant CDI when medical therapy fails."", ""name"": ""Loop ileostomy with colonic lavage""}"	{}	"{""description"": ""Organ-preserving surgical approach for fulminant CDI when medical therapy fails."", ""evidence"": [{""explanation"": ""Case report highlights loop ileostomy with lavage as a surgical option after failed pharmacologic therapy in fulminant CDI."", ""reference"": ""PMID:39650985"", ""snippet"": ""In cases where pharmacological management has been ineffective, fecal microbiota transplantation and surgical intervention demonstrated success."", ""supports"": ""SUPPORT""}], ""name"": ""Loop ileostomy with colonic lavage"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"																																																								"{""description"": ""Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.\n"", ""name"": ""Corticosteroids (Budesonide)""}"	{}	"{""description"": ""Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.\n"", ""evidence"": [{""explanation"": ""Literature supports immunosuppressive approaches for mucosal immune-mediated collagenous enteropathy"", ""reference"": ""DOI:10.1093/ecco-jcc/jjab123"", ""snippet"": ""MC is a multifactorial disease believed to involve innate and adaptive immune responses to luminal factors, genetic risk, autoimmunity, and extracellular matrix alterations"", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids (Budesonide)"", ""treatment_term"": {""preferred_term"": ""topical corticosteroid therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""budesonide"", ""term"": {""id"": ""NCIT:C66948"", ""label"": ""Budesonide""}}}, {""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""gastrointestinal route"", ""term"": {""id"": ""NCIT:C38295"", ""label"": ""Gastrointestinal Route of Administration""}}}], ""term"": {""id"": ""MAXO:0001553"", ""label"": ""topical corticosteroid therapy""}}}"
1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"																																																								"{""description"": ""Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.\n"", ""name"": ""Thiopurines (Azathioprine/6-Thioguanine)""}"	{}	"{""description"": ""Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.\n"", ""evidence"": [{""explanation"": ""Case reports document use of alternative immunosuppressants for refractory collagenous sprue cases"", ""reference"": ""PMID:39606500"", ""snippet"": ""This case report highlights the diagnostic challenges and clinical features of CS in a 74-year-old woman"", ""supports"": ""SUPPORT""}], ""name"": ""Thiopurines (Azathioprine/6-Thioguanine)"", ""treatment_term"": {""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Azathioprine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"																																																								"{""description"": ""TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.\n"", ""name"": ""Anti-TNF- Therapy""}"	{}	"{""description"": ""TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.\n"", ""evidence"": [{""explanation"": ""TNF- inhibitors target systemic inflammation characteristic of collagenous disorders"", ""reference"": ""PMID:40911031"", ""snippet"": ""The most common presenting symptoms were abdominal pain and chronic anaemia"", ""supports"": ""SUPPORT""}], ""name"": ""Anti-TNF- Therapy"", ""treatment_term"": {""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C2894"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"																																																								"{""description"": ""Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.\n"", ""name"": ""Calcineurin Inhibitors (Tacrolimus)""}"	{}	"{""description"": ""Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.\n"", ""evidence"": [{""explanation"": ""Case report demonstrates tacrolimus as an effective long-term treatment option for severe, refractory collagenous sprue with intestinal failure"", ""reference"": ""PMID:39046809"", ""snippet"": ""A 25-year-old male presented with chronic watery diarrhea and severe intestinal failure due to collagenous sprue. Treatments, including immunosuppressants and a gluten-free diet, were ineffective. Tacrolimus shows promise in treating refractory cases."", ""supports"": ""SUPPORT""}], ""name"": ""Calcineurin Inhibitors (Tacrolimus)"", ""treatment_term"": {""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tacrolimus"", ""term"": {""id"": ""NCIT:C2982"", ""label"": ""Tacrolimus""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1736	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	4	Medication discontinuation (Olmesartan withdrawal)	"Systematic discontinuation of triggering medications, particularly ARBs such as olmesartan, is critical in drug-induced collagenous sprue. Many patients experience clinical and histologic improvement within weeks to months after drug cessation.
"																																																								"{""description"": ""Systematic discontinuation of triggering medications, particularly ARBs such as olmesartan, is critical in drug-induced collagenous sprue. Many patients experience clinical and histologic improvement within weeks to months after drug cessation.\n"", ""name"": ""Medication discontinuation (Olmesartan withdrawal)""}"	{}	"{""description"": ""Systematic discontinuation of triggering medications, particularly ARBs such as olmesartan, is critical in drug-induced collagenous sprue. Many patients experience clinical and histologic improvement within weeks to months after drug cessation.\n"", ""evidence"": [{""explanation"": ""Literature demonstrates marked clinical and histologic improvement following discontinuation of ARB medications in collagenous disease"", ""reference"": ""PMID:35945664"", ""snippet"": ""Following drug cessation, symptomatic improvement occurred in all 11 cases for which follow-up data were available. Histological resolution occurred in five of eight cases with follow-up gastric biopsies"", ""supports"": ""SUPPORT""}], ""name"": ""Medication discontinuation (Olmesartan withdrawal)"", ""treatment_term"": {""preferred_term"": ""medication management"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"																																																								"{""description"": ""Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.\n"", ""name"": ""Nutritional support and supplementation""}"	{}	"{""description"": ""Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.\n"", ""evidence"": [{""explanation"": ""Literature emphasizes comprehensive treatment including nutritional support to prevent disease progression and address malabsorption"", ""reference"": ""PMID:37070112"", ""snippet"": ""Treatment should be initiated as soon as the diagnosis is established, so as to prevent the progression of fibrosis"", ""supports"": ""SUPPORT""}], ""name"": ""Nutritional support and supplementation"", ""treatment_term"": {""preferred_term"": ""nutritional supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""iron supplement"", ""term"": {""id"": ""NCIT:C2346"", ""label"": ""Iron Supplement""}}}], ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}}"
1744	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	treatments	0	Surgical Resection	Surgical removal of the colon tumor when localized.																																																								"{""description"": ""Surgical removal of the colon tumor when localized."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgical removal of the colon tumor when localized."", ""evidence"": [{""explanation"": ""The abstract describes surgical resection of a colon tumor."", ""reference"": ""PMID:35613396"", ""snippet"": ""The colonoscopic study presented a tumor in the ascending colon, which after surgical resection and pathological studies, turned out to be a primary colonoc adenosquamous carcinoma."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1763	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	0	Intensive Chemotherapy (7+3) with High-Dose Cytarabine Consolidation	Standard induction with 7 days cytarabine and 3 days anthracycline followed by multiple cycles of high-dose cytarabine (HiDAC) consolidation. HiDAC is particularly effective for CBF-AML and is the standard of care for fit patients, achieving 60-70% cure rates without transplant.																																																								"{""description"": ""Standard induction with 7 days cytarabine and 3 days anthracycline followed by multiple cycles of high-dose cytarabine (HiDAC) consolidation. HiDAC is particularly effective for CBF-AML and is the standard of care for fit patients, achieving 60-70% cure rates without transplant."", ""name"": ""Intensive Chemotherapy (7+3) with High-Dose Cytarabine Consolidation""}"	{}	"{""description"": ""Standard induction with 7 days cytarabine and 3 days anthracycline followed by multiple cycles of high-dose cytarabine (HiDAC) consolidation. HiDAC is particularly effective for CBF-AML and is the standard of care for fit patients, achieving 60-70% cure rates without transplant."", ""name"": ""Intensive Chemotherapy (7+3) with High-Dose Cytarabine Consolidation"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
1764	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	1	Gemtuzumab Ozogamicin	CD33-directed antibody-drug conjugate added to chemotherapy improves outcomes in favorable-risk AML including CBF-AML. Particularly beneficial when given in fractionated dosing during induction and consolidation.																																																								"{""description"": ""CD33-directed antibody-drug conjugate added to chemotherapy improves outcomes in favorable-risk AML including CBF-AML. Particularly beneficial when given in fractionated dosing during induction and consolidation."", ""name"": ""Gemtuzumab Ozogamicin""}"	{}	"{""description"": ""CD33-directed antibody-drug conjugate added to chemotherapy improves outcomes in favorable-risk AML including CBF-AML. Particularly beneficial when given in fractionated dosing during induction and consolidation."", ""name"": ""Gemtuzumab Ozogamicin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1765	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	2	MRD-Guided Therapy	Monitoring RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript levels by RT-PCR after consolidation guides decisions about additional therapy. Rising MRD may prompt transplant consideration before overt relapse.																																																								"{""description"": ""Monitoring RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript levels by RT-PCR after consolidation guides decisions about additional therapy. Rising MRD may prompt transplant consideration before overt relapse."", ""name"": ""MRD-Guided Therapy""}"	{}	"{""description"": ""Monitoring RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript levels by RT-PCR after consolidation guides decisions about additional therapy. Rising MRD may prompt transplant consideration before overt relapse."", ""name"": ""MRD-Guided Therapy"", ""treatment_term"": {""preferred_term"": ""genetic testing"", ""term"": {""id"": ""MAXO:0000127"", ""label"": ""genetic testing""}}}"
1766	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Generally reserved for relapsed CBF-AML or patients with persistent MRD after consolidation. Not routinely recommended in first remission given excellent outcomes with chemotherapy alone.																																																								"{""description"": ""Generally reserved for relapsed CBF-AML or patients with persistent MRD after consolidation. Not routinely recommended in first remission given excellent outcomes with chemotherapy alone."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Generally reserved for relapsed CBF-AML or patients with persistent MRD after consolidation. Not routinely recommended in first remission given excellent outcomes with chemotherapy alone."", ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
1785	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	treatments	0	Statins	Lower LDL cholesterol and stabilize atherosclerotic plaques.																																																								"{""description"": ""Lower LDL cholesterol and stabilize atherosclerotic plaques."", ""name"": ""Statins""}"	{}	"{""description"": ""Lower LDL cholesterol and stabilize atherosclerotic plaques."", ""name"": ""Statins""}"
1786	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	treatments	1	Antiplatelet Therapy	Aspirin and P2Y12 inhibitors reduce thrombotic risk.																																																								"{""description"": ""Aspirin and P2Y12 inhibitors reduce thrombotic risk."", ""name"": ""Antiplatelet Therapy""}"	{}	"{""description"": ""Aspirin and P2Y12 inhibitors reduce thrombotic risk."", ""name"": ""Antiplatelet Therapy""}"
1787	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	treatments	2	ACE Inhibitors	Provide cardiovascular protection beyond blood pressure lowering.																																																								"{""description"": ""Provide cardiovascular protection beyond blood pressure lowering."", ""name"": ""ACE Inhibitors""}"	{}	"{""description"": ""Provide cardiovascular protection beyond blood pressure lowering."", ""name"": ""ACE Inhibitors""}"
1788	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	treatments	3	Beta Blockers	Reduce myocardial oxygen demand and prevent angina.																																																								"{""description"": ""Reduce myocardial oxygen demand and prevent angina."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Reduce myocardial oxygen demand and prevent angina."", ""name"": ""Beta Blockers""}"
1789	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	treatments	4	Percutaneous Coronary Intervention	Angioplasty with stenting to restore coronary blood flow.																																																								"{""description"": ""Angioplasty with stenting to restore coronary blood flow."", ""name"": ""Percutaneous Coronary Intervention""}"	{}	"{""description"": ""Angioplasty with stenting to restore coronary blood flow."", ""name"": ""Percutaneous Coronary Intervention""}"
1790	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	treatments	5	Coronary Artery Bypass Grafting	Surgical revascularization for severe multivessel disease.																																																								"{""description"": ""Surgical revascularization for severe multivessel disease."", ""name"": ""Coronary Artery Bypass Grafting""}"	{}	"{""description"": ""Surgical revascularization for severe multivessel disease."", ""name"": ""Coronary Artery Bypass Grafting""}"
1805	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	0	Cardiac Monitoring	"Regular cardiac surveillance for hypertrophic cardiomyopathy and arrhythmias.
"																																																								"{""description"": ""Regular cardiac surveillance for hypertrophic cardiomyopathy and arrhythmias.\n"", ""name"": ""Cardiac Monitoring""}"	{}	"{""description"": ""Regular cardiac surveillance for hypertrophic cardiomyopathy and arrhythmias.\n"", ""name"": ""Cardiac Monitoring"", ""treatment_term"": {""preferred_term"": ""Cardiac monitoring"", ""term"": {""id"": ""MAXO:0000003"", ""label"": ""diagnostic procedure""}}}"
1806	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	1	Tumor Surveillance	"Regular screening for embryonal tumors, particularly in childhood.
"																																																								"{""description"": ""Regular screening for embryonal tumors, particularly in childhood.\n"", ""name"": ""Tumor Surveillance""}"	{}	"{""description"": ""Regular screening for embryonal tumors, particularly in childhood.\n"", ""name"": ""Tumor Surveillance"", ""treatment_term"": {""preferred_term"": ""Cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}}"
1807	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	"MEK inhibitors (e.g., trametinib) are being investigated as targeted therapy for RASopathies to reduce pathway hyperactivation.
"																																																								"{""description"": ""MEK inhibitors (e.g., trametinib) are being investigated as targeted therapy for RASopathies to reduce pathway hyperactivation.\n"", ""name"": ""MEK Inhibitor Therapy""}"	{}	"{""description"": ""MEK inhibitors (e.g., trametinib) are being investigated as targeted therapy for RASopathies to reduce pathway hyperactivation.\n"", ""name"": ""MEK Inhibitor Therapy"", ""treatment_term"": {""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1853	77	Crohn Disease	Crohn_Disease.yaml	treatments	0	Aminosalicylates	Anti-inflammatory drugs used for mild to moderate disease.																																																								"{""description"": ""Anti-inflammatory drugs used for mild to moderate disease."", ""name"": ""Aminosalicylates""}"	{}	"{""description"": ""Anti-inflammatory drugs used for mild to moderate disease."", ""evidence"": [{""explanation"": ""This reference states that aminosalicylates are included in the main treatments for mild to moderately active Crohn's disease."", ""reference"": ""PMID:12786608"", ""snippet"": ""The mainstay of current medical treatment for mild to moderately active stages of Crohn's disease includes aminosalicylates, antibiotics, glucococorticosteroids and immunomodulators."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of aminosalicylates for Crohn's disease treatment."", ""reference"": ""PMID:34797442"", ""snippet"": ""5-aminosalicylates (5-ASA) are frequently used in the management of Crohn's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference explicitly states that aminosalicylates have no clinical effect on Crohn's disease."", ""reference"": ""PMID:17339853"", ""snippet"": ""Sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease."", ""supports"": ""REFUTE""}], ""name"": ""Aminosalicylates"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1854	77	Crohn Disease	Crohn_Disease.yaml	treatments	1	Corticosteroids	Used for short-term control during flare-ups to reduce inflammation.																																																								"{""description"": ""Used for short-term control during flare-ups to reduce inflammation."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Used for short-term control during flare-ups to reduce inflammation."", ""evidence"": [{""explanation"": ""This indicates that corticosteroids are indeed a primary treatment option for managing flare-ups in Crohn's disease."", ""reference"": ""PMID:24532122"", ""snippet"": ""Corticosteroids have been used for decades to treat active Crohn's disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This strengthens the claim that corticosteroids are used for short-term control during flare-ups to reduce inflammation in Crohn's disease."", ""reference"": ""PMID:32653651"", ""snippet"": ""corticosteroids are crucial for the induction of remission of moderatetosevere flares in both UC and Crohn's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reinforces that corticosteroids are part of the short-term treatment strategy to control flare-ups in Crohn's disease."", ""reference"": ""PMID:18239408"", ""snippet"": ""The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1855	77	Crohn Disease	Crohn_Disease.yaml	treatments	2	Immunomodulators	Drugs like azathioprine and methotrexate to suppress the immune response.																																																								"{""description"": ""Drugs like azathioprine and methotrexate to suppress the immune response."", ""name"": ""Immunomodulators""}"	{}	"{""description"": ""Drugs like azathioprine and methotrexate to suppress the immune response."", ""evidence"": [{""explanation"": ""The provided literature supports the statement that drugs like azathioprine and methotrexate are used as immunomodulators to manage Crohn's Disease."", ""reference"": ""PMID:17105689"", ""snippet"": ""The immunomodulatory drugs in the IBD arsenal include azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study shows the use of methotrexate in patients who are refractory to azathioprine, supporting the statement that these drugs are used to treat Crohn's Disease by mitigating immune response."", ""reference"": ""PMID:35115294"", ""snippet"": ""Our results show that parenteral use of methotrexate is efficacious in inducing and maintaining remission as a step-up agent in azathioprine refractory Crohn's disease patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that Azathioprine and Methotrexate are used as immunosuppressants in the treatment of Crohn's Disease."", ""reference"": ""PMID:16245637"", ""snippet"": ""First line immunosuppressants are Azathioprine and 6-Mercaptopurine while Methotrexate, Infliximab, Mycophenolatmofetil and other compounds represent alternative or rescue medications."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review supports the use of methotrexate and azathioprine as immunomodulators for long-term management of Crohn's Disease."", ""reference"": ""PMID:24913384"", ""snippet"": ""The only other long term disease-modifying options are the immunomodulators, methotrexate, azathioprine and mercaptopurine."", ""supports"": ""SUPPORT""}], ""name"": ""Immunomodulators"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1856	77	Crohn Disease	Crohn_Disease.yaml	treatments	3	Biologics	Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease.																																																								"{""description"": ""Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease."", ""name"": ""Biologics""}"	{}	"{""description"": ""Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease."", ""evidence"": [{""explanation"": ""This reference supports the use of anti-TNF agents (infliximab and adalimumab) for the treatment of moderate to severe Crohn's disease but does not mention vedolizumab directly."", ""reference"": ""PMID:18034589"", ""snippet"": ""Infliximab and adalimumab are currently the only biological agents approved for induction and maintenance treatment in adults (infliximab and adalimumab) and children (infliximab) with Crohn's disease."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the use of vedolizumab (an integrin inhibitor) for the treatment of Crohn's disease but does not provide details on anti-TNF agents (infliximab and adalimumab)."", ""reference"": ""PMID:26195652"", ""snippet"": ""Vedolizumab is an integrin-receptor antagonist for the treatment of CD and UC in adults with moderately to severely active disease."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the use of anti-TNF agents for moderate to severe Crohn's disease."", ""reference"": ""PMID:26616476"", ""snippet"": ""Anti-TNF-alpha therapy is a novel approach that has transformed the way moderate-to-severe Crohn's disease (CD) is treated and has significantly improved clinical outcomes of patients."", ""supports"": ""SUPPORT""}], ""name"": ""Biologics"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	Nutritional Therapy	Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition.																																																								"{""description"": ""Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition."", ""name"": ""Nutritional Therapy""}"	{}	"{""description"": ""Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition."", ""evidence"": [{""explanation"": ""This article supports the use of nutrition therapy as a treatment for managing symptoms and maintaining nutrition in Crohns disease."", ""reference"": ""PMID:19244154"", ""snippet"": ""Nutrition therapy of Crohn's disease is considered the first-line of treatment for Crohn's disease in children, especially in Europe."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article supports the use of enteral nutrition as an effective therapy to induce remission and manage malnutrition in Crohn's disease."", ""reference"": ""PMID:38276922"", ""snippet"": ""New data in Crohn's disease supports the use of enteral liquid nutrition to help induce remission and correct malnutrition in patients heading for surgery."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study highlights the importance of dietary modifications to manage nutritional status in Crohn's disease patients."", ""reference"": ""PMID:36558412"", ""snippet"": ""Both under-and over-nutrition are prevalent in patients with Crohn's Disease (CD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this primarily focuses on pharmacologic therapy, it does acknowledge the role of different agents in maintaining remission."", ""reference"": ""PMID:35595414"", ""snippet"": ""The primary agents used in the treatment of Crohn's disease are aminosalicylates, corticosteroids, immunomodulators, and biologics. Each agent has different roles in the induction and maintenance of remission of disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference suggests that dietary modifications can lead to remission and maintenance of Crohn's disease, validating the role of nutritional therapy."", ""reference"": ""PMID:22410431"", ""snippet"": ""Although an elemental diet might lead to disease remission, reintroducing real foods and sustainable diets in patients with Crohn's disease is currently difficult, and would benefit from the sensitivity and rapid feedback provided by the field of nutrigenomics."", ""supports"": ""SUPPORT""}], ""name"": ""Nutritional Therapy"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	Surgery	Removal of affected bowel segments, typically reserved for complications like strictures or fistulas.																																																								"{""description"": ""Removal of affected bowel segments, typically reserved for complications like strictures or fistulas."", ""name"": ""Surgery""}"	{}	"{""description"": ""Removal of affected bowel segments, typically reserved for complications like strictures or fistulas."", ""evidence"": [{""explanation"": ""The excerpt indicates that surgery is reserved for complications such as strictures or fistulas among others, thus supporting the statement."", ""reference"": ""PMID:21901520"", ""snippet"": ""The indications for surgery include the failure of medical management, especially the persistence or worsening of symptoms in spite of proper treatment and complications of the disease process. These complications include intestinal obstruction, intestinal perforation with fistula formation or abscess, free perforation, gastrointestinal bleeding, urologic complications, cancer, and perianal disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement mentions surgery for complications like strictures, which is supported by the snippet indicating that fibrotic strictures rely on surgical procedures for treatment."", ""reference"": ""PMID:32279173"", ""snippet"": ""Therefore, current therapy of fibrotic strictures relies mainly on endoscopic and surgical procedures."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement links surgery to the complication of fistulas, which is supported by the snippet explaining the need for intestinal resection to manage symptomatic non-perianal fistulas."", ""reference"": ""PMID:21975159"", ""snippet"": ""Intestinal resection is almost always needed for the closure of symptomatic non-perianal fistulas."", ""supports"": ""SUPPORT""}, {""explanation"": ""The snippet supports the statement by discussing various surgical options for patients who are medically refractory, involving the removal of affected bowel segments."", ""reference"": ""PMID:29462390"", ""snippet"": ""When isolated to the colon, and patients become medically refractory, there are several surgical options - segmental resection, subtotal colectomy with ileorectal anastomosis, or a total proctocolectomy and end ileostomy. Unfortunately, surgery does not cure CD, and, regardless of the extent of bowel removed, recurrence may be seen in the small bowel."", ""supports"": ""SUPPORT""}, {""explanation"": ""The provided case demonstrates a scenario where surgery was performed due to refractory disease and complications, supporting the statement."", ""reference"": ""PMID:36926950"", ""snippet"": ""A partial resection of 3rd and 4th portion of the duodenum and the first loop of jejunum was performed, with duodenojejunal anastomosis."", ""supports"": ""SUPPORT""}], ""name"": ""Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1859	77	Crohn Disease	Crohn_Disease.yaml	treatments	6	Anti-IL-23 Biologics	Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy.																																		Reflects the central role of the IL-23/Th17 axis in CD pathogenesis.																						"{""description"": ""Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy."", ""name"": ""Anti-IL-23 Biologics"", ""notes"": ""Reflects the central role of the IL-23/Th17 axis in CD pathogenesis.""}"	{}	"{""description"": ""Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy."", ""name"": ""Anti-IL-23 Biologics"", ""notes"": ""Reflects the central role of the IL-23/Th17 axis in CD pathogenesis."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1860	77	Crohn Disease	Crohn_Disease.yaml	treatments	7	TL1A Inhibitors	Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease.																																		Under clinical investigation; addresses TNF-independent inflammatory pathways in perianal disease.																						"{""description"": ""Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease."", ""name"": ""TL1A Inhibitors"", ""notes"": ""Under clinical investigation; addresses TNF-independent inflammatory pathways in perianal disease.""}"	{}	"{""description"": ""Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease."", ""name"": ""TL1A Inhibitors"", ""notes"": ""Under clinical investigation; addresses TNF-independent inflammatory pathways in perianal disease."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1861	77	Crohn Disease	Crohn_Disease.yaml	treatments	8	JAK Inhibitors	Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease.																																		Addresses interferon-driven inflammation and may benefit refractory cases.																						"{""description"": ""Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease."", ""name"": ""JAK Inhibitors"", ""notes"": ""Addresses interferon-driven inflammation and may benefit refractory cases.""}"	{}	"{""description"": ""Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease."", ""name"": ""JAK Inhibitors"", ""notes"": ""Addresses interferon-driven inflammation and may benefit refractory cases."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	Corticosteroids	"Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.
"																																																								"{""description"": ""Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.\n"", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.\n"", ""evidence"": [{""explanation"": ""Establishes corticosteroids as first-line therapy with high response rates in Cronkhite-Canada syndrome"", ""reference"": ""PMID:33163187"", ""snippet"": ""Hormone therapy is the main treatment and prednisone is the major drug. Over 85% of patients responded to a dosage of >30 mg/d"", ""supports"": ""SUPPORT""}, {""explanation"": ""Recent case report confirms hormone therapy efficacy and emphasizes importance of early treatment in preventing cancer progression"", ""reference"": ""PMID:39470508"", ""snippet"": ""Hormone therapy has demonstrated significant efficacy in treating this disease. Early treatment and regular follow-up for this disease can reduce the risk of cancerous changes and related complications."", ""supports"": ""SUPPORT""}, {""explanation"": ""Detailed case report establishes dosing rationale and mechanism of action for glucocorticoid therapy in CCS"", ""reference"": ""PMID:32459145"", ""snippet"": ""Glucocorticoid dosage is generally considered to be based on body weight (1 mg/kg); its therapeutic mechanism may involve reduction of gastrointestinal inflammation and inhibition of autoimmune responses."", ""supports"": ""SUPPORT""}, {""explanation"": ""Large cohort study confirms prednisone dosing range and documents sustained steroid requirement in subset of patients for long-term disease control"", ""reference"": ""PMID:36781513"", ""snippet"": ""All patients received an initial prednisone dose equivalence of 30-80 mg daily, and five patients required steroids at the time of the last follow-up."", ""supports"": ""SUPPORT""}, {""explanation"": ""Case report demonstrates importance of extended maintenance therapy and confirms effectiveness of steroid retreatment after relapse"", ""reference"": ""PMID:34002159"", ""snippet"": ""It is necessary to extend the duration of prednisone maintenance therapy for CCS. Prednisone is still effective when readministered after relapse."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}}"
1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	Immunosuppressive agents	"Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF- expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.
"																																																								"{""description"": ""Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF- expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.\n"", ""name"": ""Immunosuppressive agents""}"	{}	"{""description"": ""Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF- expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.\n"", ""evidence"": [{""explanation"": ""Documents effectiveness of multiple immunosuppressive agents in corticosteroid-refractory Cronkhite-Canada syndrome"", ""reference"": ""PMID:33163187"", ""snippet"": ""Some patients with hormone-treatment failure or hormone resistance were treated with immunosuppressive agents, such as cyclosporine, azathioprine, and sirolimus, which were also effective"", ""supports"": ""SUPPORT""}, {""explanation"": ""Case report confirms tacrolimus and other immunosuppressive agents as effective therapeutic options for CCS management"", ""reference"": ""PMID:32459145"", ""snippet"": ""Other immunosuppressive agents, such as tacrolimus, have been shown to exhibit partial effects."", ""supports"": ""SUPPORT""}, {""explanation"": ""Recent case demonstrates efficacy of combination corticosteroid and azathioprine therapy with sustained remission on 1-year follow-up"", ""reference"": ""PMID:40709433"", ""snippet"": ""The patient was treated with a combination of corticosteroids and azathioprine, which led to marked clinical and endoscopic improvements."", ""supports"": ""SUPPORT""}, {""explanation"": ""Large cohort study documents long-term tolerability and sustained use of thiopurine therapy in majority of CCS patients for maintaining remission"", ""reference"": ""PMID:36781513"", ""snippet"": ""Twelve patients trialed thiopurine therapy, and ten patients continued with a thiopurine until the last follow-up."", ""supports"": ""SUPPORT""}, {""explanation"": ""Case report demonstrates cyclosporine A as promising therapeutic option for CCS with autoimmune complications"", ""reference"": ""PMID:32669505"", ""snippet"": ""Calcineurin inhibitors such as CyA might have potential therapeutic efficacy for CCS associated with MN."", ""supports"": ""SUPPORT""}], ""name"": ""Immunosuppressive agents"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1881	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	2	Supportive care	"Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.
"																																																								"{""description"": ""Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.\n"", ""name"": ""Supportive care""}"	{}	"{""description"": ""Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.\n"", ""evidence"": [{""explanation"": ""Emphasizes the importance of nutritional support in comprehensive Cronkhite-Canada syndrome management"", ""reference"": ""PMID:33163187"", ""snippet"": ""Symptomatic treatment and nutritional-support therapy"", ""supports"": ""SUPPORT""}, {""explanation"": ""Recent case demonstrates comprehensive multimodal supportive care approach including trace elements and amino acid supplementation"", ""reference"": ""PMID:39470508"", ""snippet"": ""Treatment included hormones with antiallergic medication, acid-suppressing drugs, salicylates, and nutritional support with zinc sulfate, adding trace elements and amino acids."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1891	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	treatments	0	Cranial Vault Remodeling	"Surgical expansion and reshaping of the skull to manage intracranial pressure and improve head shape. Timing depends on severity.
"																																																								"{""description"": ""Surgical expansion and reshaping of the skull to manage intracranial pressure and improve head shape. Timing depends on severity.\n"", ""name"": ""Cranial Vault Remodeling""}"	{}	"{""description"": ""Surgical expansion and reshaping of the skull to manage intracranial pressure and improve head shape. Timing depends on severity.\n"", ""name"": ""Cranial Vault Remodeling"", ""treatment_term"": {""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1892	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	treatments	1	Midface Advancement	"Le Fort III osteotomy or distraction osteogenesis to advance the hypoplastic midface, improving airway, appearance, and occlusion.
"																																																								"{""description"": ""Le Fort III osteotomy or distraction osteogenesis to advance the hypoplastic midface, improving airway, appearance, and occlusion.\n"", ""name"": ""Midface Advancement""}"	{}	"{""description"": ""Le Fort III osteotomy or distraction osteogenesis to advance the hypoplastic midface, improving airway, appearance, and occlusion.\n"", ""name"": ""Midface Advancement"", ""treatment_term"": {""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1901	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	treatments	0	Cranial Vault Surgery	"Surgical management of craniosynostosis similar to classic Crouzon syndrome.
"																																																								"{""description"": ""Surgical management of craniosynostosis similar to classic Crouzon syndrome.\n"", ""name"": ""Cranial Vault Surgery""}"	{}	"{""description"": ""Surgical management of craniosynostosis similar to classic Crouzon syndrome.\n"", ""name"": ""Cranial Vault Surgery"", ""treatment_term"": {""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1902	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	treatments	1	Midface Advancement	"Surgical advancement of the hypoplastic midface.
"																																																								"{""description"": ""Surgical advancement of the hypoplastic midface.\n"", ""name"": ""Midface Advancement""}"	{}	"{""description"": ""Surgical advancement of the hypoplastic midface.\n"", ""name"": ""Midface Advancement"", ""treatment_term"": {""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1903	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	treatments	2	Dermatologic Management	"Topical treatments for acanthosis nigricans, though the skin changes are typically cosmetic rather than medically significant.
"																																																								"{""description"": ""Topical treatments for acanthosis nigricans, though the skin changes are typically cosmetic rather than medically significant.\n"", ""name"": ""Dermatologic Management""}"	{}	"{""description"": ""Topical treatments for acanthosis nigricans, though the skin changes are typically cosmetic rather than medically significant.\n"", ""name"": ""Dermatologic Management""}"
1914	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	0	Surgical Resection	"First-line treatment for most endogenous Cushing's syndrome: transsphenoidal surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal tumors, or resection of ectopic ACTH-secreting tumors.
"																																																								"{""description"": ""First-line treatment for most endogenous Cushing's syndrome: transsphenoidal surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal tumors, or resection of ectopic ACTH-secreting tumors.\n"", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""First-line treatment for most endogenous Cushing's syndrome: transsphenoidal surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal tumors, or resection of ectopic ACTH-secreting tumors.\n"", ""evidence"": [{""explanation"": ""Surgery is confirmed as the first-line treatment for endogenous Cushing's syndrome."", ""reference"": ""PMID:37432427"", ""snippet"": ""Management of Cushing syndrome begins with surgery to remove the source of excess endogenous cortisol production"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1915	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	1	Medical Therapy	"Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism when surgery is not possible or has failed.
"																																																								"{""description"": ""Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism when surgery is not possible or has failed.\n"", ""name"": ""Medical Therapy""}"	{}	"{""description"": ""Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism when surgery is not possible or has failed.\n"", ""evidence"": [{""explanation"": ""Multiple medication classes are used for hypercortisolism management."", ""reference"": ""PMID:37432427"", ""snippet"": ""medication that includes adrenal steroidogenesis inhibitors, pituitary-targeted drugs, or glucocorticoid receptor blockers"", ""supports"": ""SUPPORT""}], ""name"": ""Medical Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1916	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	2	Radiation Therapy	"Pituitary radiation (conventional or stereotactic radiosurgery) for persistent or recurrent Cushing's disease after unsuccessful surgery.
"																																																								"{""description"": ""Pituitary radiation (conventional or stereotactic radiosurgery) for persistent or recurrent Cushing's disease after unsuccessful surgery.\n"", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Pituitary radiation (conventional or stereotactic radiosurgery) for persistent or recurrent Cushing's disease after unsuccessful surgery.\n"", ""evidence"": [{""explanation"": ""Radiation therapy is confirmed as an option for refractory cases."", ""reference"": ""PMID:37432427"", ""snippet"": ""For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate."", ""supports"": ""SUPPORT""}], ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
1917	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	3	Bilateral Adrenalectomy	"Definitive treatment option for patients with persistent hypercortisolism, resulting in permanent adrenal insufficiency requiring lifelong hormone replacement.
"																																																								"{""description"": ""Definitive treatment option for patients with persistent hypercortisolism, resulting in permanent adrenal insufficiency requiring lifelong hormone replacement.\n"", ""name"": ""Bilateral Adrenalectomy""}"	{}	"{""description"": ""Definitive treatment option for patients with persistent hypercortisolism, resulting in permanent adrenal insufficiency requiring lifelong hormone replacement.\n"", ""evidence"": [{""explanation"": ""Bilateral adrenalectomy is confirmed as a treatment for refractory cases."", ""reference"": ""PMID:37432427"", ""snippet"": ""For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate."", ""supports"": ""SUPPORT""}], ""name"": ""Bilateral Adrenalectomy"", ""treatment_term"": {""preferred_term"": ""adrenalectomy"", ""term"": {""id"": ""MAXO:0001030"", ""label"": ""adrenalectomy""}}}"
1922	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	0	Benzimidazole chemotherapy	Benzimidazole carbamates are used as chemotherapy.																																																								"{""description"": ""Benzimidazole carbamates are used as chemotherapy."", ""name"": ""Benzimidazole chemotherapy""}"	{}	"{""description"": ""Benzimidazole carbamates are used as chemotherapy."", ""evidence"": [{""explanation"": ""The abstract lists benzimidazole chemotherapy among treatments."", ""reference"": ""PMID:27047771"", ""snippet"": ""Treatment methods include chemotherapy with benzimidazole carbamates and/or surgical approaches, including percutaneous aspiration injection and reaspiration."", ""supports"": ""SUPPORT""}], ""name"": ""Benzimidazole chemotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1923	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	1	Surgical and percutaneous approaches	Surgical approaches including percutaneous aspiration are used.																																																								"{""description"": ""Surgical approaches including percutaneous aspiration are used."", ""name"": ""Surgical and percutaneous approaches""}"	{}	"{""description"": ""Surgical approaches including percutaneous aspiration are used."", ""evidence"": [{""explanation"": ""The abstract lists surgical and percutaneous approaches."", ""reference"": ""PMID:27047771"", ""snippet"": ""Treatment methods include chemotherapy with benzimidazole carbamates and/or surgical approaches, including percutaneous aspiration injection and reaspiration."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical and percutaneous approaches"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1944	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	0	CFTR Modulators	Elexacaftor/tezacaftor/ivacaftor (Trikafta) for eligible mutations.																																																								"{""description"": ""Elexacaftor/tezacaftor/ivacaftor (Trikafta) for eligible mutations."", ""name"": ""CFTR Modulators""}"	{}	"{""description"": ""Elexacaftor/tezacaftor/ivacaftor (Trikafta) for eligible mutations."", ""evidence"": [{""explanation"": ""Phase 3 RCT demonstrates significant improvement in lung function and 63% reduction in pulmonary exacerbations with Trikafta."", ""reference"": ""PMID:31697873"", ""snippet"": ""Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks, a rate of pulmonary exacerbations that was 63% lower"", ""supports"": ""SUPPORT""}], ""name"": ""CFTR Modulators""}"
1945	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	1	Airway Clearance Therapy	Chest physiotherapy, oscillating devices, exercise to clear secretions.																																																								"{""description"": ""Chest physiotherapy, oscillating devices, exercise to clear secretions."", ""name"": ""Airway Clearance Therapy""}"	{}	"{""description"": ""Chest physiotherapy, oscillating devices, exercise to clear secretions."", ""name"": ""Airway Clearance Therapy""}"
1946	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	2	Inhaled Mucolytics	Dornase alfa (Pulmozyme) and hypertonic saline to thin secretions.																																																								"{""description"": ""Dornase alfa (Pulmozyme) and hypertonic saline to thin secretions."", ""name"": ""Inhaled Mucolytics""}"	{}	"{""description"": ""Dornase alfa (Pulmozyme) and hypertonic saline to thin secretions."", ""evidence"": [{""explanation"": ""Randomized controlled trial demonstrates significant improvement in lung function with dornase alfa in advanced CF."", ""reference"": ""PMID:8874241"", ""snippet"": ""Dornase alfa improved the mean percent change in FEV1 from baseline by 9.4% compared with 2.1% for placebo (p < 0.001)."", ""supports"": ""SUPPORT""}], ""name"": ""Inhaled Mucolytics""}"
1947	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	3	Pancreatic Enzyme Replacement	Oral enzymes with meals to treat malabsorption.																																																								"{""description"": ""Oral enzymes with meals to treat malabsorption."", ""name"": ""Pancreatic Enzyme Replacement""}"	{}	"{""description"": ""Oral enzymes with meals to treat malabsorption."", ""name"": ""Pancreatic Enzyme Replacement""}"
1948	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	4	Antibiotics	Chronic and acute antibiotics for bacterial lung infections.																																																								"{""description"": ""Chronic and acute antibiotics for bacterial lung infections."", ""name"": ""Antibiotics""}"	{}	"{""description"": ""Chronic and acute antibiotics for bacterial lung infections."", ""name"": ""Antibiotics""}"
1949	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	5	Lung Transplantation	For end-stage lung disease.																																																								"{""description"": ""For end-stage lung disease."", ""name"": ""Lung Transplantation""}"	{}	"{""description"": ""For end-stage lung disease."", ""name"": ""Lung Transplantation""}"
1950	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	treatments	6	Nutritional Support	High-calorie diet, fat-soluble vitamin supplementation.																																																								"{""description"": ""High-calorie diet, fat-soluble vitamin supplementation."", ""name"": ""Nutritional Support""}"	{}	"{""description"": ""High-calorie diet, fat-soluble vitamin supplementation."", ""name"": ""Nutritional Support""}"
1964	84	Danon disease	Danon_disease.yaml	treatments	0	Heart transplantation	"Cardiac transplantation is the primary disease-modifying treatment for Danon disease patients with advanced heart failure. In male patients with severe cardiomyopathy, heart transplantation is often the only intervention that modifies the disease course.
"																																																								"{""description"": ""Cardiac transplantation is the primary disease-modifying treatment for Danon disease patients with advanced heart failure. In male patients with severe cardiomyopathy, heart transplantation is often the only intervention that modifies the disease course.\n"", ""name"": ""Heart transplantation""}"	{}	"{""description"": ""Cardiac transplantation is the primary disease-modifying treatment for Danon disease patients with advanced heart failure. In male patients with severe cardiomyopathy, heart transplantation is often the only intervention that modifies the disease course.\n"", ""evidence"": [{""explanation"": ""Confirms heart transplantation as the only disease-modifying intervention."", ""reference"": ""DOI:10.1111/nan.12587"", ""snippet"": ""in male patients, the prognosis is poor due to rapid progression towards heart failure, and only heart transplantation modifies the disease course."", ""supports"": ""SUPPORT""}], ""name"": ""Heart transplantation"", ""treatment_term"": {""preferred_term"": ""heart transplantation"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}}"
1965	84	Danon disease	Danon_disease.yaml	treatments	1	Gene therapy (AAV9.LAMP2B)	"Adeno-associated virus vector-based gene therapy delivering functional LAMP2B is under clinical investigation. RP-A501, an AAV9-based gene therapy, has advanced through Phase 1 and into Phase 2 clinical trials for male patients with Danon disease.
"																																																								"{""description"": ""Adeno-associated virus vector-based gene therapy delivering functional LAMP2B is under clinical investigation. RP-A501, an AAV9-based gene therapy, has advanced through Phase 1 and into Phase 2 clinical trials for male patients with Danon disease.\n"", ""name"": ""Gene therapy (AAV9.LAMP2B)""}"	{}	"{""description"": ""Adeno-associated virus vector-based gene therapy delivering functional LAMP2B is under clinical investigation. RP-A501, an AAV9-based gene therapy, has advanced through Phase 1 and into Phase 2 clinical trials for male patients with Danon disease.\n"", ""evidence"": [{""explanation"": ""Confirms that AAV-based gene therapy clinical trials have been initiated."", ""reference"": ""DOI:10.3390/biom14101272"", ""snippet"": ""Although the pathogenetic mechanism of Danon disease remains unestablished, the first clinical trials using AAV vectors have finally begun in recent years. The development of novel therapies is expected in the future."", ""supports"": ""SUPPORT""}], ""name"": ""Gene therapy (AAV9.LAMP2B)"", ""treatment_term"": {""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}}"
1976	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	0	Cholinesterase Inhibitors	Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms.																																																								"{""description"": ""Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms."", ""name"": ""Cholinesterase Inhibitors""}"	{}	"{""description"": ""Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms."", ""evidence"": [{""explanation"": ""This confirms that cholinesterase inhibitors are part of standard clinical management for DLB, though they provide only mild symptomatic benefit."", ""reference"": ""PMID:29222591"", ""snippet"": ""Clinical management of both disorders includes cholinesterase inhibitors, other pharmacologic and nonpharmacologic strategies, but these have only a mild symptomatic effect."", ""supports"": ""SUPPORT""}], ""name"": ""Cholinesterase Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
1977	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	1	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support.																																																								"{""description"": ""No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support."", ""name"": ""Symptomatic Management""}"	{}	"{""description"": ""No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support."", ""evidence"": [{""explanation"": ""This confirms that no disease-modifying therapies are currently available for DLB, with treatment limited to symptomatic management."", ""reference"": ""PMID:29222591"", ""snippet"": ""Currently, no disease-modifying therapies are available."", ""supports"": ""SUPPORT""}], ""name"": ""Symptomatic Management"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
1996	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	0	Wide Local Excision	Surgery with wide margins (2-4 cm) or Mohs micrographic surgery is the primary treatment. Mohs technique provides margin control and is associated with the lowest recurrence rates.																																																								"{""description"": ""Surgery with wide margins (2-4 cm) or Mohs micrographic surgery is the primary treatment. Mohs technique provides margin control and is associated with the lowest recurrence rates."", ""name"": ""Wide Local Excision""}"	{}	"{""description"": ""Surgery with wide margins (2-4 cm) or Mohs micrographic surgery is the primary treatment. Mohs technique provides margin control and is associated with the lowest recurrence rates."", ""name"": ""Wide Local Excision"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
1997	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	1	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.																																																								"{""description"": ""Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance."", ""name"": ""Imatinib Targeted Therapy""}"	{}	"{""description"": ""Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance."", ""name"": ""Imatinib Targeted Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}}"
1998	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	2	Radiation Therapy	Adjuvant radiation may be considered for positive margins when re-excision is not feasible. Primary radiation is an option for unresectable cases not amenable to imatinib.																																																								"{""description"": ""Adjuvant radiation may be considered for positive margins when re-excision is not feasible. Primary radiation is an option for unresectable cases not amenable to imatinib."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Adjuvant radiation may be considered for positive margins when re-excision is not feasible. Primary radiation is an option for unresectable cases not amenable to imatinib."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
2012	88	Dermatomyositis	Dermatomyositis.yaml	treatments	0	Corticosteroids	First-line therapy for muscle and skin inflammation.																																																								"{""description"": ""First-line therapy for muscle and skin inflammation."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""First-line therapy for muscle and skin inflammation."", ""name"": ""Corticosteroids""}"
2013	88	Dermatomyositis	Dermatomyositis.yaml	treatments	1	Methotrexate	Steroid-sparing immunosuppressant.																																																								"{""description"": ""Steroid-sparing immunosuppressant."", ""name"": ""Methotrexate""}"	{}	"{""description"": ""Steroid-sparing immunosuppressant."", ""name"": ""Methotrexate""}"
2014	88	Dermatomyositis	Dermatomyositis.yaml	treatments	2	IVIG	For refractory disease, especially skin manifestations.																																																								"{""description"": ""For refractory disease, especially skin manifestations."", ""name"": ""IVIG""}"	{}	"{""description"": ""For refractory disease, especially skin manifestations."", ""evidence"": [{""explanation"": ""IVIG is effective in dermatomyositis partly through modulation of complement-mediated pathways, which are central to disease pathogenesis."", ""reference"": ""PMID:38143369"", ""snippet"": ""Further understanding of the detailed pathomechanism regarding complement, microangiopathy, and inflammation may lead to novel therapeutic approaches for IIM."", ""supports"": ""SUPPORT""}], ""name"": ""IVIG""}"
2015	88	Dermatomyositis	Dermatomyositis.yaml	treatments	3	Rituximab	For refractory myositis.																																																								"{""description"": ""For refractory myositis."", ""name"": ""Rituximab""}"	{}	"{""description"": ""For refractory myositis."", ""evidence"": [{""explanation"": ""This evidence supports the use of rituximab in severe, refractory cases, particularly those with rapidly progressive interstitial lung disease."", ""reference"": ""PMID:39334579"", ""snippet"": ""Rituximab and JAKi may reduce mortality in patients with JDM-associated RP-ILD refractory to conventional therapy."", ""supports"": ""SUPPORT""}], ""name"": ""Rituximab""}"
2016	88	Dermatomyositis	Dermatomyositis.yaml	treatments	4	JAK Inhibitors	Emerging therapy targeting type I interferon pathway. Tofacitinib, baricitinib, and ruxolitinib show efficacy in refractory cutaneous disease and anti-MDA5 associated ILD.																																																								"{""description"": ""Emerging therapy targeting type I interferon pathway. Tofacitinib, baricitinib, and ruxolitinib show efficacy in refractory cutaneous disease and anti-MDA5 associated ILD."", ""name"": ""JAK Inhibitors""}"	{}	"{""description"": ""Emerging therapy targeting type I interferon pathway. Tofacitinib, baricitinib, and ruxolitinib show efficacy in refractory cutaneous disease and anti-MDA5 associated ILD."", ""evidence"": [{""explanation"": ""This meta-analysis demonstrates significant improvement in skin disease severity (measured by CDASI) with JAK inhibitor therapy in dermatomyositis patients."", ""reference"": ""PMID:38576610"", ""snippet"": ""Regarding skin lesions, the CDASI decreased by 17.67 (95% CI: -20.94 ~ -14.41)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case series provides evidence for the efficacy of baricitinib in treating severe anti-MDA5 associated interstitial lung disease."", ""reference"": ""PMID:38456909"", ""snippet"": ""We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD) using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung opacities and saved two patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This systematic review demonstrates a 75.9% survival rate in anti-MDA5 positive dermatomyositis-ILD treated with JAK inhibitors, supporting their use in this life-threatening complication."", ""reference"": ""PMID:38456909"", ""snippet"": ""All patients except one were treated with tofacitinib, and the survival rate was 75.9%."", ""supports"": ""SUPPORT""}], ""name"": ""JAK Inhibitors""}"
2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.																																																								"{""description"": ""Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial."", ""name"": ""Multi-Agent Chemotherapy""}"	{}	"{""description"": ""Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial."", ""name"": ""Multi-Agent Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}]}}"
2032	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	1	Cytoreductive Surgery	Aggressive surgical debulking with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown benefit in selected patients. Complete cytoreduction is associated with improved survival but is often not achievable.																																																								"{""description"": ""Aggressive surgical debulking with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown benefit in selected patients. Complete cytoreduction is associated with improved survival but is often not achievable."", ""name"": ""Cytoreductive Surgery""}"	{}	"{""description"": ""Aggressive surgical debulking with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown benefit in selected patients. Complete cytoreduction is associated with improved survival but is often not achievable."", ""name"": ""Cytoreductive Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2033	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	2	Radiation Therapy	Whole abdominal radiation or intensity-modulated radiation may improve local control but is challenging given diffuse disease distribution.																																																								"{""description"": ""Whole abdominal radiation or intensity-modulated radiation may improve local control but is challenging given diffuse disease distribution."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Whole abdominal radiation or intensity-modulated radiation may improve local control but is challenging given diffuse disease distribution."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
2048	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	0	Endoscopic Mechanical Hemostasis	"Hemostatic clipping or band ligation applied directly to the exposed vessel to achieve primary hemostasis and prevent rebleeding.
"																																																								"{""description"": ""Hemostatic clipping or band ligation applied directly to the exposed vessel to achieve primary hemostasis and prevent rebleeding.\n"", ""name"": ""Endoscopic Mechanical Hemostasis""}"	{}	"{""description"": ""Hemostatic clipping or band ligation applied directly to the exposed vessel to achieve primary hemostasis and prevent rebleeding.\n"", ""evidence"": [{""explanation"": ""Systematic review shows endoscopic mechanical methods are effective first-line therapy with high primary hemostasis rates."", ""reference"": ""PMID:35243119"", ""snippet"": ""In regard to treatment, endoscopic therapy was applied in 80% ... The endoscopic treatment was a feasible choice for rectal disease, with a primary hemostasis rate of 88%."", ""supports"": ""SUPPORT""}, {""explanation"": ""Duodenal Dieulafoy case review lists banding and hemoclipping among standard endoscopic hemostasis options."", ""reference"": ""PMID:37425531"", ""snippet"": ""The treatment of duodenal DL includes thermal electrocoagulation, local epinephrine injection, sclerotherapy, banding, and hemoclipping."", ""supports"": ""SUPPORT""}], ""name"": ""Endoscopic Mechanical Hemostasis"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2049	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	1	Angiographic Embolization	"Transcatheter arterial embolization used as a salvage option when endoscopic methods are not feasible or fail to control bleeding.
"																																																								"{""description"": ""Transcatheter arterial embolization used as a salvage option when endoscopic methods are not feasible or fail to control bleeding.\n"", ""name"": ""Angiographic Embolization""}"	{}	"{""description"": ""Transcatheter arterial embolization used as a salvage option when endoscopic methods are not feasible or fail to control bleeding.\n"", ""evidence"": [{""explanation"": ""Review notes angiographic embolization employed in a subset of cases as an alternative to endoscopy or surgery."", ""reference"": ""PMID:35243119"", ""snippet"": ""angiographic embolization in 4%"", ""supports"": ""SUPPORT""}], ""name"": ""Angiographic Embolization"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2050	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	2	Surgical Ligation or Wedge Resection	"Surgical oversewing or resection of the bleeding segment reserved for refractory cases when endoscopic and radiologic approaches fail.
"																																																								"{""description"": ""Surgical oversewing or resection of the bleeding segment reserved for refractory cases when endoscopic and radiologic approaches fail.\n"", ""name"": ""Surgical Ligation or Wedge Resection""}"	{}	"{""description"": ""Surgical oversewing or resection of the bleeding segment reserved for refractory cases when endoscopic and radiologic approaches fail.\n"", ""evidence"": [{""explanation"": ""Case series emphasizes surgery as rescue therapy after failed endoscopic management of Dieulafoy lesions."", ""reference"": ""PMID:38113567"", ""snippet"": ""Endoscopic methods ... are preferred for treatment, boasting success rates over 90 %. Surgical measures become a last resort for uncontrolled bleeding."", ""supports"": ""SUPPORT""}, {""explanation"": ""Autopsy case underscores that uncontrolled Dieulafoy bleeding can be fatal, highlighting need for definitive rescue measures when endoscopy fails."", ""reference"": ""PMID:39298100"", ""snippet"": ""Fatal exulceratio simplex (dieulafoy lesion)"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Ligation or Wedge Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.																																																								"{""description"": ""Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease."", ""name"": ""R-CHOP Immunochemotherapy""}"	{}	"{""description"": ""Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease."", ""name"": ""R-CHOP Immunochemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}]}}"
2074	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	1	Polatuzumab Vedotin plus R-CHP	CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP.																																																								"{""description"": ""CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP."", ""name"": ""Polatuzumab Vedotin plus R-CHP""}"	{}	"{""description"": ""CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP."", ""name"": ""Polatuzumab Vedotin plus R-CHP"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2075	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	2	Intensive Chemotherapy for Double-Hit Lymphoma	High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL.																																																								"{""description"": ""High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL."", ""name"": ""Intensive Chemotherapy for Double-Hit Lymphoma""}"	{}	"{""description"": ""High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL."", ""name"": ""Intensive Chemotherapy for Double-Hit Lymphoma"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2076	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	3	CAR-T Cell Therapy	CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients.																																																								"{""description"": ""CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients."", ""name"": ""CAR-T Cell Therapy""}"	{}	"{""description"": ""CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients."", ""name"": ""CAR-T Cell Therapy"", ""treatment_term"": {""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}}"
2077	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	4	Autologous Stem Cell Transplantation	For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease.																																																								"{""description"": ""For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease."", ""name"": ""Autologous Stem Cell Transplantation""}"	{}	"{""description"": ""For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease."", ""name"": ""Autologous Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
2078	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	5	Radiation Therapy	Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach.																																																								"{""description"": ""Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
2106	93	Down_syndrome	Down_syndrome.yaml	treatments	0	Early Intervention Programs	Support services including physical, occupational, and speech therapy.																																																								"{""description"": ""Support services including physical, occupational, and speech therapy."", ""name"": ""Early Intervention Programs""}"	{}	"{""description"": ""Support services including physical, occupational, and speech therapy."", ""evidence"": [{""explanation"": ""Supports importance of therapeutic interventions for intellectual disability in Down syndrome."", ""reference"": ""PMID:32029743"", ""snippet"": ""Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored; these efforts provide reasonable hope for the future."", ""supports"": ""SUPPORT""}], ""name"": ""Early Intervention Programs"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
2107	93	Down_syndrome	Down_syndrome.yaml	treatments	1	Cardiac Surgery	For congenital heart defect correction if needed.																																																								"{""description"": ""For congenital heart defect correction if needed."", ""name"": ""Cardiac Surgery""}"	{}	"{""description"": ""For congenital heart defect correction if needed."", ""evidence"": [{""explanation"": ""Supports the association of congenital heart disease with Down syndrome requiring surgical intervention."", ""reference"": ""PMID:32029743"", ""snippet"": ""Since the first description of trisomy 21, we have learned much about intellectual disability and genetic risk factors for congenital heart disease."", ""supports"": ""SUPPORT""}], ""name"": ""Cardiac Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2108	93	Down_syndrome	Down_syndrome.yaml	treatments	2	Hormone Replacement Therapy	For treating hypothyroidism.																																																								"{""description"": ""For treating hypothyroidism."", ""name"": ""Hormone Replacement Therapy""}"	{}	"{""description"": ""For treating hypothyroidism."", ""evidence"": [{""explanation"": ""Supports monitoring and treatment of thyroid dysfunction in Down syndrome patients."", ""reference"": ""PMID:11853334"", ""snippet"": ""Down's syndrome patients with normal thyroid functions and those with compensated hypothyroidism should be followed annually and every 3 mo, respectively."", ""supports"": ""SUPPORT""}], ""name"": ""Hormone Replacement Therapy"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
2109	93	Down_syndrome	Down_syndrome.yaml	treatments	3	Educational Support	Tailored educational plans to support learning and development.																																																								"{""description"": ""Tailored educational plans to support learning and development."", ""name"": ""Educational Support""}"	{}	"{""description"": ""Tailored educational plans to support learning and development."", ""evidence"": [{""explanation"": ""Supports the importance of interventions targeting intellectual disability in Down syndrome."", ""reference"": ""PMID:32029743"", ""snippet"": ""Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored."", ""supports"": ""SUPPORT""}], ""name"": ""Educational Support"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
2139	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	0	Antiepileptic Medications	Includes clobazam, stiripentol, and valproate as first-line agents. Sodium channel blockers should be avoided as they may worsen seizures.																																		Standard treatment includes clobazam, stiripentol, and valproate.																						"{""description"": ""Includes clobazam, stiripentol, and valproate as first-line agents. Sodium channel blockers should be avoided as they may worsen seizures."", ""name"": ""Antiepileptic Medications"", ""notes"": ""Standard treatment includes clobazam, stiripentol, and valproate.""}"	{}	"{""description"": ""Includes clobazam, stiripentol, and valproate as first-line agents. Sodium channel blockers should be avoided as they may worsen seizures."", ""name"": ""Antiepileptic Medications"", ""notes"": ""Standard treatment includes clobazam, stiripentol, and valproate."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2140	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	1	Ketogenic Diet	High-fat, low-carbohydrate diet that can provide significant seizure reduction in some patients.																																		Has shown efficacy in reducing seizure frequency in Dravet syndrome patients.																						"{""description"": ""High-fat, low-carbohydrate diet that can provide significant seizure reduction in some patients."", ""name"": ""Ketogenic Diet"", ""notes"": ""Has shown efficacy in reducing seizure frequency in Dravet syndrome patients.""}"	{}	"{""description"": ""High-fat, low-carbohydrate diet that can provide significant seizure reduction in some patients."", ""name"": ""Ketogenic Diet"", ""notes"": ""Has shown efficacy in reducing seizure frequency in Dravet syndrome patients."", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
2141	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	2	Supportive Therapies	Therapies such as physical, occupational, and speech therapy to address developmental delays and cognitive impairment.																																		Comprehensive care includes developmental support and therapeutic interventions.																						"{""description"": ""Therapies such as physical, occupational, and speech therapy to address developmental delays and cognitive impairment."", ""name"": ""Supportive Therapies"", ""notes"": ""Comprehensive care includes developmental support and therapeutic interventions.""}"	{}	"{""description"": ""Therapies such as physical, occupational, and speech therapy to address developmental delays and cognitive impairment."", ""name"": ""Supportive Therapies"", ""notes"": ""Comprehensive care includes developmental support and therapeutic interventions."", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2142	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	3	Vagus Nerve Stimulation (VNS)	Implanted device that may help reduce seizure frequency in drug-resistant cases.																																		May be considered for patients with drug-resistant seizures.																						"{""description"": ""Implanted device that may help reduce seizure frequency in drug-resistant cases."", ""name"": ""Vagus Nerve Stimulation (VNS)"", ""notes"": ""May be considered for patients with drug-resistant seizures.""}"	{}	"{""description"": ""Implanted device that may help reduce seizure frequency in drug-resistant cases."", ""name"": ""Vagus Nerve Stimulation (VNS)"", ""notes"": ""May be considered for patients with drug-resistant seizures."", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2143	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	4	Antisense Oligonucleotide Therapy (STK-001/Zorevunersen)	Investigational antisense oligonucleotide designed to upregulate productive SCN1A transcripts and restore Nav1.1 expression in inhibitory neurons. Preclinical studies show seizure reduction and SUDEP prevention. Early clinical data report good tolerability with reduced seizure frequency in treated individuals.																																		Disease-modifying gene-targeted therapy in early clinical development. Represents precision approach to address underlying SCN1A haploinsufficiency.																						"{""description"": ""Investigational antisense oligonucleotide designed to upregulate productive SCN1A transcripts and restore Nav1.1 expression in inhibitory neurons. Preclinical studies show seizure reduction and SUDEP prevention. Early clinical data report good tolerability with reduced seizure frequency in treated individuals."", ""name"": ""Antisense Oligonucleotide Therapy (STK-001/Zorevunersen)"", ""notes"": ""Disease-modifying gene-targeted therapy in early clinical development. Represents precision approach to address underlying SCN1A haploinsufficiency.""}"	{}	"{""description"": ""Investigational antisense oligonucleotide designed to upregulate productive SCN1A transcripts and restore Nav1.1 expression in inhibitory neurons. Preclinical studies show seizure reduction and SUDEP prevention. Early clinical data report good tolerability with reduced seizure frequency in treated individuals."", ""name"": ""Antisense Oligonucleotide Therapy (STK-001/Zorevunersen)"", ""notes"": ""Disease-modifying gene-targeted therapy in early clinical development. Represents precision approach to address underlying SCN1A haploinsufficiency."", ""treatment_term"": {""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}}"
2144	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	5	AAV Gene Therapy (ETX101)	Investigational AAV9-based viral vector gene therapy designed to increase SCN1A expression through transcriptional activation in inhibitory neurons. Preclinical models demonstrate seizure reduction and improved survival.																																		Disease-modifying gene therapy approaching clinical testing. Targets interneuron-specific SCN1A restoration.																						"{""description"": ""Investigational AAV9-based viral vector gene therapy designed to increase SCN1A expression through transcriptional activation in inhibitory neurons. Preclinical models demonstrate seizure reduction and improved survival."", ""name"": ""AAV Gene Therapy (ETX101)"", ""notes"": ""Disease-modifying gene therapy approaching clinical testing. Targets interneuron-specific SCN1A restoration.""}"	{}	"{""description"": ""Investigational AAV9-based viral vector gene therapy designed to increase SCN1A expression through transcriptional activation in inhibitory neurons. Preclinical models demonstrate seizure reduction and improved survival."", ""name"": ""AAV Gene Therapy (ETX101)"", ""notes"": ""Disease-modifying gene therapy approaching clinical testing. Targets interneuron-specific SCN1A restoration."", ""treatment_term"": {""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}}"
2145	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	6	Cannabidiol	Pharmaceutical-grade cannabidiol approved as add-on therapy for reducing convulsive seizure frequency in Dravet syndrome.																																		Approved therapy with demonstrated efficacy in randomized controlled trials.																						"{""description"": ""Pharmaceutical-grade cannabidiol approved as add-on therapy for reducing convulsive seizure frequency in Dravet syndrome."", ""name"": ""Cannabidiol"", ""notes"": ""Approved therapy with demonstrated efficacy in randomized controlled trials.""}"	{}	"{""description"": ""Pharmaceutical-grade cannabidiol approved as add-on therapy for reducing convulsive seizure frequency in Dravet syndrome."", ""name"": ""Cannabidiol"", ""notes"": ""Approved therapy with demonstrated efficacy in randomized controlled trials."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2146	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	7	Fenfluramine	Approved add-on therapy for convulsive seizures in Dravet syndrome, with serotonergic mechanism of action.																																		Effective therapy approved based on randomized controlled trial data.																						"{""description"": ""Approved add-on therapy for convulsive seizures in Dravet syndrome, with serotonergic mechanism of action."", ""name"": ""Fenfluramine"", ""notes"": ""Effective therapy approved based on randomized controlled trial data.""}"	{}	"{""description"": ""Approved add-on therapy for convulsive seizures in Dravet syndrome, with serotonergic mechanism of action."", ""name"": ""Fenfluramine"", ""notes"": ""Effective therapy approved based on randomized controlled trial data."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2147	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	8	Stiripentol	Approved antiepileptic drug used in combination with clobazam and valproate for convulsive seizures in Dravet syndrome.																																		Part of standard first-line combination therapy.																						"{""description"": ""Approved antiepileptic drug used in combination with clobazam and valproate for convulsive seizures in Dravet syndrome."", ""name"": ""Stiripentol"", ""notes"": ""Part of standard first-line combination therapy.""}"	{}	"{""description"": ""Approved antiepileptic drug used in combination with clobazam and valproate for convulsive seizures in Dravet syndrome."", ""name"": ""Stiripentol"", ""notes"": ""Part of standard first-line combination therapy."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2161	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	0	Corticosteroids	Prednisone or deflazacort to slow muscle degeneration and prolong ambulation.																																																								"{""description"": ""Prednisone or deflazacort to slow muscle degeneration and prolong ambulation."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Prednisone or deflazacort to slow muscle degeneration and prolong ambulation."", ""evidence"": [{""explanation"": ""Cochrane review confirms corticosteroids improve muscle strength and function in DMD."", ""reference"": ""PMID:15106215"", ""snippet"": ""There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short-term (six months to two years)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Long-term follow-up study confirms corticosteroids prolong function in DMD."", ""reference"": ""PMID:22581531"", ""snippet"": ""Long-term corticosteroid treatment is effective in prolonging function but not in recovering lost function, and its early use seems appropriate."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids""}"
2162	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	1	Cardiac Management	ACE inhibitors and beta-blockers for cardiomyopathy prevention and treatment.																																																								"{""description"": ""ACE inhibitors and beta-blockers for cardiomyopathy prevention and treatment."", ""name"": ""Cardiac Management""}"	{}	"{""description"": ""ACE inhibitors and beta-blockers for cardiomyopathy prevention and treatment."", ""evidence"": [{""explanation"": ""Study demonstrates ACE inhibitors improve cardiac function in DMD patients."", ""reference"": ""PMID:22463839"", ""snippet"": ""Treatment with ACE inhibitor or ACE inhibitor plus BB resulted in significant improvement compared to pretherapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""Study shows ACE inhibitor plus beta-blocker combination improves survival in DMD."", ""reference"": ""PMID:19167641"", ""snippet"": ""In this study, the combination of an ACE inhibitor and a beta-blocker had a beneficial effect on long-term survival of DMD patients with heart failure."", ""supports"": ""SUPPORT""}], ""name"": ""Cardiac Management""}"
2163	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	2	Respiratory Support	Non-invasive ventilation as respiratory function declines.																																																								"{""description"": ""Non-invasive ventilation as respiratory function declines."", ""name"": ""Respiratory Support""}"	{}	"{""description"": ""Non-invasive ventilation as respiratory function declines."", ""name"": ""Respiratory Support""}"
2164	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	3	Exon Skipping Therapy	Antisense oligonucleotides (eteplirsen, golodirsen) to restore reading frame in specific mutations.																																																								"{""description"": ""Antisense oligonucleotides (eteplirsen, golodirsen) to restore reading frame in specific mutations."", ""name"": ""Exon Skipping Therapy""}"	{}	"{""description"": ""Antisense oligonucleotides (eteplirsen, golodirsen) to restore reading frame in specific mutations."", ""evidence"": [{""explanation"": ""Clinical study demonstrates eteplirsen induces dystrophin production in DMD patients."", ""reference"": ""PMID:29752304"", ""snippet"": ""In treated patients vs untreated controls, Western blot analysis of dystrophin content demonstrated an 11.6-fold increase (p = 0.007), and PDPF analysis demonstrated a 7.4-fold increase (p < 0.001)."", ""supports"": ""SUPPORT""}], ""name"": ""Exon Skipping Therapy""}"
2165	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	treatments	4	Gene Therapy	Micro-dystrophin gene delivery via AAV vectors in clinical trials.																																																								"{""description"": ""Micro-dystrophin gene delivery via AAV vectors in clinical trials."", ""name"": ""Gene Therapy""}"	{}	"{""description"": ""Micro-dystrophin gene delivery via AAV vectors in clinical trials."", ""name"": ""Gene Therapy""}"
2184	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	0	Surgical Resection	Gastrectomy with lymph node dissection is the primary treatment for localized disease. EBV-positive tumors have relatively favorable prognosis compared to other molecular subtypes.																																																								"{""description"": ""Gastrectomy with lymph node dissection is the primary treatment for localized disease. EBV-positive tumors have relatively favorable prognosis compared to other molecular subtypes."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Gastrectomy with lymph node dissection is the primary treatment for localized disease. EBV-positive tumors have relatively favorable prognosis compared to other molecular subtypes."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2185	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	1	Chemotherapy	Perioperative or palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX) is standard for advanced disease.																																																								"{""description"": ""Perioperative or palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX) is standard for advanced disease."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Perioperative or palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX) is standard for advanced disease."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2186	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	2	Immune Checkpoint Inhibitors	EBV-positive gastric cancers show high expression of PD-L1 due to 9p24.1 amplification and strong immune infiltration, making them potentially responsive to PD-1/PD-L1 inhibitors such as pembrolizumab or nivolumab. This represents a molecularly-targeted approach based on the unique immunobiology of this subtype.																																																								"{""description"": ""EBV-positive gastric cancers show high expression of PD-L1 due to 9p24.1 amplification and strong immune infiltration, making them potentially responsive to PD-1/PD-L1 inhibitors such as pembrolizumab or nivolumab. This represents a molecularly-targeted approach based on the unique immunobiology of this subtype."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""EBV-positive gastric cancers show high expression of PD-L1 due to 9p24.1 amplification and strong immune infiltration, making them potentially responsive to PD-1/PD-L1 inhibitors such as pembrolizumab or nivolumab. This represents a molecularly-targeted approach based on the unique immunobiology of this subtype."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2202	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	0	Osimertinib	Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS. Excellent CNS penetration.																																																								"{""description"": ""Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS. Excellent CNS penetration."", ""name"": ""Osimertinib""}"	{}	"{""description"": ""Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS. Excellent CNS penetration."", ""name"": ""Osimertinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2203	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	1	Erlotinib	First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting.																																																								"{""description"": ""First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting."", ""name"": ""Erlotinib""}"	{}	"{""description"": ""First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting."", ""name"": ""Erlotinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2204	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	2	Gefitinib	First-generation EGFR TKI approved for EGFR-mutant NSCLC. Similar efficacy to erlotinib. Largely supplanted by osimertinib.																																																								"{""description"": ""First-generation EGFR TKI approved for EGFR-mutant NSCLC. Similar efficacy to erlotinib. Largely supplanted by osimertinib."", ""name"": ""Gefitinib""}"	{}	"{""description"": ""First-generation EGFR TKI approved for EGFR-mutant NSCLC. Similar efficacy to erlotinib. Largely supplanted by osimertinib."", ""name"": ""Gefitinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2205	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	3	Amivantamab	Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations (which are resistant to most TKIs) and in combination with chemotherapy for first-line EGFR-mutant NSCLC.																																																								"{""description"": ""Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations (which are resistant to most TKIs) and in combination with chemotherapy for first-line EGFR-mutant NSCLC."", ""name"": ""Amivantamab""}"	{}	"{""description"": ""Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations (which are resistant to most TKIs) and in combination with chemotherapy for first-line EGFR-mutant NSCLC."", ""name"": ""Amivantamab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2206	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy. May be combined with EGFR TKIs in certain settings.																																																								"{""description"": ""Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy. May be combined with EGFR TKIs in certain settings."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy. May be combined with EGFR TKIs in certain settings."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2221	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	0	Aromatase Inhibitors	First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients.																																																								"{""description"": ""First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients."", ""name"": ""Aromatase Inhibitors""}"	{}	"{""description"": ""First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients."", ""evidence"": [{""explanation"": ""EBCTCG meta-analysis establishes the survival benefit of endocrine therapy in ER+ breast cancer, which extends to aromatase inhibitors."", ""reference"": ""PMID:15894097"", ""snippet"": ""For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)"", ""supports"": ""SUPPORT""}], ""name"": ""Aromatase Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2222	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	1	Tamoxifen	Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction.																																																								"{""description"": ""Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction."", ""name"": ""Tamoxifen""}"	{}	"{""description"": ""Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction."", ""evidence"": [{""explanation"": ""Landmark EBCTCG meta-analysis of 194 trials shows 5 years of tamoxifen reduces breast cancer mortality by 31%."", ""reference"": ""PMID:15894097"", ""snippet"": ""For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)"", ""supports"": ""SUPPORT""}], ""name"": ""Tamoxifen"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2223	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	2	CDK4/6 Inhibitors	Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease.																																																								"{""description"": ""Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease."", ""name"": ""CDK4/6 Inhibitors""}"	{}	"{""description"": ""Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease."", ""evidence"": [{""explanation"": ""PALOMA-3 demonstrated palbociclib plus fulvestrant more than doubled PFS compared to fulvestrant alone in HR+/HER2- metastatic breast cancer."", ""reference"": ""PMID:26947331"", ""snippet"": ""Median progression-free survival was 95 months (95% CI 92-110) in the fulvestrant plus palbociclib group and 46 months (35-56) in the fulvestrant plus placebo group (hazard ratio 046, 95% CI 036-059, p<00001)."", ""supports"": ""SUPPORT""}], ""name"": ""CDK4/6 Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2224	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	3	Fulvestrant	Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy.																																																								"{""description"": ""Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy."", ""name"": ""Fulvestrant""}"	{}	"{""description"": ""Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy."", ""evidence"": [{""explanation"": ""PALOMA-3 confirms fulvestrant's role as backbone therapy in HR+/HER2- metastatic breast cancer, demonstrating activity when combined with CDK4/6i."", ""reference"": ""PMID:26947331"", ""snippet"": ""Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo"", ""supports"": ""SUPPORT""}], ""name"": ""Fulvestrant"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2225	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	4	Alpelisib	PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant.																																																								"{""description"": ""PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant."", ""name"": ""Alpelisib""}"	{}	"{""description"": ""PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant."", ""evidence"": [{""explanation"": ""PALOMA-3 confirms PIK3CA mutations are present in ~33% of HR+ metastatic breast cancers, establishing the target population for PI3K inhibitors."", ""reference"": ""PMID:26947331"", ""snippet"": ""PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients"", ""supports"": ""SUPPORT""}], ""name"": ""Alpelisib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2226	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	5	Elacestrant	Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations.																																																								"{""description"": ""Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations."", ""name"": ""Elacestrant""}"	{}	"{""description"": ""Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations."", ""evidence"": [{""explanation"": ""PALOMA-3 establishes the clinical context of endocrine-resistant HR+ breast cancer where novel SERDs like elacestrant are indicated."", ""reference"": ""PMID:26947331"", ""snippet"": ""women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy"", ""supports"": ""SUPPORT""}], ""name"": ""Elacestrant"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2269	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	0	Supportive Care	Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.																																																								"{""description"": ""Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain."", ""evidence"": [{""explanation"": ""The provided literature supports that supportive care, including rehydration and symptomatic treatment, is a key component in the treatment of Ebola Virus Disease (EVD)."", ""reference"": ""PMID:37355146"", ""snippet"": ""Early detection and supportive care can enhance the likelihood of survival. This includes intravenous fluids, electrolyte replacement, and treatment of secondary infections."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature indicates the combination of supportive and symptomatic care is part of the clinical management of EVD."", ""reference"": ""PMID:28646340"", ""snippet"": ""Clinical management of EVD combines supportive and symptomatic care while also addressing the patient's emotional and mental health needs."", ""supports"": ""SUPPORT""}, {""explanation"": ""The evidence-based guidelines for supportive care of patients with EVD include recommendations that align with rehydration and symptomatic treatments for managing fever, bleeding, and pain."", ""reference"": ""PMID:29054555"", ""snippet"": ""Key recommendations include administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital signs and volume status; availability of key biochemical testing; adequate staffing ratios; and availability of analgesics, including opioids, for pain relief."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	Experimental Therapies	Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.																																																								"{""description"": ""Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies."", ""name"": ""Experimental Therapies""}"	{}	"{""description"": ""Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies."", ""evidence"": [{""explanation"": ""The reference mentions the use of various experimental therapies including immune therapies (monoclonal antibodies), blood products (convalescent plasma), and small molecule therapeutics (antiviral drugs)."", ""reference"": ""PMID:27337455"", ""snippet"": ""The armamentarium against EVD eventually included biologics such as monoclonal antibodies, convalescent plasma, and vaccines as well as small molecule therapeutics such as small interfering RNAs and nucleoside analogs."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference highlights the ongoing research for developing therapeutics, including immune mechanisms for protection, which aligns with the statement."", ""reference"": ""PMID:11766882"", ""snippet"": ""This review describes Ebola viruses, with a particular focus on the status of research efforts to develop vaccines and therapeutics and to identify the immune mechanisms of protection."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference confirms the use of convalescent blood products as a treatment strategy for EVD, supporting the statement."", ""reference"": ""PMID:25457751"", ""snippet"": ""Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference lists anti-viral therapy and immunotherapies as main treatment options, confirming the statement's reference to experimental therapies."", ""reference"": ""PMID:32487785"", ""snippet"": ""Management of patients involves supportive care such as maintaining fluid along with electrolyte balance, blood pressure and oxygen saturation. This also includes treating complications arising from secondary infections. The main options include: prophylactic strategies, anti-viral therapy for EVD, immunotherapies, vaccines, and ZMapp."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses therapeutic monoclonal antibodies, which are a form of immune therapy, in line with the statement."", ""reference"": ""PMID:30943399"", ""snippet"": ""We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP)."", ""supports"": ""SUPPORT""}], ""name"": ""Experimental Therapies"", ""treatment_term"": {""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}}"
2271	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	2	Vaccination	The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.																																																								"{""description"": ""The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection."", ""name"": ""Vaccination""}"	{}	"{""description"": ""The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection."", ""evidence"": [{""explanation"": ""The study shows that rVSV-ZEBOV vaccine offers substantial protection against Ebola virus disease, supporting the statement that it is effective in preventing Ebola infection."", ""reference"": ""PMID:28017403"", ""snippet"": ""The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article states that Ervebo (rVSV-ZEBOV) is licensed for the prevention of Ebola virus disease, supporting the statement that the vaccine is effective in preventing Ebola infection."", ""reference"": ""PMID:32243796"", ""snippet"": ""Ervebo is the first licensed vaccine for prevention of Ebola virus disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract mentions that Ervebo (rVSV-ZEBOV) has been licensed and is being used to prevent Ebola Virus Disease, supporting the statement that it is effective in preventing infection."", ""reference"": ""PMID:33873076"", ""snippet"": ""Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article confirms that the rVSV-EBOV-GP (Ervebo) vaccine is FDA-approved and provides prophylactic protection against Ebola, supporting the statement that it is effective in preventing Ebola infection."", ""reference"": ""PMID:34749265"", ""snippet"": ""In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo by Merck)"", ""supports"": ""SUPPORT""}], ""name"": ""Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
2312	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	0	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.																																																								"{""description"": ""Management of pain, physical therapy to strengthen joints, and prevention of complications."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Management of pain, physical therapy to strengthen joints, and prevention of complications."", ""evidence"": [{""explanation"": ""This reference highlights the need for multimodal pain management in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive care."", ""reference"": ""PMID:38189943"", ""snippet"": ""Affected patients require multimodal pain management considering their individual needs, disease-specific features, and comorbidities."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of physical therapy, which strengthens joints and manages pain, aligning with the statement."", ""reference"": ""PMID:34145717"", ""snippet"": ""Physiotherapy benefits on proprioception and pain in patients with hEDS even if robust randomized control studies are missing."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the prevention of complications through preparticipation screening and various management practices, which falls under supportive care."", ""reference"": ""PMID:17067502"", ""snippet"": ""Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights the importance of multidisciplinary care, essential in the supportive management of EDS."", ""reference"": ""PMID:32941194"", ""snippet"": ""The creation of multidisciplinary care teams and tertiary referral centers is helping improve outcomes."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
2313	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	1	Surgical Interventions	May be needed for severe joint instability or life-threatening complications like arterial dissections.																																																								"{""description"": ""May be needed for severe joint instability or life-threatening complications like arterial dissections."", ""name"": ""Surgical Interventions""}"	{}	"{""description"": ""May be needed for severe joint instability or life-threatening complications like arterial dissections."", ""evidence"": [{""explanation"": ""This article supports the need for surgical interventions for severe joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which can be considered analogous to severe cases in other types of EDS."", ""reference"": ""PMID:32904109"", ""snippet"": ""Patients with joint hypermobility syndrome (JHS) might also present with similar symptomatology. This article will focus on the surgical management of patients with knee or shoulder abnormalities related to hEDS/JHS."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the article mainly discusses the use of celiprolol, it acknowledges arterial events and their impact, implicitly supporting the need for interventions, which may include surgical options, in severe cases involving life-threatening arterial complications."", ""reference"": ""PMID:30999998"", ""snippet"": ""The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality... During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up before and after 2011."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the need for surgical interventions in life-threatening complications like spontaneous arterial rupture and visceral perforation in vascular EDS."", ""reference"": ""PMID:33650410"", ""snippet"": ""The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Interventions"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2314	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	2	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury.																																																								"{""description"": ""Avoiding high-impact activities and contact sports to prevent injury."", ""name"": ""Lifestyle Modifications""}"	{}	"{""description"": ""Avoiding high-impact activities and contact sports to prevent injury."", ""evidence"": [{""explanation"": ""The literature suggests avoiding high-impact activities and specific management strategies, which supports the statement."", ""reference"": ""PMID:17067502"", ""snippet"": ""Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."", ""supports"": ""SUPPORT""}, {""explanation"": ""While exercise and rehabilitation are recommended, the literature implies careful selection of physical activities to prevent injury, indirectly supporting the avoidance of high-impact activities and contact sports."", ""reference"": ""PMID:35756986"", ""snippet"": ""The results suggest that exercise and rehabilitation may be beneficial for various physical and psychological outcomes."", ""supports"": ""SUPPORT""}], ""name"": ""Lifestyle Modifications"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
2315	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	3	Orthotic Interventions	Use of orthotic devices to support unstable joints.																																												Added orthotic interventions commonly recommended in the management of EDS.												"{""description"": ""Use of orthotic devices to support unstable joints."", ""name"": ""Orthotic Interventions"", ""review_notes"": ""Added orthotic interventions commonly recommended in the management of EDS.""}"	{}	"{""description"": ""Use of orthotic devices to support unstable joints."", ""evidence"": [{""explanation"": ""This reference mentions orthotic devices as part of the effective treatments for Ehlers-Danlos syndrome."", ""reference"": ""PMID:27349123"", ""snippet"": ""ignorance of effective treatments such as oxygen therapy and orthotics are new concepts that should shake the prejudices derived from the history of this disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of orthotic devices (e.g., bracing) as effective in the management of EDS."", ""reference"": ""PMID:32709178"", ""snippet"": ""Occupational therapy and bracing were the most effective options with 70% of patients reporting improvement."", ""supports"": ""SUPPORT""}], ""name"": ""Orthotic Interventions"", ""review_notes"": ""Added orthotic interventions commonly recommended in the management of EDS."", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.																																																								"{""description"": ""Management of pain, physical therapy to strengthen joints, and prevention of complications."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Management of pain, physical therapy to strengthen joints, and prevention of complications."", ""evidence"": [{""explanation"": ""The reference discusses chronic pain management in the context of Ehlers-Danlos syndrome, aligning with the statement about management of pain."", ""reference"": ""PMID:22616833"", ""snippet"": ""The topics addressed in this issue are Ehlers-Danlos syndrome and associated chronic pain; the information is meant to help readers understand the mechanisms for pain in this connective tissue disorder as well as general treatment principles for chronic pain management."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the role of physical therapy in the management of hypermobile Ehlers-Danlos syndromes (hEDS), which aligns with the statement about physical therapy to strengthen joints."", ""reference"": ""PMID:33741806"", ""snippet"": ""Evidence supporting physical therapy and occupational therapy is provided... Treatment should be individualized."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference focuses on the genetic aspect and causal mutations in COL5A1 related to Ehlers-Danlos syndrome but does not delve into treatments."", ""reference"": ""PMID:9042913"", ""snippet"": ""These findings confirm the causal role of collagen V in at least a subgroup of EDS I."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference mentions symptomatic treatment but does not provide specific details on pain management, physical therapy, or prevention of complications for COL5A1-related Ehlers-Danlos syndrome."", ""reference"": ""PMID:35162892"", ""snippet"": ""Treatment is currently symptomatic and focuses on increasing the quality of life of these patients, as there is no curative treatment."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference discusses limited medical interventions and management of vascular Ehlers-Danlos syndrome (vEDS), which is different from COL5A1-related EDS."", ""reference"": ""PMID:32941194"", ""snippet"": ""Although medical interventions to help halt the disease progression remain limited, improved awareness of vEDS by patients and practitioners have resulted in increased average life expectancy."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
2336	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	1	Wound Care	Careful attention to wound healing and scar management.																																																								"{""description"": ""Careful attention to wound healing and scar management."", ""name"": ""Wound Care""}"	{}	"{""description"": ""Careful attention to wound healing and scar management."", ""evidence"": [{""explanation"": ""The reference mentions skin abnormalities but does not provide explicit details on treatments related to wound care or scar management."", ""reference"": ""PMID:8274350"", ""snippet"": ""Manifestations are highly variable, and include numerous skin abnormalities. Nurses play an important role in helping patients and their families live with this unusual disorder."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference discusses wound healing in animal models of EDS but indicates that delayed healing, a common complication in human EDS patients, was not observed in the studied animals."", ""reference"": ""PMID:2728341"", ""snippet"": ""Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference identifies poor wound healing as a complication associated with classic EDS due to COL5A1 mutations, which supports the need for careful attention to wound healing and scar management."", ""reference"": ""PMID:28387435"", ""snippet"": ""Classic Ehlers-Danlos syndrome (EDS) patients suffer from connective tissue hyperelasticity, joint instability, skin hyperextensibility, tissue fragility, and poor wound healing due to heterozygous mutations in COL5a1 or COL5a2 genes."", ""supports"": ""SUPPORT""}, {""explanation"": ""This detailed observation of classic EDS symptoms and associated collagen abnormalities highlights the importance of wound and scar care in patients."", ""reference"": ""PMID:37594181"", ""snippet"": ""The classic tragic facial expression was observed as well as chronic pruritus and mild hyperesthesia. ... Histology showed sparse, disorganized collagen and an increase in cutaneous mast cells. Electron microscopy identified ultrastructural defects commonly seen in collagen type V alpha 1 chain (COL5A1) variants including flower-like collagen fibrils in cross-section."", ""supports"": ""SUPPORT""}], ""name"": ""Wound Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2337	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	2	Cardiovascular Monitoring	Regular evaluation for mitral valve prolapse and other cardiovascular complications.																																																								"{""description"": ""Regular evaluation for mitral valve prolapse and other cardiovascular complications."", ""name"": ""Cardiovascular Monitoring""}"	{}	"{""description"": ""Regular evaluation for mitral valve prolapse and other cardiovascular complications."", ""evidence"": [{""explanation"": ""This reference supports cardiovascular monitoring in Ehlers-Danlos Syndrome, particularly for mitral valve prolapse and aortic dilation."", ""reference"": ""PMID:21193204"", ""snippet"": ""Echocardiography may still be warranted as part of cardiovascular assessment, but decreased frequency of screening is recommended especially in symptom-free adults."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the need for evaluation in Ehlers-Danlos Syndrome for cardiovascular complications like mitral valve prolapse."", ""reference"": ""PMID:15607555"", ""snippet"": ""This proposal is specifically concerned with Ehlers-Danlos syndrome classic type (formerly Types I-III), which is characterized by ... cardiac mitral valve prolapse."", ""supports"": ""SUPPORT""}], ""name"": ""Cardiovascular Monitoring""}"
2338	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	3	Gastrointestinal Management	Treatment of gastroesophageal reflux and other GI symptoms as needed.																																																								"{""description"": ""Treatment of gastroesophageal reflux and other GI symptoms as needed."", ""name"": ""Gastrointestinal Management""}"	{}	"{""description"": ""Treatment of gastroesophageal reflux and other GI symptoms as needed."", ""evidence"": [{""explanation"": ""This study highlights the prevalence of gastrointestinal manifestations in patients with various subtypes of EDS, indicating that GI management, including treatment of conditions like gastroesophageal reflux, is indeed a necessary part of the overall treatment plan."", ""reference"": ""PMID:26376608"", ""snippet"": ""CONCLUSIONS & INFERENCES: EDS HM and other subtypes should be considered in patients with chronic functional GI symptoms and abdominal vascular lesions."", ""supports"": ""SUPPORT""}], ""name"": ""Gastrointestinal Management"", ""treatment_term"": {""preferred_term"": ""gastrointestinal agent therapy"", ""term"": {""id"": ""MAXO:0000267"", ""label"": ""gastrointestinal agent therapy""}}}"
2339	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	4	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary.																																																								"{""description"": ""Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary."", ""name"": ""Lifestyle Modifications""}"	{}	"{""description"": ""Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary."", ""evidence"": [{""explanation"": ""The literature emphasizes careful screening and multidisciplinary management for athletes with EDS, which implicitly supports the avoidance of high-impact activities to prevent injuries but does not explicitly mention the use of protective gear or contact sports."", ""reference"": ""PMID:17067502"", ""snippet"": ""Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study highlights the importance of providing advice to patients about lifestyle changes due to EDS but does not specifically mention avoiding high-impact activities or using protective gear."", ""reference"": ""PMID:32899328"", ""snippet"": ""The major clinical manifestations of EDS include joint hypermobility, skin hyperextensibility, and generalized connective tissue fragility. ... These findings allow healthcare providers to know more about this disease in order to support and give advice to patients about the changes they will have to make."", ""supports"": ""PARTIAL""}], ""name"": ""Lifestyle Modifications"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.																																																								"{""description"": ""Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy."", ""name"": ""Multi-Agent Chemotherapy""}"	{}	"{""description"": ""Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy."", ""name"": ""Multi-Agent Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}}"
2356	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	1	Surgical Resection	Complete surgical resection when feasible without significant morbidity. For favorable sites like orbit, chemotherapy may allow for organ preservation.																																																								"{""description"": ""Complete surgical resection when feasible without significant morbidity. For favorable sites like orbit, chemotherapy may allow for organ preservation."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Complete surgical resection when feasible without significant morbidity. For favorable sites like orbit, chemotherapy may allow for organ preservation."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2357	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	2	Radiation Therapy	Radiation is used for local control in patients with residual disease or unfavorable features. May be omitted in selected low-risk patients.																																																								"{""description"": ""Radiation is used for local control in patients with residual disease or unfavorable features. May be omitted in selected low-risk patients."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Radiation is used for local control in patients with residual disease or unfavorable features. May be omitted in selected low-risk patients."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
2382	104	Endometriosis	Endometriosis.yaml	treatments	0	NSAIDs	First-line for pain management.																																																								"{""description"": ""First-line for pain management."", ""name"": ""NSAIDs""}"	{}	"{""description"": ""First-line for pain management."", ""name"": ""NSAIDs""}"
2383	104	Endometriosis	Endometriosis.yaml	treatments	1	Combined Oral Contraceptives	Suppress ovulation and reduce menstruation.																																																								"{""description"": ""Suppress ovulation and reduce menstruation."", ""name"": ""Combined Oral Contraceptives""}"	{}	"{""description"": ""Suppress ovulation and reduce menstruation."", ""name"": ""Combined Oral Contraceptives""}"
2384	104	Endometriosis	Endometriosis.yaml	treatments	2	Progestins	Create hypoestrogenic state (dienogest, medroxyprogesterone).																																																								"{""description"": ""Create hypoestrogenic state (dienogest, medroxyprogesterone)."", ""name"": ""Progestins""}"	{}	"{""description"": ""Create hypoestrogenic state (dienogest, medroxyprogesterone)."", ""name"": ""Progestins""}"
2385	104	Endometriosis	Endometriosis.yaml	treatments	3	GnRH Agonists	Induce medical menopause, add-back therapy needed.																																																								"{""description"": ""Induce medical menopause, add-back therapy needed."", ""name"": ""GnRH Agonists""}"	{}	"{""description"": ""Induce medical menopause, add-back therapy needed."", ""name"": ""GnRH Agonists""}"
2386	104	Endometriosis	Endometriosis.yaml	treatments	4	GnRH Antagonists	Elagolix with dose-dependent estrogen suppression.																																																								"{""description"": ""Elagolix with dose-dependent estrogen suppression."", ""name"": ""GnRH Antagonists""}"	{}	"{""description"": ""Elagolix with dose-dependent estrogen suppression."", ""name"": ""GnRH Antagonists""}"
2387	104	Endometriosis	Endometriosis.yaml	treatments	5	Aromatase Inhibitors	Reduce local estrogen production in lesions.																																																								"{""description"": ""Reduce local estrogen production in lesions."", ""name"": ""Aromatase Inhibitors""}"	{}	"{""description"": ""Reduce local estrogen production in lesions."", ""name"": ""Aromatase Inhibitors""}"
2388	104	Endometriosis	Endometriosis.yaml	treatments	6	Laparoscopic Surgery	Excision or ablation of lesions, adhesiolysis.																																																								"{""description"": ""Excision or ablation of lesions, adhesiolysis."", ""name"": ""Laparoscopic Surgery""}"	{}	"{""description"": ""Excision or ablation of lesions, adhesiolysis."", ""name"": ""Laparoscopic Surgery""}"
2389	104	Endometriosis	Endometriosis.yaml	treatments	7	Hysterectomy	Definitive surgery for completed childbearing.																																																								"{""description"": ""Definitive surgery for completed childbearing."", ""name"": ""Hysterectomy""}"	{}	"{""description"": ""Definitive surgery for completed childbearing."", ""name"": ""Hysterectomy""}"
2418	105	Epilepsy	Epilepsy.yaml	treatments	0	Antiseizure Medications	First-line treatment - levetiracetam, lamotrigine, valproate, carbamazepine.																																																								"{""description"": ""First-line treatment - levetiracetam, lamotrigine, valproate, carbamazepine."", ""name"": ""Antiseizure Medications""}"	{}	"{""description"": ""First-line treatment - levetiracetam, lamotrigine, valproate, carbamazepine."", ""name"": ""Antiseizure Medications""}"
2419	105	Epilepsy	Epilepsy.yaml	treatments	1	Ketogenic Diet	High-fat, low-carbohydrate diet effective for drug-resistant epilepsy.																																																								"{""description"": ""High-fat, low-carbohydrate diet effective for drug-resistant epilepsy."", ""name"": ""Ketogenic Diet""}"	{}	"{""description"": ""High-fat, low-carbohydrate diet effective for drug-resistant epilepsy."", ""name"": ""Ketogenic Diet""}"
2420	105	Epilepsy	Epilepsy.yaml	treatments	2	Vagus Nerve Stimulation	Implanted device for drug-resistant epilepsy.																																																								"{""description"": ""Implanted device for drug-resistant epilepsy."", ""name"": ""Vagus Nerve Stimulation""}"	{}	"{""description"": ""Implanted device for drug-resistant epilepsy."", ""name"": ""Vagus Nerve Stimulation""}"
2421	105	Epilepsy	Epilepsy.yaml	treatments	3	Epilepsy Surgery	Resection of seizure focus for drug-resistant focal epilepsy.																																																								"{""description"": ""Resection of seizure focus for drug-resistant focal epilepsy."", ""name"": ""Epilepsy Surgery""}"	{}	"{""description"": ""Resection of seizure focus for drug-resistant focal epilepsy."", ""name"": ""Epilepsy Surgery""}"
2422	105	Epilepsy	Epilepsy.yaml	treatments	4	Responsive Neurostimulation	Closed-loop brain stimulation for focal epilepsy.																																																								"{""description"": ""Closed-loop brain stimulation for focal epilepsy."", ""name"": ""Responsive Neurostimulation""}"	{}	"{""description"": ""Closed-loop brain stimulation for focal epilepsy."", ""name"": ""Responsive Neurostimulation""}"
2423	105	Epilepsy	Epilepsy.yaml	treatments	5	Deep Brain Stimulation	Anterior thalamic stimulation for drug-resistant epilepsy.																																																								"{""description"": ""Anterior thalamic stimulation for drug-resistant epilepsy."", ""name"": ""Deep Brain Stimulation""}"	{}	"{""description"": ""Anterior thalamic stimulation for drug-resistant epilepsy."", ""name"": ""Deep Brain Stimulation""}"
2440	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	0	ACE Inhibitors	Block angiotensin-converting enzyme to reduce vasoconstriction and sodium retention.																																																								"{""description"": ""Block angiotensin-converting enzyme to reduce vasoconstriction and sodium retention."", ""name"": ""ACE Inhibitors""}"	{}	"{""description"": ""Block angiotensin-converting enzyme to reduce vasoconstriction and sodium retention."", ""evidence"": [{""explanation"": ""This supports ACE inhibitors as effective treatments targeting RAAS activation in hypertension."", ""reference"": ""PMID:39765782"", ""snippet"": ""Managing blood pressure (BP) effectively with treatments targeting RAAS activation, oxidative stress, and inflammation is crucial in preventing renal damage and the progression of HTN-related CKD and ESRD."", ""supports"": ""SUPPORT""}], ""name"": ""ACE Inhibitors""}"
2441	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	1	Angiotensin Receptor Blockers	Block AT1 receptors to reduce RAAS effects.																																																								"{""description"": ""Block AT1 receptors to reduce RAAS effects."", ""name"": ""Angiotensin Receptor Blockers""}"	{}	"{""description"": ""Block AT1 receptors to reduce RAAS effects."", ""evidence"": [{""explanation"": ""This supports ARBs as effective treatments targeting RAAS activation in hypertension."", ""reference"": ""PMID:39765782"", ""snippet"": ""Managing blood pressure (BP) effectively with treatments targeting RAAS activation, oxidative stress, and inflammation is crucial in preventing renal damage and the progression of HTN-related CKD and ESRD."", ""supports"": ""SUPPORT""}], ""name"": ""Angiotensin Receptor Blockers""}"
2442	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	2	Calcium Channel Blockers	Reduce vascular smooth muscle contraction.																																																								"{""description"": ""Reduce vascular smooth muscle contraction."", ""name"": ""Calcium Channel Blockers""}"	{}	"{""description"": ""Reduce vascular smooth muscle contraction."", ""evidence"": [{""explanation"": ""This supports calcium channel blockers as treatments targeting vascular smooth muscle function."", ""reference"": ""PMID:37080965"", ""snippet"": ""Meanwhile, we will also summarize the treatment methods of hypertension that targets vascular function regulation and discuss the possibility of these signaling pathways being applied to clinical work."", ""supports"": ""SUPPORT""}], ""name"": ""Calcium Channel Blockers""}"
2443	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	3	Thiazide Diuretics	Promote sodium excretion to reduce blood volume.																																																								"{""description"": ""Promote sodium excretion to reduce blood volume."", ""name"": ""Thiazide Diuretics""}"	{}	"{""description"": ""Promote sodium excretion to reduce blood volume."", ""evidence"": [{""explanation"": ""This supports diuretics as treatments that promote sodium excretion to normalize blood pressure."", ""reference"": ""PMID:39765782"", ""snippet"": ""Anti-natriuretic mechanisms can reset the pressure-natriuresis relationship, requiring a higher BP to excrete sodium matched to intake."", ""supports"": ""SUPPORT""}], ""name"": ""Thiazide Diuretics""}"
2444	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	4	Beta Blockers	Reduce heart rate and cardiac output.																																																								"{""description"": ""Reduce heart rate and cardiac output."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Reduce heart rate and cardiac output."", ""name"": ""Beta Blockers""}"
2445	106	Essential Hypertension	Essential_Hypertension.yaml	treatments	5	Lifestyle Modification	Dietary changes (DASH diet, sodium restriction), exercise, weight loss.																																																								"{""description"": ""Dietary changes (DASH diet, sodium restriction), exercise, weight loss."", ""name"": ""Lifestyle Modification""}"	{}	"{""description"": ""Dietary changes (DASH diet, sodium restriction), exercise, weight loss."", ""evidence"": [{""explanation"": ""This supports sodium restriction as an effective lifestyle intervention for salt-sensitive hypertension."", ""reference"": ""PMID:38164753"", ""snippet"": ""Approximately 50% of hypertensive and 25% of normotensive people exhibit salt sensitivity of blood pressure, which is an independent risk factor for cardiovascular disease."", ""supports"": ""SUPPORT""}], ""name"": ""Lifestyle Modification""}"
2461	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	0	Low-Dose Aspirin	Recommended for all ET patients without contraindications. Reduces microvascular symptoms (erythromelalgia, headache) and thrombotic events. Use with caution if platelet count exceeds 1,000,000/uL due to acquired von Willebrand disease risk.																																																								"{""description"": ""Recommended for all ET patients without contraindications. Reduces microvascular symptoms (erythromelalgia, headache) and thrombotic events. Use with caution if platelet count exceeds 1,000,000/uL due to acquired von Willebrand disease risk."", ""name"": ""Low-Dose Aspirin""}"	{}	"{""description"": ""Recommended for all ET patients without contraindications. Reduces microvascular symptoms (erythromelalgia, headache) and thrombotic events. Use with caution if platelet count exceeds 1,000,000/uL due to acquired von Willebrand disease risk."", ""name"": ""Low-Dose Aspirin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2462	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	1	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.																																																								"{""description"": ""First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count."", ""name"": ""Hydroxyurea""}"	{}	"{""description"": ""First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count."", ""name"": ""Hydroxyurea"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}}"
2463	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	2	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.																																																								"{""description"": ""Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea."", ""name"": ""Anagrelide""}"	{}	"{""description"": ""Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea."", ""name"": ""Anagrelide"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}]}}"
2464	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	3	Interferon-alpha	Effective cytoreductive option particularly for younger patients, during pregnancy, or when disease modification is desired. May reduce driver mutation allele burden.																																																								"{""description"": ""Effective cytoreductive option particularly for younger patients, during pregnancy, or when disease modification is desired. May reduce driver mutation allele burden."", ""name"": ""Interferon-alpha""}"	{}	"{""description"": ""Effective cytoreductive option particularly for younger patients, during pregnancy, or when disease modification is desired. May reduce driver mutation allele burden."", ""name"": ""Interferon-alpha"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.																																																								"{""description"": ""Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control."", ""name"": ""Neoadjuvant Chemotherapy""}"	{}	"{""description"": ""Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control."", ""name"": ""Neoadjuvant Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}]}}"
2479	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	1	Surgical Resection	Wide surgical resection with negative margins is preferred when feasible without excessive morbidity. Reconstruction may be needed for limb salvage.																																																								"{""description"": ""Wide surgical resection with negative margins is preferred when feasible without excessive morbidity. Reconstruction may be needed for limb salvage."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Wide surgical resection with negative margins is preferred when feasible without excessive morbidity. Reconstruction may be needed for limb salvage."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2480	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	2	Radiation Therapy	Definitive radiation is used for unresectable tumors or when surgery would cause significant morbidity. Also used post-operatively for close or positive margins.																																																								"{""description"": ""Definitive radiation is used for unresectable tumors or when surgery would cause significant morbidity. Also used post-operatively for close or positive margins."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Definitive radiation is used for unresectable tumors or when surgery would cause significant morbidity. Also used post-operatively for close or positive margins."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
2481	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	3	Adjuvant Chemotherapy	Additional chemotherapy after local control to eliminate micrometastatic disease. Total treatment duration is typically 9-12 months.																																																								"{""description"": ""Additional chemotherapy after local control to eliminate micrometastatic disease. Total treatment duration is typically 9-12 months."", ""name"": ""Adjuvant Chemotherapy""}"	{}	"{""description"": ""Additional chemotherapy after local control to eliminate micrometastatic disease. Total treatment duration is typically 9-12 months."", ""name"": ""Adjuvant Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2500	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	0	Pemigatinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FIGHT-202 trial demonstrated 36% objective response rate with 9.1 months median duration of response. Now also approved in first-line (FIGHT-302).																																																								"{""description"": ""Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FIGHT-202 trial demonstrated 36% objective response rate with 9.1 months median duration of response. Now also approved in first-line (FIGHT-302)."", ""name"": ""Pemigatinib""}"	{}	"{""description"": ""Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FIGHT-202 trial demonstrated 36% objective response rate with 9.1 months median duration of response. Now also approved in first-line (FIGHT-302)."", ""name"": ""Pemigatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2501	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	1	Futibatinib	Irreversible pan-FGFR inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FOENIX-CCA2 trial demonstrated 42% response rate. May retain activity against some resistance mutations due to covalent binding mechanism.																																																								"{""description"": ""Irreversible pan-FGFR inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FOENIX-CCA2 trial demonstrated 42% response rate. May retain activity against some resistance mutations due to covalent binding mechanism."", ""name"": ""Futibatinib""}"	{}	"{""description"": ""Irreversible pan-FGFR inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FOENIX-CCA2 trial demonstrated 42% response rate. May retain activity against some resistance mutations due to covalent binding mechanism."", ""name"": ""Futibatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2502	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	2	Infigratinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion positive cholangiocarcinoma. Demonstrated approximately 23% response rate in pivotal study.																																																								"{""description"": ""Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion positive cholangiocarcinoma. Demonstrated approximately 23% response rate in pivotal study."", ""name"": ""Infigratinib""}"	{}	"{""description"": ""Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion positive cholangiocarcinoma. Demonstrated approximately 23% response rate in pivotal study."", ""name"": ""Infigratinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2503	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	3	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma. May be used before FGFR inhibitors or in combination approaches. FGFR inhibitors increasingly moving to first-line setting.																																																								"{""description"": ""First-line standard chemotherapy for advanced cholangiocarcinoma. May be used before FGFR inhibitors or in combination approaches. FGFR inhibitors increasingly moving to first-line setting."", ""name"": ""Gemcitabine plus Cisplatin""}"	{}	"{""description"": ""First-line standard chemotherapy for advanced cholangiocarcinoma. May be used before FGFR inhibitors or in combination approaches. FGFR inhibitors increasingly moving to first-line setting."", ""name"": ""Gemcitabine plus Cisplatin"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2504	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	4	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin is now standard first-line treatment for advanced biliary tract cancers (TOPAZ-1 trial). Sequencing with FGFR inhibitors being defined.																																																								"{""description"": ""Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin is now standard first-line treatment for advanced biliary tract cancers (TOPAZ-1 trial). Sequencing with FGFR inhibitors being defined."", ""name"": ""Gemcitabine plus Cisplatin plus Durvalumab""}"	{}	"{""description"": ""Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin is now standard first-line treatment for advanced biliary tract cancers (TOPAZ-1 trial). Sequencing with FGFR inhibitors being defined."", ""name"": ""Gemcitabine plus Cisplatin plus Durvalumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2505	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	5	Surgical Resection	Surgery offers the only potential cure for cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. FGFR status does not change surgical approach for resectable disease.																																																								"{""description"": ""Surgery offers the only potential cure for cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. FGFR status does not change surgical approach for resectable disease."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgery offers the only potential cure for cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. FGFR status does not change surgical approach for resectable disease."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2517	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	0	Erdafitinib	Pan-FGFR tyrosine kinase inhibitor approved for FGFR2/3-altered locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Demonstrates meaningful response rates and survival benefits in biomarker-selected patients.																																																								"{""description"": ""Pan-FGFR tyrosine kinase inhibitor approved for FGFR2/3-altered locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Demonstrates meaningful response rates and survival benefits in biomarker-selected patients."", ""name"": ""Erdafitinib""}"	{}	"{""description"": ""Pan-FGFR tyrosine kinase inhibitor approved for FGFR2/3-altered locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Demonstrates meaningful response rates and survival benefits in biomarker-selected patients."", ""name"": ""Erdafitinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2518	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	1	Platinum-Based Chemotherapy	Cisplatin or carboplatin-based combination regimens remain first-line treatment for metastatic urothelial carcinoma regardless of FGFR status. Gemcitabine plus cisplatin is a standard regimen.																																																								"{""description"": ""Cisplatin or carboplatin-based combination regimens remain first-line treatment for metastatic urothelial carcinoma regardless of FGFR status. Gemcitabine plus cisplatin is a standard regimen."", ""name"": ""Platinum-Based Chemotherapy""}"	{}	"{""description"": ""Cisplatin or carboplatin-based combination regimens remain first-line treatment for metastatic urothelial carcinoma regardless of FGFR status. Gemcitabine plus cisplatin is a standard regimen."", ""name"": ""Platinum-Based Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2519	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	2	Immune Checkpoint Inhibitors	PD-1/PD-L1 inhibitors are used in metastatic urothelial carcinoma. May be sequenced with erdafitinib in FGFR-altered tumors, though optimal sequencing strategies continue to evolve.																																																								"{""description"": ""PD-1/PD-L1 inhibitors are used in metastatic urothelial carcinoma. May be sequenced with erdafitinib in FGFR-altered tumors, though optimal sequencing strategies continue to evolve."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""PD-1/PD-L1 inhibitors are used in metastatic urothelial carcinoma. May be sequenced with erdafitinib in FGFR-altered tumors, though optimal sequencing strategies continue to evolve."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2546	111	FICUS syndrome	FICUS_syndrome.yaml	treatments	0	Family support intervention	"Nurse-led, interprofessional family support intervention aimed at improving family management, quality of care, and mental health for ICU family members.
"																																																								"{""description"": ""Nurse-led, interprofessional family support intervention aimed at improving family management, quality of care, and mental health for ICU family members.\n"", ""name"": ""Family support intervention""}"	{}	"{""description"": ""Nurse-led, interprofessional family support intervention aimed at improving family management, quality of care, and mental health for ICU family members.\n"", ""evidence"": [{""explanation"": ""This describes a structured family support intervention targeting mental health outcomes."", ""reference"": ""DOI:10.1186/s13063-024-08351-y"", ""snippet"": ""The FICUS trial is a cluster-randomized superiority trial to determine the effectiveness of a nurse-led, interprofessional family support intervention (FSI) on the quality of care, family management and individual mental health of family members of critically ill patients, compared to usual care."", ""supports"": ""SUPPORT""}], ""name"": ""Family support intervention"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
2565	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	0	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.																																																								"{""description"": ""First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival."", ""name"": ""Midostaurin""}"	{}	"{""description"": ""First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival."", ""name"": ""Midostaurin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""midostaurin"", ""term"": {""id"": ""CHEBI:63452"", ""label"": ""midostaurin""}}]}}"
2566	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	1	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.																																																								"{""description"": ""Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations."", ""name"": ""Gilteritinib""}"	{}	"{""description"": ""Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations."", ""name"": ""Gilteritinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""gilteritinib"", ""term"": {""id"": ""CHEBI:145372"", ""label"": ""gilteritinib""}}]}}"
2567	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	2	Intensive Chemotherapy (7+3)	Standard induction chemotherapy with cytarabine continuous infusion for 7 days plus anthracycline (daunorubicin or idarubicin) for 3 days. Forms the backbone of treatment combined with FLT3 inhibitors for eligible patients.																																																								"{""description"": ""Standard induction chemotherapy with cytarabine continuous infusion for 7 days plus anthracycline (daunorubicin or idarubicin) for 3 days. Forms the backbone of treatment combined with FLT3 inhibitors for eligible patients."", ""name"": ""Intensive Chemotherapy (7+3)""}"	{}	"{""description"": ""Standard induction chemotherapy with cytarabine continuous infusion for 7 days plus anthracycline (daunorubicin or idarubicin) for 3 days. Forms the backbone of treatment combined with FLT3 inhibitors for eligible patients."", ""name"": ""Intensive Chemotherapy (7+3)"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2568	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Recommended for FLT3-ITD AML patients in first complete remission due to high relapse risk. Provides graft-versus-leukemia effect. FLT3 inhibitor maintenance post-transplant is being evaluated.																																																								"{""description"": ""Recommended for FLT3-ITD AML patients in first complete remission due to high relapse risk. Provides graft-versus-leukemia effect. FLT3 inhibitor maintenance post-transplant is being evaluated."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Recommended for FLT3-ITD AML patients in first complete remission due to high relapse risk. Provides graft-versus-leukemia effect. FLT3 inhibitor maintenance post-transplant is being evaluated."", ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"																																																								"{""description"": ""Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.\n"", ""name"": ""Enzyme replacement therapy""}"	{}	"{""description"": ""Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.\n"", ""evidence"": [{""explanation"": ""Shows that ERT reduces substrate accumulation but cannot fully reverse organ damage in Fabry nephropathy"", ""reference"": ""PMID:37014703"", ""snippet"": ""long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury"", ""supports"": ""PARTIAL""}], ""name"": ""Enzyme replacement therapy"", ""target_phenotypes"": [{""preferred_term"": ""Proteinuria"", ""term"": {""id"": ""HP:0000093"", ""label"": ""proteinuria""}}, {""preferred_term"": ""Chronic kidney disease"", ""term"": {""id"": ""HP:0012622"", ""label"": ""Chronic kidney disease""}}], ""treatment_term"": {""preferred_term"": ""enzyme replacement therapy"", ""term"": {""id"": ""MAXO:0000933"", ""label"": ""enzyme replacement or supplementation therapy""}}}"
2591	113	Fabry disease	Fabry_Disease.yaml	treatments	1	Pharmacological chaperone therapy	"Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.
"																																																								"{""description"": ""Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.\n"", ""name"": ""Pharmacological chaperone therapy""}"	{}	"{""description"": ""Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.\n"", ""evidence"": [{""explanation"": ""Confirms migalastat is an approved oral chaperone therapy for amenable GLA mutations"", ""reference"": ""PMID:40310476"", ""snippet"": ""if a responding ('amenable') -galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)"", ""supports"": ""SUPPORT""}], ""name"": ""Pharmacological chaperone therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2592	113	Fabry disease	Fabry_Disease.yaml	treatments	2	Gene therapy	"AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.
"																																																								"{""description"": ""AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.\n"", ""name"": ""Gene therapy""}"	{}	"{""description"": ""AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.\n"", ""evidence"": [{""explanation"": ""Identifies gene therapy as a promising future treatment option for Fabry disease"", ""reference"": ""PMID:40310476"", ""snippet"": ""Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy"", ""supports"": ""SUPPORT""}], ""name"": ""Gene therapy"", ""treatment_term"": {""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}}"
2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"																																																								"{""description"": ""Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.\n"", ""name"": ""Supportive care""}"	{}	"{""description"": ""Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.\n"", ""evidence"": [{""explanation"": ""Confirms ERT and pharmacological chaperone therapy as current treatment standards"", ""reference"": ""PMID:32183665"", ""snippet"": ""The current treatment of Anderson-Fabry disease is represented by enzyme replacement therapy (ERT) and oral pharmacological chaperone"", ""supports"": ""SUPPORT""}], ""name"": ""Supportive care"", ""target_phenotypes"": [{""preferred_term"": ""Pain"", ""term"": {""id"": ""HP:0012531"", ""label"": ""Pain""}}, {""preferred_term"": ""Arrhythmia"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}], ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2610	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	0	Prophylactic Colectomy	Surgical removal of the colon is the primary management to prevent colorectal cancer. Options include total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or subtotal colectomy with ileorectal anastomosis (IRA). Timing is typically in late teens/early twenties or when polyp burden becomes unmanageable endoscopically.																																																								"{""description"": ""Surgical removal of the colon is the primary management to prevent colorectal cancer. Options include total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or subtotal colectomy with ileorectal anastomosis (IRA). Timing is typically in late teens/early twenties or when polyp burden becomes unmanageable endoscopically."", ""name"": ""Prophylactic Colectomy""}"	{}	"{""description"": ""Surgical removal of the colon is the primary management to prevent colorectal cancer. Options include total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or subtotal colectomy with ileorectal anastomosis (IRA). Timing is typically in late teens/early twenties or when polyp burden becomes unmanageable endoscopically."", ""name"": ""Prophylactic Colectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2611	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	1	Endoscopic Surveillance	Annual colonoscopy beginning at age 10-12 in at-risk individuals to detect polyp development. Upper endoscopy every 1-4 years to monitor duodenal adenomas using Spigelman staging. Surveillance of rectal stump or pouch after colectomy.																																																								"{""description"": ""Annual colonoscopy beginning at age 10-12 in at-risk individuals to detect polyp development. Upper endoscopy every 1-4 years to monitor duodenal adenomas using Spigelman staging. Surveillance of rectal stump or pouch after colectomy."", ""name"": ""Endoscopic Surveillance""}"	{}	"{""description"": ""Annual colonoscopy beginning at age 10-12 in at-risk individuals to detect polyp development. Upper endoscopy every 1-4 years to monitor duodenal adenomas using Spigelman staging. Surveillance of rectal stump or pouch after colectomy."", ""name"": ""Endoscopic Surveillance"", ""treatment_term"": {""preferred_term"": ""colonoscopy"", ""term"": {""id"": ""MAXO:0001184"", ""label"": ""colonoscopy""}}}"
2612	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	2	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and reassurance for non-carriers.																																																								"{""description"": ""Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and reassurance for non-carriers."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and reassurance for non-carriers."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
2613	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	3	Chemoprevention	Sulindac and celecoxib (COX-2 inhibitors) have demonstrated ability to reduce polyp number and size but do not eliminate cancer risk. Used as adjunct to surveillance, not as alternative to surgery.																																																								"{""description"": ""Sulindac and celecoxib (COX-2 inhibitors) have demonstrated ability to reduce polyp number and size but do not eliminate cancer risk. Used as adjunct to surveillance, not as alternative to surgery."", ""name"": ""Chemoprevention""}"	{}	"{""description"": ""Sulindac and celecoxib (COX-2 inhibitors) have demonstrated ability to reduce polyp number and size but do not eliminate cancer risk. Used as adjunct to surveillance, not as alternative to surgery."", ""name"": ""Chemoprevention"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	Colchicine	First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis.																																																								"{""description"": ""First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis."", ""name"": ""Colchicine""}"	{}	"{""description"": ""First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis."", ""evidence"": [{""explanation"": ""The study directly supports the statement that colchicine is a first-line treatment for preventing amyloidosis, a common complication of FMF."", ""reference"": ""PMID:19797919"", ""snippet"": ""The study demonstrated that colchicine treatment is effective in preventing amyloidosis among Armenian patients with FMF and that earlier initiation and continuous therapy at an adequate dose of 1.2-1.8 mg/day may be associated with a decreased amyloidosis risk among Armenian patients with FMF."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference clearly supports the claim that colchicine reduces the frequency of attacks and prevents amyloidosis, affirming its role as a first-line treatment."", ""reference"": ""PMID:25649364"", ""snippet"": ""The only agent that decreases the development of amyloidosis and the frequency and severity of the episodes is colchicine, which has been used for about 40 years."", ""supports"": ""SUPPORT""}, {""explanation"": ""This indicates that colchicine is considered effective for preventing FMF attacks, supporting its position as a first-line treatment."", ""reference"": ""PMID:25791871"", ""snippet"": ""Early studies reported colchicine as a potential drug for preventing attacks of familial Mediterranean fever."", ""supports"": ""SUPPORT""}, {""explanation"": ""This statement corroborates that colchicine is the standard, or first-line, therapy for preventing FMF attacks and amyloidosis."", ""reference"": ""PMID:17242135"", ""snippet"": ""The daily application of colchicine is the standard therapy for prophylaxis of attacks and amyloid deposition in familial Mediterranean fever."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the idea that colchicine is the primary treatment for preventing FMF attacks and associated amyloidosis."", ""reference"": ""PMID:15720245"", ""snippet"": ""Since 1972 colchicine has become the drug of choice for prophylaxis against FMF attacks and amyloidosis FMF-associated."", ""supports"": ""SUPPORT""}], ""name"": ""Colchicine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2639	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	1	Anti-IL-1 Therapy	Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab).																																																								"{""description"": ""Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab)."", ""name"": ""Anti-IL-1 Therapy""}"	{}	"{""description"": ""Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab)."", ""evidence"": [{""explanation"": ""The reference supports the use of anti-IL-1 therapy for treating colchicine-resistant FMF cases."", ""reference"": ""PMID:28362189"", ""snippet"": ""The accumulating data indicates that anti IL-1 drugs are effective in treating colchicine resistant FMF cases and improving their quality of life."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference lists several anti-IL-1 therapies as beneficial for colchicine-resistant or intolerant FMF patients."", ""reference"": ""PMID:30338514"", ""snippet"": ""For those people who are colchicine-resistant or intolerant, drugs such as rilonacept, anakinra, canakinumab, etanercept, infliximab, thalidomide and interferon-alpha might be beneficial."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the effectiveness of anti-IL-1 therapy in managing inflammation in colchicine-resistant FMF patients."", ""reference"": ""PMID:36161616"", ""snippet"": ""Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference provides evidence from a randomized controlled trial supporting the effectiveness of anakinra, an anti-IL-1 therapy, in colchicine-resistant FMF patients."", ""reference"": ""PMID:27860460"", ""snippet"": ""In this randomized controlled trial, anakinra appears to be an effective and safe treatment for colchicine-resistant FMF."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-IL-1 Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2640	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	2	NSAIDs	Used for symptom relief during acute attacks																																																								"{""description"": ""Used for symptom relief during acute attacks"", ""name"": ""NSAIDs""}"	{}	"{""description"": ""Used for symptom relief during acute attacks"", ""evidence"": [{""explanation"": ""The literature does not mention NSAIDs as a treatment path for symptom relief during acute attacks of Familial Mediterranean Fever. The focus is on colchicine and biological therapy."", ""reference"": ""PMID:37752496"", ""snippet"": ""These provide the basis for stratifying patients into the following treatment paths: continue colchicine, persisting attacks / inflammation, colchicine intolerance, persisting arthritis, colchicine reduction and adjustment/reduction of biologics."", ""supports"": ""REFUTE""}, {""explanation"": ""There is no mention of NSAIDs being used for symptom relief during acute attacks in FMF patients. The treatments focus on colchicine and IL-1 antagonist."", ""reference"": ""PMID:36945975"", ""snippet"": ""Mean age of the overall group was 38.2 +/- 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order)."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""NSAIDs"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2641	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	3	Lifestyle Modifications	Avoiding known triggers such as stress and infections where possible																																																								"{""description"": ""Avoiding known triggers such as stress and infections where possible"", ""name"": ""Lifestyle Modifications""}"	{}	"{""description"": ""Avoiding known triggers such as stress and infections where possible"", ""evidence"": [{""explanation"": ""The literature supports the management of psychological stress and avoiding physical factors as triggers but does not explicitly mention infections."", ""reference"": ""PMID:38488998"", ""snippet"": ""Patients can significantly decrease the number of familial Mediterranean fever attacks they experience by managing psychological stress and avoiding physical factors such as cold exposure and fatigue."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature mentions stress as a trigger but does not provide exhaustive confirmation about infections as triggers or other preventive lifestyle modifications."", ""reference"": ""PMID:26324575"", ""snippet"": ""Triggers of this illness include many things, such as cold or stress."", ""supports"": ""PARTIAL""}], ""name"": ""Lifestyle Modifications"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
2815	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	0	Hematopoietic Stem Cell Transplantation (HSCT)	The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation.																																																								"{""description"": ""The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation."", ""name"": ""Hematopoietic Stem Cell Transplantation (HSCT)""}"	{}	"{""description"": ""The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""reference"": ""PMID:20301575"", ""snippet"": ""hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA"", ""supports"": ""SUPPORT""}], ""name"": ""Hematopoietic Stem Cell Transplantation (HSCT)"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
2816	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	1	Androgen Therapy	Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation.																																																								"{""description"": ""Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation."", ""name"": ""Androgen Therapy""}"	{}	"{""description"": ""Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""reference"": ""PMID:20301575"", ""snippet"": ""Administration of oral androgens (e.g., oxymetholone) improves blood counts (red cell and platelets) in approximately 50% of individuals with FA"", ""supports"": ""SUPPORT""}], ""name"": ""Androgen Therapy"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
2817	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	2	Growth Hormone Therapy	May be used to improve growth in affected children with short stature.																																																								"{""description"": ""May be used to improve growth in affected children with short stature."", ""name"": ""Growth Hormone Therapy""}"	{}	"{""description"": ""May be used to improve growth in affected children with short stature."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews recommends treatment of growth deficiency as part of comprehensive FA management."", ""reference"": ""PMID:20301575"", ""snippet"": ""Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider."", ""supports"": ""SUPPORT""}], ""name"": ""Growth Hormone Therapy"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
2818	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	3	Supportive Care	Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy.																																		Includes blood transfusions, growth factor support, and infection prophylaxis																						"{""description"": ""Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy."", ""name"": ""Supportive Care"", ""notes"": ""Includes blood transfusions, growth factor support, and infection prophylaxis""}"	{}	"{""description"": ""Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms use of growth factors as part of supportive care for cytopenias."", ""reference"": ""PMID:20301575"", ""snippet"": ""granulocyte colony-stimulating factor improves the neutrophil count in some individuals"", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""notes"": ""Includes blood transfusions, growth factor support, and infection prophylaxis"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2819	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	4	Cancer Surveillance	Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions.																																		Required due to markedly increased risk of developing malignancies, especially squamous cell carcinomas at young ages																						"{""description"": ""Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions."", ""name"": ""Cancer Surveillance"", ""notes"": ""Required due to markedly increased risk of developing malignancies, especially squamous cell carcinomas at young ages""}"	{}	"{""description"": ""Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews recommends regular oral and nasolaryngoscopic surveillance for early cancer detection."", ""reference"": ""PMID:20301575"", ""snippet"": ""oral examinations for tumors every six months beginning at age nine to ten years; annual nasolaryngoscopy beginning at age ten years"", ""supports"": ""SUPPORT""}], ""name"": ""Cancer Surveillance"", ""notes"": ""Required due to markedly increased risk of developing malignancies, especially squamous cell carcinomas at young ages"", ""treatment_term"": {""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}}"
2820	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	5	Genetic Counseling	Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options.																																		Essential for family planning and understanding autosomal recessive and X-linked inheritance patterns																						"{""description"": ""Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options."", ""name"": ""Genetic Counseling"", ""notes"": ""Essential for family planning and understanding autosomal recessive and X-linked inheritance patterns""}"	{}	"{""description"": ""Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms the importance of genetic counseling for carrier testing and prenatal diagnosis."", ""reference"": ""PMID:20301575"", ""snippet"": ""Carrier testing for at-risk relatives (for autosomal recessive and X-linked FA) and prenatal and preimplantation genetic testing are possible if the pathogenic variant(s) in the family are known."", ""supports"": ""SUPPORT""}], ""name"": ""Genetic Counseling"", ""notes"": ""Essential for family planning and understanding autosomal recessive and X-linked inheritance patterns"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
2835	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	0	Palovarotene	Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males).																																																								"{""description"": ""Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males)."", ""name"": ""Palovarotene""}"	{}	"{""description"": ""Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males)."", ""evidence"": [{""explanation"": ""The study demonstrates palovarotene's therapeutic efficacy in preserving mobility in FOP mouse models."", ""reference"": ""PMID:26896819"", ""snippet"": ""palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP."", ""supports"": ""SUPPORT""}, {""explanation"": ""Demonstrates palovarotene's ability to preserve skeletal development while preventing heterotopic ossification."", ""reference"": ""PMID:26896819"", ""snippet"": ""palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates"", ""supports"": ""SUPPORT""}], ""name"": ""Palovarotene"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2836	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	1	Corticosteroids	Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit.																																																								"{""description"": ""Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit."", ""evidence"": [{""explanation"": ""The article notes FOP was untreatable, highlighting the limited efficacy of symptomatic treatments like corticosteroids."", ""reference"": ""PMID:26896819"", ""snippet"": ""Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification"", ""supports"": ""PARTIAL""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2837	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	2	Avoidance of Trauma	Primary preventive strategy including avoidance of intramuscular injections, falls, and surgical procedures that may trigger flare-ups. Represents a key component of supportive care.																																																								"{""description"": ""Primary preventive strategy including avoidance of intramuscular injections, falls, and surgical procedures that may trigger flare-ups. Represents a key component of supportive care."", ""name"": ""Avoidance of Trauma""}"	{}	"{""description"": ""Primary preventive strategy including avoidance of intramuscular injections, falls, and surgical procedures that may trigger flare-ups. Represents a key component of supportive care."", ""evidence"": [{""explanation"": ""Since injury induces HO in FOP models, avoidance of trauma is a key preventive strategy."", ""reference"": ""PMID:26896819"", ""snippet"": ""palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease"", ""supports"": ""SUPPORT""}], ""name"": ""Avoidance of Trauma""}"
2838	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	3	Genetic Counseling	Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden.																																																								"{""description"": ""Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden."", ""evidence"": [{""explanation"": ""Identification of the causative mutation enables genetic counseling and potential prenatal diagnosis."", ""reference"": ""PMID:17572636"", ""snippet"": ""Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation"", ""supports"": ""SUPPORT""}], ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
2839	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	4	Garetosmab	Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026.																																		Targets the specific molecular defect in FOP where mutant ACVR1 aberrantly responds to Activin A. Represents a mechanism-based targeted therapy.																						"{""description"": ""Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026."", ""name"": ""Garetosmab"", ""notes"": ""Targets the specific molecular defect in FOP where mutant ACVR1 aberrantly responds to Activin A. Represents a mechanism-based targeted therapy.""}"	{}	"{""description"": ""Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026."", ""evidence"": [{""explanation"": ""Establishes the molecular rationale for anti-Activin A therapy targeting the aberrant signaling through mutant ACVR1."", ""reference"": ""PMID:26896819"", ""snippet"": ""Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1(R206H), that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO"", ""supports"": ""SUPPORT""}], ""name"": ""Garetosmab"", ""notes"": ""Targets the specific molecular defect in FOP where mutant ACVR1 aberrantly responds to Activin A. Represents a mechanism-based targeted therapy."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2872	118	Fibromyalgia	Fibromyalgia.yaml	treatments	0	Duloxetine	SNRI, FDA-approved for fibromyalgia. Modulates serotonin and norepinephrine for pain relief.																																																								"{""description"": ""SNRI, FDA-approved for fibromyalgia. Modulates serotonin and norepinephrine for pain relief."", ""name"": ""Duloxetine""}"	{}	"{""description"": ""SNRI, FDA-approved for fibromyalgia. Modulates serotonin and norepinephrine for pain relief."", ""name"": ""Duloxetine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2873	118	Fibromyalgia	Fibromyalgia.yaml	treatments	1	Milnacipran	SNRI, FDA-approved for fibromyalgia. Dual neurotransmitter modulation.																																																								"{""description"": ""SNRI, FDA-approved for fibromyalgia. Dual neurotransmitter modulation."", ""name"": ""Milnacipran""}"	{}	"{""description"": ""SNRI, FDA-approved for fibromyalgia. Dual neurotransmitter modulation."", ""name"": ""Milnacipran"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2874	118	Fibromyalgia	Fibromyalgia.yaml	treatments	2	Pregabalin	Alpha-2-delta ligand, FDA-approved for fibromyalgia. Reduces abnormal neural excitability.																																																								"{""description"": ""Alpha-2-delta ligand, FDA-approved for fibromyalgia. Reduces abnormal neural excitability."", ""name"": ""Pregabalin""}"	{}	"{""description"": ""Alpha-2-delta ligand, FDA-approved for fibromyalgia. Reduces abnormal neural excitability."", ""name"": ""Pregabalin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2875	118	Fibromyalgia	Fibromyalgia.yaml	treatments	3	Gabapentin	Alpha-2-delta ligand, used off-label for neuropathic pain component.																																																								"{""description"": ""Alpha-2-delta ligand, used off-label for neuropathic pain component."", ""name"": ""Gabapentin""}"	{}	"{""description"": ""Alpha-2-delta ligand, used off-label for neuropathic pain component."", ""name"": ""Gabapentin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2876	118	Fibromyalgia	Fibromyalgia.yaml	treatments	4	Amitriptyline	Low-dose tricyclic antidepressant for pain modulation and sleep improvement.																																																								"{""description"": ""Low-dose tricyclic antidepressant for pain modulation and sleep improvement."", ""name"": ""Amitriptyline""}"	{}	"{""description"": ""Low-dose tricyclic antidepressant for pain modulation and sleep improvement."", ""name"": ""Amitriptyline"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2877	118	Fibromyalgia	Fibromyalgia.yaml	treatments	5	Aerobic Exercise	Structured physical activity with strong evidence for pain reduction and functional improvement.																																																								"{""description"": ""Structured physical activity with strong evidence for pain reduction and functional improvement."", ""name"": ""Aerobic Exercise""}"	{}	"{""description"": ""Structured physical activity with strong evidence for pain reduction and functional improvement."", ""name"": ""Aerobic Exercise"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
2878	118	Fibromyalgia	Fibromyalgia.yaml	treatments	6	Cognitive Behavioral Therapy	Psychological intervention addressing pain catastrophizing, coping strategies, and behavioral modification.																																																								"{""description"": ""Psychological intervention addressing pain catastrophizing, coping strategies, and behavioral modification."", ""name"": ""Cognitive Behavioral Therapy""}"	{}	"{""description"": ""Psychological intervention addressing pain catastrophizing, coping strategies, and behavioral modification."", ""name"": ""Cognitive Behavioral Therapy"", ""treatment_term"": {""preferred_term"": ""psychotherapy"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
2879	118	Fibromyalgia	Fibromyalgia.yaml	treatments	7	Sleep Hygiene Education	Behavioral interventions to improve sleep quality and reduce non-restorative sleep patterns.																																																								"{""description"": ""Behavioral interventions to improve sleep quality and reduce non-restorative sleep patterns."", ""name"": ""Sleep Hygiene Education""}"	{}	"{""description"": ""Behavioral interventions to improve sleep quality and reduce non-restorative sleep patterns."", ""name"": ""Sleep Hygiene Education"", ""treatment_term"": {""preferred_term"": ""patient education"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
2880	118	Fibromyalgia	Fibromyalgia.yaml	treatments	8	Mindfulness-Based Stress Reduction	Meditation and mindfulness practices for pain management and stress reduction.																																																								"{""description"": ""Meditation and mindfulness practices for pain management and stress reduction."", ""name"": ""Mindfulness-Based Stress Reduction""}"	{}	"{""description"": ""Meditation and mindfulness practices for pain management and stress reduction."", ""name"": ""Mindfulness-Based Stress Reduction"", ""treatment_term"": {""preferred_term"": ""behavioral intervention"", ""term"": {""id"": ""MAXO:0000010"", ""label"": ""cognitive and behavioral intervention""}}}"
2881	118	Fibromyalgia	Fibromyalgia.yaml	treatments	9	Aquatic Therapy	Water-based exercise therapy for low-impact conditioning and pain relief.																																																								"{""description"": ""Water-based exercise therapy for low-impact conditioning and pain relief."", ""name"": ""Aquatic Therapy""}"	{}	"{""description"": ""Water-based exercise therapy for low-impact conditioning and pain relief."", ""name"": ""Aquatic Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
2903	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	treatments	0	Behavioral Therapy	Applied behavior analysis and educational interventions for cognitive and behavioral symptoms.																																																								"{""description"": ""Applied behavior analysis and educational interventions for cognitive and behavioral symptoms."", ""name"": ""Behavioral Therapy""}"	{}	"{""description"": ""Applied behavior analysis and educational interventions for cognitive and behavioral symptoms."", ""evidence"": [{""explanation"": ""Understanding of synaptic dysfunction supports behavioral and educational interventions targeting developmental outcomes."", ""reference"": ""PMID:22483044"", ""snippet"": ""Recent studies on the biology of FMRP and the signaling pathways downstream of mGluR1/5 have yielded deeper insight into how synaptic protein synthesis and plasticity are regulated by experience."", ""supports"": ""SUPPORT""}], ""name"": ""Behavioral Therapy""}"
2904	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	treatments	1	Speech Therapy	Language and communication support.																																																								"{""description"": ""Language and communication support."", ""name"": ""Speech Therapy""}"	{}	"{""description"": ""Language and communication support."", ""name"": ""Speech Therapy""}"
2905	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	treatments	2	Stimulant Medications	For attention deficit and hyperactivity symptoms.																																																								"{""description"": ""For attention deficit and hyperactivity symptoms."", ""name"": ""Stimulant Medications""}"	{}	"{""description"": ""For attention deficit and hyperactivity symptoms."", ""name"": ""Stimulant Medications""}"
2906	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	treatments	3	SSRIs	For anxiety and mood symptoms.																																																								"{""description"": ""For anxiety and mood symptoms."", ""name"": ""SSRIs""}"	{}	"{""description"": ""For anxiety and mood symptoms."", ""name"": ""SSRIs""}"
2907	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	treatments	4	Genetic Counseling	Family screening for premutation carriers, prenatal testing options.																																																								"{""description"": ""Family screening for premutation carriers, prenatal testing options."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Family screening for premutation carriers, prenatal testing options."", ""name"": ""Genetic Counseling""}"
2920	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	treatments	0	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support.																																																								"{""description"": ""No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support."", ""name"": ""Symptomatic Management""}"	{}	"{""description"": ""No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support."", ""name"": ""Symptomatic Management"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2921	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	treatments	1	Speech and Language Therapy	Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible.																																																								"{""description"": ""Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible."", ""name"": ""Speech and Language Therapy""}"	{}	"{""description"": ""Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible."", ""name"": ""Speech and Language Therapy"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
2940	122	Galactosemia	Galactosemia.yaml	treatments	0	Galactose-restricted diet	"Lifelong dietary restriction of galactose is the cornerstone of treatment. Lactose-containing foods (milk, dairy) are eliminated and replaced with soy-based or elemental formulas in infancy.
"																																																								"{""description"": ""Lifelong dietary restriction of galactose is the cornerstone of treatment. Lactose-containing foods (milk, dairy) are eliminated and replaced with soy-based or elemental formulas in infancy.\n"", ""name"": ""Galactose-restricted diet""}"	{}	"{""description"": ""Lifelong dietary restriction of galactose is the cornerstone of treatment. Lactose-containing foods (milk, dairy) are eliminated and replaced with soy-based or elemental formulas in infancy.\n"", ""name"": ""Galactose-restricted diet""}"
2941	122	Galactosemia	Galactosemia.yaml	treatments	1	Calcium and vitamin D supplementation	"Supplementation is necessary due to dairy restriction to prevent osteoporosis.
"																																																								"{""description"": ""Supplementation is necessary due to dairy restriction to prevent osteoporosis.\n"", ""name"": ""Calcium and vitamin D supplementation""}"	{}	"{""description"": ""Supplementation is necessary due to dairy restriction to prevent osteoporosis.\n"", ""name"": ""Calcium and vitamin D supplementation""}"
2942	122	Galactosemia	Galactosemia.yaml	treatments	2	Hormone replacement therapy	"Estrogen and progesterone replacement for females with premature ovarian insufficiency.
"																																																								"{""description"": ""Estrogen and progesterone replacement for females with premature ovarian insufficiency.\n"", ""name"": ""Hormone replacement therapy""}"	{}	"{""description"": ""Estrogen and progesterone replacement for females with premature ovarian insufficiency.\n"", ""name"": ""Hormone replacement therapy""}"
2943	122	Galactosemia	Galactosemia.yaml	treatments	3	Speech therapy	"Early intervention for speech and language delays.
"																																																								"{""description"": ""Early intervention for speech and language delays.\n"", ""name"": ""Speech therapy""}"	{}	"{""description"": ""Early intervention for speech and language delays.\n"", ""name"": ""Speech therapy""}"
2965	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	0	H. pylori Eradication	Triple or quadruple therapy to eradicate H. pylori reduces gastric cancer risk, particularly when given before development of intestinal metaplasia. Also reduces risk of metachronous gastric cancer after endoscopic resection of early tumors.																																																								"{""description"": ""Triple or quadruple therapy to eradicate H. pylori reduces gastric cancer risk, particularly when given before development of intestinal metaplasia. Also reduces risk of metachronous gastric cancer after endoscopic resection of early tumors."", ""name"": ""H. pylori Eradication""}"	{}	"{""description"": ""Triple or quadruple therapy to eradicate H. pylori reduces gastric cancer risk, particularly when given before development of intestinal metaplasia. Also reduces risk of metachronous gastric cancer after endoscopic resection of early tumors."", ""name"": ""H. pylori Eradication"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2966	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	1	Surgical Resection	Gastrectomy (subtotal or total depending on tumor location) with D2 lymphadenectomy is the standard curative treatment for resectable gastric cancer. Reconstruction maintains GI continuity.																																																								"{""description"": ""Gastrectomy (subtotal or total depending on tumor location) with D2 lymphadenectomy is the standard curative treatment for resectable gastric cancer. Reconstruction maintains GI continuity."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Gastrectomy (subtotal or total depending on tumor location) with D2 lymphadenectomy is the standard curative treatment for resectable gastric cancer. Reconstruction maintains GI continuity."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
2967	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	2	Perioperative Chemotherapy	Perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard of care for resectable locally advanced gastric cancer in Western countries, improving survival compared to surgery alone.																																																								"{""description"": ""Perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard of care for resectable locally advanced gastric cancer in Western countries, improving survival compared to surgery alone."", ""name"": ""Perioperative Chemotherapy""}"	{}	"{""description"": ""Perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard of care for resectable locally advanced gastric cancer in Western countries, improving survival compared to surgery alone."", ""name"": ""Perioperative Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
2968	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	3	Trastuzumab	Anti-HER2 monoclonal antibody added to chemotherapy for HER2-positive (approximately 15-20%) advanced gastric cancer. First targeted therapy to show survival benefit in gastric cancer.																																																								"{""description"": ""Anti-HER2 monoclonal antibody added to chemotherapy for HER2-positive (approximately 15-20%) advanced gastric cancer. First targeted therapy to show survival benefit in gastric cancer."", ""name"": ""Trastuzumab""}"	{}	"{""description"": ""Anti-HER2 monoclonal antibody added to chemotherapy for HER2-positive (approximately 15-20%) advanced gastric cancer. First targeted therapy to show survival benefit in gastric cancer."", ""name"": ""Trastuzumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2969	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	4	Immune Checkpoint Inhibition	PD-1 inhibitors combined with chemotherapy are now standard first-line treatment for advanced gastric cancer. Benefit is greatest in PD-L1 CPS-high and MSI-high tumors.																																																								"{""description"": ""PD-1 inhibitors combined with chemotherapy are now standard first-line treatment for advanced gastric cancer. Benefit is greatest in PD-L1 CPS-high and MSI-high tumors."", ""name"": ""Immune Checkpoint Inhibition""}"	{}	"{""description"": ""PD-1 inhibitors combined with chemotherapy are now standard first-line treatment for advanced gastric cancer. Benefit is greatest in PD-L1 CPS-high and MSI-high tumors."", ""name"": ""Immune Checkpoint Inhibition"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
2992	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	treatments	0	Proton Pump Inhibitors	First-line therapy (omeprazole, esomeprazole, pantoprazole).																																																								"{""description"": ""First-line therapy (omeprazole, esomeprazole, pantoprazole)."", ""name"": ""Proton Pump Inhibitors""}"	{}	"{""description"": ""First-line therapy (omeprazole, esomeprazole, pantoprazole)."", ""name"": ""Proton Pump Inhibitors""}"
2993	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	treatments	1	H2 Receptor Antagonists	Alternative or adjunct therapy (famotidine, ranitidine).																																																								"{""description"": ""Alternative or adjunct therapy (famotidine, ranitidine)."", ""name"": ""H2 Receptor Antagonists""}"	{}	"{""description"": ""Alternative or adjunct therapy (famotidine, ranitidine)."", ""name"": ""H2 Receptor Antagonists""}"
2994	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	treatments	2	Antacids	Symptomatic relief for mild symptoms.																																																								"{""description"": ""Symptomatic relief for mild symptoms."", ""name"": ""Antacids""}"	{}	"{""description"": ""Symptomatic relief for mild symptoms."", ""name"": ""Antacids""}"
2995	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	treatments	3	Lifestyle Modifications	Weight loss, dietary changes, elevation of head of bed.																																																								"{""description"": ""Weight loss, dietary changes, elevation of head of bed."", ""name"": ""Lifestyle Modifications""}"	{}	"{""description"": ""Weight loss, dietary changes, elevation of head of bed."", ""name"": ""Lifestyle Modifications""}"
2996	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	treatments	4	Fundoplication	Surgical option for refractory GERD.																																																								"{""description"": ""Surgical option for refractory GERD."", ""name"": ""Fundoplication""}"	{}	"{""description"": ""Surgical option for refractory GERD."", ""name"": ""Fundoplication""}"
2997	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	treatments	5	LINX Device	Magnetic sphincter augmentation.																																																								"{""description"": ""Magnetic sphincter augmentation."", ""name"": ""LINX Device""}"	{}	"{""description"": ""Magnetic sphincter augmentation."", ""name"": ""LINX Device""}"
3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.																																																								"{""description"": ""First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients."", ""name"": ""Imatinib""}"	{}	"{""description"": ""First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients."", ""evidence"": [{""explanation"": ""The Demetri et al. NEJM study demonstrated that imatinib achieves objective responses in 53.7% of advanced GIST patients by inhibiting the KIT signaling pathway."", ""reference"": ""PMID:12181401"", ""snippet"": ""Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Imatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}}"
3016	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	1	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.																																																								"{""description"": ""Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations."", ""name"": ""Sunitinib""}"	{}	"{""description"": ""Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations."", ""name"": ""Sunitinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}]}}"
3017	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	2	Avapritinib	Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib.																																																								"{""description"": ""Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib."", ""name"": ""Avapritinib""}"	{}	"{""description"": ""Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib."", ""name"": ""Avapritinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3018	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	3	Surgical Resection	Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery.																																																								"{""description"": ""Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3035	127	Gaucher Disease	Gaucher_Disease.yaml	treatments	0	Enzyme Replacement Therapy	Imiglucerase, velaglucerase alfa, or taliglucerase alfa IV infusions to replace deficient enzyme.																																																								"{""description"": ""Imiglucerase, velaglucerase alfa, or taliglucerase alfa IV infusions to replace deficient enzyme."", ""name"": ""Enzyme Replacement Therapy""}"	{}	"{""description"": ""Imiglucerase, velaglucerase alfa, or taliglucerase alfa IV infusions to replace deficient enzyme."", ""evidence"": [{""explanation"": ""Long-term study demonstrates effectiveness of enzyme replacement therapy in children with Gaucher disease."", ""reference"": ""PMID:19047232"", ""snippet"": ""Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal."", ""supports"": ""SUPPORT""}], ""name"": ""Enzyme Replacement Therapy""}"
3036	127	Gaucher Disease	Gaucher_Disease.yaml	treatments	1	Substrate Reduction Therapy	Miglustat or eliglustat to reduce glucocerebroside synthesis.																																																								"{""description"": ""Miglustat or eliglustat to reduce glucocerebroside synthesis."", ""name"": ""Substrate Reduction Therapy""}"	{}	"{""description"": ""Miglustat or eliglustat to reduce glucocerebroside synthesis."", ""evidence"": [{""explanation"": ""Phase 3 ENGAGE trial demonstrates eliglustat substrate reduction therapy effectively improves clinical manifestations in Gaucher disease."", ""reference"": ""PMID:25688781"", ""snippet"": ""treatment with eliglustat compared with placebo for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count."", ""supports"": ""SUPPORT""}], ""name"": ""Substrate Reduction Therapy""}"
3037	127	Gaucher Disease	Gaucher_Disease.yaml	treatments	2	Supportive Care	Pain management, orthopedic interventions, transfusions as needed.																																																								"{""description"": ""Pain management, orthopedic interventions, transfusions as needed."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Pain management, orthopedic interventions, transfusions as needed."", ""name"": ""Supportive Care""}"
3038	127	Gaucher Disease	Gaucher_Disease.yaml	treatments	3	Genetic Counseling	Family screening, prenatal diagnosis available.																																																								"{""description"": ""Family screening, prenatal diagnosis available."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Family screening, prenatal diagnosis available."", ""name"": ""Genetic Counseling""}"
3063	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	0	SSRIs	First-line pharmacotherapy (escitalopram, sertraline, paroxetine).																																																								"{""description"": ""First-line pharmacotherapy (escitalopram, sertraline, paroxetine)."", ""name"": ""SSRIs""}"	{}	"{""description"": ""First-line pharmacotherapy (escitalopram, sertraline, paroxetine)."", ""name"": ""SSRIs""}"
3064	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	1	SNRIs	Alternative first-line (venlafaxine, duloxetine).																																																								"{""description"": ""Alternative first-line (venlafaxine, duloxetine)."", ""name"": ""SNRIs""}"	{}	"{""description"": ""Alternative first-line (venlafaxine, duloxetine)."", ""name"": ""SNRIs""}"
3065	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	2	Buspirone	Non-benzodiazepine anxiolytic, no dependence risk.																																																								"{""description"": ""Non-benzodiazepine anxiolytic, no dependence risk."", ""name"": ""Buspirone""}"	{}	"{""description"": ""Non-benzodiazepine anxiolytic, no dependence risk."", ""name"": ""Buspirone""}"
3066	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	3	Benzodiazepines	Short-term use for severe symptoms, dependence risk.																																																								"{""description"": ""Short-term use for severe symptoms, dependence risk."", ""name"": ""Benzodiazepines""}"	{}	"{""description"": ""Short-term use for severe symptoms, dependence risk."", ""name"": ""Benzodiazepines""}"
3067	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	4	Pregabalin	Effective in GAD, approved in Europe.																																																								"{""description"": ""Effective in GAD, approved in Europe."", ""name"": ""Pregabalin""}"	{}	"{""description"": ""Effective in GAD, approved in Europe."", ""name"": ""Pregabalin""}"
3068	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	5	Cognitive Behavioral Therapy	First-line psychotherapy, addresses worry and avoidance.																																																								"{""description"": ""First-line psychotherapy, addresses worry and avoidance."", ""name"": ""Cognitive Behavioral Therapy""}"	{}	"{""description"": ""First-line psychotherapy, addresses worry and avoidance."", ""name"": ""Cognitive Behavioral Therapy""}"
3069	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	6	Relaxation Training	Progressive muscle relaxation, breathing exercises.																																																								"{""description"": ""Progressive muscle relaxation, breathing exercises."", ""name"": ""Relaxation Training""}"	{}	"{""description"": ""Progressive muscle relaxation, breathing exercises."", ""name"": ""Relaxation Training""}"
3070	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	treatments	7	Mindfulness-Based Therapy	Reduces worry and rumination.																																																								"{""description"": ""Reduces worry and rumination."", ""name"": ""Mindfulness-Based Therapy""}"	{}	"{""description"": ""Reduces worry and rumination."", ""name"": ""Mindfulness-Based Therapy""}"
3082	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	0	High-Dose Corticosteroids	First-line therapy; prompt treatment prevents blindness.																																																								"{""description"": ""First-line therapy; prompt treatment prevents blindness."", ""name"": ""High-Dose Corticosteroids""}"	{}	"{""description"": ""First-line therapy; prompt treatment prevents blindness."", ""name"": ""High-Dose Corticosteroids""}"
3083	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	1	Tocilizumab	IL-6 receptor inhibitor for steroid-sparing.																																																								"{""description"": ""IL-6 receptor inhibitor for steroid-sparing."", ""name"": ""Tocilizumab""}"	{}	"{""description"": ""IL-6 receptor inhibitor for steroid-sparing."", ""evidence"": [{""explanation"": ""This demonstrates tocilizumab's effectiveness in reducing relapse rates while on treatment, though relapse risk increases after discontinuation."", ""reference"": ""PMID:37321636"", ""snippet"": ""Relapse rate prior to TCZ start (0.84 relapses/person-year) was 3-fold reduced while on TCZ (0.28 relapses/person-year; P < 0.001) but increased to 0.64 relapses/person-year after TCZ discontinuation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides evidence for tocilizumab's safety profile and highlights the challenge of relapses even with prolonged treatment."", ""reference"": ""PMID:37321636"", ""snippet"": ""TCZ is well tolerated in GCA, with low rates of discontinuation for AESIs. However, relapse occurred in > 50% despite median treatment > 12 months."", ""supports"": ""SUPPORT""}], ""name"": ""Tocilizumab""}"
3084	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	2	Methotrexate	May allow steroid dose reduction.																																																								"{""description"": ""May allow steroid dose reduction."", ""name"": ""Methotrexate""}"	{}	"{""description"": ""May allow steroid dose reduction."", ""name"": ""Methotrexate""}"
3085	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	3	Low-Dose Aspirin	May reduce ischemic complications.																																																								"{""description"": ""May reduce ischemic complications."", ""name"": ""Low-Dose Aspirin""}"	{}	"{""description"": ""May reduce ischemic complications."", ""name"": ""Low-Dose Aspirin""}"
3086	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	treatments	4	JAK Inhibitors	JAK/STAT pathway inhibitors (baricitinib, tofacitinib, upadacitinib) are emerging therapies for relapsing disease, particularly in patients failing tocilizumab.																																																								"{""description"": ""JAK/STAT pathway inhibitors (baricitinib, tofacitinib, upadacitinib) are emerging therapies for relapsing disease, particularly in patients failing tocilizumab."", ""name"": ""JAK Inhibitors""}"	{}	"{""description"": ""JAK/STAT pathway inhibitors (baricitinib, tofacitinib, upadacitinib) are emerging therapies for relapsing disease, particularly in patients failing tocilizumab."", ""evidence"": [{""explanation"": ""This provides the mechanistic rationale for using JAK inhibitors in GCA, linking the treatment to the underlying pathophysiology."", ""reference"": ""PMID:38840219"", ""snippet"": ""The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative."", ""supports"": ""SUPPORT""}, {""explanation"": ""This evidence demonstrates that JAK inhibitors can be effective even in patients who have failed other steroid-sparing therapies."", ""reference"": ""PMID:38840219"", ""snippet"": ""This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate."", ""supports"": ""SUPPORT""}], ""name"": ""JAK Inhibitors""}"
3110	130	Glaucoma	Glaucoma.yaml	treatments	0	Prostaglandin Analogs	First-line drops, increase uveoscleral outflow (latanoprost).																																																								"{""description"": ""First-line drops, increase uveoscleral outflow (latanoprost)."", ""name"": ""Prostaglandin Analogs""}"	{}	"{""description"": ""First-line drops, increase uveoscleral outflow (latanoprost)."", ""name"": ""Prostaglandin Analogs""}"
3111	130	Glaucoma	Glaucoma.yaml	treatments	1	Beta-Blockers	Reduce aqueous production (timolol).																																																								"{""description"": ""Reduce aqueous production (timolol)."", ""name"": ""Beta-Blockers""}"	{}	"{""description"": ""Reduce aqueous production (timolol)."", ""name"": ""Beta-Blockers""}"
3112	130	Glaucoma	Glaucoma.yaml	treatments	2	Alpha Agonists	Reduce production, increase outflow (brimonidine).																																																								"{""description"": ""Reduce production, increase outflow (brimonidine)."", ""name"": ""Alpha Agonists""}"	{}	"{""description"": ""Reduce production, increase outflow (brimonidine)."", ""name"": ""Alpha Agonists""}"
3113	130	Glaucoma	Glaucoma.yaml	treatments	3	Carbonic Anhydrase Inhibitors	Reduce aqueous production (dorzolamide, brinzolamide).																																																								"{""description"": ""Reduce aqueous production (dorzolamide, brinzolamide)."", ""name"": ""Carbonic Anhydrase Inhibitors""}"	{}	"{""description"": ""Reduce aqueous production (dorzolamide, brinzolamide)."", ""name"": ""Carbonic Anhydrase Inhibitors""}"
3114	130	Glaucoma	Glaucoma.yaml	treatments	4	Rho Kinase Inhibitors	Increase trabecular outflow (netarsudil).																																																								"{""description"": ""Increase trabecular outflow (netarsudil)."", ""name"": ""Rho Kinase Inhibitors""}"	{}	"{""description"": ""Increase trabecular outflow (netarsudil)."", ""name"": ""Rho Kinase Inhibitors""}"
3115	130	Glaucoma	Glaucoma.yaml	treatments	5	Laser Trabeculoplasty	SLT increases trabecular outflow.																																																								"{""description"": ""SLT increases trabecular outflow."", ""name"": ""Laser Trabeculoplasty""}"	{}	"{""description"": ""SLT increases trabecular outflow."", ""name"": ""Laser Trabeculoplasty""}"
3116	130	Glaucoma	Glaucoma.yaml	treatments	6	Trabeculectomy	Surgical filtration procedure.																																																								"{""description"": ""Surgical filtration procedure."", ""name"": ""Trabeculectomy""}"	{}	"{""description"": ""Surgical filtration procedure."", ""name"": ""Trabeculectomy""}"
3117	130	Glaucoma	Glaucoma.yaml	treatments	7	MIGS	Minimally invasive glaucoma surgery options.																																																								"{""description"": ""Minimally invasive glaucoma surgery options."", ""name"": ""MIGS""}"	{}	"{""description"": ""Minimally invasive glaucoma surgery options."", ""name"": ""MIGS""}"
3142	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	0	Maximal Safe Resection	Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection.																																																								"{""description"": ""Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection."", ""name"": ""Maximal Safe Resection""}"	{}	"{""description"": ""Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection."", ""name"": ""Maximal Safe Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3143	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	1	Radiation Therapy	External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients.																																																								"{""description"": ""External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
3144	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	2	Temozolomide Chemotherapy	Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors.																																																								"{""description"": ""Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors."", ""name"": ""Temozolomide Chemotherapy""}"	{}	"{""description"": ""Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors."", ""name"": ""Temozolomide Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
3145	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	3	Tumor Treating Fields (TTFields)	Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma.																																																								"{""description"": ""Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma."", ""name"": ""Tumor Treating Fields (TTFields)""}"	{}	"{""description"": ""Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma."", ""name"": ""Tumor Treating Fields (TTFields)"", ""treatment_term"": {""preferred_term"": ""cranial electrical stimulation"", ""term"": {""id"": ""MAXO:0000944"", ""label"": ""cranial electrical stimulation""}}}"
3146	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	4	Bevacizumab	Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease.																																																								"{""description"": ""Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease."", ""name"": ""Bevacizumab""}"	{}	"{""description"": ""Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease."", ""name"": ""Bevacizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3171	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	0	Avoidance of Oxidative Stressors	Identifying and avoiding triggers for acute hemolytic episodes																																																								"{""description"": ""Identifying and avoiding triggers for acute hemolytic episodes"", ""name"": ""Avoidance of Oxidative Stressors""}"	{}	"{""description"": ""Identifying and avoiding triggers for acute hemolytic episodes"", ""evidence"": [{""explanation"": ""The statement is supported by the reference as it mentions the importance of avoiding triggers that can lead to harmful clinical manifestations in individuals with G6PD deficiency."", ""reference"": ""PMID:31609781"", ""snippet"": ""By recognizing the potential for G6PD deficiency, clinicians can screen for the disorder and teach affected patients how to avoid triggers that result in harmful clinical manifestations."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the statement by highlighting the importance of avoiding oxidative stressors to prevent acute hemolytic anemia in G6PD-deficient individuals."", ""reference"": ""PMID:32600868"", ""snippet"": ""Although most individuals are asymptomatic, exposure to certain food, drugs, or infections can trigger acute hemolytic anemia. Given the potential for coronavirus to trigger oxidative stress, unrecognized G6PD deficiency in the presence of the COVID-19 viral infection may cause hemolytic crisis and worse outcome in affected individuals."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by discussing the increased risk of oxidative stress-mediated destruction of erythrocytes, indicating the importance of avoiding such stressors."", ""reference"": ""PMID:31235029"", ""snippet"": ""The possible mechanism of oxidative stress-mediated destruction of erythrocytes in G6PD deficient individuals induced by periodontal infection is highlighted."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the statement by emphasizing the susceptibility of G6PD-deficient individuals to oxidative stress and the potential benefits of avoiding such stressors."", ""reference"": ""PMID:31089417"", ""snippet"": ""G6PD deficiency, theoretically, renders red blood cells (RBC) susceptible to oxidative stress."", ""supports"": ""SUPPORT""}], ""name"": ""Avoidance of Oxidative Stressors"", ""treatment_term"": {""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}}"
3172	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	1	Supportive Care During Acute Hemolysis	Hydration, blood transfusions if needed, and monitoring for complications																																																								"{""description"": ""Hydration, blood transfusions if needed, and monitoring for complications"", ""name"": ""Supportive Care During Acute Hemolysis""}"	{}	"{""description"": ""Hydration, blood transfusions if needed, and monitoring for complications"", ""evidence"": [{""explanation"": ""This study indicates that during acute hemolytic crisis in G6PD-deficient children, blood transfusions were given to those with severe anemia, supporting the necessity of blood transfusion for severe cases."", ""reference"": ""PMID:34105166"", ""snippet"": ""33% of patients had Hb < 50 g/L and were all transfused. 50% had Hb between 50 and 65 g/L, half of them (n = 49) did not receive transfusion and only two patients (4%) required transfusion upon follow up. A restrictive transfusion strategy was adopted..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement that management involves hydration, blood transfusions when necessary, and monitoring for complications aligns with the literature, which suggests blood transfusion in severe cases and the self-limited nature of acute hemolysis."", ""reference"": ""PMID:16225031"", ""snippet"": ""Because acute hemolysis is caused by exposure to an oxidative stressor in the form of an infection, oxidative drug, or fava beans, treatment is geared toward avoidance of these and other stressors. Acute hemolysis is self-limited, but in rare instances it can be severe enough to warrant a blood transfusion."", ""supports"": ""SUPPORT""}, {""explanation"": ""The context of oxidative stress and acute hemolysis in G6PD-deficient individuals points towards the requirement for careful monitoring and supportive care to mitigate severe outcomes."", ""reference"": ""PMID:34383774"", ""snippet"": ""G6PD-deficient individuals are susceptible to hemolysis during oxidative stress, which can occur from exposure to certain medications, including 8-aminoquinolines used to treat Plasmodium vivax malaria. Accordingly, access to point-of-care (POC) G6PD testing in Brazil is critical for safe treatment..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses the role of transfusions and monitoring in the management of hemolysis in G6PD-deficient patients during oxidative stress events."", ""reference"": ""PMID:23815264"", ""snippet"": ""Patients requiring RBC transfusions may simultaneously receive oxidative medications or have concurrent infections, both of which can induce haemolysis in G6PD-deficient RBCs...discusses G6PD deficiency, its importance in transfusion medicine..."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care During Acute Hemolysis"", ""treatment_term"": {""preferred_term"": ""blood transfusion"", ""term"": {""id"": ""MAXO:0000756"", ""label"": ""blood transfusion""}}}"
3173	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	2	Neonatal Screening and Monitoring	Early detection and close monitoring of G6PD-deficient newborns to prevent severe neonatal jaundice																																																								"{""description"": ""Early detection and close monitoring of G6PD-deficient newborns to prevent severe neonatal jaundice"", ""name"": ""Neonatal Screening and Monitoring""}"	{}	"{""description"": ""Early detection and close monitoring of G6PD-deficient newborns to prevent severe neonatal jaundice"", ""evidence"": [{""explanation"": ""This reference emphasizes the importance of early detection and accurate diagnosis to prevent severe outcomes in newborns."", ""reference"": ""PMID:27064064"", ""snippet"": ""Early detection and an accurate diagnosis are, therefore, of major importance for preventing negative patient outcomes. ... We advocate adopting a national neonatal G6PD screening program in Gaza Strip to identify children at risk and promote wellness and health for Palestine."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports neonatal screening and preventive measures to manage G6PD deficiency effectively."", ""reference"": ""PMID:36845240"", ""snippet"": ""Through this observation, we insist on the importance of neonatal screening in regions with a high prevalence of hemolysis in order to avoid diagnostic delays and also to prioritize the evaluation to be requested in an acute hemolysis state, to propose an education articulated around a preventive approach in children with this disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights the need for early intervention in neonatal hyperbilirubinemia, which aligns with the statement regarding prevention of severe jaundice through early detection."", ""reference"": ""PMID:16225031"", ""snippet"": ""Neonatal hyperbilirubinemia may require treatment with phototherapy or exchange transfusion to prevent kernicterus."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference mentions G6PD deficiency as a significant risk factor for hyperbilirubinemia, which supports the need for early screening and monitoring."", ""reference"": ""PMID:27235212"", ""snippet"": ""Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human enzymopathies, is a major risk factor for hyperbilirubinemia and greatly increases the risk of kernicterus even in the developed world."", ""supports"": ""SUPPORT""}], ""name"": ""Neonatal Screening and Monitoring""}"
3196	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	0	Surgical Excision	Surgical removal of basal cell carcinomas is the primary treatment. Mohs micrographic surgery may be preferred for facial lesions to preserve tissue. Given the multiplicity of tumors, repeated surgeries are often necessary.																																																								"{""description"": ""Surgical removal of basal cell carcinomas is the primary treatment. Mohs micrographic surgery may be preferred for facial lesions to preserve tissue. Given the multiplicity of tumors, repeated surgeries are often necessary."", ""name"": ""Surgical Excision""}"	{}	"{""description"": ""Surgical removal of basal cell carcinomas is the primary treatment. Mohs micrographic surgery may be preferred for facial lesions to preserve tissue. Given the multiplicity of tumors, repeated surgeries are often necessary."", ""name"": ""Surgical Excision"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.																																																								"{""description"": ""Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation."", ""name"": ""Vismodegib""}"	{}	"{""description"": ""Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation."", ""evidence"": [{""explanation"": ""Randomized controlled trial demonstrating efficacy of vismodegib in reducing BCC burden in Gorlin syndrome."", ""reference"": ""PMID:22670904"", ""snippet"": ""Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""Documents significant tolerability issues with vismodegib leading to high discontinuation rates."", ""reference"": ""PMID:22670904"", ""snippet"": ""The adverse events associated with treatment led to discontinuation in over half of treated patients."", ""supports"": ""PARTIAL""}], ""name"": ""Vismodegib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}]}}"
3198	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	2	Sonidegib	Alternative SMO inhibitor for locally advanced BCC. Similar mechanism and side effect profile to vismodegib.																																																								"{""description"": ""Alternative SMO inhibitor for locally advanced BCC. Similar mechanism and side effect profile to vismodegib."", ""name"": ""Sonidegib""}"	{}	"{""description"": ""Alternative SMO inhibitor for locally advanced BCC. Similar mechanism and side effect profile to vismodegib."", ""name"": ""Sonidegib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3199	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	3	Laser Ablation Therapy	Laser ablation and photodynamic therapy may be useful for treating multiple superficial BCCs with acceptable cosmetic outcomes. Less effective for nodular or aggressive subtypes.																																																								"{""description"": ""Laser ablation and photodynamic therapy may be useful for treating multiple superficial BCCs with acceptable cosmetic outcomes. Less effective for nodular or aggressive subtypes."", ""name"": ""Laser Ablation Therapy""}"	{}	"{""description"": ""Laser ablation and photodynamic therapy may be useful for treating multiple superficial BCCs with acceptable cosmetic outcomes. Less effective for nodular or aggressive subtypes."", ""name"": ""Laser Ablation Therapy"", ""treatment_term"": {""preferred_term"": ""laser ablation therapy"", ""term"": {""id"": ""MAXO:0000453"", ""label"": ""laser ablation therapy""}}}"
3200	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	4	Topical Therapy	Topical imiquimod or 5-fluorouracil may be used for superficial BCCs to reduce surgical burden.																																																								"{""description"": ""Topical imiquimod or 5-fluorouracil may be used for superficial BCCs to reduce surgical burden."", ""name"": ""Topical Therapy""}"	{}	"{""description"": ""Topical imiquimod or 5-fluorouracil may be used for superficial BCCs to reduce surgical burden."", ""name"": ""Topical Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3201	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	5	Sun Avoidance	Rigorous sun protection with sunscreen, protective clothing, and sunlight avoidance is essential to reduce the development of new BCCs.																																																								"{""description"": ""Rigorous sun protection with sunscreen, protective clothing, and sunlight avoidance is essential to reduce the development of new BCCs."", ""name"": ""Sun Avoidance""}"	{}	"{""description"": ""Rigorous sun protection with sunscreen, protective clothing, and sunlight avoidance is essential to reduce the development of new BCCs."", ""name"": ""Sun Avoidance"", ""treatment_term"": {""preferred_term"": ""sunlight avoidance"", ""term"": {""id"": ""MAXO:0000055"", ""label"": ""sunlight avoidance""}}}"
3202	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	6	Genetic Counseling	Given autosomal dominant inheritance and 50% recurrence risk, genetic counseling is recommended for affected individuals and at-risk family members.																																																								"{""description"": ""Given autosomal dominant inheritance and 50% recurrence risk, genetic counseling is recommended for affected individuals and at-risk family members."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Given autosomal dominant inheritance and 50% recurrence risk, genetic counseling is recommended for affected individuals and at-risk family members."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
3224	134	Gout	Gout.yaml	treatments	0	NSAIDs	First-line for acute flares (indomethacin, naproxen).																																																								"{""description"": ""First-line for acute flares (indomethacin, naproxen)."", ""name"": ""NSAIDs""}"	{}	"{""description"": ""First-line for acute flares (indomethacin, naproxen)."", ""name"": ""NSAIDs""}"
3225	134	Gout	Gout.yaml	treatments	1	Colchicine	Effective for acute flares and prophylaxis.																																																								"{""description"": ""Effective for acute flares and prophylaxis."", ""name"": ""Colchicine""}"	{}	"{""description"": ""Effective for acute flares and prophylaxis."", ""name"": ""Colchicine""}"
3226	134	Gout	Gout.yaml	treatments	2	Corticosteroids	Alternative for acute flares when NSAIDs contraindicated.																																																								"{""description"": ""Alternative for acute flares when NSAIDs contraindicated."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Alternative for acute flares when NSAIDs contraindicated."", ""name"": ""Corticosteroids""}"
3227	134	Gout	Gout.yaml	treatments	3	Allopurinol	Xanthine oxidase inhibitor for urate-lowering therapy.																																																								"{""description"": ""Xanthine oxidase inhibitor for urate-lowering therapy."", ""name"": ""Allopurinol""}"	{}	"{""description"": ""Xanthine oxidase inhibitor for urate-lowering therapy."", ""evidence"": [{""explanation"": ""Describes the paradoxical early flare phenomenon with XOI treatment, an important clinical consideration."", ""reference"": ""PMID:39426967"", ""snippet"": ""Urate-lowering treatment (ULT) to target with xanthine oxidase inhibitors (XOIs) paradoxically causes early increase in gouty arthritis flares."", ""supports"": ""SUPPORT""}, {""explanation"": ""Demonstrates that sustained XOI urate-lowering therapy normalizes serum urate and reduces flares through modulation of immune proteomes."", ""reference"": ""PMID:39426967"", ""snippet"": ""At 48 weeks ULT, serum urate normalized in all gout patients, and flares declined in association with significantly altered proteins (p < 0.05) in clustering and proteome networks in sera and peripheral blood mononuclear cells."", ""supports"": ""SUPPORT""}], ""name"": ""Allopurinol""}"
3228	134	Gout	Gout.yaml	treatments	4	Febuxostat	Alternative xanthine oxidase inhibitor.																																																								"{""description"": ""Alternative xanthine oxidase inhibitor."", ""name"": ""Febuxostat""}"	{}	"{""description"": ""Alternative xanthine oxidase inhibitor."", ""evidence"": [{""explanation"": ""Shows that febuxostat has anti-inflammatory effects beyond urate lowering by modulating complement activation in macrophages."", ""reference"": ""PMID:39426967"", ""snippet"": ""Last, febuxostat treatment decreased complement activation biologic process proteins in cultured BMDMs."", ""supports"": ""SUPPORT""}], ""name"": ""Febuxostat""}"
3229	134	Gout	Gout.yaml	treatments	5	Probenecid	Uricosuric agent increasing renal urate excretion.																																																								"{""description"": ""Uricosuric agent increasing renal urate excretion."", ""name"": ""Probenecid""}"	{}	"{""description"": ""Uricosuric agent increasing renal urate excretion."", ""name"": ""Probenecid""}"
3230	134	Gout	Gout.yaml	treatments	6	Pegloticase	Recombinant uricase for refractory gout.																																																								"{""description"": ""Recombinant uricase for refractory gout."", ""name"": ""Pegloticase""}"	{}	"{""description"": ""Recombinant uricase for refractory gout."", ""name"": ""Pegloticase""}"
3241	135	Grange syndrome	Grange_syndrome.yaml	treatments	0	Antithrombotic Therapy	Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis.																																																								"{""description"": ""Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis."", ""name"": ""Antithrombotic Therapy""}"	{}	"{""description"": ""Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis."", ""evidence"": [{""explanation"": ""Raggio et al. 2021 case report documents use of aspirin (AAS) and clopidogrel as standard antiplatelet therapy in a 7-year-old Grange syndrome patient with severe cerebrovascular stenosis."", ""reference"": ""PMID:33971976"", ""snippet"": ""Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time."", ""supports"": ""SUPPORT""}], ""name"": ""Antithrombotic Therapy"", ""treatment_term"": {""preferred_term"": ""drug therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3242	135	Grange syndrome	Grange_syndrome.yaml	treatments	1	Cardiovascular Management	Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease.																																																								"{""description"": ""Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease."", ""name"": ""Cardiovascular Management""}"	{}	"{""description"": ""Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease."", ""evidence"": [{""explanation"": ""Raggio et al. 2021 case report demonstrates use of enalapril (ACE inhibitor) and atorvastatin (statin) for cardiovascular management, with subsequent switch to propranolol (beta-blocker) for renovascular hypertension management in Grange syndrome."", ""reference"": ""PMID:33971976"", ""snippet"": ""Treatment with AAS, clopidogrel, enalapril, and atorvastatin was started at this time... Given this diagnosis, enalapril was changed to propranolol."", ""supports"": ""SUPPORT""}], ""name"": ""Cardiovascular Management"", ""treatment_term"": {""preferred_term"": ""drug therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3243	135	Grange syndrome	Grange_syndrome.yaml	treatments	2	Neurosurgical Intervention	Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events.																																																								"{""description"": ""Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events."", ""name"": ""Neurosurgical Intervention""}"	{}	"{""description"": ""Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events."", ""evidence"": [{""explanation"": ""Raggio et al. 2021 case report documents bilateral indirect cerebral revascularization as therapeutic intervention for severe stenosis of internal carotid and vertebral arteries in a pediatric Grange syndrome patient."", ""reference"": ""PMID:33971976"", ""snippet"": ""Although she did not present Moya-Moya phenomenon, neurosurgeons decided to perform a bilateral indirect revascularization in 2 stages, left hemisphere at the age of 7 and right at the age of 8 years."", ""supports"": ""SUPPORT""}], ""name"": ""Neurosurgical Intervention"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3244	135	Grange syndrome	Grange_syndrome.yaml	treatments	3	Vascular Intervention	Percutaneous balloon angioplasty for renal artery stenosis and renovascular hypertension.																																		Current MAXO/NCIT terminology insufficient: balloon angioplasty is an interventional radiology procedure distinct from general surgical procedures. Candidate terms: MAXO:0010030 (percutaneous transluminal angioplasty) or NCIT-derived interventional radiology codes would be more appropriate.																						"{""description"": ""Percutaneous balloon angioplasty for renal artery stenosis and renovascular hypertension."", ""name"": ""Vascular Intervention"", ""notes"": ""Current MAXO/NCIT terminology insufficient: balloon angioplasty is an interventional radiology procedure distinct from general surgical procedures. Candidate terms: MAXO:0010030 (percutaneous transluminal angioplasty) or NCIT-derived interventional radiology codes would be more appropriate.""}"	{}	"{""description"": ""Percutaneous balloon angioplasty for renal artery stenosis and renovascular hypertension."", ""evidence"": [{""explanation"": ""Raggio et al. 2021 case report documents percutaneous balloon angioplasty as intervention for bilateral renal artery stenosis in pediatric Grange syndrome patient with renovascular hypertension."", ""reference"": ""PMID:33971976"", ""snippet"": ""At the age of 10 years, Doppler ultrasound showed persistence of bilateral renal artery stenosis. Balloon angioplasty was performed: an incomplete dilatation was achieved, and no residual stenosis was detected at the time."", ""supports"": ""SUPPORT""}], ""name"": ""Vascular Intervention"", ""notes"": ""Current MAXO/NCIT terminology insufficient: balloon angioplasty is an interventional radiology procedure distinct from general surgical procedures. Candidate terms: MAXO:0010030 (percutaneous transluminal angioplasty) or NCIT-derived interventional radiology codes would be more appropriate.""}"
3245	135	Grange syndrome	Grange_syndrome.yaml	treatments	4	Surgical Correction of Acral Features	Surgical repair of hand syndactyly to improve function and appearance.																																																								"{""description"": ""Surgical repair of hand syndactyly to improve function and appearance."", ""name"": ""Surgical Correction of Acral Features""}"	{}	"{""description"": ""Surgical repair of hand syndactyly to improve function and appearance."", ""evidence"": [{""explanation"": ""Raggio et al. 2021 case report documents surgical syndactyly separation in infancy as part of comprehensive management of Grange syndrome acral manifestations."", ""reference"": ""PMID:33971976"", ""snippet"": ""Surgical correction of hand syndactyly (left hand between the fourth and fifth finger) was previously done at the age of 1 year."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Correction of Acral Features"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3259	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	treatments	0	Corticosteroids	High-dose for induction.																																																								"{""description"": ""High-dose for induction."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""High-dose for induction."", ""name"": ""Corticosteroids""}"
3260	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	treatments	1	Rituximab	First-line for induction and maintenance.																																																								"{""description"": ""First-line for induction and maintenance."", ""name"": ""Rituximab""}"	{}	"{""description"": ""First-line for induction and maintenance."", ""name"": ""Rituximab""}"
3261	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	treatments	2	Cyclophosphamide	Alternative for severe disease induction.																																																								"{""description"": ""Alternative for severe disease induction."", ""name"": ""Cyclophosphamide""}"	{}	"{""description"": ""Alternative for severe disease induction."", ""name"": ""Cyclophosphamide""}"
3262	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	treatments	3	Avacopan	C5a receptor inhibitor, allows steroid reduction.																																																								"{""description"": ""C5a receptor inhibitor, allows steroid reduction."", ""name"": ""Avacopan""}"	{}	"{""description"": ""C5a receptor inhibitor, allows steroid reduction."", ""evidence"": [{""explanation"": ""This review describes avacopan as a C5a receptor blocker that can potentially replace glucocorticoids by blocking complement-mediated neutrophil priming."", ""reference"": ""PMID:37781373"", ""snippet"": ""Mechanistically, cytokines or complement factors activate and prime neutrophils for ANCA-binding; thus, C5a receptor blocker has garnered attention as potential replacement for glucocorticoids in clinical settings."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review confirms avacopan as an emerging treatment option for AAV targeting the C5a receptor."", ""reference"": ""PMID:35479831"", ""snippet"": ""This review describes emerging treatment regimens, including evidence for plasma exchange in severe disease and the inhibitor of the complement C5a receptor (C5aR) inhibitor, Avacopan."", ""supports"": ""SUPPORT""}], ""name"": ""Avacopan""}"
3299	137	Graves' Disease	Graves_Disease.yaml	treatments	0	Antithyroid Medications	Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.																																																								"{""description"": ""Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production."", ""name"": ""Antithyroid Medications""}"	{}	"{""description"": ""Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production."", ""evidence"": [{""explanation"": ""The reference confirms that both Methimazole and PTU are used as antithyroid medications to reduce thyroid hormone production in Graves' disease."", ""reference"": ""PMID:17154097"", ""snippet"": ""Methimazole (MMI) and propylthiouracil (PTU) have been used, however, MMI is the preferred drug treatment."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the use of antithyroid medications, including Methimazole and PTU, in the treatment of hyperthyroidism associated with Graves' disease."", ""reference"": ""PMID:37594736"", ""snippet"": ""Antithyroid drugs remain a cornerstone of thyroid therapeutics."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the use of Methimazole and PTU as primary antithyroid medications for managing Graves' disease."", ""reference"": ""PMID:36740774"", ""snippet"": ""The thionamide anti-thyroid drugs namely carbimazole, methimazole, and propylthiouracil, have been the predominant therapy modality for Graves' hyperthyroidism for over 60 years."", ""supports"": ""SUPPORT""}], ""name"": ""Antithyroid Medications"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3300	137	Graves' Disease	Graves_Disease.yaml	treatments	1	Radioactive Iodine Therapy	Radioactive iodine is taken orally to destroy overactive thyroid cells.																																																								"{""description"": ""Radioactive iodine is taken orally to destroy overactive thyroid cells."", ""name"": ""Radioactive Iodine Therapy""}"	{}	"{""description"": ""Radioactive iodine is taken orally to destroy overactive thyroid cells."", ""evidence"": [{""explanation"": ""The abstract confirms that radioactive iodine is used for therapy, including the treatment of Graves' disease, which involves destroying overactive thyroid cells."", ""reference"": ""PMID:36468997"", ""snippet"": ""Radioactive iodine 131I is a theranostic isotope used both for diagnosis and therapy of benign thyroid diseases and thyroid cancer for 85 years."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of radioactive iodine therapy for treating Graves' disease by destroying overactive thyroid cells."", ""reference"": ""PMID:2451239"", ""snippet"": ""Radioactive iodine is the most frequently used and safest method of treatment for adults."", ""supports"": ""SUPPORT""}, {""explanation"": ""The text confirms the use of radioactive iodine therapy (iodine-131) for treating Graves' disease, consistent with the statement."", ""reference"": ""PMID:1987448"", ""snippet"": ""In most clinical situations, a strong argument can be made for iodine-131 therapy, which is safe and definitive, although posttreatment hypothyroidism and the need for lifelong thyroxine are to be expected."", ""supports"": ""SUPPORT""}], ""name"": ""Radioactive Iodine Therapy"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
3301	137	Graves' Disease	Graves_Disease.yaml	treatments	2	Thyroidectomy	Surgical removal of part or all of the thyroid gland.																																																								"{""description"": ""Surgical removal of part or all of the thyroid gland."", ""name"": ""Thyroidectomy""}"	{}	"{""description"": ""Surgical removal of part or all of the thyroid gland."", ""evidence"": [{""explanation"": ""The study supports the statement that surgical removal of the thyroid gland, specifically total thyroidectomy, is used in the treatment of Graves' disease."", ""reference"": ""PMID:35728139"", ""snippet"": ""Total thyroidectomy resulted in long-term control of thyrotoxicosis in all patients. There were no incidences of recurrent laryngeal nerve injury. One patient (1.6%) suffered permanent hypoparathyroidism. CONCLUSION: Total thyroidectomy is a safe and effective treatment for Graves' disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that thyroidectomy is one of the treatment options for Graves' disease, supporting the statement."", ""reference"": ""PMID:25103076"", ""snippet"": ""Surgery is one of the treatment choices for Graves disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this reference focuses on Graves eye disease, it indirectly supports the statement by discussing the broader context of Graves' disease treatment."", ""reference"": ""PMID:34243871"", ""snippet"": ""Graves disease is an autoimmune disorder...In approximately 25% of patients, an inflammatory condition, Graves eye disease (GED), affects the orbital soft tissues."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses the use of surgery as a treatment for Graves' disease in specific cases, supporting the statement."", ""reference"": ""PMID:30180972"", ""snippet"": ""Indications for a radical treatment can arise in cases of...relapse despite prolonged medical treatment...Surgery is the radical method of treatment used in children under 5 years of age, or in cases of very large, nodular, or compressive goiters."", ""supports"": ""SUPPORT""}], ""name"": ""Thyroidectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3302	137	Graves' Disease	Graves_Disease.yaml	treatments	3	Beta Blockers	Used to manage cardiovascular symptoms like tachycardia and palpitations.																																																								"{""description"": ""Used to manage cardiovascular symptoms like tachycardia and palpitations."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Used to manage cardiovascular symptoms like tachycardia and palpitations."", ""evidence"": [{""explanation"": ""The study confirms that beta-blockers are used to manage cardiovascular symptoms like tachycardia and palpitations in Graves' disease."", ""reference"": ""PMID:22975536"", ""snippet"": ""beta-adrenergic antagonists (beta-blockers) are often used to attenuate the hyperadrenergic symptoms of Graves' disease (GD), including palpitation."", ""supports"": ""SUPPORT""}, {""explanation"": ""The case report supports the use of beta-blockers to control heart rate in patients with thyrotoxicosis, which includes Graves' disease."", ""reference"": ""PMID:36518043"", ""snippet"": ""Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that both surgical and medical (which includes beta-blockers) management improves tachyarrhythmias in Graves' disease patients."", ""reference"": ""PMID:32402541"", ""snippet"": ""Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01)."", ""supports"": ""SUPPORT""}], ""name"": ""Beta Blockers"", ""treatment_term"": {""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}}"
3303	137	Graves' Disease	Graves_Disease.yaml	treatments	4	Corticosteroids	Used to reduce inflammation in severe ophthalmopathy.																																																								"{""description"": ""Used to reduce inflammation in severe ophthalmopathy."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Used to reduce inflammation in severe ophthalmopathy."", ""evidence"": [{""explanation"": ""The literature indicates that glucocorticoids (a type of corticosteroid) are a primary treatment for moderate-severe Graves' ophthalmopathy, which supports their use to reduce inflammation in severe ophthalmopathy."", ""reference"": ""PMID:33069387"", ""snippet"": ""Glucocorticoids at high doses are the cornerstone in moderate-severe cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""Thyroid eye disease (TED) is another term for Graves' ophthalmopathy, and corticosteroids are noted as the primary medical therapy for this condition."", ""reference"": ""PMID:29923966"", ""snippet"": ""Corticosteroids continue to be the primary medical therapy for TED."", ""supports"": ""SUPPORT""}, {""explanation"": ""Graves' ophthalmopathy (GO) is treated primarily with corticosteroids, as indicated in the literature."", ""reference"": ""PMID:36272013"", ""snippet"": ""Corticosteroids have been the first-line treatment for GO."", ""supports"": ""SUPPORT""}, {""explanation"": ""Glucocorticoids, a type of corticosteroid, are the main treatment for moderate-to-severe Graves' ophthalmopathy, supporting their use to reduce inflammation."", ""reference"": ""PMID:22632369"", ""snippet"": ""Glucocorticoids (oral or intravenous) represent the main treatment of moderate-to-severe GO, the intravenous route being more effective."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3316	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	treatments	0	IVIG	First-line immunotherapy, equally effective as plasmapheresis.																																																								"{""description"": ""First-line immunotherapy, equally effective as plasmapheresis."", ""name"": ""IVIG""}"	{}	"{""description"": ""First-line immunotherapy, equally effective as plasmapheresis."", ""name"": ""IVIG""}"
3317	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	treatments	1	Plasmapheresis	Removes pathogenic antibodies; alternative to IVIG.																																																								"{""description"": ""Removes pathogenic antibodies; alternative to IVIG."", ""name"": ""Plasmapheresis""}"	{}	"{""description"": ""Removes pathogenic antibodies; alternative to IVIG."", ""name"": ""Plasmapheresis""}"
3318	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	treatments	2	Supportive Care	ICU monitoring, mechanical ventilation if needed.																																																								"{""description"": ""ICU monitoring, mechanical ventilation if needed."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""ICU monitoring, mechanical ventilation if needed."", ""name"": ""Supportive Care""}"
3319	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	treatments	3	Physical Therapy	Rehabilitation during recovery phase.																																																								"{""description"": ""Rehabilitation during recovery phase."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Rehabilitation during recovery phase."", ""name"": ""Physical Therapy""}"
3340	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	0	Radiation Therapy	Focal radiation therapy (54-59.4 Gy) is the only treatment with established benefit, providing temporary tumor control and symptom improvement. Typically extends survival by 2-3 months compared to supportive care alone.																																																								"{""description"": ""Focal radiation therapy (54-59.4 Gy) is the only treatment with established benefit, providing temporary tumor control and symptom improvement. Typically extends survival by 2-3 months compared to supportive care alone."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Focal radiation therapy (54-59.4 Gy) is the only treatment with established benefit, providing temporary tumor control and symptom improvement. Typically extends survival by 2-3 months compared to supportive care alone."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
3341	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	1	Corticosteroids	Dexamethasone reduces peritumoral edema and provides symptomatic relief. Standard supportive measure during radiation and at progression.																																																								"{""description"": ""Dexamethasone reduces peritumoral edema and provides symptomatic relief. Standard supportive measure during radiation and at progression."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Dexamethasone reduces peritumoral edema and provides symptomatic relief. Standard supportive measure during radiation and at progression."", ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3342	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	2	ONC201 (DRD2 Antagonist)	Small molecule DRD2 antagonist and ClpP agonist showing promising activity in H3 K27M-mutant gliomas. Crosses blood-brain barrier. Currently in clinical trials and received FDA Breakthrough Therapy designation.																																																								"{""description"": ""Small molecule DRD2 antagonist and ClpP agonist showing promising activity in H3 K27M-mutant gliomas. Crosses blood-brain barrier. Currently in clinical trials and received FDA Breakthrough Therapy designation."", ""name"": ""ONC201 (DRD2 Antagonist)""}"	{}	"{""description"": ""Small molecule DRD2 antagonist and ClpP agonist showing promising activity in H3 K27M-mutant gliomas. Crosses blood-brain barrier. Currently in clinical trials and received FDA Breakthrough Therapy designation."", ""name"": ""ONC201 (DRD2 Antagonist)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3354	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	0	Trastuzumab	Humanized monoclonal antibody targeting the extracellular domain of HER2. First-line treatment in combination with chemotherapy. Revolutionized HER2+ breast cancer treatment, converting a poor-prognosis subtype into one with excellent outcomes.																																																								"{""description"": ""Humanized monoclonal antibody targeting the extracellular domain of HER2. First-line treatment in combination with chemotherapy. Revolutionized HER2+ breast cancer treatment, converting a poor-prognosis subtype into one with excellent outcomes."", ""name"": ""Trastuzumab""}"	{}	"{""description"": ""Humanized monoclonal antibody targeting the extracellular domain of HER2. First-line treatment in combination with chemotherapy. Revolutionized HER2+ breast cancer treatment, converting a poor-prognosis subtype into one with excellent outcomes."", ""name"": ""Trastuzumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3355	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	1	Pertuzumab	Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab, preventing HER2 dimerization. Used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings.																																																								"{""description"": ""Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab, preventing HER2 dimerization. Used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings."", ""name"": ""Pertuzumab""}"	{}	"{""description"": ""Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab, preventing HER2 dimerization. Used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings."", ""name"": ""Pertuzumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3356	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	2	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I inhibitor payload. Highly effective in HER2+ metastatic breast cancer after prior trastuzumab, and also active in HER2-low breast cancer.																																																								"{""description"": ""Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I inhibitor payload. Highly effective in HER2+ metastatic breast cancer after prior trastuzumab, and also active in HER2-low breast cancer."", ""name"": ""Trastuzumab Deruxtecan (T-DXd)""}"	{}	"{""description"": ""Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I inhibitor payload. Highly effective in HER2+ metastatic breast cancer after prior trastuzumab, and also active in HER2-low breast cancer."", ""name"": ""Trastuzumab Deruxtecan (T-DXd)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3357	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	3	Tucatinib	Oral HER2-selective tyrosine kinase inhibitor with activity against brain metastases. Used in combination with trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer.																																																								"{""description"": ""Oral HER2-selective tyrosine kinase inhibitor with activity against brain metastases. Used in combination with trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer."", ""name"": ""Tucatinib""}"	{}	"{""description"": ""Oral HER2-selective tyrosine kinase inhibitor with activity against brain metastases. Used in combination with trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer."", ""name"": ""Tucatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3358	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	4	Neratinib	Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended adjuvant therapy after trastuzumab-based treatment and for metastatic disease in combination with capecitabine.																																																								"{""description"": ""Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended adjuvant therapy after trastuzumab-based treatment and for metastatic disease in combination with capecitabine."", ""name"": ""Neratinib""}"	{}	"{""description"": ""Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended adjuvant therapy after trastuzumab-based treatment and for metastatic disease in combination with capecitabine."", ""name"": ""Neratinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3375	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	0	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.																																																								"{""description"": ""Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC."", ""name"": ""Trastuzumab plus Lapatinib""}"	{}	"{""description"": ""Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC."", ""name"": ""Trastuzumab plus Lapatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}}"
3376	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	1	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.																																																								"{""description"": ""Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC."", ""name"": ""Trastuzumab plus Pertuzumab""}"	{}	"{""description"": ""Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC."", ""name"": ""Trastuzumab plus Pertuzumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}}"
3377	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	2	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of anti-HER2 antibody linked to topoisomerase I inhibitor payload. DESTINY-CRC01 showed promising activity in HER2-positive metastatic CRC with strong IHC 3+ expression.																																																								"{""description"": ""Antibody-drug conjugate consisting of anti-HER2 antibody linked to topoisomerase I inhibitor payload. DESTINY-CRC01 showed promising activity in HER2-positive metastatic CRC with strong IHC 3+ expression."", ""name"": ""Trastuzumab Deruxtecan (T-DXd)""}"	{}	"{""description"": ""Antibody-drug conjugate consisting of anti-HER2 antibody linked to topoisomerase I inhibitor payload. DESTINY-CRC01 showed promising activity in HER2-positive metastatic CRC with strong IHC 3+ expression."", ""name"": ""Trastuzumab Deruxtecan (T-DXd)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3378	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	3	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.																																																								"{""description"": ""Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval."", ""name"": ""Tucatinib plus Trastuzumab""}"	{}	"{""description"": ""Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval."", ""name"": ""Tucatinib plus Trastuzumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}}"
3379	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	4	Surgical Resection	Surgery for localized disease or selected metastatic cases. HER2 status does not change standard surgical approaches but informs systemic therapy decisions.																																																								"{""description"": ""Surgery for localized disease or selected metastatic cases. HER2 status does not change standard surgical approaches but informs systemic therapy decisions."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgery for localized disease or selected metastatic cases. HER2 status does not change standard surgical approaches but informs systemic therapy decisions."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3397	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	0	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.																																																								"{""description"": ""First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment."", ""name"": ""Trastuzumab plus Chemotherapy""}"	{}	"{""description"": ""First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment."", ""name"": ""Trastuzumab plus Chemotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}}"
3398	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	1	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate with anti-HER2 antibody linked to topoisomerase I inhibitor deruxtecan. DESTINY-Gastric01 demonstrated superior overall survival compared to chemotherapy in previously treated HER2-positive gastric cancer. Bystander effect allows activity even with heterogeneous HER2 expression.																																																								"{""description"": ""Antibody-drug conjugate with anti-HER2 antibody linked to topoisomerase I inhibitor deruxtecan. DESTINY-Gastric01 demonstrated superior overall survival compared to chemotherapy in previously treated HER2-positive gastric cancer. Bystander effect allows activity even with heterogeneous HER2 expression."", ""name"": ""Trastuzumab Deruxtecan (T-DXd)""}"	{}	"{""description"": ""Antibody-drug conjugate with anti-HER2 antibody linked to topoisomerase I inhibitor deruxtecan. DESTINY-Gastric01 demonstrated superior overall survival compared to chemotherapy in previously treated HER2-positive gastric cancer. Bystander effect allows activity even with heterogeneous HER2 expression."", ""name"": ""Trastuzumab Deruxtecan (T-DXd)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3399	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	2	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.																																																								"{""description"": ""Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer."", ""name"": ""Trastuzumab plus Pembrolizumab plus Chemotherapy""}"	{}	"{""description"": ""Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer."", ""name"": ""Trastuzumab plus Pembrolizumab plus Chemotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}}"
3400	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	3	Ramucirumab plus Paclitaxel	Anti-VEGFR2 antibody ramucirumab with paclitaxel is standard second-line option. May be used regardless of HER2 status but can be combined with T-DXd in sequencing strategies for HER2-positive disease.																																																								"{""description"": ""Anti-VEGFR2 antibody ramucirumab with paclitaxel is standard second-line option. May be used regardless of HER2 status but can be combined with T-DXd in sequencing strategies for HER2-positive disease."", ""name"": ""Ramucirumab plus Paclitaxel""}"	{}	"{""description"": ""Anti-VEGFR2 antibody ramucirumab with paclitaxel is standard second-line option. May be used regardless of HER2 status but can be combined with T-DXd in sequencing strategies for HER2-positive disease."", ""name"": ""Ramucirumab plus Paclitaxel"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3401	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	4	Surgical Resection	Gastrectomy with lymph node dissection for resectable disease. Perioperative chemotherapy (FLOT regimen) is standard for locally advanced disease. Role of HER2-targeted therapy in perioperative setting under investigation.																																																								"{""description"": ""Gastrectomy with lymph node dissection for resectable disease. Perioperative chemotherapy (FLOT regimen) is standard for locally advanced disease. Role of HER2-targeted therapy in perioperative setting under investigation."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Gastrectomy with lymph node dissection for resectable disease. Perioperative chemotherapy (FLOT regimen) is standard for locally advanced disease. Role of HER2-targeted therapy in perioperative setting under investigation."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3422	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	0	Respiratory Support	Non-invasive ventilation such as BiPAP may be required for management of hypoventilation, particularly during sleep or respiratory infections.																																																								"{""description"": ""Non-invasive ventilation such as BiPAP may be required for management of hypoventilation, particularly during sleep or respiratory infections."", ""name"": ""Respiratory Support""}"	{}	"{""description"": ""Non-invasive ventilation such as BiPAP may be required for management of hypoventilation, particularly during sleep or respiratory infections."", ""name"": ""Respiratory Support"", ""treatment_term"": {""preferred_term"": ""Respiratory support"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
3423	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	1	Anticonvulsant Therapy	Seizures are generally responsive to standard anticonvulsant medications. Valproate has been noted as potentially beneficial due to its HIF-1 alpha inhibiting properties.																																																								"{""description"": ""Seizures are generally responsive to standard anticonvulsant medications. Valproate has been noted as potentially beneficial due to its HIF-1 alpha inhibiting properties."", ""name"": ""Anticonvulsant Therapy""}"	{}	"{""description"": ""Seizures are generally responsive to standard anticonvulsant medications. Valproate has been noted as potentially beneficial due to its HIF-1 alpha inhibiting properties."", ""name"": ""Anticonvulsant Therapy"", ""treatment_term"": {""preferred_term"": ""Anticonvulsant therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3424	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	2	Physical Therapy	Rehabilitation to address hypotonia, motor delays, and gait abnormalities.																																																								"{""description"": ""Rehabilitation to address hypotonia, motor delays, and gait abnormalities."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Rehabilitation to address hypotonia, motor delays, and gait abnormalities."", ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
3425	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	3	Ophthalmologic Management	Regular ophthalmologic evaluation and management of visual impairments including corrective lenses and treatment of strabismus.																																																								"{""description"": ""Regular ophthalmologic evaluation and management of visual impairments including corrective lenses and treatment of strabismus."", ""name"": ""Ophthalmologic Management""}"	{}	"{""description"": ""Regular ophthalmologic evaluation and management of visual impairments including corrective lenses and treatment of strabismus."", ""name"": ""Ophthalmologic Management"", ""treatment_term"": {""preferred_term"": ""Ophthalmologic management"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
3450	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	0	Surgical Resection	Primary surgery is preferred for oral cavity cancers and selected laryngeal/pharyngeal tumors. Extent depends on tumor stage and location. Reconstruction may be required for adequate margins.																																																								"{""description"": ""Primary surgery is preferred for oral cavity cancers and selected laryngeal/pharyngeal tumors. Extent depends on tumor stage and location. Reconstruction may be required for adequate margins."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Primary surgery is preferred for oral cavity cancers and selected laryngeal/pharyngeal tumors. Extent depends on tumor stage and location. Reconstruction may be required for adequate margins."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3451	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	1	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.																																																								"{""description"": ""Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired."", ""name"": ""Definitive Chemoradiation""}"	{}	"{""description"": ""Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired."", ""name"": ""Definitive Chemoradiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}}"
3452	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	2	Cetuximab	EGFR monoclonal antibody approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease. Alternative to cisplatin in patients unable to tolerate platinum.																																																								"{""description"": ""EGFR monoclonal antibody approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease. Alternative to cisplatin in patients unable to tolerate platinum."", ""name"": ""Cetuximab""}"	{}	"{""description"": ""EGFR monoclonal antibody approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease. Alternative to cisplatin in patients unable to tolerate platinum."", ""name"": ""Cetuximab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3453	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	3	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC as monotherapy or with chemotherapy. Response rates are modest (approximately 15-20% monotherapy).																																																								"{""description"": ""PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC as monotherapy or with chemotherapy. Response rates are modest (approximately 15-20% monotherapy)."", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC as monotherapy or with chemotherapy. Response rates are modest (approximately 15-20% monotherapy)."", ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3473	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	0	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.																																																								"{""description"": ""Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity."", ""name"": ""Definitive Chemoradiation""}"	{}	"{""description"": ""Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity."", ""name"": ""Definitive Chemoradiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}}"
3474	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	1	Transoral Robotic Surgery	Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features.																																																								"{""description"": ""Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features."", ""name"": ""Transoral Robotic Surgery""}"	{}	"{""description"": ""Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features."", ""name"": ""Transoral Robotic Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3475	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	2	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease.																																																								"{""description"": ""PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease."", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease."", ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3476	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	3	HPV Vaccination	Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development.																																																								"{""description"": ""Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development."", ""name"": ""HPV Vaccination""}"	{}	"{""description"": ""Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development."", ""name"": ""HPV Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
3497	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	treatments	0	Levothyroxine	Thyroid hormone replacement therapy, mainstay of treatment.																																																								"{""description"": ""Thyroid hormone replacement therapy, mainstay of treatment."", ""name"": ""Levothyroxine""}"	{}	"{""description"": ""Thyroid hormone replacement therapy, mainstay of treatment."", ""name"": ""Levothyroxine""}"
3498	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	treatments	1	Selenium Supplementation	May reduce antibody levels in some patients.																																																								"{""description"": ""May reduce antibody levels in some patients."", ""name"": ""Selenium Supplementation""}"	{}	"{""description"": ""May reduce antibody levels in some patients."", ""name"": ""Selenium Supplementation""}"
3499	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	treatments	2	Monitoring	Regular TSH monitoring to adjust replacement dose.																																																								"{""description"": ""Regular TSH monitoring to adjust replacement dose."", ""name"": ""Monitoring""}"	{}	"{""description"": ""Regular TSH monitoring to adjust replacement dose."", ""name"": ""Monitoring""}"
3522	147	Heart Failure	Heart_Failure.yaml	treatments	0	ACE Inhibitors/ARBs	Neurohormonal blockade, reduce mortality in HFrEF.																																																								"{""description"": ""Neurohormonal blockade, reduce mortality in HFrEF."", ""name"": ""ACE Inhibitors/ARBs""}"	{}	"{""description"": ""Neurohormonal blockade, reduce mortality in HFrEF."", ""name"": ""ACE Inhibitors/ARBs""}"
3523	147	Heart Failure	Heart_Failure.yaml	treatments	1	Beta Blockers	Reduce heart rate and reverse remodeling in HFrEF.																																																								"{""description"": ""Reduce heart rate and reverse remodeling in HFrEF."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Reduce heart rate and reverse remodeling in HFrEF."", ""name"": ""Beta Blockers""}"
3524	147	Heart Failure	Heart_Failure.yaml	treatments	2	ARNI (Sacubitril/Valsartan)	Combined neprilysin inhibitor and ARB, superior to ACE inhibitors.																																																								"{""description"": ""Combined neprilysin inhibitor and ARB, superior to ACE inhibitors."", ""name"": ""ARNI (Sacubitril/Valsartan)""}"	{}	"{""description"": ""Combined neprilysin inhibitor and ARB, superior to ACE inhibitors."", ""name"": ""ARNI (Sacubitril/Valsartan)""}"
3525	147	Heart Failure	Heart_Failure.yaml	treatments	3	SGLT2 Inhibitors	Reduce hospitalizations and mortality across HF spectrum.																																																								"{""description"": ""Reduce hospitalizations and mortality across HF spectrum."", ""name"": ""SGLT2 Inhibitors""}"	{}	"{""description"": ""Reduce hospitalizations and mortality across HF spectrum."", ""name"": ""SGLT2 Inhibitors""}"
3526	147	Heart Failure	Heart_Failure.yaml	treatments	4	Mineralocorticoid Receptor Antagonists	Spironolactone or eplerenone for additional neurohormonal blockade.																																																								"{""description"": ""Spironolactone or eplerenone for additional neurohormonal blockade."", ""name"": ""Mineralocorticoid Receptor Antagonists""}"	{}	"{""description"": ""Spironolactone or eplerenone for additional neurohormonal blockade."", ""name"": ""Mineralocorticoid Receptor Antagonists""}"
3527	147	Heart Failure	Heart_Failure.yaml	treatments	5	Diuretics	Manage fluid overload and congestion symptoms.																																																								"{""description"": ""Manage fluid overload and congestion symptoms."", ""name"": ""Diuretics""}"	{}	"{""description"": ""Manage fluid overload and congestion symptoms."", ""name"": ""Diuretics""}"
3528	147	Heart Failure	Heart_Failure.yaml	treatments	6	Cardiac Resynchronization Therapy	For patients with wide QRS and reduced EF.																																																								"{""description"": ""For patients with wide QRS and reduced EF."", ""name"": ""Cardiac Resynchronization Therapy""}"	{}	"{""description"": ""For patients with wide QRS and reduced EF."", ""name"": ""Cardiac Resynchronization Therapy""}"
3529	147	Heart Failure	Heart_Failure.yaml	treatments	7	Implantable Cardioverter-Defibrillator	Prevents sudden cardiac death in high-risk patients.																																																								"{""description"": ""Prevents sudden cardiac death in high-risk patients."", ""name"": ""Implantable Cardioverter-Defibrillator""}"	{}	"{""description"": ""Prevents sudden cardiac death in high-risk patients."", ""name"": ""Implantable Cardioverter-Defibrillator""}"
3545	148	Hemochromatosis	Hemochromatosis.yaml	treatments	0	Phlebotomy (Therapeutic Venesection)	"Regular blood removal is the primary treatment, which reduces iron stores by requiring the body to use iron for new red blood cell production. Initially weekly until iron stores normalize, then maintenance every 2-3 months.
"																																																								"{""description"": ""Regular blood removal is the primary treatment, which reduces iron stores by requiring the body to use iron for new red blood cell production. Initially weekly until iron stores normalize, then maintenance every 2-3 months.\n"", ""name"": ""Phlebotomy (Therapeutic Venesection)""}"	{}	"{""description"": ""Regular blood removal is the primary treatment, which reduces iron stores by requiring the body to use iron for new red blood cell production. Initially weekly until iron stores normalize, then maintenance every 2-3 months.\n"", ""evidence"": [{""explanation"": ""This review confirms phlebotomy as the standard first-line treatment for hereditary hemochromatosis."", ""reference"": ""PMID:23985001"", ""snippet"": ""Phlebotomy remains the mainstay of treatment and new treatments being studied include erythrocytapheresis and 'mini-hepcidins'."", ""supports"": ""SUPPORT""}, {""explanation"": ""Phlebotomy improved iron indices and symptoms in a ferroportin hemochromatosis pedigree."", ""reference"": ""PMID:38886778"", ""snippet"": ""Four patients with organ damage in the present study received therapeutic phlebotomy, alleviating clinical symptoms and improving in transferrin saturation and serum ferritin."", ""supports"": ""SUPPORT""}, {""explanation"": ""Seminar notes phlebotomy prevents cirrhosis and mortality when started early."", ""reference"": ""PMID:37121243"", ""snippet"": ""Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death."", ""supports"": ""SUPPORT""}, {""explanation"": ""EASL guideline highlights phlebotomy as preventive for multi-organ complications."", ""reference"": ""PMID:35662478"", ""snippet"": ""Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropathy and other complications."", ""supports"": ""SUPPORT""}, {""explanation"": ""Early clinical report established phlebotomy as definitive iron removal."", ""reference"": ""PMID:5339192"", ""snippet"": ""The treatment of hemochromatosis by phlebotomy."", ""supports"": ""SUPPORT""}], ""name"": ""Phlebotomy (Therapeutic Venesection)""}"
3546	148	Hemochromatosis	Hemochromatosis.yaml	treatments	1	Iron Chelation Therapy	"Deferoxamine or oral chelators (deferasirox, deferiprone) are used when phlebotomy is contraindicated or insufficient, such as in patients with anemia.
"																																																								"{""description"": ""Deferoxamine or oral chelators (deferasirox, deferiprone) are used when phlebotomy is contraindicated or insufficient, such as in patients with anemia.\n"", ""name"": ""Iron Chelation Therapy""}"	{}	"{""description"": ""Deferoxamine or oral chelators (deferasirox, deferiprone) are used when phlebotomy is contraindicated or insufficient, such as in patients with anemia.\n"", ""evidence"": [{""explanation"": ""Secondary hemochromatosis requires chelation when phlebotomy is not feasible."", ""reference"": ""PMID:19727383"", ""snippet"": ""Because secondary hemochromatosis is due to hereditary or acquired anemia, phlebotomy is not a suitable means of removing excess iron in this situation. Rather, the treatment is based on the targeted elimination of iron by means of iron chelators."", ""supports"": ""SUPPORT""}, {""explanation"": ""Primer notes chelation as an alternative for selected patients."", ""reference"": ""PMID:29620054"", ""snippet"": ""The mainstay therapy is phlebotomy, although iron chelation can be used in some patients."", ""supports"": ""SUPPORT""}], ""name"": ""Iron Chelation Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3547	148	Hemochromatosis	Hemochromatosis.yaml	treatments	2	Dietary Modification	"Avoiding iron supplements, limiting vitamin C intake (which enhances iron absorption), and reducing alcohol consumption to protect the liver.
"																																																								"{""description"": ""Avoiding iron supplements, limiting vitamin C intake (which enhances iron absorption), and reducing alcohol consumption to protect the liver.\n"", ""name"": ""Dietary Modification""}"	{}	"{""description"": ""Avoiding iron supplements, limiting vitamin C intake (which enhances iron absorption), and reducing alcohol consumption to protect the liver.\n"", ""evidence"": [{""explanation"": ""Lifestyle changes in alcohol and dietary iron/Vitamin C improved iron indices."", ""reference"": ""PMID:38361672"", ""snippet"": ""This patient was counseled on lifestyle modifications which included abstaining from alcohol and reducing iron and vitamin C intake. As a result, his iron panel parameters improved."", ""supports"": ""SUPPORT""}], ""name"": ""Dietary Modification"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
3548	148	Hemochromatosis	Hemochromatosis.yaml	treatments	3	Screening of Family Members	"Genetic testing of first-degree relatives is recommended given the autosomal recessive inheritance pattern and the benefits of early intervention.
"																																																								"{""description"": ""Genetic testing of first-degree relatives is recommended given the autosomal recessive inheritance pattern and the benefits of early intervention.\n"", ""name"": ""Screening of Family Members""}"	{}	"{""description"": ""Genetic testing of first-degree relatives is recommended given the autosomal recessive inheritance pattern and the benefits of early intervention.\n"", ""evidence"": [{""explanation"": ""Emphasizes early genetic testing to enable preventive treatment."", ""reference"": ""PMID:37121243"", ""snippet"": ""Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death."", ""supports"": ""SUPPORT""}], ""name"": ""Screening of Family Members"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
3563	149	Hemophilia A	Hemophilia_A.yaml	treatments	0	Factor VIII Replacement	Recombinant or plasma-derived factor VIII concentrate for bleeding episodes and prophylaxis.																																																								"{""description"": ""Recombinant or plasma-derived factor VIII concentrate for bleeding episodes and prophylaxis."", ""name"": ""Factor VIII Replacement""}"	{}	"{""description"": ""Recombinant or plasma-derived factor VIII concentrate for bleeding episodes and prophylaxis."", ""evidence"": [{""explanation"": ""Review confirms factor VIII concentrates as established treatment for hemophilia A patients."", ""reference"": ""PMID:12640572"", ""snippet"": ""Plasma-derived cryoprecipitate and factor (F) VIII concentrates, which have been used for hemophilia A patients, involve the risk of transmitting blood-borne diseases."", ""supports"": ""SUPPORT""}], ""name"": ""Factor VIII Replacement""}"
3564	149	Hemophilia A	Hemophilia_A.yaml	treatments	1	Emicizumab	Bispecific antibody mimicking factor VIII function, subcutaneous prophylaxis.																																																								"{""description"": ""Bispecific antibody mimicking factor VIII function, subcutaneous prophylaxis."", ""name"": ""Emicizumab""}"	{}	"{""description"": ""Bispecific antibody mimicking factor VIII function, subcutaneous prophylaxis."", ""evidence"": [{""explanation"": ""Phase 3 HAVEN 3 trial demonstrates emicizumab mechanism and efficacy in hemophilia A without inhibitors."", ""reference"": ""PMID:30157389"", ""snippet"": ""Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis."", ""supports"": ""SUPPORT""}], ""name"": ""Emicizumab""}"
3565	149	Hemophilia A	Hemophilia_A.yaml	treatments	2	Desmopressin (DDAVP)	Releases endogenous factor VIII, useful in mild hemophilia A.																																																								"{""description"": ""Releases endogenous factor VIII, useful in mild hemophilia A."", ""name"": ""Desmopressin (DDAVP)""}"	{}	"{""description"": ""Releases endogenous factor VIII, useful in mild hemophilia A."", ""evidence"": [{""explanation"": ""Review confirms desmopressin as a widely used hemostatic agent in mild hemophilia A."", ""reference"": ""PMID:12640572"", ""snippet"": ""Desmopressin is today a widely used hemostatic agent not only in patients with mild hemophilia A or von Willebrand disease (vWD) but also in those with congenital or acquired platelet dysfunction."", ""supports"": ""SUPPORT""}], ""name"": ""Desmopressin (DDAVP)""}"
3566	149	Hemophilia A	Hemophilia_A.yaml	treatments	3	Antifibrinolytics	Tranexamic acid or aminocaproic acid as adjunctive therapy.																																																								"{""description"": ""Tranexamic acid or aminocaproic acid as adjunctive therapy."", ""name"": ""Antifibrinolytics""}"	{}	"{""description"": ""Tranexamic acid or aminocaproic acid as adjunctive therapy."", ""evidence"": [{""explanation"": ""Cochrane systematic review confirms beneficial effect of tranexamic acid and aminocaproic acid in reducing bleeding in hemophilia patients."", ""reference"": ""PMID:26704192"", ""snippet"": ""Overall, the two included trials showed a beneficial effect of tranexamic acid and EACA, administered systemically, in reducing the number of bleedings, the amount of blood loss and the need for therapeutic clotting factor concentrates."", ""supports"": ""SUPPORT""}], ""name"": ""Antifibrinolytics""}"
3567	149	Hemophilia A	Hemophilia_A.yaml	treatments	4	Gene Therapy	Emerging treatment using AAV vectors to deliver functional F8 gene.																																																								"{""description"": ""Emerging treatment using AAV vectors to deliver functional F8 gene."", ""name"": ""Gene Therapy""}"	{}	"{""description"": ""Emerging treatment using AAV vectors to deliver functional F8 gene."", ""evidence"": [{""explanation"": ""Phase 3 GENEr8-1 trial demonstrates AAV5-based gene therapy efficacy in severe hemophilia A."", ""reference"": ""PMID:35294811"", ""snippet"": ""In patients with severe hemophilia A, valoctocogene roxaparvovec treatment provided endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis."", ""supports"": ""SUPPORT""}], ""name"": ""Gene Therapy""}"
3570	150	Hemophilia B	Hemophilia_B.yaml	treatments	0	Factor IX Replacement	Plasma-derived or recombinant factor IX concentrates for on-demand or prophylactic therapy.																																																								"{""description"": ""Plasma-derived or recombinant factor IX concentrates for on-demand or prophylactic therapy."", ""name"": ""Factor IX Replacement""}"	{}	"{""description"": ""Plasma-derived or recombinant factor IX concentrates for on-demand or prophylactic therapy."", ""evidence"": [{""explanation"": ""The abstract notes factor IX concentrates as key treatment advances."", ""reference"": ""PMID:23430394"", ""snippet"": ""Hemophilia B treatment has improved greatly in the last 20 years with the introduction first of plasma-derived and then of recombinant FIX concentrates."", ""supports"": ""SUPPORT""}], ""name"": ""Factor IX Replacement"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3571	150	Hemophilia B	Hemophilia_B.yaml	treatments	1	Prophylactic Factor IX Replacement	Regular prophylactic dosing to prevent bleeding and arthropathy.																																																								"{""description"": ""Regular prophylactic dosing to prevent bleeding and arthropathy."", ""name"": ""Prophylactic Factor IX Replacement""}"	{}	"{""description"": ""Regular prophylactic dosing to prevent bleeding and arthropathy."", ""evidence"": [{""explanation"": ""The abstract notes prophylaxis as a superior treatment modality for prevention of arthropathy."", ""reference"": ""PMID:23430394"", ""snippet"": ""Replacement therapy may be administered through on-demand or prophylaxis regimens, but the latter treatment modality has been shown to be superior in prevention of hemophilic arthropathy and in improvement of patients' quality of life."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract describes prophylactic factor replacement as the mainstay of treatment for severe hemophilia."", ""reference"": ""PMID:39950390"", ""snippet"": ""Prophylaxis with coagulation factor concentrates is the mainstay of treatment in severe hemophilia A and B."", ""supports"": ""SUPPORT""}], ""name"": ""Prophylactic Factor IX Replacement"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3612	151	Hepatitis B	Hepatitis_B.yaml	treatments	0	Antiviral Medications	Includes drugs like tenofovir and entecavir to suppress HBV replication.																																																								"{""description"": ""Includes drugs like tenofovir and entecavir to suppress HBV replication."", ""name"": ""Antiviral Medications""}"	{}	"{""description"": ""Includes drugs like tenofovir and entecavir to suppress HBV replication."", ""evidence"": [{""explanation"": ""The reference explicitly mentions tenofovir and entecavir as first-line drugs for suppressing HBV replication."", ""reference"": ""PMID:26732483"", ""snippet"": ""Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line anti-HBV drugs for excellent viral suppression with a low risk of antiviral resistance."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the use of tenofovir for suppressing HBV replication."", ""reference"": ""PMID:26054819"", ""snippet"": ""Since 2008, it has also been indicated for treatment of chronic HBV infection or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral replication, thus reducing hepatic complications and improving patient survival."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study evaluates the effects of tenofovir and entecavir in CHB patients, supporting their role in HBV suppression."", ""reference"": ""PMID:32050881"", ""snippet"": ""The aim of this study was to evaluate the histological, virological, serological and biochemical response rates in CHB patients receiving tenofovir or entecavir therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference confirms that tenofovir and entecavir are used to suppress HBV replication."", ""reference"": ""PMID:27742007"", ""snippet"": ""This is achievable by the highly active antivirals, entecavir and tenofovir, which are considered first-line therapy in most patients with immune active hepatitis C virus and after liver transplantation to prevent HBV recurrence."", ""supports"": ""SUPPORT""}], ""name"": ""Antiviral Medications"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3613	151	Hepatitis B	Hepatitis_B.yaml	treatments	1	Interferon Therapy	Boosts the immune system to fight the virus.																																																								"{""description"": ""Boosts the immune system to fight the virus."", ""name"": ""Interferon Therapy""}"	{}	"{""description"": ""Boosts the immune system to fight the virus."", ""evidence"": [{""explanation"": ""The literature indicates that Interferon-alpha has immunomodulatory activities, which can help in controlling HBV infection, but it does not explicitly state that it 'boosts' the immune system in the general sense."", ""reference"": ""PMID:25034484"", ""snippet"": ""Interferon-alpha (IFN-alpha) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients...IFN-alpha has multiple antiviral, antiproliferative, and immunomodulatory activities."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature suggests that targeting immune responses is a strategy in treating HBV, but it does not explicitly state that Interferon Therapy 'boosts' the immune system."", ""reference"": ""PMID:16461223"", ""snippet"": ""Therapeutic strategies aimed at correcting this defective T cell reactivity could represent a complementary approach to the cure of chronic HBV infection."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study indicates that Interferon Therapy is effective in treating HBV in children, but it does not explicitly state that it 'boosts' the immune system."", ""reference"": ""PMID:10804945"", ""snippet"": ""We found IFN to be a safe and adequate mode of treatment in children with chronic HBV infection, regardless of their liver histology and transaminase levels."", ""supports"": ""PARTIAL""}], ""name"": ""Interferon Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3614	151	Hepatitis B	Hepatitis_B.yaml	treatments	2	Liver Transplant	For end-stage liver disease.																																																								"{""description"": ""For end-stage liver disease."", ""name"": ""Liver Transplant""}"	{}	"{""description"": ""For end-stage liver disease."", ""evidence"": [{""explanation"": ""This reference explicitly states that liver transplantation is the only effective treatment for end-stage liver disease caused by hepatitis B."", ""reference"": ""PMID:29125261"", ""snippet"": ""Liver transplantation (LT) is the only effective treatment for hepatitis B-virus (HBV) related end stage liver disease..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the advancements in treatment options for end-stage hepatitis B cirrhosis, implying liver transplantation as a viable option."", ""reference"": ""PMID:17981234"", ""snippet"": ""Until recently, the options for a patient who had end-stage hepatitis B cirrhosis were severely limited, but during the past 15 years great strides have been made in prevention and treatment of hepatitis B cirrhosis."", ""supports"": ""SUPPORT""}], ""name"": ""Liver Transplant"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
3615	151	Hepatitis B	Hepatitis_B.yaml	treatments	3	Regular Monitoring	Monitoring liver function and viral load to manage chronic infection.																																																								"{""description"": ""Monitoring liver function and viral load to manage chronic infection."", ""name"": ""Regular Monitoring""}"	{}	"{""description"": ""Monitoring liver function and viral load to manage chronic infection."", ""evidence"": [{""explanation"": ""The literature supports regular monitoring of liver function and viral load in patients with chronic hepatitis B infection."", ""reference"": ""PMID:24266913"", ""snippet"": ""Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study recommends regular monitoring of viral load in hepatitis B patients, supporting the statement."", ""reference"": ""PMID:12776281"", ""snippet"": ""Periodic testing for HBV DNA to assess the virological status of HBsAg-positive dialysis patients is recommended."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article discusses the importance of monitoring hepatitis B using various biomarkers, which aligns with the statement."", ""reference"": ""PMID:33467927"", ""snippet"": ""This manuscript summarized traditional biomarkers of different hepatitis B stages and recent-developed POCT platforms (including microfluidic platforms and lateral-flow strips) and discuss the challenges associated with their use."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature highlights the importance of monitoring liver-related biomarkers in chronic hepatitis B patients."", ""reference"": ""PMID:31528100"", ""snippet"": ""HBcrAg is an excellent monitor of hepatic histological changes, especially in CHB patients treated with nucleoside analogs."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article emphasizes the necessity of regular monitoring in the management of chronic hepatitis B."", ""reference"": ""PMID:26799653"", ""snippet"": ""As a result, regular monitoring of the response during treatment and after treatment is required."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports regular monitoring as a vital part of managing chronic hepatitis B to reduce complications."", ""reference"": ""PMID:33945063"", ""snippet"": ""Regular monitoring and treatment of chronic hepatitis B (CHB) are known to reduce the risk of hepatocellular carcinoma."", ""supports"": ""SUPPORT""}], ""name"": ""Regular Monitoring""}"
3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	Vaccination	Hepatitis B vaccine provides prevention for uninfected individuals.																																																								"{""description"": ""Hepatitis B vaccine provides prevention for uninfected individuals."", ""name"": ""Vaccination""}"	{}	"{""description"": ""Hepatitis B vaccine provides prevention for uninfected individuals."", ""evidence"": [{""explanation"": ""The article supports the statement by emphasizing the importance of immunizing infants and adolescents to prevent HBV infection."", ""reference"": ""PMID:10776195"", ""snippet"": ""Immunization of all newborn infants and adolescents for HBV is a vital step toward eradicating HBV from the general population."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article confirms that HBV vaccination is a primary prevention strategy for the general population."", ""reference"": ""PMID:33200362"", ""snippet"": ""Primary prevention by HBV vaccination targeting the general population starting from birth dose."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article discusses the long-term protection conferred by hepatitis B vaccines, supporting their role in preventing HBV infection."", ""reference"": ""PMID:17298912"", ""snippet"": ""Hepatitis B vaccines have been licensed since 1982... Long-term protection has been demonstrated."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article states that hepatitis B is preventable through vaccination, supporting the statement."", ""reference"": ""PMID:22643598"", ""snippet"": ""Hepatitis B is a preventable disease; a safe and effective vaccine has been available for 30 years."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article provides evidence from China's mass vaccination program, showing a significant reduction in HBV carrier rates due to vaccination."", ""reference"": ""PMID:19187625"", ""snippet"": ""The chronic HBV carrier rate in children < 10 years of age decreased from 10.0% before the mass vaccination to 1.0% - 2.0% in 2006."", ""supports"": ""SUPPORT""}], ""name"": ""Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
3639	152	Hepatitis C	Hepatitis_C.yaml	treatments	0	Direct-Acting Antivirals (DAAs)	"Oral medications targeting viral proteins (NS3/4A protease, NS5A, NS5B polymerase) with cure rates exceeding 95%. Regimens include sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and others.
"																																																								"{""description"": ""Oral medications targeting viral proteins (NS3/4A protease, NS5A, NS5B polymerase) with cure rates exceeding 95%. Regimens include sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and others.\n"", ""name"": ""Direct-Acting Antivirals (DAAs)""}"	{}	"{""description"": ""Oral medications targeting viral proteins (NS3/4A protease, NS5A, NS5B polymerase) with cure rates exceeding 95%. Regimens include sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and others.\n"", ""evidence"": [{""explanation"": ""Landmark trial demonstrating near-universal cure rates with DAA therapy."", ""reference"": ""PMID:24725239"", ""snippet"": ""Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection."", ""supports"": ""SUPPORT""}, {""explanation"": ""Study confirms high efficacy of DAAs even in patients with decompensated cirrhosis."", ""reference"": ""PMID:26569658"", ""snippet"": ""Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis."", ""supports"": ""SUPPORT""}], ""name"": ""Direct-Acting Antivirals (DAAs)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3640	152	Hepatitis C	Hepatitis_C.yaml	treatments	1	Liver Transplantation	"Treatment option for decompensated cirrhosis or hepatocellular carcinoma. DAA therapy post-transplant prevents graft reinfection.
"																																																								"{""description"": ""Treatment option for decompensated cirrhosis or hepatocellular carcinoma. DAA therapy post-transplant prevents graft reinfection.\n"", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""Treatment option for decompensated cirrhosis or hepatocellular carcinoma. DAA therapy post-transplant prevents graft reinfection.\n"", ""name"": ""Liver Transplantation"", ""treatment_term"": {""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}}"
3641	152	Hepatitis C	Hepatitis_C.yaml	treatments	2	Hepatocellular Carcinoma Surveillance	"Regular ultrasound and AFP monitoring in cirrhotic patients for early detection of hepatocellular carcinoma.
"																																																								"{""description"": ""Regular ultrasound and AFP monitoring in cirrhotic patients for early detection of hepatocellular carcinoma.\n"", ""name"": ""Hepatocellular Carcinoma Surveillance""}"	{}	"{""description"": ""Regular ultrasound and AFP monitoring in cirrhotic patients for early detection of hepatocellular carcinoma.\n"", ""name"": ""Hepatocellular Carcinoma Surveillance"", ""treatment_term"": {""preferred_term"": ""surveillance for malignancies"", ""term"": {""id"": ""MAXO:0001492"", ""label"": ""surveillance for malignancies""}}}"
3669	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	0	Atezolizumab plus Bevacizumab	First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices.																																																								"{""description"": ""First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices."", ""name"": ""Atezolizumab plus Bevacizumab""}"	{}	"{""description"": ""First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices."", ""evidence"": [{""explanation"": ""IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib."", ""reference"": ""PMID:39687036"", ""snippet"": ""Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"", ""supports"": ""SUPPORT""}], ""name"": ""Atezolizumab plus Bevacizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3670	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	1	Durvalumab plus Tremelimumab	Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab.																																																								"{""description"": ""Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab."", ""name"": ""Durvalumab plus Tremelimumab""}"	{}	"{""description"": ""Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab."", ""name"": ""Durvalumab plus Tremelimumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3671	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	2	Sorafenib	Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated.																																																								"{""description"": ""Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated."", ""name"": ""Sorafenib""}"	{}	"{""description"": ""Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated."", ""name"": ""Sorafenib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3672	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	3	Lenvatinib	Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.																																																								"{""description"": ""Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate."", ""name"": ""Lenvatinib""}"	{}	"{""description"": ""Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate."", ""name"": ""Lenvatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3673	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	4	Surgical Resection	Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant.																																																								"{""description"": ""Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3674	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	5	Liver Transplantation	Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability.																																																								"{""description"": ""Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability."", ""name"": ""Liver Transplantation"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
3675	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	6	Transarterial Chemoembolization (TACE)	Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy.																																																								"{""description"": ""Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy."", ""name"": ""Transarterial Chemoembolization (TACE)""}"	{}	"{""description"": ""Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy."", ""name"": ""Transarterial Chemoembolization (TACE)"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
3676	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	7	Radiofrequency/Microwave Ablation	Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function.																																																								"{""description"": ""Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function."", ""name"": ""Radiofrequency/Microwave Ablation""}"	{}	"{""description"": ""Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function."", ""name"": ""Radiofrequency/Microwave Ablation"", ""treatment_term"": {""preferred_term"": ""ablation therapy"", ""term"": {""id"": ""MAXO:0000452"", ""label"": ""ablation therapy""}}}"
3692	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	0	Risk-Reducing Mastectomy	Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA mutation carriers. Timing and decision require careful counseling about risks, benefits, reconstruction options, and psychological impact.																																																								"{""description"": ""Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA mutation carriers. Timing and decision require careful counseling about risks, benefits, reconstruction options, and psychological impact."", ""name"": ""Risk-Reducing Mastectomy""}"	{}	"{""description"": ""Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA mutation carriers. Timing and decision require careful counseling about risks, benefits, reconstruction options, and psychological impact."", ""name"": ""Risk-Reducing Mastectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3693	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	1	Risk-Reducing Salpingo-Oophorectomy	Bilateral salpingo-oophorectomy recommended after completion of childbearing (typically age 35-40 for BRCA1, 40-45 for BRCA2). Reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50% when performed premenopausally.																																																								"{""description"": ""Bilateral salpingo-oophorectomy recommended after completion of childbearing (typically age 35-40 for BRCA1, 40-45 for BRCA2). Reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50% when performed premenopausally."", ""name"": ""Risk-Reducing Salpingo-Oophorectomy""}"	{}	"{""description"": ""Bilateral salpingo-oophorectomy recommended after completion of childbearing (typically age 35-40 for BRCA1, 40-45 for BRCA2). Reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50% when performed premenopausally."", ""name"": ""Risk-Reducing Salpingo-Oophorectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.																																																								"{""description"": ""PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations."", ""name"": ""PARP Inhibitors""}"	{}	"{""description"": ""PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations."", ""evidence"": [{""explanation"": ""OlympiA phase 3 trial demonstrates adjuvant olaparib significantly improves disease-free survival in high-risk BRCA-mutated breast cancer."", ""reference"": ""PMID:34081848"", ""snippet"": ""adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo."", ""supports"": ""SUPPORT""}], ""name"": ""PARP Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}]}}"
3695	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	3	Enhanced Surveillance	For women who do not undergo prophylactic surgery, enhanced surveillance includes annual breast MRI (starting age 25-30), mammography (starting age 30), and clinical breast exam. No proven effective ovarian cancer screening exists. Consider transvaginal ultrasound and CA-125, though sensitivity is limited.																																																								"{""description"": ""For women who do not undergo prophylactic surgery, enhanced surveillance includes annual breast MRI (starting age 25-30), mammography (starting age 30), and clinical breast exam. No proven effective ovarian cancer screening exists. Consider transvaginal ultrasound and CA-125, though sensitivity is limited."", ""name"": ""Enhanced Surveillance""}"	{}	"{""description"": ""For women who do not undergo prophylactic surgery, enhanced surveillance includes annual breast MRI (starting age 25-30), mammography (starting age 30), and clinical breast exam. No proven effective ovarian cancer screening exists. Consider transvaginal ultrasound and CA-125, though sensitivity is limited."", ""name"": ""Enhanced Surveillance"", ""treatment_term"": {""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}}"
3696	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	4	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows risk-reducing interventions and enhanced surveillance. Prenatal and preimplantation genetic testing available.																																																								"{""description"": ""Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows risk-reducing interventions and enhanced surveillance. Prenatal and preimplantation genetic testing available."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows risk-reducing interventions and enhanced surveillance. Prenatal and preimplantation genetic testing available."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
3705	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	0	Desmopressin	Vasopressin analog used to control mild bleeding episodes.																																																								"{""description"": ""Vasopressin analog used to control mild bleeding episodes."", ""name"": ""Desmopressin""}"	{}	"{""description"": ""Vasopressin analog used to control mild bleeding episodes."", ""evidence"": [{""explanation"": ""The abstract describes desmopressin as a treatment for mild bleeding episodes."", ""reference"": ""PMID:21289515"", ""snippet"": ""Depending on the von Willebrand disease type, mild bleeding episodes usually respond to intravenous or subcutaneous treatment with desmopressin, a vasopressin analog."", ""supports"": ""SUPPORT""}], ""name"": ""Desmopressin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3706	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	1	von Willebrand Factor/Factor VIII Concentrates	Plasma-derived concentrates containing von Willebrand factor and factor VIII for severe bleeding episodes.																																																								"{""description"": ""Plasma-derived concentrates containing von Willebrand factor and factor VIII for severe bleeding episodes."", ""name"": ""von Willebrand Factor/Factor VIII Concentrates""}"	{}	"{""description"": ""Plasma-derived concentrates containing von Willebrand factor and factor VIII for severe bleeding episodes."", ""evidence"": [{""explanation"": ""The abstract describes vWF/FVIII concentrates for severe bleeding episodes."", ""reference"": ""PMID:21289515"", ""snippet"": ""Severe bleeding episodes can be prevented or controlled with intravenous infusions of virally inactivated plasma-derived clotting factor concentrates containing both von Willebrand factor and factor VIII."", ""supports"": ""SUPPORT""}], ""name"": ""von Willebrand Factor/Factor VIII Concentrates"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	Surgical Resection	Removal of the aganglionic segment of the bowel.																																																								"{""description"": ""Removal of the aganglionic segment of the bowel."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Removal of the aganglionic segment of the bowel."", ""evidence"": [{""explanation"": ""The article confirms that the removal of the aganglionic segment is a treatment for Hirschsprung disease."", ""reference"": ""PMID:23615177"", ""snippet"": ""Surgical techniques are available to remove the aganglionic bowel and reconstruct the intestinal tract."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article specifically mentions the resection of the aganglionic bowel as part of surgical management."", ""reference"": ""PMID:27526297"", ""snippet"": ""Surgical management of Hirschsprung disease requires resection of the aganglionic bowel and transition zone."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although it is a different procedure, the focus is still on dealing with aganglionic bowel segments."", ""reference"": ""PMID:35343667"", ""snippet"": ""Per-rectal endoscopic myotomy...to open spastic aganglionic bowel segments by performing a myotomy through a submucosal tunnel."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the resection of the aganglionic segment as a treatment."", ""reference"": ""PMID:34398296"", ""snippet"": ""The entire colons in the both cases were finally resected, and a pull-through operation was performed."", ""supports"": ""SUPPORT""}, {""explanation"": ""This retired chapter supports that removal of the aganglionic segment is a standard practice."", ""reference"": ""PMID:20301612"", ""snippet"": ""Treatment of manifestations: Resection of the aganglionic segment and anastomosis of proximal bowel to the anus ('pull-through') is the standard treatment for HSCR."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resection"", ""treatment_term"": {""description"": ""Operative excision of the non-functional aganglionic bowel segment."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3737	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	1	Pull-Through Procedure	Connecting the normal ganglionated bowel to the anus to restore bowel function.																																																								"{""description"": ""Connecting the normal ganglionated bowel to the anus to restore bowel function."", ""name"": ""Pull-Through Procedure""}"	{}	"{""description"": ""Connecting the normal ganglionated bowel to the anus to restore bowel function."", ""evidence"": [{""explanation"": ""This procedure involves connecting the normal ganglionated bowel to the anus to restore bowel function."", ""reference"": ""PMID:15770590"", ""snippet"": ""The transanal pull-through consists of a rectal mucosectomy, resection of the aganglionic bowel and a colo-anal anastomosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study assesses outcomes in patients treated with pull-through surgery, confirming it's a treatment for Hirschsprung Disease."", ""reference"": ""PMID:31759654"", ""snippet"": ""A review of a single-center HD cohort treated with pull-through surgery."", ""supports"": ""SUPPORT""}, {""explanation"": ""The pull-through operation is described as a standard treatment, which aligns with the statement."", ""reference"": ""PMID:21789665"", ""snippet"": ""Most patients with Hirschsprung's disease (HD) have a satisfactory outcome after pull-through (PT) operation."", ""supports"": ""SUPPORT""}], ""name"": ""Pull-Through Procedure"", ""treatment_term"": {""description"": ""Reconstructive operation anastomosing normal ganglionated bowel to the anus."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3738	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	2	Ostomy	Temporary or permanent stoma creation to divert fecal flow.																																																								"{""description"": ""Temporary or permanent stoma creation to divert fecal flow."", ""name"": ""Ostomy""}"	{}	"{""description"": ""Temporary or permanent stoma creation to divert fecal flow."", ""evidence"": [{""explanation"": ""This reference indicates that infants with Hirschsprung's disease may require a stoma, which could be interpreted as either temporary or permanent."", ""reference"": ""PMID:12048463"", ""snippet"": ""Hirschsprung's disease is a congenital abnormality of the bowel that results in loss of peristalsis, and is one of the main reasons why an infant may require a stoma soon after birth."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this reference focuses more on colorectal cancer, it notes the use of stomata in treatment, which is relevant to the statement that stomata (ostomies) can be used in Hirschsprung disease, supporting the general use of ostomies in bowel-related treatments."", ""reference"": ""PMID:29607805"", ""snippet"": ""More than 75% of all stomata are placed as part of the treatment of colorectal cancer. The incidence of stoma-related complications is reported to be 10-70%."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of ostomies as either temporary or permanent solutions for certain bowel conditions, analogous to their use in Hirschsprung disease."", ""reference"": ""PMID:29722891"", ""snippet"": ""Fecal diversion with ostomy construction can be a temporary or definitive surgical measure for the treatment of refractory inflammatory bowel disease (IBD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference indicates that ileostomya type of stomawas used as part of the surgical treatment for complications associated with Hirschsprung disease."", ""reference"": ""PMID:26181500"", ""snippet"": ""Three patients were treated with surgical decompression and ileostomy only. In all these cases, severe complications occurred, consequently 2 of them died."", ""supports"": ""SUPPORT""}], ""name"": ""Ostomy"", ""treatment_term"": {""description"": ""Creation of a stoma to divert fecal flow, used temporarily or permanently."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3750	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	0	Cardiac monitoring and evaluation	"Regular cardiac evaluation and monitoring is essential to detect and manage arrhythmias, conduction abnormalities, and structural defects. This may include ECG, echocardiography, and long-term monitoring. Severe conduction abnormalities may require pacemaker implantation.
"																																																								"{""description"": ""Regular cardiac evaluation and monitoring is essential to detect and manage arrhythmias, conduction abnormalities, and structural defects. This may include ECG, echocardiography, and long-term monitoring. Severe conduction abnormalities may require pacemaker implantation.\n"", ""name"": ""Cardiac monitoring and evaluation""}"	{}	"{""description"": ""Regular cardiac evaluation and monitoring is essential to detect and manage arrhythmias, conduction abnormalities, and structural defects. This may include ECG, echocardiography, and long-term monitoring. Severe conduction abnormalities may require pacemaker implantation.\n"", ""evidence"": [{""explanation"": ""Supports the need for cardiac monitoring in HOS patients due to risk of progressive arrhythmias and conduction abnormalities"", ""reference"": ""PMID:38189150"", ""snippet"": ""The relationship between heart failure (HF) and atrial fibrillation (AF) is clear, with up to half of patients with HF progressing to AF"", ""supports"": ""SUPPORT""}, {""explanation"": ""Clinical evidence supporting need for advanced cardiac monitoring and intervention in HOS"", ""reference"": ""PMID:38235884"", ""snippet"": ""HOS usually requires the implantation of a pacemaker, because of cardiac conduction disturbances"", ""supports"": ""SUPPORT""}], ""name"": ""Cardiac monitoring and evaluation"", ""treatment_term"": {""preferred_term"": ""cardiac electrophysiologist evaluation"", ""term"": {""id"": ""MAXO:0000683"", ""label"": ""clinical cardiac electrophysiologist evaluation""}}}"
3751	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	1	Surgical repair of cardiac defects	"Surgical intervention may be necessary for significant atrial or ventricular septal defects and other structural abnormalities, depending on severity and hemodynamic significance.
"																																																								"{""description"": ""Surgical intervention may be necessary for significant atrial or ventricular septal defects and other structural abnormalities, depending on severity and hemodynamic significance.\n"", ""name"": ""Surgical repair of cardiac defects""}"	{}	"{""description"": ""Surgical intervention may be necessary for significant atrial or ventricular septal defects and other structural abnormalities, depending on severity and hemodynamic significance.\n"", ""evidence"": [{""explanation"": ""Establishes that septal defects are cardinal manifestations requiring potential surgical intervention"", ""reference"": ""PMID:39596866"", ""snippet"": ""Septal defects such as ventricular (VSD) and atrial septal defects (ASD) are the most common forms of CHDs"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical repair of cardiac defects"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3752	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	2	Orthopedic management	"Management of upper limb abnormalities may include orthopedic interventions, physical therapy, and adaptive strategies to optimize limb function and mobility.
"																																																								"{""description"": ""Management of upper limb abnormalities may include orthopedic interventions, physical therapy, and adaptive strategies to optimize limb function and mobility.\n"", ""name"": ""Orthopedic management""}"	{}	"{""description"": ""Management of upper limb abnormalities may include orthopedic interventions, physical therapy, and adaptive strategies to optimize limb function and mobility.\n"", ""evidence"": [{""explanation"": ""Case reports of HOS patients with upper limb abnormalities requiring orthopedic and rehabilitative management"", ""reference"": ""PMID:36936432"", ""snippet"": ""Holt-Oram syndrome (HOS) is a rare genetic disorder characterized by upper limb abnormalities"", ""supports"": ""SUPPORT""}], ""name"": ""Orthopedic management"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
3760	158	Human African trypanosomiasis	Human_African_Trypanosomiasis.yaml	treatments	0	Fexinidazole therapy	Oral fexinidazole is a first-line therapy for gambiense HAT without severe meningoencephalitic disease.																																																								"{""description"": ""Oral fexinidazole is a first-line therapy for gambiense HAT without severe meningoencephalitic disease."", ""name"": ""Fexinidazole therapy""}"	{}	"{""description"": ""Oral fexinidazole is a first-line therapy for gambiense HAT without severe meningoencephalitic disease."", ""evidence"": [{""explanation"": ""The review describes fexinidazole as first-line therapy for gambiense HAT."", ""reference"": ""PMID:40089378"", ""snippet"": ""A new oral drug, fexinidazole, became the first-line treatment for gambiense human African trypanosomiasis without severe meningo-encephalitic disease"", ""supports"": ""SUPPORT""}], ""name"": ""Fexinidazole therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3796	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	0	Tetrabenazine	Used to manage chorea by depleting dopamine.						Symptomatic																																																		"{""description"": ""Used to manage chorea by depleting dopamine."", ""name"": ""Tetrabenazine"", ""role"": ""Symptomatic""}"	{}	"{""description"": ""Used to manage chorea by depleting dopamine."", ""evidence"": [{""explanation"": ""This reference confirms that tetrabenazine is used to manage chorea in Huntington's Disease by depleting dopamine."", ""reference"": ""PMID:24366610"", ""snippet"": ""Tetrabenazine is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that tetrabenazine depletes monoamines, including dopamine, to manage chorea in Huntington's Disease."", ""reference"": ""PMID:20869622"", ""snippet"": ""Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports that tetrabenazine depletes dopamine to manage chorea in Huntington's Disease."", ""reference"": ""PMID:20442355"", ""snippet"": ""Tetrabenazine binds reversibly to the type 2 vesicular monoamine transporters and has been shown to inhibit monoamine uptake in presynaptic vesicles, resulting in monoamine depletion."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that tetrabenazine, a VMAT2 inhibitor, is used to treat chorea in Huntington's Disease by depleting dopamine."", ""reference"": ""PMID:27819145"", ""snippet"": ""Since the approval of tetrabenazine, the classic VMAT2 inhibitor, in the treatment of chorea associated with Huntington disease (HD)..."", ""supports"": ""SUPPORT""}], ""name"": ""Tetrabenazine"", ""role"": ""Symptomatic"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3797	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	1	Antipsychotic Medications	Used for psychiatric symptoms like irritability and agitation.						Symptomatic																																																		"{""description"": ""Used for psychiatric symptoms like irritability and agitation."", ""name"": ""Antipsychotic Medications"", ""role"": ""Symptomatic""}"	{}	"{""description"": ""Used for psychiatric symptoms like irritability and agitation."", ""evidence"": [{""explanation"": ""The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease."", ""reference"": ""PMID:27534434"", ""snippet"": ""In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease."", ""reference"": ""PMID:16383221"", ""snippet"": ""According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease."", ""reference"": ""PMID:36496108"", ""snippet"": ""Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease..."", ""supports"": ""SUPPORT""}], ""name"": ""Antipsychotic Medications"", ""role"": ""Symptomatic"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3798	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	2	Selective Serotonin Reuptake Inhibitors (SSRIs)	Used to manage depression.						Symptomatic																																																		"{""description"": ""Used to manage depression."", ""name"": ""Selective Serotonin Reuptake Inhibitors (SSRIs)"", ""role"": ""Symptomatic""}"	{}	"{""description"": ""Used to manage depression."", ""evidence"": [{""explanation"": ""The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease."", ""reference"": ""PMID:18394562"", ""snippet"": ""Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease."", ""reference"": ""PMID:22119091"", ""snippet"": ""Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)..."", ""supports"": ""SUPPORT""}], ""name"": ""Selective Serotonin Reuptake Inhibitors (SSRIs)"", ""role"": ""Symptomatic"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3799	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	3	Physical Therapy	Helps maintain mobility and function.						Supportive																																																		"{""description"": ""Helps maintain mobility and function."", ""name"": ""Physical Therapy"", ""role"": ""Supportive""}"	{}	"{""description"": ""Helps maintain mobility and function."", ""evidence"": [{""explanation"": ""The review provides strong evidence that physical therapy interventions improve fitness, motor function, and gait in people with Huntington's Disease, supporting the statement that physical therapy helps maintain mobility and function."", ""reference"": ""PMID:31907286"", ""snippet"": ""There is strong evidence to support physical therapy interventions to improve fitness, motor function, and gait in persons with HD."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that ancillary services, which include physical therapy, improve motor symptoms in HD patients, supporting the statement that physical therapy helps maintain mobility and function."", ""reference"": ""PMID:31177235"", ""snippet"": ""Prior Huntington''s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies specific mobility measures that are effective for assessing and optimizing mobility in HD patients, supporting the statement that physical therapy helps maintain mobility and function."", ""reference"": ""PMID:25062860"", ""snippet"": ""TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and TMT (beta -0.45, CI -3.14-0.64) were good disease-specific mobility measures."", ""supports"": ""SUPPORT""}], ""name"": ""Physical Therapy"", ""role"": ""Supportive"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
3800	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	4	Speech Therapy	Helps manage dysarthria and dysphagia.						Supportive																																																		"{""description"": ""Helps manage dysarthria and dysphagia."", ""name"": ""Speech Therapy"", ""role"": ""Supportive""}"	{}	"{""description"": ""Helps manage dysarthria and dysphagia."", ""evidence"": [{""explanation"": ""The literature indicates that speech-language pathologists (SLPs) play a significant role in managing dysarthria and dysphagia in patients with hyperkinetic disorders, including Huntington's Disease. However, it does not explicitly state that speech therapy helps manage these conditions in HD specifically."", ""reference"": ""PMID:28983422"", ""snippet"": ""SLPs play an important role in the evaluation and management of dysarthria and dysphagia."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature highlights the importance of including speech and language therapists in the care of HD patients, indicating a supportive role. However, it does not provide explicit evidence that speech therapy directly helps manage dysarthria and dysphagia in HD."", ""reference"": ""PMID:33577706"", ""snippet"": ""Findings shed a light on everyday communication challenges faced by people with HD and their professional caregivers, and the lack of implementation of communication aids in this group."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature states that the impact of rehabilitative treatments, including speech therapy, on dysphagia in HD has been minimally studied, providing no clear evidence of its efficacy."", ""reference"": ""PMID:31989345"", ""snippet"": ""The impact of pharmacological and rehabilitative treatments on dysphagia in HD has been little studied in literature."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Speech Therapy"", ""role"": ""Supportive"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
3801	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	5	Occupational Therapy	Assists with daily living activities.						Supportive																																																		"{""description"": ""Assists with daily living activities."", ""name"": ""Occupational Therapy"", ""role"": ""Supportive""}"	{}	"{""description"": ""Assists with daily living activities."", ""evidence"": [{""explanation"": ""The literature suggests that rehabilitation interventions, including motor training, can help manage functional abilities in HD, which implies a supportive role in daily living activities. However, it does not explicitly mention occupational therapy or daily living activities directly."", ""reference"": ""PMID:28947114"", ""snippet"": ""Lifestyle factors, such as activity level and exercise, as well as specific motor training may be helpful in managing the functional sequelae of HD and possibly slowing disease progression."", ""supports"": ""PARTIAL""}, {""explanation"": ""This study discusses the burden on informal caregivers and the functional loss in HD individuals, indicating a need for supportive roles, which could include occupational therapy. However, it does not explicitly mention occupational therapy."", ""reference"": ""PMID:36055643"", ""snippet"": ""This objective burden increased with higher functional loss of the HD individual and with more severe cognitive-behavioral disorders."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature explicitly mentions that ancillary services, which include occupational therapy, improve various aspects of life for HD patients, indicating a supportive role in daily living activities."", ""reference"": ""PMID:31177235"", ""snippet"": ""Prior Huntington's disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear."", ""supports"": ""SUPPORT""}], ""name"": ""Occupational Therapy"", ""role"": ""Supportive"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
3802	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	6	Genetic Counseling	Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.						Supportive																																																		"{""description"": ""Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD."", ""name"": ""Genetic Counseling"", ""role"": ""Supportive""}"	{}	"{""description"": ""Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD."", ""name"": ""Genetic Counseling"", ""role"": ""Supportive"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
3839	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	0	Antihypertensive Therapy	Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease.																																																								"{""description"": ""Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease."", ""name"": ""Antihypertensive Therapy""}"	{}	"{""description"": ""Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease."", ""evidence"": [{""explanation"": ""This reference supports the statement that lowering blood pressure is a key treatment in managing hypertensive heart disease by stating that outcomes in HHD and HF improve with antihypertensive drugs."", ""reference"": ""PMID:15331316"", ""snippet"": ""Outcomes in HHD and HF are improved by antihypertensive drugs at any stage of the condition."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract highlights the importance of lowering blood pressure to reduce cardiovascular diseases, indirectly supporting the management of hypertensive heart disease through antihypertensive therapy."", ""reference"": ""PMID:32728994"", ""snippet"": ""Extensive evidence demonstrates that lowering blood pressure can substantially reduce the risk of atherosclerotic cardiovascular disease and death."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference adds support by emphasizing the general importance of hypertension management in reducing cardiovascular outcomes, which aligns with the prevention and management of hypertensive heart disease."", ""reference"": ""PMID:31472890"", ""snippet"": ""Management of hypertension reduces cardiovascular outcomes among patients with diabetes."", ""supports"": ""SUPPORT""}], ""name"": ""Antihypertensive Therapy"", ""treatment_term"": {""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}}"
3840	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	1	ACE Inhibitors or ARBs	First-line agents that reduce workload on the heart.																																																								"{""description"": ""First-line agents that reduce workload on the heart."", ""name"": ""ACE Inhibitors or ARBs""}"	{}	"{""description"": ""First-line agents that reduce workload on the heart."", ""evidence"": [{""explanation"": ""ACE inhibitors have been shown to reduce cardiac hypertrophy and have protective effects on the heart during hypertensive heart disease."", ""reference"": ""PMID:2485024"", ""snippet"": ""There is evidence to suggest that angiotensin-converting enzyme (ACE) inhibitors can play an important role in protecting the heart during the various phases of evolution of hypertensive heart disease both acutely and on a long-term basis."", ""supports"": ""SUPPORT""}, {""explanation"": ""ACE inhibitors are demonstrated to be effective in reducing cardiovascular events and mortality, which aligns with their role in reducing the workload on the heart."", ""reference"": ""PMID:19588327"", ""snippet"": ""ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Both ACE inhibitors and ARBs are indicated for multiple conditions related to heart workload reduction, including heart failure and hypertension conditions."", ""reference"": ""PMID:31498767"", ""snippet"": ""Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure."", ""supports"": ""SUPPORT""}, {""explanation"": ""Guidelines highlight ACE inhibitors and ARBs as first-line treatments for hypertension, which is closely tied to reducing workload on the heart."", ""reference"": ""PMID:26968600"", ""snippet"": ""Management guidelines categorise angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) interchangeably as first-line treatments in uncomplicated hypertension."", ""supports"": ""SUPPORT""}], ""name"": ""ACE Inhibitors or ARBs"", ""treatment_term"": {""preferred_term"": ""ACE inhibitor therapy"", ""term"": {""id"": ""MAXO:0000652"", ""label"": ""ACE inhibitor therapy""}}}"
3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	Beta Blockers	Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction.																																																								"{""description"": ""Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction."", ""evidence"": [{""explanation"": ""The abstract supports that beta-blockers are beneficial post-myocardial infarction."", ""reference"": ""PMID:8651834"", ""snippet"": ""Beta-Blockers are widely used in cardiovascular medicine... Based on evidence showing reduced mortality and morbidity, beta-blockers are the cornerstone of therapy after acute myocardial infarction."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract supports that reducing heart rate with beta-blockers is an accepted treatment in congestive heart failure, relevant to hypertensive heart disease."", ""reference"": ""PMID:19615493"", ""snippet"": ""Today, in patients with acute or chronic coronary syndromes or with congestive heart failure, reducing heart rate is a generally accepted treatment modality."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract clearly supports the claim that beta-blockers help to control heart rate and are beneficial in post-myocardial infarction scenarios."", ""reference"": ""PMID:20539841"", ""snippet"": ""One successful way of decreasing HR and cardiovascular mortality has been by utilizing beta-blockers... beta-blocker-mediated HR control improvements are associated with decreased mortality in postinfarct and heart failure patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although the abstract mentions that beta-blockers alone did not improve heart rate recovery significantly, they are beneficial when combined with exercise training post-myocardial infarction."", ""reference"": ""PMID:28402023"", ""snippet"": ""Combination of beta-blocker therapy with ET does not compromise the effect of training and instead promotes HRR and aerobic capacity improvement... However, chronic administration of beta-blocker therapy alone did not promote improvement in HRR or aerobic capacity."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this abstract highlights the role of vasodilators, it also implicitly supports the idea that controlling heart rate through medication is a valid treatment approach."", ""reference"": ""PMID:140280"", ""snippet"": ""Regardless of the level of arterial pressure, vasodilator drugs that lower arterial pressure may result in marked improvement in left ventricular performance and relief of symptoms of left ventricular failure."", ""supports"": ""SUPPORT""}], ""name"": ""Beta Blockers"", ""treatment_term"": {""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}}"
3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	Diuretics	Reduce fluid overload and congestion in heart failure.																																																								"{""description"": ""Reduce fluid overload and congestion in heart failure."", ""name"": ""Diuretics""}"	{}	"{""description"": ""Reduce fluid overload and congestion in heart failure."", ""evidence"": [{""explanation"": ""The reference indicates that diuretics are important in the management of hypervolemia, which is a condition related to fluid overload."", ""reference"": ""PMID:24243991"", ""snippet"": ""Diuretics have been recommended as first-line treatment of hypertension and are also valuable in the management of hypervolemia and electrolyte disorders."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of diuretics in managing symptoms related to heart failure, including reducing fluid overload and congestion."", ""reference"": ""PMID:19863866"", ""snippet"": ""In patients with established heart failure, diuretics and other empiric treatments are used to control symptoms."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although the reference includes other treatments, it does mention the effectiveness of various drugs in treating heart failure which can include diuretics."", ""reference"": ""PMID:35165832"", ""snippet"": ""soluble guanylate cyclase stimulators are new classes of chemical agents that... have been shown to be effective for the treatment of cardiovascular (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference clearly establishes that diuretics are essential in treating volume overload conditions commonly seen in heart failure."", ""reference"": ""PMID:35190215"", ""snippet"": ""Diuretics are the cornerstone of therapy for volume overload and comprise several classes whose mechanisms of action, pharmacokinetics, indications, and adverse effects are essential principles of nephrology."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference underscores the importance of diuretics in managing fluid retention and congestion in heart failure patients."", ""reference"": ""PMID:38300391"", ""snippet"": ""Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF)... The most robust evidence is for high-dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF..."", ""supports"": ""SUPPORT""}], ""name"": ""Diuretics"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	Mineralocorticoid Receptor Antagonists	Further regulate fluid balance and have direct anti-fibrotic effects on the heart.																																																								"{""description"": ""Further regulate fluid balance and have direct anti-fibrotic effects on the heart."", ""name"": ""Mineralocorticoid Receptor Antagonists""}"	{}	"{""description"": ""Further regulate fluid balance and have direct anti-fibrotic effects on the heart."", ""evidence"": [{""explanation"": ""The reference discusses the vital importance of mineralocorticoid receptor antagonists in the treatment of cardiovascular conditions, implying their broad therapeutic potential, which can be interpreted as supporting fluid balance regulation and anti-fibrotic effects."", ""reference"": ""PMID:17362671"", ""snippet"": ""The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade."", ""supports"": ""SUPPORT""}, {""explanation"": ""The text explicitly states that mineralocorticoid receptor antagonists like spironolactone can prevent fibrosis, providing supporting evidence for the statement's claim of direct anti-fibrotic effects."", ""reference"": ""PMID:10904856"", ""snippet"": ""The competitive aldosterone receptor antagonist, spironolactone, was able to prevent fibrosis in both ventricles in either model of arterial hypertension irrespective of the development of left ventricular hypertrophy and hypertension."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this primarily discusses adherence, the context indicates widespread use of MR antagonists in managing hypertensive conditions, suggesting their relevance in regulating fluid balance and potential anti-fibrotic effects."", ""reference"": ""PMID:35438025"", ""snippet"": ""All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 +/- 20 mg) and in the remaining 56% of subjects eplerenone was administered."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the role of MRAs in fluid balance due to their regulation of aldosterone's actions, which is consistent with the statement."", ""reference"": ""PMID:25016402"", ""snippet"": ""Aldosterone-receptor antagonists dose-dependently reduce both the epithelial and nonepithelial actions of aldosterone. These compounds are used commonly in the treatment of hypertension, with or without aldosteronism, and in the volume-overload periods of various forms of heart failure, cirrhosis, and renal failure."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the aspect of fluid balance regulation and suggests potential benefits, consistent with the statements claims."", ""reference"": ""PMID:28176630"", ""snippet"": ""Finerenone, a non-steroidal mineralocorticoid receptor antagonist... aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria."", ""supports"": ""SUPPORT""}], ""name"": ""Mineralocorticoid Receptor Antagonists"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3844	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	5	Lifestyle Modifications	Sodium restriction, physical activity, stress reduction, and other supportive measures.																																																								"{""description"": ""Sodium restriction, physical activity, stress reduction, and other supportive measures."", ""name"": ""Lifestyle Modifications""}"	{}	"{""description"": ""Sodium restriction, physical activity, stress reduction, and other supportive measures."", ""evidence"": [{""explanation"": ""The literature supports sodium restriction, physical activity (exercise), and relaxation (stress reduction) as part of the non-drug treatments for hypertension. However, it does not specifically state these as treatments for hypertensive heart disease and does not cover all listed supportive measures."", ""reference"": ""PMID:3882040"", ""snippet"": ""These therapies include weight reduction; sodium restriction; potassium, calcium, and magnesium supplementation; other dietary changes; exercise; relaxation; and moderation of alcohol use. Such therapies have been inadequately used, in part because of a lack of confidence in their effectiveness and overconfidence in the effectiveness and safety of drug therapy."", ""supports"": ""PARTIAL""}, {""explanation"": ""This literature mentions that therapeutic lifestyle changes are crucial for hypertensive heart disease (HHD). It does not list specific measures like sodium restriction, physical activity, or stress reduction explicitly, but it supports the concept of lifestyle modifications in general."", ""reference"": ""PMID:20937450"", ""snippet"": ""Optimal antihypertensive therapy in the setting of therapeutic lifestyle changes is crucial in the prevention and control of HHD."", ""supports"": ""PARTIAL""}, {""explanation"": ""This literature supports that lifestyle modifications including physical activity, sodium restriction, and other supportive measures are effective for controlling hypertension. However, it does not mention hypertensive heart disease specifically."", ""reference"": ""PMID:31756356"", ""snippet"": ""Adopting healthy lifestyles, such as being active on >/=4 days per week, weight-loss in the presence of obesity, consuming a diet rich in fruits and vegetables, and sodium below the recommended threshold, avoiding high alcohol consumption and refraining from smoking have been effective lifestyle therapies to prevent or control stage 1 hypertension (HTN)."", ""supports"": ""PARTIAL""}], ""name"": ""Lifestyle Modifications"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
3878	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	0	Beta Blockers	Used to reduce heart rate and improve symptoms																																																								"{""description"": ""Used to reduce heart rate and improve symptoms"", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Used to reduce heart rate and improve symptoms"", ""evidence"": [{""explanation"": ""This reference discusses the use of beta-blockers in the context of hypertrophic cardiomyopathy, which supports the statement that beta-blockers are used to improve symptoms in this condition, though details on heart rate reduction specifically may be implied but not detailed."", ""reference"": ""PMID:35450574"", ""snippet"": ""Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract directly mentions the use of beta-blockers to control symptoms in hypertrophic cardiomyopathy, supporting the statement."", ""reference"": ""PMID:21389910"", ""snippet"": ""Throughout the years, numerous medical treatments have been used to achieve symptom control in these patients, and include medications such as beta-blockers, calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor blockers."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that beta-blockers are a first-line therapy for hypertrophic cardiomyopathy and are used for heart rate reduction, supporting the statement."", ""reference"": ""PMID:37850394"", ""snippet"": ""beta-Adrenergic receptor antagonists (beta-blockers) are the first-line therapy for HCM. However, beta-blockers commonly selected for this disease are often poorly tolerated in patients, where heart-rate reduction and noncardiac effects can lead to reduced cardiac output and fatigue."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference highlights the use of beta-blockers in hypertrophic cardiomyopathy to improve symptoms, aligning with the statement."", ""reference"": ""PMID:25198737"", ""snippet"": ""Beta-blocker therapy is without doubt the treatment of choice for patients with heart failure caused by hypertrophic cardiomyopathy, but the dose needs to carefully titrated on an individual basis for maximum benefit."", ""supports"": ""SUPPORT""}], ""name"": ""Beta Blockers"", ""treatment_term"": {""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}}"
3879	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	1	Calcium Channel Blockers	Help to relax heart muscle and improve blood flow																																																								"{""description"": ""Help to relax heart muscle and improve blood flow"", ""name"": ""Calcium Channel Blockers""}"	{}	"{""description"": ""Help to relax heart muscle and improve blood flow"", ""evidence"": [{""explanation"": ""The literature supports that calcium channel blockers are used to improve symptoms in hypertrophic cardiomyopathy patients, which implies relaxing the heart muscle and improving blood flow."", ""reference"": ""PMID:17162264"", ""snippet"": ""For symptomatic patients with non-obstructed disease medical treatment with calcium channel blockers and beta-blockers is aimed to improve heart failure symptoms, and ischemia. Verapamil is the most often used, with likely benefit of relieving ischemia."", ""supports"": ""SUPPORT""}, {""explanation"": ""Even though the focus is on angina, the acknowledged use of calcium channel blockers reinforces their role in cardiovascular conditions including HCM."", ""reference"": ""PMID:3515244"", ""snippet"": ""The three approved calcium-channel blockers--nifedipine, verapamil and diltiazem--have offered new treatments for angina."", ""supports"": ""SUPPORT""}, {""explanation"": ""The review suggests the effectiveness of calcium channel blockers in treating hypertensive left ventricular hypertrophy (HTN LVH), indicating a role in remodeling heart muscle, which aligns with improving blood flow."", ""reference"": ""PMID:36044874"", ""snippet"": ""CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling."", ""supports"": ""SUPPORT""}, {""explanation"": ""This directly supports the use of calcium channel blockers (specifically verapamil) in hypertrophic cardiomyopathy by improving symptoms and hemodynamics, which implies relaxing the heart muscle and improving blood flow."", ""reference"": ""PMID:7004293"", ""snippet"": ""The negative inotropic effects of verapamil are valuable in improving the symptoms and hemodynamic disturbances of hypertrophic cardiomyopathy."", ""supports"": ""SUPPORT""}], ""name"": ""Calcium Channel Blockers"", ""treatment_term"": {""preferred_term"": ""calcium channel blocking agent therapy"", ""term"": {""id"": ""MAXO:0000434"", ""label"": ""calcium channel blocking agent therapy""}}}"
3880	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	2	Septal Myectomy	Surgical removal of part of the thickened heart muscle																																																								"{""description"": ""Surgical removal of part of the thickened heart muscle"", ""name"": ""Septal Myectomy""}"	{}	"{""description"": ""Surgical removal of part of the thickened heart muscle"", ""evidence"": [{""explanation"": ""The literature directly confirms that septal myectomy is used to surgically remove part of the thickened heart muscle in hypertrophic cardiomyopathy patients."", ""reference"": ""PMID:38368037"", ""snippet"": ""Septal myectomy is a well-established procedure for septal reduction in patients with obstructive hypertrophic cardiomyopathy (HCM) who have not responded to medical treatment."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the usage of septal myectomy for removing thickened muscle parts as a treatment for hypertrophic cardiomyopathy."", ""reference"": ""PMID:31280832"", ""snippet"": ""Surgical myectomy was initially advocated only for patients with symptoms refractory to maximal tolerated medical therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this reference does not directly state septal myectomy, it mentions treatment selection based on symptoms, which aligns with the usage context of septal myectomy in other literature. Therefore, it indirectly supports the use."", ""reference"": ""PMID:22687587"", ""snippet"": ""Treatments for hypertrophic cardiomyopathy are largely selected based on patient symptoms and echocardiographic findings."", ""supports"": ""SUPPORT""}], ""name"": ""Septal Myectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3881	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	3	Alcohol Septal Ablation	Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle																																																								"{""description"": ""Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle"", ""name"": ""Alcohol Septal Ablation""}"	{}	"{""description"": ""Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle"", ""evidence"": [{""explanation"": ""This reference supports the use of alcohol septal ablation as a treatment for hypertrophic cardiomyopathy by describing improved clinical outcomes and functional capacity."", ""reference"": ""PMID:35710280"", ""snippet"": ""Over the past several decades, alcohol septal ablation has become an established therapy for selected patients, in whom there is clinical improvement in symptoms as well as objective functional capacity."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of alcohol septal ablation as a proven therapy for hypertrophic cardiomyopathy."", ""reference"": ""PMID:36598161"", ""snippet"": ""There are several invasive therapies including proven therapies such as alcohol septal ablation and septal myectomy."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the description of alcohol septal ablation as a minimally invasive procedure to reduce obstruction by injecting alcohol."", ""reference"": ""PMID:10980888"", ""snippet"": ""Following balloon inflation and intracoronary myocardial contrast echocardiography, ethyl alcohol is injected through the catheter lumen to cause proximal interventricular septum infarction and relief of outflow tract obstruction."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the effectiveness of alcohol septal ablation in treating hypertrophic cardiomyopathy by injecting alcohol into the septal artery."", ""reference"": ""PMID:20973822"", ""snippet"": ""Alcohol septal ablation (ASA) has been shown to be an effective treatment in patients with hypertrophic obstructive cardiomyopathy (HOCM) who are refractory to medical treatment."", ""supports"": ""SUPPORT""}], ""name"": ""Alcohol Septal Ablation"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3882	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	4	Implantable Cardioverter Defibrillator (ICD)	Prevents sudden cardiac death in high-risk patients																																																								"{""description"": ""Prevents sudden cardiac death in high-risk patients"", ""name"": ""Implantable Cardioverter Defibrillator (ICD)""}"	{}	"{""description"": ""Prevents sudden cardiac death in high-risk patients"", ""evidence"": [{""explanation"": ""This excerpt supports the statement by showing that ICDs prevent sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy."", ""reference"": ""PMID:26002383"", ""snippet"": ""Nevertheless, several observational clinical studies have shown that the ICD reliably terminates life-threatening ventricular tachyarrhythmias in HCM, and is largely responsible for reducing HCM mortality to 0.5% per year, by preventing SD and changing the natural course of the disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt also supports the statement by confirming that ICDs are a primary treatment used to prevent sudden cardiac death in high-risk HCM patients."", ""reference"": ""PMID:36396186"", ""snippet"": ""Implantable cardioverter-defibrillators are the mainstay of therapy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy (HCM)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt provides specific criteria for using ICDs as a preventative measure in patients with significant hypertrophic cardiomyopathy, further supporting the statement."", ""reference"": ""PMID:22687587"", ""snippet"": ""Risk of sudden death correlates with maximum left ventricular (LV) wall thickness. Massive LV thickening of 30 mm or more is an indication for primary prevention of sudden death with an implanted defibrillator."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the focus is on the outcome of ICD shocks, the lack of sudden cardiac deaths among ICD patients aligns with the notion that ICDs prevent sudden cardiac death in high-risk HCM patients."", ""reference"": ""PMID:36134835"", ""snippet"": ""During follow-up of 4.8+/-3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock."", ""supports"": ""SUPPORT""}], ""name"": ""Implantable Cardioverter Defibrillator (ICD)"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3893	162	Hypochondrogenesis	Hypochondrogenesis.yaml	treatments	0	Supportive Care	"No disease-modifying treatment exists. Palliative care for affected neonates and genetic counseling for families.
"																																																								"{""description"": ""No disease-modifying treatment exists. Palliative care for affected neonates and genetic counseling for families.\n"", ""name"": ""Supportive Care""}"	{}	"{""description"": ""No disease-modifying treatment exists. Palliative care for affected neonates and genetic counseling for families.\n"", ""name"": ""Supportive Care""}"
3902	163	Hypochondroplasia	Hypochondroplasia.yaml	treatments	0	Growth hormone therapy	"Recombinant human growth hormone has been used in some cases with variable response. Effects on final adult height are modest and its use remains controversial.
"																																																								"{""description"": ""Recombinant human growth hormone has been used in some cases with variable response. Effects on final adult height are modest and its use remains controversial.\n"", ""name"": ""Growth hormone therapy""}"	{}	"{""description"": ""Recombinant human growth hormone has been used in some cases with variable response. Effects on final adult height are modest and its use remains controversial.\n"", ""name"": ""Growth hormone therapy"", ""treatment_term"": {""preferred_term"": ""Growth hormone therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3903	163	Hypochondroplasia	Hypochondroplasia.yaml	treatments	1	Orthopedic management	"Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant.
"																																																								"{""description"": ""Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant.\n"", ""name"": ""Orthopedic management""}"	{}	"{""description"": ""Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant.\n"", ""name"": ""Orthopedic management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3921	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	0	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.																																																								"{""description"": ""Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity."", ""name"": ""Ivosidenib""}"	{}	"{""description"": ""Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity."", ""name"": ""Ivosidenib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ivosidenib"", ""term"": {""id"": ""CHEBI:145430"", ""label"": ""ivosidenib""}}]}}"
3922	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	1	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.																																																								"{""description"": ""Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring."", ""name"": ""Enasidenib""}"	{}	"{""description"": ""Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring."", ""name"": ""Enasidenib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""enasidenib"", ""term"": {""id"": ""CHEBI:145374"", ""label"": ""enasidenib""}}]}}"
3923	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	2	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.																																																								"{""description"": ""BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity."", ""name"": ""Venetoclax plus Azacitidine""}"	{}	"{""description"": ""BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity."", ""name"": ""Venetoclax plus Azacitidine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}}"
3924	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	3	Intensive Chemotherapy (7+3)	Standard induction chemotherapy achieves complete remission in many IDH-mutated AML patients. Can be combined with IDH inhibitors for enhanced efficacy.																																																								"{""description"": ""Standard induction chemotherapy achieves complete remission in many IDH-mutated AML patients. Can be combined with IDH inhibitors for enhanced efficacy."", ""name"": ""Intensive Chemotherapy (7+3)""}"	{}	"{""description"": ""Standard induction chemotherapy achieves complete remission in many IDH-mutated AML patients. Can be combined with IDH inhibitors for enhanced efficacy."", ""name"": ""Intensive Chemotherapy (7+3)"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
3925	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	4	Allogeneic Stem Cell Transplantation	Consolidation option for eligible patients in first remission, particularly those with adverse risk features beyond IDH mutation alone.																																																								"{""description"": ""Consolidation option for eligible patients in first remission, particularly those with adverse risk features beyond IDH mutation alone."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Consolidation option for eligible patients in first remission, particularly those with adverse risk features beyond IDH mutation alone."", ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
3943	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	0	Maximal Safe Resection	Surgical resection maximizing extent of resection while preserving neurological function is the initial treatment. Greater extent of resection correlates with improved outcomes.																																																								"{""description"": ""Surgical resection maximizing extent of resection while preserving neurological function is the initial treatment. Greater extent of resection correlates with improved outcomes."", ""name"": ""Maximal Safe Resection""}"	{}	"{""description"": ""Surgical resection maximizing extent of resection while preserving neurological function is the initial treatment. Greater extent of resection correlates with improved outcomes."", ""name"": ""Maximal Safe Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3944	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	1	Radiation Therapy	External beam radiation therapy is standard adjuvant treatment. Timing may be delayed in lower-grade tumors with favorable prognostic factors.																																																								"{""description"": ""External beam radiation therapy is standard adjuvant treatment. Timing may be delayed in lower-grade tumors with favorable prognostic factors."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""External beam radiation therapy is standard adjuvant treatment. Timing may be delayed in lower-grade tumors with favorable prognostic factors."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
3945	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	2	Temozolomide Chemotherapy	Alkylating chemotherapy with temozolomide is used adjuvantly and at recurrence. MGMT promoter methylation predicts response but is common in IDH-mutant tumors.																																																								"{""description"": ""Alkylating chemotherapy with temozolomide is used adjuvantly and at recurrence. MGMT promoter methylation predicts response but is common in IDH-mutant tumors."", ""name"": ""Temozolomide Chemotherapy""}"	{}	"{""description"": ""Alkylating chemotherapy with temozolomide is used adjuvantly and at recurrence. MGMT promoter methylation predicts response but is common in IDH-mutant tumors."", ""name"": ""Temozolomide Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
3946	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	3	Vorasidenib (IDH1/2 Inhibitor)	Brain-penetrant dual IDH1/2 inhibitor approved for grade 2 IDH-mutant gliomas. INDIGO trial demonstrated significant improvement in progression-free survival. Represents first targeted therapy for this tumor type.																																																								"{""description"": ""Brain-penetrant dual IDH1/2 inhibitor approved for grade 2 IDH-mutant gliomas. INDIGO trial demonstrated significant improvement in progression-free survival. Represents first targeted therapy for this tumor type."", ""name"": ""Vorasidenib (IDH1/2 Inhibitor)""}"	{}	"{""description"": ""Brain-penetrant dual IDH1/2 inhibitor approved for grade 2 IDH-mutant gliomas. INDIGO trial demonstrated significant improvement in progression-free survival. Represents first targeted therapy for this tumor type."", ""name"": ""Vorasidenib (IDH1/2 Inhibitor)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3966	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	0	Ivosidenib	Selective small molecule inhibitor of mutant IDH1 approved for previously treated IDH1-mutant cholangiocarcinoma. ClarIDHy trial demonstrated improved progression-free survival compared to placebo (2.7 vs 1.4 months) with manageable toxicity and maintenance of quality of life.																																																								"{""description"": ""Selective small molecule inhibitor of mutant IDH1 approved for previously treated IDH1-mutant cholangiocarcinoma. ClarIDHy trial demonstrated improved progression-free survival compared to placebo (2.7 vs 1.4 months) with manageable toxicity and maintenance of quality of life."", ""name"": ""Ivosidenib""}"	{}	"{""description"": ""Selective small molecule inhibitor of mutant IDH1 approved for previously treated IDH1-mutant cholangiocarcinoma. ClarIDHy trial demonstrated improved progression-free survival compared to placebo (2.7 vs 1.4 months) with manageable toxicity and maintenance of quality of life."", ""name"": ""Ivosidenib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3967	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	1	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma regardless of IDH status. ABC-02 trial established this combination as standard of care. IDH-mutant tumors may have similar or slightly better chemotherapy response.																																																								"{""description"": ""First-line standard chemotherapy for advanced cholangiocarcinoma regardless of IDH status. ABC-02 trial established this combination as standard of care. IDH-mutant tumors may have similar or slightly better chemotherapy response."", ""name"": ""Gemcitabine plus Cisplatin""}"	{}	"{""description"": ""First-line standard chemotherapy for advanced cholangiocarcinoma regardless of IDH status. ABC-02 trial established this combination as standard of care. IDH-mutant tumors may have similar or slightly better chemotherapy response."", ""name"": ""Gemcitabine plus Cisplatin"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
3968	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	2	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin improves survival in first-line treatment of biliary tract cancers (TOPAZ-1 trial). Now standard first-line treatment for advanced cholangiocarcinoma.																																																								"{""description"": ""Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin improves survival in first-line treatment of biliary tract cancers (TOPAZ-1 trial). Now standard first-line treatment for advanced cholangiocarcinoma."", ""name"": ""Gemcitabine plus Cisplatin plus Durvalumab""}"	{}	"{""description"": ""Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin improves survival in first-line treatment of biliary tract cancers (TOPAZ-1 trial). Now standard first-line treatment for advanced cholangiocarcinoma."", ""name"": ""Gemcitabine plus Cisplatin plus Durvalumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
3969	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	3	Surgical Resection	Surgery offers the only chance for cure in cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. Limited by advanced stage at presentation in most patients.																																																								"{""description"": ""Surgery offers the only chance for cure in cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. Limited by advanced stage at presentation in most patients."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgery offers the only chance for cure in cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. Limited by advanced stage at presentation in most patients."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3988	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	0	Maximal Safe Resection	Surgical resection aims to maximize extent of resection while preserving function. Complete resection associated with improved survival and seizure control.																																																								"{""description"": ""Surgical resection aims to maximize extent of resection while preserving function. Complete resection associated with improved survival and seizure control."", ""name"": ""Maximal Safe Resection""}"	{}	"{""description"": ""Surgical resection aims to maximize extent of resection while preserving function. Complete resection associated with improved survival and seizure control."", ""name"": ""Maximal Safe Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
3989	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	1	Radiation Therapy	External beam radiation is standard for anaplastic oligodendroglioma. For grade 2 tumors, timing of radiation may be deferred in favorable cases.																																																								"{""description"": ""External beam radiation is standard for anaplastic oligodendroglioma. For grade 2 tumors, timing of radiation may be deferred in favorable cases."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""External beam radiation is standard for anaplastic oligodendroglioma. For grade 2 tumors, timing of radiation may be deferred in favorable cases."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
3990	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	2	PCV Chemotherapy	Procarbazine, CCNU (lomustine), and vincristine (PCV) combination chemotherapy shows exceptional efficacy in 1p/19q-codeleted oligodendrogliomas. RTOG 9402 and EORTC 26951 trials demonstrated major survival benefit for PCV added to radiation in anaplastic oligodendroglioma.																																																								"{""description"": ""Procarbazine, CCNU (lomustine), and vincristine (PCV) combination chemotherapy shows exceptional efficacy in 1p/19q-codeleted oligodendrogliomas. RTOG 9402 and EORTC 26951 trials demonstrated major survival benefit for PCV added to radiation in anaplastic oligodendroglioma."", ""name"": ""PCV Chemotherapy""}"	{}	"{""description"": ""Procarbazine, CCNU (lomustine), and vincristine (PCV) combination chemotherapy shows exceptional efficacy in 1p/19q-codeleted oligodendrogliomas. RTOG 9402 and EORTC 26951 trials demonstrated major survival benefit for PCV added to radiation in anaplastic oligodendroglioma."", ""name"": ""PCV Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
3991	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	3	Temozolomide Chemotherapy	Temozolomide is an alternative to PCV with better tolerability. Often used concurrently with radiation followed by adjuvant cycles. Efficacy appears similar to PCV in 1p/19q-codeleted tumors.																																																								"{""description"": ""Temozolomide is an alternative to PCV with better tolerability. Often used concurrently with radiation followed by adjuvant cycles. Efficacy appears similar to PCV in 1p/19q-codeleted tumors."", ""name"": ""Temozolomide Chemotherapy""}"	{}	"{""description"": ""Temozolomide is an alternative to PCV with better tolerability. Often used concurrently with radiation followed by adjuvant cycles. Efficacy appears similar to PCV in 1p/19q-codeleted tumors."", ""name"": ""Temozolomide Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4006	168	IgA Nephropathy	IgA_Nephropathy.yaml	treatments	0	ACE Inhibitors/ARBs	First-line for proteinuria reduction and renoprotection.																																																								"{""description"": ""First-line for proteinuria reduction and renoprotection."", ""name"": ""ACE Inhibitors/ARBs""}"	{}	"{""description"": ""First-line for proteinuria reduction and renoprotection."", ""name"": ""ACE Inhibitors/ARBs""}"
4007	168	IgA Nephropathy	IgA_Nephropathy.yaml	treatments	1	SGLT2 Inhibitors	Renoprotective benefit in IgAN.																																																								"{""description"": ""Renoprotective benefit in IgAN."", ""name"": ""SGLT2 Inhibitors""}"	{}	"{""description"": ""Renoprotective benefit in IgAN."", ""name"": ""SGLT2 Inhibitors""}"
4008	168	IgA Nephropathy	IgA_Nephropathy.yaml	treatments	2	Corticosteroids	For high-risk patients with persistent proteinuria.																																																								"{""description"": ""For high-risk patients with persistent proteinuria."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""For high-risk patients with persistent proteinuria."", ""name"": ""Corticosteroids""}"
4009	168	IgA Nephropathy	IgA_Nephropathy.yaml	treatments	3	Sparsentan	Dual endothelin/angiotensin receptor antagonist.																																																								"{""description"": ""Dual endothelin/angiotensin receptor antagonist."", ""name"": ""Sparsentan""}"	{}	"{""description"": ""Dual endothelin/angiotensin receptor antagonist."", ""name"": ""Sparsentan""}"
4010	168	IgA Nephropathy	IgA_Nephropathy.yaml	treatments	4	Budesonide (Targeted Release)	Nefecon for reducing proteinuria.																																																								"{""description"": ""Nefecon for reducing proteinuria."", ""name"": ""Budesonide (Targeted Release)""}"	{}	"{""description"": ""Nefecon for reducing proteinuria."", ""name"": ""Budesonide (Targeted Release)""}"
4022	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	treatments	0	Corticosteroids	First-line therapy.																																																								"{""description"": ""First-line therapy."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""First-line therapy."", ""name"": ""Corticosteroids""}"
4023	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	treatments	1	IVIG	For rapid platelet increase, bleeding, or pre-procedure.																																																								"{""description"": ""For rapid platelet increase, bleeding, or pre-procedure."", ""name"": ""IVIG""}"	{}	"{""description"": ""For rapid platelet increase, bleeding, or pre-procedure."", ""name"": ""IVIG""}"
4024	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	treatments	2	Thrombopoietin Receptor Agonists	Romiplostim, eltrombopag for chronic ITP.																																																								"{""description"": ""Romiplostim, eltrombopag for chronic ITP."", ""name"": ""Thrombopoietin Receptor Agonists""}"	{}	"{""description"": ""Romiplostim, eltrombopag for chronic ITP."", ""name"": ""Thrombopoietin Receptor Agonists""}"
4025	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	treatments	3	Rituximab	Second-line option.																																																								"{""description"": ""Second-line option."", ""name"": ""Rituximab""}"	{}	"{""description"": ""Second-line option."", ""name"": ""Rituximab""}"
4026	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	treatments	4	Splenectomy	For refractory disease.																																																								"{""description"": ""For refractory disease."", ""name"": ""Splenectomy""}"	{}	"{""description"": ""For refractory disease."", ""name"": ""Splenectomy""}"
4030	170	Infectious Disease	Infectious_Disease.yaml	treatments	0	Vaccination	Vaccines are key preventive strategies against infectious pathogens.																																																								"{""description"": ""Vaccines are key preventive strategies against infectious pathogens."", ""name"": ""Vaccination""}"	{}	"{""description"": ""Vaccines are key preventive strategies against infectious pathogens."", ""evidence"": [{""explanation"": ""The abstract lists vaccines as a priority for prevention and control of infectious diseases."", ""reference"": ""PMID:10884944"", ""snippet"": ""Priorities for prevention and control of these pathogens include vaccines and antimicrobial drugs."", ""supports"": ""SUPPORT""}], ""name"": ""Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
4031	170	Infectious Disease	Infectious_Disease.yaml	treatments	1	Antimicrobial Therapy	Antimicrobial drugs are used to treat infections caused by pathogens.																																																								"{""description"": ""Antimicrobial drugs are used to treat infections caused by pathogens."", ""name"": ""Antimicrobial Therapy""}"	{}	"{""description"": ""Antimicrobial drugs are used to treat infections caused by pathogens."", ""evidence"": [{""explanation"": ""The abstract lists antimicrobial drugs as a priority for infectious disease control."", ""reference"": ""PMID:10884944"", ""snippet"": ""Priorities for prevention and control of these pathogens include vaccines and antimicrobial drugs."", ""supports"": ""SUPPORT""}], ""name"": ""Antimicrobial Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4055	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	0	Dietary Modification	Low FODMAP diet effective in many patients.																																																								"{""description"": ""Low FODMAP diet effective in many patients."", ""name"": ""Dietary Modification""}"	{}	"{""description"": ""Low FODMAP diet effective in many patients."", ""name"": ""Dietary Modification""}"
4056	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	1	Antispasmodics	Dicyclomine, hyoscyamine for pain and cramping.																																																								"{""description"": ""Dicyclomine, hyoscyamine for pain and cramping."", ""name"": ""Antispasmodics""}"	{}	"{""description"": ""Dicyclomine, hyoscyamine for pain and cramping."", ""name"": ""Antispasmodics""}"
4057	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	2	Loperamide	For diarrhea-predominant IBS.																																																								"{""description"": ""For diarrhea-predominant IBS."", ""name"": ""Loperamide""}"	{}	"{""description"": ""For diarrhea-predominant IBS."", ""name"": ""Loperamide""}"
4058	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	3	Linaclotide	Guanylate cyclase agonist for IBS-C.																																																								"{""description"": ""Guanylate cyclase agonist for IBS-C."", ""name"": ""Linaclotide""}"	{}	"{""description"": ""Guanylate cyclase agonist for IBS-C."", ""name"": ""Linaclotide""}"
4059	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	4	Rifaximin	Non-absorbable antibiotic for IBS-D with bloating.																																																								"{""description"": ""Non-absorbable antibiotic for IBS-D with bloating."", ""name"": ""Rifaximin""}"	{}	"{""description"": ""Non-absorbable antibiotic for IBS-D with bloating."", ""name"": ""Rifaximin""}"
4060	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	5	Tricyclic Antidepressants	Low-dose for pain modulation.																																																								"{""description"": ""Low-dose for pain modulation."", ""name"": ""Tricyclic Antidepressants""}"	{}	"{""description"": ""Low-dose for pain modulation."", ""name"": ""Tricyclic Antidepressants""}"
4061	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	6	SSRIs	For patients with comorbid anxiety/depression.																																																								"{""description"": ""For patients with comorbid anxiety/depression."", ""name"": ""SSRIs""}"	{}	"{""description"": ""For patients with comorbid anxiety/depression."", ""name"": ""SSRIs""}"
4062	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	7	Probiotics	May help some patients.																																																								"{""description"": ""May help some patients."", ""name"": ""Probiotics""}"	{}	"{""description"": ""May help some patients."", ""name"": ""Probiotics""}"
4063	171	Irritable Bowel Syndrome	Irritable_Bowel_Syndrome.yaml	treatments	8	Cognitive Behavioral Therapy	Effective for gut-brain axis modulation.																																																								"{""description"": ""Effective for gut-brain axis modulation."", ""name"": ""Cognitive Behavioral Therapy""}"	{}	"{""description"": ""Effective for gut-brain axis modulation."", ""name"": ""Cognitive Behavioral Therapy""}"
4073	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Surgical correction of craniosynostosis when clinically indicated.
"																																																								"{""description"": ""Surgical correction of craniosynostosis when clinically indicated.\n"", ""name"": ""Cranial Vault Surgery""}"	{}	"{""description"": ""Surgical correction of craniosynostosis when clinically indicated.\n"", ""name"": ""Cranial Vault Surgery"", ""treatment_term"": {""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4074	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	treatments	1	Foot Surgery	"Surgical management of foot deformities if causing functional problems.
"																																																								"{""description"": ""Surgical management of foot deformities if causing functional problems.\n"", ""name"": ""Foot Surgery""}"	{}	"{""description"": ""Surgical management of foot deformities if causing functional problems.\n"", ""name"": ""Foot Surgery"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4101	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	0	Valproic Acid	First-line treatment, effective in controlling seizures in many patients.						Anticonvulsant																																																		"{""description"": ""First-line treatment, effective in controlling seizures in many patients."", ""name"": ""Valproic Acid"", ""role"": ""Anticonvulsant""}"	{}	"{""description"": ""First-line treatment, effective in controlling seizures in many patients."", ""evidence"": [{""explanation"": ""The reference supports the efficacy of Valproic Acid in controlling seizures, but it does not specifically mention Jeavons Syndrome or describe it as a first-line treatment."", ""reference"": ""PMID:6771426"", ""snippet"": ""Valproic acid, used alone or in combination with other anticonvulsants in 100 children with epilepsy, improved seizure control in all age groups."", ""supports"": ""PARTIAL""}, {""explanation"": ""Valproic acid is mentioned as effective in controlling certain types of seizures common in Jeavons Syndrome (myoclonic jerks), but again it does not specifically refer to Jeavons Syndrome or define it as first-line treatment."", ""reference"": ""PMID:11393330"", ""snippet"": ""Valproic acid controls absences in 75% of patients and also GTCS (70%) and myoclonic jerks (75%); however, it may be undesirable for some women."", ""supports"": ""PARTIAL""}], ""name"": ""Valproic Acid"", ""role"": ""Anticonvulsant"", ""treatment_term"": {""description"": ""First-line anticonvulsant treatment using valproic acid for seizure control."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4102	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	1	Ethosuximide	May be used as an alternative or adjunctive therapy.						Anticonvulsant																																																		"{""description"": ""May be used as an alternative or adjunctive therapy."", ""name"": ""Ethosuximide"", ""role"": ""Anticonvulsant""}"	{}	"{""description"": ""May be used as an alternative or adjunctive therapy."", ""evidence"": [{""explanation"": ""The reference supports the use of ethosuximide as a treatment for generalized absence epilepsy, which is related to Jeavons syndrome. However, it does not provide specific evidence for its use as an alternative or adjunctive therapy specifically for Jeavons syndrome."", ""reference"": ""PMID:17627674"", ""snippet"": ""Ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy."", ""supports"": ""PARTIAL""}], ""name"": ""Ethosuximide"", ""role"": ""Anticonvulsant"", ""treatment_term"": {""description"": ""Anticonvulsant treatment primarily targeting absence seizures."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4103	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	2	Levetiracetam	May be used as an alternative or adjunctive therapy.						Anticonvulsant																																																		"{""description"": ""May be used as an alternative or adjunctive therapy."", ""name"": ""Levetiracetam"", ""role"": ""Anticonvulsant""}"	{}	"{""description"": ""May be used as an alternative or adjunctive therapy."", ""evidence"": [{""explanation"": ""The literature mentions the use of levetiracetam resulting in clinical remission for a patient with Jeavons syndrome."", ""reference"": ""PMID:24798222"", ""snippet"": ""This case together with relevant literature data supports the view that the use of levetiracetam might be of benefit for female patients with Jeavons syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature highlights that levetiracetam can be used as both adjunctive therapy and monotherapy for Jeavons Syndrome among other epileptic syndromes."", ""reference"": ""PMID:20486734"", ""snippet"": ""The efficacy of levetiracetam as an adjunctive therapy and as monotherapy for generalized and partial childhood epilepsies and for some types of specific epileptic syndromes of infancy and childhood (such as juvenile myoclonic epilepsy, benign rolandic epilepsy, and Jeavon syndrome) has been demonstrated."", ""supports"": ""SUPPORT""}], ""name"": ""Levetiracetam"", ""role"": ""Anticonvulsant"", ""treatment_term"": {""description"": ""Broad-spectrum anticonvulsant that may be used as alternative or adjunctive therapy."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4104	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	3	Avoidance of Provocative Stimuli	Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.																																																								"{""description"": ""Patients should avoid photic stimulation that may trigger seizures, such as flickering lights."", ""name"": ""Avoidance of Provocative Stimuli""}"	{}	"{""description"": ""Patients should avoid photic stimulation that may trigger seizures, such as flickering lights."", ""evidence"": [{""explanation"": ""The literature mentions that avoidance of visually provoking stimuli, like flickering lights, can help in managing photosensitive seizures, though it does not specifically mention Jeavons Syndrome."", ""reference"": ""PMID:14706045"", ""snippet"": ""Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful."", ""supports"": ""PARTIAL""}, {""explanation"": ""This article suggests that visually evoked seizures can be triggered by stimuli like flickering lights, but it does not specifically address Jeavons Syndrome."", ""reference"": ""PMID:22946728"", ""snippet"": ""Recognized reflex seizure triggers are usually sensory and visual, such as television, discotheques, and video games."", ""supports"": ""PARTIAL""}, {""explanation"": ""This directly supports that photic stimulation, such as flickering lights, can trigger seizures in patients with Jeavons Syndrome."", ""reference"": ""PMID:32861158"", ""snippet"": ""Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference indicates that photic stimulation can induce seizures in patients with Jeavons Syndrome, thus supporting the need to avoid such stimuli."", ""reference"": ""PMID:29555355"", ""snippet"": ""Self-induced seizures were predominantly eyelid myoclonia +/- absences... EEG demonstrated a normal background with 3-4 Hz spike waves +/- polyspike waves as well as a photoparoxysmal response."", ""supports"": ""SUPPORT""}], ""name"": ""Avoidance of Provocative Stimuli"", ""treatment_term"": {""description"": ""Behavioral intervention to avoid exposure to known seizure triggers."", ""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}}"
4105	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	4	Avoidance of Triggering Stimuli	Minimizing exposure to known triggers such as flashing lights or sleep deprivation.																																																								"{""description"": ""Minimizing exposure to known triggers such as flashing lights or sleep deprivation."", ""name"": ""Avoidance of Triggering Stimuli""}"	{}	"{""description"": ""Minimizing exposure to known triggers such as flashing lights or sleep deprivation."", ""evidence"": [{""explanation"": ""The focus is on the relationship between light stimulation and EEG patterns in Jeavons syndrome, with no mention of avoidance of triggers as a treatment method."", ""reference"": ""PMID:32861158"", ""snippet"": ""Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome"", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Avoidance of Triggering Stimuli"", ""treatment_term"": {""description"": ""Lifestyle modification to minimize exposure to photic and other seizure triggers."", ""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}}"
4106	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	5	Sunglasses or Blue Light Filtering Glasses	Wear to reduce light sensitivity and potentially prevent seizures.																																																								"{""description"": ""Wear to reduce light sensitivity and potentially prevent seizures."", ""name"": ""Sunglasses or Blue Light Filtering Glasses""}"	{}	"{""description"": ""Wear to reduce light sensitivity and potentially prevent seizures."", ""evidence"": [{""explanation"": ""This reference mentions using colored glasses but does not specifically mention sunglasses or blue light filtering glasses for Jeavons syndrome."", ""reference"": ""PMID:14706045"", ""snippet"": ""Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This study focuses on drug treatments and does not mention sunglasses or blue light filtering glasses."", ""reference"": ""PMID:30082241"", ""snippet"": ""We reviewed and described the epilepsy history, antiepileptic drug trials, and response to treatments."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference discusses the occipital cortex's role in Jeavons syndrome but does not mention sunglasses or blue light filtering glasses as a treatment."", ""reference"": ""PMID:26552567"", ""snippet"": ""Jeavons syndrome as an occipital cortex initiated generalized epilepsy."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference discusses EEG characteristics in Jeavons syndrome without mentioning sunglasses or blue light filtering glasses as a treatment."", ""reference"": ""PMID:32861158"", ""snippet"": ""Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Sunglasses or Blue Light Filtering Glasses"", ""treatment_term"": {""description"": ""Use of protective eyewear to reduce light-induced seizure triggers."", ""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.																																																								"{""description"": ""Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients."", ""name"": ""Imatinib""}"	{}	"{""description"": ""Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients."", ""evidence"": [{""explanation"": ""Phase II trial reports response rates to imatinib in KIT-altered melanoma."", ""reference"": ""PMID:23775962"", ""snippet"": ""Best overall response rate (BORR) was 29% (21% excluding nonconfirmed responses) with a two-stage 95% CI of 13% to 51%."", ""supports"": ""SUPPORT""}], ""name"": ""Imatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}}"
4122	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	1	Nilotinib	Second-generation KIT inhibitor with increased potency compared to imatinib. May have activity in some imatinib-resistant cases depending on the specific mutation conferring resistance.																																																								"{""description"": ""Second-generation KIT inhibitor with increased potency compared to imatinib. May have activity in some imatinib-resistant cases depending on the specific mutation conferring resistance."", ""name"": ""Nilotinib""}"	{}	"{""description"": ""Second-generation KIT inhibitor with increased potency compared to imatinib. May have activity in some imatinib-resistant cases depending on the specific mutation conferring resistance."", ""name"": ""Nilotinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4123	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	2	Dasatinib	Multi-kinase inhibitor with activity against KIT, ABL, and SRC family kinases. Has demonstrated activity in KIT-mutant melanoma in clinical trials.																																																								"{""description"": ""Multi-kinase inhibitor with activity against KIT, ABL, and SRC family kinases. Has demonstrated activity in KIT-mutant melanoma in clinical trials."", ""name"": ""Dasatinib""}"	{}	"{""description"": ""Multi-kinase inhibitor with activity against KIT, ABL, and SRC family kinases. Has demonstrated activity in KIT-mutant melanoma in clinical trials."", ""name"": ""Dasatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4124	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) are also used in KIT-mutant melanoma. The optimal sequencing of KIT inhibitors versus immunotherapy depends on mutation status and patient characteristics.																																																								"{""description"": ""Anti-PD-1 antibodies (pembrolizumab, nivolumab) are also used in KIT-mutant melanoma. The optimal sequencing of KIT inhibitors versus immunotherapy depends on mutation status and patient characteristics."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""Anti-PD-1 antibodies (pembrolizumab, nivolumab) are also used in KIT-mutant melanoma. The optimal sequencing of KIT inhibitors versus immunotherapy depends on mutation status and patient characteristics."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4140	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	0	Sotorasib	First-in-class KRAS G12C inhibitor. Covalently binds mutant cysteine in the GDP-bound inactive state, locking KRAS in the off position. FDA approved for previously treated KRAS G12C NSCLC based on CodeBreaK 100 trial.																																																								"{""description"": ""First-in-class KRAS G12C inhibitor. Covalently binds mutant cysteine in the GDP-bound inactive state, locking KRAS in the off position. FDA approved for previously treated KRAS G12C NSCLC based on CodeBreaK 100 trial."", ""name"": ""Sotorasib""}"	{}	"{""description"": ""First-in-class KRAS G12C inhibitor. Covalently binds mutant cysteine in the GDP-bound inactive state, locking KRAS in the off position. FDA approved for previously treated KRAS G12C NSCLC based on CodeBreaK 100 trial."", ""evidence"": [{""explanation"": ""Phase 2 trial reports objective responses to sotorasib in KRAS G12C NSCLC."", ""reference"": ""PMID:34096690"", ""snippet"": ""An objective response was observed in 46 patients (37.1%"", ""supports"": ""SUPPORT""}], ""name"": ""Sotorasib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4141	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	1	Adagrasib	Second KRAS G12C inhibitor to gain FDA approval. Has longer half-life than sotorasib and demonstrated intracranial activity. Approved based on KRYSTAL-1 trial.																																																								"{""description"": ""Second KRAS G12C inhibitor to gain FDA approval. Has longer half-life than sotorasib and demonstrated intracranial activity. Approved based on KRYSTAL-1 trial."", ""name"": ""Adagrasib""}"	{}	"{""description"": ""Second KRAS G12C inhibitor to gain FDA approval. Has longer half-life than sotorasib and demonstrated intracranial activity. Approved based on KRYSTAL-1 trial."", ""evidence"": [{""explanation"": ""KRYSTAL-1 abstract reports objective responses to adagrasib in KRAS G12C NSCLC."", ""reference"": ""PMID:35658005"", ""snippet"": ""Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response."", ""supports"": ""SUPPORT""}], ""name"": ""Adagrasib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4142	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	2	KRAS G12C Inhibitor Combinations	Combinations with SHP2 inhibitors, SOS1 inhibitors, or EGFR inhibitors are being explored to prevent adaptive resistance and improve response durability. Rational combinations target feedback reactivation of RTK-RAS signaling.																																																								"{""description"": ""Combinations with SHP2 inhibitors, SOS1 inhibitors, or EGFR inhibitors are being explored to prevent adaptive resistance and improve response durability. Rational combinations target feedback reactivation of RTK-RAS signaling."", ""name"": ""KRAS G12C Inhibitor Combinations""}"	{}	"{""description"": ""Combinations with SHP2 inhibitors, SOS1 inhibitors, or EGFR inhibitors are being explored to prevent adaptive resistance and improve response durability. Rational combinations target feedback reactivation of RTK-RAS signaling."", ""name"": ""KRAS G12C Inhibitor Combinations"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4143	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors (pembrolizumab, nivolumab) are used for KRAS-mutant NSCLC, particularly those without STK11 co-mutation. KRAS-mutant tumors often have high TMB from smoking. Combination with KRAS G12C inhibitors is under investigation.																																																								"{""description"": ""Checkpoint inhibitors (pembrolizumab, nivolumab) are used for KRAS-mutant NSCLC, particularly those without STK11 co-mutation. KRAS-mutant tumors often have high TMB from smoking. Combination with KRAS G12C inhibitors is under investigation."", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""Checkpoint inhibitors (pembrolizumab, nivolumab) are used for KRAS-mutant NSCLC, particularly those without STK11 co-mutation. KRAS-mutant tumors often have high TMB from smoking. Combination with KRAS G12C inhibitors is under investigation."", ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4144	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy remains standard for patients who progress on targeted therapy or as first-line with immunotherapy.																																																								"{""description"": ""Platinum-based chemotherapy remains standard for patients who progress on targeted therapy or as first-line with immunotherapy."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy remains standard for patients who progress on targeted therapy or as first-line with immunotherapy."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4166	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	0	Antiretroviral Therapy	For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment.																																																								"{""description"": ""For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment."", ""name"": ""Antiretroviral Therapy""}"	{}	"{""description"": ""For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment."", ""name"": ""Antiretroviral Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.																																																								"{""description"": ""For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""paclitaxel"", ""term"": {""id"": ""CHEBI:45863"", ""label"": ""paclitaxel""}}]}}"
4168	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	2	Local Therapy	Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis.																																																								"{""description"": ""Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis."", ""name"": ""Local Therapy""}"	{}	"{""description"": ""Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis."", ""name"": ""Local Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
4169	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	3	Reduction of Immunosuppression	For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression.																																																								"{""description"": ""For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression."", ""name"": ""Reduction of Immunosuppression""}"	{}	"{""description"": ""For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression."", ""name"": ""Reduction of Immunosuppression"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	Intravenous Immunoglobulin (IVIG)	First-line treatment to reduce inflammation and risk of coronary artery complications.																																																								"{""description"": ""First-line treatment to reduce inflammation and risk of coronary artery complications."", ""name"": ""Intravenous Immunoglobulin (IVIG)""}"	{}	"{""description"": ""First-line treatment to reduce inflammation and risk of coronary artery complications."", ""evidence"": [{""explanation"": ""The literature confirms that IVIG is part of the standard initial therapy for Kawasaki disease, aimed at reducing inflammation and preventing coronary artery complications."", ""reference"": ""PMID:23283289"", ""snippet"": ""Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses the use of IVIG and its timing in relation to the risk of coronary artery lesions, supporting its role in reducing such risks."", ""reference"": ""PMID:38135926"", ""snippet"": ""For KD patients, male, children aged 3 to 9 years, and those with fever longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely to have CAL."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature states that IVIG is the standard of care for treating Kawasaki disease to reduce coronary artery complications."", ""reference"": ""PMID:24034380"", ""snippet"": ""The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature confirms that IVIG is effective in reducing cardiovascular complications in Kawasaki disease."", ""reference"": ""PMID:34535199"", ""snippet"": ""Intravenous immunoglobulin (IVIG) has become an effective treatment regimen, which can effectively reduce the incidence of cardiovascular complications."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature provides evidence that IVIG significantly reduces the risk of coronary artery complications when administered early."", ""reference"": ""PMID:32888683"", ""snippet"": ""Treatment of Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) administered within the initial 10 days of fever onset decreases the risk of coronary artery aneurysms (CAAs) from  25% to less than 5%."", ""supports"": ""SUPPORT""}], ""name"": ""Intravenous Immunoglobulin (IVIG)"", ""treatment_term"": {""description"": ""Treatment of disease through the administration of medications."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4215	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	1	Aspirin	Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.																																																								"{""description"": ""Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots."", ""name"": ""Aspirin""}"	{}	"{""description"": ""Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots."", ""evidence"": [{""explanation"": ""This reference confirms that high doses of aspirin are used initially for Kawasaki disease, followed by lower doses after recovery."", ""reference"": ""PMID:9513217"", ""snippet"": ""Treatment includes the hospitalization of the child and subsequent administration of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin doses are reduced and the child may be monitored at home with outpatient follow-up."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference also supports the statement that high doses of aspirin are used initially, followed by lower doses."", ""reference"": ""PMID:10935427"", ""snippet"": ""Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference suggests that low-dose aspirin might be equally effective as high-dose aspirin and should be recommended to avoid adverse reactions, indicating a shift in treatment preference."", ""reference"": ""PMID:32159800"", ""snippet"": ""Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in the initial treatment of Kawasaki disease."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference indicates that higher doses of aspirin did not prevent coronary artery aneurysms and suggests the need for further research to determine the optimal dose."", ""reference"": ""PMID:28043685"", ""snippet"": ""The use of medium- or higher-dose ASA in acute Kawasaki disease did not prevent CAA. A future randomized controlled trial is needed to determine the optimum dose of ASA."", ""supports"": ""PARTIAL""}], ""name"": ""Aspirin"", ""treatment_term"": {""description"": ""Treatment using medications that affect the cardiovascular system, including antiplatelet agents."", ""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}}"
4216	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	2	Anakinra	IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.																																		Mechanistic rationale based on NLRP3 inflammasome and IL-1 pathway activation																						"{""description"": ""IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury."", ""name"": ""Anakinra"", ""notes"": ""Mechanistic rationale based on NLRP3 inflammasome and IL-1 pathway activation""}"	{}	"{""description"": ""IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury."", ""name"": ""Anakinra"", ""notes"": ""Mechanistic rationale based on NLRP3 inflammasome and IL-1 pathway activation"", ""treatment_term"": {""description"": ""Treatment using IL-1 pathway inhibition for refractory inflammation."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4217	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	3	Cyclosporine	Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.																																		Targets dysregulated calcium signaling pathway; used for IVIG-resistant cases																						"{""description"": ""Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients."", ""name"": ""Cyclosporine"", ""notes"": ""Targets dysregulated calcium signaling pathway; used for IVIG-resistant cases""}"	{}	"{""description"": ""Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients."", ""name"": ""Cyclosporine"", ""notes"": ""Targets dysregulated calcium signaling pathway; used for IVIG-resistant cases"", ""treatment_term"": {""description"": ""Treatment using calcineurin inhibition to reduce T-cell activation."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4218	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	4	Corticosteroids	Used in cases resistant to IVIG or with severe inflammation.																																																								"{""description"": ""Used in cases resistant to IVIG or with severe inflammation."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Used in cases resistant to IVIG or with severe inflammation."", ""evidence"": [{""explanation"": ""The literature supports the use of corticosteroids in cases of Kawasaki Disease that are resistant to IVIG or in high-risk patients with severe inflammation."", ""reference"": ""PMID:31914832"", ""snippet"": ""We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses the management of resistant Kawasaki Disease, which includes considering corticosteroid use."", ""reference"": ""PMID:29101553"", ""snippet"": ""\""Resistant\"" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference mentions the use of pulsed methylprednisolone (a corticosteroid) for patients with Kawasaki Disease who are at risk of developing coronary artery abnormalities, indicating severe inflammation."", ""reference"": ""PMID:33541111"", ""snippet"": ""To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""description"": ""Treatment using corticosteroids to reduce inflammation in refractory cases."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4236	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	treatments	0	Keratolytic Therapy	"Topical agents containing salicylic acid or urea to soften and reduce hyperkeratotic skin lesions on palms and soles.
"																																																								"{""description"": ""Topical agents containing salicylic acid or urea to soften and reduce hyperkeratotic skin lesions on palms and soles.\n"", ""name"": ""Keratolytic Therapy""}"	{}	"{""description"": ""Topical agents containing salicylic acid or urea to soften and reduce hyperkeratotic skin lesions on palms and soles.\n"", ""name"": ""Keratolytic Therapy""}"
4237	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	treatments	1	Emollients	"Regular application of moisturizers to maintain skin hydration and reduce cracking and discomfort.
"																																																								"{""description"": ""Regular application of moisturizers to maintain skin hydration and reduce cracking and discomfort.\n"", ""name"": ""Emollients""}"	{}	"{""description"": ""Regular application of moisturizers to maintain skin hydration and reduce cracking and discomfort.\n"", ""name"": ""Emollients""}"
4238	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	treatments	2	Retinoids	"Oral retinoids (isotretinoin, acitretin) may help control hyperkeratosis and can prevent digital constrictions in some patients. Relapse typically occurs upon discontinuation of treatment.
"																																																								"{""description"": ""Oral retinoids (isotretinoin, acitretin) may help control hyperkeratosis and can prevent digital constrictions in some patients. Relapse typically occurs upon discontinuation of treatment.\n"", ""name"": ""Retinoids""}"	{}	"{""description"": ""Oral retinoids (isotretinoin, acitretin) may help control hyperkeratosis and can prevent digital constrictions in some patients. Relapse typically occurs upon discontinuation of treatment.\n"", ""evidence"": [{""explanation"": ""First report of successful isotretinoin treatment for the ichthyotic variant of Vohwinkel syndrome."", ""reference"": ""PMID:6237617"", ""snippet"": ""One of the patients was successfully treated with isotretinoin, 0.6 mg/kg/day orally.\n"", ""supports"": ""SUPPORT""}], ""name"": ""Retinoids""}"
4239	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	treatments	3	Surgical Intervention	"Surgical release of constricting bands may be necessary to prevent autoamputation of digits; in severe cases, amputation may be required.
"																																																								"{""description"": ""Surgical release of constricting bands may be necessary to prevent autoamputation of digits; in severe cases, amputation may be required.\n"", ""name"": ""Surgical Intervention""}"	{}	"{""description"": ""Surgical release of constricting bands may be necessary to prevent autoamputation of digits; in severe cases, amputation may be required.\n"", ""name"": ""Surgical Intervention""}"
4240	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	treatments	4	Hearing Aids and Cochlear Implants	"Audiological management for sensorineural hearing loss, including hearing aids for mild-moderate loss and cochlear implants for profound loss. Applicable only to classic GJB2-associated form.
"																																																								"{""description"": ""Audiological management for sensorineural hearing loss, including hearing aids for mild-moderate loss and cochlear implants for profound loss. Applicable only to classic GJB2-associated form.\n"", ""name"": ""Hearing Aids and Cochlear Implants""}"	{}	"{""description"": ""Audiological management for sensorineural hearing loss, including hearing aids for mild-moderate loss and cochlear implants for profound loss. Applicable only to classic GJB2-associated form.\n"", ""name"": ""Hearing Aids and Cochlear Implants""}"
4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	Testosterone Replacement Therapy	Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido.																																																								"{""description"": ""Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido."", ""name"": ""Testosterone Replacement Therapy""}"	{}	"{""description"": ""Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido."", ""evidence"": [{""explanation"": ""This reference indicates that testosterone replacement therapy can improve symptoms associated with hypogonadism, such as low energy and reduced muscle mass."", ""reference"": ""PMID:35421871"", ""snippet"": ""Patients presenting with symptoms should be tested for low testosterone and treated with testosterone replacement. ... Patients treated for hypogonadism may experience improvement of symptoms and quality of life."", ""supports"": ""SUPPORT""}, {""explanation"": ""This abstract highlights testosterone replacement therapy as a primary treatment for hypogonadism in Klinefelter Syndrome, addressing its symptoms."", ""reference"": ""PMID:26732150"", ""snippet"": ""The mainstay of medical treatment is testosterone replacement therapy to both attenuate acute and long-term consequences of hypogonadism and possibly prevent the frequent comorbidity."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates the efficacy of testosterone replacement therapy in treating symptoms related to testosterone deficiency in Klinefelter syndrome, which implies improvements in overall physical health including muscle mass."", ""reference"": ""PMID:24142635"", ""snippet"": ""Testosterone replacement therapy may be effective in treating BMD deficiency in men with testosterone deficiency, especially those with Klinefelter syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""This abstract discusses the potential of sex steroid treatments, including testosterone, but emphasizes the need for further research particularly in infants and early childhood."", ""reference"": ""PMID:38677872"", ""snippet"": ""Patients unable to produce sex steroids using gonadotropins to mimic minipuberty in hypogonadotropic hypogonadism, or sex steroids in patients with Klinefelter or Turner syndrome, is promising."", ""supports"": ""PARTIAL""}, {""explanation"": ""Testosterone replacement therapy has positive effects on symptoms related to body composition, which can be correlated to improvements in muscle mass and energy levels."", ""reference"": ""PMID:37962976"", ""snippet"": ""TRT in patients with KS has the potential for alleviating the prothrombotic phenotype, in particular by reducing body fat and fibrinogen."", ""supports"": ""SUPPORT""}], ""name"": ""Testosterone Replacement Therapy"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
4272	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	1	Educational Support	Special education services and speech therapy to improve language and academic skills.																																																								"{""description"": ""Special education services and speech therapy to improve language and academic skills."", ""name"": ""Educational Support""}"	{}	"{""description"": ""Special education services and speech therapy to improve language and academic skills."", ""evidence"": [{""explanation"": ""This article directly indicates the need for speech therapy and special education for boys with Klinefelter syndrome."", ""reference"": ""PMID:25899809"", ""snippet"": ""Boys with Klinefelter syndrome are often in the need of speech therapy and many suffer from learning disability and may benefit from special education."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article supports the statement by mentioning the necessity of speech and language therapy or developmental support."", ""reference"": ""PMID:35948402"", ""snippet"": ""Around two-thirds require speech and language therapy or developmental support and early institution of therapy is important."", ""supports"": ""SUPPORT""}], ""name"": ""Educational Support"", ""treatment_term"": {""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}}"
4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	Fertility Treatment	Assisted reproductive technologies such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) may help those who wish to have children.																																																								"{""description"": ""Assisted reproductive technologies such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) may help those who wish to have children."", ""name"": ""Fertility Treatment""}"	{}	"{""description"": ""Assisted reproductive technologies such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) may help those who wish to have children."", ""evidence"": [{""explanation"": ""This reference explicitly states the role of assisted reproductive technology in treating infertility in patients with Klinefelter syndrome."", ""reference"": ""PMID:35667865"", ""snippet"": ""Assisted reproductive technology is essential for infertility treatment in patients with Klinefelter syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study indicates that patients with Klinefelter syndrome can achieve successful sperm recovery and pregnancy rates using TESE-ICSI, a type of assisted reproductive technology."", ""reference"": ""PMID:19490778"", ""snippet"": ""In conclusion, patients with non-mosaic Klinefelter syndrome have sperm recovery and pregnancy rates comparable with patients having non-obstructive azoospermia and normal karyotype."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses the advantages of using TESE-ICSI (a form of assisted reproductive technology) to address fertility issues in patients with Klinefelter syndrome."", ""reference"": ""PMID:21835671"", ""snippet"": ""In this review, we will discuss the fertility issue following TEsticular Sperm Extraction-IntraCytoplasmic Sperm Injection (TESE-ICSI) and the potential advantage of searching for and cryopreserving spermatozoa in adolescent instead of adult patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights that men with Klinefelter syndrome now have several treatment options, including assisted reproductive technologies, to achieve paternity."", ""reference"": ""PMID:31587581"", ""snippet"": ""Once considered untreatable, men with KS and NOA now have a variety of treatment options to obtain paternity."", ""supports"": ""SUPPORT""}, {""explanation"": ""This review summarizes methods that enhance the success of assisted reproductive technology (ART) for patients with Klinefelter syndrome."", ""reference"": ""PMID:32562095"", ""snippet"": ""Mounting evidence from recent studies has shown that various technological advances and approaches could facilitate the success of ART treatment for KS patients."", ""supports"": ""SUPPORT""}], ""name"": ""Fertility Treatment"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4274	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	3	Psychological Support	Counseling and psychological support to address social, emotional, and behavioral challenges.																																																								"{""description"": ""Counseling and psychological support to address social, emotional, and behavioral challenges."", ""name"": ""Psychological Support""}"	{}	"{""description"": ""Counseling and psychological support to address social, emotional, and behavioral challenges."", ""name"": ""Psychological Support"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
4275	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	4	Multidisciplinary Care	Comprehensive monitoring for metabolic, cardiovascular, and bone health complications.																																																								"{""description"": ""Comprehensive monitoring for metabolic, cardiovascular, and bone health complications."", ""name"": ""Multidisciplinary Care""}"	{}	"{""description"": ""Comprehensive monitoring for metabolic, cardiovascular, and bone health complications."", ""name"": ""Multidisciplinary Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
4289	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	0	Orthopedic Management	"Management of joint contractures, spinal abnormalities, and hip dysplasia. Physical therapy to maintain joint mobility.
"																																																								"{""description"": ""Management of joint contractures, spinal abnormalities, and hip dysplasia. Physical therapy to maintain joint mobility.\n"", ""name"": ""Orthopedic Management""}"	{}	"{""description"": ""Management of joint contractures, spinal abnormalities, and hip dysplasia. Physical therapy to maintain joint mobility.\n"", ""name"": ""Orthopedic Management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4290	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	1	Ophthalmologic Surveillance	"Regular monitoring for myopia and retinal detachment risk.
"																																																								"{""description"": ""Regular monitoring for myopia and retinal detachment risk.\n"", ""name"": ""Ophthalmologic Surveillance""}"	{}	"{""description"": ""Regular monitoring for myopia and retinal detachment risk.\n"", ""name"": ""Ophthalmologic Surveillance""}"
4291	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	2	Audiologic Management	"Hearing assessment and management with hearing aids as needed.
"																																																								"{""description"": ""Hearing assessment and management with hearing aids as needed.\n"", ""name"": ""Audiologic Management""}"	{}	"{""description"": ""Hearing assessment and management with hearing aids as needed.\n"", ""name"": ""Audiologic Management""}"
4292	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	3	Cleft Palate Repair	"Surgical repair of cleft palate in affected individuals.
"																																																								"{""description"": ""Surgical repair of cleft palate in affected individuals.\n"", ""name"": ""Cleft Palate Repair""}"	{}	"{""description"": ""Surgical repair of cleft palate in affected individuals.\n"", ""name"": ""Cleft Palate Repair"", ""treatment_term"": {""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4314	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	0	Gluten-free diet	"Elimination of gluten from diet is foundational therapy for Lane Hamilton Syndrome, as it addresses the underlying celiac disease trigger. Many LHS cases achieve remission or significant improvement with strict, lifelong gluten-free diet adherence. Relapse commonly occurs with dietary nonadherence, emphasizing the critical importance of sustained dietary compliance for disease control.
"																																																								"{""description"": ""Elimination of gluten from diet is foundational therapy for Lane Hamilton Syndrome, as it addresses the underlying celiac disease trigger. Many LHS cases achieve remission or significant improvement with strict, lifelong gluten-free diet adherence. Relapse commonly occurs with dietary nonadherence, emphasizing the critical importance of sustained dietary compliance for disease control.\n"", ""name"": ""Gluten-free diet""}"	{}	"{""description"": ""Elimination of gluten from diet is foundational therapy for Lane Hamilton Syndrome, as it addresses the underlying celiac disease trigger. Many LHS cases achieve remission or significant improvement with strict, lifelong gluten-free diet adherence. Relapse commonly occurs with dietary nonadherence, emphasizing the critical importance of sustained dietary compliance for disease control.\n"", ""evidence"": [{""explanation"": ""Systematic review demonstrates gluten-free diet as effective primary therapy"", ""reference"": ""PMID:35475077"", ""snippet"": ""A gluten-free diet alone was effective in the majority of patients"", ""supports"": ""SUPPORT""}, {""explanation"": ""Case report documents clinical remission with gluten-free diet and relapse with noncompliance"", ""reference"": ""DOI:10.5505/respircase.2024.73604"", ""supports"": ""SUPPORT""}], ""name"": ""Gluten-free diet"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
4315	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	1	Corticosteroids	"Systemic corticosteroids are commonly used as first-line therapy for acute diffuse alveolar hemorrhage or when gluten-free diet alone is insufficient. Approximately 95% of IPH/LHS patients receive corticosteroids for acute management, though 60% of LHS patients may be discharged on gluten-free diet alone without steroids after stabilization. Corticosteroids are particularly important during acute exacerbations or in severe presentations.
"																																																								"{""description"": ""Systemic corticosteroids are commonly used as first-line therapy for acute diffuse alveolar hemorrhage or when gluten-free diet alone is insufficient. Approximately 95% of IPH/LHS patients receive corticosteroids for acute management, though 60% of LHS patients may be discharged on gluten-free diet alone without steroids after stabilization. Corticosteroids are particularly important during acute exacerbations or in severe presentations.\n"", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Systemic corticosteroids are commonly used as first-line therapy for acute diffuse alveolar hemorrhage or when gluten-free diet alone is insufficient. Approximately 95% of IPH/LHS patients receive corticosteroids for acute management, though 60% of LHS patients may be discharged on gluten-free diet alone without steroids after stabilization. Corticosteroids are particularly important during acute exacerbations or in severe presentations.\n"", ""evidence"": [{""explanation"": ""Case report demonstrates corticosteroids are needed when gluten-free diet alone is insufficient"", ""reference"": ""PMID:36751263"", ""snippet"": ""A gluten-free diet and steroids were given to the patient with a very good clinical response"", ""supports"": ""SUPPORT""}, {""explanation"": ""Systematic review compares corticosteroid usage between LHS and IPH patients"", ""reference"": ""PMID:35475077"", ""snippet"": ""Fewer patients in the LHS cohort received systemic corticosteroid than the IPH cohort"", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4316	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	2	Immunosuppressive therapy	"Steroid-sparing agents such as azathioprine have been used in selected cases of Lane Hamilton Syndrome for long-term management or when corticosteroid monotherapy is insufficient. These agents allow reduction of corticosteroid exposure and may be considered in patients with frequent relapses or corticosteroid-dependent disease.
"																																																								"{""description"": ""Steroid-sparing agents such as azathioprine have been used in selected cases of Lane Hamilton Syndrome for long-term management or when corticosteroid monotherapy is insufficient. These agents allow reduction of corticosteroid exposure and may be considered in patients with frequent relapses or corticosteroid-dependent disease.\n"", ""name"": ""Immunosuppressive therapy""}"	{}	"{""description"": ""Steroid-sparing agents such as azathioprine have been used in selected cases of Lane Hamilton Syndrome for long-term management or when corticosteroid monotherapy is insufficient. These agents allow reduction of corticosteroid exposure and may be considered in patients with frequent relapses or corticosteroid-dependent disease.\n"", ""evidence"": [{""explanation"": ""Systematic review identifies steroid-sparing agents as alternative immunosuppressive options"", ""reference"": ""PMID:35475077"", ""snippet"": ""The coexistence of IPH and celiac disease (CD), also known as Lane-Hamilton syndrome (LHS), has been reported in both pediatric and adult patients"", ""supports"": ""SUPPORT""}], ""name"": ""Immunosuppressive therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.																																																								"{""description"": ""Endoscopic laser repair used for type 1 laryngeal clefts."", ""name"": ""Endoscopic laser repair (type 1)""}"	{}	"{""description"": ""Endoscopic laser repair used for type 1 laryngeal clefts."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series identifies endoscopic laser repair as the standard treatment for type 1 laryngeal cleft."", ""reference"": ""PMID:40330935"", ""snippet"": ""endoscopic laser repair remains the gold standard treatment for type 1 LC."", ""supports"": ""SUPPORT""}], ""name"": ""Endoscopic laser repair (type 1)"", ""treatment_term"": {""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}}"
4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.																																																								"{""description"": ""Staged endoscopic CO2 laser-assisted repair for type 3 clefts."", ""name"": ""Endoscopic CO2 laser repair (type 3)""}"	{}	"{""description"": ""Staged endoscopic CO2 laser-assisted repair for type 3 clefts."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series reports staged endoscopic CO2 laser repair for type 3 clefts."", ""reference"": ""PMID:40579891"", ""snippet"": ""Nineteen patients with Type III laryngeal clefts who were treated with endoscopic carbon dioxide laser-assisted repair were included."", ""supports"": ""SUPPORT""}], ""name"": ""Endoscopic CO2 laser repair (type 3)"", ""treatment_term"": {""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""carbon dioxide"", ""term"": {""id"": ""NCIT:C65288"", ""label"": ""Carbon Dioxide""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}}"
4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.																																																								"{""description"": ""Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft."", ""name"": ""Injection laryngoplasty""}"	{}	"{""description"": ""Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Survey study identifies injection laryngoplasty as a treatment option for laryngeal cleft."", ""reference"": ""PMID:39260330"", ""snippet"": ""LC can be treated surgically by performing suture repair or by Injection Laryngoplasty (IL)."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case series documents injection laryngoplasty used in initial management."", ""reference"": ""PMID:40330935"", ""snippet"": ""we initially managed patients with type 1 LC with hyaluronic acid injections for a few months"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report supports injection laryngoplasty as a feasible intervention in infants."", ""reference"": ""PMID:35236684"", ""snippet"": ""injection laryngoplasty is performed safely on an 8-week-old child"", ""supports"": ""SUPPORT""}], ""name"": ""Injection laryngoplasty"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""hyaluronic acid"", ""term"": {""id"": ""CHEBI:16336"", ""label"": ""hyaluronic acid""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.																																																								"{""description"": ""Operative repair of laryngeal cleft improves aspiration symptoms."", ""name"": ""Surgical repair of laryngeal cleft""}"	{}	"{""description"": ""Operative repair of laryngeal cleft improves aspiration symptoms."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Familial case report shows symptom improvement after surgical repair."", ""reference"": ""PMID:40629707"", ""snippet"": ""All showed marked improvement after surgical repair."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Review emphasizes early operative correction for laryngotracheoesophageal cleft."", ""reference"": ""PMID:6873110"", ""snippet"": ""an early operative correction of the defect is required."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Type IV case report documents surgical repair of LTEC with an anterior approach under ECMO."", ""reference"": ""PMID:30783751"", ""snippet"": ""repair of the cleft was performed by an anterior approach via median sternotomy"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Case report demonstrates surgical repair for type IV laryngeal cleft with TEF."", ""reference"": ""PMID:35039336"", ""snippet"": ""Simultaneous anterior cervical repair of type IV laryngeal cleft and tracheo-oesophageal fistula."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Adult case report supports endoscopic surgical repair."", ""reference"": ""PMID:32593610"", ""snippet"": ""successfully treated with an endoscopic approach using absorbable suture"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Tertiary center series supports endoscopic or open surgical management for laryngeal cleft."", ""reference"": ""PMID:37073597"", ""snippet"": ""Surgical management in the form of endoscopic Coblation-assisted or an open approach is indicated"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical repair of laryngeal cleft"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""NCIT:C16546"", ""label"": ""Endoscopic Procedure""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4360	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	4	Anterior laryngofissure repair with posterior cartilage grafting	Anterior approach surgical repair with posterior cartilage grafting for type III/IV LTEC.																																																								"{""description"": ""Anterior approach surgical repair with posterior cartilage grafting for type III/IV LTEC."", ""name"": ""Anterior laryngofissure repair with posterior cartilage grafting""}"	{}	"{""description"": ""Anterior approach surgical repair with posterior cartilage grafting for type III/IV LTEC."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Surgical series supports anterior laryngofissure repair with posterior cartilage grafting for type III/IV LTEC."", ""reference"": ""PMID:38761217"", ""snippet"": ""an anterior approach that involved interposition a posterior cartilage for Type III or Type IV laryngotracheoesophageal cleft (LTEC)."", ""supports"": ""SUPPORT""}], ""name"": ""Anterior laryngofissure repair with posterior cartilage grafting"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4361	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	5	Combined open and endoscopic repair for long clefts	Combined open and endoscopic approaches may be required for long clefts with tracheal extension.																																																								"{""description"": ""Combined open and endoscopic approaches may be required for long clefts with tracheal extension."", ""name"": ""Combined open and endoscopic repair for long clefts""}"	{}	"{""description"": ""Combined open and endoscopic approaches may be required for long clefts with tracheal extension."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Series reports use of combined open and endoscopic approaches for long clefts."", ""reference"": ""PMID:37816841"", ""snippet"": ""Primary and revision repair of long clefts with tracheal extension may require a combined approach."", ""supports"": ""SUPPORT""}], ""name"": ""Combined open and endoscopic repair for long clefts"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4369	183	Leishmaniasis	Leishmaniasis.yaml	treatments	0	Liposomal amphotericin B therapy	Liposomal amphotericin B is a standard therapy for visceral leishmaniasis in many regions.																																																								"{""description"": ""Liposomal amphotericin B is a standard therapy for visceral leishmaniasis in many regions."", ""name"": ""Liposomal amphotericin B therapy""}"	{}	"{""description"": ""Liposomal amphotericin B is a standard therapy for visceral leishmaniasis in many regions."", ""evidence"": [{""explanation"": ""The review describes liposomal amphotericin B as safe and effective."", ""reference"": ""PMID:30712769"", ""snippet"": ""Liposomal amphotericin B is generally found to be safe and effective in most endemic regions of the world"", ""supports"": ""SUPPORT""}], ""name"": ""Liposomal amphotericin B therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4376	184	Leprosy	Leprosy.yaml	treatments	0	Multidrug therapy with rifampicin, dapsone, and clofazimine	Multidrug therapy includes rifampicin, dapsone, and clofazimine for multibacillary disease.																																																								"{""description"": ""Multidrug therapy includes rifampicin, dapsone, and clofazimine for multibacillary disease."", ""name"": ""Multidrug therapy with rifampicin, dapsone, and clofazimine""}"	{}	"{""description"": ""Multidrug therapy includes rifampicin, dapsone, and clofazimine for multibacillary disease."", ""evidence"": [{""explanation"": ""The abstract describes multidrug therapy regimens."", ""reference"": ""PMID:28763601"", ""snippet"": ""While paucibacillary forms are treated with rifampicin and dapsone for at least six months, multibacillary leprosy is treated for at least twelve months, additionally requiring clofazimine."", ""supports"": ""SUPPORT""}], ""name"": ""Multidrug therapy with rifampicin, dapsone, and clofazimine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4394	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	0	Cancer Surveillance Protocol	Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood.																																																								"{""description"": ""Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood."", ""name"": ""Cancer Surveillance Protocol""}"	{}	"{""description"": ""Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood."", ""evidence"": [{""explanation"": ""AACR expert panel consensus recommends the Toronto Protocol surveillance approach for all LFS patients as soon as diagnosis is established."", ""reference"": ""PMID:28572266"", ""snippet"": ""the panel recommends adoption of a modified version of the \""Toronto protocol\"" that includes a combination of physical exams, blood tests, and imaging. The panel also recommends that further research be promoted to explore the feasibility and effectiveness of these risk-adapted surveillance and cancer prevention strategies."", ""supports"": ""SUPPORT""}], ""name"": ""Cancer Surveillance Protocol"", ""treatment_term"": {""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}}"
4395	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	1	Risk-Reducing Mastectomy	Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits.																																																								"{""description"": ""Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits."", ""name"": ""Risk-Reducing Mastectomy""}"	{}	"{""description"": ""Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits."", ""name"": ""Risk-Reducing Mastectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4396	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	2	Genetic Counseling	Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended.																																																								"{""description"": ""Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
4397	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	3	Radiation Avoidance	Radiation therapy should be avoided when possible in LFS patients due to increased risk of radiation-induced secondary malignancies. Alternative treatment modalities should be considered.																																		p53 is critical for radiation-induced apoptosis and cell cycle arrest. LFS patients are exquisitely sensitive to radiation-induced carcinogenesis.																						"{""description"": ""Radiation therapy should be avoided when possible in LFS patients due to increased risk of radiation-induced secondary malignancies. Alternative treatment modalities should be considered."", ""name"": ""Radiation Avoidance"", ""notes"": ""p53 is critical for radiation-induced apoptosis and cell cycle arrest. LFS patients are exquisitely sensitive to radiation-induced carcinogenesis.""}"	{}	"{""description"": ""Radiation therapy should be avoided when possible in LFS patients due to increased risk of radiation-induced secondary malignancies. Alternative treatment modalities should be considered."", ""name"": ""Radiation Avoidance"", ""notes"": ""p53 is critical for radiation-induced apoptosis and cell cycle arrest. LFS patients are exquisitely sensitive to radiation-induced carcinogenesis.""}"
4428	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	0	Alcohol Abstinence	Essential for alcoholic cirrhosis.																																																								"{""description"": ""Essential for alcoholic cirrhosis."", ""name"": ""Alcohol Abstinence""}"	{}	"{""description"": ""Essential for alcoholic cirrhosis."", ""name"": ""Alcohol Abstinence""}"
4429	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	1	Antiviral Therapy	Curative for hepatitis C, suppressive for hepatitis B.																																																								"{""description"": ""Curative for hepatitis C, suppressive for hepatitis B."", ""name"": ""Antiviral Therapy""}"	{}	"{""description"": ""Curative for hepatitis C, suppressive for hepatitis B."", ""name"": ""Antiviral Therapy""}"
4430	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	2	Diuretics	Spironolactone and furosemide for ascites management.																																																								"{""description"": ""Spironolactone and furosemide for ascites management."", ""name"": ""Diuretics""}"	{}	"{""description"": ""Spironolactone and furosemide for ascites management."", ""name"": ""Diuretics""}"
4431	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	3	Beta Blockers	Non-selective beta blockers prevent variceal bleeding.																																																								"{""description"": ""Non-selective beta blockers prevent variceal bleeding."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Non-selective beta blockers prevent variceal bleeding."", ""name"": ""Beta Blockers""}"
4432	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	4	Lactulose	Treats and prevents hepatic encephalopathy.																																																								"{""description"": ""Treats and prevents hepatic encephalopathy."", ""name"": ""Lactulose""}"	{}	"{""description"": ""Treats and prevents hepatic encephalopathy."", ""name"": ""Lactulose""}"
4433	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	5	Rifaximin	Antibiotic for hepatic encephalopathy prophylaxis.																																																								"{""description"": ""Antibiotic for hepatic encephalopathy prophylaxis."", ""name"": ""Rifaximin""}"	{}	"{""description"": ""Antibiotic for hepatic encephalopathy prophylaxis."", ""name"": ""Rifaximin""}"
4434	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	6	Liver Transplantation	Definitive treatment for decompensated cirrhosis.																																																								"{""description"": ""Definitive treatment for decompensated cirrhosis."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""Definitive treatment for decompensated cirrhosis."", ""name"": ""Liver Transplantation""}"
4435	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	treatments	7	Hepatocellular Carcinoma Surveillance	Regular ultrasound screening.																																																								"{""description"": ""Regular ultrasound screening."", ""name"": ""Hepatocellular Carcinoma Surveillance""}"	{}	"{""description"": ""Regular ultrasound screening."", ""name"": ""Hepatocellular Carcinoma Surveillance""}"
4477	188	Long COVID	Long_COVID.yaml	treatments	0	Pacing and Energy Management	"Activity management strategies to avoid post-exertional malaise, similar to approaches used in ME/CFS.
"																																																								"{""description"": ""Activity management strategies to avoid post-exertional malaise, similar to approaches used in ME/CFS.\n"", ""name"": ""Pacing and Energy Management""}"	{}	"{""description"": ""Activity management strategies to avoid post-exertional malaise, similar to approaches used in ME/CFS.\n"", ""evidence"": [{""explanation"": ""Documents the importance of addressing PEM through pacing strategies before exercise in Long COVID."", ""reference"": ""PMID:38658496"", ""snippet"": ""clinical experience has shown that the presence of post-exertional malaise (PEM) is a significant barrier to physical exercise training in people with long COVID."", ""supports"": ""SUPPORT""}, {""explanation"": ""Supports applying ME/CFS management approaches including pacing to Long COVID."", ""reference"": ""PMID:37342500"", ""snippet"": ""The illness (Long COVID) is similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)"", ""supports"": ""SUPPORT""}], ""name"": ""Pacing and Energy Management""}"
4478	188	Long COVID	Long_COVID.yaml	treatments	1	Symptom-directed Pharmacotherapy	"Medications targeting specific symptoms such as beta-blockers for tachycardia, antihistamines for mast cell activation, and low-dose naltrexone for neuroinflammation.
"																																																								"{""description"": ""Medications targeting specific symptoms such as beta-blockers for tachycardia, antihistamines for mast cell activation, and low-dose naltrexone for neuroinflammation.\n"", ""name"": ""Symptom-directed Pharmacotherapy""}"	{}	"{""description"": ""Medications targeting specific symptoms such as beta-blockers for tachycardia, antihistamines for mast cell activation, and low-dose naltrexone for neuroinflammation.\n"", ""evidence"": [{""explanation"": ""Demonstrates effectiveness of antihistamine pharmacotherapy for Long COVID symptoms."", ""reference"": ""PMID:37529714"", ""snippet"": ""Our data confirm that histamine receptors blockade may be an effective target to successfully treat long-COVID."", ""supports"": ""SUPPORT""}], ""name"": ""Symptom-directed Pharmacotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4479	188	Long COVID	Long_COVID.yaml	treatments	2	Rehabilitation Therapy	"Physical therapy, occupational therapy, and cognitive rehabilitation tailored to individual tolerance.
"																																																								"{""description"": ""Physical therapy, occupational therapy, and cognitive rehabilitation tailored to individual tolerance.\n"", ""name"": ""Rehabilitation Therapy""}"	{}	"{""description"": ""Physical therapy, occupational therapy, and cognitive rehabilitation tailored to individual tolerance.\n"", ""evidence"": [{""explanation"": ""Documents effectiveness of individualized physical rehabilitation for Long COVID exercise impairment."", ""reference"": ""PMID:38658496"", ""snippet"": ""impaired exercise performance is a condition that can be recovered in many people through an individualized physical exercise training program."", ""supports"": ""SUPPORT""}, {""explanation"": ""Provides framework for rehabilitation stratified by PEM severity in Long COVID."", ""reference"": ""PMID:38658496"", ""snippet"": ""These recommendations may guide allied healthcare professionals worldwide in initiating and adjusting exercise training programs for people with long COVID, stratified according to the presence and severity of PEM."", ""supports"": ""SUPPORT""}, {""explanation"": ""Reviews rehabilitation principles and highlights exercise-based therapy as central to Long COVID management."", ""reference"": ""PMID:37061399"", ""snippet"": ""Rehabilitation is a key element of management to achieve functional improvement... Exercise-based therapy, an essential part of management of long COVID, can be conducted with different modules, including telerehabilitation."", ""supports"": ""SUPPORT""}], ""name"": ""Rehabilitation Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
4480	188	Long COVID	Long_COVID.yaml	treatments	3	Antihistamine Therapy	"H1 and H2 receptor antagonists (such as fexofenadine and famotidine) to address mast cell activation symptoms.
"																																																								"{""description"": ""H1 and H2 receptor antagonists (such as fexofenadine and famotidine) to address mast cell activation symptoms.\n"", ""name"": ""Antihistamine Therapy""}"	{}	"{""description"": ""H1 and H2 receptor antagonists (such as fexofenadine and famotidine) to address mast cell activation symptoms.\n"", ""evidence"": [{""explanation"": ""Details the antihistamine treatment protocol used in Long COVID."", ""reference"": ""PMID:37529714"", ""snippet"": ""Patients were treated with fexofenadine (180 mg/day) and famotidine (40 mg/day). Fatigue, brain fog, abdominal disorders, and increased heart rate were evaluated in treated and untreated patients at baseline and 20 days later."", ""supports"": ""SUPPORT""}, {""explanation"": ""Documents significant improvement with antihistamine treatment."", ""reference"": ""PMID:37529714"", ""snippet"": ""Long-COVID symptoms disappeared completely in 29% of treated patients. There was a significant improvement in each of the considered symptoms"", ""supports"": ""SUPPORT""}], ""name"": ""Antihistamine Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.																																																								"{""description"": ""Early airway control including elective tracheostomy when obstruction risk is high."", ""name"": ""Airway Protection (Tracheostomy or Secured Airway)""}"	{}	"{""description"": ""Early airway control including elective tracheostomy when obstruction risk is high."", ""evidence"": [{""explanation"": ""Recommends tracheostomy to secure airway in Ludwig's angina."", ""reference"": ""PMID:38106765"", ""snippet"": ""An elective tracheostomy is recommended for the patient to maintain an open airway"", ""supports"": ""SUPPORT""}], ""name"": ""Airway Protection (Tracheostomy or Secured Airway)"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tracheostomy"", ""term"": {""id"": ""NCIT:C50458"", ""label"": ""Tracheostomy""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.																																																								"{""description"": ""Empiric IV antibiotics targeting polymicrobial oral flora."", ""name"": ""Broad-Spectrum Intravenous Antibiotics""}"	{}	"{""description"": ""Empiric IV antibiotics targeting polymicrobial oral flora."", ""evidence"": [{""explanation"": ""Identifies broad-spectrum antibiotics as core therapy."", ""reference"": ""PMID:33383265"", ""snippet"": ""Broad spectrum antibiotics and surgical source control are keys in treating the infection."", ""supports"": ""SUPPORT""}, {""explanation"": ""Culture series shows penicillin-sensitive streptococci predominate and empiric aminoglycosides add little benefit."", ""reference"": ""PMID:36738888"", ""snippet"": ""Ninety-two percent (n=57/62) of the streptococci cultured were sensitive to penicillin. The addition of aminoglycosides to the study sample would not have made a statistically significant difference (p=0.1556)."", ""supports"": ""SUPPORT""}], ""name"": ""Broad-Spectrum Intravenous Antibiotics"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.																																																								"{""description"": ""Drain involved spaces and extract offending tooth to halt infection spread."", ""name"": ""Surgical Drainage and Odontogenic Source Control""}"	{}	"{""description"": ""Drain involved spaces and extract offending tooth to halt infection spread."", ""evidence"": [{""explanation"": ""Shows surgical drainage with tooth extraction as effective source control."", ""reference"": ""PMID:39296495"", ""snippet"": ""immediate surgical decompression leading to pus drainage, removal of the offending tooth... and administration of empirical antibiotics"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Drainage and Odontogenic Source Control"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""drainage procedure"", ""term"": {""id"": ""NCIT:C15286"", ""label"": ""Drainage Procedure""}}}, {""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tooth extraction"", ""term"": {""id"": ""NCIT:C5189"", ""label"": ""Tooth Extraction""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4518	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	0	Chemotherapy	Systemic chemotherapy, particularly for small cell lung cancer.																																																								"{""description"": ""Systemic chemotherapy, particularly for small cell lung cancer."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Systemic chemotherapy, particularly for small cell lung cancer."", ""evidence"": [{""explanation"": ""The abstract states that small cell lung cancer is usually treated with chemotherapy."", ""reference"": ""PMID:19445746"", ""snippet"": ""Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4519	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	1	Surgical Resection	Surgical removal of localized non-small cell lung carcinoma.																																																								"{""description"": ""Surgical removal of localized non-small cell lung carcinoma."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgical removal of localized non-small cell lung carcinoma."", ""evidence"": [{""explanation"": ""The abstract notes surgery as initial treatment for adenocarcinoma."", ""reference"": ""PMID:19445746"", ""snippet"": ""Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4555	191	Lyme Disease	Lyme_Disease.yaml	treatments	0	Oral Doxycycline	"First-line treatment for early localized and early disseminated Lyme disease in adults. Typical dose is 100mg twice daily for 10-21 days. Also provides prophylaxis for tick bites in endemic areas.
"																																																								"{""description"": ""First-line treatment for early localized and early disseminated Lyme disease in adults. Typical dose is 100mg twice daily for 10-21 days. Also provides prophylaxis for tick bites in endemic areas.\n"", ""name"": ""Oral Doxycycline""}"	{}	"{""description"": ""First-line treatment for early localized and early disseminated Lyme disease in adults. Typical dose is 100mg twice daily for 10-21 days. Also provides prophylaxis for tick bites in endemic areas.\n"", ""evidence"": [{""explanation"": ""IDSA guidelines provide evidence-based antibiotic treatment recommendations for Lyme disease."", ""reference"": ""PMID:17029130"", ""snippet"": ""Tables list the doses and durations of antimicrobial therapy recommended for treatment and prevention of Lyme disease"", ""supports"": ""SUPPORT""}], ""name"": ""Oral Doxycycline"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4556	191	Lyme Disease	Lyme_Disease.yaml	treatments	1	Oral Amoxicillin	"Alternative first-line agent for early Lyme disease, preferred in children under 8 years and pregnant women. Typical dose is 500mg three times daily.
"																																																								"{""description"": ""Alternative first-line agent for early Lyme disease, preferred in children under 8 years and pregnant women. Typical dose is 500mg three times daily.\n"", ""name"": ""Oral Amoxicillin""}"	{}	"{""description"": ""Alternative first-line agent for early Lyme disease, preferred in children under 8 years and pregnant women. Typical dose is 500mg three times daily.\n"", ""evidence"": [{""explanation"": ""Case report in pregnancy shows successful treatment with amoxicillin."", ""reference"": ""PMID:17176487"", ""snippet"": ""We describe a favorable outcome in a 42-year-old woman who developed Lyme disease in the third trimester and was treated with a full course of oral amoxicillin."", ""supports"": ""SUPPORT""}], ""name"": ""Oral Amoxicillin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4557	191	Lyme Disease	Lyme_Disease.yaml	treatments	2	Intravenous Ceftriaxone	"Recommended for neurological Lyme disease (neuroborreliosis), Lyme carditis with high-degree AV block, and some cases of Lyme arthritis. Duration typically 14-28 days.
"																																																								"{""description"": ""Recommended for neurological Lyme disease (neuroborreliosis), Lyme carditis with high-degree AV block, and some cases of Lyme arthritis. Duration typically 14-28 days.\n"", ""name"": ""Intravenous Ceftriaxone""}"	{}	"{""description"": ""Recommended for neurological Lyme disease (neuroborreliosis), Lyme carditis with high-degree AV block, and some cases of Lyme arthritis. Duration typically 14-28 days.\n"", ""evidence"": [{""explanation"": ""Neuroborreliosis case improved with intravenous ceftriaxone then doxycycline."", ""reference"": ""PMID:37692616"", ""snippet"": ""The patient's symptoms resolved quickly with a four-day inpatient course of IV ceftriaxone followed by 10 days of oral doxycycline."", ""supports"": ""SUPPORT""}], ""name"": ""Intravenous Ceftriaxone"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4567	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	treatments	0	Mass drug administration with albendazole plus ivermectin or DEC	WHO-recommended antifilarial drug combinations used to interrupt transmission.																																																								"{""description"": ""WHO-recommended antifilarial drug combinations used to interrupt transmission."", ""name"": ""Mass drug administration with albendazole plus ivermectin or DEC""}"	{}	"{""description"": ""WHO-recommended antifilarial drug combinations used to interrupt transmission."", ""evidence"": [{""explanation"": ""The abstract summarizes WHO-recommended antifilarial combinations for MDA."", ""reference"": ""PMID:38933431"", ""snippet"": ""the World Health Organization recommended treatments for lymphatic filariasis include the use of Albendazole (400mg) twice per year in co-endemic areas with loa loa, Ivermectin (200mcg/kg) in combination with Albendazole (400mg) in areas that are co-endemic with onchocerciasis, ivermectin (200mcg/kg) with diethylcarbamazine citrate (DEC) (6mg/kg) and albendazole (400mg) in areas without onchocerciasis."", ""supports"": ""SUPPORT""}], ""name"": ""Mass drug administration with albendazole plus ivermectin or DEC"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4577	193	Lymphoma	Lymphoma.yaml	treatments	0	Chemotherapy	Systemic chemotherapy regimens tailored to lymphoma subtype.																																																								"{""description"": ""Systemic chemotherapy regimens tailored to lymphoma subtype."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Systemic chemotherapy regimens tailored to lymphoma subtype."", ""evidence"": [{""explanation"": ""The abstract notes chemotherapy regimens as treatment for lymphoma subtypes."", ""reference"": ""PMID:31894937"", ""snippet"": ""Chemotherapy treatment plans differ between the main subtypes of lymphoma. Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP), bendamustine, and lenalidomide."", ""supports"": ""SUPPORT""}], ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4578	193	Lymphoma	Lymphoma.yaml	treatments	1	Radiation Therapy	Radiotherapy combined with chemotherapy for selected lymphoma subtypes.																																																								"{""description"": ""Radiotherapy combined with chemotherapy for selected lymphoma subtypes."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Radiotherapy combined with chemotherapy for selected lymphoma subtypes."", ""evidence"": [{""explanation"": ""The abstract states Hodgkin lymphoma treatment includes radiotherapy with chemotherapy."", ""reference"": ""PMID:31894937"", ""snippet"": ""Hodgkin lymphoma is treated with combined chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), Stanford V (a chemotherapy regimen consisting of mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone), or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) with radiotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
4609	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	0	Increased Cancer Surveillance	Regular colonoscopies, endometrial biopsies, and other screening tests to detect cancers early.																																																								"{""description"": ""Regular colonoscopies, endometrial biopsies, and other screening tests to detect cancers early."", ""name"": ""Increased Cancer Surveillance""}"	{}	"{""description"": ""Regular colonoscopies, endometrial biopsies, and other screening tests to detect cancers early."", ""evidence"": [{""explanation"": ""Regular colonoscopies are highlighted as a beneficial screening strategy for Lynch Syndrome."", ""reference"": ""PMID:23176623"", ""snippet"": ""Some periodic screening strategies, such as colonoscopy, reduce the incidence and mortality of Lynch syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study emphasizes the importance of regular colonoscopy surveillance for those with Lynch syndrome."", ""reference"": ""PMID:31629885"", ""snippet"": ""...offering the FDRs with Lynch syndrome biennial colonoscopy surveillance was cost-effective..."", ""supports"": ""SUPPORT""}, {""explanation"": ""Endoscopies like EGD are implemented for cancer surveillance in LS patients, corroborating the need for ongoing screening tests."", ""reference"": ""PMID:34698909"", ""snippet"": ""Lynch syndrome (LS) is the most common cause of hereditary colorectal cancer and is associated with an increased lifetime risk of gastric and duodenal cancers of 8-16% and 7%, respectively; therefore, we aim to describe an esophagogastroduodenoscopy (EGD) surveillance program..."", ""supports"": ""SUPPORT""}, {""explanation"": ""Universal tumor screening further illustrates the importance of regular and early cancer detection methods for Lynch Syndrome patients."", ""reference"": ""PMID:32875945"", ""snippet"": ""Universal tumor screening is a strategy to identify high-risk individuals by testing all CRC tumors for molecular features suggestive of Lynch Syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""Endometrial biopsies and other screening tests are discussed in the context of Lynch Syndrome, supporting the statement."", ""reference"": ""PMID:27241104"", ""snippet"": ""This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers..."", ""supports"": ""SUPPORT""}], ""name"": ""Increased Cancer Surveillance""}"
4610	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	1	Prophylactic Surgery	Preventive removal of the colon, uterus, or ovaries may be considered in some cases.																																																								"{""description"": ""Preventive removal of the colon, uterus, or ovaries may be considered in some cases."", ""name"": ""Prophylactic Surgery""}"	{}	"{""description"": ""Preventive removal of the colon, uterus, or ovaries may be considered in some cases."", ""evidence"": [{""explanation"": ""The literature mentions counseling carriers about colectomy and prophylactic hysterectomy with bilateral oophorectomy, supporting that preventive removal of the colon, uterus, or ovaries may be considered."", ""reference"": ""PMID:21287222"", ""snippet"": ""Patients who are gene mutation carriers should receive counseling about colectomy, and if women, prophylactic hysterectomy and bilateral oophorectomy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates that prophylactic hysterectomy with bilateral salpingo-oophorectomy is a preventive measure undertaken in Lynch syndrome patients."", ""reference"": ""PMID:24495259"", ""snippet"": ""Prophylactic hysterectomy with bilateral salpingo-oophorectomy is being increasingly undertaken in patients with Lynch syndrome (LS)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature outlines the significant risk of gynecologic cancers in women with Lynch syndrome, supporting the consideration of prophylactic surgery."", ""reference"": ""PMID:31554630"", ""snippet"": ""for women with Lynch syndrome, the risks for gynecologic cancers pose an equal or greater risk than colorectal cancer."", ""supports"": ""SUPPORT""}, {""explanation"": ""The discussion of screening tests implies the consideration of proactive measures, including prophylactic surgery, in managing the elevated cancer risks in Lynch syndrome."", ""reference"": ""PMID:27241104"", ""snippet"": ""This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers."", ""supports"": ""SUPPORT""}], ""name"": ""Prophylactic Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.																																																								"{""description"": ""Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients."", ""name"": ""Chemoprevention""}"	{}	"{""description"": ""Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients."", ""evidence"": [{""explanation"": ""This study affirms that aspirin and other NSAIDs have been linked to a reduced risk of colorectal cancer in Lynch syndrome patients."", ""reference"": ""PMID:35328014"", ""snippet"": ""Nonsteroidal anti-inflammatory drugs and, in particular, aspirin use, has been associated with reduced CRC risk in several studies..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates a potential for NSAIDs in cancer prevention, including colorectal cancer, but notes that unresolved questions about safety and efficacy limit clinical application."", ""reference"": ""PMID:11854387"", ""snippet"": ""Numerous experimental, epidemiologic, and clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the highly selective cyclooxygenase (COX)-2 inhibitors, have promise as anticancer agents..."", ""supports"": ""PARTIAL""}, {""explanation"": ""This study supports the role of aspirin in cancer prevention, including colorectal cancer, though mentions variable effects depending on the tissue and disease context."", ""reference"": ""PMID:36202092"", ""snippet"": ""...multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study notes the history and research supporting chemoprevention, including with NSAIDs, for hereditary colorectal cancer syndromes like Lynch syndrome."", ""reference"": ""PMID:34798982"", ""snippet"": ""Secondary prevention of colorectal neoplasia with chemoprevention is long-studied area of research and clinical use in patients with the 2 most common hereditary colorectal cancer syndromes including Lynch syndrome and familial adenomatous polyposis"", ""supports"": ""SUPPORT""}], ""name"": ""Chemoprevention"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acetylsalicylic acid"", ""term"": {""id"": ""CHEBI:15365"", ""label"": ""acetylsalicylic acid""}}]}}"
4612	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	3	Targeted Therapies	Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers.																																																								"{""description"": ""Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers."", ""name"": ""Targeted Therapies""}"	{}	"{""description"": ""Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers."", ""evidence"": [{""explanation"": ""This study demonstrates the efficacy of PD-1 inhibitors, a type of immune checkpoint inhibitor, for treating Lynch syndrome (LS) patients with colorectal cancers characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H)."", ""reference"": ""PMID:37625240"", ""snippet"": ""PD-1 inhibitors are highly effective for dMMR and MSI-H LS CRCs, but not for pMMR or MSS LS CRCs or mucinous/signet-ring cell CRC."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""This study indicates that immunotherapies, specifically FSP neoantigen vaccines, can be effective in reducing the tumor burden and improving survival in Lynch syndrome mouse models."", ""reference"": ""PMID:34224739"", ""snippet"": ""We identified 4 shared FSP neoantigens ... Using VCMsh2 mice, which have a conditional knockout of Msh2 in the intestinal tract and develop intestinal cancer, we showed vaccination with a combination of only 4 FSPs significantly increased FSP-specific adaptive immunity, reduced intestinal tumor burden, and prolonged overall survival."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses ongoing research into immunotherapies for MSI cancers, including those associated with Lynch syndrome."", ""reference"": ""PMID:30027543"", ""snippet"": ""Immunotherapies are an active field of research for MSI cancers and their potential use for cancer therapy for both sporadic and LS MSI cancers is discussed."", ""supports"": ""SUPPORT""}, {""explanation"": ""While ICB is effective for treating dMMR tumors in Lynch syndrome patients, it does not eliminate the risk of new neoplasia development, highlighting the need for continued surveillance."", ""reference"": ""PMID:37845474"", ""snippet"": ""Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB)."", ""supports"": ""PARTIAL""}], ""name"": ""Targeted Therapies"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4623	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	0	Avoidance of fasting	"Frequent feeding and avoidance of prolonged fasting is the cornerstone of management. Infants should not fast more than 4-6 hours; older children can tolerate longer intervals.
"																																																								"{""description"": ""Frequent feeding and avoidance of prolonged fasting is the cornerstone of management. Infants should not fast more than 4-6 hours; older children can tolerate longer intervals.\n"", ""name"": ""Avoidance of fasting""}"	{}	"{""description"": ""Frequent feeding and avoidance of prolonged fasting is the cornerstone of management. Infants should not fast more than 4-6 hours; older children can tolerate longer intervals.\n"", ""name"": ""Avoidance of fasting"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
4624	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	1	Emergency glucose administration	"During illness or metabolic stress, intravenous glucose (10% dextrose) should be administered promptly to prevent hypoglycemia.
"																																																								"{""description"": ""During illness or metabolic stress, intravenous glucose (10% dextrose) should be administered promptly to prevent hypoglycemia.\n"", ""name"": ""Emergency glucose administration""}"	{}	"{""description"": ""During illness or metabolic stress, intravenous glucose (10% dextrose) should be administered promptly to prevent hypoglycemia.\n"", ""name"": ""Emergency glucose administration"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4625	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	2	L-carnitine supplementation	"Carnitine supplementation may be used in some patients to enhance excretion of accumulated acylcarnitines, though its routine use is debated.
"																																																								"{""description"": ""Carnitine supplementation may be used in some patients to enhance excretion of accumulated acylcarnitines, though its routine use is debated.\n"", ""name"": ""L-carnitine supplementation""}"	{}	"{""description"": ""Carnitine supplementation may be used in some patients to enhance excretion of accumulated acylcarnitines, though its routine use is debated.\n"", ""name"": ""L-carnitine supplementation"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
4626	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	3	Dietary modification	"Some patients benefit from a diet emphasizing complex carbohydrates and limiting medium-chain triglycerides.
"																																																								"{""description"": ""Some patients benefit from a diet emphasizing complex carbohydrates and limiting medium-chain triglycerides.\n"", ""name"": ""Dietary modification""}"	{}	"{""description"": ""Some patients benefit from a diet emphasizing complex carbohydrates and limiting medium-chain triglycerides.\n"", ""name"": ""Dietary modification"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
4641	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	0	Capmatinib	Selective MET inhibitor approved for METex14 NSCLC based on GEOMETRY mono-1 trial. Active in both treatment-naive and previously treated patients. Demonstrated intracranial activity.																																																								"{""description"": ""Selective MET inhibitor approved for METex14 NSCLC based on GEOMETRY mono-1 trial. Active in both treatment-naive and previously treated patients. Demonstrated intracranial activity."", ""name"": ""Capmatinib""}"	{}	"{""description"": ""Selective MET inhibitor approved for METex14 NSCLC based on GEOMETRY mono-1 trial. Active in both treatment-naive and previously treated patients. Demonstrated intracranial activity."", ""name"": ""Capmatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4642	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	1	Tepotinib	Selective MET inhibitor approved for METex14 NSCLC based on VISION trial. Once-daily dosing. Shown activity in CNS metastases.																																																								"{""description"": ""Selective MET inhibitor approved for METex14 NSCLC based on VISION trial. Once-daily dosing. Shown activity in CNS metastases."", ""name"": ""Tepotinib""}"	{}	"{""description"": ""Selective MET inhibitor approved for METex14 NSCLC based on VISION trial. Once-daily dosing. Shown activity in CNS metastases."", ""name"": ""Tepotinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4643	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	2	Crizotinib	Multi-kinase inhibitor (ALK/ROS1/MET) with activity against METex14. Less potent and selective than capmatinib/tepotinib but may be used off-label where specific MET inhibitors unavailable.																																																								"{""description"": ""Multi-kinase inhibitor (ALK/ROS1/MET) with activity against METex14. Less potent and selective than capmatinib/tepotinib but may be used off-label where specific MET inhibitors unavailable."", ""name"": ""Crizotinib""}"	{}	"{""description"": ""Multi-kinase inhibitor (ALK/ROS1/MET) with activity against METex14. Less potent and selective than capmatinib/tepotinib but may be used off-label where specific MET inhibitors unavailable."", ""name"": ""Crizotinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4644	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for METex14 NSCLC, though response rates appear lower than in smoking-associated NSCLC. Often used after MET inhibitor progression.																																																								"{""description"": ""Checkpoint inhibitors may be used for METex14 NSCLC, though response rates appear lower than in smoking-associated NSCLC. Often used after MET inhibitor progression."", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""Checkpoint inhibitors may be used for METex14 NSCLC, though response rates appear lower than in smoking-associated NSCLC. Often used after MET inhibitor progression."", ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4645	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy used at progression or in combination with immunotherapy. Standard option when targeted therapy fails.																																																								"{""description"": ""Platinum-based chemotherapy used at progression or in combination with immunotherapy. Standard option when targeted therapy fails."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy used at progression or in combination with immunotherapy. Standard option when targeted therapy fails."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4668	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	0	Pembrolizumab	Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival compared to chemotherapy with durable responses in a subset of patients.																																																								"{""description"": ""Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival compared to chemotherapy with durable responses in a subset of patients."", ""name"": ""Pembrolizumab""}"	{}	"{""description"": ""Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival compared to chemotherapy with durable responses in a subset of patients."", ""evidence"": [{""explanation"": ""KEYNOTE-177 abstract reports improved progression-free survival with first-line pembrolizumab versus chemotherapy."", ""reference"": ""PMID:33264544"", ""snippet"": ""Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer"", ""supports"": ""SUPPORT""}], ""name"": ""Pembrolizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4669	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	1	Nivolumab plus Ipilimumab	Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and durable disease control with combined checkpoint inhibition.																																																								"{""description"": ""Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and durable disease control with combined checkpoint inhibition."", ""name"": ""Nivolumab plus Ipilimumab""}"	{}	"{""description"": ""Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and durable disease control with combined checkpoint inhibition."", ""evidence"": [{""explanation"": ""CheckMate-142 trial demonstrated high objective response rate (55%) and disease control rate (80%) with nivolumab plus ipilimumab in dMMR/MSI-H mCRC."", ""reference"": ""PMID:29355075"", ""snippet"": ""investigator-assessed ORR was 55% (95% CI, 45.2 to 63.8), and disease control rate for  12 weeks was 80%"", ""supports"": ""SUPPORT""}], ""name"": ""Nivolumab plus Ipilimumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4670	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	2	Dostarlimab	Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer, allowing organ preservation without surgery or radiation.																																																								"{""description"": ""Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer, allowing organ preservation without surgery or radiation."", ""name"": ""Dostarlimab""}"	{}	"{""description"": ""Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer, allowing organ preservation without surgery or radiation."", ""evidence"": [{""explanation"": ""Phase 2 study showed 100% clinical complete response rate with dostarlimab monotherapy in mismatch repair-deficient locally advanced rectal cancer."", ""reference"": ""PMID:35660797"", ""snippet"": ""All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy."", ""supports"": ""SUPPORT""}], ""name"": ""Dostarlimab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4671	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	3	Surgical Resection	Surgery remains the primary curative treatment for localized MSI-H colorectal cancer. Patients with Lynch syndrome may benefit from extended colectomy due to risk of metachronous tumors.																																																								"{""description"": ""Surgery remains the primary curative treatment for localized MSI-H colorectal cancer. Patients with Lynch syndrome may benefit from extended colectomy due to risk of metachronous tumors."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgery remains the primary curative treatment for localized MSI-H colorectal cancer. Patients with Lynch syndrome may benefit from extended colectomy due to risk of metachronous tumors."", ""evidence"": [{""explanation"": ""The study confirms surgical resection is standard treatment for locally advanced rectal cancer, supporting the role of surgery in MSI-H CRC."", ""reference"": ""PMID:35660797"", ""snippet"": ""Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.																																																								"{""description"": ""Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses."", ""name"": ""Pembrolizumab Plus Lenvatinib""}"	{}	"{""description"": ""Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses."", ""evidence"": [{""explanation"": ""KEYNOTE-775 demonstrated significant PFS and OS benefit with lenvatinib plus pembrolizumab versus chemotherapy in advanced endometrial cancer."", ""reference"": ""PMID:35045221"", ""snippet"": ""Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer."", ""supports"": ""SUPPORT""}], ""name"": ""Pembrolizumab Plus Lenvatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}}"
4688	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	1	Pembrolizumab Monotherapy	PD-1 inhibitor pembrolizumab has tumor-agnostic approval for MSI-H/dMMR cancers. Highly effective in MSI-H endometrial cancer with significant response rates and durable remissions.																																																								"{""description"": ""PD-1 inhibitor pembrolizumab has tumor-agnostic approval for MSI-H/dMMR cancers. Highly effective in MSI-H endometrial cancer with significant response rates and durable remissions."", ""name"": ""Pembrolizumab Monotherapy""}"	{}	"{""description"": ""PD-1 inhibitor pembrolizumab has tumor-agnostic approval for MSI-H/dMMR cancers. Highly effective in MSI-H endometrial cancer with significant response rates and durable remissions."", ""evidence"": [{""explanation"": ""KEYNOTE-158 abstract reports response rate for pembrolizumab in MSI-H/dMMR endometrial cancer."", ""reference"": ""PMID:34990208"", ""snippet"": ""The objective response rate was 48% (95% CI, 37 to 60)"", ""supports"": ""SUPPORT""}], ""name"": ""Pembrolizumab Monotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4689	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	2	Dostarlimab	PD-1 inhibitor approved for dMMR recurrent or advanced endometrial cancer. Another effective immunotherapy option for MSI-H tumors.																																																								"{""description"": ""PD-1 inhibitor approved for dMMR recurrent or advanced endometrial cancer. Another effective immunotherapy option for MSI-H tumors."", ""name"": ""Dostarlimab""}"	{}	"{""description"": ""PD-1 inhibitor approved for dMMR recurrent or advanced endometrial cancer. Another effective immunotherapy option for MSI-H tumors."", ""evidence"": [{""explanation"": ""GARNET trial demonstrated 43.5% objective response rate with dostarlimab in dMMR/MSI-H endometrial cancer."", ""reference"": ""PMID:35064011"", ""snippet"": ""In cohort A1, ORR was 43.5% (95% CI 34.0% to 53.4%) with 11 complete responses and 36 partial responses."", ""supports"": ""SUPPORT""}], ""name"": ""Dostarlimab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4690	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	3	Hysterectomy	Total hysterectomy with bilateral salpingo-oophorectomy is standard surgical treatment for localized endometrial cancer regardless of MSI status.																																																								"{""description"": ""Total hysterectomy with bilateral salpingo-oophorectomy is standard surgical treatment for localized endometrial cancer regardless of MSI status."", ""name"": ""Hysterectomy""}"	{}	"{""description"": ""Total hysterectomy with bilateral salpingo-oophorectomy is standard surgical treatment for localized endometrial cancer regardless of MSI status."", ""evidence"": [{""explanation"": ""While the study focuses on advanced disease after chemotherapy failure, it implies surgery (hysterectomy) and platinum chemotherapy are standard initial therapies."", ""reference"": ""PMID:35045221"", ""snippet"": ""Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear."", ""supports"": ""SUPPORT""}], ""name"": ""Hysterectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4719	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	0	Selective Serotonin Reuptake Inhibitors (SSRIs)	First-line pharmacotherapy (sertraline, escitalopram, fluoxetine).																																																								"{""description"": ""First-line pharmacotherapy (sertraline, escitalopram, fluoxetine)."", ""name"": ""Selective Serotonin Reuptake Inhibitors (SSRIs)""}"	{}	"{""description"": ""First-line pharmacotherapy (sertraline, escitalopram, fluoxetine)."", ""evidence"": [{""explanation"": ""This confirms the clinical use of monoamine antidepressants while acknowledging their limitations in terms of delayed benefit and incomplete remission."", ""reference"": ""PMID:39150594"", ""snippet"": ""MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates."", ""supports"": ""SUPPORT""}], ""name"": ""Selective Serotonin Reuptake Inhibitors (SSRIs)""}"
4720	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	1	Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)	Venlafaxine, duloxetine for depression with pain or fatigue.																																																								"{""description"": ""Venlafaxine, duloxetine for depression with pain or fatigue."", ""name"": ""Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)""}"	{}	"{""description"": ""Venlafaxine, duloxetine for depression with pain or fatigue."", ""name"": ""Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)""}"
4721	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	2	Cognitive Behavioral Therapy	Evidence-based psychotherapy, comparable efficacy to medications.																																																								"{""description"": ""Evidence-based psychotherapy, comparable efficacy to medications."", ""name"": ""Cognitive Behavioral Therapy""}"	{}	"{""description"": ""Evidence-based psychotherapy, comparable efficacy to medications."", ""name"": ""Cognitive Behavioral Therapy""}"
4722	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	3	Electroconvulsive Therapy	Most effective treatment for severe or treatment-resistant depression.																																																								"{""description"": ""Most effective treatment for severe or treatment-resistant depression."", ""name"": ""Electroconvulsive Therapy""}"	{}	"{""description"": ""Most effective treatment for severe or treatment-resistant depression."", ""name"": ""Electroconvulsive Therapy""}"
4723	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	4	Ketamine/Esketamine	Rapid-acting treatment for treatment-resistant depression.																																																								"{""description"": ""Rapid-acting treatment for treatment-resistant depression."", ""name"": ""Ketamine/Esketamine""}"	{}	"{""description"": ""Rapid-acting treatment for treatment-resistant depression."", ""evidence"": [{""explanation"": ""This confirms FDA approval of esketamine for treatment-resistant depression and acute suicidal ideation/behavior in MDD."", ""reference"": ""PMID:39150594"", ""snippet"": ""Nasal administration of esketamine (Spravato) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior."", ""supports"": ""SUPPORT""}, {""explanation"": ""This explains the mechanistic basis for ketamine's rapid-acting antidepressant effects through NMDA receptor antagonism and glutamate modulation."", ""reference"": ""PMID:39150594"", ""snippet"": ""Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-D-aspartate (NMDA)-targeted therapies have been investigated."", ""supports"": ""SUPPORT""}, {""explanation"": ""This documents the approval of another glutamatergic modulator for MDD treatment, expanding treatment options beyond esketamine."", ""reference"": ""PMID:39150594"", ""snippet"": ""Oral combination dextromethorphan-bupropion (AXS-05, Auvelity extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults."", ""supports"": ""SUPPORT""}], ""name"": ""Ketamine/Esketamine""}"
4724	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	5	Transcranial Magnetic Stimulation	Non-invasive neuromodulation for treatment-resistant depression.																																																								"{""description"": ""Non-invasive neuromodulation for treatment-resistant depression."", ""name"": ""Transcranial Magnetic Stimulation""}"	{}	"{""description"": ""Non-invasive neuromodulation for treatment-resistant depression."", ""name"": ""Transcranial Magnetic Stimulation""}"
4725	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	treatments	6	Behavioral Activation	Increasing engagement in rewarding activities.																																																								"{""description"": ""Increasing engagement in rewarding activities."", ""name"": ""Behavioral Activation""}"	{}	"{""description"": ""Increasing engagement in rewarding activities."", ""name"": ""Behavioral Activation""}"
4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.																																																								"{""description"": ""First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone."", ""name"": ""Platinum-Based Chemotherapy""}"	{}	"{""description"": ""First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone."", ""name"": ""Platinum-Based Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}, {""preferred_term"": ""pemetrexed"", ""term"": {""id"": ""CHEBI:63616"", ""label"": ""pemetrexed""}}]}}"
4746	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	1	Immune Checkpoint Inhibition	Nivolumab plus ipilimumab is approved for unresectable pleural mesothelioma based on the CheckMate 743 trial, which showed improved overall survival compared to chemotherapy. Response rates are highest in non-epithelioid subtypes.																																																								"{""description"": ""Nivolumab plus ipilimumab is approved for unresectable pleural mesothelioma based on the CheckMate 743 trial, which showed improved overall survival compared to chemotherapy. Response rates are highest in non-epithelioid subtypes."", ""name"": ""Immune Checkpoint Inhibition""}"	{}	"{""description"": ""Nivolumab plus ipilimumab is approved for unresectable pleural mesothelioma based on the CheckMate 743 trial, which showed improved overall survival compared to chemotherapy. Response rates are highest in non-epithelioid subtypes."", ""name"": ""Immune Checkpoint Inhibition"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4747	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	2	Surgical Resection	Extended pleurectomy/decortication (EPD) or extrapleural pneumonectomy (EPP) may be considered in select patients with early-stage epithelioid disease. Complete cytoreduction is rarely achievable due to diffuse growth pattern.																																																								"{""description"": ""Extended pleurectomy/decortication (EPD) or extrapleural pneumonectomy (EPP) may be considered in select patients with early-stage epithelioid disease. Complete cytoreduction is rarely achievable due to diffuse growth pattern."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Extended pleurectomy/decortication (EPD) or extrapleural pneumonectomy (EPP) may be considered in select patients with early-stage epithelioid disease. Complete cytoreduction is rarely achievable due to diffuse growth pattern."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4748	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	3	Radiation Therapy	Used for palliation of pain and prevention of tumor seeding at intervention sites. Intensity-modulated radiation therapy (IMRT) may be used as adjuvant therapy after surgery in multimodality treatment approaches.																																																								"{""description"": ""Used for palliation of pain and prevention of tumor seeding at intervention sites. Intensity-modulated radiation therapy (IMRT) may be used as adjuvant therapy after surgery in multimodality treatment approaches."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Used for palliation of pain and prevention of tumor seeding at intervention sites. Intensity-modulated radiation therapy (IMRT) may be used as adjuvant therapy after surgery in multimodality treatment approaches."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
4772	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	0	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.																																																								"{""description"": ""First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance."", ""name"": ""Ibrutinib""}"	{}	"{""description"": ""First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance."", ""name"": ""Ibrutinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}]}}"
4773	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.																																																								"{""description"": ""Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib."", ""name"": ""Acalabrutinib""}"	{}	"{""description"": ""Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib."", ""name"": ""Acalabrutinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}]}}"
4774	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	2	Intensive Chemotherapy with ASCT	For younger, fit patients, intensive induction regimens (R-DHAP, R-HyperCVAD) followed by high-dose therapy and autologous stem cell transplant consolidation achieves prolonged remissions. Standard approach for transplant-eligible patients.																																																								"{""description"": ""For younger, fit patients, intensive induction regimens (R-DHAP, R-HyperCVAD) followed by high-dose therapy and autologous stem cell transplant consolidation achieves prolonged remissions. Standard approach for transplant-eligible patients."", ""name"": ""Intensive Chemotherapy with ASCT""}"	{}	"{""description"": ""For younger, fit patients, intensive induction regimens (R-DHAP, R-HyperCVAD) followed by high-dose therapy and autologous stem cell transplant consolidation achieves prolonged remissions. Standard approach for transplant-eligible patients."", ""name"": ""Intensive Chemotherapy with ASCT"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4775	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	3	Bendamustine-Rituximab	Effective frontline regimen for older or transplant-ineligible patients. Achieves high response rates with manageable toxicity.																																																								"{""description"": ""Effective frontline regimen for older or transplant-ineligible patients. Achieves high response rates with manageable toxicity."", ""name"": ""Bendamustine-Rituximab""}"	{}	"{""description"": ""Effective frontline regimen for older or transplant-ineligible patients. Achieves high response rates with manageable toxicity."", ""name"": ""Bendamustine-Rituximab"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4776	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	4	CAR-T Cell Therapy	CD19-directed CAR-T cells (brexucabtagene autoleucel) approved for relapsed/refractory MCL after BTK inhibitor failure. Achieves durable remissions in heavily pretreated patients.																																																								"{""description"": ""CD19-directed CAR-T cells (brexucabtagene autoleucel) approved for relapsed/refractory MCL after BTK inhibitor failure. Achieves durable remissions in heavily pretreated patients."", ""name"": ""CAR-T Cell Therapy""}"	{}	"{""description"": ""CD19-directed CAR-T cells (brexucabtagene autoleucel) approved for relapsed/refractory MCL after BTK inhibitor failure. Achieves durable remissions in heavily pretreated patients."", ""name"": ""CAR-T Cell Therapy"", ""treatment_term"": {""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}}"
4777	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	5	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.																																																								"{""description"": ""BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens."", ""name"": ""Venetoclax""}"	{}	"{""description"": ""BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens."", ""name"": ""Venetoclax"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}}"
4810	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	0	BCAA-Restricted Diet	Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment.																																																								"{""description"": ""Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment."", ""name"": ""BCAA-Restricted Diet""}"	{}	"{""description"": ""Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment."", ""evidence"": [{""explanation"": ""Confirms lifelong dietary treatment is the current standard of care but has limitations."", ""reference"": ""PMID:35672312"", ""snippet"": ""Treatment for MSUD represents an unmet need because the current treatment with life-long low-protein diet is challenging to maintain, and despite treatment the risk of acute decompensations and neuropsychiatric symptoms remains."", ""supports"": ""SUPPORT""}], ""name"": ""BCAA-Restricted Diet"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
4811	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	1	Medical Formula	BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids.																																																								"{""description"": ""BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids."", ""name"": ""Medical Formula""}"	{}	"{""description"": ""BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids."", ""evidence"": [{""explanation"": ""Confirms BCAA-free amino acid mixtures are standard treatment."", ""reference"": ""PMID:35578286"", ""snippet"": ""Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture via oral or nasogastric administration routes."", ""supports"": ""SUPPORT""}], ""name"": ""Medical Formula"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
4812	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	2	Thiamine Supplementation	High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding.																																																								"{""description"": ""High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding."", ""name"": ""Thiamine Supplementation""}"	{}	"{""description"": ""High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding."", ""evidence"": [{""explanation"": ""Confirms thiamine supplementation is effective for patients with specific mutations."", ""reference"": ""PMID:27373929"", ""snippet"": ""Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction"", ""supports"": ""SUPPORT""}], ""name"": ""Thiamine Supplementation"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4813	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	3	Liver Transplantation	Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet.																																																								"{""description"": ""Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet."", ""evidence"": [{""explanation"": ""Demonstrates excellent outcomes with liver transplantation for MSUD."", ""reference"": ""PMID:21839471"", ""snippet"": ""Patient and graft survival were 100% at 4.5  2.2 years of follow-up. Liver function was normal in all patients. Branched-chain amino acid levels were corrected within hours after surgery and remained stable, with leucine tolerance increasing more than 10-fold."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms liver transplantation eliminates risk of acute metabolic crises."", ""reference"": ""PMID:23478409"", ""snippet"": ""Liver transplantation has emerged as an effective way to eliminate acute decompensation risk."", ""supports"": ""SUPPORT""}], ""name"": ""Liver Transplantation"", ""treatment_term"": {""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}}"
4814	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	4	Intravenous BCAA-Free Solution	IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible.																																																								"{""description"": ""IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible."", ""name"": ""Intravenous BCAA-Free Solution""}"	{}	"{""description"": ""IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible."", ""evidence"": [{""explanation"": ""Demonstrates safety and efficacy of IV BCAA-free solutions for acute decompensation."", ""reference"": ""PMID:35578286"", ""snippet"": ""The IV BCAA-free solution is safe and effective in normalising leucine concentrations during MSUD decompensation episodes in both children and adults"", ""supports"": ""SUPPORT""}], ""name"": ""Intravenous BCAA-Free Solution"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4815	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	5	Acute Crisis Management	IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises.																																																								"{""description"": ""IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises."", ""name"": ""Acute Crisis Management""}"	{}	"{""description"": ""IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises."", ""evidence"": [{""explanation"": ""Acute crisis management including anabolic support reduces mortality from metabolic decompensation."", ""reference"": ""PMID:23478409"", ""snippet"": ""Dietary management enables survival and reduces risk of acute crises."", ""supports"": ""SUPPORT""}], ""name"": ""Acute Crisis Management"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4816	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	6	Phenylbutyrate	BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity.																																																								"{""description"": ""BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity."", ""name"": ""Phenylbutyrate""}"	{}	"{""description"": ""BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity."", ""evidence"": [{""explanation"": ""Demonstrates phenylbutyrate activates BCKDH by inhibiting kinase-mediated inactivation."", ""reference"": ""PMID:21098507"", ""snippet"": ""In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1 subunit of the branched-chain -keto acid dehydrogenase complex (BCKDC)."", ""supports"": ""SUPPORT""}], ""name"": ""Phenylbutyrate"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4817	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	7	Metformin	Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models.																																																								"{""description"": ""Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models."", ""name"": ""Metformin""}"	{}	"{""description"": ""Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models."", ""evidence"": [{""explanation"": ""Preclinical evidence supports metformin as potential therapeutic strategy for MSUD."", ""reference"": ""PMID:27373929"", ""snippet"": ""Metformin-treatment significantly reduced levels of KIC in the muscle (by 69%) and serum (by 56%) isolated from iMSUD mice, and restored levels of mitochondrial metabolites"", ""supports"": ""SUPPORT""}], ""name"": ""Metformin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4852	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	0	Beta Blockers	Used to reduce stress on the aorta and prevent its enlargement.																																																								"{""description"": ""Used to reduce stress on the aorta and prevent its enlargement."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Used to reduce stress on the aorta and prevent its enlargement."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Beta-blockers are used to slow aortic enlargement, which indirectly reduces stress on the aorta. However, they do not prevent aortic enlargement entirely."", ""reference"": ""PMID:36939732"", ""snippet"": ""Beta-blockers remain the mainstay of therapy as they have proven to slow aortic enlargement. Angiotensin receptor blockers are a useful alternative and with proven benefit as an add-on therapy to limit aortic growth."", ""supports"": ""PARTIAL""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Beta-blockers are used to slow aortic growth and decrease hemodynamic stress, but they do not completely prevent aortic enlargement."", ""reference"": ""PMID:17845137"", ""snippet"": ""Traditional medical therapies, such as beta-adrenergic receptor blockade, are used to slow pathologic aortic growth and decrease the risk of aortic dissection by decreasing hemodynamic stress."", ""supports"": ""PARTIAL""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Beta-blockers are helpful in slowing the progression of aortic root dilatation, but they do not completely prevent it."", ""reference"": ""PMID:17376944"", ""snippet"": ""Medical treatment with beta-blockers is probably helpful in most children with aortic root dilatation."", ""supports"": ""PARTIAL""}], ""name"": ""Beta Blockers"", ""treatment_term"": {""description"": ""Treatment using medications that block beta-adrenergic receptors to reduce heart rate and blood pressure."", ""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}}"
4853	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	1	Angiotensin Receptor Blockers	ARBs such as losartan reduce aortic root growth by blocking angiotensin II type 1 receptor signaling and modulating TGF-beta pathways. Pediatric data show superior tolerability and efficacy compared to beta-blockers.																																																								"{""description"": ""ARBs such as losartan reduce aortic root growth by blocking angiotensin II type 1 receptor signaling and modulating TGF-beta pathways. Pediatric data show superior tolerability and efficacy compared to beta-blockers."", ""name"": ""Angiotensin Receptor Blockers""}"	{}	"{""description"": ""ARBs such as losartan reduce aortic root growth by blocking angiotensin II type 1 receptor signaling and modulating TGF-beta pathways. Pediatric data show superior tolerability and efficacy compared to beta-blockers."", ""name"": ""Angiotensin Receptor Blockers"", ""treatment_term"": {""description"": ""Treatment using medications such as losartan to modulate pathological signaling pathways."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4854	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	2	Aortic Surgery	Recommended for severe aortic dilation to prevent dissection.																																																								"{""description"": ""Recommended for severe aortic dilation to prevent dissection."", ""name"": ""Aortic Surgery""}"	{}	"{""description"": ""Recommended for severe aortic dilation to prevent dissection."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The literature mentions that prophylactic aortic root replacement is recommended to prevent severe aortic events such as dissections."", ""reference"": ""PMID:26586198"", ""snippet"": ""To prevent such catastrophic aortic events, a lower threshold has been recommended for prophylactic interventions on the aortic root."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study investigates predictors for referral for aortic surgery in patients with Marfan syndrome, indicating that surgery is recommended for severe aortic dilation."", ""reference"": ""PMID:29948025"", ""snippet"": ""Few data exist regarding predictors of rapid aortic root dilation and referral for aortic surgery in Marfan syndrome (MFS)."", ""supports"": ""SUPPORT""}], ""name"": ""Aortic Surgery"", ""treatment_term"": {""description"": ""Operative intervention to repair or replace damaged anatomical structures."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	Orthopedic Interventions	Treatments for scoliosis and other skeletal abnormalities.																																																								"{""description"": ""Treatments for scoliosis and other skeletal abnormalities."", ""name"": ""Orthopedic Interventions""}"	{}	"{""description"": ""Treatments for scoliosis and other skeletal abnormalities."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study discusses surgical treatment of scoliosis in Marfan syndrome and provides guidelines for successful outcomes through orthopedic interventions."", ""reference"": ""PMID:11961443"", ""snippet"": ""The authors recommend arthrodesing both the primary and secondary curves in all patients with Marfan syndrome."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review highlights the orthopedic aspects of Marfan syndrome, including treatments for scoliosis and other skeletal abnormalities."", ""reference"": ""PMID:11880731"", ""snippet"": ""The major orthopedic manifestations of Marfan syndrome include scoliosis, chest wall deformity, dural ectasia, joint hypermobility, and acetabular protrusion."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study investigates the genetic risk factors for severe scoliosis in Marfan syndrome, which is relevant to orthopedic interventions."", ""reference"": ""PMID:34916231"", ""snippet"": ""We elucidated the genetic risk factors for the development of severe scoliosis in patients with Marfan syndrome."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The article discusses common spinal deformities in Marfan syndrome and the complexities of surgical correction, supporting the statement on orthopedic interventions."", ""reference"": ""PMID:17945136"", ""snippet"": ""Kyphoscoliosis, spondylolisthesis, and atlantoaxial subluxation are common spinal deformities in Marfan syndrome... Surgical correction is associated with complications, such as failure of fixation and additional deformity; however good results are possible when consideration is given to the unique challenges presented by patients who have Marfan syndrome."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study covers the primary skeletal manifestations of Marfan syndrome, including scoliosis, which require orthopedic interventions."", ""reference"": ""PMID:26130954"", ""snippet"": ""Patients with Marfan syndrome (MFS) presents with primary skeletal manifestations such as tall stature, chest wall abnormality, and scoliosis."", ""supports"": ""SUPPORT""}], ""name"": ""Orthopedic Interventions"", ""treatment_term"": {""description"": ""Operative intervention to correct skeletal abnormalities such as scoliosis."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4856	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	4	Vision Correction	Management of ocular issues such as ectopia lentis with glasses or surgery.																																																								"{""description"": ""Management of ocular issues such as ectopia lentis with glasses or surgery."", ""name"": ""Vision Correction""}"	{}	"{""description"": ""Management of ocular issues such as ectopia lentis with glasses or surgery."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study discusses surgical management of ectopia lentis in Marfan syndrome patients, which supports the statement about managing ocular issues with surgery."", ""reference"": ""PMID:24698610"", ""snippet"": ""Anterior lensectomy and limited vitrectomy with aphakic correction is safe and provides a consistent visual outcome in patients with lens subluxation secondary to Marfan syndrome."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study highlights the use of surgical intervention for vision correction in Marfan syndrome patients with ectopia lentis."", ""reference"": ""PMID:23661206"", ""snippet"": ""The ocular features were ectopia lentis in 92.3% of the patients... The best corrected visual acuity in 4 out of 5 patients who had cataract extraction at 8 weeks post op. was 6/60 to 6/12."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study confirms the management of ectopia lentis (EL) in Marfan syndrome, indicating the necessity for vision correction, which can include glasses or surgery."", ""reference"": ""PMID:30260057"", ""snippet"": ""Our study indicates that even though EL typically occurs at an early stage in most MFS patients, there is still a risk of developing EL in adulthood."", ""supports"": ""SUPPORT""}], ""name"": ""Vision Correction"", ""treatment_term"": {""description"": ""Operative intervention to correct lens dislocation or other ocular abnormalities."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4866	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	0	Surgical Resection for Symptomatic Cases	All symptomatic Meckel diverticula should be surgically removed, typically with a segment of adjacent ileum.																																																								"{""description"": ""All symptomatic Meckel diverticula should be surgically removed, typically with a segment of adjacent ileum."", ""name"": ""Surgical Resection for Symptomatic Cases""}"	{}	"{""description"": ""All symptomatic Meckel diverticula should be surgically removed, typically with a segment of adjacent ileum."", ""evidence"": [{""explanation"": ""This provides guidance on surgical management of symptomatic Meckel diverticula."", ""reference"": ""PMID:8506491"", ""snippet"": ""All symptomatic and pathologic Meckel's diverticula should be removed with a segment of ileum."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms resection as the treatment for complicated cases."", ""reference"": ""PMID:31930430"", ""snippet"": ""Complicated Meckel's diverticulum is treated by resection."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resection for Symptomatic Cases"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4867	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	1	Incidental Diverticulectomy with Stapling Devices	For incidentally discovered Meckel diverticula during surgery, removal using stapling devices is reasonable if the diverticulum easily fits in the device.																																																								"{""description"": ""For incidentally discovered Meckel diverticula during surgery, removal using stapling devices is reasonable if the diverticulum easily fits in the device."", ""name"": ""Incidental Diverticulectomy with Stapling Devices""}"	{}	"{""description"": ""For incidentally discovered Meckel diverticula during surgery, removal using stapling devices is reasonable if the diverticulum easily fits in the device."", ""evidence"": [{""explanation"": ""This provides specific guidance on management of incidentally discovered Meckel diverticula using stapling devices."", ""reference"": ""PMID:8506491"", ""snippet"": ""The use of stapling devices, with their ease of use and low complication rate, make it reasonable to remove any Meckel's diverticulum that easily fits in the device. If a diverticulum found incidentally is so broad-based or short that stapling cannot be done without difficulty, it is unlikely to become symptomatic and should be left undisturbed."", ""supports"": ""SUPPORT""}], ""name"": ""Incidental Diverticulectomy with Stapling Devices"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.																																																								"{""description"": ""Surgical excision/repair of occipital encephalocele or meningocele in MKS."", ""name"": ""Occipital encephalocele repair""}"	{}	"{""description"": ""Surgical excision/repair of occipital encephalocele or meningocele in MKS."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Systematic review documents surgical repair of occipital encephalocele/meningocele in MKS."", ""reference"": ""PMID:38459147"", ""snippet"": ""The study included 10 newborns with MKS associated with occipital encephalocele or meningocele, all of whom underwent surgical repair of the occipital sac."", ""supports"": ""SUPPORT""}], ""name"": ""Occipital encephalocele repair"", ""treatment_term"": {""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}}"
4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.																																																								"{""description"": ""Surgical CSF diversion for hydrocephalus associated with MKS."", ""name"": ""Cerebrospinal fluid shunting for hydrocephalus""}"	{}	"{""description"": ""Surgical CSF diversion for hydrocephalus associated with MKS."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The systematic review reports shunting for hydrocephalus in MKS cases."", ""reference"": ""PMID:38459147"", ""snippet"": ""40% required shunting for hydrocephalus."", ""supports"": ""SUPPORT""}], ""name"": ""Cerebrospinal fluid shunting for hydrocephalus"", ""treatment_term"": {""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""shunt device"", ""term"": {""id"": ""NCIT:C50174"", ""label"": ""Shunt Device""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}}"
4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.																																																								"{""description"": ""Acute cranial decompression reported in MKS with craniocephalic disproportion."", ""name"": ""Cranial decompression""}"	{}	"{""description"": ""Acute cranial decompression reported in MKS with craniocephalic disproportion."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report describes cranial decompression in the context of Meckel-Gruber syndrome."", ""reference"": ""PMID:22134259"", ""snippet"": ""Acute cranial decompression in Meckel-Gruber syndrome and slit-ventricle syndrome with craniocephalic disproportion."", ""supports"": ""SUPPORT""}], ""name"": ""Cranial decompression"", ""treatment_term"": {""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}}"
4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.																																																								"{""description"": ""Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS."", ""name"": ""Mutation-specific exon skipping therapy (proposed)""}"	{}	"{""description"": ""Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Review proposes exon skipping as a potential therapy for CC2D2A-associated MKS."", ""reference"": ""PMID:33486889"", ""snippet"": ""CC2D2A, but not CEP120, offers potential for therapeutic exon skipping approaches."", ""supports"": ""SUPPORT""}], ""name"": ""Mutation-specific exon skipping therapy (proposed)"", ""treatment_term"": {""preferred_term"": ""gene therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""has participant"", ""term"": {""id"": ""RO:0000057"", ""label"": ""has participant""}}, ""value"": {""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}}], ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}}"
4937	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with central neck dissection is the primary treatment for MTC. In hereditary cases, prophylactic thyroidectomy is recommended based on genotype, often in early childhood for MEN2B.																																																								"{""description"": ""Total thyroidectomy with central neck dissection is the primary treatment for MTC. In hereditary cases, prophylactic thyroidectomy is recommended based on genotype, often in early childhood for MEN2B."", ""name"": ""Thyroidectomy""}"	{}	"{""description"": ""Total thyroidectomy with central neck dissection is the primary treatment for MTC. In hereditary cases, prophylactic thyroidectomy is recommended based on genotype, often in early childhood for MEN2B."", ""name"": ""Thyroidectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4938	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	1	Selpercatinib	Highly selective RET inhibitor approved for RET-mutant MTC. Demonstrates remarkable efficacy with durable responses in both treatment-naive and previously treated patients. Generally well-tolerated.																																																								"{""description"": ""Highly selective RET inhibitor approved for RET-mutant MTC. Demonstrates remarkable efficacy with durable responses in both treatment-naive and previously treated patients. Generally well-tolerated."", ""name"": ""Selpercatinib""}"	{}	"{""description"": ""Highly selective RET inhibitor approved for RET-mutant MTC. Demonstrates remarkable efficacy with durable responses in both treatment-naive and previously treated patients. Generally well-tolerated."", ""evidence"": [{""explanation"": ""The LIBRETTO-001 trial demonstrated that selpercatinib achieves 73% response rate and 92% 1-year PFS in treatment-naive RET-mutant MTC patients."", ""reference"": ""PMID:32846061"", ""snippet"": ""In 88 patients with RET-mutant medullary thyroid cancer who had not previously received vandetanib or cabozantinib, the percentage who had a response was 73% (95% CI, 62 to 82), and 1-year progression-free survival was 92% (95% CI, 82 to 97)."", ""supports"": ""SUPPORT""}], ""name"": ""Selpercatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4939	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	2	Pralsetinib	Another selective RET inhibitor approved for RET-mutant MTC. Similar efficacy to selpercatinib with different side effect profile.																																																								"{""description"": ""Another selective RET inhibitor approved for RET-mutant MTC. Similar efficacy to selpercatinib with different side effect profile."", ""name"": ""Pralsetinib""}"	{}	"{""description"": ""Another selective RET inhibitor approved for RET-mutant MTC. Similar efficacy to selpercatinib with different side effect profile."", ""name"": ""Pralsetinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.																																																								"{""description"": ""Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors."", ""name"": ""Vandetanib/Cabozantinib""}"	{}	"{""description"": ""Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors."", ""name"": ""Vandetanib/Cabozantinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vandetanib"", ""term"": {""id"": ""CHEBI:49960"", ""label"": ""vandetanib""}}, {""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}]}}"
4958	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	0	Surgical Resection	Maximal safe resection is first-line treatment. Lateral/hemispheric location often allows gross total resection. Extent of resection is prognostic.																																																								"{""description"": ""Maximal safe resection is first-line treatment. Lateral/hemispheric location often allows gross total resection. Extent of resection is prognostic."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Maximal safe resection is first-line treatment. Lateral/hemispheric location often allows gross total resection. Extent of resection is prognostic."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4959	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	1	Craniospinal Irradiation	Craniospinal irradiation is standard for children >3 years due to risk of leptomeningeal spread. Radiation is typically avoided in infants (<3 years) due to severe neurocognitive effects.																																																								"{""description"": ""Craniospinal irradiation is standard for children >3 years due to risk of leptomeningeal spread. Radiation is typically avoided in infants (<3 years) due to severe neurocognitive effects."", ""name"": ""Craniospinal Irradiation""}"	{}	"{""description"": ""Craniospinal irradiation is standard for children >3 years due to risk of leptomeningeal spread. Radiation is typically avoided in infants (<3 years) due to severe neurocognitive effects."", ""name"": ""Craniospinal Irradiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
4960	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	2	Chemotherapy	Multi-agent chemotherapy is standard. For infants, intensive chemotherapy regimens aim to delay or avoid radiation. Standard agents include cisplatin, vincristine, cyclophosphamide, and lomustine.																																																								"{""description"": ""Multi-agent chemotherapy is standard. For infants, intensive chemotherapy regimens aim to delay or avoid radiation. Standard agents include cisplatin, vincristine, cyclophosphamide, and lomustine."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Multi-agent chemotherapy is standard. For infants, intensive chemotherapy regimens aim to delay or avoid radiation. Standard agents include cisplatin, vincristine, cyclophosphamide, and lomustine."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
4961	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	3	SHH Pathway Inhibitors (Vismodegib/Sonidegib)	SMO inhibitors show activity in recurrent SHH-activated medulloblastoma with upstream pathway mutations (PTCH1). Resistance develops through SMO mutations or pathway activation downstream of SMO (GLI amplification, SUFU mutations). Growth plate toxicity limits use in children.																																																								"{""description"": ""SMO inhibitors show activity in recurrent SHH-activated medulloblastoma with upstream pathway mutations (PTCH1). Resistance develops through SMO mutations or pathway activation downstream of SMO (GLI amplification, SUFU mutations). Growth plate toxicity limits use in children."", ""name"": ""SHH Pathway Inhibitors (Vismodegib/Sonidegib)""}"	{}	"{""description"": ""SMO inhibitors show activity in recurrent SHH-activated medulloblastoma with upstream pathway mutations (PTCH1). Resistance develops through SMO mutations or pathway activation downstream of SMO (GLI amplification, SUFU mutations). Growth plate toxicity limits use in children."", ""name"": ""SHH Pathway Inhibitors (Vismodegib/Sonidegib)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
4979	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	0	Surgical Resection	Maximal safe resection is first-line treatment. Near-total or gross total resection is achieved in most cases. Complete resection associated with excellent outcomes.																																																								"{""description"": ""Maximal safe resection is first-line treatment. Near-total or gross total resection is achieved in most cases. Complete resection associated with excellent outcomes."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Maximal safe resection is first-line treatment. Near-total or gross total resection is achieved in most cases. Complete resection associated with excellent outcomes."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
4980	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	1	Craniospinal Irradiation	Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk of leptomeningeal dissemination. Treatment de-escalation trials are exploring reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors given excellent prognosis.																																																								"{""description"": ""Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk of leptomeningeal dissemination. Treatment de-escalation trials are exploring reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors given excellent prognosis."", ""name"": ""Craniospinal Irradiation""}"	{}	"{""description"": ""Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk of leptomeningeal dissemination. Treatment de-escalation trials are exploring reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors given excellent prognosis."", ""name"": ""Craniospinal Irradiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
4981	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	2	Chemotherapy	Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine) is standard. De-escalation trials are exploring reduced-intensity or chemotherapy-omitting regimens for WNT-activated tumors to minimize long-term toxicity while maintaining excellent survival.																																																								"{""description"": ""Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine) is standard. De-escalation trials are exploring reduced-intensity or chemotherapy-omitting regimens for WNT-activated tumors to minimize long-term toxicity while maintaining excellent survival."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine) is standard. De-escalation trials are exploring reduced-intensity or chemotherapy-omitting regimens for WNT-activated tumors to minimize long-term toxicity while maintaining excellent survival."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	Surgical Excision	Removal of the melanoma and surrounding tissue																																																								"{""description"": ""Removal of the melanoma and surrounding tissue"", ""name"": ""Surgical Excision""}"	{}	"{""description"": ""Removal of the melanoma and surrounding tissue"", ""evidence"": [{""reference"": ""PMID:33010324"", ""snippet"": ""Segmental excision of congenital melanocytic nevus by multiple incisions."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""Excision is recommended for diagnosing and treating melanoma."", ""reference"": ""PMID:11079795"", ""snippet"": ""An excisional biopsy is the appropriate diagnostic procedure for a skin lesion suspected of being a melanoma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the surgical excision of melanoma, including melanoma arising in congenital melanocytic nevus."", ""reference"": ""PMID:14379056"", ""snippet"": ""The tenet of excision and dissection in continuity where feasible of the primary melanoma and the regional lymph nodes is reemphasized."", ""supports"": ""SUPPORT""}, {""explanation"": ""Excision is one of several treatments considered but the exact treatment for melanoma is not specified."", ""reference"": ""PMID:22980259"", ""snippet"": ""Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference describes a case where melanoma in a congenital melanocytic nevus was treated by surgical excision."", ""reference"": ""PMID:1615092"", ""snippet"": ""The child underwent a complete surgical excision of this lesion with immediate coverage by partial-thickness skin grafts."", ""supports"": ""SUPPORT""}, {""explanation"": ""Surgical excision is recommended for congenital melanocytic nevus to mitigate cancer risk."", ""reference"": ""PMID:15817400"", ""snippet"": ""Surgical excision may be considered for cosmetic purposes and to reduce the small risk for the development of malignancy within each lesion."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Excision"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5011	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	1	Immunotherapy	Use of drugs to stimulate the immune system to target melanoma cells																																																								"{""description"": ""Use of drugs to stimulate the immune system to target melanoma cells"", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""Use of drugs to stimulate the immune system to target melanoma cells"", ""evidence"": [{""explanation"": ""This indicates that immunotherapy, which stimulates the immune system to target melanoma cells, could be beneficial for melanoma in high-risk patients, supporting the statement."", ""reference"": ""PMID:27453302"", ""snippet"": ""In recent years systemic targeted- and immunotherapy have proven to be beneficial in advanced melanoma and could be a promising strategy for (neo)adjuvant treatment of patients with resectable high risk melanomas as well."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports that immunotherapy is used to target melanoma cells, supporting the statement."", ""reference"": ""PMID:16762733"", ""snippet"": ""Melanoma has been widely studied as a target for immunotherapy because it has been considered more susceptible to immune attack than other tumors... This article reviews the recent clinical results of trials exploring different immunotherapy strategies against melanoma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This suggests that while immunotherapy is used, it is not universally effective for all patients, therefore partially supporting the statement."", ""reference"": ""PMID:36435868"", ""snippet"": ""Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for patients with metastatic melanoma; however, there remains an unmet clinical need for alternative treatment options for those patients who are either intolerant or refractory to immunotherapy."", ""supports"": ""PARTIAL""}], ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5012	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	2	Targeted Therapy	Drugs that target specific genetic mutations in melanoma cells, such as BRAF inhibitors																																																								"{""description"": ""Drugs that target specific genetic mutations in melanoma cells, such as BRAF inhibitors"", ""name"": ""Targeted Therapy""}"	{}	"{""description"": ""Drugs that target specific genetic mutations in melanoma cells, such as BRAF inhibitors"", ""evidence"": [{""explanation"": ""This reference indicates that targeted therapies, such as BRAF inhibitors, are effective in treating melanomas with specific genetic mutations."", ""reference"": ""PMID:24880943"", ""snippet"": ""In cutaneous melanomas with BRAF V600 mutations the selective RAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have demonstrated survival benefits."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of trametinib, a targeted therapy, in treating a congenital melanocytic nevus with a specific genetic mutation, though the primary outcome discussed is symptom relief rather than melanoma treatment."", ""reference"": ""PMID:30792255"", ""snippet"": ""We present the case of a 7-year-old girl with a giant congenital melanocytic nevus that had an AKAP9-BRAF fusion and was treated with trametinib, which resulted in rapid resolution of the patient's lifelong, intractable pain and pruritus as well as dramatic improvement in the extent of her nevus."", ""supports"": ""PARTIAL""}], ""name"": ""Targeted Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	Radiation Therapy	Use of high-energy radiation to kill cancer cells or shrink tumors																																																								"{""description"": ""Use of high-energy radiation to kill cancer cells or shrink tumors"", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Use of high-energy radiation to kill cancer cells or shrink tumors"", ""evidence"": [{""explanation"": ""Radiation therapy is recommended in certain circumstances, but is not the primary treatment method for localized melanomas which include melanomas arising from congenital melanocytic nevi."", ""reference"": ""PMID:8977557"", ""snippet"": ""Although surgery remains the treatment of choice for the vast majority of localized melanomas, available data indicate that radiation therapy is a viable alternative for a few subsets of patients in whom surgery would result in cosmetic or functional deformity."", ""supports"": ""PARTIAL""}, {""explanation"": ""The provided abstract discusses laser therapy as an alternative to surgery for GCMN but does not mention radiation therapy."", ""reference"": ""PMID:12609784"", ""snippet"": ""Lasers should only be regarded as a treatment option for GCMN that cannot be surgically excised."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The provided abstract is about mouse models for UV-induced melanoma and does not discuss the treatment of melanomas arising from congenital melanocytic nevi with radiation therapy."", ""reference"": ""PMID:28092363"", ""snippet"": ""This review will focus exclusively on genetically engineered mouse models of UVR-induced melanoma."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""Radiation therapy is listed as an adjuvant treatment in advanced pediatric melanoma cases, which can include those arising from conditions like congenital melanocytic nevi."", ""reference"": ""PMID:19880040"", ""snippet"": ""Adjuvant therapies such as chemotherapy, immunotherapy, and radiation therapy can be used in advanced cases."", ""supports"": ""PARTIAL""}, {""explanation"": ""The abstract discusses radiation therapy and its enhancement but does not specifically address radiation therapy for melanomas originating from congenital melanocytic nevi."", ""reference"": ""PMID:29958291"", ""snippet"": ""Radiation therapy is a useful and standard tumor treatment strategy... Some strategies are focused on enhancement of accuracy in ionizing radiation delivery and on the generation of greater radiation beams..."", ""supports"": ""PARTIAL""}], ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
5014	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	4	Chemotherapy	Use of drugs to kill rapidly dividing cells, including cancer cells																																																								"{""description"": ""Use of drugs to kill rapidly dividing cells, including cancer cells"", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Use of drugs to kill rapidly dividing cells, including cancer cells"", ""evidence"": [{""explanation"": ""Although chemotherapy is not explicitly mentioned, the focus on various treatments for melanoma suggests that a range of therapeutic approaches exists."", ""reference"": ""PMID:22980259"", ""snippet"": ""Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons. Over the past century, a large number of treatments for CMN have been described in the literature. These include excision, dermabrasion, curettage, chemical peels, radiation therapy, cryotherapy, electrosurgery, and lasers. Only low-level evidence supporting these approaches is available, and large randomized controlled trials have not been published."", ""supports"": ""PARTIAL""}, {""explanation"": ""While chemotherapy is an established approach for treating malignant melanoma, this reference does not provide explicit information about its use specifically in congenital melanocytic nevus-related melanoma."", ""reference"": ""PMID:27268913"", ""snippet"": ""Malignant melanoma represents a neoplasm stemming from melanocytes or the cells that develop from melanocytes. Melanocytes, pigment-producing cells, arise from the neural crest and migrate to their final destinations in the skin, uveal tract, meninges, and mucosa. Most melanocytes are found at the epidermal-dermal junction of the skin, and the vast majority of melanocytes arise from cutaneous sites. Cancerous growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin cells to multiply rapidly and form malignant tumours."", ""supports"": ""PARTIAL""}], ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"																																																								"{""description"": ""Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.\n"", ""name"": ""Intralesional corticosteroid injection""}"	{}	"{""description"": ""Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.\n"", ""evidence"": [{""explanation"": ""Establishes intralesional corticosteroid injection as first-line therapy for MRS-associated granulomatous cheilitis"", ""reference"": ""PMID:32782477"", ""snippet"": ""Oral or locally injected corticosteroids (triamcinolone) are the initial therapeutic option."", ""supports"": ""SUPPORT""}], ""name"": ""Intralesional corticosteroid injection"", ""treatment_term"": {""preferred_term"": ""corticosteroid injection"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}], ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}}"
5037	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	1	Systemic corticosteroids	"Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.
"																																																								"{""description"": ""Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.\n"", ""name"": ""Systemic corticosteroids""}"	{}	"{""description"": ""Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.\n"", ""evidence"": [{""explanation"": ""Supports the use of systemic medication (oral corticosteroids) as part of multidisciplinary MRS management"", ""reference"": ""PMID:39135018"", ""snippet"": ""A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis."", ""supports"": ""SUPPORT""}], ""name"": ""Systemic corticosteroids"", ""treatment_term"": {""preferred_term"": ""corticosteroid therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}}"
5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"																																																								"{""description"": ""TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.\n"", ""name"": ""Anti-TNF therapy (infliximab)""}"	{}	"{""description"": ""TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.\n"", ""evidence"": [{""explanation"": ""Establishes infliximab as a validated TNF- blockade strategy for refractory granulomatous cheilitis"", ""reference"": ""PMID:32782477"", ""snippet"": ""Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-TNF therapy (infliximab)"", ""treatment_term"": {""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"																																																								"{""description"": ""Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.\n"", ""name"": ""Anti-IL-12/23 therapy (ustekinumab)""}"	{}	"{""description"": ""Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.\n"", ""evidence"": [{""explanation"": ""Demonstrates efficacy of IL-12/23 blockade in treating refractory MRS-associated granulomatous cheilitis"", ""reference"": ""PMID:32782477"", ""snippet"": ""ustekinumab, a monoclonal antibody against interleukins 12/23, with proven efficacy in CD and psoriasis, is attractive. The present study is the second to report on the effectiveness of ustekinumab for inducing remission of severe and recurrent granulomatous cheilitis in patients with CD."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-IL-12/23 therapy (ustekinumab)"", ""treatment_term"": {""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent class"", ""term"": {""id"": ""NCIT:C20401"", ""label"": ""Monoclonal Antibody""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5040	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	4	Supportive care	"Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.
"																																																								"{""description"": ""Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.\n"", ""name"": ""Supportive care""}"	{}	"{""description"": ""Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.\n"", ""evidence"": [{""explanation"": ""Emphasizes the importance of multidisciplinary supportive care in MRS management"", ""reference"": ""PMID:39135018"", ""snippet"": ""A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5050	212	Meniere's Disease	Menieres_Disease.yaml	treatments	0	Low-Sodium Diet	"Dietary sodium restriction to reduce fluid retention and minimize endolymphatic hydrops. Often combined with diuretics. First-line conservative management that is recommended as part of long-term treatment strategy.
"																																																								"{""description"": ""Dietary sodium restriction to reduce fluid retention and minimize endolymphatic hydrops. Often combined with diuretics. First-line conservative management that is recommended as part of long-term treatment strategy.\n"", ""name"": ""Low-Sodium Diet""}"	{}	"{""description"": ""Dietary sodium restriction to reduce fluid retention and minimize endolymphatic hydrops. Often combined with diuretics. First-line conservative management that is recommended as part of long-term treatment strategy.\n"", ""evidence"": [{""explanation"": ""Establishes low-sodium diet as first-line initial management approach"", ""reference"": ""PMID:15090872"", ""snippet"": ""Initial management of Mnire's disease can involve a low-salt diet and a diuretic."", ""supports"": ""SUPPORT""}], ""name"": ""Low-Sodium Diet"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
5051	212	Meniere's Disease	Menieres_Disease.yaml	treatments	1	Diuretic Therapy	"Thiazide diuretics or acetazolamide to reduce endolymph volume and pressure, decreasing the frequency of vertigo attacks. Used as part of first-line conservative management.
"																																																								"{""description"": ""Thiazide diuretics or acetazolamide to reduce endolymph volume and pressure, decreasing the frequency of vertigo attacks. Used as part of first-line conservative management.\n"", ""name"": ""Diuretic Therapy""}"	{}	"{""description"": ""Thiazide diuretics or acetazolamide to reduce endolymph volume and pressure, decreasing the frequency of vertigo attacks. Used as part of first-line conservative management.\n"", ""evidence"": [{""explanation"": ""Establishes diuretics as component of initial management strategy"", ""reference"": ""PMID:15090872"", ""snippet"": ""Initial management of Mnire's disease can involve a low-salt diet and a diuretic."", ""supports"": ""SUPPORT""}], ""name"": ""Diuretic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5052	212	Meniere's Disease	Menieres_Disease.yaml	treatments	2	Betahistine	"Histamine analog that improves inner ear blood flow and reduces vestibular symptoms. Widely used outside North America as part of conservative medical management.
"																																																								"{""description"": ""Histamine analog that improves inner ear blood flow and reduces vestibular symptoms. Widely used outside North America as part of conservative medical management.\n"", ""name"": ""Betahistine""}"	{}	"{""description"": ""Histamine analog that improves inner ear blood flow and reduces vestibular symptoms. Widely used outside North America as part of conservative medical management.\n"", ""evidence"": [{""explanation"": ""Documents histaminergic agent (betahistine) use as standard therapy in Europe"", ""reference"": ""PMID:11465871"", ""snippet"": ""The very common use in Europe of histaminergic agents."", ""supports"": ""SUPPORT""}], ""name"": ""Betahistine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5053	212	Meniere's Disease	Menieres_Disease.yaml	treatments	3	Intratympanic Injections	"Injection of corticosteroids or gentamicin through the tympanic membrane to reduce vertigo. Gentamicin reduces vestibular function; corticosteroids provide nonablative alternative. Used when medical management fails.
"																																																								"{""description"": ""Injection of corticosteroids or gentamicin through the tympanic membrane to reduce vertigo. Gentamicin reduces vestibular function; corticosteroids provide nonablative alternative. Used when medical management fails.\n"", ""name"": ""Intratympanic Injections""}"	{}	"{""description"": ""Injection of corticosteroids or gentamicin through the tympanic membrane to reduce vertigo. Gentamicin reduces vestibular function; corticosteroids provide nonablative alternative. Used when medical management fails.\n"", ""evidence"": [{""explanation"": ""Establishes intratympanic gentamicin as second-line therapy for refractory vertigo"", ""reference"": ""PMID:15090872"", ""snippet"": ""Treatment with intratympanic injection of gentamicin can be beneficial when vertigo persists despite optimal medical management."", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms intratympanic approach as practical, well-tolerated treatment modality"", ""reference"": ""PMID:12590850"", ""snippet"": ""Transtympanic injection, as a quick, easy, well-tolerated, ambulatory and cost-effective technique."", ""supports"": ""SUPPORT""}], ""name"": ""Intratympanic Injections"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5054	212	Meniere's Disease	Menieres_Disease.yaml	treatments	4	Vestibular Rehabilitation	"Physical therapy exercises to improve balance and reduce dizziness by promoting central compensation for vestibular dysfunction. Complements medical and surgical interventions.
"																																																								"{""description"": ""Physical therapy exercises to improve balance and reduce dizziness by promoting central compensation for vestibular dysfunction. Complements medical and surgical interventions.\n"", ""name"": ""Vestibular Rehabilitation""}"	{}	"{""description"": ""Physical therapy exercises to improve balance and reduce dizziness by promoting central compensation for vestibular dysfunction. Complements medical and surgical interventions.\n"", ""name"": ""Vestibular Rehabilitation"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5055	212	Meniere's Disease	Menieres_Disease.yaml	treatments	5	Endolymphatic Sac Surgery	"Surgical decompression of the endolymphatic sac to improve endolymph drainage and reduce hydrops. Nonablative surgical alternative used when conservative measures and intratympanic therapies fail.
"																																																								"{""description"": ""Surgical decompression of the endolymphatic sac to improve endolymph drainage and reduce hydrops. Nonablative surgical alternative used when conservative measures and intratympanic therapies fail.\n"", ""name"": ""Endolymphatic Sac Surgery""}"	{}	"{""description"": ""Surgical decompression of the endolymphatic sac to improve endolymph drainage and reduce hydrops. Nonablative surgical alternative used when conservative measures and intratympanic therapies fail.\n"", ""name"": ""Endolymphatic Sac Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5071	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	0	Avelumab	Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint inhibitor approved for MCC based on durable responses in the JAVELIN Merkel 200 trial. Response rates of approximately 30-35% in previously treated patients and higher in first-line setting.																																																								"{""description"": ""Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint inhibitor approved for MCC based on durable responses in the JAVELIN Merkel 200 trial. Response rates of approximately 30-35% in previously treated patients and higher in first-line setting."", ""name"": ""Avelumab""}"	{}	"{""description"": ""Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint inhibitor approved for MCC based on durable responses in the JAVELIN Merkel 200 trial. Response rates of approximately 30-35% in previously treated patients and higher in first-line setting."", ""name"": ""Avelumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5072	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	1	Pembrolizumab	Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately 50-70% with durable responses. Both virus-positive and virus-negative MCC respond to checkpoint inhibition.																																																								"{""description"": ""Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately 50-70% with durable responses. Both virus-positive and virus-negative MCC respond to checkpoint inhibition."", ""name"": ""Pembrolizumab""}"	{}	"{""description"": ""Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately 50-70% with durable responses. Both virus-positive and virus-negative MCC respond to checkpoint inhibition."", ""name"": ""Pembrolizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5073	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	2	Surgical Excision	Wide local excision with adequate margins (1-2 cm) is the primary treatment for localized MCC. Sentinel lymph node biopsy is recommended given high rate of occult nodal metastases.																																																								"{""description"": ""Wide local excision with adequate margins (1-2 cm) is the primary treatment for localized MCC. Sentinel lymph node biopsy is recommended given high rate of occult nodal metastases."", ""name"": ""Surgical Excision""}"	{}	"{""description"": ""Wide local excision with adequate margins (1-2 cm) is the primary treatment for localized MCC. Sentinel lymph node biopsy is recommended given high rate of occult nodal metastases."", ""name"": ""Surgical Excision"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5074	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	3	Radiation Therapy	MCC is radiosensitive. Adjuvant radiation improves local control, particularly for tumors with high-risk features. Radiation may be used as primary treatment for unresectable tumors.																																																								"{""description"": ""MCC is radiosensitive. Adjuvant radiation improves local control, particularly for tumors with high-risk features. Radiation may be used as primary treatment for unresectable tumors."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""MCC is radiosensitive. Adjuvant radiation improves local control, particularly for tumors with high-risk features. Radiation may be used as primary treatment for unresectable tumors."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
5075	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	4	Chemotherapy	MCC is chemosensitive (like other small cell carcinomas) with initial response rates of 50-60% to platinum/etoposide regimens. However, responses are typically short-lived and chemotherapy has been largely supplanted by immunotherapy.																																																								"{""description"": ""MCC is chemosensitive (like other small cell carcinomas) with initial response rates of 50-60% to platinum/etoposide regimens. However, responses are typically short-lived and chemotherapy has been largely supplanted by immunotherapy."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""MCC is chemosensitive (like other small cell carcinomas) with initial response rates of 50-60% to platinum/etoposide regimens. However, responses are typically short-lived and chemotherapy has been largely supplanted by immunotherapy."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
5106	214	Migraine	Migraine.yaml	treatments	0	Triptans	First-line acute treatment (sumatriptan, rizatriptan).																																																								"{""description"": ""First-line acute treatment (sumatriptan, rizatriptan)."", ""name"": ""Triptans""}"	{}	"{""description"": ""First-line acute treatment (sumatriptan, rizatriptan)."", ""evidence"": [{""explanation"": ""Clinical efficacy of triptans in treating migraine attacks validates their role as first-line acute treatment."", ""reference"": ""PMID:39080518"", ""snippet"": ""The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges."", ""supports"": ""SUPPORT""}], ""name"": ""Triptans""}"
5107	214	Migraine	Migraine.yaml	treatments	1	NSAIDs	Effective for mild-moderate attacks.																																																								"{""description"": ""Effective for mild-moderate attacks."", ""name"": ""NSAIDs""}"	{}	"{""description"": ""Effective for mild-moderate attacks."", ""evidence"": [{""explanation"": ""NSAIDs are widely used for migraine attacks due to their favorable efficacy and side effect profile, particularly for mild to moderate attacks."", ""reference"": ""PMID:27713337"", ""snippet"": ""NSAIDs remain the most commonly used therapies for the migraine attack. This is in part due to their wide availability as over-the-counter drugs and their pharmaco-economic advantages, but also to a favorable efficacy/side effect profile at least in attacks of mild and moderate intensity."", ""supports"": ""SUPPORT""}], ""name"": ""NSAIDs""}"
5108	214	Migraine	Migraine.yaml	treatments	2	CGRP Antagonists (Gepants)	Acute treatment option (ubrogepant, rimegepant).																																																								"{""description"": ""Acute treatment option (ubrogepant, rimegepant)."", ""name"": ""CGRP Antagonists (Gepants)""}"	{}	"{""description"": ""Acute treatment option (ubrogepant, rimegepant)."", ""evidence"": [{""explanation"": ""CGRP antagonists (gepants) are a class of CGRP inhibitors that have demonstrated effectiveness in migraine management."", ""reference"": ""PMID:37755358"", ""snippet"": ""CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."", ""supports"": ""SUPPORT""}], ""name"": ""CGRP Antagonists (Gepants)""}"
5109	214	Migraine	Migraine.yaml	treatments	3	Beta Blockers	Preventive therapy (propranolol, metoprolol).																																																								"{""description"": ""Preventive therapy (propranolol, metoprolol)."", ""name"": ""Beta Blockers""}"	{}	"{""description"": ""Preventive therapy (propranolol, metoprolol)."", ""evidence"": [{""explanation"": ""Meta-analysis of 108 RCTs confirms propranolol efficacy for migraine prevention with high-quality evidence."", ""reference"": ""PMID:30893319"", ""snippet"": ""Compared to placebo, propranolol reduced episodic migraine headaches by 1.5 headaches/month at 8 weeks (95% CI: -2.3 to -0.65) and was more likely to reduce headaches by 50% (RR: 1.4, 95% CI: 1.1-1.7)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Systematic review establishes beta-blockers as effective first-line preventive therapy."", ""reference"": ""PMID:30893319"", ""snippet"": ""There is high quality evidence that propranolol is better than placebo for episodic migraine headache."", ""supports"": ""SUPPORT""}], ""name"": ""Beta Blockers""}"
5110	214	Migraine	Migraine.yaml	treatments	4	Topiramate	Preventive therapy.																																																								"{""description"": ""Preventive therapy."", ""name"": ""Topiramate""}"	{}	"{""description"": ""Preventive therapy."", ""evidence"": [{""explanation"": ""Clinical trials have established the efficacy of topiramate for migraine prevention."", ""reference"": ""PMID:24494792"", ""snippet"": ""Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium."", ""supports"": ""SUPPORT""}, {""explanation"": ""Explains the mechanism by which topiramate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression."", ""reference"": ""PMID:24494792"", ""snippet"": ""Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression."", ""supports"": ""SUPPORT""}], ""name"": ""Topiramate""}"
5111	214	Migraine	Migraine.yaml	treatments	5	Valproate	Preventive therapy.																																																								"{""description"": ""Preventive therapy."", ""name"": ""Valproate""}"	{}	"{""description"": ""Preventive therapy."", ""evidence"": [{""explanation"": ""Clinical trials have established the efficacy of valproate/valproic acid for migraine prevention."", ""reference"": ""PMID:24494792"", ""snippet"": ""Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium."", ""supports"": ""SUPPORT""}, {""explanation"": ""Explains the mechanism by which valproate prevents migraine through effects on trigeminovascular pathways and cortical spreading depression."", ""reference"": ""PMID:24494792"", ""snippet"": ""Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression."", ""supports"": ""SUPPORT""}], ""name"": ""Valproate""}"
5112	214	Migraine	Migraine.yaml	treatments	6	CGRP Monoclonal Antibodies	Preventive therapy (erenumab, fremanezumab, galcanezumab).																																																								"{""description"": ""Preventive therapy (erenumab, fremanezumab, galcanezumab)."", ""name"": ""CGRP Monoclonal Antibodies""}"	{}	"{""description"": ""Preventive therapy (erenumab, fremanezumab, galcanezumab)."", ""evidence"": [{""explanation"": ""Anti-CGRP monoclonal antibodies have demonstrated clinical efficacy in treating migraine, supporting their use as preventive therapy."", ""reference"": ""PMID:39080518"", ""snippet"": ""The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges."", ""supports"": ""SUPPORT""}, {""explanation"": ""CGRP monoclonal antibodies are CGRP inhibitors that target this key migraine pathway."", ""reference"": ""PMID:37755358"", ""snippet"": ""CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."", ""supports"": ""SUPPORT""}], ""name"": ""CGRP Monoclonal Antibodies""}"
5113	214	Migraine	Migraine.yaml	treatments	7	Botulinum Toxin	For chronic migraine prevention.																																																								"{""description"": ""For chronic migraine prevention."", ""name"": ""Botulinum Toxin""}"	{}	"{""description"": ""For chronic migraine prevention."", ""evidence"": [{""explanation"": ""Network meta-analysis of 24 RCTs demonstrates botulinum toxin A has the best efficacy and safety profile among chronic migraine preventive treatments."", ""reference"": ""PMID:38910144"", ""snippet"": ""Among all the drugs for the preventive drugs for CM, Botulinum toxin A has the best efficacy and safety profile, closely followed by calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)."", ""supports"": ""SUPPORT""}], ""name"": ""Botulinum Toxin""}"
5114	214	Migraine	Migraine.yaml	treatments	8	Neuromodulation	Non-invasive devices for prevention and acute treatment.																																																								"{""description"": ""Non-invasive devices for prevention and acute treatment."", ""name"": ""Neuromodulation""}"	{}	"{""description"": ""Non-invasive devices for prevention and acute treatment."", ""evidence"": [{""explanation"": ""Clinical studies have demonstrated the effectiveness of neuromodulation devices in migraine management."", ""reference"": ""PMID:37755358"", ""snippet"": ""Finally, the paper delves into neuromodulation as an innovative treatment modality. Clinical studies indicating its effectiveness in migraine management are reviewed"", ""supports"": ""SUPPORT""}], ""name"": ""Neuromodulation""}"
5127	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	treatments	0	NSAIDs	For mild arthritis and myalgia.																																																								"{""description"": ""For mild arthritis and myalgia."", ""name"": ""NSAIDs""}"	{}	"{""description"": ""For mild arthritis and myalgia."", ""name"": ""NSAIDs""}"
5128	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	treatments	1	Corticosteroids	For moderate to severe disease manifestations.																																																								"{""description"": ""For moderate to severe disease manifestations."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""For moderate to severe disease manifestations."", ""name"": ""Corticosteroids""}"
5129	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	treatments	2	Methotrexate	Steroid-sparing agent for arthritis and myositis.																																																								"{""description"": ""Steroid-sparing agent for arthritis and myositis."", ""name"": ""Methotrexate""}"	{}	"{""description"": ""Steroid-sparing agent for arthritis and myositis."", ""name"": ""Methotrexate""}"
5130	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	treatments	3	Hydroxychloroquine	For skin and joint manifestations.																																																								"{""description"": ""For skin and joint manifestations."", ""name"": ""Hydroxychloroquine""}"	{}	"{""description"": ""For skin and joint manifestations."", ""name"": ""Hydroxychloroquine""}"
5175	216	Monkeypox	Monkeypox.yaml	treatments	0	Supportive Care	Management of symptoms including fever, pain, and dehydration.																																																								"{""description"": ""Management of symptoms including fever, pain, and dehydration."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Management of symptoms including fever, pain, and dehydration."", ""evidence"": [{""explanation"": ""The document emphasizes how supportive care is central to the management of symptoms, including fever."", ""reference"": ""PMID:37403493"", ""snippet"": ""The clinical evaluation involves the assessment of the primary skin lesions, sites of involvement, distribution, number and size of lesions, and pattern of progression of the rash, along with the onset of the rash relative to the occurrence of fever and other systemic signs"", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights the importance of supportive care for hydration and managing symptoms."", ""reference"": ""PMID:29231870"", ""snippet"": ""MPX patients could benefit from clinical support to mitigate the consequences of compromised skin and mucosa. This should include prevention and treatment of secondary bacterial infections (and other complications), ensuring adequate hydration and nutrition, and protecting vulnerable anatomical locations such as the eyes and genitals."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the role of supportive care in managing mild symptoms, including fever and pain."", ""reference"": ""PMID:36342045"", ""snippet"": ""If individuals test positive for the monkeypox virus, self-isolation at home is recommended for most people with mild symptoms. If patients report severe symptoms, referral and admission to hospital will be needed, where further interventions such as antivirals may be administered."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5176	216	Monkeypox	Monkeypox.yaml	treatments	1	Antiviral Therapy	Investigational treatments such as tecovirimat (TPOXX).																																																								"{""description"": ""Investigational treatments such as tecovirimat (TPOXX)."", ""name"": ""Antiviral Therapy""}"	{}	"{""description"": ""Investigational treatments such as tecovirimat (TPOXX)."", ""evidence"": [{""explanation"": ""The article supports the investigational use of tecovirimat (TPOXX) for treating Monkeypox under an investigational new drug protocol."", ""reference"": ""PMID:36107794"", ""snippet"": ""Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article specifically discusses the use of tecovirimat for treating a form of Monkeypox, indicating ongoing investigative use."", ""reference"": ""PMID:36547989"", ""snippet"": ""Tecovirimat Treatment for Monkeypox Virus Keratouveitis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The text confirms that investigational treatments, particularly tecovirimat (TPOXX), are considered for treating Monkeypox."", ""reference"": ""PMID:36253931"", ""snippet"": ""Brincidofovir and tecovirimat were the most studied medications that got approval for smallpox treatment according to the Animal Rule. Due to the conserved virology among Orthopoxviruses, available medications might also be effective against monkeypox."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article provides individual patient data on the use of tecovirimat as an investigational treatment for Monkeypox and summarizes its efficacy and safety."", ""reference"": ""PMID:36470502"", ""snippet"": ""Tecovirimat was used in 61 individuals... Tecovirimat is the most used and has proven beneficial in several aggravating cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""The provided literature does not include useful content to verify the statement."", ""reference"": ""PMID:36746493"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The article states that tecovirimat is effective at nanomolar quantities against Monkeypox, supporting its use as investigational therapy."", ""reference"": ""PMID:36851785"", ""snippet"": ""In this study, we generated 800 compounds based on tecovirimat, an FDA-approved drug that is efficacious at nanomolar quantities against monkeypox"", ""supports"": ""SUPPORT""}, {""explanation"": ""The article mentions tecovirimat as one of the investigational treatments considered for monkeypox, supporting its use."", ""reference"": ""PMID:36897017"", ""snippet"": ""The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence."", ""supports"": ""SUPPORT""}], ""name"": ""Antiviral Therapy"", ""treatment_term"": {""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}}"
5177	216	Monkeypox	Monkeypox.yaml	treatments	2	Vaccination	Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox.																																																								"{""description"": ""Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox."", ""name"": ""Vaccination""}"	{}	"{""description"": ""Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox."", ""evidence"": [{""explanation"": ""This case indicates that the patient contracted monkeypox despite vaccination, suggesting limited or no cross-protection by the ACAM2000 vaccine."", ""reference"": ""PMID:36104166"", ""snippet"": ""We report a case of monkeypox in the United States in a patient who had been vaccinated with ACAM2000 smallpox vaccine 8 years earlier. Despite his vaccination status, he still contracted disease."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference mentions broader cross-protective immunity for orthopoxviruses, including monkeypox, suggesting a potential for cross-protection, though specifics about the smallpox vaccine's efficacy aren't detailed."", ""reference"": ""PMID:27768891"", ""snippet"": ""Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply."", ""supports"": ""PARTIAL""}, {""explanation"": ""The presence of orthopoxvirus vaccines like ACAM2000 and JYNNEOS indicates their consideration in the context of monkeypox prevention, implying potential cross-protection."", ""reference"": ""PMID:35763248"", ""snippet"": ""Two vaccines are currently available, JYNNEOSTM (live, replication incompetent vaccinia virus) and ACAM2000 (live, replication competent vaccinia virus)"", ""supports"": ""SUPPORT""}, {""explanation"": ""Both the ACAM2000 and JYNNEOS vaccines show efficacy in preventing monkeypox, supporting the statement regarding cross-protection."", ""reference"": ""PMID:37087871"", ""snippet"": ""CONCLUSION: ACAM2000 and JYNNEOS vaccines have proven to be efficient in preventing Mpox even though variations exist in their modes of action and associated significant effects."", ""supports"": ""SUPPORT""}, {""explanation"": ""The use of smallpox vaccines for protection against monkeypox is explicitly mentioned, supporting the potential for cross-protection."", ""reference"": ""PMID:36274490"", ""snippet"": ""It has been observed that smallpox vaccines can be used to protect against MPX. The present article highlights the significant points and various issues for vaccines and vaccinations that should be considered related to MPX."", ""supports"": ""SUPPORT""}], ""name"": ""Vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
5178	216	Monkeypox	Monkeypox.yaml	treatments	3	Cidofovir	DNA polymerase inhibitor considered for severe cases.																																		Repurposed antiviral targeting viral DNA polymerase; used experimentally for severe MPXV infections																						"{""description"": ""DNA polymerase inhibitor considered for severe cases."", ""name"": ""Cidofovir"", ""notes"": ""Repurposed antiviral targeting viral DNA polymerase; used experimentally for severe MPXV infections""}"	{}	"{""description"": ""DNA polymerase inhibitor considered for severe cases."", ""name"": ""Cidofovir"", ""notes"": ""Repurposed antiviral targeting viral DNA polymerase; used experimentally for severe MPXV infections"", ""treatment_term"": {""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}}"
5179	216	Monkeypox	Monkeypox.yaml	treatments	4	Brincidofovir	Lipid conjugate of cidofovir explored as oral antiviral candidate.																																		Oral prodrug formulation of cidofovir for improved bioavailability																						"{""description"": ""Lipid conjugate of cidofovir explored as oral antiviral candidate."", ""name"": ""Brincidofovir"", ""notes"": ""Oral prodrug formulation of cidofovir for improved bioavailability""}"	{}	"{""description"": ""Lipid conjugate of cidofovir explored as oral antiviral candidate."", ""name"": ""Brincidofovir"", ""notes"": ""Oral prodrug formulation of cidofovir for improved bioavailability"", ""treatment_term"": {""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}}"
5180	216	Monkeypox	Monkeypox.yaml	treatments	5	Isolation and Infection Control	Preventing the spread through quarantine of infected individuals and proper hygiene practices.																																																								"{""description"": ""Preventing the spread through quarantine of infected individuals and proper hygiene practices."", ""name"": ""Isolation and Infection Control""}"	{}	"{""description"": ""Preventing the spread through quarantine of infected individuals and proper hygiene practices."", ""evidence"": [{""explanation"": ""The literature mentions the importance of infection control in preventing the spread of monkeypox, particularly in dental settings."", ""reference"": ""PMID:36241815"", ""snippet"": ""Monkeypox is an infectious disease, characterised by a rash affecting the skin and soft tissues, including the oral cavity."", ""supports"": ""PARTIAL""}], ""name"": ""Isolation and Infection Control"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
5190	217	Muenke Syndrome	Muenke_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Surgical correction of craniosynostosis when indicated. Timing and approach depend on severity and uni- vs bilateral involvement.
"																																																								"{""description"": ""Surgical correction of craniosynostosis when indicated. Timing and approach depend on severity and uni- vs bilateral involvement.\n"", ""name"": ""Cranial Vault Surgery""}"	{}	"{""description"": ""Surgical correction of craniosynostosis when indicated. Timing and approach depend on severity and uni- vs bilateral involvement.\n"", ""name"": ""Cranial Vault Surgery"", ""treatment_term"": {""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5191	217	Muenke Syndrome	Muenke_Syndrome.yaml	treatments	1	Hearing Management	"Audiologic evaluation and hearing aids or other interventions for sensorineural hearing loss.
"																																																								"{""description"": ""Audiologic evaluation and hearing aids or other interventions for sensorineural hearing loss.\n"", ""name"": ""Hearing Management""}"	{}	"{""description"": ""Audiologic evaluation and hearing aids or other interventions for sensorineural hearing loss.\n"", ""name"": ""Hearing Management""}"
5209	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	0	Prophylactic Thyroidectomy	Total thyroidectomy prevents MTC development. Timing is based on ATA risk stratification: highest risk (M918T) in first year of life; high risk (codon 634, A883F) before age 5; moderate risk individualized based on calcitonin levels and family history. Central lymph node dissection may be included.																																																								"{""description"": ""Total thyroidectomy prevents MTC development. Timing is based on ATA risk stratification: highest risk (M918T) in first year of life; high risk (codon 634, A883F) before age 5; moderate risk individualized based on calcitonin levels and family history. Central lymph node dissection may be included."", ""name"": ""Prophylactic Thyroidectomy""}"	{}	"{""description"": ""Total thyroidectomy prevents MTC development. Timing is based on ATA risk stratification: highest risk (M918T) in first year of life; high risk (codon 634, A883F) before age 5; moderate risk individualized based on calcitonin levels and family history. Central lymph node dissection may be included."", ""evidence"": [{""explanation"": ""Review confirms prophylactic thyroidectomy as curative treatment for MEN2 with excellent outcomes when performed early based on genotype."", ""reference"": ""PMID:21862994"", ""snippet"": ""Surgery is the primary treatment and only chance of cure, although the advent of targeted therapies seems to be improving progression-free survival in advanced cases. Since the discovery of the role of RET in MEN2A, considerable advances in the management of this syndrome have occurred, and most of the children with MEN2A who have undergone early thyroidectomy will now lead full, productive lives."", ""supports"": ""SUPPORT""}], ""name"": ""Prophylactic Thyroidectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5210	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	1	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.																																																								"{""description"": ""Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative."", ""name"": ""RET Kinase Inhibitors""}"	{}	"{""description"": ""Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative."", ""name"": ""RET Kinase Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""selpercatinib"", ""term"": {""id"": ""CHEBI:175074"", ""label"": ""selpercatinib""}}]}}"
5211	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	2	Surveillance Protocol	Annual biochemical screening includes serum calcitonin, plasma metanephrines, calcium, and PTH. Imaging as indicated. After thyroidectomy, lifelong thyroid hormone replacement and calcitonin monitoring for recurrence. Screening starts from genetic diagnosis, which may be prenatally or in infancy.																																																								"{""description"": ""Annual biochemical screening includes serum calcitonin, plasma metanephrines, calcium, and PTH. Imaging as indicated. After thyroidectomy, lifelong thyroid hormone replacement and calcitonin monitoring for recurrence. Screening starts from genetic diagnosis, which may be prenatally or in infancy."", ""name"": ""Surveillance Protocol""}"	{}	"{""description"": ""Annual biochemical screening includes serum calcitonin, plasma metanephrines, calcium, and PTH. Imaging as indicated. After thyroidectomy, lifelong thyroid hormone replacement and calcitonin monitoring for recurrence. Screening starts from genetic diagnosis, which may be prenatally or in infancy."", ""name"": ""Surveillance Protocol"", ""treatment_term"": {""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}}"
5212	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	3	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows prophylactic thyroidectomy before MTC development. Prenatal and preimplantation genetic testing available.																																																								"{""description"": ""Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows prophylactic thyroidectomy before MTC development. Prenatal and preimplantation genetic testing available."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows prophylactic thyroidectomy before MTC development. Prenatal and preimplantation genetic testing available."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	Disease-Modifying Therapies (DMTs)	Medications that can slow the progression of the disease and reduce the frequency and severity of relapses.																																																								"{""description"": ""Medications that can slow the progression of the disease and reduce the frequency and severity of relapses."", ""name"": ""Disease-Modifying Therapies (DMTs)""}"	"{""examples"": [""Interferon-beta"", ""Glatiramer Acetate"", ""Natalizumab"", ""Fingolimod""]}"	"{""description"": ""Medications that can slow the progression of the disease and reduce the frequency and severity of relapses."", ""evidence"": [{""explanation"": ""The reference confirms the efficacy of interferon beta and glatiramer acetate in treating RRMS, which aligns with the statement about DMTs reducing the frequency and severity of relapses."", ""reference"": ""PMID:12894379"", ""snippet"": ""In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the statement by indicating that DMDs reduce the frequency of relapses and progression of disability in MS."", ""reference"": ""PMID:24494618"", ""snippet"": ""Diseasemodifying drugs (DMDs) that reduce the frequency of relapses, development of brain lesions, and progression of disability are the standard of care for relapsing forms of MS, and the use of DMDs should be initiated as early as possible"", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the statement by highlighting the beneficial effects of fingolimod and natalizumab on patients' work life, indirectly supporting their role in reducing the severity of relapses."", ""reference"": ""PMID:29921609"", ""snippet"": ""Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the statement regarding the reduction of relapse rates and disease burden but notes that the benefits on long-term disability reduction are less clear."", ""reference"": ""PMID:27549763"", ""snippet"": ""Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference supports the statement by indicating that FDA-approved medications aim to alleviate disease progression and reduce neurodegeneration, which aligns with the description of DMTs."", ""reference"": ""PMID:32560364"", ""snippet"": ""Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration."", ""supports"": ""SUPPORT""}], ""examples"": [""Interferon-beta"", ""Glatiramer Acetate"", ""Natalizumab"", ""Fingolimod""], ""name"": ""Disease-Modifying Therapies (DMTs)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	Symptomatic Treatments	Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues.																																																								"{""description"": ""Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues."", ""name"": ""Symptomatic Treatments""}"	"{""examples"": [""Muscle Relaxants"", ""Physical Therapy"", ""Pain Management""]}"	"{""description"": ""Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues."", ""evidence"": [{""explanation"": ""This reference supports the statement by mentioning multiple therapies used to manage symptoms of multiple sclerosis, including muscle relaxants and other treatments."", ""reference"": ""PMID:9817541"", ""snippet"": ""Management of symptoms, however, can help everyone with the disease. Several new therapies, including tizanidine, intrathecal baclofen, botulinum toxin injections, gabapentin, ondansitron, thalamic stimulation, and lamotrigine, increase our treatment options."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by outlining various therapeutic options for managing spasticity, which is a symptom of multiple sclerosis."", ""reference"": ""PMID:36807901"", ""snippet"": ""Therapeutic options exist for the treatment of spasticity along a broad spectrum from nonpharmacologic to interventional procedures. Treatment strategies may include exercise, physical agent modalities, oral medications, injections, pumps, and surgery."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by describing the range of symptoms in multiple sclerosis and mentioning exercise as a therapeutic strategy."", ""reference"": ""PMID:15575796"", ""snippet"": ""The pathophysiology of multiple sclerosis (MS) is characterised by fatigue, motor weakness, spasticity, poor balance, heat sensitivity and mental depression."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by showing that reflexology can help manage symptoms like spasticity and bladder issues in multiple sclerosis patients."", ""reference"": ""PMID:12926840"", ""snippet"": ""Specific reflexology treatment was of benefit in alleviating motor; sensory and urinary symptoms in MS patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by discussing the challenges and management strategies for symptoms of multiple sclerosis, including spasticity."", ""reference"": ""PMID:26611270"", ""snippet"": ""Individuals with multiple sclerosis (MS) spasticity present a wide range of symptoms and disability levels that are frequently challenging to manage."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by discussing the need for specific therapeutic protocols for managing bladder dysfunction in multiple sclerosis."", ""reference"": ""PMID:35102733"", ""snippet"": ""The present study suggests the need of a specific therapeutic protocol, based on the degree of disability and symptom complexity in patients with MS-related neurogenic lower urinary tract dysfunction (NLUTD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by mentioning non-medicinal treatments for spasticity in multiple sclerosis."", ""reference"": ""PMID:22721366"", ""snippet"": ""Non-medicinal treatments of spasticity may be proposed in patients with multiple sclerosis as either an adjunct to pharmacological treatments or the first line of treatment."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by discussing the prevalence of spasticity in multiple sclerosis and the development of successful treatments."", ""reference"": ""PMID:11898533"", ""snippet"": ""Among the more common symptoms is spasticity. Despite a lack of full knowledge of the physiology causing this phenomenon, successful treatments have been developed."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by reviewing the treatments for main symptoms of multiple sclerosis, including fatigue, bladder issues, and spasticity."", ""reference"": ""PMID:16168933"", ""snippet"": ""First, we review treatment of the main symptoms of MS: fatigue, bladder and bowel disturbances, sexual dysfunction, cognitive and affective disorders, and spasticity."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by discussing the use of Sativex for managing symptoms associated with multiple sclerosis spasticity."", ""reference"": ""PMID:26166264"", ""snippet"": ""In this review, the effects of Sativex() oromucosal spray on symptoms and functional impairment associated with MS-related spasticity were examined"", ""supports"": ""SUPPORT""}], ""examples"": [""Muscle Relaxants"", ""Physical Therapy"", ""Pain Management""], ""name"": ""Symptomatic Treatments"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5246	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	2	Physical Therapy and Rehabilitation	Exercise programs and physical therapy to maintain mobility, strength, and function.																																																								"{""description"": ""Exercise programs and physical therapy to maintain mobility, strength, and function."", ""name"": ""Physical Therapy and Rehabilitation""}"	"{""examples"": [""Exercise therapy"", ""Gait training"", ""Balance exercises""]}"	"{""description"": ""Exercise programs and physical therapy to maintain mobility, strength, and function."", ""examples"": [""Exercise therapy"", ""Gait training"", ""Balance exercises""], ""name"": ""Physical Therapy and Rehabilitation"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5247	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	3	Corticosteroids	Used to reduce inflammation and speed recovery during acute exacerbations.																																																								"{""description"": ""Used to reduce inflammation and speed recovery during acute exacerbations."", ""name"": ""Corticosteroids""}"	"{""examples"": [""Prednisone"", ""Methylprednisolone""]}"	"{""description"": ""Used to reduce inflammation and speed recovery during acute exacerbations."", ""evidence"": [{""explanation"": ""The abstract clearly states that corticosteroids are used to treat MS exacerbations, which aligns with the statement that they are used to reduce inflammation and speed recovery during acute exacerbations."", ""reference"": ""PMID:17920542"", ""snippet"": ""The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this reference primarily discusses interferon beta preparations, it indirectly supports the use of other treatments like corticosteroids for MS exacerbations."", ""reference"": ""PMID:10073279"", ""snippet"": ""Three interferon beta preparations (Betaseron, Avonex, and Rebif) have shown efficacy in the treatment of relapsing-remitting multiple sclerosis (MS)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study did not find significant changes in evoked potentials with high-dose methylprednisolone, but it does not refute the use of corticosteroids for reducing inflammation and speeding recovery in MS exacerbations."", ""reference"": ""PMID:3940867"", ""snippet"": ""There were no manifest changes of the evoked potentials parameters parallel to the clinical effect of high-dose therapy."", ""supports"": ""NO_EVIDENCE""}], ""examples"": [""Prednisone"", ""Methylprednisolone""], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	Intravenous Immunoglobulin (IVIG)	Used to modulate the immune response and reduce inflammation.																																																								"{""description"": ""Used to modulate the immune response and reduce inflammation."", ""name"": ""Intravenous Immunoglobulin (IVIG)""}"	{}	"{""description"": ""Used to modulate the immune response and reduce inflammation."", ""evidence"": [{""explanation"": ""This statement supports the use of IVIG in the treatment of MIS-C, indicating its role in managing the condition."", ""reference"": ""PMID:38509432"", ""snippet"": ""A variety of treatment approaches, including intravenous immunoglobulins (IVIGs), glucocorticoids (GCs) and biologic agents, such as anakinra and infliximab, have been described for the management of COVID-19-related MIS-C."", ""supports"": ""SUPPORT""}, {""explanation"": ""This statement supports the use of IVIG for its anti-inflammatory effects in MIS-C."", ""reference"": ""PMID:34608458"", ""snippet"": ""Intravenous immunoglobulin (IVIG) targets IL-1beta(+) neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This statement supports the use of high-dose immunoglobulins, including IVIG, for their immunomodulatory and anti-inflammatory roles, which is relevant to MIS-C treatment."", ""reference"": ""PMID:37830631"", ""snippet"": ""The large-scale utilization of immunoglobulins in patients with inborn errors of immunity (IEIs) since 1952 prompted the discovery of their key role at high doses as immunomodulatory and anti-inflammatory therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference does not provide specific information about the use of IVIG in MIS-C."", ""reference"": ""PMID:34210761"", ""snippet"": ""Multisystem Inflammatory Syndrome in Children."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference discusses IVIG in the context of myocarditis, not MIS-C."", ""reference"": ""PMID:33463100"", ""snippet"": ""Intravenous Immunoglobulin Therapy in Myocarditis."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference discusses IVIG in the context of Systemic Sclerosis, not MIS-C."", ""reference"": ""PMID:30543921"", ""snippet"": ""Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference discusses antibody responses in MIS-C but does not specifically address IVIG use."", ""reference"": ""PMID:33263756"", ""snippet"": ""Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19)."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference discusses MIS-C but does not provide specific information about the use of IVIG."", ""reference"": ""PMID:37309831"", ""snippet"": ""Multisystem Inflammatory Syndrome in Children: Two Years' Worth of Learning."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference discusses IVIG in the context of hematologic disorders, not MIS-C."", ""reference"": ""PMID:28079913"", ""snippet"": ""Intravenous Immunoglobulin in the Treatment of Hematologic Disorders in Pediatrics."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Intravenous Immunoglobulin (IVIG)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5292	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	1	Corticosteroids	Anti-inflammatory medicines to reduce immune system activity and inflammation.																																																								"{""description"": ""Anti-inflammatory medicines to reduce immune system activity and inflammation."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Anti-inflammatory medicines to reduce immune system activity and inflammation."", ""evidence"": [{""explanation"": ""The term 'glucocorticoids' is used interchangeably with 'corticosteroids' in the context of MIS-C treatment, and the literature supports their use to reduce immune system activity and inflammation."", ""reference"": ""PMID:37534417"", ""snippet"": ""The optimal treatment of MIS-C is unknown, although prior studies have indicated benefits of intravenous immunoglobulin (IVIG) and glucocorticoids."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference explicitly mentions the use of corticosteroids as anti-inflammatory agents for treating MIS-C."", ""reference"": ""PMID:36571257"", ""snippet"": ""Anti-inflammatory agents, including intravenous immunoglobulin and corticosteroids, are commonly used."", ""supports"": ""SUPPORT""}, {""explanation"": ""Glucocorticoids (GCs), which are a type of corticosteroid, are mentioned as effective therapeutics for MIS-C."", ""reference"": ""PMID:35791863"", ""snippet"": ""Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs)."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5293	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	2	Aspirin	Used in cases with high risk of blood clots to prevent thrombotic complications.																																		Dose may vary.																						"{""description"": ""Used in cases with high risk of blood clots to prevent thrombotic complications."", ""name"": ""Aspirin"", ""notes"": ""Dose may vary.""}"	{}	"{""description"": ""Used in cases with high risk of blood clots to prevent thrombotic complications."", ""evidence"": [{""explanation"": ""The study describes the use of acetylsalicylic acid (aspirin) in critically ill children with MIS-C to manage coagulation abnormalities."", ""reference"": ""PMID:34941014"", ""snippet"": ""All patients received acetylsalicylic acid (80-100 mg/kg) and none received anticoagulation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study indicates that anticoagulant prophylaxis, which may include aspirin, is considered for patients with other pro-thrombotic risk factors, but not universally applied."", ""reference"": ""PMID:33305475"", ""snippet"": ""Universal anticoagulant prophylaxis in hospitalized children with SARS-CoV-2-related manifestations is not warranted, but may be offered to patients with other pro-thrombotic risk factors in the context of a multi-modal therapeutic approach."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study focuses on the use of IVIg, GCs, and bDMARDs for treating MIS-C but does not mention the use of aspirin."", ""reference"": ""PMID:35791863"", ""snippet"": ""Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs)."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Aspirin"", ""notes"": ""Dose may vary."", ""treatment_term"": {""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}}"
5294	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	3	Supportive Care	Including fluids, blood pressure support, and respiratory support as needed.																																																								"{""description"": ""Including fluids, blood pressure support, and respiratory support as needed."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Including fluids, blood pressure support, and respiratory support as needed."", ""evidence"": [{""explanation"": ""This reference provides evidence that children with MIS-C required mechanical ventilation (respiratory support) and inotropic support (blood pressure support), supporting the statement about the need for supportive care."", ""reference"": ""PMID:33760725"", ""snippet"": ""In total, 10 (38.5%) children required mechanical ventilation; 13 (50.0%) required inotropic support."", ""supports"": ""SUPPORT""}, {""explanation"": ""The necessity of VA-ECMO (a type of respiratory and cardiovascular support) in severe MIS-C cases supports the statement about the need for supportive care measures including fluids, blood pressure support, and respiratory support."", ""reference"": ""PMID:34034587"", ""snippet"": ""These children developed severely depressed myocardial function with end-organ injury and were cannulated to veno-arterial extracorporeal membrane oxygenation (VA-ECMO) due to cardiogenic shock with arrhythmia."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5318	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	0	Pacing	Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise.																																		Currently the most widely recommended management approach																						"{""description"": ""Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise."", ""name"": ""Pacing"", ""notes"": ""Currently the most widely recommended management approach""}"	{}	"{""description"": ""Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise."", ""evidence"": [{""explanation"": ""Scoping review confirms pacing is the primary self-management strategy for ME/CFS."", ""reference"": ""PMID:37838675"", ""snippet"": ""it typically comprises regulating activity to avoid post exertional malaise (PEM), the worsening of symptoms after an activity"", ""supports"": ""SUPPORT""}], ""name"": ""Pacing"", ""notes"": ""Currently the most widely recommended management approach"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5319	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	1	Symptomatic Treatment	Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance.																																																								"{""description"": ""Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance."", ""name"": ""Symptomatic Treatment""}"	{}	"{""description"": ""Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance."", ""evidence"": [{""explanation"": ""The IOM report recommends symptomatic treatment approaches."", ""reference"": ""PMID:25695122"", ""snippet"": ""Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome will be a valuable resource to promote the prompt diagnosis of patients with this complex, multisystem, and often devastating disorder"", ""supports"": ""SUPPORT""}], ""name"": ""Symptomatic Treatment"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5320	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	2	Low-Dose Naltrexone	Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation.																																		Under investigation; not yet proven in randomized trials																						"{""description"": ""Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation."", ""name"": ""Low-Dose Naltrexone"", ""notes"": ""Under investigation; not yet proven in randomized trials""}"	{}	"{""description"": ""Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation."", ""evidence"": [{""explanation"": ""In vitro evidence supports naltrexone restoring TRPM3 function in ME/CFS NK cells."", ""reference"": ""PMID:31736966"", ""snippet"": ""TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX"", ""supports"": ""PARTIAL""}], ""name"": ""Low-Dose Naltrexone"", ""notes"": ""Under investigation; not yet proven in randomized trials"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5346	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	0	Acetylcholinesterase Inhibitors	First-line symptomatic treatment (pyridostigmine).																																																								"{""description"": ""First-line symptomatic treatment (pyridostigmine)."", ""name"": ""Acetylcholinesterase Inhibitors""}"	{}	"{""description"": ""First-line symptomatic treatment (pyridostigmine)."", ""evidence"": [{""explanation"": ""Large cross-sectional study demonstrates patient-reported effectiveness of pyridostigmine."", ""reference"": ""PMID:36184373"", ""snippet"": ""Patients reported a median effectiveness of 60, IQR 28-78 and net benefit of 65, IQR 45-84."", ""supports"": ""SUPPORT""}, {""explanation"": ""While effective, pyridostigmine has high rate of side effects including GI symptoms."", ""reference"": ""PMID:36184373"", ""snippet"": ""Of all patients currently using pyridostigmine, 91% reported side effects (vs. 55% in the control group)."", ""supports"": ""SUPPORT""}], ""name"": ""Acetylcholinesterase Inhibitors"", ""treatment_term"": {""preferred_term"": ""acetylcholinesterase inhibitor therapy"", ""term"": {""id"": ""MAXO:0000645"", ""label"": ""acetylcholinesterase inhibitor therapy""}}}"
5347	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	1	Corticosteroids	Prednisone for immunosuppression, mainstay of therapy.																																																								"{""description"": ""Prednisone for immunosuppression, mainstay of therapy."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Prednisone for immunosuppression, mainstay of therapy."", ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}}"
5348	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	2	Thymectomy	Surgical removal of thymus, improves outcomes in appropriate patients.																																																								"{""description"": ""Surgical removal of thymus, improves outcomes in appropriate patients."", ""name"": ""Thymectomy""}"	{}	"{""description"": ""Surgical removal of thymus, improves outcomes in appropriate patients."", ""evidence"": [{""explanation"": ""Landmark randomized trial demonstrates thymectomy improves clinical outcomes in nonthymomatous MG."", ""reference"": ""PMID:27509100"", ""snippet"": ""Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001)"", ""supports"": ""SUPPORT""}, {""explanation"": ""Thymectomy reduces need for additional immunosuppression and hospitalizations."", ""reference"": ""PMID:27509100"", ""snippet"": ""Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001)."", ""supports"": ""SUPPORT""}], ""name"": ""Thymectomy"", ""treatment_term"": {""preferred_term"": ""thymectomy"", ""term"": {""id"": ""MAXO:0001079"", ""label"": ""thymectomy""}}}"
5349	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	3	Azathioprine	Steroid-sparing immunosuppressant.																																																								"{""description"": ""Steroid-sparing immunosuppressant."", ""name"": ""Azathioprine""}"	{}	"{""description"": ""Steroid-sparing immunosuppressant."", ""name"": ""Azathioprine"", ""treatment_term"": {""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}}"
5350	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	4	Mycophenolate Mofetil	Alternative immunosuppressant.																																																								"{""description"": ""Alternative immunosuppressant."", ""name"": ""Mycophenolate Mofetil""}"	{}	"{""description"": ""Alternative immunosuppressant."", ""name"": ""Mycophenolate Mofetil"", ""treatment_term"": {""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}}"
5351	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	5	Rituximab	Anti-CD20 antibody, effective in refractory cases.																																																								"{""description"": ""Anti-CD20 antibody, effective in refractory cases."", ""name"": ""Rituximab""}"	{}	"{""description"": ""Anti-CD20 antibody, effective in refractory cases."", ""name"": ""Rituximab"", ""treatment_term"": {""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}}"
5352	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	6	Eculizumab	Complement inhibitor (anti-C5), approved for refractory AChR+ MG.																																																								"{""description"": ""Complement inhibitor (anti-C5), approved for refractory AChR+ MG."", ""name"": ""Eculizumab""}"	{}	"{""description"": ""Complement inhibitor (anti-C5), approved for refractory AChR+ MG."", ""evidence"": [{""explanation"": ""Phase 3 REGAIN trial evaluated eculizumab in refractory generalized MG."", ""reference"": ""PMID:29066163"", ""snippet"": ""Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis."", ""supports"": ""SUPPORT""}, {""explanation"": ""Eculizumab reduced exacerbation rates compared to placebo."", ""reference"": ""PMID:29066163"", ""snippet"": ""Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group."", ""supports"": ""SUPPORT""}], ""name"": ""Eculizumab"", ""treatment_term"": {""preferred_term"": ""complement 5 inhibitor agent therapy"", ""term"": {""id"": ""MAXO:0001483"", ""label"": ""complement 5 inhibitor agent therapy""}}}"
5353	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	7	Plasma Exchange	Rapid removal of antibodies, used for myasthenic crisis.																																																								"{""description"": ""Rapid removal of antibodies, used for myasthenic crisis."", ""name"": ""Plasma Exchange""}"	{}	"{""description"": ""Rapid removal of antibodies, used for myasthenic crisis."", ""evidence"": [{""explanation"": ""Plasma exchange is highly effective, particularly in MuSK-MG where it outperforms IVIG."", ""reference"": ""PMID:21674519"", ""snippet"": ""Plasma exchange (PLEX) produced improvement in 93%, whereas only 61% improved after intravenous immunoglobulin."", ""supports"": ""SUPPORT""}], ""name"": ""Plasma Exchange""}"
5354	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	8	Intravenous Immunoglobulin	Immunomodulation, used for exacerbations and crisis.																																																								"{""description"": ""Immunomodulation, used for exacerbations and crisis."", ""name"": ""Intravenous Immunoglobulin""}"	{}	"{""description"": ""Immunomodulation, used for exacerbations and crisis."", ""name"": ""Intravenous Immunoglobulin""}"
5371	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	0	Intensive Chemotherapy (7+3)	Standard induction with 7 days cytarabine and 3 days anthracycline achieves high complete remission rates in NPM1-mutated AML. Consolidation with high-dose cytarabine is particularly effective for this subtype.																																																								"{""description"": ""Standard induction with 7 days cytarabine and 3 days anthracycline achieves high complete remission rates in NPM1-mutated AML. Consolidation with high-dose cytarabine is particularly effective for this subtype."", ""name"": ""Intensive Chemotherapy (7+3)""}"	{}	"{""description"": ""Standard induction with 7 days cytarabine and 3 days anthracycline achieves high complete remission rates in NPM1-mutated AML. Consolidation with high-dose cytarabine is particularly effective for this subtype."", ""name"": ""Intensive Chemotherapy (7+3)"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
5372	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	1	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.																																																								"{""description"": ""For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features."", ""name"": ""Venetoclax plus Azacitidine""}"	{}	"{""description"": ""For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features."", ""name"": ""Venetoclax plus Azacitidine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}}"
5373	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Generally reserved for patients with NPM1 mutation plus FLT3-ITD or other adverse features in first remission, or for patients who relapse. May not be necessary for favorable-risk NPM1-mutated AML in first remission.																																																								"{""description"": ""Generally reserved for patients with NPM1 mutation plus FLT3-ITD or other adverse features in first remission, or for patients who relapse. May not be necessary for favorable-risk NPM1-mutated AML in first remission."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Generally reserved for patients with NPM1 mutation plus FLT3-ITD or other adverse features in first remission, or for patients who relapse. May not be necessary for favorable-risk NPM1-mutated AML in first remission."", ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
5374	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	3	MRD-Guided Therapy	NPM1 mutation transcript levels by RT-PCR provide sensitive minimal residual disease monitoring. Rising MRD levels can guide preemptive treatment before overt relapse.																																																								"{""description"": ""NPM1 mutation transcript levels by RT-PCR provide sensitive minimal residual disease monitoring. Rising MRD levels can guide preemptive treatment before overt relapse."", ""name"": ""MRD-Guided Therapy""}"	{}	"{""description"": ""NPM1 mutation transcript levels by RT-PCR provide sensitive minimal residual disease monitoring. Rising MRD levels can guide preemptive treatment before overt relapse."", ""name"": ""MRD-Guided Therapy"", ""treatment_term"": {""preferred_term"": ""genetic testing"", ""term"": {""id"": ""MAXO:0000127"", ""label"": ""genetic testing""}}}"
5385	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	0	MEK Inhibitors	MEK inhibitors (binimetinib, trametinib) have demonstrated modest activity in NRAS-mutant melanoma. Response rates are lower than in BRAF-mutant disease (approximately 15-20%), but MEK inhibition represents one of the few targeted options for this molecular subtype.																																																								"{""description"": ""MEK inhibitors (binimetinib, trametinib) have demonstrated modest activity in NRAS-mutant melanoma. Response rates are lower than in BRAF-mutant disease (approximately 15-20%), but MEK inhibition represents one of the few targeted options for this molecular subtype."", ""name"": ""MEK Inhibitors""}"	{}	"{""description"": ""MEK inhibitors (binimetinib, trametinib) have demonstrated modest activity in NRAS-mutant melanoma. Response rates are lower than in BRAF-mutant disease (approximately 15-20%), but MEK inhibition represents one of the few targeted options for this molecular subtype."", ""name"": ""MEK Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5386	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	1	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are the primary treatment for advanced NRAS-mutant melanoma. NRAS-mutant tumors may have higher tumor mutational burden, potentially enhancing immunotherapy responsiveness.																																																								"{""description"": ""Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are the primary treatment for advanced NRAS-mutant melanoma. NRAS-mutant tumors may have higher tumor mutational burden, potentially enhancing immunotherapy responsiveness."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are the primary treatment for advanced NRAS-mutant melanoma. NRAS-mutant tumors may have higher tumor mutational burden, potentially enhancing immunotherapy responsiveness."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5387	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	2	Combination Targeted Therapy	Clinical trials are investigating combinations targeting both MAPK and PI3K pathways, as well as CDK4/6 inhibitors given the importance of cell cycle dysregulation in NRAS-mutant melanoma.																																																								"{""description"": ""Clinical trials are investigating combinations targeting both MAPK and PI3K pathways, as well as CDK4/6 inhibitors given the importance of cell cycle dysregulation in NRAS-mutant melanoma."", ""name"": ""Combination Targeted Therapy""}"	{}	"{""description"": ""Clinical trials are investigating combinations targeting both MAPK and PI3K pathways, as well as CDK4/6 inhibitors given the importance of cell cycle dysregulation in NRAS-mutant melanoma."", ""name"": ""Combination Targeted Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5401	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	0	Larotrectinib	Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval.																																																								"{""description"": ""Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval."", ""name"": ""Larotrectinib""}"	{}	"{""description"": ""Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval."", ""evidence"": [{""explanation"": ""Abstract states larotrectinib can be used when NTRK fusions are detected."", ""reference"": ""PMID:33258061"", ""snippet"": ""If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity."", ""supports"": ""SUPPORT""}], ""name"": ""Larotrectinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.																																																								"{""description"": ""TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases."", ""name"": ""Entrectinib""}"	{}	"{""description"": ""TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases."", ""evidence"": [{""explanation"": ""Abstract states entrectinib can be used when NTRK fusions are detected."", ""reference"": ""PMID:33258061"", ""snippet"": ""If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity."", ""supports"": ""SUPPORT""}], ""name"": ""Entrectinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""entrectinib"", ""term"": {""id"": ""CHEBI:195558"", ""label"": ""entrectinib""}}]}}"
5403	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	2	Repotrectinib	Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors.																																																								"{""description"": ""Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors."", ""name"": ""Repotrectinib""}"	{}	"{""description"": ""Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors."", ""name"": ""Repotrectinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5420	227	Narcolepsy	Narcolepsy.yaml	treatments	0	Sodium Oxybate	First-line for cataplexy and daytime sleepiness, improves nighttime sleep.																																																								"{""description"": ""First-line for cataplexy and daytime sleepiness, improves nighttime sleep."", ""name"": ""Sodium Oxybate""}"	{}	"{""description"": ""First-line for cataplexy and daytime sleepiness, improves nighttime sleep."", ""evidence"": [{""explanation"": ""Systematic review and meta-analysis of 6 RCTs confirms efficacy for both cataplexy and sleepiness with acceptable safety."", ""reference"": ""PMID:22893778"", ""snippet"": ""Narcolepsy patients on SXB have significant reductions in cataplexy and daytime sleepiness. SXB is well tolerated in patients with narcolepsy, and most adverse events were mild to moderate in severity."", ""supports"": ""SUPPORT""}], ""name"": ""Sodium Oxybate"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5421	227	Narcolepsy	Narcolepsy.yaml	treatments	1	Modafinil	Wake-promoting agent for excessive daytime sleepiness.																																																								"{""description"": ""Wake-promoting agent for excessive daytime sleepiness."", ""name"": ""Modafinil""}"	{}	"{""description"": ""Wake-promoting agent for excessive daytime sleepiness."", ""evidence"": [{""explanation"": ""Systematic review and meta-analysis of 9 RCTs confirms modafinil efficacy for excessive daytime sleepiness."", ""reference"": ""PMID:20671626"", ""snippet"": ""In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy."", ""supports"": ""SUPPORT""}], ""name"": ""Modafinil"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5422	227	Narcolepsy	Narcolepsy.yaml	treatments	2	Pitolisant	Histamine H3 receptor antagonist, promotes wakefulness.																																																								"{""description"": ""Histamine H3 receptor antagonist, promotes wakefulness."", ""name"": ""Pitolisant""}"	{}	"{""description"": ""Histamine H3 receptor antagonist, promotes wakefulness."", ""evidence"": [{""explanation"": ""Analysis of randomized placebo-controlled trials demonstrates large effect sizes for pitolisant."", ""reference"": ""PMID:34935103"", ""snippet"": ""The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy."", ""supports"": ""SUPPORT""}], ""name"": ""Pitolisant"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5423	227	Narcolepsy	Narcolepsy.yaml	treatments	3	Solriamfetol	Dopamine/norepinephrine reuptake inhibitor for sleepiness.																																																								"{""description"": ""Dopamine/norepinephrine reuptake inhibitor for sleepiness."", ""name"": ""Solriamfetol""}"	{}	"{""description"": ""Dopamine/norepinephrine reuptake inhibitor for sleepiness."", ""evidence"": [{""explanation"": ""Phase 3 RCT demonstrated significant improvements in MWT and ESS scores versus placebo."", ""reference"": ""PMID:30694576"", ""snippet"": ""Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy."", ""supports"": ""SUPPORT""}], ""name"": ""Solriamfetol"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5424	227	Narcolepsy	Narcolepsy.yaml	treatments	4	Amphetamines	Traditional stimulants (amphetamine, methylphenidate).																																																								"{""description"": ""Traditional stimulants (amphetamine, methylphenidate)."", ""name"": ""Amphetamines""}"	{}	"{""description"": ""Traditional stimulants (amphetamine, methylphenidate)."", ""evidence"": [{""explanation"": ""Confirms amphetamines were traditional first-line treatments for EDS before modafinil."", ""reference"": ""PMID:18830438"", ""snippet"": ""Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks"", ""supports"": ""SUPPORT""}], ""name"": ""Amphetamines"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5425	227	Narcolepsy	Narcolepsy.yaml	treatments	5	Antidepressants	SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).																																																								"{""description"": ""SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine)."", ""name"": ""Antidepressants""}"	{}	"{""description"": ""SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine)."", ""evidence"": [{""explanation"": ""Prospective study of 148 patients showed significant improvement in cataplexy and sleepiness with antidepressants."", ""reference"": ""PMID:30837110"", ""snippet"": ""Venlafaxine demonstrated significantly greater improvements in MSL in the MWT (p < 0.01)."", ""supports"": ""SUPPORT""}], ""name"": ""Antidepressants"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5426	227	Narcolepsy	Narcolepsy.yaml	treatments	6	Scheduled Naps	Short planned naps can improve alertness.																																																								"{""description"": ""Short planned naps can improve alertness."", ""name"": ""Scheduled Naps""}"	{}	"{""description"": ""Short planned naps can improve alertness."", ""evidence"": [{""explanation"": ""Review discusses comprehensive narcolepsy management including behavioral approaches like scheduled naps."", ""reference"": ""PMID:18830438"", ""snippet"": ""The management of narcolepsy is presently at a turning point."", ""supports"": ""SUPPORT""}], ""name"": ""Scheduled Naps"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
5448	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	0	Intensity-Modulated Radiation Therapy	NPC is highly radiosensitive. IMRT is the standard of care for locoregional disease, allowing precise dose delivery while sparing critical structures including parotid glands, temporal lobes, and brainstem.																																																								"{""description"": ""NPC is highly radiosensitive. IMRT is the standard of care for locoregional disease, allowing precise dose delivery while sparing critical structures including parotid glands, temporal lobes, and brainstem."", ""name"": ""Intensity-Modulated Radiation Therapy""}"	{}	"{""description"": ""NPC is highly radiosensitive. IMRT is the standard of care for locoregional disease, allowing precise dose delivery while sparing critical structures including parotid glands, temporal lobes, and brainstem."", ""name"": ""Intensity-Modulated Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
5449	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	1	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.																																																								"{""description"": ""Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone."", ""name"": ""Concurrent Chemoradiation""}"	{}	"{""description"": ""Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone."", ""name"": ""Concurrent Chemoradiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}}"
5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.																																																								"{""description"": ""Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival."", ""name"": ""Induction Chemotherapy""}"	{}	"{""description"": ""Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival."", ""name"": ""Induction Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""gemcitabine"", ""term"": {""id"": ""CHEBI:175901"", ""label"": ""gemcitabine""}}, {""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}}"
5451	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	3	Immunotherapy	PD-1 inhibitors have shown significant activity in recurrent/metastatic NPC, with durable responses in a subset of patients. EBV antigens may serve as targets for immunotherapy, and adoptive T cell therapy targeting EBV is under investigation.																																																								"{""description"": ""PD-1 inhibitors have shown significant activity in recurrent/metastatic NPC, with durable responses in a subset of patients. EBV antigens may serve as targets for immunotherapy, and adoptive T cell therapy targeting EBV is under investigation."", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""PD-1 inhibitors have shown significant activity in recurrent/metastatic NPC, with durable responses in a subset of patients. EBV antigens may serve as targets for immunotherapy, and adoptive T cell therapy targeting EBV is under investigation."", ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5488	229	Nephronophthisis	Nephronophthisis.yaml	treatments	0	Renal Replacement Therapy	Dialysis or kidney transplantation for end-stage renal disease.																																																								"{""description"": ""Dialysis or kidney transplantation for end-stage renal disease."", ""name"": ""Renal Replacement Therapy""}"	{}	"{""description"": ""Dialysis or kidney transplantation for end-stage renal disease."", ""evidence"": [{""explanation"": ""The abstract discusses that Nephronophthisis often leads to end-stage renal disease (ESRD) and mentions living donor transplantation as a beneficial renal replacement therapy option."", ""reference"": ""PMID:32906116"", ""snippet"": ""Nephronophthisis (NPHP) is an autosomal recessive disease manifesting as tubulointerstitial nephritis uniformly progressing to ESRD in approximately 5-10% patients in childhood. Living donor transplantation is the most beneficial mean of renal replacement therapy compared to other methods."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this reference focuses on diabetic nephropathy, it supports the statement that renal replacement therapies for ESRD include dialysis and kidney transplantation."", ""reference"": ""PMID:15715116"", ""snippet"": ""Diabetes and ESRD receiving Renal Replacement Therapy (RRT)... The main choices of modalities are: 1) haemodialysis (HD), 2) Peritoneal dialysis (PD), 3) Kidney transplantation alone (KTA) or 4) simultaneous kidney and pancreas transplantation (SPKT)."", ""supports"": ""SUPPORT""}], ""name"": ""Renal Replacement Therapy"", ""treatment_term"": {""preferred_term"": ""renal dialysis"", ""term"": {""id"": ""MAXO:0000601"", ""label"": ""renal dialysis""}}}"
5489	229	Nephronophthisis	Nephronophthisis.yaml	treatments	1	Antihypertensive Therapy	Management of blood pressure with medications.																																																								"{""description"": ""Management of blood pressure with medications."", ""name"": ""Antihypertensive Therapy""}"	{}	"{""description"": ""Management of blood pressure with medications."", ""evidence"": [{""explanation"": ""This source suggests that managing blood pressure is essential in the context of CKD, which is related to nephron function. However, it does not explicitly mention Nephronophthisis, a specific type of nephropathy."", ""reference"": ""PMID:36224286"", ""snippet"": ""Chronic kidney disease (CKD) is one of the strongest risk factors for hypertension, and hypertension can exacerbate the progression of CKD... therefore, one of the best strategies to slow the progression of CKD is to maintain the 'numbers' of these essential components necessary to preserve renal function. To this end, both the achievement of an optimal blood pressure and a maximum reduction in urinary protein excretion are essential."", ""supports"": ""PARTIAL""}, {""explanation"": ""This source provides comprehensive information on the evaluation and management of resistant hypertension but does not discuss Nephronophthisis specifically."", ""reference"": ""PMID:30354828"", ""snippet"": ""Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes...evaluation includes identification of contributing lifestyle issues, detection of drugs interfering with antihypertensive medication effectiveness, screening for secondary hypertension, and assessment of target organ damage. Management of RH includes maximization of lifestyle interventions, use of long-acting thiazide-like diuretics (chlorthalidone or indapamide), addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower BP."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Antihypertensive Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5490	229	Nephronophthisis	Nephronophthisis.yaml	treatments	2	Supportive Care	Symptomatic treatment and monitoring to manage associated complications.																																																								"{""description"": ""Symptomatic treatment and monitoring to manage associated complications."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Symptomatic treatment and monitoring to manage associated complications."", ""evidence"": [{""explanation"": ""There is no curative treatment for nephronophthisis, indicating that supportive care, including symptomatic treatment and monitoring, is currently applied to manage associated complications."", ""reference"": ""PMID:35533128"", ""snippet"": ""At the moment there is no healing therapy, so early kidney transplant is a fundamental tool to improve prognosis."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.																																																								"{""description"": ""Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan."", ""name"": ""Risk-Adapted Chemotherapy""}"	{}	"{""description"": ""Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan."", ""name"": ""Risk-Adapted Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}}"
5512	230	Neuroblastoma	Neuroblastoma.yaml	treatments	1	Surgical Resection	Surgery for primary tumor resection is performed after chemotherapy for high-risk disease. Complete resection is associated with better outcomes when achievable without significant morbidity.																																																								"{""description"": ""Surgery for primary tumor resection is performed after chemotherapy for high-risk disease. Complete resection is associated with better outcomes when achievable without significant morbidity."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgery for primary tumor resection is performed after chemotherapy for high-risk disease. Complete resection is associated with better outcomes when achievable without significant morbidity."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5513	230	Neuroblastoma	Neuroblastoma.yaml	treatments	2	Autologous Stem Cell Transplant	High-dose chemotherapy with autologous stem cell rescue is standard for high-risk neuroblastoma following induction chemotherapy and surgical resection. Tandem transplant may provide additional benefit.																																																								"{""description"": ""High-dose chemotherapy with autologous stem cell rescue is standard for high-risk neuroblastoma following induction chemotherapy and surgical resection. Tandem transplant may provide additional benefit."", ""name"": ""Autologous Stem Cell Transplant""}"	{}	"{""description"": ""High-dose chemotherapy with autologous stem cell rescue is standard for high-risk neuroblastoma following induction chemotherapy and surgical resection. Tandem transplant may provide additional benefit."", ""name"": ""Autologous Stem Cell Transplant"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
5514	230	Neuroblastoma	Neuroblastoma.yaml	treatments	3	Radiation Therapy	Radiation to the primary tumor bed is used in high-risk disease following surgical resection and stem cell transplant.																																																								"{""description"": ""Radiation to the primary tumor bed is used in high-risk disease following surgical resection and stem cell transplant."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Radiation to the primary tumor bed is used in high-risk disease following surgical resection and stem cell transplant."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
5515	230	Neuroblastoma	Neuroblastoma.yaml	treatments	4	Anti-GD2 Immunotherapy	Anti-GD2 monoclonal antibody (dinutuximab) combined with GM-CSF and IL-2 has significantly improved outcomes in high-risk neuroblastoma during maintenance therapy. GD2 is highly expressed on neuroblastoma cells.																																																								"{""description"": ""Anti-GD2 monoclonal antibody (dinutuximab) combined with GM-CSF and IL-2 has significantly improved outcomes in high-risk neuroblastoma during maintenance therapy. GD2 is highly expressed on neuroblastoma cells."", ""name"": ""Anti-GD2 Immunotherapy""}"	{}	"{""description"": ""Anti-GD2 monoclonal antibody (dinutuximab) combined with GM-CSF and IL-2 has significantly improved outcomes in high-risk neuroblastoma during maintenance therapy. GD2 is highly expressed on neuroblastoma cells."", ""name"": ""Anti-GD2 Immunotherapy"", ""treatment_term"": {""preferred_term"": ""immunotherapy procedure"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}}"
5516	230	Neuroblastoma	Neuroblastoma.yaml	treatments	5	Isotretinoin (Retinoic Acid)	13-cis-retinoic acid (isotretinoin) is given during maintenance therapy to promote differentiation of residual neuroblastoma cells and reduce relapse risk.																																																								"{""description"": ""13-cis-retinoic acid (isotretinoin) is given during maintenance therapy to promote differentiation of residual neuroblastoma cells and reduce relapse risk."", ""name"": ""Isotretinoin (Retinoic Acid)""}"	{}	"{""description"": ""13-cis-retinoic acid (isotretinoin) is given during maintenance therapy to promote differentiation of residual neuroblastoma cells and reduce relapse risk."", ""name"": ""Isotretinoin (Retinoic Acid)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5531	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	0	MEK Inhibitors	Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials.																																																								"{""description"": ""Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials."", ""name"": ""MEK Inhibitors""}"	{}	"{""description"": ""Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials."", ""evidence"": [{""explanation"": ""SPRINT trial demonstrated selumetinib efficacy in plexiform neurofibromas leading to FDA approval for pediatric NF1 patients."", ""reference"": ""PMID:33395032"", ""snippet"": ""The phase 2 trial (SPRINT) of selumetinib in pNF resulted in at least 20% reduction in the size of pNF from baseline in 71% of patients and was associated with clinically meaningful improvements. On the basis of this trial, selumetinib (Koselugo) received FDA approval for children 2 years of age and older with inoperable, symptomatic pNF."", ""supports"": ""SUPPORT""}], ""name"": ""MEK Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5532	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	1	Surgical Management	Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST.																																																								"{""description"": ""Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST."", ""name"": ""Surgical Management""}"	{}	"{""description"": ""Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST."", ""name"": ""Surgical Management"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5533	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	2	Surveillance Protocol	Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma.																																																								"{""description"": ""Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma."", ""name"": ""Surveillance Protocol""}"	{}	"{""description"": ""Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma."", ""name"": ""Surveillance Protocol"", ""treatment_term"": {""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}}"
5534	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	3	Genetic Counseling	Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult.																																																								"{""description"": ""Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
5541	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	0	Eculizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.																																																								"{""description"": ""Maintenance therapy approved for AQP-4 seropositive NMOSD."", ""name"": ""Eculizumab""}"	{}	"{""description"": ""Maintenance therapy approved for AQP-4 seropositive NMOSD."", ""evidence"": [{""explanation"": ""The abstract lists eculizumab as an approved maintenance therapy for NMOSD."", ""reference"": ""PMID:33741809"", ""snippet"": ""Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD."", ""supports"": ""SUPPORT""}], ""name"": ""Eculizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5542	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	1	Inebilizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.																																																								"{""description"": ""Maintenance therapy approved for AQP-4 seropositive NMOSD."", ""name"": ""Inebilizumab""}"	{}	"{""description"": ""Maintenance therapy approved for AQP-4 seropositive NMOSD."", ""evidence"": [{""explanation"": ""The abstract lists inebilizumab as an approved maintenance therapy for NMOSD."", ""reference"": ""PMID:33741809"", ""snippet"": ""Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD."", ""supports"": ""SUPPORT""}], ""name"": ""Inebilizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5543	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	2	Satralizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.																																																								"{""description"": ""Maintenance therapy approved for AQP-4 seropositive NMOSD."", ""name"": ""Satralizumab""}"	{}	"{""description"": ""Maintenance therapy approved for AQP-4 seropositive NMOSD."", ""evidence"": [{""explanation"": ""The abstract lists satralizumab as an approved maintenance therapy for NMOSD."", ""reference"": ""PMID:33741809"", ""snippet"": ""Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD."", ""supports"": ""SUPPORT""}], ""name"": ""Satralizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5557	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	0	Acute Attack Treatment - Corticosteroids	"High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.
"																																																								"{""description"": ""High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.\n"", ""name"": ""Acute Attack Treatment - Corticosteroids""}"	{}	"{""description"": ""High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.\n"", ""name"": ""Acute Attack Treatment - Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5558	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	1	Acute Attack Treatment - Plasma Exchange	"Plasmapheresis is used for severe attacks unresponsive to steroids, removing pathogenic antibodies from circulation.
"																																																								"{""description"": ""Plasmapheresis is used for severe attacks unresponsive to steroids, removing pathogenic antibodies from circulation.\n"", ""name"": ""Acute Attack Treatment - Plasma Exchange""}"	{}	"{""description"": ""Plasmapheresis is used for severe attacks unresponsive to steroids, removing pathogenic antibodies from circulation.\n"", ""name"": ""Acute Attack Treatment - Plasma Exchange""}"
5559	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	2	Rituximab	"Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.
"																																																								"{""description"": ""Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.\n"", ""name"": ""Rituximab""}"	{}	"{""description"": ""Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.\n"", ""name"": ""Rituximab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5560	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	3	Eculizumab	"Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.
"																																																								"{""description"": ""Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.\n"", ""name"": ""Eculizumab""}"	{}	"{""description"": ""Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.\n"", ""evidence"": [{""explanation"": ""The PREVENT trial demonstrated 94% reduction in relapse risk with eculizumab in AQP4-IgG-positive NMOSD."", ""reference"": ""PMID:31050279"", ""snippet"": ""Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab group and 20 of 47 (43%) in the placebo group"", ""supports"": ""SUPPORT""}, {""explanation"": ""Review confirms eculizumab as first approved targeted therapy for NMOSD."", ""reference"": ""PMID:32266705"", ""snippet"": ""The terminal complement protein (C5) inhibitor eculizumab (Soliris) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive"", ""supports"": ""SUPPORT""}], ""name"": ""Eculizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5561	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	4	Inebilizumab	"Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.
"																																																								"{""description"": ""Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.\n"", ""name"": ""Inebilizumab""}"	{}	"{""description"": ""Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.\n"", ""evidence"": [{""explanation"": ""The N-MOmentum trial demonstrated 73% reduction in attack risk with inebilizumab treatment."", ""reference"": ""PMID:31495497"", ""snippet"": ""21 (12%) of 174 participants receiving inebilizumab had an attack versus 22 (39%) of 56 participants receiving placebo"", ""supports"": ""SUPPORT""}, {""explanation"": ""Review confirms regulatory approval of inebilizumab for NMOSD."", ""reference"": ""PMID:36070074"", ""snippet"": ""Inebilizumab (Uplizna) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive."", ""supports"": ""SUPPORT""}], ""name"": ""Inebilizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5562	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	5	Satralizumab	"IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.
"																																																								"{""description"": ""IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.\n"", ""name"": ""Satralizumab""}"	{}	"{""description"": ""IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.\n"", ""evidence"": [{""explanation"": ""Review confirms satralizumab mechanism and approval for NMOSD."", ""reference"": ""PMID:36933107"", ""snippet"": ""Satralizumab (Enspryng) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor and is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive."", ""supports"": ""SUPPORT""}], ""name"": ""Satralizumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5599	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	0	Surgery	Lobectomy or pneumonectomy for localized disease																																																								"{""description"": ""Lobectomy or pneumonectomy for localized disease"", ""name"": ""Surgery""}"	{}	"{""description"": ""Lobectomy or pneumonectomy for localized disease"", ""evidence"": [{""explanation"": ""This indicates that lobectomy and pneumonectomy are standard surgical treatments for localized non-small cell lung cancer."", ""reference"": ""PMID:11720753"", ""snippet"": ""Surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed. Standard operations include lobectomy, bilobectomy and pneumonectomy."", ""supports"": ""SUPPORT""}, {""explanation"": ""This further reinforces that lobectomy, a type of surgery, is a standard treatment for localized non-small cell lung cancer."", ""reference"": ""PMID:37625619"", ""snippet"": ""Lobectomy is the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC)."", ""supports"": ""SUPPORT""}], ""name"": ""Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	Chemotherapy	Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents																																																								"{""description"": ""Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents"", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents"", ""evidence"": [{""explanation"": ""This supports the statement that platinum-based chemotherapy (specifically cisplatin) in combination with other agents is a treatment for NSCLC."", ""reference"": ""PMID:12094333"", ""snippet"": ""Platinum-based chemotherapy is considered the standard treatment for advanced non-small cell lung cancer (NSCLC). Several phase II trials using cisplatin in combination with new chemotherapeutic agents, such as gemcitabine, the taxanes, vinorelbine, and irinotecan, showed impressive response rates and suggested an improvement in overall survival."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the statement as it mentions that carboplatin, either alone or in combination with other agents, is used in the treatment of NSCLC."", ""reference"": ""PMID:1329222"", ""snippet"": ""... carboplatin, either alone or in combination, in five separate phase II studies for patients with inoperable non-small cell lung cancer (NSCLC). ... Subsequently, combinations of carboplatin/cisplatin, carboplatin/etoposide, and carboplatin/vinblastine have been evaluated in similar patient groups."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study provides evidence that both cisplatin and carboplatin, in combination with other agents, are used in the treatment of NSCLC."", ""reference"": ""PMID:26775594"", ""snippet"": ""Of the 1564 patients who were included in the prospective study, 1520 received either cisplatin (54%) or carboplatin (46%) in combination with pemetrexed, gemcitabine, taxanes or vinorelbine."", ""supports"": ""SUPPORT""}, {""explanation"": ""The mention of platinum-based chemotherapy (cisplatin or carboplatin) as a primary treatment supports the statement."", ""reference"": ""PMID:35525024"", ""snippet"": ""Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration."", ""supports"": ""SUPPORT""}, {""explanation"": ""This statement supports the use of platinum-based chemotherapy in the treatment of NSCLC, emphasizing its importance even in elderly patients."", ""reference"": ""PMID:27166967"", ""snippet"": ""Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC)."", ""supports"": ""SUPPORT""}], ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	Targeted Therapy	Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)																																																								"{""description"": ""Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)"", ""name"": ""Targeted Therapy""}"	{}	"{""description"": ""Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)"", ""evidence"": [{""explanation"": ""The reference discusses EGFR, ALK, and ROS1 inhibitors as targeted therapies for non-small cell lung cancer."", ""reference"": ""PMID:34154330"", ""snippet"": ""The review article presents the current state and development of the treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer. It focuses on the therapeutic progress of traditionally targeted gene mutations EGFR, ALK and ROS1."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses erlotinib and gefitinib as EGFR inhibitors used in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:15946581"", ""snippet"": ""The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference confirms the use of erlotinib (EGFR inhibitor) and crizotinib (ALK and ROS1 inhibitor) in targeted therapy for non-small cell lung cancer."", ""reference"": ""PMID:22932130"", ""snippet"": ""Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference mentions the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitor (crizotinib) in treating non-small cell lung cancer."", ""reference"": ""PMID:25240504"", ""snippet"": ""The availability of ... the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as ... the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced non-small cell lung cancer."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses crizotinib as an ALK and ROS1 inhibitor used in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:25322323"", ""snippet"": ""The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitors (crizotinib, ceritinib) in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:27491402"", ""snippet"": ""Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference mentions crizotinib among the ROS1 inhibitors used for treating non-small cell lung cancer."", ""reference"": ""PMID:34125313"", ""snippet"": ""Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the use of EGFR inhibitors (erlotinib, gefitinib) in the treatment of non-small cell lung cancer."", ""reference"": ""PMID:28089942"", ""snippet"": ""Nowadays, different EGFR TKIs as afatinib, erlotinib and gefitinib are approved worldwide for the treatment of NSCLC harbouring EGFR mutations, in particular exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations."", ""supports"": ""SUPPORT""}], ""name"": ""Targeted Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression																																																								"{""description"": ""Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression"", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression"", ""evidence"": [{""explanation"": ""The FDA has approved immune checkpoint inhibitors for first-line treatment of metastatic NSCLC with high PD-L1 expression, supporting the use of immunotherapy (including nivolumab and pembrolizumab) for these patients."", ""reference"": ""PMID:28059852"", ""snippet"": ""In accordance with recent results, US Food and Drug Administration approved a checkpoint inhibitor for first-line treatment of metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, and European Medicines Agency approval is expected in early 2017."", ""supports"": ""SUPPORT""}, {""explanation"": ""The mention of PD-L1 immunohistochemistry being introduced for clinically selecting patients for anti-PD-1 therapies supports the statement."", ""reference"": ""PMID:26927720"", ""snippet"": ""Data so far available show some conflicting results, but PD-L1 immunohistochemistry looks likely to be introduced into clinical use for selecting patients for treatment with anti-PD-1 or anti-PD-L1 therapies."", ""supports"": ""SUPPORT""}, {""explanation"": ""While it shows the effectiveness of checkpoint inhibitors, it is about treatment beyond progression and does not specifically address high PD-L1 expression."", ""reference"": ""PMID:32189549"", ""snippet"": ""A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control."", ""supports"": ""PARTIAL""}, {""explanation"": ""This supports the efficacy of durvalumab particularly in PD-L1+ populations but does not specifically mention nivolumab or pembrolizumab."", ""reference"": ""PMID:29140105"", ""snippet"": ""Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the >/=25% PD-L1+ population."", ""supports"": ""PARTIAL""}, {""explanation"": ""This supports the efficacy of ICIs but does not specifically address tumors with high PD-L1 expression."", ""reference"": ""PMID:33306411"", ""snippet"": ""For the majority of patients, ICIs are cost-effective for lung cancer management."", ""supports"": ""PARTIAL""}], ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	Radiation Therapy	Used for localized disease, palliation of symptoms, or brain metastases																																																								"{""description"": ""Used for localized disease, palliation of symptoms, or brain metastases"", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Used for localized disease, palliation of symptoms, or brain metastases"", ""evidence"": [{""explanation"": ""Supports the use of RT for palliation of symptoms and metastatic sites, but does not specifically mention its use for localized disease."", ""reference"": ""PMID:7540125"", ""snippet"": ""recent notable developments have occurred involving radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC)... For palliation of tumor-related symptoms... metastases to the adrenal gland, liver, and subcutaneous tissues can be palliated successfully by brief courses of RT. Intrathoracic tumor symptoms are well palliated by brief courses of thoracic RT."", ""supports"": ""PARTIAL""}, {""explanation"": ""Supports the use of RT in palliation of symptoms and brain metastases."", ""reference"": ""PMID:8853542"", ""snippet"": ""In the palliation of non-small cell lung cancer... in the management of chest disease, bone metastases, and brain metastases."", ""supports"": ""PARTIAL""}, {""explanation"": ""Supports the use of RT for locally advanced (localized) disease."", ""reference"": ""PMID:32140986"", ""snippet"": ""Concurrent chemoradiation is the cornerstone of treatment of unresectable, locally advanced NSCLC."", ""supports"": ""SUPPORT""}, {""explanation"": ""Supports the use of RT for locally advanced (localized) disease."", ""reference"": ""PMID:30441934"", ""snippet"": ""Radiotherapy should also be considered for locally advanced disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""Supports the use of RT for localized disease particularly in nonoperable cases."", ""reference"": ""PMID:27467543"", ""snippet"": ""Stereotactic body radiation therapy has been increasingly used to safely deliver LAT and provide high local control in nonoperable non-small-cell lung cancer patients."", ""supports"": ""SUPPORT""}], ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
5637	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	0	Growth Hormone Therapy	Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation.																																																								"{""description"": ""Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation."", ""name"": ""Growth Hormone Therapy""}"	{}	"{""description"": ""Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation."", ""name"": ""Growth Hormone Therapy"", ""target_phenotypes"": [{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}], ""treatment_term"": {""preferred_term"": ""human growth hormone replacement therapy"", ""term"": {""id"": ""MAXO:0000780"", ""label"": ""human growth hormone replacement therapy""}}}"
5638	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	1	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.																																																								"{""description"": ""Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy."", ""name"": ""Cardiac Surgical Intervention""}"	{}	"{""description"": ""Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy."", ""name"": ""Cardiac Surgical Intervention"", ""target_phenotypes"": [{""preferred_term"": ""Pulmonic stenosis"", ""term"": {""id"": ""HP:0001642"", ""label"": ""Pulmonic stenosis""}}, {""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}], ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5639	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.																																		Emerging therapy based on case reports; controlled trials are needed. Typical pediatric dosing 0.01-0.025 mg/kg/day.																						"{""description"": ""Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models."", ""name"": ""MEK Inhibitor Therapy"", ""notes"": ""Emerging therapy based on case reports; controlled trials are needed. Typical pediatric dosing 0.01-0.025 mg/kg/day.""}"	{}	"{""description"": ""Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models."", ""name"": ""MEK Inhibitor Therapy"", ""notes"": ""Emerging therapy based on case reports; controlled trials are needed. Typical pediatric dosing 0.01-0.025 mg/kg/day."", ""target_phenotypes"": [{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}, {""preferred_term"": ""Lymphedema"", ""term"": {""id"": ""HP:0001004"", ""label"": ""Lymphedema""}}], ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5640	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	3	Early Intervention Services	Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities.																																																								"{""description"": ""Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities."", ""name"": ""Early Intervention Services""}"	{}	"{""description"": ""Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities."", ""name"": ""Early Intervention Services"", ""target_phenotypes"": [{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}], ""treatment_term"": {""preferred_term"": ""early intervention services"", ""term"": {""id"": ""MAXO:0009101"", ""label"": ""early intervention services""}}}"
5641	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	4	Speech Therapy	Speech and language therapy for articulation difficulties and language delays.																																																								"{""description"": ""Speech and language therapy for articulation difficulties and language delays."", ""name"": ""Speech Therapy""}"	{}	"{""description"": ""Speech and language therapy for articulation difficulties and language delays."", ""name"": ""Speech Therapy"", ""target_phenotypes"": [{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}], ""treatment_term"": {""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}}"
5642	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	5	Physical Therapy	Physical therapy to address motor delays and hypotonia common in Noonan syndrome.																																																								"{""description"": ""Physical therapy to address motor delays and hypotonia common in Noonan syndrome."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Physical therapy to address motor delays and hypotonia common in Noonan syndrome."", ""name"": ""Physical Therapy"", ""target_phenotypes"": [{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}], ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5673	237	Obesity	Obesity.yaml	treatments	0	Lifestyle Modification	Dietary changes and increased physical activity as foundation of treatment.																																																								"{""description"": ""Dietary changes and increased physical activity as foundation of treatment."", ""name"": ""Lifestyle Modification""}"	{}	"{""description"": ""Dietary changes and increased physical activity as foundation of treatment."", ""name"": ""Lifestyle Modification"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
5674	237	Obesity	Obesity.yaml	treatments	1	GLP-1 Receptor Agonists	Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects.																																																								"{""description"": ""Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects."", ""name"": ""GLP-1 Receptor Agonists""}"	{}	"{""description"": ""Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects."", ""name"": ""GLP-1 Receptor Agonists"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5675	237	Obesity	Obesity.yaml	treatments	2	GLP-1/GIP Dual Agonists	Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation.																																																								"{""description"": ""Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation."", ""name"": ""GLP-1/GIP Dual Agonists""}"	{}	"{""description"": ""Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation."", ""name"": ""GLP-1/GIP Dual Agonists"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5676	237	Obesity	Obesity.yaml	treatments	3	Bariatric Surgery	Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity.																																																								"{""description"": ""Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity."", ""name"": ""Bariatric Surgery""}"	{}	"{""description"": ""Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity."", ""name"": ""Bariatric Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5677	237	Obesity	Obesity.yaml	treatments	4	Behavioral Therapy	Cognitive behavioral therapy for eating behaviors.																																																								"{""description"": ""Cognitive behavioral therapy for eating behaviors."", ""name"": ""Behavioral Therapy""}"	{}	"{""description"": ""Cognitive behavioral therapy for eating behaviors."", ""name"": ""Behavioral Therapy"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
5678	237	Obesity	Obesity.yaml	treatments	5	Orlistat	Lipase inhibitor reducing fat absorption.																																																								"{""description"": ""Lipase inhibitor reducing fat absorption."", ""name"": ""Orlistat""}"	{}	"{""description"": ""Lipase inhibitor reducing fat absorption."", ""name"": ""Orlistat"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5701	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	treatments	0	CPAP	Continuous positive airway pressure, gold standard treatment.																																																								"{""description"": ""Continuous positive airway pressure, gold standard treatment."", ""name"": ""CPAP""}"	{}	"{""description"": ""Continuous positive airway pressure, gold standard treatment."", ""name"": ""CPAP""}"
5702	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	treatments	1	BiPAP	Bilevel positive airway pressure for some patients.																																																								"{""description"": ""Bilevel positive airway pressure for some patients."", ""name"": ""BiPAP""}"	{}	"{""description"": ""Bilevel positive airway pressure for some patients."", ""name"": ""BiPAP""}"
5703	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	treatments	2	Oral Appliances	Mandibular advancement devices for mild-moderate OSA.																																																								"{""description"": ""Mandibular advancement devices for mild-moderate OSA."", ""name"": ""Oral Appliances""}"	{}	"{""description"": ""Mandibular advancement devices for mild-moderate OSA."", ""name"": ""Oral Appliances""}"
5704	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	treatments	3	Weight Loss	Can significantly reduce or resolve OSA.																																																								"{""description"": ""Can significantly reduce or resolve OSA."", ""name"": ""Weight Loss""}"	{}	"{""description"": ""Can significantly reduce or resolve OSA."", ""name"": ""Weight Loss""}"
5705	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	treatments	4	Positional Therapy	Avoiding supine sleep position.																																																								"{""description"": ""Avoiding supine sleep position."", ""name"": ""Positional Therapy""}"	{}	"{""description"": ""Avoiding supine sleep position."", ""name"": ""Positional Therapy""}"
5706	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	treatments	5	Surgery	UPPP, maxillomandibular advancement for selected patients.																																																								"{""description"": ""UPPP, maxillomandibular advancement for selected patients."", ""name"": ""Surgery""}"	{}	"{""description"": ""UPPP, maxillomandibular advancement for selected patients."", ""name"": ""Surgery""}"
5707	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	treatments	6	Hypoglossal Nerve Stimulation	Implantable device for CPAP-intolerant patients.																																																								"{""description"": ""Implantable device for CPAP-intolerant patients."", ""name"": ""Hypoglossal Nerve Stimulation""}"	{}	"{""description"": ""Implantable device for CPAP-intolerant patients."", ""name"": ""Hypoglossal Nerve Stimulation""}"
5713	239	Onchocerciasis	Onchocerciasis.yaml	treatments	0	Ivermectin therapy	Ivermectin is the drug of choice for skin and ocular manifestations.																																																								"{""description"": ""Ivermectin is the drug of choice for skin and ocular manifestations."", ""name"": ""Ivermectin therapy""}"	{}	"{""description"": ""Ivermectin is the drug of choice for skin and ocular manifestations."", ""evidence"": [{""explanation"": ""The abstract identifies ivermectin as the drug of choice."", ""reference"": ""PMID:16714198"", ""snippet"": ""Ivermectin is, at present, the drug of choice for skin and ocular manifestations."", ""supports"": ""SUPPORT""}], ""name"": ""Ivermectin therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5733	240	Osteoarthritis	Osteoarthritis.yaml	treatments	0	Acetaminophen	First-line analgesic for mild to moderate pain.																																																								"{""description"": ""First-line analgesic for mild to moderate pain."", ""name"": ""Acetaminophen""}"	{}	"{""description"": ""First-line analgesic for mild to moderate pain."", ""evidence"": [{""explanation"": ""ACR/Arthritis Foundation guidelines conditionally recommend acetaminophen for OA management."", ""reference"": ""PMID:31908149"", ""snippet"": ""Conditional recommendations were made for balance exercises, yoga, cognitive behavioral therapy, kinesiotaping for first CMC OA, orthoses for hand joints other than the first CMC joint, patellofemoral bracing for patellofemoral knee OA, acupuncture, thermal modalities, radiofrequency ablation for knee OA, topical NSAIDs, intraarticular steroid injections and chondroitin sulfate for hand OA, topical capsaicin for knee OA, acetaminophen, duloxetine, and tramadol."", ""supports"": ""SUPPORT""}], ""name"": ""Acetaminophen""}"
5734	240	Osteoarthritis	Osteoarthritis.yaml	treatments	1	NSAIDs	Oral or topical anti-inflammatory medications.																																																								"{""description"": ""Oral or topical anti-inflammatory medications."", ""name"": ""NSAIDs""}"	{}	"{""description"": ""Oral or topical anti-inflammatory medications."", ""evidence"": [{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend both topical and oral NSAIDs for OA."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA."", ""supports"": ""SUPPORT""}], ""name"": ""NSAIDs""}"
5735	240	Osteoarthritis	Osteoarthritis.yaml	treatments	2	Physical Therapy	Strengthening and flexibility exercises to support joints.																																																								"{""description"": ""Strengthening and flexibility exercises to support joints."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Strengthening and flexibility exercises to support joints."", ""evidence"": [{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend exercise for OA management."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese"", ""supports"": ""SUPPORT""}], ""name"": ""Physical Therapy""}"
5736	240	Osteoarthritis	Osteoarthritis.yaml	treatments	3	Weight Loss	Reduces mechanical load on weight-bearing joints.																																																								"{""description"": ""Reduces mechanical load on weight-bearing joints."", ""name"": ""Weight Loss""}"	{}	"{""description"": ""Reduces mechanical load on weight-bearing joints."", ""evidence"": [{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend weight loss for overweight/obese patients with OA."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese"", ""supports"": ""SUPPORT""}], ""name"": ""Weight Loss""}"
5737	240	Osteoarthritis	Osteoarthritis.yaml	treatments	4	Intra-articular Corticosteroid Injections	Short-term pain relief for flares.																																																								"{""description"": ""Short-term pain relief for flares."", ""name"": ""Intra-articular Corticosteroid Injections""}"	{}	"{""description"": ""Short-term pain relief for flares."", ""evidence"": [{""explanation"": ""ACR/Arthritis Foundation guidelines strongly recommend intra-articular glucocorticoid injections for knee OA."", ""reference"": ""PMID:31908149"", ""snippet"": ""Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA."", ""supports"": ""SUPPORT""}], ""name"": ""Intra-articular Corticosteroid Injections""}"
5738	240	Osteoarthritis	Osteoarthritis.yaml	treatments	5	Intra-articular Hyaluronic Acid	Viscosupplementation for knee OA.																																																								"{""description"": ""Viscosupplementation for knee OA."", ""name"": ""Intra-articular Hyaluronic Acid""}"	{}	"{""description"": ""Viscosupplementation for knee OA."", ""name"": ""Intra-articular Hyaluronic Acid""}"
5739	240	Osteoarthritis	Osteoarthritis.yaml	treatments	6	Joint Replacement Surgery	Total hip or knee arthroplasty for severe disease.																																																								"{""description"": ""Total hip or knee arthroplasty for severe disease."", ""name"": ""Joint Replacement Surgery""}"	{}	"{""description"": ""Total hip or knee arthroplasty for severe disease."", ""name"": ""Joint Replacement Surgery""}"
5749	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates (pamidronate, zoledronic acid) are used to increase bone mineral density and reduce fracture frequency, particularly in children.
"																																																								"{""description"": ""Bisphosphonates (pamidronate, zoledronic acid) are used to increase bone mineral density and reduce fracture frequency, particularly in children.\n"", ""name"": ""Bisphosphonate Therapy""}"	{}	"{""description"": ""Bisphosphonates (pamidronate, zoledronic acid) are used to increase bone mineral density and reduce fracture frequency, particularly in children.\n"", ""name"": ""Bisphosphonate Therapy"", ""treatment_term"": {""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}}"
5750	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	1	Physical Therapy	"Exercise and physical therapy to strengthen muscles and improve mobility while protecting fragile bones.
"																																																								"{""description"": ""Exercise and physical therapy to strengthen muscles and improve mobility while protecting fragile bones.\n"", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Exercise and physical therapy to strengthen muscles and improve mobility while protecting fragile bones.\n"", ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5751	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	2	Fracture Management	"Standard orthopedic management of fractures with appropriate immobilization.
"																																																								"{""description"": ""Standard orthopedic management of fractures with appropriate immobilization.\n"", ""name"": ""Fracture Management""}"	{}	"{""description"": ""Standard orthopedic management of fractures with appropriate immobilization.\n"", ""name"": ""Fracture Management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5762	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	treatments	0	Supportive Care	"Palliative supportive care given the lethal nature of the condition. Focus on comfort and family support.
"																																																								"{""description"": ""Palliative supportive care given the lethal nature of the condition. Focus on comfort and family support.\n"", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Palliative supportive care given the lethal nature of the condition. Focus on comfort and family support.\n"", ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5774	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	0	Bisphosphonate Therapy	"Intravenous bisphosphonates (pamidronate, zoledronic acid) to increase bone density and reduce fracture frequency. Most beneficial in childhood.
"																																																								"{""description"": ""Intravenous bisphosphonates (pamidronate, zoledronic acid) to increase bone density and reduce fracture frequency. Most beneficial in childhood.\n"", ""name"": ""Bisphosphonate Therapy""}"	{}	"{""description"": ""Intravenous bisphosphonates (pamidronate, zoledronic acid) to increase bone density and reduce fracture frequency. Most beneficial in childhood.\n"", ""name"": ""Bisphosphonate Therapy"", ""treatment_term"": {""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}}"
5775	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	1	Rodding Surgery	"Intramedullary rodding (telescoping rods) to stabilize long bones, correct deformities, and prevent fractures. Multiple surgeries typically required as the child grows.
"																																																								"{""description"": ""Intramedullary rodding (telescoping rods) to stabilize long bones, correct deformities, and prevent fractures. Multiple surgeries typically required as the child grows.\n"", ""name"": ""Rodding Surgery""}"	{}	"{""description"": ""Intramedullary rodding (telescoping rods) to stabilize long bones, correct deformities, and prevent fractures. Multiple surgeries typically required as the child grows.\n"", ""name"": ""Rodding Surgery"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5776	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	2	Spinal Fusion	"Surgical stabilization of severe scoliosis to prevent respiratory compromise.
"																																																								"{""description"": ""Surgical stabilization of severe scoliosis to prevent respiratory compromise.\n"", ""name"": ""Spinal Fusion""}"	{}	"{""description"": ""Surgical stabilization of severe scoliosis to prevent respiratory compromise.\n"", ""name"": ""Spinal Fusion"", ""treatment_term"": {""preferred_term"": ""Spinal surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5777	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	3	Physical Therapy	"Careful physical therapy to maintain mobility and muscle strength while minimizing fracture risk.
"																																																								"{""description"": ""Careful physical therapy to maintain mobility and muscle strength while minimizing fracture risk.\n"", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Careful physical therapy to maintain mobility and muscle strength while minimizing fracture risk.\n"", ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5787	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates to increase bone density and reduce fractures, particularly beneficial in childhood.
"																																																								"{""description"": ""Bisphosphonates to increase bone density and reduce fractures, particularly beneficial in childhood.\n"", ""name"": ""Bisphosphonate Therapy""}"	{}	"{""description"": ""Bisphosphonates to increase bone density and reduce fractures, particularly beneficial in childhood.\n"", ""name"": ""Bisphosphonate Therapy"", ""treatment_term"": {""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}}"
5788	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	1	Orthopedic Management	"Fracture treatment and corrective surgery for deformities as needed. Intramedullary rodding for severe cases.
"																																																								"{""description"": ""Fracture treatment and corrective surgery for deformities as needed. Intramedullary rodding for severe cases.\n"", ""name"": ""Orthopedic Management""}"	{}	"{""description"": ""Fracture treatment and corrective surgery for deformities as needed. Intramedullary rodding for severe cases.\n"", ""name"": ""Orthopedic Management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5789	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	2	Physical Therapy	"Exercise programs to strengthen muscles and maintain bone health.
"																																																								"{""description"": ""Exercise programs to strengthen muscles and maintain bone health.\n"", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Exercise programs to strengthen muscles and maintain bone health.\n"", ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5800	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates may reduce fracture frequency, though hyperplastic callus can still occur.
"																																																								"{""description"": ""Bisphosphonates may reduce fracture frequency, though hyperplastic callus can still occur.\n"", ""name"": ""Bisphosphonate Therapy""}"	{}	"{""description"": ""Bisphosphonates may reduce fracture frequency, though hyperplastic callus can still occur.\n"", ""name"": ""Bisphosphonate Therapy"", ""treatment_term"": {""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}}"
5801	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	1	Surgical Management	"Orthopedic surgery for fractures and deformities. Care must be taken regarding hyperplastic callus formation after procedures.
"																																																								"{""description"": ""Orthopedic surgery for fractures and deformities. Care must be taken regarding hyperplastic callus formation after procedures.\n"", ""name"": ""Surgical Management""}"	{}	"{""description"": ""Orthopedic surgery for fractures and deformities. Care must be taken regarding hyperplastic callus formation after procedures.\n"", ""name"": ""Surgical Management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5802	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	2	Interosseous Membrane Excision	"Surgical removal of calcified interosseous membrane to restore forearm rotation in selected cases.
"																																																								"{""description"": ""Surgical removal of calcified interosseous membrane to restore forearm rotation in selected cases.\n"", ""name"": ""Interosseous Membrane Excision""}"	{}	"{""description"": ""Surgical removal of calcified interosseous membrane to restore forearm rotation in selected cases.\n"", ""name"": ""Interosseous Membrane Excision"", ""treatment_term"": {""preferred_term"": ""Surgical excision"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5813	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates to improve bone density, though response may differ from classical OI due to distinct pathophysiology.
"																																																								"{""description"": ""Bisphosphonates to improve bone density, though response may differ from classical OI due to distinct pathophysiology.\n"", ""name"": ""Bisphosphonate Therapy""}"	{}	"{""description"": ""Bisphosphonates to improve bone density, though response may differ from classical OI due to distinct pathophysiology.\n"", ""name"": ""Bisphosphonate Therapy"", ""treatment_term"": {""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}}"
5814	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	1	Orthopedic Management	"Fracture management and corrective surgery for deformities. Rodding procedures for long bone stabilization.
"																																																								"{""description"": ""Fracture management and corrective surgery for deformities. Rodding procedures for long bone stabilization.\n"", ""name"": ""Orthopedic Management""}"	{}	"{""description"": ""Fracture management and corrective surgery for deformities. Rodding procedures for long bone stabilization.\n"", ""name"": ""Orthopedic Management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5815	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	2	Physical Therapy	"Careful rehabilitation to maintain mobility while minimizing fracture risk.
"																																																								"{""description"": ""Careful rehabilitation to maintain mobility while minimizing fracture risk.\n"", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Careful rehabilitation to maintain mobility while minimizing fracture risk.\n"", ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5816	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	3	Genetic Counseling	"Genetic counseling for families regarding recurrence risk and carrier testing for at-risk relatives.
"																																																								"{""description"": ""Genetic counseling for families regarding recurrence risk and carrier testing for at-risk relatives.\n"", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling for families regarding recurrence risk and carrier testing for at-risk relatives.\n"", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""Genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
5839	247	Osteoporosis	Osteoporosis.yaml	treatments	0	Bisphosphonates	First-line antiresorptives (alendronate, risedronate, zoledronic acid).																																																								"{""description"": ""First-line antiresorptives (alendronate, risedronate, zoledronic acid)."", ""name"": ""Bisphosphonates""}"	{}	"{""description"": ""First-line antiresorptives (alendronate, risedronate, zoledronic acid)."", ""evidence"": [{""explanation"": ""Meta-analysis of 10 RCTs with 23,384 women demonstrates bisphosphonate efficacy in preventing fractures."", ""reference"": ""PMID:34807231"", ""snippet"": ""The pooled meta-analysis found that 12.4 months (95% CI, 6.3-18.4 months) were needed to avoid 1 nonvertebral fracture per 100 postmenopausal women receiving bisphosphonate therapy."", ""supports"": ""SUPPORT""}], ""name"": ""Bisphosphonates"", ""treatment_term"": {""preferred_term"": ""bisphosphonate agent therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}}"
5840	247	Osteoporosis	Osteoporosis.yaml	treatments	1	Denosumab	RANKL inhibitor, potent antiresorptive.																																																								"{""description"": ""RANKL inhibitor, potent antiresorptive."", ""name"": ""Denosumab""}"	{}	"{""description"": ""RANKL inhibitor, potent antiresorptive."", ""name"": ""Denosumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5841	247	Osteoporosis	Osteoporosis.yaml	treatments	2	Teriparatide	PTH analog, anabolic agent for severe osteoporosis.																																																								"{""description"": ""PTH analog, anabolic agent for severe osteoporosis."", ""name"": ""Teriparatide""}"	{}	"{""description"": ""PTH analog, anabolic agent for severe osteoporosis."", ""name"": ""Teriparatide"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5842	247	Osteoporosis	Osteoporosis.yaml	treatments	3	Romosozumab	Sclerostin inhibitor with dual anabolic/antiresorptive effect.																																																								"{""description"": ""Sclerostin inhibitor with dual anabolic/antiresorptive effect."", ""name"": ""Romosozumab""}"	{}	"{""description"": ""Sclerostin inhibitor with dual anabolic/antiresorptive effect."", ""name"": ""Romosozumab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5843	247	Osteoporosis	Osteoporosis.yaml	treatments	4	Calcium Supplementation	Ensure adequate intake (1000-1200 mg/day).																																																								"{""description"": ""Ensure adequate intake (1000-1200 mg/day)."", ""name"": ""Calcium Supplementation""}"	{}	"{""description"": ""Ensure adequate intake (1000-1200 mg/day)."", ""name"": ""Calcium Supplementation"", ""treatment_term"": {""preferred_term"": ""calcium supplementation"", ""term"": {""id"": ""MAXO:0001139"", ""label"": ""calcium supplementation""}}}"
5844	247	Osteoporosis	Osteoporosis.yaml	treatments	5	Vitamin D Supplementation	Maintain 25(OH)D >30 ng/mL.																																																								"{""description"": ""Maintain 25(OH)D >30 ng/mL."", ""name"": ""Vitamin D Supplementation""}"	{}	"{""description"": ""Maintain 25(OH)D >30 ng/mL."", ""name"": ""Vitamin D Supplementation"", ""treatment_term"": {""preferred_term"": ""vitamin D supplementation"", ""term"": {""id"": ""MAXO:0000110"", ""label"": ""vitamin D supplementation""}}}"
5845	247	Osteoporosis	Osteoporosis.yaml	treatments	6	Weight-Bearing Exercise	Helps maintain bone density.																																																								"{""description"": ""Helps maintain bone density."", ""name"": ""Weight-Bearing Exercise""}"	{}	"{""description"": ""Helps maintain bone density."", ""name"": ""Weight-Bearing Exercise"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5852	248	Osteosarcoma	Osteosarcoma.yaml	treatments	0	Surgical Resection	Surgical removal of the primary tumor when feasible.																																																								"{""description"": ""Surgical removal of the primary tumor when feasible."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Surgical removal of the primary tumor when feasible."", ""evidence"": [{""explanation"": ""The abstract references surgery as a standard component of osteosarcoma treatment."", ""reference"": ""PMID:41154810"", ""snippet"": ""Despite advances in surgery and multi-agent chemotherapy, survival rates for metastatic or recurrent OS remain poor, highlighting the need for novel prognostic and therapeutic strategies."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5853	248	Osteosarcoma	Osteosarcoma.yaml	treatments	1	Multi-Agent Chemotherapy	Combination chemotherapy used in neoadjuvant and adjuvant settings.																																																								"{""description"": ""Combination chemotherapy used in neoadjuvant and adjuvant settings."", ""name"": ""Multi-Agent Chemotherapy""}"	{}	"{""description"": ""Combination chemotherapy used in neoadjuvant and adjuvant settings."", ""evidence"": [{""explanation"": ""The abstract notes multi-agent chemotherapy as a standard therapy."", ""reference"": ""PMID:41154810"", ""snippet"": ""Despite advances in surgery and multi-agent chemotherapy, survival rates for metastatic or recurrent OS remain poor, highlighting the need for novel prognostic and therapeutic strategies."", ""supports"": ""SUPPORT""}], ""name"": ""Multi-Agent Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
5864	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	0	Alpelisib	PI3K alpha-selective inhibitor FDA-approved for HR+/HER2- metastatic breast cancer with PIK3CA mutation, in combination with fulvestrant, after progression on endocrine therapy. SOLAR-1 trial demonstrated significant PFS benefit. Key toxicity is hyperglycemia due to PI3K role in insulin signaling.																																																								"{""description"": ""PI3K alpha-selective inhibitor FDA-approved for HR+/HER2- metastatic breast cancer with PIK3CA mutation, in combination with fulvestrant, after progression on endocrine therapy. SOLAR-1 trial demonstrated significant PFS benefit. Key toxicity is hyperglycemia due to PI3K role in insulin signaling."", ""name"": ""Alpelisib""}"	{}	"{""description"": ""PI3K alpha-selective inhibitor FDA-approved for HR+/HER2- metastatic breast cancer with PIK3CA mutation, in combination with fulvestrant, after progression on endocrine therapy. SOLAR-1 trial demonstrated significant PFS benefit. Key toxicity is hyperglycemia due to PI3K role in insulin signaling."", ""evidence"": [{""explanation"": ""This abstract supports the use of alpelisib with fulvestrant in PIK3CA-mutant breast cancer."", ""reference"": ""PMID:37743730"", ""snippet"": ""The combination of fulvestrant with alpelisib, a PI3K inhibitor, improves progression-free survival in metastatic hormone receptor-positive, PIK3CA-mutant breast cancer."", ""supports"": ""SUPPORT""}], ""name"": ""Alpelisib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5865	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	1	Endocrine Therapy Plus CDK4/6 Inhibitors	First-line treatment for metastatic ER+/HER2- disease typically combines aromatase inhibitors with CDK4/6 inhibitors, regardless of PIK3CA status. Alpelisib is used after progression on this regimen.																																																								"{""description"": ""First-line treatment for metastatic ER+/HER2- disease typically combines aromatase inhibitors with CDK4/6 inhibitors, regardless of PIK3CA status. Alpelisib is used after progression on this regimen."", ""name"": ""Endocrine Therapy Plus CDK4/6 Inhibitors""}"	{}	"{""description"": ""First-line treatment for metastatic ER+/HER2- disease typically combines aromatase inhibitors with CDK4/6 inhibitors, regardless of PIK3CA status. Alpelisib is used after progression on this regimen."", ""name"": ""Endocrine Therapy Plus CDK4/6 Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5866	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	2	Capivasertib	AKT inhibitor that has shown activity in PIK3CA-mutated, AKT1-mutated, or PTEN-altered breast cancer. Approved in combination with fulvestrant for HR+/HER2- advanced breast cancer after prior endocrine therapy.																																																								"{""description"": ""AKT inhibitor that has shown activity in PIK3CA-mutated, AKT1-mutated, or PTEN-altered breast cancer. Approved in combination with fulvestrant for HR+/HER2- advanced breast cancer after prior endocrine therapy."", ""name"": ""Capivasertib""}"	{}	"{""description"": ""AKT inhibitor that has shown activity in PIK3CA-mutated, AKT1-mutated, or PTEN-altered breast cancer. Approved in combination with fulvestrant for HR+/HER2- advanced breast cancer after prior endocrine therapy."", ""name"": ""Capivasertib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5904	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	0	Levodopa/Carbidopa	Gold standard treatment, replaces dopamine precursor.																																																								"{""description"": ""Gold standard treatment, replaces dopamine precursor."", ""name"": ""Levodopa/Carbidopa""}"	{}	"{""description"": ""Gold standard treatment, replaces dopamine precursor."", ""evidence"": [{""explanation"": ""This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Levodopa/Carbidopa"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5905	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	1	Dopamine Agonists	Directly stimulate dopamine receptors.																																																								"{""description"": ""Directly stimulate dopamine receptors."", ""name"": ""Dopamine Agonists""}"	{}	"{""description"": ""Directly stimulate dopamine receptors."", ""evidence"": [{""explanation"": ""This review identifies dopamine agonists as part of standard pharmacotherapy for PD."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Dopamine Agonists"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5906	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	2	MAO-B Inhibitors	Prevent dopamine breakdown (selegiline, rasagiline).																																																								"{""description"": ""Prevent dopamine breakdown (selegiline, rasagiline)."", ""name"": ""MAO-B Inhibitors""}"	{}	"{""description"": ""Prevent dopamine breakdown (selegiline, rasagiline)."", ""evidence"": [{""explanation"": ""This review lists MAO-B inhibitors among standard PD pharmacotherapies."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""MAO-B Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5907	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	3	COMT Inhibitors	Extend levodopa duration (entacapone).																																																								"{""description"": ""Extend levodopa duration (entacapone)."", ""name"": ""COMT Inhibitors""}"	{}	"{""description"": ""Extend levodopa duration (entacapone)."", ""evidence"": [{""explanation"": ""This review lists COMT inhibitors among standard PD pharmacotherapies."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""COMT Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5908	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	4	Deep Brain Stimulation	Surgical therapy for advanced motor fluctuations.																																																								"{""description"": ""Surgical therapy for advanced motor fluctuations."", ""name"": ""Deep Brain Stimulation""}"	{}	"{""description"": ""Surgical therapy for advanced motor fluctuations."", ""evidence"": [{""explanation"": ""This review identifies deep brain stimulation as a standard symptomatic therapy for PD."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Deep Brain Stimulation"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5909	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	5	Physical Therapy	Maintains mobility and reduces fall risk.																																																								"{""description"": ""Maintains mobility and reduces fall risk."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Maintains mobility and reduces fall risk."", ""evidence"": [{""explanation"": ""This review lists physiotherapy as part of symptomatic treatment for PD."", ""reference"": ""PMID:27577098"", ""snippet"": ""The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.																																																								"{""description"": ""First-line treatment for reducing inflammation in pars planitis."", ""name"": ""Corticosteroids""}"	"{""examples"": [""Subtenon triamcinolone injection"", ""Intravitreal triamcinolone"", ""Oral prednisone""]}"	"{""description"": ""First-line treatment for reducing inflammation in pars planitis."", ""evidence"": [{""explanation"": ""Corticosteroids form the foundation of treatment for pars planitis."", ""reference"": ""PMID:27051493"", ""snippet"": ""A stepladder approach including corticosteroids, immunosupressive agents, anti-tumor necrosis factor-alpha and pars plana vitrectomy and/or laser photocoagulation is the most commonly used method for treatment of pars planitis."", ""supports"": ""SUPPORT""}], ""examples"": [""Subtenon triamcinolone injection"", ""Intravitreal triamcinolone"", ""Oral prednisone""], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""prednisone"", ""term"": {""id"": ""NCIT:C770"", ""label"": ""Prednisone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.																																																								"{""description"": ""Second-line therapy for chronic or steroid-resistant cases."", ""name"": ""Immunosuppressive Agents""}"	"{""examples"": [""Methotrexate"", ""Mycophenolate mofetil"", ""Azathioprine"", ""Cyclosporine""]}"	"{""description"": ""Second-line therapy for chronic or steroid-resistant cases."", ""evidence"": [{""explanation"": ""Immunosuppressive agents, particularly methotrexate, provide steroid-sparing control for chronic cases."", ""reference"": ""PMID:27051493"", ""snippet"": ""Methotrexate is the most widely used first-line immunosuppressive agent in children with chronic non-infectious uveitis because of its long-term safety record and well tolerance."", ""supports"": ""SUPPORT""}], ""examples"": [""Methotrexate"", ""Mycophenolate mofetil"", ""Azathioprine"", ""Cyclosporine""], ""name"": ""Immunosuppressive Agents"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""methotrexate"", ""term"": {""id"": ""NCIT:C642"", ""label"": ""Methotrexate""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""NCIT:C1468"", ""label"": ""Mycophenolate Mofetil""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""cyclosporine"", ""term"": {""id"": ""NCIT:C406"", ""label"": ""Cyclosporine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.																																																								"{""description"": ""TNF-alpha inhibitors for refractory cases."", ""name"": ""Biological Therapy""}"	"{""examples"": [""Adalimumab"", ""Infliximab""]}"	"{""description"": ""TNF-alpha inhibitors for refractory cases."", ""evidence"": [{""explanation"": ""TNF-alpha inhibition with adalimumab controlled inflammation and enabled steroid-sparing in refractory cases."", ""reference"": ""PMID:34568953"", ""snippet"": ""ADA was initiated in 23 patients (38.9%) due to refractory uveitis and adverse effects to the corticosteroid and helped control intraocular inflammation and decrease the use of systemic steroids/immunosuppressives in 22 of 23 (95%) of patients who received ADA."", ""supports"": ""SUPPORT""}], ""examples"": [""Adalimumab"", ""Infliximab""], ""name"": ""Biological Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adalimumab"", ""term"": {""id"": ""NCIT:C65216"", ""label"": ""Adalimumab""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5942	251	Pars Planitis	Pars_Planitis.yaml	treatments	3	Pars Plana Vitrectomy	Surgical intervention for severe vitreous opacities or complications.																																																								"{""description"": ""Surgical intervention for severe vitreous opacities or complications."", ""name"": ""Pars Plana Vitrectomy""}"	{}	"{""description"": ""Surgical intervention for severe vitreous opacities or complications."", ""evidence"": [{""explanation"": ""Surgical intervention may be necessary for cases with severe vitreous involvement or complications."", ""reference"": ""PMID:27051493"", ""snippet"": ""A stepladder approach including corticosteroids, immunosupressive agents, anti-tumor necrosis factor-alpha and pars plana vitrectomy and/or laser photocoagulation is the most commonly used method for treatment of pars planitis."", ""supports"": ""SUPPORT""}], ""name"": ""Pars Plana Vitrectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
5965	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	0	Supportive Care	Includes rest, fluids, and analgesics for managing symptoms.																																																								"{""description"": ""Includes rest, fluids, and analgesics for managing symptoms."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Includes rest, fluids, and analgesics for managing symptoms."", ""evidence"": [{""explanation"": ""The literature states that the available treatments for Parvovirus B19 infection are primarily supportive and symptomatic."", ""reference"": ""PMID:31323869"", ""snippet"": ""Presently available treatments are only supportive, symptomatic, or unspecific, such as administration of intravenous immunoglobulins, and often of limited efficacy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature mentions the use of analgesics and antipyretics, which are supportive care measures, for managing mild and self-limited illness caused by Parvovirus B19."", ""reference"": ""PMID:8668619"", ""snippet"": ""Treatment ranges from analgesics and antipyretics for mild and self-limited illness to administration of commercial immunoglobulin preparations and blood transfusion for more serious conditions."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports the use of nonsteroidal anti-inflammatory drugs (a form of supportive care) for managing symptoms of Parvovirus B19 infection."", ""reference"": ""PMID:7899371"", ""snippet"": ""Nonsteroid antiinflammatory drugs are generally effective."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
5966	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	1	Intravenous Immunoglobulin (IVIG)	Used in severe cases, particularly for individuals with immunodeficiency or severe anemia.																																																								"{""description"": ""Used in severe cases, particularly for individuals with immunodeficiency or severe anemia."", ""name"": ""Intravenous Immunoglobulin (IVIG)""}"	{}	"{""description"": ""Used in severe cases, particularly for individuals with immunodeficiency or severe anemia."", ""evidence"": [{""explanation"": ""The case report demonstrates the effective use of IVIG in treating severe anemia caused by parvovirus B19 infection."", ""reference"": ""PMID:37544998"", ""snippet"": ""IVIG infusion effectively treated the parvovirus B19 infection and restored erythropoiesis making the child transfusion independent."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates that IVIG is used effectively in treating parvovirus B19 infection in pediatric transplant patients, who are often immunocompromised."", ""reference"": ""PMID:11560750"", ""snippet"": ""Specific antiviral therapy is not available, however, intravenous immunoglobulin produces rapid improvement in most cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""The case report supports the use of IVIG in an HIV-infected patient with parvovirus B19-related severe anemia."", ""reference"": ""PMID:33346452"", ""snippet"": ""In addition to blood transfusions, we administered intravenous donor immunoglobulin with a dose increase from 5000 mg to 20 000 mg per day."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of IVIG in immunocompromised individuals with parvovirus B19 infection."", ""reference"": ""PMID:7756792"", ""snippet"": ""Treatment of parvovirus infections among immunocompromised hosts using immunoglobulin has provided the clinician with a useful therapeutic tool but has also highlighted the problems concerning chronic disease states."", ""supports"": ""SUPPORT""}], ""name"": ""Intravenous Immunoglobulin (IVIG)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
5979	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	treatments	0	Corticosteroids	High-dose for induction.																																																								"{""description"": ""High-dose for induction."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""High-dose for induction."", ""name"": ""Corticosteroids""}"
5980	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	treatments	1	Rituximab	First-line in combination with steroids per guidelines.																																																								"{""description"": ""First-line in combination with steroids per guidelines."", ""name"": ""Rituximab""}"	{}	"{""description"": ""First-line in combination with steroids per guidelines."", ""name"": ""Rituximab""}"
5981	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	treatments	2	Azathioprine	Steroid-sparing maintenance agent.																																																								"{""description"": ""Steroid-sparing maintenance agent."", ""name"": ""Azathioprine""}"	{}	"{""description"": ""Steroid-sparing maintenance agent."", ""name"": ""Azathioprine""}"
5982	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	treatments	3	Mycophenolate Mofetil	Alternative steroid-sparing agent.																																																								"{""description"": ""Alternative steroid-sparing agent."", ""name"": ""Mycophenolate Mofetil""}"	{}	"{""description"": ""Alternative steroid-sparing agent."", ""name"": ""Mycophenolate Mofetil""}"
6003	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	treatments	0	Smoking Cessation	Most important intervention, reduces progression.																																																								"{""description"": ""Most important intervention, reduces progression."", ""name"": ""Smoking Cessation""}"	{}	"{""description"": ""Most important intervention, reduces progression."", ""name"": ""Smoking Cessation""}"
6004	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	treatments	1	Antiplatelet Therapy	Aspirin or clopidogrel to reduce cardiovascular events.																																																								"{""description"": ""Aspirin or clopidogrel to reduce cardiovascular events."", ""name"": ""Antiplatelet Therapy""}"	{}	"{""description"": ""Aspirin or clopidogrel to reduce cardiovascular events."", ""name"": ""Antiplatelet Therapy""}"
6005	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	treatments	2	Statins	LDL lowering, plaque stabilization.																																																								"{""description"": ""LDL lowering, plaque stabilization."", ""name"": ""Statins""}"	{}	"{""description"": ""LDL lowering, plaque stabilization."", ""name"": ""Statins""}"
6006	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	treatments	3	ACE Inhibitors	Cardiovascular risk reduction.																																																								"{""description"": ""Cardiovascular risk reduction."", ""name"": ""ACE Inhibitors""}"	{}	"{""description"": ""Cardiovascular risk reduction."", ""name"": ""ACE Inhibitors""}"
6007	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	treatments	4	Supervised Exercise Therapy	First-line for claudication, improves walking distance.																																																								"{""description"": ""First-line for claudication, improves walking distance."", ""name"": ""Supervised Exercise Therapy""}"	{}	"{""description"": ""First-line for claudication, improves walking distance."", ""name"": ""Supervised Exercise Therapy""}"
6008	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	treatments	5	Cilostazol	Phosphodiesterase inhibitor for claudication symptoms.																																																								"{""description"": ""Phosphodiesterase inhibitor for claudication symptoms."", ""name"": ""Cilostazol""}"	{}	"{""description"": ""Phosphodiesterase inhibitor for claudication symptoms."", ""name"": ""Cilostazol""}"
6009	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	treatments	6	Revascularization	Endovascular or surgical for severe disease.																																																								"{""description"": ""Endovascular or surgical for severe disease."", ""name"": ""Revascularization""}"	{}	"{""description"": ""Endovascular or surgical for severe disease."", ""name"": ""Revascularization""}"
6052	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	0	Symptomatic Management	Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management.																																																								"{""description"": ""Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management."", ""name"": ""Symptomatic Management""}"	{}	"{""description"": ""Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management."", ""evidence"": [{""explanation"": ""The statement about supportive care and symptomatic therapy is accurate but does not explicitly mention physical therapy for hypotonia and seizure management."", ""reference"": ""PMID:11060787"", ""snippet"": ""Treatment of PBD patients has generally involved only supportive care and symptomatic therapy."", ""supports"": ""PARTIAL""}, {""explanation"": ""The statement supports symptomatic care but does not detail specific treatments such as physical therapy for hypotonia or seizure management."", ""reference"": ""PMID:38409970"", ""snippet"": ""Despite an absence of treatment options, prompt diagnosis of Zellweger syndrome is important for providing appropriate symptomatic care."", ""supports"": ""PARTIAL""}], ""name"": ""Symptomatic Management"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
6053	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	1	Nutritional Support	Specialized diet and supplements to manage biochemical abnormalities.																																																								"{""description"": ""Specialized diet and supplements to manage biochemical abnormalities."", ""name"": ""Nutritional Support""}"	{}	"{""description"": ""Specialized diet and supplements to manage biochemical abnormalities."", ""evidence"": [{""explanation"": ""This snippet indicates that dietary supplementation and/or modification has been evaluated to manage biochemical abnormalities in PBD patients, supporting the statement that specialized diet and supplements can be a treatment strategy."", ""reference"": ""PMID:11060787"", ""snippet"": ""A number of experimental therapies have been evaluated to determine whether or not correction of biochemical abnormalities through dietary supplementation and/or modification is of clinical benefit to PBD patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses the use of diet as a measure to manage biochemical abnormalities in metabolic disorders, including peroxisomal diseases, which supports the statement."", ""reference"": ""PMID:18758655"", ""snippet"": ""The most important measures used to manage the intoxication present in many inborn errors of intermediate metabolism were presented (restriction of substrate build-up by means of diet or enzymatic inhibition, removal of toxic products, stimulation of residual enzyme activity, replacement of the deficient product)."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this reference discusses a specific bile-acid therapy, it does not provide evidence about dietary or supplemental approaches for managing biochemical abnormalities in PBDs."", ""reference"": ""PMID:16819396"", ""snippet"": ""Bile-acid therapy using oral cholic acid has proven effective in most of these bile acid synthetic defects making early diagnosis crucial to optimum clinical prognosis."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Nutritional Support"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
6054	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	2	Liver Transplant	Considered in severe cases with significant liver dysfunction.																																																								"{""description"": ""Considered in severe cases with significant liver dysfunction."", ""name"": ""Liver Transplant""}"	{}	"{""description"": ""Considered in severe cases with significant liver dysfunction."", ""evidence"": [{""explanation"": ""The reference indicates that liver transplantation is the standard of care for congenital inherited hepatic disorders, which includes peroxisomal disorders like Peroxisome Biogenesis Disorder (PBD), supporting that liver transplant is considered in severe cases with significant liver dysfunction."", ""reference"": ""PMID:35331403"", ""snippet"": ""Most of these disorders are currently treated by liver transplantation as standard of care."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this reference confirms liver involvement in Peroxisome Biogenesis Disorders such as Zellweger Syndrome, it does not specifically mention liver transplantation as a treatment."", ""reference"": ""PMID:26615381"", ""snippet"": ""ZS should be considered in the list of differential diagnosis in infants with stereotypical phenotype, neurodevelopmental delay, and severe hypotonia in association with liver and other organs involvement."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the use of liver transplantation in severe liver conditions, though it does not directly mention Peroxisome Biogenesis Disorder."", ""reference"": ""PMID:22974902"", ""snippet"": ""When none of the liver parenchyma is spared, or kidney insufficiency is marked, the only potentially curable treatment is liver transplantation (LT)."", ""supports"": ""PARTIAL""}], ""name"": ""Liver Transplant"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
6055	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	3	Genetic Counseling	Providing information and support to families regarding inheritance and implications.																																																								"{""description"": ""Providing information and support to families regarding inheritance and implications."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Providing information and support to families regarding inheritance and implications."", ""evidence"": [{""explanation"": ""The literature describes genetic counseling as a discipline developed to educate patients, families, and professionals about genetic mechanisms and their application in healthcare, which supports the statement about providing information and support to families regarding inheritance and implications."", ""reference"": ""PMID:14619605"", ""snippet"": ""Genetic counseling has developed as a discipline in response to the need to educate patients, families and professionals about genetic mechanisms and their application in health care. ... Genetic counseling is a process of medical education based upon empathy, patient autonomy and confidentiality in an atmosphere of empathy, support and understanding."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature discusses the importance of providing disease information and genetic counseling to families, supporting the statement about providing information and support to families regarding inheritance and implications in the context of peroxisomal diseases."", ""reference"": ""PMID:30237433"", ""snippet"": ""Furthermore, it is also important to identify pre-symptomatic patients by family analysis of probands by providing appropriate disease information and genetic counseling, which will also lead to early intervention."", ""supports"": ""SUPPORT""}], ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
6073	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	0	Endoscopic polypectomy	"Regular surveillance endoscopy with removal of polyps >10-15 mm reduces bleeding complications and cancer risk. Multiple sessions may be needed given the polyp burden.
"																																																								"{""description"": ""Regular surveillance endoscopy with removal of polyps >10-15 mm reduces bleeding complications and cancer risk. Multiple sessions may be needed given the polyp burden.\n"", ""name"": ""Endoscopic polypectomy""}"	{}	"{""description"": ""Regular surveillance endoscopy with removal of polyps >10-15 mm reduces bleeding complications and cancer risk. Multiple sessions may be needed given the polyp burden.\n"", ""evidence"": [{""explanation"": ""Endoscopic polyp removal is the standard therapeutic approach to prevent complications from Peutz-Jeghers polyps"", ""reference"": ""PMID:20301443"", ""snippet"": ""Routine endoscopic surveillance with polypectomy decreases the frequency of emergency laparotomy and bowel loss resulting from intussusception"", ""supports"": ""SUPPORT""}], ""name"": ""Endoscopic polypectomy"", ""treatment_term"": {""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""MAXO:0000130"", ""label"": ""endoscopic procedure""}}}"
6074	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	1	Surgical resection	"Reserved for cases with severe polyp burden, recurrent intussusception, or malignant transformation.
"																																																								"{""description"": ""Reserved for cases with severe polyp burden, recurrent intussusception, or malignant transformation.\n"", ""name"": ""Surgical resection""}"	{}	"{""description"": ""Reserved for cases with severe polyp burden, recurrent intussusception, or malignant transformation.\n"", ""evidence"": [{""explanation"": ""Surgical resection is indicated for intussusception and polyps with neoplastic transformation"", ""reference"": ""PMID:34928720"", ""snippet"": ""The patient underwent exploratory laparotomy during which right hemicolectomy and small bowel resection were performed"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical resection"", ""treatment_term"": {""preferred_term"": ""surgical resection"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6075	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	2	Genetic counseling	"Family members should receive counseling and cascade genetic testing for STK11 mutations.
"																																																								"{""description"": ""Family members should receive counseling and cascade genetic testing for STK11 mutations.\n"", ""name"": ""Genetic counseling""}"	{}	"{""description"": ""Family members should receive counseling and cascade genetic testing for STK11 mutations.\n"", ""evidence"": [{""explanation"": ""Genetic counseling for at-risk family members and molecular testing are critical given the autosomal dominant inheritance pattern and health implications of STK11 mutations"", ""reference"": ""PMID:36998347"", ""snippet"": ""Endoscopic resection was conducted for a definitive diagnosis and treatment. The resected specimen showed a branching bundle of smooth muscle fibers covered by hyperplastic mucosa, consistent with a hamartomatous polyp"", ""supports"": ""SUPPORT""}], ""name"": ""Genetic counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
6086	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Early surgical intervention for craniosynostosis, especially urgent in Types 2 and 3 to manage intracranial pressure.
"																																																								"{""description"": ""Early surgical intervention for craniosynostosis, especially urgent in Types 2 and 3 to manage intracranial pressure.\n"", ""name"": ""Cranial Vault Surgery""}"	{}	"{""description"": ""Early surgical intervention for craniosynostosis, especially urgent in Types 2 and 3 to manage intracranial pressure.\n"", ""name"": ""Cranial Vault Surgery"", ""treatment_term"": {""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6087	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	treatments	1	Airway Management	"Tracheostomy may be required in severe cases (Types 2 and 3) due to combined midface hypoplasia and choanal stenosis.
"																																																								"{""description"": ""Tracheostomy may be required in severe cases (Types 2 and 3) due to combined midface hypoplasia and choanal stenosis.\n"", ""name"": ""Airway Management""}"	{}	"{""description"": ""Tracheostomy may be required in severe cases (Types 2 and 3) due to combined midface hypoplasia and choanal stenosis.\n"", ""name"": ""Airway Management"", ""treatment_term"": {""preferred_term"": ""Airway management"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.																																																								"{""description"": ""Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance."", ""name"": ""Tyrosine Kinase Inhibitor plus Chemotherapy""}"	{}	"{""description"": ""Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance."", ""name"": ""Tyrosine Kinase Inhibitor plus Chemotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}, {""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}}"
6105	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	1	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.																																																								"{""description"": ""Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy."", ""name"": ""Ponatinib""}"	{}	"{""description"": ""Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy."", ""name"": ""Ponatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}]}}"
6106	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	2	Blinatumomab	CD19-CD3 bispecific T-cell engager antibody effective in relapsed/refractory Ph+ ALL. Can be combined with TKIs. Achieves molecular remissions in many patients, potentially enabling chemotherapy-free regimens.																																																								"{""description"": ""CD19-CD3 bispecific T-cell engager antibody effective in relapsed/refractory Ph+ ALL. Can be combined with TKIs. Achieves molecular remissions in many patients, potentially enabling chemotherapy-free regimens."", ""name"": ""Blinatumomab""}"	{}	"{""description"": ""CD19-CD3 bispecific T-cell engager antibody effective in relapsed/refractory Ph+ ALL. Can be combined with TKIs. Achieves molecular remissions in many patients, potentially enabling chemotherapy-free regimens."", ""name"": ""Blinatumomab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6107	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Historically considered standard for all Ph+ ALL patients in first remission. With improved TKI-based regimens, transplant may be reserved for patients with persistent MRD or high-risk features. Provides graft-versus-leukemia effect.																																																								"{""description"": ""Historically considered standard for all Ph+ ALL patients in first remission. With improved TKI-based regimens, transplant may be reserved for patients with persistent MRD or high-risk features. Provides graft-versus-leukemia effect."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Historically considered standard for all Ph+ ALL patients in first remission. With improved TKI-based regimens, transplant may be reserved for patients with persistent MRD or high-risk features. Provides graft-versus-leukemia effect."", ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
6108	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	4	CAR-T Cell Therapy	CD19-directed CAR-T cells are effective in relapsed/refractory Ph+ ALL. Can achieve durable remissions in patients who have failed TKIs and chemotherapy.																																																								"{""description"": ""CD19-directed CAR-T cells are effective in relapsed/refractory Ph+ ALL. Can achieve durable remissions in patients who have failed TKIs and chemotherapy."", ""name"": ""CAR-T Cell Therapy""}"	{}	"{""description"": ""CD19-directed CAR-T cells are effective in relapsed/refractory Ph+ ALL. Can achieve durable remissions in patients who have failed TKIs and chemotherapy."", ""name"": ""CAR-T Cell Therapy"", ""treatment_term"": {""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}}"
6132	259	Phenylketonuria	Phenylketonuria.yaml	treatments	0	Phenylalanine-Restricted Diet	Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.																																																								"{""description"": ""Lifelong dietary restriction of phenylalanine intake, mainstay of treatment."", ""name"": ""Phenylalanine-Restricted Diet""}"	{}	"{""description"": ""Lifelong dietary restriction of phenylalanine intake, mainstay of treatment."", ""evidence"": [{""explanation"": ""Confirms diet as the primary and long-standing treatment approach."", ""reference"": ""PMID:34017006"", ""snippet"": ""Dietary restriction of phenylalanine has been the mainstay of treatment for over 60 years and has been highly successful, although outcomes are still suboptimal and patients can find the treatment difficult to adhere to."", ""supports"": ""SUPPORT""}], ""name"": ""Phenylalanine-Restricted Diet"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
6133	259	Phenylketonuria	Phenylketonuria.yaml	treatments	1	Medical Formula	Phenylalanine-free amino acid supplements to provide protein needs.																																																								"{""description"": ""Phenylalanine-free amino acid supplements to provide protein needs."", ""name"": ""Medical Formula""}"	{}	"{""description"": ""Phenylalanine-free amino acid supplements to provide protein needs."", ""name"": ""Medical Formula"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
6134	259	Phenylketonuria	Phenylketonuria.yaml	treatments	2	Sapropterin (Kuvan)	BH4 cofactor replacement for responsive patients, allows dietary liberalization.																																																								"{""description"": ""BH4 cofactor replacement for responsive patients, allows dietary liberalization."", ""name"": ""Sapropterin (Kuvan)""}"	{}	"{""description"": ""BH4 cofactor replacement for responsive patients, allows dietary liberalization."", ""evidence"": [{""explanation"": ""Confirms sapropterin (BH4) effectiveness in a subset of patients with milder disease."", ""reference"": ""PMID:34017006"", ""snippet"": ""Pharmacological treatments are available, such as tetrahydrobiopterin, which is effective in only a minority of patients (usually those with milder PKU)"", ""supports"": ""SUPPORT""}], ""name"": ""Sapropterin (Kuvan)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6135	259	Phenylketonuria	Phenylketonuria.yaml	treatments	3	Pegvaliase (Palynziq)	Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.																																																								"{""description"": ""Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase."", ""name"": ""Pegvaliase (Palynziq)""}"	{}	"{""description"": ""Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase."", ""evidence"": [{""explanation"": ""Confirms pegvaliase as an available treatment, noting its route and immunogenicity concerns."", ""reference"": ""PMID:34017006"", ""snippet"": ""pegylated phenylalanine ammonia lyase, which requires daily subcutaneous injections and causes adverse immune responses"", ""supports"": ""SUPPORT""}], ""name"": ""Pegvaliase (Palynziq)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6136	259	Phenylketonuria	Phenylketonuria.yaml	treatments	4	Large Neutral Amino Acids	Compete with phenylalanine for brain transport, adjunctive therapy.																																																								"{""description"": ""Compete with phenylalanine for brain transport, adjunctive therapy."", ""name"": ""Large Neutral Amino Acids""}"	{}	"{""description"": ""Compete with phenylalanine for brain transport, adjunctive therapy."", ""name"": ""Large Neutral Amino Acids"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
6156	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	0	Surgical Resection	Complete surgical resection is the primary treatment for localized PPGL. Requires careful preoperative alpha-blockade followed by beta-blockade to prevent perioperative hypertensive crisis.																																																								"{""description"": ""Complete surgical resection is the primary treatment for localized PPGL. Requires careful preoperative alpha-blockade followed by beta-blockade to prevent perioperative hypertensive crisis."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Complete surgical resection is the primary treatment for localized PPGL. Requires careful preoperative alpha-blockade followed by beta-blockade to prevent perioperative hypertensive crisis."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6157	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	1	Alpha-Adrenergic Blockade	Preoperative alpha-blockade with phenoxybenzamine or doxazosin is essential to control hypertension and allow volume expansion before surgery.																																																								"{""description"": ""Preoperative alpha-blockade with phenoxybenzamine or doxazosin is essential to control hypertension and allow volume expansion before surgery."", ""name"": ""Alpha-Adrenergic Blockade""}"	{}	"{""description"": ""Preoperative alpha-blockade with phenoxybenzamine or doxazosin is essential to control hypertension and allow volume expansion before surgery."", ""name"": ""Alpha-Adrenergic Blockade"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6158	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	2	MIBG Therapy	131I-MIBG (metaiodobenzylguanidine) is a targeted radiotherapy for MIBG-avid metastatic PPGL. High-specific-activity 131I-MIBG is FDA-approved.																																																								"{""description"": ""131I-MIBG (metaiodobenzylguanidine) is a targeted radiotherapy for MIBG-avid metastatic PPGL. High-specific-activity 131I-MIBG is FDA-approved."", ""name"": ""MIBG Therapy""}"	{}	"{""description"": ""131I-MIBG (metaiodobenzylguanidine) is a targeted radiotherapy for MIBG-avid metastatic PPGL. High-specific-activity 131I-MIBG is FDA-approved."", ""name"": ""MIBG Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
6159	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	3	Temozolomide	Alkylating chemotherapy showing activity in metastatic PPGL, particularly SDHB-mutated tumors with MGMT promoter methylation.																																																								"{""description"": ""Alkylating chemotherapy showing activity in metastatic PPGL, particularly SDHB-mutated tumors with MGMT promoter methylation."", ""name"": ""Temozolomide""}"	{}	"{""description"": ""Alkylating chemotherapy showing activity in metastatic PPGL, particularly SDHB-mutated tumors with MGMT promoter methylation."", ""name"": ""Temozolomide"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
6160	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	4	Sunitinib	Multi-kinase inhibitor with antiangiogenic activity showing benefit in progressive metastatic PPGL. Used in clinical practice despite limited prospective data.																																																								"{""description"": ""Multi-kinase inhibitor with antiangiogenic activity showing benefit in progressive metastatic PPGL. Used in clinical practice despite limited prospective data."", ""name"": ""Sunitinib""}"	{}	"{""description"": ""Multi-kinase inhibitor with antiangiogenic activity showing benefit in progressive metastatic PPGL. Used in clinical practice despite limited prospective data."", ""name"": ""Sunitinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6186	261	Pick Disease	Pick_Disease.yaml	treatments	0	Symptomatic Management	Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function.																																																								"{""description"": ""Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function."", ""name"": ""Symptomatic Management""}"	{}	"{""description"": ""Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function."", ""evidence"": [{""explanation"": ""The reference discusses the management of Pick's disease by addressing symptoms, but does not explicitly mention the use of medications to manage behavior and support cognitive function. Hence, it provides partial support."", ""reference"": ""PMID:12080867"", ""snippet"": ""Pick's disease is a progressive illness that affects brain function, eventually causing loss of verbal skills and problem-solving abilities"", ""supports"": ""PARTIAL""}], ""name"": ""Symptomatic Management"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
6187	261	Pick Disease	Pick_Disease.yaml	treatments	1	Physical Therapy	Physical therapy to maintain mobility and manage motor symptoms that may emerge in later disease stages.																																																								"{""description"": ""Physical therapy to maintain mobility and manage motor symptoms that may emerge in later disease stages."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Physical therapy to maintain mobility and manage motor symptoms that may emerge in later disease stages."", ""evidence"": [], ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
6188	261	Pick Disease	Pick_Disease.yaml	treatments	2	Occupational Therapy	Occupational therapy to support daily living activities and maintain independence as cognitive and behavioral symptoms progress.																																																								"{""description"": ""Occupational therapy to support daily living activities and maintain independence as cognitive and behavioral symptoms progress."", ""name"": ""Occupational Therapy""}"	{}	"{""description"": ""Occupational therapy to support daily living activities and maintain independence as cognitive and behavioral symptoms progress."", ""evidence"": [], ""name"": ""Occupational Therapy"", ""treatment_term"": {""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}}"
6189	261	Pick Disease	Pick_Disease.yaml	treatments	3	Speech Therapy	Speech therapy for patients with language variant (primary progressive aphasia) to support communication abilities.																																																								"{""description"": ""Speech therapy for patients with language variant (primary progressive aphasia) to support communication abilities."", ""name"": ""Speech Therapy""}"	{}	"{""description"": ""Speech therapy for patients with language variant (primary progressive aphasia) to support communication abilities."", ""evidence"": [], ""name"": ""Speech Therapy"", ""treatment_term"": {""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}}"
6190	261	Pick Disease	Pick_Disease.yaml	treatments	4	Caregiver Support	Education and resources for caregivers to manage progressive symptoms and provide quality care.																																																								"{""description"": ""Education and resources for caregivers to manage progressive symptoms and provide quality care."", ""name"": ""Caregiver Support""}"	{}	"{""description"": ""Education and resources for caregivers to manage progressive symptoms and provide quality care."", ""evidence"": [{""explanation"": ""This reference discusses the responsibilities of nurses to educate caregivers, aligning with the statement that education and resources for caregivers are part of the treatments for Pick's disease."", ""reference"": ""PMID:12080867"", ""snippet"": ""Nurses have the responsibility of educating the primary caregiver about nutrition, skin protection, incontinence care, safety, and end-of-life decisions."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference provides clinical and biological descriptions of Pick's disease and does not explicitly mention caregiver support or education, thus only partially supporting the statement."", ""reference"": ""PMID:18090424"", ""snippet"": ""Clinical and biologic evidence in favor the entity is discussed. The changing and proliferating knowledge and terminology requires the integration of several levels of descriptions, while keeping the work in the past in sight."", ""supports"": ""PARTIAL""}], ""name"": ""Caregiver Support"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
6193	262	Pinta	Pinta.yaml	treatments	0	Penicillin injection	Single-dose intramuscular penicillin treats all stages of pinta.																																																								"{""description"": ""Single-dose intramuscular penicillin treats all stages of pinta."", ""name"": ""Penicillin injection""}"	{}	"{""description"": ""Single-dose intramuscular penicillin treats all stages of pinta."", ""evidence"": [{""explanation"": ""The abstract states that penicillin injection treats pinta."", ""reference"": ""PMID:26304920"", ""snippet"": ""All stages of pinta are treatable with a single intramuscular injection of penicillin."", ""supports"": ""SUPPORT""}], ""name"": ""Penicillin injection"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6208	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	0	Albendazole therapy	Benzimidazole antiparasitic used for smaller or inoperable hydatid cysts and as adjunct around surgery.																																																								"{""description"": ""Benzimidazole antiparasitic used for smaller or inoperable hydatid cysts and as adjunct around surgery."", ""name"": ""Albendazole therapy""}"	{}	"{""description"": ""Benzimidazole antiparasitic used for smaller or inoperable hydatid cysts and as adjunct around surgery."", ""evidence"": [{""explanation"": ""Review guidance highlights albendazole as standard medical therapy for hydatid cysts."", ""reference"": ""PMID:34034501"", ""snippet"": ""Treatment with albendazole, whether combined or not with praziquantel, is useful for smaller, uncomplicated cysts (< 5 cm)."", ""supports"": ""SUPPORT""}], ""name"": ""Albendazole therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6209	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	1	Radical hepatic resection	Surgical removal of involved hepatic segments for large polycystic echinococcosis lesions or when malignancy is suspected.																																																								"{""description"": ""Surgical removal of involved hepatic segments for large polycystic echinococcosis lesions or when malignancy is suspected."", ""name"": ""Radical hepatic resection""}"	{}	"{""description"": ""Surgical removal of involved hepatic segments for large polycystic echinococcosis lesions or when malignancy is suspected."", ""evidence"": [{""explanation"": ""The case demonstrates radical liver resection as operative management for polycystic echinococcosis."", ""reference"": ""PMID:33553405"", ""snippet"": ""According to Romic classification, the case belongs to type IIb, and radical left hemi-hepatectomy was performed."", ""supports"": ""SUPPORT""}], ""name"": ""Radical hepatic resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6233	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	0	Tolvaptan	"Vasopressin V2 receptor antagonist that slows cyst growth and kidney enlargement in ADPKD. First disease-modifying therapy approved for ADPKD. Requires hepatic monitoring due to risk of elevated liver enzymes.
"																																																								"{""description"": ""Vasopressin V2 receptor antagonist that slows cyst growth and kidney enlargement in ADPKD. First disease-modifying therapy approved for ADPKD. Requires hepatic monitoring due to risk of elevated liver enzymes.\n"", ""name"": ""Tolvaptan""}"	{}	"{""description"": ""Vasopressin V2 receptor antagonist that slows cyst growth and kidney enlargement in ADPKD. First disease-modifying therapy approved for ADPKD. Requires hepatic monitoring due to risk of elevated liver enzymes.\n"", ""evidence"": [{""explanation"": ""REPRISE trial demonstrated tolvaptan efficacy in slowing GFR decline in PKD patients."", ""reference"": ""PMID:29105594"", ""snippet"": ""Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD."", ""supports"": ""SUPPORT""}], ""name"": ""Tolvaptan"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6234	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	1	Blood Pressure Control	"Aggressive hypertension management with ACE inhibitors or ARBs to slow disease progression and reduce cardiovascular risk.
"																																																								"{""description"": ""Aggressive hypertension management with ACE inhibitors or ARBs to slow disease progression and reduce cardiovascular risk.\n"", ""name"": ""Blood Pressure Control""}"	{}	"{""description"": ""Aggressive hypertension management with ACE inhibitors or ARBs to slow disease progression and reduce cardiovascular risk.\n"", ""evidence"": [{""explanation"": ""JAMA review confirms blood pressure control as first-line treatment for ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration."", ""supports"": ""SUPPORT""}], ""name"": ""Blood Pressure Control"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6235	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	2	Renal Dialysis	"Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease. PKD is one of the leading causes of kidney failure requiring dialysis.
"																																																								"{""description"": ""Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease. PKD is one of the leading causes of kidney failure requiring dialysis.\n"", ""name"": ""Renal Dialysis""}"	{}	"{""description"": ""Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease. PKD is one of the leading causes of kidney failure requiring dialysis.\n"", ""evidence"": [{""explanation"": ""JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."", ""supports"": ""SUPPORT""}], ""name"": ""Renal Dialysis"", ""treatment_term"": {""preferred_term"": ""renal dialysis"", ""term"": {""id"": ""MAXO:0000601"", ""label"": ""renal dialysis""}}}"
6236	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	3	Kidney Transplantation	"Kidney transplantation is the preferred treatment for end-stage renal disease in PKD. Native nephrectomy may be required if kidneys are too large.
"																																																								"{""description"": ""Kidney transplantation is the preferred treatment for end-stage renal disease in PKD. Native nephrectomy may be required if kidneys are too large.\n"", ""name"": ""Kidney Transplantation""}"	{}	"{""description"": ""Kidney transplantation is the preferred treatment for end-stage renal disease in PKD. Native nephrectomy may be required if kidneys are too large.\n"", ""evidence"": [{""explanation"": ""JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."", ""reference"": ""PMID:40126492"", ""snippet"": ""Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."", ""supports"": ""SUPPORT""}], ""name"": ""Kidney Transplantation"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
6259	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	treatments	0	Combined Oral Contraceptives	First-line for menstrual irregularity and hyperandrogenism.																																																								"{""description"": ""First-line for menstrual irregularity and hyperandrogenism."", ""name"": ""Combined Oral Contraceptives""}"	{}	"{""description"": ""First-line for menstrual irregularity and hyperandrogenism."", ""name"": ""Combined Oral Contraceptives""}"
6260	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	treatments	1	Metformin	Improves insulin sensitivity and may restore ovulation.																																																								"{""description"": ""Improves insulin sensitivity and may restore ovulation."", ""name"": ""Metformin""}"	{}	"{""description"": ""Improves insulin sensitivity and may restore ovulation."", ""name"": ""Metformin""}"
6261	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	treatments	2	Spironolactone	Anti-androgen for hirsutism and acne.																																																								"{""description"": ""Anti-androgen for hirsutism and acne."", ""name"": ""Spironolactone""}"	{}	"{""description"": ""Anti-androgen for hirsutism and acne."", ""name"": ""Spironolactone""}"
6262	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	treatments	3	Letrozole	First-line ovulation induction for fertility.																																																								"{""description"": ""First-line ovulation induction for fertility."", ""name"": ""Letrozole""}"	{}	"{""description"": ""First-line ovulation induction for fertility."", ""name"": ""Letrozole""}"
6263	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	treatments	4	Clomiphene Citrate	Alternative ovulation induction agent.																																																								"{""description"": ""Alternative ovulation induction agent."", ""name"": ""Clomiphene Citrate""}"	{}	"{""description"": ""Alternative ovulation induction agent."", ""name"": ""Clomiphene Citrate""}"
6264	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	treatments	5	Lifestyle Modification	Weight loss improves all PCOS features.																																																								"{""description"": ""Weight loss improves all PCOS features."", ""name"": ""Lifestyle Modification""}"	{}	"{""description"": ""Weight loss improves all PCOS features."", ""name"": ""Lifestyle Modification""}"
6280	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	0	Therapeutic Phlebotomy	Therapeutic phlebotomy to maintain hematocrit below 45% is the cornerstone of treatment for all PV patients. Reduces thrombotic risk by lowering blood viscosity.																																																								"{""description"": ""Therapeutic phlebotomy to maintain hematocrit below 45% is the cornerstone of treatment for all PV patients. Reduces thrombotic risk by lowering blood viscosity."", ""name"": ""Therapeutic Phlebotomy""}"	{}	"{""description"": ""Therapeutic phlebotomy to maintain hematocrit below 45% is the cornerstone of treatment for all PV patients. Reduces thrombotic risk by lowering blood viscosity."", ""name"": ""Therapeutic Phlebotomy"", ""treatment_term"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""MAXO:0000002"", ""label"": ""therapeutic procedure""}}}"
6281	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	1	Low-Dose Aspirin	Low-dose aspirin (81-100 mg daily) is recommended for all PV patients without contraindications to reduce thrombotic risk. Reduces arterial and possibly venous thrombosis.																																																								"{""description"": ""Low-dose aspirin (81-100 mg daily) is recommended for all PV patients without contraindications to reduce thrombotic risk. Reduces arterial and possibly venous thrombosis."", ""name"": ""Low-Dose Aspirin""}"	{}	"{""description"": ""Low-dose aspirin (81-100 mg daily) is recommended for all PV patients without contraindications to reduce thrombotic risk. Reduces arterial and possibly venous thrombosis."", ""name"": ""Low-Dose Aspirin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6282	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	2	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.																																																								"{""description"": ""First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events."", ""name"": ""Hydroxyurea""}"	{}	"{""description"": ""First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events."", ""name"": ""Hydroxyurea"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}}"
6283	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	3	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.																																																								"{""description"": ""JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue."", ""name"": ""Ruxolitinib""}"	{}	"{""description"": ""JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue."", ""name"": ""Ruxolitinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}]}}"
6284	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	4	Interferon-alpha	Alternative to hydroxyurea, particularly for younger patients and during pregnancy. May induce molecular remissions with reduction in JAK2 V617F allele burden.																																																								"{""description"": ""Alternative to hydroxyurea, particularly for younger patients and during pregnancy. May induce molecular remissions with reduction in JAK2 V617F allele burden."", ""name"": ""Interferon-alpha""}"	{}	"{""description"": ""Alternative to hydroxyurea, particularly for younger patients and during pregnancy. May induce molecular remissions with reduction in JAK2 V617F allele burden."", ""name"": ""Interferon-alpha"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6301	267	Polymyositis	Polymyositis.yaml	treatments	0	Corticosteroids	First-line therapy; high-dose initially with gradual taper.																																																								"{""description"": ""First-line therapy; high-dose initially with gradual taper."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""First-line therapy; high-dose initially with gradual taper."", ""name"": ""Corticosteroids""}"
6302	267	Polymyositis	Polymyositis.yaml	treatments	1	Methotrexate	Most commonly used steroid-sparing agent.																																																								"{""description"": ""Most commonly used steroid-sparing agent."", ""name"": ""Methotrexate""}"	{}	"{""description"": ""Most commonly used steroid-sparing agent."", ""name"": ""Methotrexate""}"
6303	267	Polymyositis	Polymyositis.yaml	treatments	2	Azathioprine	Alternative immunosuppressant for maintenance.																																																								"{""description"": ""Alternative immunosuppressant for maintenance."", ""name"": ""Azathioprine""}"	{}	"{""description"": ""Alternative immunosuppressant for maintenance."", ""name"": ""Azathioprine""}"
6304	267	Polymyositis	Polymyositis.yaml	treatments	3	IVIG	For refractory cases or when immunosuppression contraindicated.																																																								"{""description"": ""For refractory cases or when immunosuppression contraindicated."", ""name"": ""IVIG""}"	{}	"{""description"": ""For refractory cases or when immunosuppression contraindicated."", ""name"": ""IVIG""}"
6317	268	Pouchitis	Pouchitis.yaml	treatments	0	Antibiotic Therapy	"First-line treatment with antibiotics such as ciprofloxacin and metronidazole to reduce bacterial overgrowth and restore microbial balance. Response rates are typically 80-90% for acute pouchitis.
"																																																								"{""description"": ""First-line treatment with antibiotics such as ciprofloxacin and metronidazole to reduce bacterial overgrowth and restore microbial balance. Response rates are typically 80-90% for acute pouchitis.\n"", ""name"": ""Antibiotic Therapy""}"	{}	"{""description"": ""First-line treatment with antibiotics such as ciprofloxacin and metronidazole to reduce bacterial overgrowth and restore microbial balance. Response rates are typically 80-90% for acute pouchitis.\n"", ""name"": ""Antibiotic Therapy"", ""treatment_term"": {""preferred_term"": ""antibacterial agent therapy"", ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}}"
6318	268	Pouchitis	Pouchitis.yaml	treatments	1	Probiotic Therapy	"VSL#3 (now marketed as Visbiome), a high-potency probiotic mixture containing 8 bacterial strains, has demonstrated efficacy in preventing recurrent pouchitis and maintaining remission.
"																																																								"{""description"": ""VSL#3 (now marketed as Visbiome), a high-potency probiotic mixture containing 8 bacterial strains, has demonstrated efficacy in preventing recurrent pouchitis and maintaining remission.\n"", ""name"": ""Probiotic Therapy""}"	{}	"{""description"": ""VSL#3 (now marketed as Visbiome), a high-potency probiotic mixture containing 8 bacterial strains, has demonstrated efficacy in preventing recurrent pouchitis and maintaining remission.\n"", ""name"": ""Probiotic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6319	268	Pouchitis	Pouchitis.yaml	treatments	2	Anti-inflammatory Medications	"Topical or oral 5-aminosalicylic acid (5-ASA) compounds, topical corticosteroids, or corticosteroid enemas for management of chronic or refractory pouchitis.
"																																																								"{""description"": ""Topical or oral 5-aminosalicylic acid (5-ASA) compounds, topical corticosteroids, or corticosteroid enemas for management of chronic or refractory pouchitis.\n"", ""name"": ""Anti-inflammatory Medications""}"	{}	"{""description"": ""Topical or oral 5-aminosalicylic acid (5-ASA) compounds, topical corticosteroids, or corticosteroid enemas for management of chronic or refractory pouchitis.\n"", ""name"": ""Anti-inflammatory Medications"", ""treatment_term"": {""preferred_term"": ""anti-inflammatory agent therapy"", ""term"": {""id"": ""MAXO:0000169"", ""label"": ""anti-inflammatory agent therapy""}}}"
6320	268	Pouchitis	Pouchitis.yaml	treatments	3	Immunosuppressive Therapy	"For chronic refractory pouchitis, biologic agents (anti-TNF therapy such as infliximab or adalimumab) or immunomodulators (azathioprine, 6-mercaptopurine) may be necessary.
"																																																								"{""description"": ""For chronic refractory pouchitis, biologic agents (anti-TNF therapy such as infliximab or adalimumab) or immunomodulators (azathioprine, 6-mercaptopurine) may be necessary.\n"", ""name"": ""Immunosuppressive Therapy""}"	{}	"{""description"": ""For chronic refractory pouchitis, biologic agents (anti-TNF therapy such as infliximab or adalimumab) or immunomodulators (azathioprine, 6-mercaptopurine) may be necessary.\n"", ""name"": ""Immunosuppressive Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6335	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	treatments	0	Ursodeoxycholic Acid (UDCA)	First-line therapy, improves biochemistry and transplant-free survival.																																																								"{""description"": ""First-line therapy, improves biochemistry and transplant-free survival."", ""name"": ""Ursodeoxycholic Acid (UDCA)""}"	{}	"{""description"": ""First-line therapy, improves biochemistry and transplant-free survival."", ""name"": ""Ursodeoxycholic Acid (UDCA)""}"
6336	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	treatments	1	Obeticholic Acid	Second-line for inadequate UDCA response.																																																								"{""description"": ""Second-line for inadequate UDCA response."", ""name"": ""Obeticholic Acid""}"	{}	"{""description"": ""Second-line for inadequate UDCA response."", ""name"": ""Obeticholic Acid""}"
6337	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	treatments	2	Fibrates	Bezafibrate or fenofibrate as add-on therapy.																																																								"{""description"": ""Bezafibrate or fenofibrate as add-on therapy."", ""name"": ""Fibrates""}"	{}	"{""description"": ""Bezafibrate or fenofibrate as add-on therapy."", ""name"": ""Fibrates""}"
6338	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	treatments	3	Liver Transplantation	For end-stage disease.																																																								"{""description"": ""For end-stage disease."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""For end-stage disease."", ""name"": ""Liver Transplantation""}"
6373	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	0	Airway Clearance Techniques	Methods to help clear mucus from the lungs, such as chest physical therapy.																																																								"{""description"": ""Methods to help clear mucus from the lungs, such as chest physical therapy."", ""name"": ""Airway Clearance Techniques""}"	{}	"{""description"": ""Methods to help clear mucus from the lungs, such as chest physical therapy."", ""evidence"": [{""explanation"": ""The reference acknowledges the use of airway clearance techniques in patients with Primary Ciliary Dyskinesia (PCD) to help clear mucus from the lungs."", ""reference"": ""PMID:28408202"", ""snippet"": ""Airway clearance techniques (ACTs) are commonly recommended for patients with PCD to facilitate mucus clearance, despite a lack of evidence in this group."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the importance of ACTs in managing conditions with mucus hypersecretion and impaired clearance, which aligns with the use of these techniques in PCD."", ""reference"": ""PMID:38861625"", ""snippet"": ""Airway clearance techniques (ACTs) are critical in managing respiratory conditions characterized by mucus hypersecretion and impaired clearance, such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and various neuromuscular disorders."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference mentions PCD and discusses airway hygiene and mucociliary clearance, supporting the relevance of airway clearance techniques in PCD."", ""reference"": ""PMID:11376511"", ""snippet"": ""There are three principal disorders of MCC. Firstly, primary ciliary dyskinesia (PCD)..."", ""supports"": ""SUPPORT""}], ""name"": ""Airway Clearance Techniques"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	Antibiotic Therapy	Long-term or prophylactic antibiotics to control respiratory infections.																																																								"{""description"": ""Long-term or prophylactic antibiotics to control respiratory infections."", ""name"": ""Antibiotic Therapy""}"	{}	"{""description"": ""Long-term or prophylactic antibiotics to control respiratory infections."", ""evidence"": [{""explanation"": ""The literature mentions the importance of postponing chronic lung infection in patients with impaired MCC, which is a characteristic of PCD. This aligns with the use of long-term antibiotic therapy to manage such infections."", ""reference"": ""PMID:28552099"", ""snippet"": ""Non-functional airway cilia impair the mucociliary clearance (MCC), causing mucostasis, lung infections and destruction, chronic rhinosinusitis (CRS) and hearing impairment. It is of paramount importance to postpone chronic lung infection mainly with Gram-negative bacteria (GNB) in patients with an impaired MCC. When successful, lung function can be stabilized and quality of life (QoL) improved."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference states that antibiotic treatment for pulmonary exacerbation is a mainstay of therapy for PCD, supporting the use of long-term or prophylactic antibiotics."", ""reference"": ""PMID:26586601"", ""snippet"": ""Most of the treatments recommended in PCD have been extrapolated from cystic fibrosis (CF) and non-CF bronchiectasis literature. Mainstays of therapy are reviewed in detail, and should include at a minimum: regular airway clearance, routine microbiological surveillance, antibiotic treatment for pulmonary exacerbation, and health vaccinations."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the focus is on primary immunodeficiencies, the principle of using antibiotic prophylaxis can be extended to PCD due to similar needs for managing chronic infections."", ""reference"": ""PMID:19812481"", ""snippet"": ""Antibiotic prophylaxis is one of the mainstays of therapy of primary immunodeficiencies."", ""supports"": ""SUPPORT""}], ""name"": ""Antibiotic Therapy"", ""target_phenotypes"": [{""preferred_term"": ""Recurrent Respiratory Infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}], ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6375	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	2	Bronchodilators	Medications to help open airways and ease breathing.																																																								"{""description"": ""Medications to help open airways and ease breathing."", ""name"": ""Bronchodilators""}"	{}	"{""description"": ""Medications to help open airways and ease breathing."", ""evidence"": [{""explanation"": ""The reference discusses new data and future challenges related to Primary Ciliary Dyskinesia (PCD) and bronchiectasis but does not provide specific information about the use of bronchodilators for PCD."", ""reference"": ""PMID:36639347"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference focuses on airway clearance techniques in PCD and does not mention the use of bronchodilators."", ""reference"": ""PMID:39269762"", ""snippet"": ""Primary ciliary dyskinesia (PCD) is a respiratory disorder that impairs mucociliary clearance, leading to decreased lung function."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference discusses intrapulmonary percussive ventilation for PCD but does not mention bronchodilators."", ""reference"": ""PMID:33507585"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference discusses treatment response to pulmonary exacerbation in PCD but does not mention bronchodilators."", ""reference"": ""PMID:37449771"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Bronchodilators"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6376	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	3	Nasal Steroids	Used to treat nasal polyps and chronic sinusitis.																																																								"{""description"": ""Used to treat nasal polyps and chronic sinusitis."", ""name"": ""Nasal Steroids""}"	{}	"{""description"": ""Used to treat nasal polyps and chronic sinusitis."", ""evidence"": [{""explanation"": ""While nasal steroids are used to treat nasal polyps and chronic rhinosinusitis, the statement should specify that they are used to manage symptoms rather than being a description of Primary Ciliary Dyskinesia (PCD)."", ""reference"": ""PMID:19879441"", ""snippet"": ""Long-term treatment with corticosteroid nasal spray reduces inflammation and nasal polyp size, and improves nasal symptoms such as nasal blockage, rhinorrea, and the loss of smell."", ""supports"": ""PARTIAL""}, {""explanation"": ""Nasal steroids are used in the treatment of chronic rhinosinusitis (CRS), which can be a condition associated with PCD. However, the statement should clarify that nasal steroids are for symptom management rather than a direct description of PCD."", ""reference"": ""PMID:33305974"", ""snippet"": ""Topical nasal steroids play an important role in the treatment of CRS."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference indicates that chronic rhinosinusitis with nasal polyps (CRSwNP) is more severe in PCD patients. However, it does not directly state that nasal steroids are used to treat these conditions in the context of PCD."", ""reference"": ""PMID:35312075"", ""snippet"": ""Our findings indicate for the first time that PCD patients with CRSwNP display a more severe disease than those with CRSsNP."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference suggests that surgical and adjuvant therapies, including possibly nasal steroids, can ameliorate CRS symptoms in PCD patients. However, it does not explicitly state the use of nasal steroids."", ""reference"": ""PMID:28552099"", ""snippet"": ""Implementing ESS with adjuvant therapy to PCD patients (I, IV) significantly ameliorated CRS symptoms."", ""supports"": ""PARTIAL""}], ""name"": ""Nasal Steroids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	Hearing Aids	Assistive devices for hearing loss management.																																																								"{""description"": ""Assistive devices for hearing loss management."", ""name"": ""Hearing Aids""}"	{}	"{""description"": ""Assistive devices for hearing loss management."", ""evidence"": [{""explanation"": ""The study discusses the prevalence and types of hearing loss in children with PCD but does not mention the use of hearing aids or other assistive devices for management."", ""reference"": ""PMID:29287859"", ""snippet"": ""CONCLUSIONS: Slight to mild CHL and all types of otitis media are prevalent among patients with PCD, and some of these children have sensorineural hearing loss (SNHL)."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This study focuses on the use of hearing technologies among students with hearing impairment but does not specifically address children with PCD."", ""reference"": ""PMID:22960754"", ""snippet"": ""This article explores factors pertaining to children's use of and attitudes toward hearing technologies, such as hearing aids, cochlear implants, teacher-worn microphones, and student-worn microphones."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The study evaluates the impact of hearing assistive devices on gait and balance in adults but does not mention their use in patients with PCD."", ""reference"": ""PMID:28187057"", ""snippet"": ""OBJECTIVE: To evaluate whether wearing auditory assistive devices can improve gait and dynamic balance."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The article discusses implantable auditory devices as a hearing restoration option but does not specifically mention hearing aids for patients with PCD."", ""reference"": ""PMID:30827358"", ""snippet"": ""Implantable auditory devices (IADs) are a viable hearing restoration option for patients with hearing loss."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This study discusses middle ear function in patients with PCD but does not mention the use of hearing aids or other assistive devices."", ""reference"": ""PMID:2062156"", ""snippet"": ""In patients with primary ciliary dyskinesia, a discrepancy was found between subjective ear complaints and the actual middle ear function."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Hearing Aids"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
6378	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	5	Genetic Counseling	Provides information and support for affected individuals and families.																																																								"{""description"": ""Provides information and support for affected individuals and families."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Provides information and support for affected individuals and families."", ""evidence"": [{""explanation"": ""The reference discusses advances in genetics and diagnostic testing for primary ciliary dyskinesia but does not mention genetic counseling providing information and support for affected individuals and families."", ""reference"": ""PMID:29800551"", ""snippet"": ""Our knowledge of cilia genetics and the function of the proteins encoded has led to a greater understanding of the clinical manifestations of motile ciliopathies. These advances have changed our approach toward diagnostic testing for primary ciliary dyskinesia."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The guideline focuses on diagnostic practices and does not mention genetic counseling or support for affected individuals and families."", ""reference"": ""PMID:29905515"", ""snippet"": ""This document presents the American Thoracic Society clinical practice guidelines for the diagnosis of primary ciliary dyskinesia (PCD)."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference discusses potential future therapies for PCD but does not mention genetic counseling or support services."", ""reference"": ""PMID:19410203"", ""snippet"": ""Newer genetic modifiers show an exciting potential for personalized medication, combining selection of patients with a common genetic mutation and a drug treatment that has been specifically designed to overcome that mutation, and will greatly enhance the therapeutic arsenal for PCD."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference discusses diagnostic delays and clinical outcomes but does not mention genetic counseling or support services."", ""reference"": ""PMID:35854386"", ""snippet"": ""Diagnostic delay and under-recognition of PCD remain a big issue in China, which contributes to progressive lung disease and PA infection indicating worse outcome."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
6384	271	Primary Lateral Sclerosis	Primary_Lateral_Sclerosis.yaml	treatments	0	Supportive Care	Symptomatic management and supportive interventions.																																																								"{""description"": ""Symptomatic management and supportive interventions."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Symptomatic management and supportive interventions."", ""evidence"": [{""explanation"": ""The abstract states that management is supportive."", ""reference"": ""PMID:26515619"", ""snippet"": ""Treatment is largely supportive."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
6404	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	0	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.																																																								"{""description"": ""JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation."", ""name"": ""Ruxolitinib""}"	{}	"{""description"": ""JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation."", ""name"": ""Ruxolitinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}]}}"
6405	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	1	Fedratinib	JAK2 inhibitor approved for intermediate-2 and high-risk PMF, including patients previously treated with ruxolitinib. Selective JAK2 inhibition with similar efficacy profile.																																																								"{""description"": ""JAK2 inhibitor approved for intermediate-2 and high-risk PMF, including patients previously treated with ruxolitinib. Selective JAK2 inhibition with similar efficacy profile."", ""name"": ""Fedratinib""}"	{}	"{""description"": ""JAK2 inhibitor approved for intermediate-2 and high-risk PMF, including patients previously treated with ruxolitinib. Selective JAK2 inhibition with similar efficacy profile."", ""name"": ""Fedratinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6406	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for PMF. Considered for younger patients with high-risk disease. Significant transplant-related morbidity and mortality must be weighed against disease risk.																																																								"{""description"": ""Only potentially curative treatment for PMF. Considered for younger patients with high-risk disease. Significant transplant-related morbidity and mortality must be weighed against disease risk."", ""name"": ""Allogeneic Stem Cell Transplantation""}"	{}	"{""description"": ""Only potentially curative treatment for PMF. Considered for younger patients with high-risk disease. Significant transplant-related morbidity and mortality must be weighed against disease risk."", ""name"": ""Allogeneic Stem Cell Transplantation"", ""treatment_term"": {""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}}"
6407	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	3	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.																																																								"{""description"": ""Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors."", ""name"": ""Hydroxyurea""}"	{}	"{""description"": ""Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors."", ""name"": ""Hydroxyurea"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}}"
6408	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	4	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.																																																								"{""description"": ""Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor."", ""name"": ""Anagrelide""}"	{}	"{""description"": ""Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor."", ""name"": ""Anagrelide"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}]}}"
6417	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	treatments	0	Speech Therapy and Counseling	Supportive management with speech therapy, counseling, and education for patients and caregivers.																																																								"{""description"": ""Supportive management with speech therapy, counseling, and education for patients and caregivers."", ""name"": ""Speech Therapy and Counseling""}"	{}	"{""description"": ""Supportive management with speech therapy, counseling, and education for patients and caregivers."", ""evidence"": [{""explanation"": ""The abstract highlights speech therapy and counseling as helpful supportive interventions."", ""reference"": ""PMID:19300609"", ""snippet"": ""Referral to specialized centers where speech therapy, counseling, and education for both patient and caregiver are available may be helpful."", ""supports"": ""SUPPORT""}], ""name"": ""Speech Therapy and Counseling""}"
6432	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	treatments	0	Ursodeoxycholic Acid	May improve biochemistry but no proven survival benefit.																																																								"{""description"": ""May improve biochemistry but no proven survival benefit."", ""name"": ""Ursodeoxycholic Acid""}"	{}	"{""description"": ""May improve biochemistry but no proven survival benefit."", ""evidence"": [{""explanation"": ""Confirms that despite widespread use, UDCA lacks proven efficacy for delaying transplantation or improving survival in PSC."", ""reference"": ""PMID:39404413"", ""snippet"": ""there is no evidence that the use of UDCA delays the time to liver transplant or increases survival."", ""supports"": ""SUPPORT""}], ""name"": ""Ursodeoxycholic Acid""}"
6433	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	treatments	1	Endoscopic Therapy	Balloon dilation for dominant strictures.																																																								"{""description"": ""Balloon dilation for dominant strictures."", ""name"": ""Endoscopic Therapy""}"	{}	"{""description"": ""Balloon dilation for dominant strictures."", ""name"": ""Endoscopic Therapy""}"
6434	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	treatments	2	Liver Transplantation	Only curative treatment; disease may recur.																																																								"{""description"": ""Only curative treatment; disease may recur."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""Only curative treatment; disease may recur."", ""evidence"": [{""explanation"": ""Highlights the limited treatment options for PSC, with transplantation remaining the primary definitive therapy."", ""reference"": ""PMID:39250501"", ""snippet"": ""Treatment for these diseases is limited, and collectively, they are one of the therapeutic \""black boxes\"" in clinical hepatology."", ""supports"": ""SUPPORT""}], ""name"": ""Liver Transplantation""}"
6435	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	treatments	3	Cholangiocarcinoma Surveillance	Regular imaging due to cancer risk.																																																								"{""description"": ""Regular imaging due to cancer risk."", ""name"": ""Cholangiocarcinoma Surveillance""}"	{}	"{""description"": ""Regular imaging due to cancer risk."", ""name"": ""Cholangiocarcinoma Surveillance""}"
6461	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	0	Chemotherapy	Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone).																																																								"{""description"": ""Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)."", ""evidence"": [{""explanation"": ""The study discusses the use of chemotherapy, including CHOP regimen, for the treatment of primary tonsillar lymphoma, which supports the statement."", ""reference"": ""PMID:10592134"", ""snippet"": ""We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. There were two lymphoma cases with diffuse large cells, two cases with mixed small and large cells, one with small cells and one indeterminate. They were treated with six cycles of chemotherapy and cervical radiotherapy. All patients achieved durable complete remission."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions the use of CHOP regimen for treating non-Hodgkin lymphoma, which includes primary tonsillar lymphoma."", ""reference"": ""PMID:31894937"", ""snippet"": ""Non-Hodgkin lymphoma is treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab (R-CHOP)... Chemotherapy treatment plans differ between the main subtypes of lymphoma."", ""supports"": ""SUPPORT""}], ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	Radiation Therapy	Targeted radiation to the tonsil and surrounding structures to control local disease.																																																								"{""description"": ""Targeted radiation to the tonsil and surrounding structures to control local disease."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Targeted radiation to the tonsil and surrounding structures to control local disease."", ""evidence"": [{""explanation"": ""The study is focused on squamous cell carcinoma of the tonsil, not primary tonsillar lymphoma."", ""reference"": ""PMID:8189757"", ""snippet"": ""CONCLUSION: This study substantiates the effectiveness of radiation therapy in patients with squamous cell carcinoma of the tonsil."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference mentions primary tonsillar lymphoma but does not provide specific evidence on the effectiveness of targeted radiation therapy for local disease control."", ""reference"": ""PMID:20706049"", ""snippet"": ""Non-Hodgkin lymphomas quite often present in the head and neck but primary tonsillar lymphomas of extranodal non-Hodgkin lymphomas are far less than 1% of head and neck malignancies."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference discusses radiation therapy for Hodgkin lymphoma, not primary tonsillar lymphoma."", ""reference"": ""PMID:23790512"", ""snippet"": ""Radiation therapy (RT) is the most effective single modality for local control of Hodgkin lymphoma (HL) and an important component of therapy for many patients."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference discusses a combination of chemotherapy and radiotherapy for primary tonsillar lymphoma but does not provide specific details on targeted radiation therapy for local disease control."", ""reference"": ""PMID:10592134"", ""snippet"": ""There have been many reports that favor aggressive systemic treatment with chemotherapy and radiotherapy, even for well-localized lymphomas, avoiding the need for tonsillectomy of the normal tonsil."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference focuses on the ultrasonic features of tonsillar lymphoma and does not provide evidence on targeted radiation therapy for local disease control."", ""reference"": ""PMID:38742359"", ""snippet"": ""The clinical, pathological and ultrasonic data of nine patients with tonsillar lymphoma confirmed by pathology at Tianjin Medical University Cancer Institute and Hospital during June 2015 and June 2022 were analyzed retrospectively."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	Targeted Therapy	Use of drugs like rituximab for B-cell lymphomas.																																																								"{""description"": ""Use of drugs like rituximab for B-cell lymphomas."", ""name"": ""Targeted Therapy""}"	{}	"{""description"": ""Use of drugs like rituximab for B-cell lymphomas."", ""evidence"": [{""explanation"": ""This reference supports the use of rituximab as a targeted therapy for B-cell lymphomas."", ""reference"": ""PMID:15252219"", ""snippet"": ""Rituximab, a monoclonal antibody directed against the B cell-specific protein CD20, has revolutionized lymphoma treatment by providing a highly effective form of therapy with relatively mild toxic side effects."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses chemotherapy and radiotherapy for primary tonsillar lymphoma but does not mention rituximab."", ""reference"": ""PMID:10592134"", ""snippet"": ""We report six cases of primary tonsillar lymphoma with a median patient age of 42 years. ... They were treated with six cycles of chemotherapy and cervical radiotherapy."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference supports the use of targeted therapies, specifically mentioning CD20-targeting agents for B-cell lymphomas, which includes rituximab."", ""reference"": ""PMID:18381106"", ""snippet"": ""Iodine 131-tositumomab and ibritumomab tiuxetan, radioimmunoconjugates that target the CD20 antigen, have been approved in the United States for use in relapsed or refractory, indolent, and transformed B-cell lymphomas."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference mentions rituximab as part of the treatment for a specific type of B-cell lymphoma, but not specifically for primary tonsillar lymphoma."", ""reference"": ""PMID:30709635"", ""snippet"": ""While the innovations in terms of B-cell lymphomas are certainly less significant, mention must also be made of the value of rituximab combined with polychemotherapy (CHOP) and of lenalidomide (as second-line therapy) in primary cutaneous diffuse large B-cell lymphoma, leg type."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the use of rituximab as a targeted therapy for B-cell lymphomas."", ""reference"": ""PMID:32755987"", ""snippet"": ""The addition of rituximab, a monoclonal antibody against CD20, to upfront therapy has improved survival outcomes for high-risk patients and may allow decreased total chemotherapy in those with low-risk disease."", ""supports"": ""SUPPORT""}], ""name"": ""Targeted Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6464	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	3	Stem Cell Transplant	Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function.																																																								"{""description"": ""Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function."", ""name"": ""Stem Cell Transplant""}"	{}	"{""description"": ""Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function."", ""evidence"": [{""explanation"": ""The reference discusses the use of high-dose chemotherapy followed by stem-cell transplant as a consolidation therapy, which aligns with the statement about primary tonsillar lymphoma."", ""reference"": ""PMID:32725379"", ""snippet"": ""Based on high rates of long-term remission, our first choice for consolidation therapy is high-dose chemotherapy with autologous stem-cell transplant using thiotepa, busulfan, and cyclophosphamide as a myeloablative regimen, with a curative intent."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference indicates that high-dose chemotherapy followed by stem cell transplantation is considered for certain types of lymphoma, supporting the statement."", ""reference"": ""PMID:20359581"", ""snippet"": ""Results of conventional or high-dose chemotherapy for peripheral T-cell lymphoma (PTCL) are unsatisfactory, leaving a potential role for autologous or allogeneic stem cell transplantation."", ""supports"": ""SUPPORT""}], ""name"": ""Stem Cell Transplant"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.																																																								"{""description"": ""Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome."", ""name"": ""AKT inhibitor (miransertib/ARQ 092)""}"	{}	"{""description"": ""Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome."", ""evidence"": [{""explanation"": ""This shows AKT pathway suppression by ARQ 092 in Proteus syndrome samples."", ""reference"": ""DOI:10.1038/srep17162"", ""snippet"": ""ARQ 092 reduced phosphorylation of AKT and downstream targets of AKT in a concentration-dependent manner in as little as two hours."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case report describes clinical benefit with miransertib (ARQ 092)."", ""reference"": ""DOI:10.1101/mcs.a006134"", ""snippet"": ""The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi."", ""supports"": ""SUPPORT""}], ""name"": ""AKT inhibitor (miransertib/ARQ 092)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""miransertib"", ""term"": {""id"": ""NCIT:C99172"", ""label"": ""Miransertib""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6513	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	1	Surgical intervention	Surgical debulking or corrective procedures used to manage focal overgrowth and deformity.																																																								"{""description"": ""Surgical debulking or corrective procedures used to manage focal overgrowth and deformity."", ""name"": ""Surgical intervention""}"	{}	"{""description"": ""Surgical debulking or corrective procedures used to manage focal overgrowth and deformity."", ""evidence"": [{""explanation"": ""This case report documents surgical intervention for overgrowth management."", ""reference"": ""DOI:10.1055/a-2300-7002"", ""snippet"": ""We report a case of PS in a two-year-old female patient with the following clinical features: unilateral overgrowth of connective tissue in the right buttock and right foot, where multiple surgeries were performed to achieve a desirable aesthetic outcome and ensure psychological comfort of the young patient."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical intervention"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6543	278	Psoriasis	Psoriasis.yaml	treatments	0	Topical Corticosteroids	First-line for limited disease.																																																								"{""description"": ""First-line for limited disease."", ""name"": ""Topical Corticosteroids""}"	{}	"{""description"": ""First-line for limited disease."", ""name"": ""Topical Corticosteroids""}"
6544	278	Psoriasis	Psoriasis.yaml	treatments	1	Topical Vitamin D Analogues	Calcipotriene, calcitriol for mild to moderate disease.																																																								"{""description"": ""Calcipotriene, calcitriol for mild to moderate disease."", ""name"": ""Topical Vitamin D Analogues""}"	{}	"{""description"": ""Calcipotriene, calcitriol for mild to moderate disease."", ""name"": ""Topical Vitamin D Analogues""}"
6545	278	Psoriasis	Psoriasis.yaml	treatments	2	Phototherapy	Narrowband UVB or PUVA for moderate to severe disease.																																																								"{""description"": ""Narrowband UVB or PUVA for moderate to severe disease."", ""name"": ""Phototherapy""}"	{}	"{""description"": ""Narrowband UVB or PUVA for moderate to severe disease."", ""name"": ""Phototherapy""}"
6546	278	Psoriasis	Psoriasis.yaml	treatments	3	Methotrexate	Traditional systemic therapy for moderate to severe disease.																																																								"{""description"": ""Traditional systemic therapy for moderate to severe disease."", ""name"": ""Methotrexate""}"	{}	"{""description"": ""Traditional systemic therapy for moderate to severe disease."", ""name"": ""Methotrexate""}"
6547	278	Psoriasis	Psoriasis.yaml	treatments	4	TNF Inhibitors	Adalimumab, etanercept, infliximab for moderate to severe disease.																																																								"{""description"": ""Adalimumab, etanercept, infliximab for moderate to severe disease."", ""name"": ""TNF Inhibitors""}"	{}	"{""description"": ""Adalimumab, etanercept, infliximab for moderate to severe disease."", ""name"": ""TNF Inhibitors""}"
6548	278	Psoriasis	Psoriasis.yaml	treatments	5	IL-17 Inhibitors	Secukinumab, ixekizumab - highly effective targeted therapy.																																																								"{""description"": ""Secukinumab, ixekizumab - highly effective targeted therapy."", ""name"": ""IL-17 Inhibitors""}"	{}	"{""description"": ""Secukinumab, ixekizumab - highly effective targeted therapy."", ""name"": ""IL-17 Inhibitors""}"
6549	278	Psoriasis	Psoriasis.yaml	treatments	6	IL-23 Inhibitors	Guselkumab, risankizumab - high efficacy with infrequent dosing.																																																								"{""description"": ""Guselkumab, risankizumab - high efficacy with infrequent dosing."", ""name"": ""IL-23 Inhibitors""}"	{}	"{""description"": ""Guselkumab, risankizumab - high efficacy with infrequent dosing."", ""evidence"": [{""explanation"": ""This paper reviews the therapeutic effect of IL-23 inhibition in treating psoriasis and other immune-mediated inflammatory diseases, supporting the use of IL-23 inhibitors like guselkumab and risankizumab."", ""reference"": ""PMID:38686385"", ""snippet"": ""We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases."", ""supports"": ""SUPPORT""}], ""name"": ""IL-23 Inhibitors""}"
6550	278	Psoriasis	Psoriasis.yaml	treatments	7	IL-12/23 Inhibitor	Ustekinumab targets shared p40 subunit.																																																								"{""description"": ""Ustekinumab targets shared p40 subunit."", ""name"": ""IL-12/23 Inhibitor""}"	{}	"{""description"": ""Ustekinumab targets shared p40 subunit."", ""evidence"": [{""explanation"": ""Ustekinumab targets the p40 subunit shared by IL-12 and IL-23. Given IL-23's hierarchically dominant role, blocking this shared subunit provides therapeutic benefit in psoriasis."", ""reference"": ""PMID:38686385"", ""snippet"": ""Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease."", ""supports"": ""SUPPORT""}], ""name"": ""IL-12/23 Inhibitor""}"
6551	278	Psoriasis	Psoriasis.yaml	treatments	8	JAK Inhibitors	Oral therapy option (deucravacitinib - TYK2 inhibitor).																																																								"{""description"": ""Oral therapy option (deucravacitinib - TYK2 inhibitor)."", ""name"": ""JAK Inhibitors""}"	{}	"{""description"": ""Oral therapy option (deucravacitinib - TYK2 inhibitor)."", ""name"": ""JAK Inhibitors""}"
6559	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	treatments	0	Targeted Cytokine Biologic Therapy	Biologic agents targeting IL-23/IL-17 and TNF pathways to reduce inflammation and control disease activity.																																																								"{""description"": ""Biologic agents targeting IL-23/IL-17 and TNF pathways to reduce inflammation and control disease activity."", ""name"": ""Targeted Cytokine Biologic Therapy""}"	{}	"{""description"": ""Biologic agents targeting IL-23/IL-17 and TNF pathways to reduce inflammation and control disease activity."", ""evidence"": [{""explanation"": ""The abstract links cytokine pathways to targeted therapies in psoriatic arthritis."", ""reference"": ""PMID:36902329"", ""snippet"": ""Research has identified several immune-inflammatory pathways defined by cytokines (IL-23/IL-17, TNF), leading to the development of efficacious therapeutic targets."", ""supports"": ""SUPPORT""}], ""name"": ""Targeted Cytokine Biologic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6592	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	0	Phosphodiesterase-5 Inhibitors	Medications like sildenafil and tadalafil that relax blood vessels in the lungs																																																								"{""description"": ""Medications like sildenafil and tadalafil that relax blood vessels in the lungs"", ""name"": ""Phosphodiesterase-5 Inhibitors""}"	{}	"{""description"": ""Medications like sildenafil and tadalafil that relax blood vessels in the lungs"", ""name"": ""Phosphodiesterase-5 Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6593	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	1	Endothelin Receptor Antagonists	Medications that block the effects of endothelin and help decrease blood pressure in the lungs																																																								"{""description"": ""Medications that block the effects of endothelin and help decrease blood pressure in the lungs"", ""name"": ""Endothelin Receptor Antagonists""}"	{}	"{""description"": ""Medications that block the effects of endothelin and help decrease blood pressure in the lungs"", ""name"": ""Endothelin Receptor Antagonists"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6594	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	2	Prostacyclin Analogues	Medications that mimic the effects of prostacyclin, dilating pulmonary and systemic arterial vascular beds																																																								"{""description"": ""Medications that mimic the effects of prostacyclin, dilating pulmonary and systemic arterial vascular beds"", ""name"": ""Prostacyclin Analogues""}"	{}	"{""description"": ""Medications that mimic the effects of prostacyclin, dilating pulmonary and systemic arterial vascular beds"", ""name"": ""Prostacyclin Analogues"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6595	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	3	Oxygen Therapy	Used to reduce symptoms in patients with hypoxemia																																																								"{""description"": ""Used to reduce symptoms in patients with hypoxemia"", ""name"": ""Oxygen Therapy""}"	{}	"{""description"": ""Used to reduce symptoms in patients with hypoxemia"", ""name"": ""Oxygen Therapy"", ""treatment_term"": {""preferred_term"": ""artificial respiration"", ""term"": {""id"": ""MAXO:0000503"", ""label"": ""artificial respiration""}}}"
6596	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	4	Anticoagulation	Used particularly in chronic thromboembolic pulmonary hypertension to prevent clotting complications																																																								"{""description"": ""Used particularly in chronic thromboembolic pulmonary hypertension to prevent clotting complications"", ""name"": ""Anticoagulation""}"	{}	"{""description"": ""Used particularly in chronic thromboembolic pulmonary hypertension to prevent clotting complications"", ""name"": ""Anticoagulation"", ""treatment_term"": {""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}}"
6610	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with lymph node dissection is the primary treatment. Most RET fusion-positive PTCs have excellent outcomes with surgery alone.																																																								"{""description"": ""Total thyroidectomy with lymph node dissection is the primary treatment. Most RET fusion-positive PTCs have excellent outcomes with surgery alone."", ""name"": ""Thyroidectomy""}"	{}	"{""description"": ""Total thyroidectomy with lymph node dissection is the primary treatment. Most RET fusion-positive PTCs have excellent outcomes with surgery alone."", ""name"": ""Thyroidectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6611	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	1	Radioiodine Therapy	Adjuvant radioactive iodine therapy is used for intermediate and high-risk disease. RET fusion-positive tumors generally maintain radioiodine avidity better than BRAF-mutant tumors.																																																								"{""description"": ""Adjuvant radioactive iodine therapy is used for intermediate and high-risk disease. RET fusion-positive tumors generally maintain radioiodine avidity better than BRAF-mutant tumors."", ""name"": ""Radioiodine Therapy""}"	{}	"{""description"": ""Adjuvant radioactive iodine therapy is used for intermediate and high-risk disease. RET fusion-positive tumors generally maintain radioiodine avidity better than BRAF-mutant tumors."", ""name"": ""Radioiodine Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
6612	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	2	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive thyroid cancer that is radioiodine-refractory. Demonstrates high response rates with durable disease control.																																																								"{""description"": ""Highly selective RET inhibitor approved for RET fusion-positive thyroid cancer that is radioiodine-refractory. Demonstrates high response rates with durable disease control."", ""name"": ""Selpercatinib""}"	{}	"{""description"": ""Highly selective RET inhibitor approved for RET fusion-positive thyroid cancer that is radioiodine-refractory. Demonstrates high response rates with durable disease control."", ""name"": ""Selpercatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6613	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	3	Pralsetinib	Another selective RET inhibitor with activity in RET fusion-positive thyroid cancer. Similar efficacy profile to selpercatinib.																																																								"{""description"": ""Another selective RET inhibitor with activity in RET fusion-positive thyroid cancer. Similar efficacy profile to selpercatinib."", ""name"": ""Pralsetinib""}"	{}	"{""description"": ""Another selective RET inhibitor with activity in RET fusion-positive thyroid cancer. Similar efficacy profile to selpercatinib."", ""name"": ""Pralsetinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6614	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	4	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.																																																								"{""description"": ""Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors."", ""name"": ""Lenvatinib or Sorafenib""}"	{}	"{""description"": ""Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors."", ""name"": ""Lenvatinib or Sorafenib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}}"
6630	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	0	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive NSCLC based on LIBRETTO-001 trial. Excellent CNS penetration with demonstrated intracranial activity. Well-tolerated with manageable side effects (hypertension, LFT elevation).																																																								"{""description"": ""Highly selective RET inhibitor approved for RET fusion-positive NSCLC based on LIBRETTO-001 trial. Excellent CNS penetration with demonstrated intracranial activity. Well-tolerated with manageable side effects (hypertension, LFT elevation)."", ""name"": ""Selpercatinib""}"	{}	"{""description"": ""Highly selective RET inhibitor approved for RET fusion-positive NSCLC based on LIBRETTO-001 trial. Excellent CNS penetration with demonstrated intracranial activity. Well-tolerated with manageable side effects (hypertension, LFT elevation)."", ""name"": ""Selpercatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6631	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	1	Pralsetinib	Selective RET inhibitor approved for RET fusion-positive NSCLC based on ARROW trial. Active in treatment-naive and previously treated patients. Side effects include hypertension and pneumonitis.																																																								"{""description"": ""Selective RET inhibitor approved for RET fusion-positive NSCLC based on ARROW trial. Active in treatment-naive and previously treated patients. Side effects include hypertension and pneumonitis."", ""name"": ""Pralsetinib""}"	{}	"{""description"": ""Selective RET inhibitor approved for RET fusion-positive NSCLC based on ARROW trial. Active in treatment-naive and previously treated patients. Side effects include hypertension and pneumonitis."", ""name"": ""Pralsetinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6632	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	2	Cabozantinib	Multi-kinase inhibitor (RET/VEGFR/MET) with RET activity. Less selective than selpercatinib/pralsetinib, used historically before selective inhibitors were available. More toxicity due to VEGFR inhibition.																																																								"{""description"": ""Multi-kinase inhibitor (RET/VEGFR/MET) with RET activity. Less selective than selpercatinib/pralsetinib, used historically before selective inhibitors were available. More toxicity due to VEGFR inhibition."", ""name"": ""Cabozantinib""}"	{}	"{""description"": ""Multi-kinase inhibitor (RET/VEGFR/MET) with RET activity. Less selective than selpercatinib/pralsetinib, used historically before selective inhibitors were available. More toxicity due to VEGFR inhibition."", ""name"": ""Cabozantinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6633	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for RET-positive NSCLC at progression, though driver mutation-positive tumors often have lower response rates to immunotherapy.																																																								"{""description"": ""Checkpoint inhibitors may be used for RET-positive NSCLC at progression, though driver mutation-positive tumors often have lower response rates to immunotherapy."", ""name"": ""Immunotherapy""}"	{}	"{""description"": ""Checkpoint inhibitors may be used for RET-positive NSCLC at progression, though driver mutation-positive tumors often have lower response rates to immunotherapy."", ""name"": ""Immunotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6634	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on RET inhibitors or historically before RET inhibitors were available.																																																								"{""description"": ""Platinum-based chemotherapy (pemetrexed-based) used at progression on RET inhibitors or historically before RET inhibitors were available."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy (pemetrexed-based) used at progression on RET inhibitors or historically before RET inhibitors were available."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
6650	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	0	Crizotinib	First ROS1 inhibitor approved for ROS1-rearranged NSCLC. Originally developed as ALK/MET inhibitor, cross-reactive with ROS1 due to kinase domain homology. Limited CNS penetration is a clinical limitation.																																																								"{""description"": ""First ROS1 inhibitor approved for ROS1-rearranged NSCLC. Originally developed as ALK/MET inhibitor, cross-reactive with ROS1 due to kinase domain homology. Limited CNS penetration is a clinical limitation."", ""name"": ""Crizotinib""}"	{}	"{""description"": ""First ROS1 inhibitor approved for ROS1-rearranged NSCLC. Originally developed as ALK/MET inhibitor, cross-reactive with ROS1 due to kinase domain homology. Limited CNS penetration is a clinical limitation."", ""name"": ""Crizotinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6651	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	1	Entrectinib	ROS1/TRK/ALK inhibitor with excellent CNS penetration. Approved for ROS1-positive NSCLC including patients with CNS metastases. Also active against NTRK fusions.																																																								"{""description"": ""ROS1/TRK/ALK inhibitor with excellent CNS penetration. Approved for ROS1-positive NSCLC including patients with CNS metastases. Also active against NTRK fusions."", ""name"": ""Entrectinib""}"	{}	"{""description"": ""ROS1/TRK/ALK inhibitor with excellent CNS penetration. Approved for ROS1-positive NSCLC including patients with CNS metastases. Also active against NTRK fusions."", ""name"": ""Entrectinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6652	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	2	Lorlatinib	Third-generation ALK/ROS1 inhibitor with activity against many resistance mutations including G2032R. Excellent CNS penetration. Used after progression on prior ROS1 inhibitors.																																																								"{""description"": ""Third-generation ALK/ROS1 inhibitor with activity against many resistance mutations including G2032R. Excellent CNS penetration. Used after progression on prior ROS1 inhibitors."", ""name"": ""Lorlatinib""}"	{}	"{""description"": ""Third-generation ALK/ROS1 inhibitor with activity against many resistance mutations including G2032R. Excellent CNS penetration. Used after progression on prior ROS1 inhibitors."", ""name"": ""Lorlatinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6653	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	3	Repotrectinib	Next-generation ROS1/TRK inhibitor designed to overcome G2032R solvent front mutation. Compact macrocyclic structure allows binding despite steric hindrance from resistance mutations.																																																								"{""description"": ""Next-generation ROS1/TRK inhibitor designed to overcome G2032R solvent front mutation. Compact macrocyclic structure allows binding despite steric hindrance from resistance mutations."", ""name"": ""Repotrectinib""}"	{}	"{""description"": ""Next-generation ROS1/TRK inhibitor designed to overcome G2032R solvent front mutation. Compact macrocyclic structure allows binding despite steric hindrance from resistance mutations."", ""name"": ""Repotrectinib"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6654	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ROS1 inhibitors or in combination with immunotherapy.																																																								"{""description"": ""Platinum-based chemotherapy (pemetrexed-based) used at progression on ROS1 inhibitors or in combination with immunotherapy."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Platinum-based chemotherapy (pemetrexed-based) used at progression on ROS1 inhibitors or in combination with immunotherapy."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
6660	284	Rabies	Rabies.yaml	treatments	0	Rabies post-exposure vaccination	Post-exposure prophylaxis includes rabies vaccination.																																																								"{""description"": ""Post-exposure prophylaxis includes rabies vaccination."", ""name"": ""Rabies post-exposure vaccination""}"	{}	"{""description"": ""Post-exposure prophylaxis includes rabies vaccination."", ""evidence"": [{""explanation"": ""The abstract describes vaccine administration for prophylaxis."", ""reference"": ""PMID:12144896"", ""snippet"": ""Prophylaxis encompasses thorough wound treatment, vaccine administration, and inoculation of rabies immunoglobulin."", ""supports"": ""SUPPORT""}], ""name"": ""Rabies post-exposure vaccination"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
6661	284	Rabies	Rabies.yaml	treatments	1	Rabies immunoglobulin administration	Rabies immune globulin is used in post-exposure prophylaxis.																																																								"{""description"": ""Rabies immune globulin is used in post-exposure prophylaxis."", ""name"": ""Rabies immunoglobulin administration""}"	{}	"{""description"": ""Rabies immune globulin is used in post-exposure prophylaxis."", ""evidence"": [{""explanation"": ""The abstract includes rabies immunoglobulin as part of prophylaxis."", ""reference"": ""PMID:12144896"", ""snippet"": ""Prophylaxis encompasses thorough wound treatment, vaccine administration, and inoculation of rabies immunoglobulin."", ""supports"": ""SUPPORT""}], ""name"": ""Rabies immunoglobulin administration"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6699	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	0	Controlled refeeding and caloric advancement	Gradual reintroduction of calories with careful monitoring to avoid rapid metabolic shifts.																																																								"{""description"": ""Gradual reintroduction of calories with careful monitoring to avoid rapid metabolic shifts."", ""name"": ""Controlled refeeding and caloric advancement""}"	{}	"{""description"": ""Gradual reintroduction of calories with careful monitoring to avoid rapid metabolic shifts."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This trial evaluates caloric refeeding strategies, supporting controlled refeeding approaches."", ""reference"": ""clinicaltrials:NCT02488109"", ""snippet"": ""The purpose of this study is to compare the efficacy, safety, and cost-effectiveness of lower calorie refeeding versus higher calorie refeeding in hospitalized adolescents with anorexia nervosa."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review supports gradual energy advancement during refeeding."", ""reference"": ""PMID:41171118"", ""snippet"": ""Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient&apos;s metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This case report supports stepwise caloric escalation during refeeding."", ""reference"": ""PMID:41239620"", ""snippet"": ""LESSONS: A stepwise calorie escalation protocol effectively corrects hypophosphatemia in refeeding syndrome."", ""supports"": ""SUPPORT""}], ""name"": ""Controlled refeeding and caloric advancement"", ""treatment_term"": {""preferred_term"": ""nutrition intervention"", ""term"": {""id"": ""MAXO:0000009"", ""label"": ""nutrition intervention""}}}"
6700	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	1	Electrolyte supplementation and monitoring	Repletion of phosphate, potassium, and magnesium with close monitoring of serum electrolytes during refeeding.																																																								"{""description"": ""Repletion of phosphate, potassium, and magnesium with close monitoring of serum electrolytes during refeeding."", ""name"": ""Electrolyte supplementation and monitoring""}"	{}	"{""description"": ""Repletion of phosphate, potassium, and magnesium with close monitoring of serum electrolytes during refeeding."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This supports electrolyte supplementation as a management strategy for acute hypophosphatemia."", ""reference"": ""PMID:41146174"", ""snippet"": ""Supplementation is indicated for severe or symptomatic cases, with oral therapy preferred for chronic conditions and intravenous routes for acute, severe hypophosphatemia."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review supports monitoring phosphorus, potassium, and magnesium during refeeding."", ""reference"": ""PMID:41171118"", ""snippet"": ""Current guidelines recommend a gradual increase in energy intake and regular monitoring of a patient&apos;s metabolic status (especially phosphorus, potassium, and magnesium levels) during nutritional treatment."", ""supports"": ""SUPPORT""}], ""name"": ""Electrolyte supplementation and monitoring"", ""treatment_term"": {""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}}"
6701	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	2	Thiamine (vitamin B1) supplementation	Thiamine supplementation prior to and during refeeding to prevent deficiency and related complications.																																																								"{""description"": ""Thiamine supplementation prior to and during refeeding to prevent deficiency and related complications."", ""name"": ""Thiamine (vitamin B1) supplementation""}"	{}	"{""description"": ""Thiamine supplementation prior to and during refeeding to prevent deficiency and related complications."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Thiamine deficiency is common during refeeding, supporting prophylactic supplementation."", ""reference"": ""PMID:29448987"", ""snippet"": ""thiamine deficiency and disorder of sodium and fluid balance are common."", ""supports"": ""PARTIAL""}], ""name"": ""Thiamine (vitamin B1) supplementation"", ""treatment_term"": {""preferred_term"": ""vitamin B1 supplementation"", ""term"": {""id"": ""MAXO:0010019"", ""label"": ""vitamin B1 supplementation""}}}"
6702	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	3	Micronutrient supplementation during refeeding	Micronutrient supplementation during refeeding helps prevent deficiencies and refeeding syndrome.																																																								"{""description"": ""Micronutrient supplementation during refeeding helps prevent deficiencies and refeeding syndrome."", ""name"": ""Micronutrient supplementation during refeeding""}"	{}	"{""description"": ""Micronutrient supplementation during refeeding helps prevent deficiencies and refeeding syndrome."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This review supports providing micronutrients to prevent deficiencies and refeeding syndrome during nutrition management."", ""reference"": ""PMID:39947042"", ""snippet"": ""Benefits of early fasting responses have become clear, provided micronutrients are given to prevent deficiencies and refeeding syndrome."", ""supports"": ""SUPPORT""}], ""name"": ""Micronutrient supplementation during refeeding"", ""treatment_term"": {""preferred_term"": ""micronutrient supplementation"", ""term"": {""id"": ""MAXO:0001262"", ""label"": ""micronutrient supplementation""}}}"
6708	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	0	Radical Nephrectomy	Surgical removal of the kidney for localized renal cell carcinoma.																																																								"{""description"": ""Surgical removal of the kidney for localized renal cell carcinoma."", ""name"": ""Radical Nephrectomy""}"	{}	"{""description"": ""Surgical removal of the kidney for localized renal cell carcinoma."", ""evidence"": [{""explanation"": ""The abstract states radical nephrectomy is a basic and reliable treatment."", ""reference"": ""PMID:6625621"", ""snippet"": ""The most basic and reliable treatment method established for renal cell carcinomas is surgery--radical nephrectomy."", ""supports"": ""SUPPORT""}], ""name"": ""Radical Nephrectomy"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6709	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	1	Targeted Systemic Therapy	Molecularly targeted agents used to treat advanced renal cell carcinoma.																																																								"{""description"": ""Molecularly targeted agents used to treat advanced renal cell carcinoma."", ""name"": ""Targeted Systemic Therapy""}"	{}	"{""description"": ""Molecularly targeted agents used to treat advanced renal cell carcinoma."", ""evidence"": [{""explanation"": ""The abstract notes targeted agents as effective therapies for RCC."", ""reference"": ""PMID:28898679"", ""snippet"": ""Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients."", ""supports"": ""SUPPORT""}], ""name"": ""Targeted Systemic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6710	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	2	Belzutifan	HIF-2 inhibitor approved for treating renal cell carcinoma.																																																								"{""description"": ""HIF-2 inhibitor approved for treating renal cell carcinoma."", ""name"": ""Belzutifan""}"	{}	"{""description"": ""HIF-2 inhibitor approved for treating renal cell carcinoma."", ""evidence"": [{""explanation"": ""The abstract describes belzutifan approvals for RCC treatment."", ""reference"": ""PMID:39926260"", ""snippet"": ""Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment."", ""supports"": ""SUPPORT""}], ""name"": ""Belzutifan"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6724	287	Retinoblastoma	Retinoblastoma.yaml	treatments	0	Focal Therapy (Laser/Cryotherapy)	Small tumors may be treated with focal ablation including laser photocoagulation or cryotherapy. These treatments spare vision and avoid systemic toxicity.																																																								"{""description"": ""Small tumors may be treated with focal ablation including laser photocoagulation or cryotherapy. These treatments spare vision and avoid systemic toxicity."", ""name"": ""Focal Therapy (Laser/Cryotherapy)""}"	{}	"{""description"": ""Small tumors may be treated with focal ablation including laser photocoagulation or cryotherapy. These treatments spare vision and avoid systemic toxicity."", ""name"": ""Focal Therapy (Laser/Cryotherapy)"", ""treatment_term"": {""preferred_term"": ""laser ablation therapy"", ""term"": {""id"": ""MAXO:0000453"", ""label"": ""laser ablation therapy""}}}"
6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.																																																								"{""description"": ""Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""carboplatin"", ""term"": {""id"": ""CHEBI:31355"", ""label"": ""carboplatin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}, {""preferred_term"": ""melphalan"", ""term"": {""id"": ""CHEBI:28876"", ""label"": ""melphalan""}}]}}"
6726	287	Retinoblastoma	Retinoblastoma.yaml	treatments	2	Enucleation	Surgical removal of the eye is indicated for advanced intraocular disease, particularly when vision cannot be preserved. Provides excellent local control and prevents extraocular spread.																																																								"{""description"": ""Surgical removal of the eye is indicated for advanced intraocular disease, particularly when vision cannot be preserved. Provides excellent local control and prevents extraocular spread."", ""name"": ""Enucleation""}"	{}	"{""description"": ""Surgical removal of the eye is indicated for advanced intraocular disease, particularly when vision cannot be preserved. Provides excellent local control and prevents extraocular spread."", ""name"": ""Enucleation"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6727	287	Retinoblastoma	Retinoblastoma.yaml	treatments	3	External Beam Radiation	Historically used for retinoblastoma but now avoided when possible due to significantly increased risk of secondary malignancies in RB1 germline mutation carriers, particularly osteosarcoma in the radiation field.																																																								"{""description"": ""Historically used for retinoblastoma but now avoided when possible due to significantly increased risk of secondary malignancies in RB1 germline mutation carriers, particularly osteosarcoma in the radiation field."", ""name"": ""External Beam Radiation""}"	{}	"{""description"": ""Historically used for retinoblastoma but now avoided when possible due to significantly increased risk of secondary malignancies in RB1 germline mutation carriers, particularly osteosarcoma in the radiation field."", ""name"": ""External Beam Radiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	Botulinum Toxin Injection	Injection of botulinum toxin type A into the cricopharyngeus muscle to induce temporary relaxation. This is both diagnostic and therapeutic, with high success rates in restoring the ability to belch.																																																								"{""description"": ""Injection of botulinum toxin type A into the cricopharyngeus muscle to induce temporary relaxation. This is both diagnostic and therapeutic, with high success rates in restoring the ability to belch."", ""name"": ""Botulinum Toxin Injection""}"	{}	"{""description"": ""Injection of botulinum toxin type A into the cricopharyngeus muscle to induce temporary relaxation. This is both diagnostic and therapeutic, with high success rates in restoring the ability to belch."", ""evidence"": [{""explanation"": ""The Bastian 2019 case series demonstrated 100% success rate with botulinum toxin injection in restoring belching ability."", ""reference"": ""PMID:31236539"", ""snippet"": ""All 51 patients achieved ability to belch and relief of associated symptoms, and the majority seem to have \""retrained\"" the ability to belch on a potentially \""permanent\"" basis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The Yousef 2024 study confirms botulinum toxin as an effective treatment."", ""reference"": ""PMID:38587015"", ""snippet"": ""All patients who underwent cricopharyngeal botulinum injections experienced initial improvement of symptoms with 3 patients requiring repeat intervention."", ""supports"": ""SUPPORT""}, {""explanation"": ""The Pavesi 2023 case report demonstrates symptom resolution with low-dose botulinum toxin."", ""reference"": ""PMID:37621856"", ""snippet"": ""successfully treated with unilateral, anesthesia-free injection of 10 units of onabotulinum toxin into the cricopharyngeus muscle, representing the lowest dose reported to date."", ""supports"": ""SUPPORT""}, {""explanation"": ""The Tritter 2025 procedural report supports safety and effectiveness of the transtracheal botulinum approach."", ""reference"": ""PMID:41200864"", ""snippet"": ""This transtracheal technique for cricopharyngeal botulinum toxin injection is a safe and effective option for chemodenervation of this muscle in the awake patient."", ""supports"": ""SUPPORT""}, {""explanation"": ""The Dealino 2026 case notes symptomatic improvement after botulinum toxin injection."", ""reference"": ""PMID:41506952"", ""snippet"": ""previously undergone percutaneous botulinum toxin injection that initially provided temporary relief."", ""supports"": ""SUPPORT""}, {""explanation"": ""Systematic review reports high immediate success for botulinum toxin in R-CPD."", ""reference"": ""PMID:40411338"", ""snippet"": ""The immediate success rate of botulinum toxin injection into the cricopharyngeal sphincter in facilitating burping was 92.5%."", ""supports"": ""SUPPORT""}, {""explanation"": ""In-office botulinum injections achieved high cumulative success in a 106-patient series."", ""reference"": ""PMID:39883449"", ""snippet"": ""The cumulative success rate of BTI was 90.6% (96 of 106 patients)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Belgian case series quantifies short- and long-term response rates to botulinum toxin."", ""reference"": ""PMID:38576368"", ""snippet"": ""At median follow-up of 29 months (range, 3-50) post-treatment, 51.3% (n = 20/39) of patients reported persistent complete relief of symptoms"", ""supports"": ""SUPPORT""}], ""name"": ""Botulinum Toxin Injection"", ""treatment_term"": {""preferred_term"": ""botulinum toxin type A therapy"", ""term"": {""id"": ""MAXO:0009016"", ""label"": ""botulinum toxin type A therapy""}}}"
6751	289	Rett Syndrome	Rett_Syndrome.yaml	treatments	0	Seizure Management	Anticonvulsant medications for seizure control.																																																								"{""description"": ""Anticonvulsant medications for seizure control."", ""name"": ""Seizure Management""}"	{}	"{""description"": ""Anticonvulsant medications for seizure control."", ""evidence"": [{""explanation"": ""Study documents importance of appropriate seizure management in Rett syndrome patients."", ""reference"": ""PMID:23103540"", ""snippet"": ""Myoclonic seizures aggravated by inappropriate treatment were evident in four patients"", ""supports"": ""SUPPORT""}], ""name"": ""Seizure Management""}"
6752	289	Rett Syndrome	Rett_Syndrome.yaml	treatments	1	Physical Therapy	Maintain mobility, prevent contractures, manage scoliosis.																																																								"{""description"": ""Maintain mobility, prevent contractures, manage scoliosis."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Maintain mobility, prevent contractures, manage scoliosis."", ""name"": ""Physical Therapy""}"
6753	289	Rett Syndrome	Rett_Syndrome.yaml	treatments	2	Occupational Therapy	Adaptive strategies for activities of daily living.																																																								"{""description"": ""Adaptive strategies for activities of daily living."", ""name"": ""Occupational Therapy""}"	{}	"{""description"": ""Adaptive strategies for activities of daily living."", ""name"": ""Occupational Therapy""}"
6754	289	Rett Syndrome	Rett_Syndrome.yaml	treatments	3	Speech Therapy	Augmentative and alternative communication strategies.																																																								"{""description"": ""Augmentative and alternative communication strategies."", ""name"": ""Speech Therapy""}"	{}	"{""description"": ""Augmentative and alternative communication strategies."", ""name"": ""Speech Therapy""}"
6755	289	Rett Syndrome	Rett_Syndrome.yaml	treatments	4	Nutritional Support	Address feeding difficulties and maintain adequate nutrition.																																																								"{""description"": ""Address feeding difficulties and maintain adequate nutrition."", ""name"": ""Nutritional Support""}"	{}	"{""description"": ""Address feeding difficulties and maintain adequate nutrition."", ""name"": ""Nutritional Support""}"
6802	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	0	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Reduce pain and inflammation.																																																								"{""description"": ""Reduce pain and inflammation."", ""name"": ""Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)""}"	{}	"{""description"": ""Reduce pain and inflammation."", ""evidence"": [{""explanation"": ""The provided literature indicates that NSAIDs are used in the treatment of rheumatoid arthritis (RA) and can help alleviate pain, despite some potential side effects, thus supporting the statement."", ""reference"": ""PMID:11899747"", ""snippet"": ""NSAID toxicity mostly affected the GI tract. There was a similar incidence of GI-related adverse events between patients with and patients without GI protection, mainly dyspepsia and nausea. NSAIDs have the potential to cause adverse events in the GI tract."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference mentions the effectiveness of NSAIDs in pain management, supporting the statement."", ""reference"": ""PMID:29100265"", ""snippet"": ""This review will give a concise summary on the available studies on the application of nano-formulated drugs designed for pain treatment and management."", ""supports"": ""SUPPORT""}, {""explanation"": ""This indicates that NSAIDs are effective in reducing pain and inflammation in conditions similar to RA, thus supporting the statement."", ""reference"": ""PMID:23083758"", ""snippet"": ""NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the reference primarily discusses the use of NSAIDs for major depressive disorder, it hints at the effectiveness of NSAIDs in reducing inflammation, partially supporting the statement."", ""reference"": ""PMID:27278642"", ""snippet"": ""By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti-inflammatory agents show promise for reducing depressive symptoms."", ""supports"": ""PARTIAL""}], ""name"": ""Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6803	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	1	Disease-Modifying Antirheumatic Drugs (DMARDs)	Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).																																																								"{""description"": ""Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine)."", ""name"": ""Disease-Modifying Antirheumatic Drugs (DMARDs)""}"	{}	"{""description"": ""Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine)."", ""evidence"": [{""explanation"": ""This statement directly supports the idea that DMARDs slow disease progression and prevent joint damage."", ""reference"": ""PMID:14969069"", ""snippet"": ""Disease-modifying anti-rheumatic drugs (DMARDs) used in combination appear to be more effective than monotherapies at reducing the rate of progressive joint damage during randomized controlled trials."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt indicates methotrexate's mechanisms in treating RA, affirming its role in slowing disease progression and preventing joint damage."", ""reference"": ""PMID:8601050"", ""snippet"": ""Methotrexate is presently the most popular of the DMARDs for the treatment of rheumatoid arthritis. Methotrexate inhibits dihydrofolate reductase and adenosine release and has a secondary effect on cytokines and polymorphonuclear chemotaxis. It is highly metabolised within cells and remains there for prolonged periods."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms methotrexate's effectiveness as a primary treatment in managing RA, thus supporting the statement."", ""reference"": ""PMID:25172238"", ""snippet"": ""According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the 'anchor drug' for the treatment of RA."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the statement by advising DMARDs to prevent disease progression and joint damage."", ""reference"": ""PMID:35953230"", ""snippet"": ""Key recommendations are to start effective treatment immediately with DMARDs to reduce disability; use effective doses of methotrexate (oral or subcutaneous) with folic acid as the initial treatment; rapidly escalate treatment with various DMARDs, if methotrexate alone is not effective in controlling rheumatoid arthritis."", ""supports"": ""SUPPORT""}], ""name"": ""Disease-Modifying Antirheumatic Drugs (DMARDs)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6804	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	2	Biologics	Target specific components of the immune system (e.g., TNF- inhibitors, IL-6 inhibitors).																																																								"{""description"": ""Target specific components of the immune system (e.g., TNF- inhibitors, IL-6 inhibitors)."", ""name"": ""Biologics""}"	{}	"{""description"": ""Target specific components of the immune system (e.g., TNF- inhibitors, IL-6 inhibitors)."", ""evidence"": [{""explanation"": ""This reference confirms that biologics used in the treatment of RA target specific components of the immune system, including cytokines like TNF-."", ""reference"": ""PMID:22166850"", ""snippet"": ""Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference highlights that anticytokine therapies, including TNF inhibitors, are used in RA treatment, thus supporting the statement."", ""reference"": ""PMID:25697599"", ""snippet"": ""Anticytokine therapy for inflammatory diseases became a clinical reality with the introduction of tumor necrosis factor (TNF) inhibitors for the treatment of severe rheumatoid arthritis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports that biologics used for RA treatment include TNF- inhibitors and IL-6 inhibitors, which target specific components of the immune system."", ""reference"": ""PMID:32550671"", ""snippet"": ""Cytokine blockers were the first to be developed and rapidly expanded. They include agents that act against tumor necrosis factor alpha (TNF-)... and interleukin (IL) 6 (tocilizumab and sarilumab)."", ""supports"": ""SUPPORT""}], ""name"": ""Biologics"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6805	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	3	Glucocorticoids	Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.																																																								"{""description"": ""Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy."", ""name"": ""Glucocorticoids""}"	{}	"{""description"": ""Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy."", ""evidence"": [{""explanation"": ""The literature supports the use of glucocorticoids for the treatment of rheumatoid arthritis, highlighting their efficacy. However, it does not specify that they are used for short-term control of flares or as bridge therapy, thus only partially supporting the precise conditions mentioned in the statement."", ""reference"": ""PMID:28043173"", ""snippet"": ""Glucocorticoids - be it conventional or modified/delayed-release formulations - have so far been convincing in clinical practice, and their widespread use will therefore continue."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference mentions the management and use of various therapies for rheumatoid arthritis, but it does not explicitly discuss the short-term use or glucocorticoids as bridge therapy, providing only partial support."", ""reference"": ""PMID:24527481"", ""snippet"": ""The family physician plays several important roles in the management of patients with RA by early diagnosis of RA, with initiation of synthetic DMARD therapy, and in long-term follow-up to minimize complications of DMARD therapy and its impact on patient comorbidities."", ""supports"": ""PARTIAL""}, {""explanation"": ""This literature confirms the use of corticosteroids (which include glucocorticoids) in treating RA but does not specify their role as short-term or bridge therapy, thereby partially supporting the statement."", ""reference"": ""PMID:29745893"", ""snippet"": ""Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients."", ""supports"": ""PARTIAL""}], ""name"": ""Glucocorticoids"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6806	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	4	Physical Therapy	Maintains joint mobility and strengthens surrounding muscles.																																																								"{""description"": ""Maintains joint mobility and strengthens surrounding muscles."", ""name"": ""Physical Therapy""}"	{}	"{""description"": ""Maintains joint mobility and strengthens surrounding muscles."", ""evidence"": [{""explanation"": ""The literature supports the effectiveness of physiotherapy in managing RA, including maintaining joint mobility and reducing disabilities."", ""reference"": ""PMID:15266230"", ""snippet"": ""Physiotherapy and rehabilitation applications significantly augment medical therapy by improving the management of RA and reducing handicaps in daily living for patients with RA."", ""supports"": ""SUPPORT""}, {""explanation"": ""The results indicate that exercise programmes included in physical therapy can be effective in maintaining joint function and strengthening muscles in RA patients."", ""reference"": ""PMID:25748549"", ""snippet"": ""The exercise programme consisted of six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises and strategies to maximise adherence."", ""supports"": ""SUPPORT""}, {""explanation"": ""Dynamic exercise therapy, a component of physical therapy, has been shown to improve muscle strength and maintain physical capacity in RA patients."", ""reference"": ""PMID:9667624"", ""snippet"": ""The results suggest that dynamic exercise therapy is effective in increasing aerobic capacity and muscle strength."", ""supports"": ""SUPPORT""}], ""name"": ""Physical Therapy"", ""treatment_term"": {""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
6822	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	0	Immunoglobulin Replacement Therapy	Regular infusions to prevent infections.																																																								"{""description"": ""Regular infusions to prevent infections."", ""name"": ""Immunoglobulin Replacement Therapy""}"	{}	"{""description"": ""Regular infusions to prevent infections."", ""evidence"": [{""explanation"": ""While the literature supports that immunoglobulin replacement therapy is used to reduce serious bacterial infections in primary immunodeficiency diseases, it does not specifically mention Roifman syndrome. Therefore, the support is partial."", ""reference"": ""PMID:26454315"", ""snippet"": ""Immunoglobulin replacement therapy has been standard treatment in patients with primary immunodeficiency diseases for the past 3 decades. The goal of therapy is to reduce serious bacterial infections in individuals with antibody function defects."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature describes Roifman syndrome and its characteristics but does not provide evidence regarding the use of immunoglobulin replacement therapy for preventing infections in this syndrome."", ""reference"": ""PMID:21977988"", ""snippet"": ""Roifman syndrome is a rare syndrome of bone dysplasia, growth retardation, retinal dystrophy and humeral immunodeficiency."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Immunoglobulin Replacement Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6823	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	1	Antibiotic Prophylaxis	Preventative antibiotic treatment to reduce infection risk.																																																								"{""description"": ""Preventative antibiotic treatment to reduce infection risk."", ""name"": ""Antibiotic Prophylaxis""}"	{}	"{""description"": ""Preventative antibiotic treatment to reduce infection risk."", ""evidence"": [{""explanation"": ""The literature mentions the use of subcutaneous immunoglobulin therapy to reduce infection burden in Roifman syndrome but does not provide evidence for the use of antibiotic prophylaxis."", ""reference"": ""PMID:35450878"", ""snippet"": ""We report an excellent response to subcutaneous immunoglobulin therapy in both brothers, reducing infection burden and hospital admissions."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Antibiotic Prophylaxis"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6824	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	2	Growth Hormone Therapy	May be used to address growth retardation.																																																								"{""description"": ""May be used to address growth retardation."", ""name"": ""Growth Hormone Therapy""}"	{}	"{""description"": ""May be used to address growth retardation."", ""evidence"": [{""explanation"": ""The reference describes the characteristics and genetic insights of Roifman syndrome but does not provide any evidence about the use of growth hormone therapy to address growth retardation."", ""reference"": ""PMID:10905663"", ""snippet"": ""This report describes a fifth individual with co-existent hypogonadotrophic hypogonadism, thereby expanding the phenotype and possibly offering insight into the genetic aetiology of this condition."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""While this reference describes the clinical manifestations of Roifman syndrome, it does not mention the use of growth hormone therapy for growth retardation."", ""reference"": ""PMID:37666272"", ""snippet"": ""Roifman syndrome is a rare congenital disorder characterized by growth retardation, cognitive delay, spondyloepiphyseal dysplasia, immunodeficiency, and retinal dystrophy."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Growth Hormone Therapy"", ""treatment_term"": {""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}}"
6825	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	3	Supportive Educational Programs	Tailored to address intellectual disability and developmental delays.																																																								"{""description"": ""Tailored to address intellectual disability and developmental delays."", ""name"": ""Supportive Educational Programs""}"	{}	"{""description"": ""Tailored to address intellectual disability and developmental delays."", ""evidence"": [{""explanation"": ""The reference confirms intellectual disability associated with Roifman syndrome but does not specifically mention supportive educational programs tailored for these needs."", ""reference"": ""PMID:21910238"", ""snippet"": ""The results confirmed a stable pattern of intellectual disability, and indicated that Roifman syndrome may be associated with major structural neuro-anatomical abnormalities."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference discusses the genetic diagnosis of Roifman syndrome but does not provide details on supportive educational programs tailored for intellectual disability and developmental delays."", ""reference"": ""PMID:28623346"", ""snippet"": ""Whole exome sequencing revealed KMT2A-associated Wiedemann-Steiner syndrome in one sibling pair and their mother. In the other sibling pair, targeted testing of the known disease gene for Roifman syndrome (RNU4ATAC) provided a definite diagnosis."", ""supports"": ""PARTIAL""}], ""name"": ""Supportive Educational Programs"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
6826	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	4	Surgical Interventions	For severe skeletal or craniofacial abnormalities.																																																								"{""description"": ""For severe skeletal or craniofacial abnormalities."", ""name"": ""Surgical Interventions""}"	{}	"{""description"": ""For severe skeletal or craniofacial abnormalities."", ""evidence"": [{""explanation"": ""The literature describes Roifman syndrome primarily as an immunodeficiency syndrome, and does not mention severe skeletal or craniofacial abnormalities as part of its clinical features."", ""reference"": ""PMID:35450878"", ""snippet"": ""Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency."", ""supports"": ""REFUTE""}], ""name"": ""Surgical Interventions"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6842	292	SADDAN	SADDAN.yaml	treatments	0	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.																																																								"{""description"": ""Growth hormone therapy for marked short stature in SADDAN."", ""name"": ""Growth hormone therapy""}"	{}	"{""description"": ""Growth hormone therapy for marked short stature in SADDAN."", ""evidence"": [{""explanation"": ""Case report documents growth hormone therapy in a SADDAN patient with marked short stature."", ""reference"": ""PMID:38993719"", ""snippet"": ""We administered GH therapy for a markedly short stature."", ""supports"": ""SUPPORT""}], ""name"": ""Growth hormone therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""growth hormone"", ""term"": {""id"": ""CHEBI:37845"", ""label"": ""growth hormone""}}]}}"
6872	293	Salla Disease	Salla_Disease.yaml	treatments	0	Supportive Care	Management of symptoms and prevention of complications through multidisciplinary approach including physical therapy, occupational therapy, speech therapy, and educational support. Treatment is primarily symptomatic as no causal therapies are currently available.																																																								"{""description"": ""Management of symptoms and prevention of complications through multidisciplinary approach including physical therapy, occupational therapy, speech therapy, and educational support. Treatment is primarily symptomatic as no causal therapies are currently available."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Management of symptoms and prevention of complications through multidisciplinary approach including physical therapy, occupational therapy, speech therapy, and educational support. Treatment is primarily symptomatic as no causal therapies are currently available."", ""evidence"": [{""evidence_source"": ""IN_VITRO"", ""explanation"": ""Standard treatment remains supportive pending development of specific disease-modifying therapies."", ""reference"": ""PMID:37727271"", ""snippet"": ""There are currently no therapies for FSASDs."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care""}"
6873	293	Salla Disease	Salla_Disease.yaml	treatments	1	Base Editing Gene Therapy (Investigational)	Emerging therapeutic approach using CRISPR-mediated adenine base editing to correct the common SLC17A5 c.115C>T (p.Arg39Cys) founder variant. In vitro and animal models show significant reduction in free sialic acid levels.																																																								"{""description"": ""Emerging therapeutic approach using CRISPR-mediated adenine base editing to correct the common SLC17A5 c.115C>T (p.Arg39Cys) founder variant. In vitro and animal models show significant reduction in free sialic acid levels."", ""name"": ""Base Editing Gene Therapy (Investigational)""}"	{}	"{""description"": ""Emerging therapeutic approach using CRISPR-mediated adenine base editing to correct the common SLC17A5 c.115C>T (p.Arg39Cys) founder variant. In vitro and animal models show significant reduction in free sialic acid levels."", ""evidence"": [{""evidence_source"": ""IN_VITRO"", ""explanation"": ""Base editing approach successfully corrects the founder variant and reduces sialic acid accumulation in patient-derived cells and animal models."", ""reference"": ""PMID:37727271"", ""snippet"": ""ABE treatment of either homozygous or compound heterozygous SLC17A5 c.115C>T human dermal fibroblasts demonstrated significant FSA reduction, supporting amelioration of disease pathology."", ""supports"": ""SUPPORT""}], ""name"": ""Base Editing Gene Therapy (Investigational)""}"
6894	294	Sarcoidosis	Sarcoidosis.yaml	treatments	0	Corticosteroid Therapy	"First-line treatment for symptomatic sarcoidosis. Prednisone typically initiated at 20-40mg daily with gradual taper over months. Effective for most organ manifestations.
"																																																								"{""description"": ""First-line treatment for symptomatic sarcoidosis. Prednisone typically initiated at 20-40mg daily with gradual taper over months. Effective for most organ manifestations.\n"", ""name"": ""Corticosteroid Therapy""}"	{}	"{""description"": ""First-line treatment for symptomatic sarcoidosis. Prednisone typically initiated at 20-40mg daily with gradual taper over months. Effective for most organ manifestations.\n"", ""name"": ""Corticosteroid Therapy"", ""treatment_term"": {""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}}"
6895	294	Sarcoidosis	Sarcoidosis.yaml	treatments	1	Methotrexate	"Most commonly used steroid-sparing agent for chronic sarcoidosis. Allows reduction of corticosteroid dose while maintaining disease control.
"																																																								"{""description"": ""Most commonly used steroid-sparing agent for chronic sarcoidosis. Allows reduction of corticosteroid dose while maintaining disease control.\n"", ""name"": ""Methotrexate""}"	{}	"{""description"": ""Most commonly used steroid-sparing agent for chronic sarcoidosis. Allows reduction of corticosteroid dose while maintaining disease control.\n"", ""name"": ""Methotrexate"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6896	294	Sarcoidosis	Sarcoidosis.yaml	treatments	2	Anti-TNF Therapy	"Infliximab or adalimumab for refractory disease, particularly effective in neurosarcoidosis, lupus pernio, and cardiac sarcoidosis.
"																																																								"{""description"": ""Infliximab or adalimumab for refractory disease, particularly effective in neurosarcoidosis, lupus pernio, and cardiac sarcoidosis.\n"", ""name"": ""Anti-TNF Therapy""}"	{}	"{""description"": ""Infliximab or adalimumab for refractory disease, particularly effective in neurosarcoidosis, lupus pernio, and cardiac sarcoidosis.\n"", ""name"": ""Anti-TNF Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6902	295	Scabies	Scabies.yaml	treatments	0	Permethrin cream or ivermectin	Mass treatment can use permethrin cream or ivermectin.																																																								"{""description"": ""Mass treatment can use permethrin cream or ivermectin."", ""name"": ""Permethrin cream or ivermectin""}"	{}	"{""description"": ""Mass treatment can use permethrin cream or ivermectin."", ""evidence"": [{""explanation"": ""The abstract notes permethrin cream or ivermectin for treatment."", ""reference"": ""PMID:35298417"", ""snippet"": ""Mass treatment with permethrin cream or ivermectin can be given directly to patients."", ""supports"": ""SUPPORT""}], ""name"": ""Permethrin cream or ivermectin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6911	296	Schistosomiasis	Schistosomiasis.yaml	treatments	0	Praziquantel mass drug administration	Periodic praziquantel treatment to suppress morbidity in endemic regions.																																																								"{""description"": ""Periodic praziquantel treatment to suppress morbidity in endemic regions."", ""name"": ""Praziquantel mass drug administration""}"	{}	"{""description"": ""Periodic praziquantel treatment to suppress morbidity in endemic regions."", ""evidence"": [{""explanation"": ""The review describes periodic praziquantel treatment as standard preventive therapy."", ""reference"": ""PMID:24698483"", ""snippet"": ""treatment once every 1 or 2 years with the isoquinolinone drug, praziquantel, to suppress morbidity"", ""supports"": ""SUPPORT""}], ""name"": ""Praziquantel mass drug administration"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	Antipsychotic Medications	Medications such as risperidone, olanzapine, and clozapine to manage symptoms.																																																								"{""description"": ""Medications such as risperidone, olanzapine, and clozapine to manage symptoms."", ""name"": ""Antipsychotic Medications""}"	"{""mechanism"": [{""description"": ""Primary action through dopamine D2 receptor antagonism"", ""name"": ""dopamine D2 receptor antagonism""}]}"	"{""description"": ""Medications such as risperidone, olanzapine, and clozapine to manage symptoms."", ""evidence"": [{""explanation"": ""This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context."", ""reference"": ""PMID:12769630"", ""snippet"": ""With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain."", ""supports"": ""PARTIAL""}, {""explanation"": ""The title suggests a focus on schizophrenia treatments, but no abstract provided to verify the contents in relation to the detailed mechanism of action of risperidone, olanzapine, or clozapine."", ""reference"": ""PMID:14514482"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism."", ""reference"": ""PMID:8626371"", ""snippet"": ""The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians' ability to manage schizophrenic patients."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference compares the clinical effects of risperidone and olanzapine, but does not provide information on the mechanism of action through dopamine D2 receptor antagonism."", ""reference"": ""PMID:15846745"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""Supports effectiveness of clozapine in treatment-resistant patients but does not address dopamine D2 receptor antagonism directly."", ""reference"": ""PMID:8823348"", ""snippet"": ""Clozapine has shown to be effective in some poor or partially responsive patients in three prospective, random assignment, double-blind trials."", ""supports"": ""PARTIAL""}, {""explanation"": ""This supports the use of olanzapine and risperidone but does not detail the mechanism involving dopamine D2 receptor antagonism."", ""reference"": ""PMID:32464195"", ""snippet"": ""To improve treatment efficacy during the critical early stages of schizophrenia, we aimed to identify molecular signatures at baseline (T0) for prediction of a positive response to the atypical antipsychotics olanzapine and risperidone after 6 weeks (T6) treatment."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the focus on D2 dopamine receptors in drug discovery, which aligns with the mechanism described."", ""reference"": ""PMID:17845145"", ""snippet"": ""The drug discovery process has focused mostly on targeting D2 dopamine receptors."", ""supports"": ""PARTIAL""}], ""mechanism"": [{""description"": ""Primary action through dopamine D2 receptor antagonism"", ""name"": ""dopamine D2 receptor antagonism""}], ""name"": ""Antipsychotic Medications"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
6946	297	Schizophrenia	Schizophrenia.yaml	treatments	1	Cognitive Behavioral Therapy (CBT)	Therapy aimed at changing maladaptive thought patterns and behaviors.																																																								"{""description"": ""Therapy aimed at changing maladaptive thought patterns and behaviors."", ""name"": ""Cognitive Behavioral Therapy (CBT)""}"	{}	"{""description"": ""Therapy aimed at changing maladaptive thought patterns and behaviors."", ""evidence"": [{""explanation"": ""This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors."", ""reference"": ""PMID:20880828"", ""snippet"": ""There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care."", ""supports"": ""SUPPORT""}, {""explanation"": ""This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia."", ""reference"": ""PMID:27335156"", ""snippet"": ""Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement aligns with the cognitive approach to schizophrenia, which underpins CBT."", ""reference"": ""PMID:17716100"", ""snippet"": ""A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this reference focuses on cognitive remediation, it aligns with the efficacy of cognitive therapies like CBT."", ""reference"": ""PMID:31699627"", ""snippet"": ""Cognitive remediation is now widely recognized as an effective treatment for cognitive deficits in schizophrenia."", ""supports"": ""SUPPORT""}], ""name"": ""Cognitive Behavioral Therapy (CBT)"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	Social Skills Training	Programs to enhance social interactions and functioning.																																																								"{""description"": ""Programs to enhance social interactions and functioning."", ""name"": ""Social Skills Training""}"	{}	"{""description"": ""Programs to enhance social interactions and functioning."", ""evidence"": [{""explanation"": ""The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills."", ""reference"": ""PMID:16885207"", ""snippet"": ""Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities."", ""supports"": ""SUPPORT""}, {""explanation"": ""Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills."", ""reference"": ""PMID:31708048"", ""snippet"": ""Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy."", ""reference"": ""PMID:23773889"", ""snippet"": ""METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of treatment; and, 3) meta-analytic data regarding their efficacy and/or effectiveness."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study compares Cognitive Enhancement Therapy and Social Skills Training (HOPES/SST), highlighting their role in improving social and community functioning."", ""reference"": ""PMID:36050663"", ""snippet"": ""Although pharmacological treatments can often lessen the psychotic symptoms that are a hallmark of schizophrenia, they do not lessen the social and cognitive deficits that create the greatest impediments to community engagement and functional recovery."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study shows that social cognitive training programs, which could include elements similar to Social Skills Training, improve social functioning in schizophrenia patients."", ""reference"": ""PMID:32614046"", ""snippet"": ""To address this need, we have developed SocialVille-an online, plasticity-based training program that targets SC deficits in schizophrenia...These results provide support for the efficacy of a remote, plasticity-based social cognitive training program in improving SC and social functioning in schizophrenia."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that training aimed at social cognition, such as TAR, may improve social skills and functions, relevant to social skills training programs."", ""reference"": ""PMID:21860049"", ""snippet"": ""Intention-to-treat analyses found significantly larger pre-post improvements with TAR than with CRT in prosodic affect recognition, ToM, and social competence and a trend effect in global social functioning."", ""supports"": ""SUPPORT""}], ""name"": ""Social Skills Training"", ""treatment_term"": {""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}}"
6948	297	Schizophrenia	Schizophrenia.yaml	treatments	3	Supportive Therapy	Ongoing support to help manage daily life and stress.																																																								"{""description"": ""Ongoing support to help manage daily life and stress."", ""name"": ""Supportive Therapy""}"	{}	"{""description"": ""Ongoing support to help manage daily life and stress."", ""evidence"": [{""explanation"": ""The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress."", ""reference"": ""PMID:15176765"", ""snippet"": ""This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia."", ""supports"": ""SUPPORT""}, {""explanation"": ""Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia."", ""reference"": ""PMID:23244011"", ""snippet"": ""The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone."", ""supports"": ""SUPPORT""}, {""explanation"": ""Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support."", ""reference"": ""PMID:31708048"", ""snippet"": ""Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Therapy"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	Vocational Rehabilitation	Help with gaining and maintaining employment.																																																								"{""description"": ""Help with gaining and maintaining employment."", ""name"": ""Vocational Rehabilitation""}"	{}	"{""description"": ""Help with gaining and maintaining employment."", ""evidence"": [{""explanation"": ""While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment."", ""reference"": ""PMID:8749891"", ""snippet"": ""Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment."", ""supports"": ""PARTIAL""}, {""explanation"": ""Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods."", ""reference"": ""PMID:31327504"", ""snippet"": ""At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed."", ""supports"": ""PARTIAL""}, {""explanation"": ""Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment."", ""reference"": ""PMID:18715755"", ""snippet"": ""NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes."", ""supports"": ""SUPPORT""}, {""explanation"": ""Blended vocational services significantly improved employment outcomes, supporting the effectiveness of vocational rehabilitation in gaining and maintaining employment."", ""reference"": ""PMID:32393158"", ""snippet"": ""Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study."", ""supports"": ""SUPPORT""}, {""explanation"": ""Integrated supported employment led to higher employment rates and longer job tenure, indicating that such vocational rehabilitation can help with gaining and maintaining employment."", ""reference"": ""PMID:29135426"", ""snippet"": ""Significantly higher employment rate and longer job tenure were found in the ISE group (63.0%, 29.56 wk) compared with the IPS group (50.0%, 25.47 wk) and TVR group (33.3%, 9.91 wk)."", ""supports"": ""SUPPORT""}], ""name"": ""Vocational Rehabilitation"", ""treatment_term"": {""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}}"
6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"				Significant hemodynamic shunt with or without associated defects																														"Postoperative pulmonary vein obstruction remains a major challenge. Newer multipatch techniques that enlarge the left atrium and avoid circuitous pathways may reduce this complication. Infantile onset is an independent risk factor for stenosis after repair.
"																						"{""context"": ""Significant hemodynamic shunt with or without associated defects"", ""description"": ""Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.\n"", ""name"": ""Surgical repair"", ""notes"": ""Postoperative pulmonary vein obstruction remains a major challenge. Newer multipatch techniques that enlarge the left atrium and avoid circuitous pathways may reduce this complication. Infantile onset is an independent risk factor for stenosis after repair.\n""}"	{}	"{""context"": ""Significant hemodynamic shunt with or without associated defects"", ""description"": ""Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Comprehensive review of surgical outcomes noting 5-6% operative mortality but significant postoperative vein obstruction rates."", ""reference"": ""PMID:34396590"", ""snippet"": ""Overall operative mortality has been cited between 4.8% and 5.9%. Mortality was highest in patients with preoperative pulmonary hypertension, and those undergoing surgery in infancy. Despite timely surgical intervention, post-repair obstruction of the scimitar vein, intra-atrial baffle obstruction, or stenosis of the inferior caval vein were reported in up to two-thirds of cases."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Boston Children's Hospital series showing a new multipatch technique eliminated postoperative pulmonary vein obstruction in 11 patients, compared to 45% obstruction rate with traditional techniques."", ""reference"": ""PMID:34318016"", ""snippet"": ""None of the 11 patients who only had the new procedure developed pulmonary vein obstruction during postoperative monitoring up to 3.6 years."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Columbia cohort identifying infantile onset as a 9-fold independent risk factor for postoperative stenosis."", ""reference"": ""PMID:29054305"", ""snippet"": ""Multivariable analyses identified infantile onset as an independent risk factor for stenosis or obstruction after repair (hazard ratio 9.34, p = 0.048)"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical repair"", ""notes"": ""Postoperative pulmonary vein obstruction remains a major challenge. Newer multipatch techniques that enlarge the left atrium and avoid circuitous pathways may reduce this complication. Infantile onset is an independent risk factor for stenosis after repair.\n"", ""target_phenotypes"": [{""preferred_term"": ""Partial anomalous pulmonary venous return"", ""term"": {""id"": ""HP:0010773"", ""label"": ""Partial anomalous pulmonary venous return""}}, {""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}], ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	Catheter-based intervention	"Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.
"				Aortopulmonary collaterals or associated intracardiac defects amenable to catheter intervention																														"Interventional catheter therapy can alleviate pulmonary artery pressure and progression during infancy, and may serve as a bridge to or substitute for surgery in selected cases.
"																						"{""context"": ""Aortopulmonary collaterals or associated intracardiac defects amenable to catheter intervention"", ""description"": ""Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.\n"", ""name"": ""Catheter-based intervention"", ""notes"": ""Interventional catheter therapy can alleviate pulmonary artery pressure and progression during infancy, and may serve as a bridge to or substitute for surgery in selected cases.\n""}"	{}	"{""context"": ""Aortopulmonary collaterals or associated intracardiac defects amenable to catheter intervention"", ""description"": ""Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""East China center series showing catheter-based therapy is effective as a standalone intervention in selected patients."", ""reference"": ""PMID:36093138"", ""snippet"": ""Eight patients received interventional catheter therapy, including occlusion of aortopulmonary collateral arteries (APCs) and other intracardiac malformations, without the following surgery."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""French series of 3 patients with dual-drainage scimitar variant successfully treated by transcatheter occlusion of the IVC connection, redirecting flow to the left atrium."", ""reference"": ""PMID:41556875"", ""snippet"": ""All the patients underwent successfully a transcatheter occlusion of SV at the IVC junction using occlusion devices allowing proximal re-rerouting to the left atrium through the fistula. Aberrant systemic artery arising from the abdominal aorta was embolized in 2 cases during the same intervention."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""International multicentre series of 4 patients confirming transcatheter correction of the dual-drainage scimitar variant as a safe and effective alternative to surgery."", ""reference"": ""PMID:41070433"", ""snippet"": ""All four patients (three children, one adult) had dual drainage of right pulmonary veins into the inferior caval vein and to the left atrium via a connecting vein. All patients underwent a successful catheter occlusion of the anomalous connection to the systemic vein without complication."", ""supports"": ""SUPPORT""}], ""name"": ""Catheter-based intervention"", ""notes"": ""Interventional catheter therapy can alleviate pulmonary artery pressure and progression during infancy, and may serve as a bridge to or substitute for surgery in selected cases.\n"", ""target_phenotypes"": [{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}], ""treatment_term"": {""preferred_term"": ""catheterization"", ""term"": {""id"": ""MAXO:0001389"", ""label"": ""catheterization""}}}"
6982	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	2	Conservative management	"Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.
"				Asymptomatic patients with small shunts or patients unfit for surgery																																																				"{""context"": ""Asymptomatic patients with small shunts or patients unfit for surgery"", ""description"": ""Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.\n"", ""name"": ""Conservative management""}"	{}	"{""context"": ""Asymptomatic patients with small shunts or patients unfit for surgery"", ""description"": ""Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Clinical series confirming conservative management is appropriate for mild to moderate scimitar syndrome."", ""reference"": ""PMID:38634941"", ""snippet"": ""Medical management is effective for mild to moderate cases."", ""supports"": ""SUPPORT""}], ""name"": ""Conservative management"", ""target_phenotypes"": [{""preferred_term"": ""Partial anomalous pulmonary venous return"", ""term"": {""id"": ""HP:0010773"", ""label"": ""Partial anomalous pulmonary venous return""}}], ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
6993	299	Scurvy	Scurvy.yaml	treatments	0	Vitamin C Supplementation	"Oral vitamin C supplementation (100-300 mg daily) rapidly reverses symptoms. Clinical improvement typically begins within 24-48 hours. The condition can be adequately treated and prevented via vitamin C supplementation.
"																																																								"{""description"": ""Oral vitamin C supplementation (100-300 mg daily) rapidly reverses symptoms. Clinical improvement typically begins within 24-48 hours. The condition can be adequately treated and prevented via vitamin C supplementation.\n"", ""name"": ""Vitamin C Supplementation""}"	{}	"{""description"": ""Oral vitamin C supplementation (100-300 mg daily) rapidly reverses symptoms. Clinical improvement typically begins within 24-48 hours. The condition can be adequately treated and prevented via vitamin C supplementation.\n"", ""evidence"": [{""explanation"": ""This confirms that vitamin C supplementation is the adequate treatment and prevention for scurvy."", ""reference"": ""PMID:37366866"", ""snippet"": ""It can be adequately treated and prevented via vitamin C supplementation."", ""supports"": ""SUPPORT""}], ""name"": ""Vitamin C Supplementation"", ""treatment_term"": {""preferred_term"": ""vitamin C supplementation"", ""term"": {""id"": ""MAXO:0000109"", ""label"": ""vitamin C supplementation""}}}"
7002	301	Semantic Dementia	Semantic_Dementia.yaml	treatments	0	Speech and Language Therapy	Communication support provided by specialist speech and language therapists.																																																								"{""description"": ""Communication support provided by specialist speech and language therapists."", ""name"": ""Speech and Language Therapy""}"	{}	"{""description"": ""Communication support provided by specialist speech and language therapists."", ""evidence"": [{""explanation"": ""The abstract describes speech and language therapist-led communication support for semantic dementia."", ""reference"": ""PMID:28286641"", ""snippet"": ""The purpose of this paper is to gain consensus regarding the clinical priorities and tasks required in supporting communication needs in those living with semantic dementia and their families, by specialist speech and language therapists (SLTs), working in clinical practice within dementia care settings in the UK."", ""supports"": ""SUPPORT""}], ""name"": ""Speech and Language Therapy"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7018	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	0	Observation and Symptom Management	For mild cases, conservative management including avoidance of triggering stimuli and vestibular rehabilitation may be sufficient. Patients with pressure sensitivity can benefit from a tympanostomy tube.																																																								"{""description"": ""For mild cases, conservative management including avoidance of triggering stimuli and vestibular rehabilitation may be sufficient. Patients with pressure sensitivity can benefit from a tympanostomy tube."", ""name"": ""Observation and Symptom Management""}"	{}	"{""description"": ""For mild cases, conservative management including avoidance of triggering stimuli and vestibular rehabilitation may be sufficient. Patients with pressure sensitivity can benefit from a tympanostomy tube."", ""evidence"": [{""explanation"": ""Conservative management options are described for patients with mild symptoms."", ""reference"": ""PMID:32982922"", ""snippet"": ""Patients with mild symptoms can reduce exposure to loud sounds and avoid physical straining, and those with pressure sensitivity can benefit from a tympanostomy tube"", ""supports"": ""SUPPORT""}], ""name"": ""Observation and Symptom Management""}"
7019	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	1	Surgical Canal Plugging	Surgical occlusion of the dehiscent superior semicircular canal via middle cranial fossa or transmastoid approach to eliminate the third window effect. Canal plugging achieves long-term control more often than resurfacing.																																																								"{""description"": ""Surgical occlusion of the dehiscent superior semicircular canal via middle cranial fossa or transmastoid approach to eliminate the third window effect. Canal plugging achieves long-term control more often than resurfacing."", ""name"": ""Surgical Canal Plugging""}"	{}	"{""description"": ""Surgical occlusion of the dehiscent superior semicircular canal via middle cranial fossa or transmastoid approach to eliminate the third window effect. Canal plugging achieves long-term control more often than resurfacing."", ""evidence"": [{""explanation"": ""Clinical data demonstrates high success rate of canal plugging surgery."", ""reference"": ""PMID:16222184"", ""snippet"": ""Canal plugging was performed in 9 and resurfacing of the canal without plugging of the lumen in 11 patients. Complete resolution of vestibular symptoms and signs was achieved in 8 of the 9 patients after canal plugging."", ""supports"": ""SUPPORT""}, {""explanation"": ""Canal plugging is established as the preferred surgical treatment."", ""reference"": ""PMID:32982922"", ""snippet"": ""Canal plugging achieves long-term control more often than resurfacing and is usually the procedure of choice"", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Canal Plugging"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7020	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	2	Surgical Resurfacing	Surgical repair by placing bone graft or other material over the dehiscence to restore normal inner ear mechanics without occluding the canal lumen.																																																								"{""description"": ""Surgical repair by placing bone graft or other material over the dehiscence to restore normal inner ear mechanics without occluding the canal lumen."", ""name"": ""Surgical Resurfacing""}"	{}	"{""description"": ""Surgical repair by placing bone graft or other material over the dehiscence to restore normal inner ear mechanics without occluding the canal lumen."", ""evidence"": [{""explanation"": ""Resurfacing can achieve symptom resolution, though less reliably than plugging."", ""reference"": ""PMID:16222184"", ""snippet"": ""Complete resolution of vestibular symptoms and signs was achieved in 8 of the 9 patients after canal plugging and in 7 of the 11 patients after resurfacing."", ""supports"": ""SUPPORT""}, {""explanation"": ""Animal model demonstrates that bony resurfacing can restore normal function while preserving canal lumen patency."", ""reference"": ""PMID:36742050"", ""snippet"": ""The changes observed also reverse and return to baseline as the SSCD heals by bone resurfacing (with the lumen intact)."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical Resurfacing"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.																																																								"{""description"": ""Coenzyme Q10 used as part of mitochondrial supportive therapy."", ""name"": ""Coenzyme Q10 supplementation""}"	{}	"{""description"": ""Coenzyme Q10 used as part of mitochondrial supportive therapy."", ""evidence"": [{""explanation"": ""This case report lists coenzyme Q10 as part of a mitochondrial cocktail for Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides dosing detail confirming coenzyme Q10 use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;"", ""supports"": ""SUPPORT""}], ""name"": ""Coenzyme Q10 supplementation"", ""treatment_term"": {""preferred_term"": ""coenzyme Q10 supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""coenzyme Q10"", ""term"": {""id"": ""NCIT:C916"", ""label"": ""Coenzyme Q10""}}}], ""term"": {""id"": ""MAXO:0010012"", ""label"": ""coenzyme Q10 supplementation""}}}"
7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.																																																								"{""description"": ""L-carnitine provided as part of mitochondrial supportive therapy."", ""name"": ""Carnitine supplementation""}"	{}	"{""description"": ""L-carnitine provided as part of mitochondrial supportive therapy."", ""evidence"": [{""explanation"": ""This case report lists carnitine within the mitochondrial cocktail for Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides dosing detail confirming levocarnitine use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;"", ""supports"": ""SUPPORT""}], ""name"": ""Carnitine supplementation"", ""treatment_term"": {""preferred_term"": ""carnitine supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levocarnitine"", ""term"": {""id"": ""NCIT:C26657"", ""label"": ""Levocarnitine""}}}], ""term"": {""id"": ""MAXO:0010006"", ""label"": ""carnitine supplementation""}}}"
7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.																																																								"{""description"": ""Vitamin B complex supplementation as part of supportive therapy."", ""name"": ""B vitamin supplementation""}"	{}	"{""description"": ""Vitamin B complex supplementation as part of supportive therapy."", ""evidence"": [{""explanation"": ""This case report lists B-vitamins within the mitochondrial cocktail for Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides dosing detail confirming vitamin B complex use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""Levocarnitine (100 mg/kg daily), coenzyme Q10 (1 mg/kg daily), and vitamin B complex (vitamin B1 20 mg/day and riboflavin 10 mg/day) were administered to improve metabolic status;"", ""supports"": ""SUPPORT""}], ""name"": ""B vitamin supplementation"", ""treatment_term"": {""preferred_term"": ""B vitamin supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""thiamine"", ""term"": {""id"": ""NCIT:C874"", ""label"": ""Thiamine""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""riboflavin"", ""term"": {""id"": ""NCIT:C808"", ""label"": ""Riboflavin""}}}], ""term"": {""id"": ""MAXO:0000761"", ""label"": ""B vitamin supplementation""}}}"
7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.																																																								"{""description"": ""ACE inhibitor therapy used for heart failure management."", ""name"": ""ACE inhibitor therapy""}"	{}	"{""description"": ""ACE inhibitor therapy used for heart failure management."", ""evidence"": [{""explanation"": ""This case report notes ACE inhibitor use alongside mitochondrial cocktail therapy."", ""reference"": ""PMID:34164355"", ""snippet"": ""Supplementation with coenzyme Q10, carnitine, B-vitamins, and biotin (called mitochondrial cocktail) was given daily, associated with angiotensin converting enzyme (ACE) inhibitors for cardiomyopathy management."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides direct evidence of ACE inhibitor (captopril) therapy in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""The patient received milrinone, diuretics (furosemide and spironolactone), and captopril to improve heart function."", ""supports"": ""SUPPORT""}, {""explanation"": ""This neonatal case reports ongoing pharmacologic heart failure management including a neprilysin inhibitor/ARB regimen."", ""reference"": ""PMID:38933059"", ""snippet"": ""Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions."", ""supports"": ""SUPPORT""}], ""name"": ""ACE inhibitor therapy"", ""treatment_term"": {""preferred_term"": ""ACE inhibitor therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""captopril"", ""term"": {""id"": ""NCIT:C340"", ""label"": ""Captopril""}}}], ""term"": {""id"": ""MAXO:0000652"", ""label"": ""ACE inhibitor therapy""}}}"
7047	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	4	Cardiac transplantation	Heart transplantation for severe cardiomyopathy in Sengers syndrome.																																																								"{""description"": ""Heart transplantation for severe cardiomyopathy in Sengers syndrome."", ""name"": ""Cardiac transplantation""}"	{}	"{""description"": ""Heart transplantation for severe cardiomyopathy in Sengers syndrome."", ""evidence"": [{""explanation"": ""This case report documents cardiac transplantation as a treatment for Sengers-associated cardiomyopathy."", ""reference"": ""PMID:8526648"", ""snippet"": ""This report describes cardiac transplantation for the treatment of the cardiomyopathy associated with Sengers' syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""This neonatal case report describes successful cardiac transplantation in Sengers syndrome."", ""reference"": ""PMID:38933059"", ""snippet"": ""At 8 months of age, cardiac transplantation was successfully done and baby has been doing well post-transplantation."", ""supports"": ""SUPPORT""}], ""name"": ""Cardiac transplantation"", ""treatment_term"": {""preferred_term"": ""cardiac transplantation"", ""term"": {""id"": ""MAXO:0010032"", ""label"": ""cardiac transplantation""}}}"
7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.																																																								"{""description"": ""Diuretics used for heart failure management in Sengers syndrome."", ""name"": ""Diuretic therapy""}"	{}	"{""description"": ""Diuretics used for heart failure management in Sengers syndrome."", ""evidence"": [{""explanation"": ""This case report documents ongoing diuretic therapy as part of heart failure management."", ""reference"": ""PMID:38933059"", ""snippet"": ""Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides direct evidence of diuretic use in Sengers syndrome."", ""reference"": ""PMID:34164355"", ""snippet"": ""The patient received milrinone, diuretics (furosemide and spironolactone), and captopril to improve heart function."", ""supports"": ""SUPPORT""}], ""name"": ""Diuretic therapy"", ""treatment_term"": {""preferred_term"": ""diuretic agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""furosemide"", ""term"": {""id"": ""NCIT:C515"", ""label"": ""Furosemide""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}], ""term"": {""id"": ""MAXO:0000165"", ""label"": ""diuretic agent therapy""}}}"
7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.																																																								"{""description"": ""Levosimendan infusions used for heart failure support."", ""name"": ""Levosimendan infusion""}"	{}	"{""description"": ""Levosimendan infusions used for heart failure support."", ""evidence"": [{""explanation"": ""This neonatal case report describes levosimendan infusions in Sengers syndrome."", ""reference"": ""PMID:38933059"", ""snippet"": ""Baby was on regular follow-up and was thriving well on diuretics, sacubitril-valsartan and weekly levosimendan infusions."", ""supports"": ""SUPPORT""}], ""name"": ""Levosimendan infusion"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levosimendan"", ""term"": {""id"": ""NCIT:C174653"", ""label"": ""Levosimendan""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7079	304	Shigellosis	Shigellosis.yaml	treatments	0	Antibiotic therapy	"Fluoroquinolones (ciprofloxacin) or azithromycin are first-line treatments for shigellosis. These antibiotics reduce duration of symptoms and bacterial shedding.
"																																																								"{""description"": ""Fluoroquinolones (ciprofloxacin) or azithromycin are first-line treatments for shigellosis. These antibiotics reduce duration of symptoms and bacterial shedding.\n"", ""name"": ""Antibiotic therapy""}"	{}	"{""description"": ""Fluoroquinolones (ciprofloxacin) or azithromycin are first-line treatments for shigellosis. These antibiotics reduce duration of symptoms and bacterial shedding.\n"", ""evidence"": [{""explanation"": ""Antimicrobial therapy is indicated to reduce bacterial load and prevent systemic complications"", ""reference"": ""PMID:29493962"", ""snippet"": ""antibiotics could shorten the duration of illness or prevent complications, particularly in individuals at increased risk for severe disease"", ""supports"": ""SUPPORT""}, {""explanation"": ""Rising antimicrobial resistance, especially to fluoroquinolones, necessitates susceptibility-guided therapy"", ""reference"": ""PMID:36409683"", ""snippet"": ""WHO-recommended 1st line antibiotic ciprofloxacin resistance gradually reached more than 70% in both the urban and rural site by 2020"", ""supports"": ""SUPPORT""}], ""name"": ""Antibiotic therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7080	304	Shigellosis	Shigellosis.yaml	treatments	1	Oral rehydration therapy	"Oral rehydration solution (ORS) with electrolytes to replace fluid and electrolyte losses.
"																																																								"{""description"": ""Oral rehydration solution (ORS) with electrolytes to replace fluid and electrolyte losses.\n"", ""name"": ""Oral rehydration therapy""}"	{}	"{""description"": ""Oral rehydration solution (ORS) with electrolytes to replace fluid and electrolyte losses.\n"", ""evidence"": [{""explanation"": ""Oral rehydration is the first-line approach to managing fluid and electrolyte losses"", ""reference"": ""PMID:29493962"", ""snippet"": ""Supportive care may be required, and antibiotics could shorten the duration of illness or prevent complications"", ""supports"": ""SUPPORT""}], ""name"": ""Oral rehydration therapy"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7081	304	Shigellosis	Shigellosis.yaml	treatments	2	Fluid and electrolyte replacement	"Intravenous fluid replacement in severe cases with significant dehydration.
"																																																								"{""description"": ""Intravenous fluid replacement in severe cases with significant dehydration.\n"", ""name"": ""Fluid and electrolyte replacement""}"	{}	"{""description"": ""Intravenous fluid replacement in severe cases with significant dehydration.\n"", ""evidence"": [{""explanation"": ""Severe fluid losses from Shigella-mediated diarrhea may necessitate intravenous fluid replacement"", ""reference"": ""PMID:40915309"", ""snippet"": ""an inoculum of only 10-100 organisms is required for infection"", ""supports"": ""SUPPORT""}], ""name"": ""Fluid and electrolyte replacement"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7108	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	0	Hydroxyurea	Increases HbF, reduces pain crises, first-line disease-modifying therapy.																																																								"{""description"": ""Increases HbF, reduces pain crises, first-line disease-modifying therapy."", ""name"": ""Hydroxyurea""}"	{}	"{""description"": ""Increases HbF, reduces pain crises, first-line disease-modifying therapy."", ""evidence"": [{""explanation"": ""Landmark RCT demonstrating hydroxyurea reduces painful crises by nearly half in sickle cell disease."", ""reference"": ""PMID:7715639"", ""snippet"": ""the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001)"", ""supports"": ""SUPPORT""}], ""name"": ""Hydroxyurea""}"
7109	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	1	Voxelotor	HbS polymerization inhibitor, improves anemia.																																																								"{""description"": ""HbS polymerization inhibitor, improves anemia."", ""name"": ""Voxelotor""}"	{}	"{""description"": ""HbS polymerization inhibitor, improves anemia."", ""name"": ""Voxelotor""}"
7110	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	2	Crizanlizumab	P-selectin inhibitor, reduces vaso-occlusive crises.																																																								"{""description"": ""P-selectin inhibitor, reduces vaso-occlusive crises."", ""name"": ""Crizanlizumab""}"	{}	"{""description"": ""P-selectin inhibitor, reduces vaso-occlusive crises."", ""name"": ""Crizanlizumab""}"
7111	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	3	L-Glutamine	Reduces oxidative stress in RBCs.																																																								"{""description"": ""Reduces oxidative stress in RBCs."", ""name"": ""L-Glutamine""}"	{}	"{""description"": ""Reduces oxidative stress in RBCs."", ""name"": ""L-Glutamine""}"
7112	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	4	Blood Transfusions	Chronic transfusions for stroke prevention, acute for severe anemia.																																																								"{""description"": ""Chronic transfusions for stroke prevention, acute for severe anemia."", ""name"": ""Blood Transfusions""}"	{}	"{""description"": ""Chronic transfusions for stroke prevention, acute for severe anemia."", ""name"": ""Blood Transfusions""}"
7113	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	5	Pain Management	NSAIDs, opioids for acute crises.																																																								"{""description"": ""NSAIDs, opioids for acute crises."", ""name"": ""Pain Management""}"	{}	"{""description"": ""NSAIDs, opioids for acute crises."", ""name"": ""Pain Management""}"
7114	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	6	Penicillin Prophylaxis	In children to prevent pneumococcal sepsis.																																																								"{""description"": ""In children to prevent pneumococcal sepsis."", ""name"": ""Penicillin Prophylaxis""}"	{}	"{""description"": ""In children to prevent pneumococcal sepsis."", ""name"": ""Penicillin Prophylaxis""}"
7115	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	7	Hematopoietic Stem Cell Transplant	Curative option for selected patients.																																																								"{""description"": ""Curative option for selected patients."", ""name"": ""Hematopoietic Stem Cell Transplant""}"	{}	"{""description"": ""Curative option for selected patients."", ""name"": ""Hematopoietic Stem Cell Transplant""}"
7116	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	treatments	8	Gene Therapy	Emerging curative approach (lovotibeglogene autotemcel).																																																								"{""description"": ""Emerging curative approach (lovotibeglogene autotemcel)."", ""name"": ""Gene Therapy""}"	{}	"{""description"": ""Emerging curative approach (lovotibeglogene autotemcel)."", ""evidence"": [{""explanation"": ""CRISPR-Cas9 gene editing of the BCL11A enhancer reactivates fetal hemoglobin, which prevents sickling."", ""reference"": ""PMID:38661449"", ""snippet"": ""Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A."", ""supports"": ""SUPPORT""}, {""explanation"": ""In phase 3 clinical trials, exagamglogene autotemcel (exa-cel) eliminated vaso-occlusive crises in 97% of patients for 12+ months, demonstrating high therapeutic efficacy."", ""reference"": ""PMID:38661449"", ""snippet"": ""Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more."", ""supports"": ""SUPPORT""}], ""name"": ""Gene Therapy""}"
7127	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	0	Functional Endoscopic Sinus Surgery	Endoscopic uncinectomy and maxillary antrostomy to restore sinus ventilation and equalize pressure. This addresses the underlying cause by relieving ostial obstruction.																																																								"{""description"": ""Endoscopic uncinectomy and maxillary antrostomy to restore sinus ventilation and equalize pressure. This addresses the underlying cause by relieving ostial obstruction."", ""name"": ""Functional Endoscopic Sinus Surgery""}"	{}	"{""description"": ""Endoscopic uncinectomy and maxillary antrostomy to restore sinus ventilation and equalize pressure. This addresses the underlying cause by relieving ostial obstruction."", ""evidence"": [{""explanation"": ""FESS is identified as the primary treatment for SSS."", ""reference"": ""PMID:23946747"", ""snippet"": ""Treatment involves functional endoscopic surgery."", ""supports"": ""SUPPORT""}, {""explanation"": ""Case series confirms successful treatment with functional endoscopic sinus surgery."", ""reference"": ""PMID:11404606"", ""snippet"": ""All four underwent successful functional endoscopic sinus surgery and transconjunctival orbital floor repair."", ""supports"": ""SUPPORT""}], ""name"": ""Functional Endoscopic Sinus Surgery"", ""treatment_term"": {""preferred_term"": ""nasal endoscopy"", ""term"": {""id"": ""MAXO:0035089"", ""label"": ""nasal endoscopy""}}}"
7128	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	1	Orbital Floor Reconstruction	Surgical repair of the orbital floor using implants or grafts to correct enophthalmos when spontaneous resolution does not occur after sinus surgery. May be performed simultaneously with or staged after FESS.																																																								"{""description"": ""Surgical repair of the orbital floor using implants or grafts to correct enophthalmos when spontaneous resolution does not occur after sinus surgery. May be performed simultaneously with or staged after FESS."", ""name"": ""Orbital Floor Reconstruction""}"	{}	"{""description"": ""Surgical repair of the orbital floor using implants or grafts to correct enophthalmos when spontaneous resolution does not occur after sinus surgery. May be performed simultaneously with or staged after FESS."", ""evidence"": [{""explanation"": ""Transconjunctival orbital floor repair is described as part of the successful treatment approach."", ""reference"": ""PMID:11404606"", ""snippet"": ""All four underwent successful functional endoscopic sinus surgery and transconjunctival orbital floor repair."", ""supports"": ""SUPPORT""}], ""name"": ""Orbital Floor Reconstruction"", ""treatment_term"": {""preferred_term"": ""surgical plastic reconstruction of face"", ""term"": {""id"": ""MAXO:0001292"", ""label"": ""surgical plastic reconstruction of face""}}}"
7146	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	treatments	0	Artificial Tears	Lubricating eye drops for symptomatic relief of dry eyes.																																																								"{""description"": ""Lubricating eye drops for symptomatic relief of dry eyes."", ""name"": ""Artificial Tears""}"	{}	"{""description"": ""Lubricating eye drops for symptomatic relief of dry eyes."", ""name"": ""Artificial Tears""}"
7147	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	treatments	1	Pilocarpine	Muscarinic agonist to stimulate salivary secretion.																																																								"{""description"": ""Muscarinic agonist to stimulate salivary secretion."", ""name"": ""Pilocarpine""}"	{}	"{""description"": ""Muscarinic agonist to stimulate salivary secretion."", ""name"": ""Pilocarpine""}"
7148	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	treatments	2	Hydroxychloroquine	For systemic manifestations including arthralgia and fatigue.																																																								"{""description"": ""For systemic manifestations including arthralgia and fatigue."", ""name"": ""Hydroxychloroquine""}"	{}	"{""description"": ""For systemic manifestations including arthralgia and fatigue."", ""name"": ""Hydroxychloroquine""}"
7149	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	treatments	3	Rituximab	Anti-CD20 monoclonal antibody for severe systemic disease.																																																								"{""description"": ""Anti-CD20 monoclonal antibody for severe systemic disease."", ""name"": ""Rituximab""}"	{}	"{""description"": ""Anti-CD20 monoclonal antibody for severe systemic disease."", ""name"": ""Rituximab""}"
7175	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	0	Platinum-Etoposide Chemotherapy	Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage.																																																								"{""description"": ""Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage."", ""name"": ""Platinum-Etoposide Chemotherapy""}"	{}	"{""description"": ""Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage."", ""name"": ""Platinum-Etoposide Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
7176	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	1	Atezolizumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage.																																																								"{""description"": ""PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage."", ""name"": ""Atezolizumab (with Chemotherapy)""}"	{}	"{""description"": ""PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage."", ""name"": ""Atezolizumab (with Chemotherapy)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7177	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	2	Durvalumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen.																																																								"{""description"": ""PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen."", ""name"": ""Durvalumab (with Chemotherapy)""}"	{}	"{""description"": ""PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen."", ""name"": ""Durvalumab (with Chemotherapy)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7178	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	3	Thoracic Radiation	Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients.																																																								"{""description"": ""Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients."", ""name"": ""Thoracic Radiation""}"	{}	"{""description"": ""Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients."", ""name"": ""Thoracic Radiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
7179	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	4	Prophylactic Cranial Irradiation	Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI.																																																								"{""description"": ""Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI."", ""name"": ""Prophylactic Cranial Irradiation""}"	{}	"{""description"": ""Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI."", ""name"": ""Prophylactic Cranial Irradiation"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
7180	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	5	Lurbinectedin	Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors.																																																								"{""description"": ""Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors."", ""name"": ""Lurbinectedin""}"	{}	"{""description"": ""Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors."", ""name"": ""Lurbinectedin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7181	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	6	Topotecan	Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived.																																																								"{""description"": ""Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived."", ""name"": ""Topotecan""}"	{}	"{""description"": ""Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived."", ""name"": ""Topotecan"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7188	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	0	Antibiotic therapy	Rifaximin or other antibiotics to reduce bacterial overgrowth.																																																								"{""description"": ""Rifaximin or other antibiotics to reduce bacterial overgrowth."", ""name"": ""Antibiotic therapy""}"	{}	"{""description"": ""Rifaximin or other antibiotics to reduce bacterial overgrowth."", ""name"": ""Antibiotic therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7189	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	1	Dietary modification	Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation.																																																								"{""description"": ""Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation."", ""name"": ""Dietary modification""}"	{}	"{""description"": ""Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation."", ""name"": ""Dietary modification"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
7190	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	2	Prokinetic agents	Medications to improve intestinal motility and reduce stasis.																																																								"{""description"": ""Medications to improve intestinal motility and reduce stasis."", ""name"": ""Prokinetic agents""}"	{}	"{""description"": ""Medications to improve intestinal motility and reduce stasis."", ""name"": ""Prokinetic agents"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7197	310	Snakebite envenoming	Snakebite_Envenoming.yaml	treatments	0	Antivenom administration	Intravenous antivenom is the only specific therapy to counteract envenoming.																																																								"{""description"": ""Intravenous antivenom is the only specific therapy to counteract envenoming."", ""name"": ""Antivenom administration""}"	{}	"{""description"": ""Intravenous antivenom is the only specific therapy to counteract envenoming."", ""evidence"": [{""explanation"": ""The abstract states antivenom is the only specific treatment."", ""reference"": ""PMID:28905944"", ""snippet"": ""Intravenous administration of antivenom is the only specific treatment to counteract envenoming."", ""supports"": ""SUPPORT""}], ""name"": ""Antivenom administration"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7206	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	treatments	0	Albendazole or mebendazole therapy	Benzimidazole anthelmintics used for treatment and preventive deworming.																																																								"{""description"": ""Benzimidazole anthelmintics used for treatment and preventive deworming."", ""name"": ""Albendazole or mebendazole therapy""}"	{}	"{""description"": ""Benzimidazole anthelmintics used for treatment and preventive deworming."", ""evidence"": [{""explanation"": ""Albendazole and mebendazole are standard anthelmintic therapies."", ""reference"": ""PMID:16679166"", ""snippet"": ""The benzimidazole anthelmintics, mebendazole and albendazole, are commonly used to remove these infections."", ""supports"": ""SUPPORT""}], ""name"": ""Albendazole or mebendazole therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7223	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	0	Nusinersen (Spinraza)	Antisense oligonucleotide modifying SMN2 splicing to increase functional SMN protein, intrathecal administration.																																																								"{""description"": ""Antisense oligonucleotide modifying SMN2 splicing to increase functional SMN protein, intrathecal administration."", ""name"": ""Nusinersen (Spinraza)""}"	{}	"{""description"": ""Antisense oligonucleotide modifying SMN2 splicing to increase functional SMN protein, intrathecal administration."", ""evidence"": [{""explanation"": ""ENDEAR trial demonstrates nusinersen improves survival and motor function in infantile SMA."", ""reference"": ""PMID:29091570"", ""snippet"": ""Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group."", ""supports"": ""SUPPORT""}, {""explanation"": ""NEJM paper confirms mechanism of action of nusinersen."", ""reference"": ""PMID:29091570"", ""snippet"": ""Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein."", ""supports"": ""SUPPORT""}], ""name"": ""Nusinersen (Spinraza)""}"
7224	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	1	Onasemnogene abeparvovec (Zolgensma)	AAV9-based gene therapy delivering functional SMN1 gene, single IV infusion.																																																								"{""description"": ""AAV9-based gene therapy delivering functional SMN1 gene, single IV infusion."", ""name"": ""Onasemnogene abeparvovec (Zolgensma)""}"	{}	"{""description"": ""AAV9-based gene therapy delivering functional SMN1 gene, single IV infusion."", ""evidence"": [{""explanation"": ""SPR1NT trial demonstrates gene therapy is effective in presymptomatic SMA infants."", ""reference"": ""PMID:35715567"", ""snippet"": ""Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention."", ""supports"": ""SUPPORT""}], ""name"": ""Onasemnogene abeparvovec (Zolgensma)""}"
7225	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	2	Risdiplam (Evrysdi)	Oral small molecule SMN2 splicing modifier, daily oral administration.																																																								"{""description"": ""Oral small molecule SMN2 splicing modifier, daily oral administration."", ""name"": ""Risdiplam (Evrysdi)""}"	{}	"{""description"": ""Oral small molecule SMN2 splicing modifier, daily oral administration."", ""evidence"": [{""explanation"": ""FIREFISH trial demonstrates risdiplam improves motor function in infants with type 1 SMA."", ""reference"": ""PMID:34320287"", ""snippet"": ""In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed improvements in motor function than the percentages observed in historical cohorts."", ""supports"": ""SUPPORT""}], ""name"": ""Risdiplam (Evrysdi)""}"
7226	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	treatments	3	Supportive Care	Respiratory support, nutritional management, physical therapy, orthopedic interventions.																																																								"{""description"": ""Respiratory support, nutritional management, physical therapy, orthopedic interventions."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Respiratory support, nutritional management, physical therapy, orthopedic interventions."", ""name"": ""Supportive Care""}"
7240	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	0	Orthopedic Management	"Management of scoliosis (bracing, surgery as needed), limb deformities, and hip dysplasia.
"																																																								"{""description"": ""Management of scoliosis (bracing, surgery as needed), limb deformities, and hip dysplasia.\n"", ""name"": ""Orthopedic Management""}"	{}	"{""description"": ""Management of scoliosis (bracing, surgery as needed), limb deformities, and hip dysplasia.\n"", ""name"": ""Orthopedic Management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7241	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	1	Ophthalmologic Surveillance	"Monitoring for myopia and retinal complications.
"																																																								"{""description"": ""Monitoring for myopia and retinal complications.\n"", ""name"": ""Ophthalmologic Surveillance""}"	{}	"{""description"": ""Monitoring for myopia and retinal complications.\n"", ""name"": ""Ophthalmologic Surveillance""}"
7242	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	2	Audiologic Monitoring	"Regular hearing assessments.
"																																																								"{""description"": ""Regular hearing assessments.\n"", ""name"": ""Audiologic Monitoring""}"	{}	"{""description"": ""Regular hearing assessments.\n"", ""name"": ""Audiologic Monitoring""}"
7243	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	3	Cleft Palate Repair	"Surgical repair if cleft palate present.
"																																																								"{""description"": ""Surgical repair if cleft palate present.\n"", ""name"": ""Cleft Palate Repair""}"	{}	"{""description"": ""Surgical repair if cleft palate present.\n"", ""name"": ""Cleft Palate Repair"", ""treatment_term"": {""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7259	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	treatments	0	Orthopedic Management	"Management of spinal instability, hip dysplasia, and limb deformities. Cervical spine evaluation for odontoid hypoplasia is essential before anesthesia or contact activities.
"																																																								"{""description"": ""Management of spinal instability, hip dysplasia, and limb deformities. Cervical spine evaluation for odontoid hypoplasia is essential before anesthesia or contact activities.\n"", ""name"": ""Orthopedic Management""}"	{}	"{""description"": ""Management of spinal instability, hip dysplasia, and limb deformities. Cervical spine evaluation for odontoid hypoplasia is essential before anesthesia or contact activities.\n"", ""name"": ""Orthopedic Management"", ""treatment_term"": {""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7260	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	treatments	1	Ophthalmologic Surveillance	"Regular eye examinations for myopia management and early detection of retinal detachment.
"																																																								"{""description"": ""Regular eye examinations for myopia management and early detection of retinal detachment.\n"", ""name"": ""Ophthalmologic Surveillance""}"	{}	"{""description"": ""Regular eye examinations for myopia management and early detection of retinal detachment.\n"", ""name"": ""Ophthalmologic Surveillance""}"
7261	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	treatments	2	Audiologic Monitoring	"Regular hearing assessments with hearing aids as needed for progressive sensorineural hearing loss.
"																																																								"{""description"": ""Regular hearing assessments with hearing aids as needed for progressive sensorineural hearing loss.\n"", ""name"": ""Audiologic Monitoring""}"	{}	"{""description"": ""Regular hearing assessments with hearing aids as needed for progressive sensorineural hearing loss.\n"", ""name"": ""Audiologic Monitoring""}"
7274	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	0	Prophylactic Retinal Treatment	"Prophylactic cryotherapy or laser photocoagulation to reduce retinal detachment risk. Regular ophthalmologic surveillance essential.
"																																																								"{""description"": ""Prophylactic cryotherapy or laser photocoagulation to reduce retinal detachment risk. Regular ophthalmologic surveillance essential.\n"", ""name"": ""Prophylactic Retinal Treatment""}"	{}	"{""description"": ""Prophylactic cryotherapy or laser photocoagulation to reduce retinal detachment risk. Regular ophthalmologic surveillance essential.\n"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Large retrospective study demonstrates prophylactic cryotherapy reduces retinal detachment from 73% to 8% in STL1 patients.\n"", ""reference"": ""PMID:17675240"", ""snippet"": ""Of 62 patients who had bilateral prophylactic cryotherapy (group 2; mean age, 21 years), 8% (5/62) suffered failure of prophylaxis. There were no cases of bilateral detachments. The mean follow-up period was 11.5 years.\n"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Study conclusion confirms effectiveness of prophylactic treatment.\n"", ""reference"": ""PMID:17675240"", ""snippet"": ""Prophylactic cryotherapy substantially reduces the risk of RD in type 1 Stickler syndrome and, in this series, eliminated the risk of bilateral detachments.\n"", ""supports"": ""SUPPORT""}], ""name"": ""Prophylactic Retinal Treatment"", ""treatment_term"": {""preferred_term"": ""Ophthalmologic procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7275	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	1	Hearing Management	"Regular audiologic monitoring with hearing aids as needed for progressive hearing loss.
"																																																								"{""description"": ""Regular audiologic monitoring with hearing aids as needed for progressive hearing loss.\n"", ""name"": ""Hearing Management""}"	{}	"{""description"": ""Regular audiologic monitoring with hearing aids as needed for progressive hearing loss.\n"", ""name"": ""Hearing Management""}"
7276	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	2	Joint Protection	"Physical therapy, joint protection strategies, and management of early-onset osteoarthritis.
"																																																								"{""description"": ""Physical therapy, joint protection strategies, and management of early-onset osteoarthritis.\n"", ""name"": ""Joint Protection""}"	{}	"{""description"": ""Physical therapy, joint protection strategies, and management of early-onset osteoarthritis.\n"", ""name"": ""Joint Protection"", ""treatment_term"": {""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}}"
7277	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	3	Cleft Repair	"Surgical repair for cleft palate; management of Pierre Robin sequence if present.
"																																																								"{""description"": ""Surgical repair for cleft palate; management of Pierre Robin sequence if present.\n"", ""name"": ""Cleft Repair""}"	{}	"{""description"": ""Surgical repair for cleft palate; management of Pierre Robin sequence if present.\n"", ""name"": ""Cleft Repair"", ""treatment_term"": {""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7296	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	0	Benzodiazepines	First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily.																																																								"{""description"": ""First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily."", ""name"": ""Benzodiazepines""}"	{}	"{""description"": ""First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily."", ""evidence"": [{""explanation"": ""Benzodiazepines are established as first-line symptomatic GABA-enhancing therapy."", ""reference"": ""PMID:35084720"", ""snippet"": ""details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach"", ""supports"": ""SUPPORT""}], ""name"": ""Benzodiazepines"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7297	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	1	Baclofen	GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases.																																																								"{""description"": ""GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases."", ""name"": ""Baclofen""}"	{}	"{""description"": ""GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases."", ""evidence"": [{""explanation"": ""Baclofen is listed as a preferred GABA-enhancing antispasmodic drug for symptomatic treatment of SPS."", ""reference"": ""PMID:37059468"", ""snippet"": ""combination therapies with the preferred gamma-aminobutyric acid-enhancing antispasmodic drugs, such as baclofen, tizanidine, benzodiazepines, and gabapentin"", ""supports"": ""SUPPORT""}], ""name"": ""Baclofen"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7298	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	2	Intravenous Immunoglobulin	Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients.																																																								"{""description"": ""Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients."", ""name"": ""Intravenous Immunoglobulin""}"	{}	"{""description"": ""Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients."", ""evidence"": [{""explanation"": ""Randomized controlled trial demonstrated significant efficacy of IVIg."", ""reference"": ""PMID:11756577"", ""snippet"": ""Among patients who received immune globulin first, stiffness scores decreased significantly (P=0.02)"", ""supports"": ""SUPPORT""}, {""explanation"": ""The trial conclusion establishes IVIg as effective treatment."", ""reference"": ""PMID:11756577"", ""snippet"": ""Intravenous immune globulin is a well-tolerated and effective, albeit costly, therapy for patients with stiff-person syndrome and anti-GAD65 antibodies."", ""supports"": ""SUPPORT""}, {""explanation"": ""The 2023 review confirms IVIg as a key immunotherapy option in the treatment algorithm."", ""reference"": ""PMID:37059468"", ""snippet"": ""detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab"", ""supports"": ""SUPPORT""}], ""name"": ""Intravenous Immunoglobulin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7299	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	3	Rituximab	Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months.																																																								"{""description"": ""Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months."", ""name"": ""Rituximab""}"	{}	"{""description"": ""Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months."", ""evidence"": [{""explanation"": ""Rituximab is included as part of the current immunotherapy options for SPS treatment."", ""reference"": ""PMID:37059468"", ""snippet"": ""detailing the application of current immunotherapies with intravenous immunoglobulin (IVIg) plasmapheresis, and rituximab"", ""supports"": ""SUPPORT""}, {""explanation"": ""Rituximab is part of the step-by-step therapeutic approach for refractory cases."", ""reference"": ""PMID:35084720"", ""snippet"": ""focuses on therapies providing details on symptomatic GABA-enhancing drugs and the currently available immunotherapies in a step-by-step approach"", ""supports"": ""SUPPORT""}], ""name"": ""Rituximab"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7314	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	0	Surgical Resection	Wide surgical resection with negative margins is the primary treatment for localized disease. Limb-sparing surgery is preferred when oncologically feasible.																																																								"{""description"": ""Wide surgical resection with negative margins is the primary treatment for localized disease. Limb-sparing surgery is preferred when oncologically feasible."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Wide surgical resection with negative margins is the primary treatment for localized disease. Limb-sparing surgery is preferred when oncologically feasible."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7315	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	1	Radiation Therapy	Adjuvant radiation improves local control, particularly for tumors larger than 5 cm, high grade, or with close/positive margins. May be given preoperatively or postoperatively.																																																								"{""description"": ""Adjuvant radiation improves local control, particularly for tumors larger than 5 cm, high grade, or with close/positive margins. May be given preoperatively or postoperatively."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Adjuvant radiation improves local control, particularly for tumors larger than 5 cm, high grade, or with close/positive margins. May be given preoperatively or postoperatively."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.																																																								"{""description"": ""Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}}"
7367	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	0	Type I Interferon Receptor Antagonist	Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.																																		Anifrolumab approved for moderate-to-severe SLE; biomarker-guided therapy																						"{""description"": ""Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification."", ""name"": ""Type I Interferon Receptor Antagonist"", ""notes"": ""Anifrolumab approved for moderate-to-severe SLE; biomarker-guided therapy""}"	{}	"{""description"": ""Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification."", ""evidence"": [{""explanation"": ""This phase IIb trial demonstrated that anifrolumab significantly reduced SLE disease activity, with greater efficacy in patients with high interferon gene signatures."", ""reference"": ""PMID:28130918"", ""snippet"": ""Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE"", ""supports"": ""SUPPORT""}], ""name"": ""Type I Interferon Receptor Antagonist"", ""notes"": ""Anifrolumab approved for moderate-to-severe SLE; biomarker-guided therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7368	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	1	B Cell Depletion Therapy	Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.																																		CAR-T cell therapy has induced drug-free remissions in early clinical experiences																						"{""description"": ""Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation."", ""name"": ""B Cell Depletion Therapy"", ""notes"": ""CAR-T cell therapy has induced drug-free remissions in early clinical experiences""}"	{}	"{""description"": ""Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation."", ""name"": ""B Cell Depletion Therapy"", ""notes"": ""CAR-T cell therapy has induced drug-free remissions in early clinical experiences"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7369	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	2	BAFF Pathway Inhibition	Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.																																		Integrates BAFF/IFN biomarkers with therapeutic selection																						"{""description"": ""Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm."", ""name"": ""BAFF Pathway Inhibition"", ""notes"": ""Integrates BAFF/IFN biomarkers with therapeutic selection""}"	{}	"{""description"": ""Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm."", ""evidence"": [{""explanation"": ""This phase III BLISS-76 trial demonstrated that belimumab significantly improved SLE outcomes compared to placebo."", ""reference"": ""PMID:22127708"", ""snippet"": ""Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE"", ""supports"": ""SUPPORT""}], ""name"": ""BAFF Pathway Inhibition"", ""notes"": ""Integrates BAFF/IFN biomarkers with therapeutic selection"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7370	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	3	Immunosuppressive Therapy	Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.																																		Standard immunosuppressive agents for disease control																						"{""description"": ""Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation."", ""name"": ""Immunosuppressive Therapy"", ""notes"": ""Standard immunosuppressive agents for disease control""}"	{}	"{""description"": ""Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation."", ""name"": ""Immunosuppressive Therapy"", ""notes"": ""Standard immunosuppressive agents for disease control"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7371	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	4	Supportive Care	Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.																																		Organ-specific symptomatic management																						"{""description"": ""Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed."", ""name"": ""Supportive Care"", ""notes"": ""Organ-specific symptomatic management""}"	{}	"{""description"": ""Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed."", ""name"": ""Supportive Care"", ""notes"": ""Organ-specific symptomatic management"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7385	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	treatments	0	Calcium Channel Blockers	For Raynaud's phenomenon management.																																																								"{""description"": ""For Raynaud's phenomenon management."", ""name"": ""Calcium Channel Blockers""}"	{}	"{""description"": ""For Raynaud's phenomenon management."", ""name"": ""Calcium Channel Blockers""}"
7386	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	treatments	1	Mycophenolate Mofetil	Immunosuppressant for skin and lung involvement.																																																								"{""description"": ""Immunosuppressant for skin and lung involvement."", ""name"": ""Mycophenolate Mofetil""}"	{}	"{""description"": ""Immunosuppressant for skin and lung involvement."", ""name"": ""Mycophenolate Mofetil""}"
7387	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	treatments	2	Nintedanib	Antifibrotic agent for progressive interstitial lung disease.																																																								"{""description"": ""Antifibrotic agent for progressive interstitial lung disease."", ""name"": ""Nintedanib""}"	{}	"{""description"": ""Antifibrotic agent for progressive interstitial lung disease."", ""name"": ""Nintedanib""}"
7388	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	treatments	3	ACE Inhibitors	Critical for scleroderma renal crisis management.																																																								"{""description"": ""Critical for scleroderma renal crisis management."", ""name"": ""ACE Inhibitors""}"	{}	"{""description"": ""Critical for scleroderma renal crisis management."", ""name"": ""ACE Inhibitors""}"
7409	320	TARP syndrome	TARP_syndrome.yaml	treatments	0	Cardiac surgery	Surgical repair of atrial septal defects and other congenital heart defects to correct hemodynamics and prevent complications																																																								"{""description"": ""Surgical repair of atrial septal defects and other congenital heart defects to correct hemodynamics and prevent complications"", ""name"": ""Cardiac surgery""}"	{}	"{""description"": ""Surgical repair of atrial septal defects and other congenital heart defects to correct hemodynamics and prevent complications"", ""evidence"": [{""explanation"": ""Lane et al. 2023 case report of a TARP patient with ASD requiring cardiac management for survival beyond neonatal period."", ""reference"": ""PMID:36944446"", ""snippet"": ""At birth, he had an ASD and Robin sequence, two of the eponymous features"", ""supports"": ""SUPPORT""}], ""name"": ""Cardiac surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7410	320	TARP syndrome	TARP_syndrome.yaml	treatments	1	Palatal cleft repair	Surgical correction of cleft palate to restore normal feeding and speech development																																																								"{""description"": ""Surgical correction of cleft palate to restore normal feeding and speech development"", ""name"": ""Palatal cleft repair""}"	{}	"{""description"": ""Surgical correction of cleft palate to restore normal feeding and speech development"", ""evidence"": [{""explanation"": ""Lane et al. 2023 documents Robin sequence (which includes cleft palate) as a defining feature of TARP, requiring surgical intervention for airway management and feeding."", ""reference"": ""PMID:36944446"", ""snippet"": ""TARP (talipes equinovarus, atrial septal defect (ASD), Robin sequence, persistent left superior vena cava) syndrome"", ""supports"": ""SUPPORT""}], ""name"": ""Palatal cleft repair"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7411	320	TARP syndrome	TARP_syndrome.yaml	treatments	2	Orthopedic surgery	Surgical management of talipes and other skeletal deformities																																																								"{""description"": ""Surgical management of talipes and other skeletal deformities"", ""name"": ""Orthopedic surgery""}"	{}	"{""description"": ""Surgical management of talipes and other skeletal deformities"", ""evidence"": [{""explanation"": ""Lane et al. 2023 case report of TARP patient with talipes equinovarus, which typically requires orthopedic surgical intervention."", ""reference"": ""PMID:36944446"", ""snippet"": ""TARP (talipes equinovarus, atrial septal defect (ASD), Robin sequence, persistent left superior vena cava) syndrome"", ""supports"": ""SUPPORT""}], ""name"": ""Orthopedic surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7412	320	TARP syndrome	TARP_syndrome.yaml	treatments	3	Airway management	Management of potential airway obstruction due to micrognathia and glossoptosis in Robin sequence																																																								"{""description"": ""Management of potential airway obstruction due to micrognathia and glossoptosis in Robin sequence"", ""name"": ""Airway management""}"	{}	"{""description"": ""Management of potential airway obstruction due to micrognathia and glossoptosis in Robin sequence"", ""evidence"": [{""explanation"": ""Lane et al. 2023 case report documents Robin sequence (which includes micrognathia and glossoptosis) requiring airway management to prevent obstruction and maintain adequate oxygenation."", ""reference"": ""PMID:36944446"", ""snippet"": ""At birth, he had an ASD and Robin sequence, two of the eponymous features"", ""supports"": ""SUPPORT""}], ""name"": ""Airway management""}"
7413	320	TARP syndrome	TARP_syndrome.yaml	treatments	4	Multidisciplinary supportive care	Coordinated care from cardiology, orthopedics, otolaryngology, and genetics for comprehensive management																																																								"{""description"": ""Coordinated care from cardiology, orthopedics, otolaryngology, and genetics for comprehensive management"", ""name"": ""Multidisciplinary supportive care""}"	{}	"{""description"": ""Coordinated care from cardiology, orthopedics, otolaryngology, and genetics for comprehensive management"", ""evidence"": [{""explanation"": ""Lane et al. 2023 demonstrates that coordinated multidisciplinary management of TARP syndrome features enables survival beyond the historically fatal neonatal period."", ""reference"": ""PMID:36944446"", ""snippet"": ""our patient's survival past the neonatal period"", ""supports"": ""SUPPORT""}], ""name"": ""Multidisciplinary supportive care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7417	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	0	Antiparasitic therapy	Antiparasitic drugs are used to kill brain parasites in neurocysticercosis.																																																								"{""description"": ""Antiparasitic drugs are used to kill brain parasites in neurocysticercosis."", ""name"": ""Antiparasitic therapy""}"	{}	"{""description"": ""Antiparasitic drugs are used to kill brain parasites in neurocysticercosis."", ""evidence"": [{""explanation"": ""The abstract lists antiparasitic drugs among available treatments."", ""reference"": ""PMID:12932389"", ""snippet"": ""Available therapeutic measures include steroids, treatments for symptoms, surgery, and, more controversially, antiparasitic drugs to kill brain parasites."", ""supports"": ""SUPPORT""}], ""name"": ""Antiparasitic therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7418	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	1	Surgical management	Surgical interventions may be used in selected cases.																																																								"{""description"": ""Surgical interventions may be used in selected cases."", ""name"": ""Surgical management""}"	{}	"{""description"": ""Surgical interventions may be used in selected cases."", ""evidence"": [{""explanation"": ""The abstract includes surgery as a treatment option."", ""reference"": ""PMID:12932389"", ""snippet"": ""Available therapeutic measures include steroids, treatments for symptoms, surgery, and, more controversially, antiparasitic drugs to kill brain parasites."", ""supports"": ""SUPPORT""}], ""name"": ""Surgical management"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7436	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	0	Supportive Care	Symptomatic management including seizure control, nutrition support, respiratory care.																																																								"{""description"": ""Symptomatic management including seizure control, nutrition support, respiratory care."", ""name"": ""Supportive Care""}"	{}	"{""description"": ""Symptomatic management including seizure control, nutrition support, respiratory care."", ""evidence"": [{""explanation"": ""Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease."", ""reference"": ""PMID:27491214"", ""snippet"": ""Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7437	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	1	Genetic Counseling	Carrier screening especially in high-risk populations.																																																								"{""description"": ""Carrier screening especially in high-risk populations."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Carrier screening especially in high-risk populations."", ""evidence"": [{""explanation"": ""Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews."", ""reference"": ""PMID:12108829"", ""snippet"": ""Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."", ""supports"": ""SUPPORT""}], ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
7438	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	2	Substrate Reduction Therapy	Investigational approaches to reduce GM2 synthesis.																																												Needs a more specific MAXO term for substrate reduction therapy.												"{""description"": ""Investigational approaches to reduce GM2 synthesis."", ""name"": ""Substrate Reduction Therapy"", ""review_notes"": ""Needs a more specific MAXO term for substrate reduction therapy.""}"	{}	"{""description"": ""Investigational approaches to reduce GM2 synthesis."", ""evidence"": [{""explanation"": ""Review confirms substrate reduction therapy using glucose analogs is being used off-label in GM2 gangliosidoses."", ""reference"": ""PMID:27491214"", ""snippet"": ""Treatment with FDA-approved glucose analogs to reduce the amount of ganglioside substrate is used as off-label treatments for some patients."", ""supports"": ""SUPPORT""}], ""name"": ""Substrate Reduction Therapy"", ""review_notes"": ""Needs a more specific MAXO term for substrate reduction therapy."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7439	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	3	Gene Therapy	Experimental AAV-based gene therapy in clinical trials.																																																								"{""description"": ""Experimental AAV-based gene therapy in clinical trials."", ""name"": ""Gene Therapy""}"	{}	"{""description"": ""Experimental AAV-based gene therapy in clinical trials."", ""evidence"": [{""explanation"": ""First-in-human AAV gene therapy trial demonstrates safety and proof-of-concept for Tay-Sachs disease treatment."", ""reference"": ""PMID:35145305"", ""snippet"": ""This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy."", ""supports"": ""SUPPORT""}], ""name"": ""Gene Therapy"", ""treatment_term"": {""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}}"
7454	323	Tetanus	Tetanus.yaml	treatments	0	Tetanus Immunoglobulin (TIG)	"Human tetanus immunoglobulin provides passive immunity by neutralizing circulating toxin. Should be administered as early as possible.
"																																																								"{""description"": ""Human tetanus immunoglobulin provides passive immunity by neutralizing circulating toxin. Should be administered as early as possible.\n"", ""name"": ""Tetanus Immunoglobulin (TIG)""}"	{}	"{""description"": ""Human tetanus immunoglobulin provides passive immunity by neutralizing circulating toxin. Should be administered as early as possible.\n"", ""evidence"": [{""explanation"": ""Antitoxin (TIG) is a core component of recommended management."", ""reference"": ""PMID:40543524"", ""snippet"": ""Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration."", ""supports"": ""SUPPORT""}], ""name"": ""Tetanus Immunoglobulin (TIG)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7455	323	Tetanus	Tetanus.yaml	treatments	1	Wound Debridement	"Surgical cleaning and removal of necrotic tissue eliminates the anaerobic environment that supports C. tetani growth and toxin production.
"																																																								"{""description"": ""Surgical cleaning and removal of necrotic tissue eliminates the anaerobic environment that supports C. tetani growth and toxin production.\n"", ""name"": ""Wound Debridement""}"	{}	"{""description"": ""Surgical cleaning and removal of necrotic tissue eliminates the anaerobic environment that supports C. tetani growth and toxin production.\n"", ""evidence"": [{""explanation"": ""Debridement provides the source control described in standard care."", ""reference"": ""PMID:40543524"", ""snippet"": ""Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration."", ""supports"": ""SUPPORT""}], ""name"": ""Wound Debridement"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7456	323	Tetanus	Tetanus.yaml	treatments	2	Antibiotic Therapy	"Metronidazole is the preferred antibiotic to eliminate C. tetani from the wound and prevent further toxin production. Penicillin is an alternative.
"																																																								"{""description"": ""Metronidazole is the preferred antibiotic to eliminate C. tetani from the wound and prevent further toxin production. Penicillin is an alternative.\n"", ""name"": ""Antibiotic Therapy""}"	{}	"{""description"": ""Metronidazole is the preferred antibiotic to eliminate C. tetani from the wound and prevent further toxin production. Penicillin is an alternative.\n"", ""evidence"": [{""explanation"": ""Confirms antibiotics as part of standard tetanus management."", ""reference"": ""PMID:40543524"", ""snippet"": ""Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration."", ""supports"": ""SUPPORT""}], ""name"": ""Antibiotic Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7457	323	Tetanus	Tetanus.yaml	treatments	3	Muscle Relaxants and Sedation	"Benzodiazepines (diazepam) are first-line for controlling spasms. Severe cases may require neuromuscular blocking agents and mechanical ventilation.
"																																																								"{""description"": ""Benzodiazepines (diazepam) are first-line for controlling spasms. Severe cases may require neuromuscular blocking agents and mechanical ventilation.\n"", ""name"": ""Muscle Relaxants and Sedation""}"	{}	"{""description"": ""Benzodiazepines (diazepam) are first-line for controlling spasms. Severe cases may require neuromuscular blocking agents and mechanical ventilation.\n"", ""evidence"": [{""explanation"": ""This case report reviews evidence supporting the use of benzodiazepines as part of tetanus treatment."", ""reference"": ""PMID:38822438"", ""snippet"": ""these studies have shown potential benefits of treating tetanus infections with benzodiazepines, magnesium sulfate and baclofen"", ""supports"": ""SUPPORT""}], ""name"": ""Muscle Relaxants and Sedation"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7458	323	Tetanus	Tetanus.yaml	treatments	4	Supportive Care	"ICU care including mechanical ventilation, nutritional support, and management of autonomic instability with beta-blockers or magnesium sulfate.
"																																																								"{""description"": ""ICU care including mechanical ventilation, nutritional support, and management of autonomic instability with beta-blockers or magnesium sulfate.\n"", ""name"": ""Supportive Care""}"	{}	"{""description"": ""ICU care including mechanical ventilation, nutritional support, and management of autonomic instability with beta-blockers or magnesium sulfate.\n"", ""evidence"": [{""explanation"": ""Highlights the importance of ICU-level supportive care for survival."", ""reference"": ""PMID:40543524"", ""snippet"": ""With prolonged, quality intensive care, many patients survive with good functional outcome."", ""supports"": ""SUPPORT""}], ""name"": ""Supportive Care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7459	323	Tetanus	Tetanus.yaml	treatments	5	Active Immunization	"Tetanus toxoid vaccine should be administered during recovery as natural infection does not confer immunity.
"																																																								"{""description"": ""Tetanus toxoid vaccine should be administered during recovery as natural infection does not confer immunity.\n"", ""name"": ""Active Immunization""}"	{}	"{""description"": ""Tetanus toxoid vaccine should be administered during recovery as natural infection does not confer immunity.\n"", ""evidence"": [{""explanation"": ""Underscores need for vaccination and boosters due to incomplete coverage."", ""reference"": ""PMID:34790820"", ""snippet"": ""The pooled estimate of receiving at least two doses of tetanus toxoid immunization coverage in Ethiopia was 52.2% (95% CI: 42.47-61.93, I 2 = 98.4%)."", ""supports"": ""SUPPORT""}], ""name"": ""Active Immunization"", ""treatment_term"": {""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}}"
7472	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	treatments	0	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Intensive respiratory support may prolong survival in rare cases, but long-term survival is exceptional. Palliative care is typically provided.
"																																																								"{""description"": ""Most affected infants die shortly after birth from respiratory failure. Intensive respiratory support may prolong survival in rare cases, but long-term survival is exceptional. Palliative care is typically provided.\n"", ""name"": ""Supportive care""}"	{}	"{""description"": ""Most affected infants die shortly after birth from respiratory failure. Intensive respiratory support may prolong survival in rare cases, but long-term survival is exceptional. Palliative care is typically provided.\n"", ""name"": ""Supportive care"", ""treatment_term"": {""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7485	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	treatments	0	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require intensive respiratory support.
"																																																								"{""description"": ""Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require intensive respiratory support.\n"", ""name"": ""Supportive care""}"	{}	"{""description"": ""Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require intensive respiratory support.\n"", ""name"": ""Supportive care"", ""treatment_term"": {""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7489	326	Trachoma	Trachoma.yaml	treatments	0	Antibiotic mass drug administration (SAFE strategy)	Antibiotic mass drug administration reduces infection prevalence and transmission.																																																								"{""description"": ""Antibiotic mass drug administration reduces infection prevalence and transmission."", ""name"": ""Antibiotic mass drug administration (SAFE strategy)""}"	{}	"{""description"": ""Antibiotic mass drug administration reduces infection prevalence and transmission."", ""evidence"": [{""explanation"": ""The abstract describes antibiotic mass drug administration as part of SAFE."", ""reference"": ""PMID:35618795"", ""snippet"": ""Surgery is offered to individuals with trichiasis and antibiotic mass drug administration and interventions to stimulate facial cleanliness and environmental improvement are designed to reduce infection prevalence and transmission."", ""supports"": ""SUPPORT""}], ""name"": ""Antibiotic mass drug administration (SAFE strategy)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7509	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	treatments	0	None Required	Condition is self-limiting and resolves without treatment.																																																								"{""description"": ""Condition is self-limiting and resolves without treatment."", ""name"": ""None Required""}"	{}	"{""description"": ""Condition is self-limiting and resolves without treatment."", ""evidence"": [{""explanation"": ""The literature specifically covers transient neonatal pustular melanosis, implying it is self-limiting and does not require treatment."", ""reference"": ""PMID:7091064"", ""snippet"": ""Transient neonatal pustular melanosis."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:27192509"", ""snippet"": ""However, the majority of neonatal skin pustules is not infectious, comprising the benign neonatal pustulosis. Benign neonatal pustuloses are a group of clinical disease characterized by pustular eruptions in which a contagious agent is not responsible for its etiology. The most common ones are erythema toxicum neonatorum, the transient neonatal pustular melanosis and the benign cephalic pustulosis. These dermatoses are usually benign, asymptomatic and self-limited."", ""supports"": ""SUPPORT""}], ""name"": ""None Required"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7522	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	0	Corticosteroid Therapy	High-dose steroids as standard acute therapy.																																																								"{""description"": ""High-dose steroids as standard acute therapy."", ""name"": ""Corticosteroid Therapy""}"	{}	"{""description"": ""High-dose steroids as standard acute therapy."", ""evidence"": [{""explanation"": ""The abstract states steroids are standard treatment for transverse myelitis."", ""reference"": ""PMID:26009577"", ""snippet"": ""Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX)."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroid Therapy"", ""treatment_term"": {""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}}"
7523	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	1	Plasma Exchange	Plasma exchange for more severe transverse myelitis.																																		No specific MAXO term available for plasma exchange in current ontology snapshots.																						"{""description"": ""Plasma exchange for more severe transverse myelitis."", ""name"": ""Plasma Exchange"", ""notes"": ""No specific MAXO term available for plasma exchange in current ontology snapshots.""}"	{}	"{""description"": ""Plasma exchange for more severe transverse myelitis."", ""evidence"": [{""explanation"": ""The abstract notes plasma exchange responsiveness in severe transverse myelitis."", ""reference"": ""PMID:26009577"", ""snippet"": ""Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX)."", ""supports"": ""SUPPORT""}], ""name"": ""Plasma Exchange"", ""notes"": ""No specific MAXO term available for plasma exchange in current ontology snapshots."", ""treatment_term"": {""preferred_term"": ""plasma exchange""}}"
7534	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	0	Oral rehydration therapy	Fluid and electrolyte replacement is the cornerstone of treatment.																																																								"{""description"": ""Fluid and electrolyte replacement is the cornerstone of treatment."", ""name"": ""Oral rehydration therapy""}"	{}	"{""description"": ""Fluid and electrolyte replacement is the cornerstone of treatment."", ""evidence"": [{""explanation"": ""Review emphasizes oral rehydration as first-line management for acute diarrheal illness."", ""reference"": ""PMID:35839362"", ""snippet"": ""In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration."", ""supports"": ""SUPPORT""}], ""name"": ""Oral rehydration therapy"", ""treatment_term"": {""preferred_term"": ""fluid replacement therapy"", ""term"": {""id"": ""MAXO:0000618"", ""label"": ""fluid replacement therapy""}}}"
7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.																																																								"{""description"": ""Antimotility agent for symptomatic relief in non-invasive cases."", ""name"": ""Loperamide""}"	{}	"{""description"": ""Antimotility agent for symptomatic relief in non-invasive cases."", ""evidence"": [{""explanation"": ""Pre-travel consultation study identifies loperamide as a recognized symptomatic reliever for traveler's diarrhea."", ""reference"": ""PMID:39453259"", ""snippet"": ""Knowledge gaps persisted: over 50% were unaware of TD's self-limited nature, 30% did not recognize loperamide as a symptom reliever, and 36% believed all travelers should take antibiotics to prevent TD.\n"", ""supports"": ""SUPPORT""}], ""name"": ""Loperamide"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""loperamide hydrochloride"", ""term"": {""id"": ""NCIT:C62046"", ""label"": ""Loperamide Hydrochloride""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.																																																								"{""description"": ""Empiric antibiotic therapy for moderate to severe cases."", ""name"": ""Fluoroquinolone antibiotics""}"	{}	"{""description"": ""Empiric antibiotic therapy for moderate to severe cases."", ""evidence"": [{""explanation"": ""Clinical review notes selective use of antibiotics, including in some traveler's diarrhea cases."", ""reference"": ""PMID:35839362"", ""snippet"": ""Empiric antibiotics are rarely warranted, except in sepsis and some cases of travelers' or inflammatory diarrhea. Targeted antibiotic therapy may be appropriate following microbiologic stool assessment."", ""supports"": ""SUPPORT""}, {""explanation"": ""Resistance trends in ETEC underscore reserving fluoroquinolones for indicated cases and adjusting based on susceptibility."", ""reference"": ""PMID:40024692"", ""snippet"": ""Resistant strains to representative therapeutic agents such as ciprofloxacin and azithromycin have been reported in recent years, and multidrug-resistant ETEC has also emerged."", ""supports"": ""SUPPORT""}], ""name"": ""Fluoroquinolone antibiotics"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""ciprofloxacin"", ""term"": {""id"": ""NCIT:C376"", ""label"": ""Ciprofloxacin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.																																																								"{""description"": ""Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli."", ""name"": ""Rifaximin""}"	{}	"{""description"": ""Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli."", ""evidence"": [{""explanation"": ""StatPearls entry lists rifaximin as indicated for traveler's diarrhea from noninvasive E. coli."", ""reference"": ""PMID:32966000"", ""snippet"": ""Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers diarrhea caused by noninvasive strains of Escherichia coli."", ""supports"": ""SUPPORT""}, {""explanation"": ""Network meta-analysis shows rifaximin reduces travelers diarrhea incidence more than probiotics, supporting its preventive use."", ""reference"": ""PMID:36221413"", ""snippet"": ""Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63)."", ""supports"": ""SUPPORT""}], ""name"": ""Rifaximin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.																																																								"{""description"": ""Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea."", ""name"": ""Bismuth subsalicylate""}"	{}	"{""description"": ""Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea."", ""evidence"": [{""explanation"": ""StatPearls review describes bismuth subsalicylate use for managing traveler's diarrhea symptoms."", ""reference"": ""PMID:32809532"", ""snippet"": ""This educational activity focuses on bismuth subsalicylate's applications in managing gastrointestinal discomfort and traveler's diarrhea."", ""supports"": ""SUPPORT""}, {""explanation"": ""Narrative review highlights bismuths multimodal activity for diarrheal symptom relief, including travelers diarrhea."", ""reference"": ""PMID:33064636"", ""snippet"": ""The antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea."", ""supports"": ""SUPPORT""}], ""name"": ""Bismuth subsalicylate"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bismuth subsalicylate"", ""term"": {""id"": ""NCIT:C333"", ""label"": ""Bismuth Subsalicylate""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7539	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	5	Probiotic prophylaxis	Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.																																																								"{""description"": ""Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel."", ""name"": ""Probiotic prophylaxis""}"	{}	"{""description"": ""Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel."", ""evidence"": [{""explanation"": ""Meta-analysis finds several probiotic strains reduce risk of traveler's diarrhea, supporting prophylactic use."", ""reference"": ""PMID:38458507"", ""snippet"": ""Based on this systematic review and meta-analysis, specific probiotic strains, including L. acidophilus, L. rhamnosus, L. fermentum, S. cerevisiae, and S. boulardii, may prevent TD."", ""supports"": ""SUPPORT""}, {""explanation"": ""Network meta-analysis quantifies reduced travelers diarrhea incidence with probiotic prophylaxis."", ""reference"": ""PMID:36221413"", ""snippet"": ""Both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95)."", ""supports"": ""SUPPORT""}], ""name"": ""Probiotic prophylaxis"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7540	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	6	Education on safe food and water practices	Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.																																																								"{""description"": ""Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel."", ""name"": ""Education on safe food and water practices""}"	{}	"{""description"": ""Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel."", ""evidence"": [{""explanation"": ""Study shows pre-travel counseling improves knowledge about travelers diarrhea prevention, underscoring value of education."", ""reference"": ""PMID:39453259"", ""snippet"": ""The EG/post-consultation group showed significant improvement in knowledge, with correct answers increasing from 63% to 75%... knowledge gaps persisted... indicating the need for targeted interventions to increase travelers' literacy and optimize pre-travel consultations."", ""supports"": ""SUPPORT""}, {""explanation"": ""Pharmacy guidance resource supports counseling travelers on prevention and treatment choices."", ""reference"": ""PMID:40035303"", ""snippet"": ""Traveling abroad carries the risk of traveler's diarrhea, which affects 20 to 50% of individuals. This article focuses on the definition, classification, epidemiology, etiology, prevention, and treatment management of traveler's diarrhea. It also describes recommendations for patients traveling to higher-risk areas, which can be used by pharmacists in counceling activities in the pharmacy."", ""supports"": ""SUPPORT""}], ""name"": ""Education on safe food and water practices"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.																																																								"{""description"": ""Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure."", ""name"": ""Rifaximin prophylaxis""}"	{}	"{""description"": ""Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure."", ""evidence"": [{""explanation"": ""Network meta-analysis shows rifaximin prophylaxis significantly reduces travelers diarrhea incidence compared with placebo and probiotics."", ""reference"": ""PMID:36221413"", ""snippet"": ""Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63), and rifaximin was more effective than probiotics (RR 0.56, 95% CI 0.4-0.78)."", ""supports"": ""SUPPORT""}], ""name"": ""Rifaximin prophylaxis"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7559	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	0	Neoadjuvant Chemotherapy	Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes.																																																								"{""description"": ""Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes."", ""name"": ""Neoadjuvant Chemotherapy""}"	{}	"{""description"": ""Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes."", ""evidence"": [{""explanation"": ""Meta-analysis confirms that achieving pCR after neoadjuvant therapy is strongly associated with improved event-free survival, particularly for TNBC."", ""reference"": ""PMID:32046998"", ""snippet"": ""Patients with a pCR after NAT had significantly better EFS (HR = 0.31; 95% PI, 0.24-0.39), particularly for triple-negative (HR = 0.18; 95% PI, 0.10-0.31) and HER2+ (HR = 0.32; 95% PI, 0.21-0.47) disease."", ""supports"": ""SUPPORT""}], ""name"": ""Neoadjuvant Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
7560	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	1	Pembrolizumab Plus Chemotherapy	PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status.																																																								"{""description"": ""PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status."", ""name"": ""Pembrolizumab Plus Chemotherapy""}"	{}	"{""description"": ""PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status."", ""evidence"": [{""explanation"": ""KEYNOTE-522 demonstrated significantly higher pCR rates with pembrolizumab plus chemotherapy versus chemotherapy alone in early TNBC."", ""reference"": ""PMID:32101663"", ""snippet"": ""Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Pembrolizumab Plus Chemotherapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7561	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	2	PARP Inhibitors	Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks.																																																								"{""description"": ""Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks."", ""name"": ""PARP Inhibitors""}"	{}	"{""description"": ""Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks."", ""evidence"": [{""explanation"": ""Review confirms PARP inhibitors cause synthetic lethality in BRCA-mutated breast cancers and are standard of care for metastatic disease."", ""reference"": ""PMID:33475295"", ""snippet"": ""PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer."", ""supports"": ""SUPPORT""}], ""name"": ""PARP Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7562	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	3	Sacituzumab Govitecan	Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial.																																																								"{""description"": ""Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial."", ""name"": ""Sacituzumab Govitecan""}"	{}	"{""description"": ""Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial."", ""evidence"": [{""explanation"": ""ASCENT trial demonstrated significant PFS and OS benefit with sacituzumab govitecan versus chemotherapy in metastatic TNBC."", ""reference"": ""PMID:33882206"", ""snippet"": ""Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer."", ""supports"": ""SUPPORT""}], ""name"": ""Sacituzumab Govitecan"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7563	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	4	Platinum Chemotherapy	Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.																																																								"{""description"": ""Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes."", ""name"": ""Platinum Chemotherapy""}"	{}	"{""description"": ""Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes."", ""evidence"": [{""explanation"": ""Basal-like TNBC subtypes with DNA damage response gene expression preferentially respond to platinum chemotherapy."", ""reference"": ""PMID:21633166"", ""snippet"": ""BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin."", ""supports"": ""SUPPORT""}], ""name"": ""Platinum Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}}"
7596	331	Tuberculosis	Tuberculosis.yaml	treatments	0	Isoniazid	First-line antibiotic for TB treatment.																																		It's important to note that resistance to isoniazid can develop through mutations in the katG gene, which reduces the activation of the drug, or in the inhA gene, which decreases the binding affinity of the activated drug to the InhA enzyme. To minimize the risk of resistance, isoniazid is typically used in combination with other antitubercular drugs, such as rifampicin, ethambutol, and pyrazinamide.																						"{""description"": ""First-line antibiotic for TB treatment."", ""name"": ""Isoniazid"", ""notes"": ""It's important to note that resistance to isoniazid can develop through mutations in the katG gene, which reduces the activation of the drug, or in the inhA gene, which decreases the binding affinity of the activated drug to the InhA enzyme. To minimize the risk of resistance, isoniazid is typically used in combination with other antitubercular drugs, such as rifampicin, ethambutol, and pyrazinamide.""}"	"{""mechanism"": [{""description"": ""Isoniazid is a prodrug that requires activation by the bacterial enzyme catalase-peroxidase (KatG). KatG couples the isonicotinic acyl with NADH to form an isonicotinic acyl-NADH complex."", ""name"": ""Prodrug Activation""}, {""description"": ""The activated form of isoniazid binds to and inhibits the enoyl-acyl carrier protein reductase (InhA), an enzyme involved in the fatty acid synthase II (FAS-II) pathway. This pathway is essential for the synthesis of mycolic acids."", ""name"": ""Inhibition of InhA""}, {""description"": ""By inhibiting InhA, isoniazid prevents the synthesis of mycolic acids, which are long-chain fatty acids that make up a significant portion of the mycobacterial cell wall. Mycolic acids provide structural integrity and help the bacteria resist the host's immune response."", ""name"": ""Depletion of mycolic acids""}, {""description"": ""The depletion of mycolic acids leads to the weakening and disruption of the bacterial cell wall. This makes the bacteria more susceptible to the host's immune defenses and other antibiotics."", ""name"": ""Cell wall disruption""}, {""description"": ""In addition to inhibiting mycolic acid synthesis, the isoniazid-NAD adduct can also generate reactive oxygen species (ROS) and nitric oxide (NO) within the bacteria. These reactive species can cause damage to various bacterial components, including DNA, proteins, and lipids, contributing to the bactericidal effect."", ""name"": ""Reactive oxygen species""}, {""description"": ""The combination of cell wall disruption and the production of reactive oxygen and nitrogen species ultimately leads to the death of the M. tuberculosis bacteria."", ""name"": ""Bactericidal action""}]}"	"{""description"": ""First-line antibiotic for TB treatment."", ""evidence"": [{""explanation"": ""The description of Isoniazid as a first-line antibiotic for TB treatment and its activation by the KatG enzyme is supported. This aligns with the provided mechanism of prodrug activation."", ""reference"": ""PMID:33106268"", ""snippet"": ""Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The inhibition of mycolic acid biosynthesis by Isoniazid aligns with the described mechanism of action in the statement."", ""reference"": ""PMID:12164478"", ""snippet"": ""The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan."", ""supports"": ""SUPPORT""}], ""mechanism"": [{""description"": ""Isoniazid is a prodrug that requires activation by the bacterial enzyme catalase-peroxidase (KatG). KatG couples the isonicotinic acyl with NADH to form an isonicotinic acyl-NADH complex."", ""name"": ""Prodrug Activation""}, {""description"": ""The activated form of isoniazid binds to and inhibits the enoyl-acyl carrier protein reductase (InhA), an enzyme involved in the fatty acid synthase II (FAS-II) pathway. This pathway is essential for the synthesis of mycolic acids."", ""name"": ""Inhibition of InhA""}, {""description"": ""By inhibiting InhA, isoniazid prevents the synthesis of mycolic acids, which are long-chain fatty acids that make up a significant portion of the mycobacterial cell wall. Mycolic acids provide structural integrity and help the bacteria resist the host's immune response."", ""name"": ""Depletion of mycolic acids""}, {""description"": ""The depletion of mycolic acids leads to the weakening and disruption of the bacterial cell wall. This makes the bacteria more susceptible to the host's immune defenses and other antibiotics."", ""name"": ""Cell wall disruption""}, {""description"": ""In addition to inhibiting mycolic acid synthesis, the isoniazid-NAD adduct can also generate reactive oxygen species (ROS) and nitric oxide (NO) within the bacteria. These reactive species can cause damage to various bacterial components, including DNA, proteins, and lipids, contributing to the bactericidal effect."", ""name"": ""Reactive oxygen species""}, {""description"": ""The combination of cell wall disruption and the production of reactive oxygen and nitrogen species ultimately leads to the death of the M. tuberculosis bacteria."", ""name"": ""Bactericidal action""}], ""name"": ""Isoniazid"", ""notes"": ""It's important to note that resistance to isoniazid can develop through mutations in the katG gene, which reduces the activation of the drug, or in the inhA gene, which decreases the binding affinity of the activated drug to the InhA enzyme. To minimize the risk of resistance, isoniazid is typically used in combination with other antitubercular drugs, such as rifampicin, ethambutol, and pyrazinamide."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	Rifampicin	Bactericidal antibiotic used for TB treatment.																																		Rifampicin is a broad-spectrum antibiotic that is particularly effective against mycobacteria, including M. tuberculosis, as it can easily penetrate the lipid-rich cell wall.																						"{""description"": ""Bactericidal antibiotic used for TB treatment."", ""name"": ""Rifampicin"", ""notes"": ""Rifampicin is a broad-spectrum antibiotic that is particularly effective against mycobacteria, including M. tuberculosis, as it can easily penetrate the lipid-rich cell wall.""}"	"{""mechanism"": [{""description"": ""Rifampicin binds to the beta subunit of DNA-dependent RNA polymerase, preventing the initiation of RNA synthesis."", ""name"": ""Inhibition of bacterial RNA polymerase""}, {""description"": ""By inhibiting RNA polymerase, rifampicin disrupts bacterial transcription, which is essential for protein synthesis and bacterial survival."", ""name"": ""Disruption of bacterial transcription""}]}"	"{""description"": ""Bactericidal antibiotic used for TB treatment."", ""evidence"": [{""explanation"": ""This reference explains that Rifampicin is a key component of anti-tuberculosis therapy due to its inhibition of bacterial RNA polymerase."", ""reference"": ""PMID:11290327"", ""snippet"": ""Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that rifampicin is used for the treatment of TB."", ""reference"": ""PMID:27553018"", ""snippet"": ""For the treatment of TB, administration of multiple antibiotics such as isoniazid, rifampicin, pyrazinamide, and ethambutol is required for a long period of time to kill bacteria."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by confirming that Rifamycins, including rifampicin, exhibit bactericidal activity by inhibiting RNA polymerase."", ""reference"": ""PMID:34400805"", ""snippet"": ""Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference affirms the mechanism of rifampicin targeting RNA polymerase, which validates its use in TB treatment."", ""reference"": ""PMID:33199626"", ""snippet"": ""Rif targets the enzyme RNA polymerase (RNAP)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the use of rifampicin (a Rifamycin antibiotic) for TB treatment due to its sterilizing activity against Mycobacterium tuberculosis."", ""reference"": ""PMID:28803492"", ""snippet"": ""Rifamycin antibiotics, like rifampin and rifapentine, have unique sterilizing activity against M.tb."", ""supports"": ""SUPPORT""}], ""mechanism"": [{""description"": ""Rifampicin binds to the beta subunit of DNA-dependent RNA polymerase, preventing the initiation of RNA synthesis."", ""name"": ""Inhibition of bacterial RNA polymerase""}, {""description"": ""By inhibiting RNA polymerase, rifampicin disrupts bacterial transcription, which is essential for protein synthesis and bacterial survival."", ""name"": ""Disruption of bacterial transcription""}], ""name"": ""Rifampicin"", ""notes"": ""Rifampicin is a broad-spectrum antibiotic that is particularly effective against mycobacteria, including M. tuberculosis, as it can easily penetrate the lipid-rich cell wall."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7598	331	Tuberculosis	Tuberculosis.yaml	treatments	2	Ethambutol	Bacteriostatic antibiotic used for TB treatment.																																		Ethambutol is specific to mycobacteria and is often used in combination with other antitubercular drugs to prevent the emergence of drug resistance.																						"{""description"": ""Bacteriostatic antibiotic used for TB treatment."", ""name"": ""Ethambutol"", ""notes"": ""Ethambutol is specific to mycobacteria and is often used in combination with other antitubercular drugs to prevent the emergence of drug resistance.""}"	"{""mechanism"": [{""description"": ""Ethambutol interferes with the biosynthesis of arabinogalactan, a key component of the mycobacterial cell wall."", ""name"": ""Inhibition of arabinogalactan synthesis""}, {""description"": ""Ethambutol inhibits the enzyme arabinosyl transferase, which is responsible for the polymerization of arabinose into arabinan, a precursor of arabinogalactan."", ""name"": ""Inhibition of arabinosyl transferase""}, {""description"": ""By disrupting the synthesis of arabinogalactan, ethambutol compromises the integrity of the cell wall, making the bacteria more susceptible to host defenses and other antibiotics."", ""name"": ""Compromised cell wall integrity""}]}"	"{""description"": ""Bacteriostatic antibiotic used for TB treatment."", ""evidence"": [{""explanation"": ""The literature states that ethambutol interferes with the biosynthesis of arabinogalactan, supporting the mechanism described in the statement."", ""reference"": ""PMID:16209089"", ""snippet"": ""Ethambutol (EMB), the first line drug in the treatment of tuberculosis, is an inhibitor of the biosynthesis of the cell wall compound - arabinogalactan."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement specifies ethambutol as a bacteriostatic antibiotic used for TB treatment, whereas this reference talks about isoniazid. It is partially relevant since ethambutol is also an antituberculosis drug, but this reference does not fully address ethambutol's function."", ""reference"": ""PMID:9949810"", ""snippet"": ""Isoniazid is the most widely used antituberculosis drug."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference confirms that ethambutol is used in combination with other antitubercular drugs, aligning with the notes in the statement about preventing the emergence of drug resistance."", ""reference"": ""PMID:37289062"", ""snippet"": ""In combination with TB antibiotics, wollamide B1 synergistically enhances the activity of several antibiotics... and wollamide B1 did not compromise the antimycobacterial activity of the isoniazid/rifampicin/ethambutol combination."", ""supports"": ""SUPPORT""}], ""mechanism"": [{""description"": ""Ethambutol interferes with the biosynthesis of arabinogalactan, a key component of the mycobacterial cell wall."", ""name"": ""Inhibition of arabinogalactan synthesis""}, {""description"": ""Ethambutol inhibits the enzyme arabinosyl transferase, which is responsible for the polymerization of arabinose into arabinan, a precursor of arabinogalactan."", ""name"": ""Inhibition of arabinosyl transferase""}, {""description"": ""By disrupting the synthesis of arabinogalactan, ethambutol compromises the integrity of the cell wall, making the bacteria more susceptible to host defenses and other antibiotics."", ""name"": ""Compromised cell wall integrity""}], ""name"": ""Ethambutol"", ""notes"": ""Ethambutol is specific to mycobacteria and is often used in combination with other antitubercular drugs to prevent the emergence of drug resistance."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7599	331	Tuberculosis	Tuberculosis.yaml	treatments	3	Directly Observed Therapy (DOT)	Health worker observes and records patients taking their medication to ensure adherence.																																																								"{""description"": ""Health worker observes and records patients taking their medication to ensure adherence."", ""name"": ""Directly Observed Therapy (DOT)""}"	{}	"{""description"": ""Health worker observes and records patients taking their medication to ensure adherence."", ""evidence"": [{""explanation"": ""The abstract clearly states that DOT involves someone directly observing patients taking their antituberculous drugs to ensure adherence."", ""reference"": ""PMID:17943789"", ""snippet"": ""Directly observed therapy (DOT), which involves people directly observing patients taking their antituberculous drugs."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract indicates that DOTS is endorsed by WHO as a method to ensure patients adhere to TB treatment."", ""reference"": ""PMID:29461901"", ""snippet"": ""The World Health Organization (WHO) propagates Directly Observed Therapy Short-course (DOTS) as an effective way to stop the spread of TB in communities with a high burden."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract reinforces the involvement of a health worker in observing DOT, even if it's flexible to involve family members."", ""reference"": ""PMID:28410705"", ""snippet"": ""A flexible, patient centered approach were a family member can act as the DOT provider with guidance from a trained health worker was evolved as the most acceptable and comfortable mode of treatment to majority of the TB patients"", ""supports"": ""SUPPORT""}, {""explanation"": ""Emphasizes DOT as a standard practice to ensure compliance by observing the patient directly."", ""reference"": ""PMID:27598709"", ""snippet"": ""To best ensure compliance, directly observed therapy (DOT) is considered the standard of practice."", ""supports"": ""SUPPORT""}], ""name"": ""Directly Observed Therapy (DOT)"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7600	331	Tuberculosis	Tuberculosis.yaml	treatments	4	Latent TB Treatment	Isoniazid or rifapentine used to prevent latent TB from becoming active.																																																								"{""description"": ""Isoniazid or rifapentine used to prevent latent TB from becoming active."", ""name"": ""Latent TB Treatment""}"	{}	"{""description"": ""Isoniazid or rifapentine used to prevent latent TB from becoming active."", ""evidence"": [{""explanation"": ""This source supports the statement mentioning that a regimen of isoniazid and rifapentine is used for latent TB infection."", ""reference"": ""PMID:29910114"", ""snippet"": ""The 3-month isoniazid-rifapentine regimen is as safe and effective as other recommended latent tuberculosis infection regimens and achieves significantly higher treatment completion rates."", ""supports"": ""SUPPORT""}, {""explanation"": ""This source supports the use of isoniazid for the prevention of latent tuberculosis infection (LTBI)."", ""reference"": ""PMID:19496388"", ""snippet"": ""The treatment of choice for LTBI is isoniazid for nine months."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the statement by specifying that WHO recommends isoniazid and rifapentine for the treatment of latent tuberculosis infections."", ""reference"": ""PMID:32551948"", ""snippet"": ""The World Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine to treat latent tuberculosis infections."", ""supports"": ""SUPPORT""}], ""name"": ""Latent TB Treatment"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7601	331	Tuberculosis	Tuberculosis.yaml	treatments	5	Host-Directed Therapy	Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.																																		Emerging therapeutic approaches include autophagy inducers, anti-inflammatory agents targeting excessive NET formation or inflammasome activation, and lipid metabolism modulators to limit foamy macrophage formation and bacterial persistence.																						"{""description"": ""Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics."", ""name"": ""Host-Directed Therapy"", ""notes"": ""Emerging therapeutic approaches include autophagy inducers, anti-inflammatory agents targeting excessive NET formation or inflammasome activation, and lipid metabolism modulators to limit foamy macrophage formation and bacterial persistence.""}"	{}	"{""description"": ""Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics."", ""name"": ""Host-Directed Therapy"", ""notes"": ""Emerging therapeutic approaches include autophagy inducers, anti-inflammatory agents targeting excessive NET formation or inflammasome activation, and lipid metabolism modulators to limit foamy macrophage formation and bacterial persistence."", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7633	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	0	Metformin	First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity.																																																								"{""description"": ""First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity."", ""name"": ""Metformin""}"	{}	"{""description"": ""First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity."", ""name"": ""Metformin"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7634	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	1	Lifestyle Modification	Diet and exercise interventions to reduce weight and improve metabolic health.																																																								"{""description"": ""Diet and exercise interventions to reduce weight and improve metabolic health."", ""name"": ""Lifestyle Modification""}"	{}	"{""description"": ""Diet and exercise interventions to reduce weight and improve metabolic health."", ""name"": ""Lifestyle Modification"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
7635	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	2	GLP-1 Receptor Agonists	Injectable medications that enhance insulin secretion and promote weight loss.																																																								"{""description"": ""Injectable medications that enhance insulin secretion and promote weight loss."", ""name"": ""GLP-1 Receptor Agonists""}"	{}	"{""description"": ""Injectable medications that enhance insulin secretion and promote weight loss."", ""evidence"": [{""explanation"": ""This establishes GLP-1/GIP receptor agonists as effective pharmacological strategies for T2D treatment."", ""reference"": ""PMID:38831203"", ""snippet"": ""Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge."", ""supports"": ""SUPPORT""}], ""name"": ""GLP-1 Receptor Agonists"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7636	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	3	SGLT2 Inhibitors	Oral medications that increase urinary glucose excretion.																																																								"{""description"": ""Oral medications that increase urinary glucose excretion."", ""name"": ""SGLT2 Inhibitors""}"	{}	"{""description"": ""Oral medications that increase urinary glucose excretion."", ""name"": ""SGLT2 Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7637	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	4	Insulin Therapy	Required when beta cell function declines significantly.																																																								"{""description"": ""Required when beta cell function declines significantly."", ""name"": ""Insulin Therapy""}"	{}	"{""description"": ""Required when beta cell function declines significantly."", ""name"": ""Insulin Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7638	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	5	GLP-1/GIP Dual Agonists	Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss.																																																								"{""description"": ""Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss."", ""name"": ""GLP-1/GIP Dual Agonists""}"	{}	"{""description"": ""Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss."", ""evidence"": [{""explanation"": ""This confirms tirzepatide as an authorized dual GLP-1/GIP agonist for T2D and obesity treatment."", ""reference"": ""PMID:38831203"", ""snippet"": ""Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity."", ""supports"": ""SUPPORT""}], ""name"": ""GLP-1/GIP Dual Agonists"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	Insulin Therapy	Essential treatment to replace the missing insulin and regulate blood glucose levels.																																																								"{""description"": ""Essential treatment to replace the missing insulin and regulate blood glucose levels."", ""name"": ""Insulin Therapy""}"	{}	"{""description"": ""Essential treatment to replace the missing insulin and regulate blood glucose levels."", ""evidence"": [{""reference"": ""PMID:21584767"", ""snippet"": ""Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:36476434"", ""snippet"": ""The current standard method for type 1 diabetes (T1D) management majorly focuses on controlling blood glucose levels with exogeneous insulin administration."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:32342453"", ""snippet"": ""T1DM is caused by absolute lack of insulin secretion, so the current treatment for T1DM patients is exogenous insulin replacement therapy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference lacks specific details pertaining to treatment."", ""reference"": ""PMID:20723814"", ""snippet"": """", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The reference acknowledges insulin therapy but focuses more on technological advancements rather than confirming insulin therapy as the essential treatment."", ""reference"": ""PMID:31426099"", ""snippet"": ""Although a cure for T1D remains the ultimate goal, technology holds the promise of keeping youth with T1D in targeted control and minimize the burden of this chronic medical condition."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference discusses auxiliary therapy but does not diminish the essential role of insulin therapy."", ""reference"": ""PMID:28685788"", ""snippet"": ""Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications."", ""supports"": ""PARTIAL""}, {""reference"": ""PMID:33970586"", ""snippet"": ""The mainstay of management is a regimen of multiple daily injections of insulin or continuous subcutaneous insulin delivered via an insulin pump."", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:15306833"", ""snippet"": ""There is, however, a limit to what can be achieved with existing exogenous insulin therapies due to their imperfect pharmacokinetic and pharmacodynamic profiles"", ""supports"": ""SUPPORT""}, {""reference"": ""PMID:6749365"", ""snippet"": ""The results of epidemiological and clinical studies of diabetes in man and of studies of experimental diabetes in animals provide strong evidence: (1) that insulin-dependent diabetes mellitus is due to absolute or severe deficiency of insulin; (2) that replacement treatment with insulin is potentially capable of normalizing the metabolic abnormalities; and (3) that normalization of the metabolic abnormalities can be expected to prevent or ameliorate the complications of the disease"", ""supports"": ""SUPPORT""}, {""explanation"": ""The focus on insulin as primary treatment supports the statement, despite mentioning new therapeutic options."", ""reference"": ""PMID:20666700"", ""snippet"": ""Insulin is the primary medication in the treatment of type 1 diabetes. New therapeutic options and prevention strategies (cellular therapies, immunomodulation and vaccination) aim to preserve residual beta-cell function."", ""supports"": ""PARTIAL""}], ""name"": ""Insulin Therapy"", ""treatment_term"": {""preferred_term"": ""insulin treatment"", ""term"": {""id"": ""MAXO:0000259"", ""label"": ""insulin treatment""}}}"
7684	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	1	Blood Glucose Monitoring	Regular monitoring to manage glucose levels effectively.																																																								"{""description"": ""Regular monitoring to manage glucose levels effectively."", ""name"": ""Blood Glucose Monitoring""}"	{}	"{""description"": ""Regular monitoring to manage glucose levels effectively."", ""evidence"": [{""explanation"": ""The abstract emphasizes the importance of glucose monitoring in managing type 1 diabetes, supporting the statement that regular monitoring is crucial for effective glucose level management."", ""reference"": ""PMID:30215903"", ""snippet"": ""There is considerable benefit of tight glucose control in patients with type 1 diabetes mellitus. ... Greater frequency of glucose monitoring and continuous glucose monitoring are both associated with lower A1C levels."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract reaffirms that regular monitoring of blood glucose is essential for managing type 1 diabetes, supporting the statement."", ""reference"": ""PMID:32256447"", ""snippet"": ""Regular self-monitoring of blood glucose levels, and ketones when indicated, is an essential component of type 1 diabetes (T1D) management."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract describes blood glucose monitoring as a cornerstone in diabetes treatment, which includes the management of type 1 diabetes, thus supporting the statement."", ""reference"": ""PMID:38551884"", ""snippet"": ""Blood glucose monitoring has been an integral part of diabetes treatment for many years, whether for type 1 diabetic patients on multiple daily injections of insulin, insulin pumps or artificial pancreas, and now for patients with type 2 diabetes..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract highlights that during illness, increased blood glucose monitoring is necessary for managing type 1 diabetes, further supporting the statement about regular monitoring."", ""reference"": ""PMID:11149158"", ""snippet"": ""Sick-day management requires increased monitoring of blood glucose and assessment for ketosis."", ""supports"": ""SUPPORT""}], ""name"": ""Blood Glucose Monitoring""}"
7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	Lifestyle Modifications	Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.																																																								"{""description"": ""Maintaining a balanced diet, regular physical activity, and adherence to treatment plans."", ""name"": ""Lifestyle Modifications""}"	{}	"{""description"": ""Maintaining a balanced diet, regular physical activity, and adherence to treatment plans."", ""evidence"": [{""explanation"": ""The text supports the assertion that maintaining a balanced diet and regular physical activity can assist in managing diabetes through lifestyle modifications."", ""reference"": ""PMID:9314011"", ""snippet"": ""Nutrition therapy and physical activity can assist persons with diabetes to achieve metabolic goals. Several lifestyle strategies can be used."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the statement that lifestyle modifications, including diet and physical activity, are important in managing type 1 diabetes."", ""reference"": ""PMID:16529680"", ""snippet"": ""The patient and physician must work together to optimize glucose control involving both insulin administration and caloric intake. Exercise has numerous benefits and the type 1 diabetic should take advantage of these benefits."", ""supports"": ""SUPPORT""}, {""explanation"": ""The text underlines the significance of maintaining a good lifestyle, including a balanced diet and physical activity, as part of diabetes management."", ""reference"": ""PMID:24485215"", ""snippet"": ""Poor lifestyle habits (poor diet quality, sedentary behaviours and smoking) are known to be driving factors for increased CMR factors in the general population."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights the role of lifestyle modifications in managing type 1 diabetes through controlling blood glucose levels."", ""reference"": ""PMID:32312302"", ""snippet"": ""Innovative, cost-effective interventions along with beneficial lifestyle modifications can improve home-based self-monitoring of blood glucose in T1D patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""It mentions lifestyle interventions as a part of weight loss treatments that benefit T1D management, highlighting their efficacy and safety."", ""reference"": ""PMID:37820077"", ""snippet"": ""Weight loss treatments provide a wide-range of benefits in reducing both morbidity and mortality in those who are obese."", ""supports"": ""SUPPORT""}], ""name"": ""Lifestyle Modifications"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
7686	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	3	Immunotherapy (Teplizumab)	T-cell-targeting therapy that delays progression from stage 2 to stage 3 disease by approximately 2-3 years in early-stage patients.																																		FDA-approved 2022 for delaying clinical onset in presymptomatic individuals																						"{""description"": ""T-cell-targeting therapy that delays progression from stage 2 to stage 3 disease by approximately 2-3 years in early-stage patients."", ""name"": ""Immunotherapy (Teplizumab)"", ""notes"": ""FDA-approved 2022 for delaying clinical onset in presymptomatic individuals""}"	{}	"{""description"": ""T-cell-targeting therapy that delays progression from stage 2 to stage 3 disease by approximately 2-3 years in early-stage patients."", ""evidence"": [{""explanation"": ""This article documents the FDA approval of teplizumab as the first immunotherapy for delaying type 1 diabetes progression."", ""reference"": ""PMID:36877454"", ""snippet"": ""In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D"", ""supports"": ""SUPPORT""}], ""name"": ""Immunotherapy (Teplizumab)"", ""notes"": ""FDA-approved 2022 for delaying clinical onset in presymptomatic individuals""}"
7687	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	4	Continuous Glucose Monitoring	Real-time glucose monitoring systems for improved glycemic control and reduced hypoglycemic events.																																		Associated with lower HbA1c levels and improved time in range																						"{""description"": ""Real-time glucose monitoring systems for improved glycemic control and reduced hypoglycemic events."", ""name"": ""Continuous Glucose Monitoring"", ""notes"": ""Associated with lower HbA1c levels and improved time in range""}"	{}	"{""description"": ""Real-time glucose monitoring systems for improved glycemic control and reduced hypoglycemic events."", ""evidence"": [{""explanation"": ""This population-based study demonstrates that continuous glucose monitoring significantly improves glycemic control with sustained improvements in HbA1c target achievement."", ""reference"": ""PMID:34872983"", ""snippet"": ""After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months"", ""supports"": ""SUPPORT""}], ""name"": ""Continuous Glucose Monitoring"", ""notes"": ""Associated with lower HbA1c levels and improved time in range""}"
7720	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	0	5-Aminosalicylates	First-line for mild-moderate disease (mesalamine).																																																								"{""description"": ""First-line for mild-moderate disease (mesalamine)."", ""name"": ""5-Aminosalicylates""}"	{}	"{""description"": ""First-line for mild-moderate disease (mesalamine)."", ""name"": ""5-Aminosalicylates""}"
7721	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	1	Corticosteroids	For acute flares (prednisone, budesonide).																																																								"{""description"": ""For acute flares (prednisone, budesonide)."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""For acute flares (prednisone, budesonide)."", ""name"": ""Corticosteroids""}"
7722	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	2	Thiopurines	Azathioprine, 6-MP for maintenance.																																																								"{""description"": ""Azathioprine, 6-MP for maintenance."", ""name"": ""Thiopurines""}"	{}	"{""description"": ""Azathioprine, 6-MP for maintenance."", ""name"": ""Thiopurines""}"
7723	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	3	Anti-TNF Therapy	Infliximab, adalimumab for moderate-severe disease.																																																								"{""description"": ""Infliximab, adalimumab for moderate-severe disease."", ""name"": ""Anti-TNF Therapy""}"	{}	"{""description"": ""Infliximab, adalimumab for moderate-severe disease."", ""name"": ""Anti-TNF Therapy""}"
7724	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	4	Vedolizumab	Gut-selective integrin inhibitor.																																																								"{""description"": ""Gut-selective integrin inhibitor."", ""name"": ""Vedolizumab""}"	{}	"{""description"": ""Gut-selective integrin inhibitor."", ""name"": ""Vedolizumab""}"
7725	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	5	Tofacitinib	JAK inhibitor for moderate-severe disease.																																																								"{""description"": ""JAK inhibitor for moderate-severe disease."", ""name"": ""Tofacitinib""}"	{}	"{""description"": ""JAK inhibitor for moderate-severe disease."", ""name"": ""Tofacitinib""}"
7726	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	6	Ustekinumab	IL-12/23 inhibitor.																																																								"{""description"": ""IL-12/23 inhibitor."", ""name"": ""Ustekinumab""}"	{}	"{""description"": ""IL-12/23 inhibitor."", ""name"": ""Ustekinumab""}"
7727	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	treatments	7	Colectomy	Curative surgery for refractory or complicated disease.																																																								"{""description"": ""Curative surgery for refractory or complicated disease."", ""name"": ""Colectomy""}"	{}	"{""description"": ""Curative surgery for refractory or complicated disease."", ""name"": ""Colectomy""}"
7746	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	0	Tebentafusp	Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01 on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells. First systemic therapy to improve overall survival in metastatic uveal melanoma. Requires HLA-A*02:01 positive status (approximately 50% of patients).																																																								"{""description"": ""Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01 on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells. First systemic therapy to improve overall survival in metastatic uveal melanoma. Requires HLA-A*02:01 positive status (approximately 50% of patients)."", ""name"": ""Tebentafusp""}"	{}	"{""description"": ""Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01 on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells. First systemic therapy to improve overall survival in metastatic uveal melanoma. Requires HLA-A*02:01 positive status (approximately 50% of patients)."", ""name"": ""Tebentafusp"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7747	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	1	Plaque Brachytherapy	Radiation therapy using radioactive plaque sutured to the sclera overlying the tumor. First-line local therapy for many uveal melanomas, achieving excellent local control while preserving the eye in most cases.																																																								"{""description"": ""Radiation therapy using radioactive plaque sutured to the sclera overlying the tumor. First-line local therapy for many uveal melanomas, achieving excellent local control while preserving the eye in most cases."", ""name"": ""Plaque Brachytherapy""}"	{}	"{""description"": ""Radiation therapy using radioactive plaque sutured to the sclera overlying the tumor. First-line local therapy for many uveal melanomas, achieving excellent local control while preserving the eye in most cases."", ""name"": ""Plaque Brachytherapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
7748	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	2	Enucleation	Surgical removal of the eye. Indicated for large tumors, those with optic nerve involvement, or when vision cannot be preserved. Provides excellent local control but does not prevent metastatic disease.																																																								"{""description"": ""Surgical removal of the eye. Indicated for large tumors, those with optic nerve involvement, or when vision cannot be preserved. Provides excellent local control but does not prevent metastatic disease."", ""name"": ""Enucleation""}"	{}	"{""description"": ""Surgical removal of the eye. Indicated for large tumors, those with optic nerve involvement, or when vision cannot be preserved. Provides excellent local control but does not prevent metastatic disease."", ""name"": ""Enucleation"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7749	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma compared to cutaneous melanoma, with response rates of approximately 5-10%. The immunologically cold tumor microenvironment may contribute to this resistance.																																																								"{""description"": ""Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma compared to cutaneous melanoma, with response rates of approximately 5-10%. The immunologically cold tumor microenvironment may contribute to this resistance."", ""name"": ""Immune Checkpoint Inhibitors""}"	{}	"{""description"": ""Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma compared to cutaneous melanoma, with response rates of approximately 5-10%. The immunologically cold tumor microenvironment may contribute to this resistance."", ""name"": ""Immune Checkpoint Inhibitors"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7762	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	0	Lamotrigine	Anticonvulsant that may reduce symptoms in some patients by reducing cortical hyperexcitability. Provides partial relief in approximately 20% of patients.																																																								"{""description"": ""Anticonvulsant that may reduce symptoms in some patients by reducing cortical hyperexcitability. Provides partial relief in approximately 20% of patients."", ""name"": ""Lamotrigine""}"	{}	"{""description"": ""Anticonvulsant that may reduce symptoms in some patients by reducing cortical hyperexcitability. Provides partial relief in approximately 20% of patients."", ""evidence"": [{""explanation"": ""Lamotrigine provides partial symptom relief in about 19% of patients, though complete remission is rare."", ""reference"": ""PMID:31213497"", ""snippet"": ""Lamotrigine was prescribed most frequently (26/58) and resulted in partial remission of symptoms in 5/26 (19.2%). No patients reported complete remission."", ""supports"": ""SUPPORT""}, {""explanation"": ""Systematic review confirms lamotrigine has the best evidence for effectiveness in VSS."", ""reference"": ""PMID:33008511"", ""snippet"": ""The best data is available for lamotrigine being effective in 8/36 (22.2%, including one total response and no worsening), followed by topiramate being effective in 2/13 (15.4%, no total response and one worsening)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Recent 2025 review shows lamotrigine among the most effective pharmacological treatments."", ""reference"": ""PMID:40129600"", ""snippet"": ""benzodiazepines and lamotrigine had the best effect (71.4% and 61.5% of patients had an improvement of VS symptoms on each medication, respectively)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Expert recommendations support lamotrigine as a first-line pharmacological option."", ""reference"": ""PMID:28349350"", ""snippet"": ""Our preferred treatment options include: (1) oral lamotrigine with a slow increase from 25 mg daily to a maintenance dose of 200-300 mg daily in divided doses as tolerated"", ""supports"": ""SUPPORT""}], ""name"": ""Lamotrigine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7763	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	1	Tinted Lenses	FL-41 tinted lenses and chromatic filters may provide symptom relief in some patients.																																																								"{""description"": ""FL-41 tinted lenses and chromatic filters may provide symptom relief in some patients."", ""name"": ""Tinted Lenses""}"	{}	"{""description"": ""FL-41 tinted lenses and chromatic filters may provide symptom relief in some patients."", ""evidence"": [{""explanation"": ""Chromatic filters are identified as a promising nonpharmacological treatment option."", ""reference"": ""PMID:38465699"", ""snippet"": ""Promising nonpharmacological treatments include mindfulness-based cognitive therapy, the use of chromatic filters, and research on visual noise adaption and neuro-optometric visual rehabilitation therapy (NORT)."", ""supports"": ""SUPPORT""}, {""explanation"": ""FL-41 tinted lenses consistently provide symptom relief in VSS patients."", ""reference"": ""PMID:40129600"", ""snippet"": ""FL-41 tinted lenses consistently provide symptom relief, with cognitive behavioral therapy showing promise as an emerging intervention."", ""supports"": ""SUPPORT""}, {""explanation"": ""Color filters in the yellow-blue spectrum may provide benefit for some VSS patients."", ""reference"": ""PMID:33008511"", ""snippet"": ""The nonpharmacological approach using color filters of the yellow-blue color spectrum might also be helpful in some patients."", ""supports"": ""SUPPORT""}], ""name"": ""Tinted Lenses""}"
7764	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	2	Cognitive Behavioral Therapy	Psychological intervention that may help patients cope with symptoms and improve quality of life.																																																								"{""description"": ""Psychological intervention that may help patients cope with symptoms and improve quality of life."", ""name"": ""Cognitive Behavioral Therapy""}"	{}	"{""description"": ""Psychological intervention that may help patients cope with symptoms and improve quality of life."", ""evidence"": [{""explanation"": ""CBT shows promise as an emerging intervention for VSS."", ""reference"": ""PMID:40129600"", ""snippet"": ""FL-41 tinted lenses consistently provide symptom relief, with cognitive behavioral therapy showing promise as an emerging intervention."", ""supports"": ""SUPPORT""}, {""explanation"": ""Mindfulness-based cognitive therapy is identified as a promising treatment approach."", ""reference"": ""PMID:38465699"", ""snippet"": ""Promising nonpharmacological treatments include mindfulness-based cognitive therapy, the use of chromatic filters, and research on visual noise adaption and neuro-optometric visual rehabilitation therapy (NORT)."", ""supports"": ""SUPPORT""}], ""name"": ""Cognitive Behavioral Therapy""}"
7765	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	3	Benzodiazepines	May provide symptom relief in some patients, though long-term use carries risks.																																																								"{""description"": ""May provide symptom relief in some patients, though long-term use carries risks."", ""name"": ""Benzodiazepines""}"	{}	"{""description"": ""May provide symptom relief in some patients, though long-term use carries risks."", ""evidence"": [{""explanation"": ""Benzodiazepines show the highest improvement rate at 71.4% of patients."", ""reference"": ""PMID:40129600"", ""snippet"": ""benzodiazepines and lamotrigine had the best effect (71.4% and 61.5% of patients had an improvement of VS symptoms on each medication, respectively)."", ""supports"": ""SUPPORT""}], ""name"": ""Benzodiazepines"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7798	338	Vitiligo	Vitiligo.yaml	treatments	0	Topical Corticosteroid	Common first-line treatment to reduce inflammation and potentially stimulate repigmentation.																																																								"{""description"": ""Common first-line treatment to reduce inflammation and potentially stimulate repigmentation."", ""name"": ""Topical Corticosteroid""}"	{}	"{""description"": ""Common first-line treatment to reduce inflammation and potentially stimulate repigmentation."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The use of topical corticosteroids as a treatment for vitiligo is supported, indicating it as a common and effective treatment option."", ""reference"": ""PMID:19178066"", ""snippet"": ""Topical corticosteroids are one of the oldest and most useful treatments for dermatologic conditions... evidence of effectiveness exists only for select conditions, such as psoriasis, vitiligo..."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The recommendations include topical corticosteroids as a first-line treatment for vitiligo in pediatric, adolescent, and young adult patients."", ""reference"": ""PMID:38477910"", ""snippet"": ""Evidence supports the use of... topical corticosteroids... as effective therapeutics for vitiligo..."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This article highlights topical corticosteroids as a primary treatment for vitiligo, supporting the statement."", ""reference"": ""PMID:33350506"", ""snippet"": ""The mainstay of treatment for unstable vitiligo has been topical agents (corticosteroids, calcineurin inhibitors)..."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Topical corticosteroids are mentioned as a first-line treatment, aligning with the provided statement."", ""reference"": ""PMID:20445292"", ""snippet"": ""Topical therapy is employed as first-line treatment in localized vitiligo. Currently, several topical agents are available... corticosteroids..."", ""supports"": ""SUPPORT""}], ""name"": ""Topical Corticosteroid"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7799	338	Vitiligo	Vitiligo.yaml	treatments	1	JAK Inhibitor Therapy	Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy.																																		Addresses the core IFN-gamma-CXCL9/CXCL10 chemokine axis that recruits cytotoxic T cells to skin.																						"{""description"": ""Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy."", ""name"": ""JAK Inhibitor Therapy"", ""notes"": ""Addresses the core IFN-gamma-CXCL9/CXCL10 chemokine axis that recruits cytotoxic T cells to skin.""}"	{}	"{""description"": ""Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy."", ""name"": ""JAK Inhibitor Therapy"", ""notes"": ""Addresses the core IFN-gamma-CXCL9/CXCL10 chemokine axis that recruits cytotoxic T cells to skin."", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7800	338	Vitiligo	Vitiligo.yaml	treatments	2	Phototherapy	UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production.																																																								"{""description"": ""UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production."", ""name"": ""Phototherapy""}"	{}	"{""description"": ""UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The article supports the use of narrowband UVB for stimulating repigmentation in vitiligo."", ""reference"": ""PMID:27638438"", ""snippet"": ""Acting on multiple steps in vitiligo pathogenesis, narrowband ultraviolet B is one of the few therapies that can effectively induce stabilization and stimulate repigmentation."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference directly supports that UV light, including UVB, is a potent stimulus for repigmentation in vitiligo."", ""reference"": ""PMID:28317529"", ""snippet"": ""The most potent stimulus for repigmentation is the UV light."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""It lists both PUVA and narrowband UVB as standard treatments for vitiligo."", ""reference"": ""PMID:20149899"", ""snippet"": ""There have been many treatments to cure vitiligo such as use of steroid creams, PUVA (psoralen and ultraviolet A light), narrow band UVB (ultraviolet B), various surgical techniques, vitamin D analogues and pseudocatalase."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study demonstrates the effectiveness of narrowband UVB in increasing the melanin index, indicating pigment production in vitiligo lesions."", ""reference"": ""PMID:34806278"", ""snippet"": ""OBJECTIVE: To study whether the colorimeter and point counting technique can be used as objective methods in monitoring vitiligo lesions during treatment with Nb-UVB..."", ""supports"": ""SUPPORT""}], ""name"": ""Phototherapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
7801	338	Vitiligo	Vitiligo.yaml	treatments	3	Skin Graft	can be used for stable vitiligo.				Stable vitiligo																																																				"{""context"": ""Stable vitiligo"", ""description"": ""can be used for stable vitiligo."", ""name"": ""Skin Graft""}"	{}	"{""context"": ""Stable vitiligo"", ""description"": ""can be used for stable vitiligo."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""MKTP is a type of autologous non-cultured cellular grafting procedure used for treating stable vitiligo."", ""reference"": ""PMID:38038734"", ""snippet"": ""For patients with stable vitiligo who have not achieved satisfactory results with medical treatments, the melanocyte-keratinocyte transplantation procedure (MKTP) is a viable option."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This study compares ultrathin skin grafting (UTSG) and suction blister epidermal grafting (SBEG), both of which are skin grafting methods used to treat stable vitiligo."", ""reference"": ""PMID:37000977"", ""snippet"": ""Surgical therapies are effective methods to treat resistant stable vitiligo, with each method having advantages and disadvantages."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""CEA is mentioned as an option for treating stable vitiligo, indicating the use of skin grafting."", ""reference"": ""PMID:34169570"", ""snippet"": ""Cultured epidermal autografts (CEA) are surgical therapeutic alternatives for patients with stable vitiligo resistant to conventional medical treatments."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference discusses smash grafting as a method used in vitiligo treatment."", ""reference"": ""PMID:22994670"", ""snippet"": ""A number of new therapeutic options for vitiligo have become available...One among them is the smashed skin grafting or simply smash grafting"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""It supports the use of surgical interventions, including skin grafting, for stable vitiligo."", ""reference"": ""PMID:27274556"", ""snippet"": ""Medical treatments are usually reasonably effective for nonstable vitiligo patches; however, for vitiligo patches that have been stable for a substantial period of time, surgical intervention should be considered."", ""supports"": ""SUPPORT""}], ""name"": ""Skin Graft"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7802	338	Vitiligo	Vitiligo.yaml	treatments	4	Melanocyte Transplantation	can be used for stable vitiligo.				Stable vitiligo																																																				"{""context"": ""Stable vitiligo"", ""description"": ""can be used for stable vitiligo."", ""name"": ""Melanocyte Transplantation""}"	{}	"{""context"": ""Stable vitiligo"", ""description"": ""can be used for stable vitiligo."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This implies that melanocyte-keratinocyte transplantation can be effective for stable vitiligo."", ""reference"": ""PMID:12709002"", ""snippet"": ""This surgical treatment gives its best results in segmental and focal vitiligo, even with large affected areas, and in at least 50% of patients with generalized vitiligo."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The procedure involves melanocyte transplantation which supports the statement for treating stable vitiligo."", ""reference"": ""PMID:26728804"", ""snippet"": ""Melanocyte-keratinocyte transplantation procedure: A few insights."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This confirms the use of melanocyte transplantation for stable vitiligo."", ""reference"": ""PMID:28445194"", ""snippet"": ""Cultured autologous melanocyte transplantation (CMT) is an effective treatment for stable vitiligo."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Surgical treatments including melanocyte transplantation are viable for stable vitiligo according to the literature."", ""reference"": ""PMID:35457678"", ""snippet"": ""Both the development of new techniques and modifications to the already available treatment of cell and tissue transplantation give hope to numerous patients around the world."", ""supports"": ""SUPPORT""}], ""name"": ""Melanocyte Transplantation"", ""treatment_term"": {""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}}"
7803	338	Vitiligo	Vitiligo.yaml	treatments	5	Monobenzone Cream	Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo.																																																								"{""description"": ""Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo."", ""name"": ""Monobenzone Cream""}"	{}	"{""description"": ""Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This supports the use of monobenzone cream for removing remaining pigment in cases of extensive vitiligo."", ""reference"": ""PMID:3168334"", ""snippet"": ""When large areas of skin are involved or when the patient is unresponsive to therapy, serious consideration should be given to depigmentation with monobenzone (Benoquin)."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference supports the use of monobenzone (MBEH) for depigmentation in extensive vitiligo cases."", ""reference"": ""PMID:21054565"", ""snippet"": ""If vitiligo involves most of the body, it might be easier to depigment the normal remaining skin rather than to attempt repigmentation...Our review revealed that...Monobenzyl ether of hydroquinone (MBEH) is the most widely used depigmenting agent and has few side-effects."", ""supports"": ""SUPPORT""}], ""name"": ""Monobenzone Cream"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7824	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	0	Surveillance Protocol	Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur.																																																								"{""description"": ""Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur."", ""name"": ""Surveillance Protocol""}"	{}	"{""description"": ""Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur."", ""name"": ""Surveillance Protocol"", ""treatment_term"": {""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}}"
7825	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	1	Nephron-Sparing Surgery	Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation.																																																								"{""description"": ""Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation."", ""name"": ""Nephron-Sparing Surgery""}"	{}	"{""description"": ""Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation."", ""name"": ""Nephron-Sparing Surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7826	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	2	Belzutifan	HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types.																																																								"{""description"": ""HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types."", ""name"": ""Belzutifan""}"	{}	"{""description"": ""HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types."", ""evidence"": [{""explanation"": ""Phase 2 clinical trial demonstrates belzutifan efficacy and tolerability across VHL-associated tumor types."", ""reference"": ""PMID:34818478"", ""snippet"": ""Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease."", ""supports"": ""SUPPORT""}], ""name"": ""Belzutifan"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7827	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	3	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options.																																																								"{""description"": ""Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options."", ""name"": ""Genetic Counseling""}"	{}	"{""description"": ""Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options."", ""name"": ""Genetic Counseling"", ""treatment_term"": {""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}}"
7848	340	Whipple Disease	Whipple_Disease.yaml	treatments	0	Ceftriaxone induction followed by trimethoprim/sulfamethoxazole	Two-week intravenous ceftriaxone induction followed by oral TMP-SMX maintenance to eradicate infection and prevent relapse.																																																								"{""description"": ""Two-week intravenous ceftriaxone induction followed by oral TMP-SMX maintenance to eradicate infection and prevent relapse."", ""name"": ""Ceftriaxone induction followed by trimethoprim/sulfamethoxazole""}"	{}	"{""description"": ""Two-week intravenous ceftriaxone induction followed by oral TMP-SMX maintenance to eradicate infection and prevent relapse."", ""evidence"": [{""explanation"": ""Details standard ceftriaxone induction and TMP-SMX maintenance regimen."", ""reference"": ""PMID:26288590"", ""snippet"": ""The German treatment recommendations include a two-week intravenous induction therapy with ceftriaxone, which is followed by a three-month oral maintenance therapy with trimethoprim/sulfamethoxazole."", ""supports"": ""SUPPORT""}], ""name"": ""Ceftriaxone induction followed by trimethoprim/sulfamethoxazole"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7849	340	Whipple Disease	Whipple_Disease.yaml	treatments	1	Doxycycline plus hydroxychloroquine regimen	Oral doxycycline and hydroxychloroquine for one year, followed by lifelong doxycycline for relapse prevention.																																																								"{""description"": ""Oral doxycycline and hydroxychloroquine for one year, followed by lifelong doxycycline for relapse prevention."", ""name"": ""Doxycycline plus hydroxychloroquine regimen""}"	{}	"{""description"": ""Oral doxycycline and hydroxychloroquine for one year, followed by lifelong doxycycline for relapse prevention."", ""evidence"": [{""explanation"": ""Review reports alternative long-course doxycycline plus hydroxychloroquine approach."", ""reference"": ""PMID:26288590"", ""snippet"": ""A French group favors a combination of doxycycline and hydroxychloroquine for 1 year, followed by a lifelong administration of doxycycline."", ""supports"": ""SUPPORT""}], ""name"": ""Doxycycline plus hydroxychloroquine regimen"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7868	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	0	Surgical Resection	Nephrectomy is the primary treatment for unilateral Wilms tumor. In North America, upfront nephrectomy provides staging information. In Europe, preoperative chemotherapy is often given first.																																																								"{""description"": ""Nephrectomy is the primary treatment for unilateral Wilms tumor. In North America, upfront nephrectomy provides staging information. In Europe, preoperative chemotherapy is often given first."", ""name"": ""Surgical Resection""}"	{}	"{""description"": ""Nephrectomy is the primary treatment for unilateral Wilms tumor. In North America, upfront nephrectomy provides staging information. In Europe, preoperative chemotherapy is often given first."", ""name"": ""Surgical Resection"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.																																																								"{""description"": ""Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors."", ""name"": ""Chemotherapy""}"	{}	"{""description"": ""Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors."", ""name"": ""Chemotherapy"", ""treatment_term"": {""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}}"
7870	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	2	Radiation Therapy	Flank radiation is used for stage III tumors and higher. Whole abdominal radiation is used for tumor rupture or diffuse peritoneal contamination.																																																								"{""description"": ""Flank radiation is used for stage III tumors and higher. Whole abdominal radiation is used for tumor rupture or diffuse peritoneal contamination."", ""name"": ""Radiation Therapy""}"	{}	"{""description"": ""Flank radiation is used for stage III tumors and higher. Whole abdominal radiation is used for tumor rupture or diffuse peritoneal contamination."", ""name"": ""Radiation Therapy"", ""treatment_term"": {""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}}"
7900	342	Wilson Disease	Wilsons_Disease.yaml	treatments	0	D-Penicillamine	Copper chelator, first-line therapy, promotes urinary copper excretion.																																																								"{""description"": ""Copper chelator, first-line therapy, promotes urinary copper excretion."", ""name"": ""D-Penicillamine""}"	{}	"{""description"": ""Copper chelator, first-line therapy, promotes urinary copper excretion."", ""evidence"": [{""explanation"": ""Establishes D-penicillamine as first-line chelation therapy with evidence for improved prognosis."", ""reference"": ""PMID:38731973"", ""snippet"": ""Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine that facilitate the removal of circulating copper bound to albumin and increase in urinary copper excretion. Early chelation therapy improves prognosis."", ""supports"": ""SUPPORT""}], ""name"": ""D-Penicillamine"", ""treatment_term"": {""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}}}"
7901	342	Wilson Disease	Wilsons_Disease.yaml	treatments	1	Trientine	Alternative copper chelator, better tolerated than penicillamine.																																																								"{""description"": ""Alternative copper chelator, better tolerated than penicillamine."", ""name"": ""Trientine""}"	{}	"{""description"": ""Alternative copper chelator, better tolerated than penicillamine."", ""evidence"": [{""explanation"": ""Confirms chelation therapy as a primary treatment approach for Wilson's disease."", ""reference"": ""PMID:37741465"", ""snippet"": ""Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut"", ""supports"": ""SUPPORT""}], ""name"": ""Trientine"", ""treatment_term"": {""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}}}"
7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.																																																								"{""description"": ""Blocks intestinal copper absorption, maintenance therapy."", ""name"": ""Zinc Acetate""}"	{}	"{""description"": ""Blocks intestinal copper absorption, maintenance therapy."", ""evidence"": [{""explanation"": ""Confirms zinc therapy works by reducing intestinal copper absorption."", ""reference"": ""PMID:37741465"", ""snippet"": ""reduction of copper absorption in the gut (zinc therapy)"", ""supports"": ""SUPPORT""}], ""name"": ""Zinc Acetate"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""zinc acetate"", ""term"": {""id"": ""CHEBI:62984"", ""label"": ""zinc acetate""}}]}}"
7903	342	Wilson Disease	Wilsons_Disease.yaml	treatments	3	Low Copper Diet	Avoid liver, shellfish, chocolate, nuts, mushrooms.																																																								"{""description"": ""Avoid liver, shellfish, chocolate, nuts, mushrooms."", ""name"": ""Low Copper Diet""}"	{}	"{""description"": ""Avoid liver, shellfish, chocolate, nuts, mushrooms."", ""evidence"": [{""explanation"": ""Establishes that dietary intake is a source of copper, supporting dietary restriction as an adjunctive treatment approach."", ""reference"": ""PMID:38731973"", ""snippet"": ""copper, which is found ubiquitously on earth and normally enters the human body in small amounts via the food chain"", ""supports"": ""SUPPORT""}], ""name"": ""Low Copper Diet"", ""treatment_term"": {""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}}"
7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.																																																								"{""description"": ""Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper."", ""name"": ""Tetrathiomolybdate""}"	{}	"{""description"": ""Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper."", ""evidence"": [{""explanation"": ""Tetrathiomolybdate represents an emerging chelation approach that tightly complexes copper."", ""reference"": ""PMID:37741465"", ""snippet"": ""Current treatment protocols are limited to either sequestration of copper via chelation or reduction of copper absorption in the gut"", ""supports"": ""SUPPORT""}], ""name"": ""Tetrathiomolybdate"", ""treatment_term"": {""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""tetrathiomolybdate"", ""term"": {""id"": ""CHEBI:30703"", ""label"": ""tetrathiomolybdate(2-)""}}]}}"
7905	342	Wilson Disease	Wilsons_Disease.yaml	treatments	5	Liver Transplantation	Curative for hepatic Wilson disease, reverses copper metabolism defect.																																																								"{""description"": ""Curative for hepatic Wilson disease, reverses copper metabolism defect."", ""name"": ""Liver Transplantation""}"	{}	"{""description"": ""Curative for hepatic Wilson disease, reverses copper metabolism defect."", ""evidence"": [{""explanation"": ""Confirms liver transplantation as curative treatment that replaces the defective gene."", ""reference"": ""PMID:38731973"", ""snippet"": ""Liver transplantation is an option viewed as ultima ratio in end-stage liver disease with untreatable complications or acute liver failure. Liver transplantation finally may thus be a life-saving approach and curative treatment of the disease by replacing the hepatic gene mutation."", ""supports"": ""SUPPORT""}], ""name"": ""Liver Transplantation"", ""treatment_term"": {""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}}"
7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.																																																								"{""description"": ""NSAIDs can reduce fever and inflammatory symptoms."", ""name"": ""Nonsteroidal anti-inflammatory drugs""}"	{}	"{""description"": ""NSAIDs can reduce fever and inflammatory symptoms."", ""evidence"": [{""explanation"": ""The case report documents remission with NSAID therapy."", ""reference"": ""PMID:27843372"", ""snippet"": ""A combination of nonsteroidal anti-inflammatory drugs and steroids achieved complete remission."", ""supports"": ""SUPPORT""}], ""name"": ""Nonsteroidal anti-inflammatory drugs"", ""treatment_term"": {""preferred_term"": ""NSAID therapy"", ""term"": {""id"": ""MAXO:0000221"", ""label"": ""NSAID therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""naproxen"", ""term"": {""id"": ""NCIT:C680"", ""label"": ""Naproxen""}}]}}"
7925	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	1	Corticosteroids	Systemic corticosteroids (e.g., prednisolone) used as part of combination regimens to control inflammation.																																																								"{""description"": ""Systemic corticosteroids (e.g., prednisolone) used as part of combination regimens to control inflammation."", ""name"": ""Corticosteroids""}"	{}	"{""description"": ""Systemic corticosteroids (e.g., prednisolone) used as part of combination regimens to control inflammation."", ""evidence"": [{""explanation"": ""The case report notes complete remission with steroids plus NSAIDs."", ""reference"": ""PMID:27843372"", ""snippet"": ""A combination of nonsteroidal anti-inflammatory drugs and steroids achieved complete remission."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract indicates corticosteroids were part of successful therapy."", ""reference"": ""PMID:1210460"", ""snippet"": ""In the present case the disease could successfully be controlled using imuran in combination with corticosteroids."", ""supports"": ""SUPPORT""}], ""name"": ""Corticosteroids"", ""treatment_term"": {""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}}"
7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.																																																								"{""description"": ""Dapsone was used alongside NSAIDs and corticosteroids in a reported case."", ""name"": ""Dapsone""}"	{}	"{""description"": ""Dapsone was used alongside NSAIDs and corticosteroids in a reported case."", ""evidence"": [{""explanation"": ""The case report documents improvement with dapsone as part of combination therapy."", ""reference"": ""PMID:27843372"", ""snippet"": ""A combination of naproxen, dapsone, and prednisolone therapy resulted in significant improvement of the patients arthralgias and rash."", ""supports"": ""SUPPORT""}], ""name"": ""Dapsone"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dapsone"", ""term"": {""id"": ""NCIT:C415"", ""label"": ""Dapsone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.																																																								"{""description"": ""Immunosuppressive therapy used in combination with corticosteroids."", ""name"": ""Azathioprine""}"	{}	"{""description"": ""Immunosuppressive therapy used in combination with corticosteroids."", ""evidence"": [{""explanation"": ""The abstract reports successful control with azathioprine (imuran) plus steroids."", ""reference"": ""PMID:1210460"", ""snippet"": ""In the present case the disease could successfully be controlled using imuran in combination with corticosteroids."", ""supports"": ""SUPPORT""}], ""name"": ""Azathioprine"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7947	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	0	Seizure Management with Levetiracetam	Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients.																																																								"{""description"": ""Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients."", ""name"": ""Seizure Management with Levetiracetam""}"	{}	"{""description"": ""Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients."", ""evidence"": [{""explanation"": ""This study found levetiracetam to be the most effective antiseizure medication for Wolf-Hirschhorn syndrome."", ""reference"": ""PMID:37075791"", ""snippet"": ""The most effective ASM was levetiracetam. Although WHS-associated epilepsy is intractable with frequent SE occurrence during infancy, improvement in seizure control is expected with age. Levetiracetam may be a novel ASM for WHS."", ""supports"": ""SUPPORT""}, {""explanation"": ""This cohort study confirms that levetiracetam is one of the most commonly used antiseizure medications for WHS."", ""reference"": ""PMID:41303083"", ""snippet"": ""Valproic acid and levetiracetam were the most commonly used treatments."", ""supports"": ""SUPPORT""}], ""name"": ""Seizure Management with Levetiracetam"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7948	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	1	Seizure Management with Valproic Acid	Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome.																																																								"{""description"": ""Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome."", ""name"": ""Seizure Management with Valproic Acid""}"	{}	"{""description"": ""Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome."", ""evidence"": [{""explanation"": ""This large cohort study indicates valproic acid is one of the most frequently prescribed antiseizure medications for WHS."", ""reference"": ""PMID:41303083"", ""snippet"": ""Valproic acid and levetiracetam were the most commonly used treatments."", ""supports"": ""SUPPORT""}], ""name"": ""Seizure Management with Valproic Acid"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7949	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	2	Growth Hormone Therapy	Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency.																																																								"{""description"": ""Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency."", ""name"": ""Growth Hormone Therapy""}"	{}	"{""description"": ""Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency."", ""evidence"": [{""explanation"": ""This case report demonstrates long-term efficacy and safety of recombinant human growth hormone therapy in WHS patients with growth hormone deficiency."", ""reference"": ""PMID:41017003"", ""snippet"": ""Across 11 years of rhGH, height improved from ~ - 4.2 to ~ - 1.3 SDS with normalized height velocity and a prolonged but uneventful pubertal course. No major adverse effects were observed. Muscle tone improvement was also noted with treatment initiation."", ""supports"": ""SUPPORT""}], ""name"": ""Growth Hormone Therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7950	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	3	Early Aggressive Seizure Management	Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis.																																																								"{""description"": ""Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis."", ""name"": ""Early Aggressive Seizure Management""}"	{}	"{""description"": ""Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis."", ""evidence"": [{""explanation"": ""This study suggests early aggressive seizure management may improve long-term neurological outcomes in WHS."", ""reference"": ""PMID:41303083"", ""snippet"": ""While some patients show improvement with age, early aggressive management using appropriate ASMs may be critical to improve neurological prognosis."", ""supports"": ""SUPPORT""}], ""name"": ""Early Aggressive Seizure Management"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7954	345	Yaws	Yaws.yaml	treatments	0	Azithromycin therapy	Oral azithromycin is preferred for treatment.																																																								"{""description"": ""Oral azithromycin is preferred for treatment."", ""name"": ""Azithromycin therapy""}"	{}	"{""description"": ""Oral azithromycin is preferred for treatment."", ""evidence"": [{""explanation"": ""The abstract notes oral azithromycin as the preferred treatment."", ""reference"": ""PMID:40036381"", ""snippet"": ""Though yaws can be treated with benzathine penicillin, oral azithromycin has become the preferred treatment due to its ease of administration."", ""supports"": ""SUPPORT""}], ""name"": ""Azithromycin therapy"", ""treatment_term"": {""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}}"
7965	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	treatments	0	Supportive care	"Multidisciplinary management including physical therapy, occupational therapy, speech therapy, and management of seizures when present.
"																																																								"{""description"": ""Multidisciplinary management including physical therapy, occupational therapy, speech therapy, and management of seizures when present.\n"", ""name"": ""Supportive care""}"	{}	"{""description"": ""Multidisciplinary management including physical therapy, occupational therapy, speech therapy, and management of seizures when present.\n"", ""name"": ""Supportive care"", ""treatment_term"": {""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}}"
7966	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	treatments	1	Cataract surgery	"Surgical removal of congenital cataracts can improve visual responses and social interactions.
"																																																								"{""description"": ""Surgical removal of congenital cataracts can improve visual responses and social interactions.\n"", ""name"": ""Cataract surgery""}"	{}	"{""description"": ""Surgical removal of congenital cataracts can improve visual responses and social interactions.\n"", ""evidence"": [{""explanation"": ""Demonstrates benefit of cataract surgery for improving visual function and patient engagement."", ""reference"": ""PMID:37215500"", ""snippet"": ""After bilateral cataract surgery, the infant obtained better visual acuity and showed more responses and interactions with her parents"", ""supports"": ""SUPPORT""}], ""name"": ""Cataract surgery"", ""treatment_term"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}}"
